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IAbstract
Recent advances in the understanding of the major class of cell surface G protein
coupled receptors (GPCRs) have added complexity to their molecular
pharmacology. Firstly GPCRs signal not only through G proteins but also other
partners such as E-arrestins - adaptors initially characterised for roles in
desensitisation and endocytosis. The second is that GPCRs can form homodimers
or heterodimers between different subtypes. The functional significance of
dimerisation remains debatable, with part of the controversy surrounding an
inability to directly assign pharmacological properties to dimers, or receptor-
effector complexes, of known molecular composition.
This thesis explores the use of bimolecular fluorescence complementation (BiFC),
as a means to address this problem. In BiFC, protein-protein interactions are
identified by complementary fluorescent protein fragment tags, which refold and
generate a fluorescent signal upon association. As BiFC is irreversible it therefore
identifies receptor complexes of known composition. The Y receptor family,
which respond to neuropeptide Y (NPY), and related hormones peptide YY and
pancreatic polypeptide, were chosen as model GPCRs to explore the use of BiFC
in identifying E-arrestin interactions and investigating the behaviour of receptor
dimers. The 4 cloned Y receptor subtypes share G protein coupling pathways, but
less is known about their relative recruitment of E-arrestins and regulation by
endocytosis. Moreover, potential heterodimerisation (e.g. Y1/Y5) has largely
unproven physiological roles in central feeding and appetite regulation.
First, BiFC based high content imaging assays were established to quantify the
ƉŚĂƌŵĂĐŽůŽŐǇ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚ ƚŽ z ƌĞĐĞƉƚŽƌ ƐƵďƚǇƉĞƐ ? ĂŶĚ
demonstrate the correlation between this process and agonist induced
endocytosis (Chapter 3). Targeted mutagenesis, demonstrated the shared
involvement of key intracellular receptor domains in arrestin recruitment and
internalisation. Fluorescence recovery after photobleaching, and fluorescence
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correlation spectroscopy were used to measure the diffusion of fluorescent Y
receptor complexes and demonstrated that NPY stimulation slowed receptor
motility, reconciling with the propensity of these receptors to undergo
endocytosis (Chapter 4). The use of a novel BiFC system allowed, for the first
time, this slowed motility to be correlated with the behaviour of defined Y
receptor-Earrestin signalling complexes.
To study dimerisation, BiFC was used to constrain Y1 receptor subtypes as homo
or heterodimers of precise composition. Quantitative platereader imaging of
recomplemented YFP measured BiFC dimer internalisation as an indirect readout
ŽĨɴ ?ĂƌƌĞƐƚŝŶƌĞĐƌƵŝƚŵĞŶƚĂŶĚĚŝŵĞƌĨƵŶĐƚŝŽŶ ?ŚĂƉƚĞƌƐ ?ĂŶĚ ? Z ?ŽŶƐƚƌĂŝŶŝŶŐz ?
receptor and E2-adrenoceptor BiFC homodimers had no effect on agonist
promoted internalisation. Selective mutagenesis of residues within a single
protomer of each dimer illustrated that occupation of a single ligand binding site
and the presence of one phosphorylated C terminal domain was sufficient. These
ƌĞƐƵůƚƐ ĂůƐŽ ŝŵƉůŝĞĚƐǇŵŵĞƚƌŝĐĂů ďŝŶĚŝŶŐŽĨɴ ?ĂƌƌĞƐƚŝŶ ƚŽz ? ƌĞĐĞƉƚŽƌĚŝŵĞƌƐ ? ĂŶ
observation supported by the earlier single molecule imaging techniques.
Finally, constrained Y1/Y5 receptor BiFC heterodimers showed modified
pharmacology not evident for other heterodimer combinations (Y1/Y4, Y1/E2AR).
The most striking alterations were a switching of the behaviour of Y5 subtype
selective antagonists from surmountable (at the Y5 receptor) to insurmountable
inhibition of NPY stimulated internalisation of the Y1/Y5 dimer; while in contrast
Y1 antagonists became ineffective in inhibiting Y1/Y5 dimer responses. These
observations suggest selective allosteric interactions between the respective Y1
and Y5 receptor protomers. Previous attempts to develop anti obesity agents that
selectively target either the Y1 or Y5 receptor subtype, have lacked long term
clinical efficacy. However identification of novel pharmacology of the Y1/Y5
dimer, and a strategy to screen for selective antagonism of this pairing using the
BiFC system, may be a way to identify future therapeutic treatments for obesity.
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1Chapter 1: Introduction
1.1 The G protein coupled receptor superfamily
G-protein coupled receptors (GPCRs) represent the largest group of membrane
receptors found in the human genome, numbering over 800 unique members
(Benovic and von Zastrow, 2014) and are integral to a vast number of
physiological processes including vision, cardiac function, neurotransmission,
appetite, immune responses and olfaction (Wolfe and Trejo, 2007). GPCR targets
comprise 30-50% of drugs currently marketed (Garland, 2013), and their cognate
ligands encompass not only classical neurotransmitters such as the monoamines,
but also peptides, proteins, lipids, glycoprotein hormones, ions and sensory
signals such as photons, odorants and taste ligands (Musnier et al., 2010),(Fung
JJ, 2009). Following activation by ligand binding, GPCRs traditionally couple at
their cytoplasmic elements to heterotrimeric G proteins (Gɲɴɶ). The signalling
cascades produced can have rapid short term physiological effects via the
production of second messenger molecules as well as long term effects via
changes in gene expression.
1.1.1 The pharmacological principles of GPCR signalling
GPCRs can be activated by binding endogenous ligands naturally occurring in the
ďŽĚǇ ?ƐƵĐŚĂƐĂĚƌĞŶĂůŝŶĞƚŽƚŚĞɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌŽƌŶĞƵƌŽƉĞƉƚŝĚĞz ?EWz ZƚŽƚŚĞ
NPY Y1 receptor. The site that an endogenous ligand binds to is termed the
othosteric binding site. Exogenous ligands (eg. drugs) are also capable of binding
to this site and activating GPCRs, often by mimicking the effect of the
ĞŶĚŽŐĞŶŽƵƐůŝŐĂŶĚ ?ƐƵĐŚĂƐ/ƐŽƉƌĞŶĂůŝŶĞďŝŶĚŝŶŐƚŽƚŚĞɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ?^ĂƚŽĞƚ
al., 1996). The ability of a ligand to bind to a receptor is termed its affinity, while
the ability of a ligand to stabilise an active receptor complex once bound is
termed (intrinsic) efficacy. The potency of a ligand is a more empirical term that
relates to the concentration of ligand required to produce a functional effect (e.g.
2determined by the EC50 value (effective concentration for 50 % response on a
concentration response curve). Potency depends on both ligand affinity and
efficacy at the target receptor, but also on properties of the system, for example
the number of receptors present, or the extent of signal amplification between
the receptor and the measured endpoint.
Ligands that activate GPCRs and lead to the induction of biological responses are
termed agonists. Agonists which show high efficacy are full agonists, and can
often produce maximal responses whilst occupying only a small proportion of
expressed receptors, because of receptor reserve due to signal amplification
(Figure 1.1, A). A partial agonist shows lower efficacy at inducing responses in
relation to a full agonist. This sub maximal response, relative to a full agonist,
occurs even when the agonist occupies the entire receptor population. An
inverse agonist binds to receptors at the orthosteric binding site, but stabilises
the inactive conformation of the receptor. Thus, if receptors show constitutive
activity (by adopting an active conformation in the absence of agonist) inverse
agonists can induce functional responses opposite to that of an agonist.
An antagonist is a ligand which inhibits agonist mediated receptor responses
without activating the receptor itself. True antagonists therefore have affinity for
the receptor but no positive efficacy, though inverse agonists (with negative
efficacy) also behave as antagonists in inhibiting agonist effects. Competitive
antagonists bind to the same receptor orthosteric ligand binding site as the
agonist (B). They sterically block agonist binding, meaning that higher
concentrations of agonist are required to outcompete the antagonist occupancy
(assuming reversible binding in both cases), resulting in reduced potency of this
agonist in the presence of antagonist. In functional assays, the effect of
competitive antagonists will be seen as rightward parallel shifts of agonist
concentration response curves with no effect on maximum responses  known as
surmountable antagonism. Antagonism may also be insurmountable, in that no
amount of agonist can overcome the inhibition observed to regain the maximal
3response (C). This antagonism can occur because of irreversible covalent binding
of the antagonist to the receptor orthosteric binding site, or because the
antagonist is non-competitive, and binds to a topographically distinct allosteric
site.
4Figure 1.1: The principles of agonist and antagonist pharmacology at GPCRs
An agonist is a ligand that stabilises a GPCR conformation which activates the receptor resulting in a biological response (A). Full agonists show
high efficacy at inducing maximal responses, whereas partial agonists have lower efficacy and can only induce submaximal responses irrespective
of the degree of receptor occupation. An inverse agonist can bind and inhibit constitutively active receptors, inducing a response opposite to
that of an agonist at the same receptor. Surmountable competitive antagonists (B) are able to bind to the same orthosteric ligand binding site as
the agonist, but do not result in receptor activation, consequently sterically blocking agonist binding. In the presence of increasing
concentrations of competitive antagonist, higher concentrations of agonist are required to out compete the antagonist, resulting in a parallel
rightward shift in observed agonist concentration response curves. Antagonism may also be insurmountable, in that no amount of agonist can
overcome the inhibition (C). This antagonism can be due to an antagonist covalently binding to the receptor orthosteric binding site or binding to
a topographically distinct site termed the allosteric site. In functional assays insurmountable antagonism manifests as a drop in the magnitude of
the observed maximum response.
51.2. Structural properties of GPCRs
1.2.1 GPCR Classes
GPCRs are composed of seven helical transmembrane domains(TM I-VII), 3
intracellular (ICL 1-3) and extracellular loops (ECL 1-3), an extracellular amino
terminal and an intracellular carboxyl tail (Figure 1.2) (Unal et al., 2012). Electron
cryo-microscopy of 2D crystals of bovine rhodopsin, suggested that the 7
transmembrane helices are arranged in a counterclockwise formation with TM3
tilted towards the centre of the helical bundle (Unger and Schertler, 1995). This
orientation was confirmed from the first crystal structure of rhodopsin
(Palczewski et al., 2000) and later GPCR crystal structures. An additional
amphipathic helix (helix 8) is found at the end of TM7 and lies parallel to the
cytoplasmic face of the plasma membrane (Kirchberg et al., 2011). In rhodopsin,
Helix 8 connects the transmembrane helical bundle to the receptor C terminal tail
via two palmitoylated cysteine residues at Cys322 and Cys323.
Both within and between GPCR families, sequence analysis has shown that
particularly the N and C terminal domains can vary greatly. GPCRs can be divided
into three major structural classes  A, B and C (Pierce et al., 2002). The largest
group, Class A, comprises of 19 subgroups that includes rhodopsin, the opioid
ĨĂŵŝůǇ  ?ʃ ? ɶ ? A? ? ɷ Z ? ƚŚĞ ĂĚĞŶŽƐŝŶĞ ĨĂŵŝůǇ  ? ? ? 2A, A2B,A3), the muscarinic family
(M1-M5) and the two receptor families used in this thesis - neuropeptide Y (Y1,
z ? ?z ?ĂŶĚz ? Z ?ĂŶĚĂĚƌĞŶŽĐĞƉƚŽƌƐ  ?ɲ ? ?  ? ?  ? ?ɲ ? ?  ? ? ĂŶĚɴ ? ? ? Z ?ůĂƐƐ
GPCRs typically have a short extracellular N terminus, with ligand binding
occurring at the extracellular loops (peptide ligands) or within transmembrane
helices that form a ligand binding pocket (e.g. adrenaline at the B2AR (Strader et
al., 1989, Rasmussen et al., 2007b)).
Class B receptors include those for gastrointestinal peptide hormones, such as
glucagon and vasoactive intestinal peptide receptors (Pierce et al., 2002). The N
terminal domain is typically the site of ligand binding, and contains six cysteine
6residues that form disulphide bridges that facilitate this (Grace et al., 2004). Class
C receptors include the metabotropic glutamate receptor and GABAB receptors
(Pierce et al., 2002). They are particularly characterised by an elaborate N
terminal ligand binding region, composed of a Venus flytrap domain which can
assume a variety of conformations depending upon the presence or absence of
agonists and antagonists (Kniazeff J, 2004). As discussed in more detail later in
the thesis (chapters 5 and 6), class C GPCRs have been shown to form obligate
dimers in order to function, partly via interactions of these Venus fly trap
domains.
The typical structure of a Class A GPCR is shown in Figure 1.2 and has been
confirmed from crystal structures (Venkatakrishnan et al., 2013). The first Class A
GPCR to be crystallised was rhodopsin, long considered the model GPCR for Class
A basal and active conformations. Crystal structures were obtained from primary
retinal tissue of the inverse agonist bound (11-cis-retinal) form representative of
the inactive state (Palczewski et al., 2000) and a constitutively active opsin form,
representing the active state (Jager et al., 1996). This structure is not strictly
active rhodopsin as the opsin does not have 11-trans retinal bound, the active
isomer produced by light activation. Although many of the structural motifs
involved in receptor activation are highly conserved amongst Class A GPCRs,
rhodopsin responses are unique in that they are essentially all or nothing. This is
due to the covalently tethered ligand and requirement for photon induced
isomerisation of the covalently bound retinal from a inverse agonist
conformation (11-cis) to an active trans conformation, which is sufficient to cause
full rhodopsin activation (Jager et al., 1996) (Kobilka and Deupi, 2007).
Crystallisation of inactive rhodopsin provided an early template for modelling
other GPCR structures, but has now also been followed by the successful
crystallisation of 18 other GPCR conformations. Crystal structures of inactive
inverse agonist/ antagonist bound Class A receptors have been obtained for
human muscarinic M2 (Haga et al., 2012), rat muscarinic M3 (Kruse et al., 2012),
7human histamine H1 (Shimamura et al., 2011), human adenosine A2A (Jaakola et
al., 2008) and the opioid receptor family (Wu et al., 2012), (Manglik et al., 2012)
and (Granier et al., 2012)). in addition to the Class B receptor corticotrophin
releasing factor receptor-1 (Hollenstein et al., 2013) and the transmembrane
domain of the Class C metabotropic glutamate receptor 5 (Dore et al., 2014).
,ŽǁĞǀĞƌ ƚŚĞ ůĂƌŐĞƐƚ ƌĂŶŐĞ ŽĨ ĐƌǇƐƚĂů ƐƚƌƵĐƚƵƌĞƐ ŚĂƐ ďĞĞŶ ŽďƚĂŝŶĞĚ ĨŽƌ ƚŚĞ ɴ ? ?
ĂĚƌĞŶŽĐĞƉƚŽƌ ? hŶůŝŬĞ ƌŚŽĚŽƉƐŝŶ ? ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ƌĞĂĚŝůǇ ĐŽŶǀĞƌƚ ďĞƚǁĞĞŶ Ă
range of inactive and active conformations, with multiple ligands with differing
efficacies able to stabilise distinct receptor sub states (Bockenhauer et al., 2011),
and a level of basal constitutive activity not seen for rhodopsin (Rasmussen et al.,
2007b). Crystal structures have been obtained for the inactive receptor form
bound to the partial agonist carazolol (Cherezov et al., 2007), (Rasmussen et al.,
2007b, Rasmussen et al., 2007a), and for the active agonist bound form stabilised
using a nanobody (Rasmussen et al., 2011a) or bound to the G protein
heterotrimer (Gs) (Rasmussen et al., 2011b).
Interestingly crystallisation has implied that some Class A GPCRs form
ŚŽŵŽĚŝŵĞƌƐ ?ƐƵĐŚĂƐƚŚĞůŝŐĂŶĚĨƌĞĞɴ ?Z ?,ƵĂŶŐĞƚĂů ? ? ? ? ? ? ZŝŶĂĐƚŝǀĞĂŶƚĂŐŽŶŝƐƚ
bound chemokine CXCR4 receptors (Wu et al., 2010) and µ (Manglik et al., 2012),
ʃ ?tƵĞƚĂů ? ? ? ? ? ? ZĂŶĚɷŽƉŝŽŝĚ ?'ƌĂŶŝĞƌĞƚĂů ? ? ? ? ? ? ZƌĞĐĞƉƚŽƌƐ ?,ŽǁĞǀĞƌĐƌǇƐƚĂů
structures are a snapshot of a particular receptor conformation, normally
obtained under artificial conditions (solubilised, purified protein with substantive
modification of the receptors by mutagenesis to improve stability) (Warne et al.,
2008), therefore the functional relevance of dimerisation remains controversial
(see Chapter 5 and Chapter 6).
8Figure 1.2: Schematic of GPCR 7 transmembrane helical structure.
Residues conserved in the primary sequence of all Class A rhodopsin like GPCRs (seen in
red). They include the Asn1.50 (TM1) and Asp2.50 (TM2); Arg3.50 (TM3) a key residue of
the ionic lock and part of the conserved E (D) RY motif and Pro7.50 (TM7) of the NPxxY
motif. Furthermore Trp4.50 on TM4 is conserved in 97% of Class A GPCRs, and forms an
interhelical hydrogen bond with Asn2.50. Residues in blue are conserved in the majority
of class A GPCRs and include a cysteine (Cys3.25) at the top of TM3 which forms a
stabilising disulphide link with ECL2; Asp3.49 and Tyr3.51 of the E (D) RY motif (TM3) and
Asn7.49 and Tyr7.53 of the NPxxY motif (TM7).
ZĞƐŝĚƵĞ ŶƵŵďĞƌƐ ĂƌĞ ĂƐ ƐƚĂƚĞĚ ĨŽƌ ƚŚĞ ŚƵŵĂŶ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ƵƐŝŶŐ ƚŚĞ ĂůůĞƐƚĞƌŽƐ ?
Weinstein numbering system (Ballesteros and Weinstein, 1995).
91.2.2 The structural features of GPCRs
The traditional view of GPCR activation is the ternary complex model consisting
of a GPCR bound to agonist in a high affinity state which is simultaneously
stabilised by effector proteins binding to the intracellular face of the receptor
(Kenakin and Christopoulos, 2013, Samama et al., 1993). Agonists can activate
receptors as their binding results in conformational changes of the receptor
transmembrane domains, disrupting the molecular interactions holding the
receptor in its low energy inactive state. However the existence of multiple
receptor conformations and the phenomena of constitutive activity and biased
agonism, means the reality is likely to be far more complex.
1.2.2.1 Transmembrane helices and the ligand binding pocket
The transmembrane domains of Class A GPCRs are typically 25-35 amino acids
long, and form stable alpha helices that transverse the plasma membrane.
Mutations introduced into the helices can disrupt the formation and alignment of
the helical bundle (Unal et al., 2012). The transmembrane helices are broadly
responsible for transducing conformation changes brought about by ligand
binding, downwards to the intracellular face of the receptor. Across the
transmembrane helices of all GPCRs, structural diversity is most concentrated at
the extracellular half of the helical bundle. For this half, homology estimates from
all GPCR structures suggest only 6% of residues are conserved, compared to 26%
for the intracellular half of the helical bundle (Katritch et al., 2012).
Analysis of available crystal structures suggests there is a network of interhelical
contacts principally between residues of TM3 (eg. 3.32, 3.36 using Ballesteros
Weinstein numbering (Ballesteros and Weinstein, 1995)), TM6 (eg. 6.48, 6.51) and
TM7 (eg. 7.39) that position the helices to form a ligand binding cradle
(Venkatakrishnan et al., 2013). Additionally, the highly conserved residues
Asn1.50 of TM1 and Asp2.50 on TM2 form a hydrogen bond network with
residues in TM2 and 7 (Figure 1.2). Furthermore Trp4.50 on TM4 is conserved in
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97% of Class A GPCRs, and forms an interhelical hydrogen bond with Asn2.40 of
TM2 which locks TM3 within the helix bundle as a structural hub. A hydrogen
bond network involving a cluster of water molecules extending from the ligand
binding pocket into the cytosplamic ends of the transmembrane helices is found
ŝŶ ďŽƚŚ ƌŚŽĚŽƉƐŝŶ ĂŶĚ ĐĂƌĂǌŽůŽů ďŽƵŶĚ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĐƌǇƐƚĂů ƐƚƌƵĐƚƵƌĞƐ
(Scheerer et al., 2008), (Rosenbaum et al., 2007).
It is worth noting that although the primary sequence of residues of the binding
pocket may vary, all GPCR ligands, be that peptide, lipids or monoamines, occupy
a similar pocket within the receptor structure. This indicates that there are
conserved structural elements which are crucial to binding and receptor
activation. However subtype selective residues of the ligand binding pocket can
confer some specificity by contacting elements of the ligand directly. The ligand
ďŝŶĚŝŶŐ ĐůĞĨƚŽĨɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ĐĂƌƌŝĞƐ Ă ŶĞŐĂƚŝǀĞĐŚĂƌŐĞ ĐĞŶƚƌĞĚ ĂƌŽƵŶĚƐƉ
3.32 (Cherezov et al., 2007), (Rasmussen et al., 2007a) which reconciles with
observations from mutagenesis studies. It has been suggested that this residue
ĐŽŶƚĂĐƚƐ ƚŚĞ ƉŽƐŝƚŝǀĞ ĂŵŝŶĞ ĨŽƵŶĚ ŽŶ ƚŚĞ ĞŶĚŽŐĞŶŽƵƐ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ
catecholamine ligands adrenaline and noradrenaline (Sato et al., 1999) and the
synthetic analogue isoprenaline (Savarese and Fraser, 1992). This residue is also
responsible for binding positive amine moieties of the ligand for other
monoamine receptors such as muscarinic acetylcholine (Page et al., 1995) ,
histamine (Jongejan et al., 2005) and dopamine D2 (Lan et al., 2006). Additionally
^Ğƌ ? ? ? ?ĂŶĚ^Ğƌ ? ? ? ?ƌĞƐŝĚƵĞƐŽĨdD ?ŽĨƚŚĞɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌĂƌĞƌĞƐƉŽŶƐŝďůĞĨŽƌ
binding the hydroxyl groups found on the catechol ring of catecholamine ligands
(Sato et al., 1999). When these residues are mutated, receptor affinity for the full
agonist isoprenaline is decreased by 10-25 fold (Strader et al., 1988). Phe6.51
found in TM6 has also been shown to interact with the phenyl ring of adrenaline
(Strader et al., 1989).
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1.2.2.2 The extracellular loop 2 (ECL2)
The available crystal structures of Class A GPCRs have implied that the access of
ligand to the binding pocket may also be regulated, often by the ECL2 domain.
dŚĞɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌŚĂƐĂůĂƌŐĞ ?ƐŽůǀĞŶƚĞǆƉŽƐĞĚ> ?ƚŚĂƚĐƌĞĂƚĞƐĂĐŚĂŶŶĞůƚŽ
allow small water soluble ligands downwards access to a binding pocket buried
within the TM helical bundle (Cherezov et al., 2007) as described above. The
importance of the ECL2 in governing the charge distribution and shape of the
channel leading to the ligand binding site, may define ligand specificity. For
ĞǆĂŵƉůĞƚŚĞĐƌǇƐƚĂůƐƚƌƵĐƚƵƌĞŽĨƚŚĞɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌŚĂƐƐŚŽǁŶƚŚĂƚƚŚĞ> ?ŝƐ
ĂůƐŽŚĞĂǀŝůǇ ŝŶǀŽůǀĞĚŝŶĚĞĨŝŶŝŶŐůŝŐĂŶĚĂĐĐĞƐƐ ?ŽƚŚɴ ?ĂŶĚɴ ?ZƐƵďƚǇƉĞƐŚĂǀĞ
relatively high fidelity in the amino acids residues that line each ligand binding
ƉŽĐŬĞƚ ?ǁŝƚŚƚŚĞŽŶůǇƚǁŽƌĞƐŝĚƵĞƐĚŝĨĨĞƌĞŶƚŝŶɴ ?Z ?sĂů ? ? ? ? ?WŚĞ ? ? ? ? ZĂŶĚɴ ?Z
(Thr4.56, Tyr7.35) functionally equivalent. However marked differences have
been observed in the sequence of their ECL2 regions, suggesting that it is the
access to the ligand binding pocket that differs (Rosenbaum et al., 2007).
Regulated ligand access by ECL domains is supported by evidence from the crystal
structures obtained from receptors with diffusable ligands, such as the spingosine
1 phosphate receptor (S1P) (Hanson et al., 2012) or GPR40 (Srivastava et al.,
2014). For these receptors the ECLs, in conjunction with the amino terminus,
block the extracellular face of the receptor to ligands. In order to access the
binding pocket, ligands must traverse the lipid bilayer in order to enter laterally.
However the degree of influence the ECLs exert over ligand binding itself can
differ with GPCR or ligand. When binding large peptide ligands, such as NPY, the
ECLs can directly participate in this process. For example Asp6.59 is highly
conserved across the NPY Y receptor family. Mutation of this residue resulted in a
drastic loss of agonist binding affinity (Walker et al., 1994, Merten et al., 2007).
However functional activation of Y receptors by agonist still requires engagement
with the helical core. Even for some receptors with small molecule ligands, direct
participation of the ECLs has been observed. For the adenosine A2A receptor for
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example, interaction of adenosine with Phe5.29 located in ECL2 is necessary for
high affinity binding (Katritch et al., 2012).
Additionally disulphide bridges formed between the ECLs and transmembrane
domains have been suggested to contribute to stabilising the highly ordered
secondary structure of the receptor (Peeters et al., 2011, Katritch et al., 2012).
Several are subtype specific, but one that appears to be highly conserved across
all known GPCR Class A structures is between cysteine residues of ECL2 and TM3
(Cys3.25; (Venkatakrishnan et al., 2013)) which has been suggested to anchor the
extracellular side of TM3 close to the proposed ligand binding site to minimise
the movement of its extracellular end during receptor activation.
1.3 The role of conserved motifs in maintaining the inactive state of Class A
GPCRs
A range of non covalent interactions, predominantly found in the central
transmembrane helical core, are believed to play a role in stabilising the inactive
state of Class A GPCRs. Of these, two motifs have been found to be highly
conserved across rhodopsin-like receptors.
1.3.1 The DRY motif of TM3
dŚĞ 'ůƵ ?ƐƉ ?ƌŐ ?dǇƌ  ? ?Zz Z ŵŽƚŝĨ ŝƐ ĐĞŶƚƌĞĚ ĂƌŽƵŶĚ ƌŐ ? ? ? ? ŽĨ ƚŚĞ ɴ ? ?
adrenoceptor at the bottom of TM3 (Figure 1.2) and is found in 75% of all Class A
GPCRs (Rasmussen et al., 2007a). Insights from the crystal structure of inactive
rhodopsin have shown that ionic salt bridges form both within this motif (Glu/Asp
with Arg) and between Arg3.50 and residues of TM6 (Glu6.30 and Thr6.36;
(Scheerer et al., 2008)). This ionic lock has been proposed to constrain
rhodopsin in an inactive conformation and has also been observed in crystal
ƐƚƌƵĐƚƵƌĞƐŽĨůŝŐĂŶĚĨƌĞĞɴ ?Z ?,ƵĂŶŐĞƚĂů ? ? ? ? ? ? ZŝŶĂĐƚŝǀĞĚŽƉĂŵŝŶĞ ? ?ŚŝĞŶ
et al., 2010) and inactive adenosine A2A bound to certain antagonists (Dore et al.,
2011). However the significance of the ionic lock for other Class A GPCRs remains
debatable. Mutagenesis of DRY motif residues resulted in constitutive activity of
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ŝŶ ɴ ?Z ĂŶĚ ɴ ?Z ƌĞĐĞƉƚŽƌƐ ŝŶ ƚŚĞ ĂďƐĞŶĐĞ ŽĨ ĂŐŽŶŝƐƚ  ?^ĐŚĞĞƌ Ğƚ Ăů ? ?  ? ? ? ? Z ?
(Ballesteros et al., 2001). Molecular dynamic modelling has also suggested a
ŚŝŐŚůǇ ƐƚĂďůĞ ŝŽŶŝĐ ůŽĐŬ ŝŶ ɴ ?Z  ?'ƌĞĂƐůĞǇ Ğƚ Ăů ? ? ? ? ? ? Z ĂŶĚ A? ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌƐ
(Kolinski and Filipek, 2010). However an intact ionic lock has not been observed in
ĐƌǇƐƚĂůƐƚƌƵĐƚƵƌĞƐŽĨŝŶĂĐƚŝǀĞɴ ?Z ?ŚĞƌĞǌŽǀĞƚĂů ? ? ? ? ? ? Z ?dŚŝƐŵĂǇŚŽǁĞǀĞƌďĞĂ
consequence of the crystallisation process and the addition of large protein
modification (such as nanobodies (Rasmussen et al., 2011a)) to stabilise the
ƐƚƌƵĐƚƵƌĞ ? &Žƌ ƌĞĐĞƉƚŽƌƐ ƐƵĐŚ ĂƐ ɴ ?Z ƚŚĂƚ ŚĂǀĞ ďĞĞŶ ƐŚŽǁŶ ďǇ EDZ
spectroscopy to adopt a variety of intermediate conformations (Nygaard et al.,
2013), crystallisation can only provide a snapshot of the particular conformation
stabilised during crystallisation. Interestingly data from molecular dynamic
ŵŽĚĞůůŝŶŐŚĂƐƐƵŐŐĞƐƚĞĚƚŚĂƚĨŽƌĚǇŶĂŵŝĐƌĞĐĞƉƚŽƌƐ ?ƐƵĐŚĂƐɴ ?Z ?ƚŚĞĨŝĚĞůŝƚǇŽĨ
the ionic lock may also be dynamic (Romo et al., 2010)) or ligand dependent
(Bhattacharya et al., 2008).
1.3.2 The NPxxY motif
The NPxxY motif (Asn-Pro-X-X-Tyr) is found at the junction between TM7 and
helix 8 (Asn7.49 to Tyr7.53) and is highly conserved in Class A GPCRs. The Tyr
residue within this motif interacts with a conserved Phe residue (Phe6.52) in TM6
via its aromatic side chains (Park et al., 2008). Additionally residues in the NPxxY
motif mediate a hydrogen bond network with residues in TM1 and TM2
(Balaraman et al., 2010) and Trp 6.48 in the CWxP motif in TM 6 (see Figure 1.2)
(Bhattacharya et al., 2008).Mutations of the extended NPxxY(x)5,6F motif have also
been shown to effect receptor behaviour beyond activation, such as receptor
expression, sequestration and ligand affinity (Fritze et al., 2003).
1.4 Structural changes in GPCRs upon ligand induced activation
Conformational changes in multiple domains, involving many of the residues
holding the inactive state, are required to disrupt the molecular interactions
typically holding the receptor in its low energy inactive state.
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1.4.1 Movement of transmembrane helices
KďƐĞƌǀĂƚŝŽŶƐĨƌŽŵƚŚĞĐƌǇƐƚĂůƐƚƌƵĐƚƵƌĞƐŽĨŝŶĂĐƚŝǀĞĂŶĚĂĐƚŝǀĞɴ ?ZŚĂǀĞƐŚŽǁŶ
that the largest change in the TM domains upon activation is a 14Å outward
movement of the intracellular ends of TM6 (Rasmussen et al., 2011a).
Additionally there is a smaller movement and helical extension of the cytoplasmic
end of TM5. These movements are driven by ligand binding to the extracellular
regions of these helices pulling them inwards in a rocking motion which
subsequently displaces the intracellular ends. This suggests that local changes
surrounding the ligand binding site translate to far greater movement of the
intracellular domains of the helices (Venkatakrishnan et al., 2013).
Breakage of the DRY motif also facilitates the rotation of TM6 around a conserved
proline (Pro 6.50) that moves it away from TM3 towards TM5 (Dunham and
&ĂƌƌĞŶƐ ?  ? ? ? ? Z ?dŚŝƐƌŽƚĂƚŝŽŶŽĨdD ? ŝƐĂůƐŽŽďƐĞƌǀĞĚĨŽƌɴ ?Z  ?'ŚĂŶŽƵŶŝĞƚĂů ? ?
2001) leading TM5 and 6 to rearrange their side chains by aromatic stacking so
that TM5 interacts with the Trp residue in the CWxP motif of TM6 (Holst et al.,
2010). This rotation of TM6 is also confirmed by solid state NMR, whereby an
inward rotation of the extracellular side of TM6 close to the ligand binding site
occurs, but a substantial outward rotation of the intracellular domain is observed
(Ding et al., 2013). An additional rotation of TM7 around another conserved
proline (Pro 7.50), caused an inward movement of this helix towards TM3 closing
the entrance to the ligand binding site of both A2AĂŶĚɴ ?ƐƚƌƵĐƚƵƌĞƐ  ?:ĂĂŬŽůĂĞƚ
al., 2008), (Cherezov et al., 2007). In rhodopsin, the network of water molecules
forming hydrogen bond interactions in TM2, 3, 6 and 7 are disrupted to allow
rapid toggling to the active state and to reinforce the helical deformation of TM7
 ?WĂůĐǌĞǁƐŬŝ ?  ? ? ? ? Z ?  ůƚŚŽƵŐŚ ƚŚŝƐ ŶĞƚǁŽƌŬ ŝƐ ŶŽƚ ƐĞĞŶ ŝŶ ƚŚĞ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ
crystal structures, this may be due to inadequate resolution (Rasmussen et al.,
2011a).
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Importantly for downstream signalling, movement of helices 3, 5 and 6 sterically
facilitates the binding of effector proteins such as G proteins, by creating a
crevice in the intracellular face of the receptor (Nygaard et al., 2013).
1.4.2 The CWxP transmission switch
The transmission switch, also called the rotamer toggle switch, works in
conjunction with the movements of TM3 and TM6 and breakage of the ionic lock.
The Pro6.50 residue of the CWxP motif in TM6 causes a kink of the intracellular
end of this helix so that it moves outward from TM3 (Bhattacharya et al., 2008)
and towards TM5. This tilted TM6 helix is now stabilised via an interaction with
the Tyr residue of the NPxxY motif in TM7 (Scheerer et al., 2008). The CWxP motif
therefore effectively links conformational changes at the ligand binding site with
movements of TM5 and 6 via the rearrangement of the interface that exists
between TM3, 5 and 6 (Deupi and Standfuss, 2011).
1.4.3 The DRY motif ionic lock
The largest change upon receptor activation, suggested by crystallisation of
rhodopsin, is a 11.4 Angstrom movement outward of the intracellular ends of
TM6 away from TM3, resulting in the breakage of the ionic lock between the
conserved Arg3.50 of TM3 and Glu6.30 of TM6. The ionic lock residues in
rhodopsin compensate for this energy expenditure by forming new stabilising
hydrogen bonds with residues in TM5 (Arg3.50 to Tyr 5.64) and TM6 (Glu6.30 to
Lys5.66). However the importance of the ionic lock in the activation of other
GPCRs remains debatable as crystal structures of active (Rasmussen et al., 2011a)
ĂŶĚ ' ƉƌŽƚĞŝŶ ďŽƵŶĚ  ?ZĂƐŵƵƐƐĞŶ Ğƚ Ăů ? ?  ? ? ? ?ď Z ɴ ?ZĂůů ĐŽŶƚĂŝŶĞĚ ŝŶƚĂĐƚ ŝŽŶŝĐ
locks. However the Arg3.50 residue of this motif is highly conserved across Class
A GPCR sequences, suggesting it may fulfil an additional role. The position of this
residue at the cytoplasmic end of TM3, in conjunction with the movement of TM5
and 6 means this residue is able to directly interact with the carbonyl backbone
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ŽĨƚŚĞƚĞƌŵŝŶƵƐŽĨƚŚĞ'ƉƌŽƚĞŝŶɲƐƵďƵŶŝƚƐĞĞŶŝŶĐƌǇƐƚĂůƐƚƌƵĐƚƵƌĞƐ ?^ĐŚĞĞƌĞƌ
et al., 2008) and solid state NMR (Ding et al., 2013).
1.4.4 NPxxY motif
In the inactive receptor, a hydrophobic barrier of TM2,3 and 6 separates a water
mediated hydrogen bond network within the receptor TM domains from the DRY
motif. The movement of TM6 brought about by receptor activation, breaks the
interaction of the NPxxY motif with helix 8, connecting the hydrogen bond
network with the DRY motif at the cytoplasmic end of TM3 (Fritze et al., 2003),
(Park et al., 2008).
1.4.5 Intracellular loops
The agonist induced movement of TM5 and 6, creates a space on the intracellular
face of the receptor to allow ICL2 and 3 residues to interact with G proteins.
ǀŝĚĞŶĐĞ ĨƌŽŵ ƚŚĞ ĐƌǇƐƚĂů ƐƚƌƵĐƚƵƌĞ ŽĨ ɴ ?Z ?'S complex has suggested that
receptor activation causes a 6Å displacement of the GɲƐƵďƵŶŝƚƚŽǁĂƌĚƐƚŚĞɴ ?Z
C terminal and transmembrane core (Rasmussen et al., 2011b). No changes were
observed for the Gɴɶsubunits. Interaction of receptor ICL2 with the N terminus of
the Gɲsubunit led to substantial changes in the highly conserved G protein P loop
ƚŚĂƚƐƵƌƌŽƵŶĚĞĚƚŚĞɴƉŚŽƐƉŚĂƚĞŽĨ'W ?ƐƵŐŐĞƐƚŝŶŐƚŚĞŬĞǇƐƚĞƉƉƌŽŵŽƚŝŶŐ'W
release (Figure 1.3; see description of the G protein cycle in section 1.5). These
results were also confirmed by peptide amine hydrogen deuterium exchange
mass spectroscopy (Chung et al., 2011) suggesting that these changes in G
protein interaction are not a consequence of the protein modifications required
for crystallisation. Interestingly this study also found evidence for pre coupling of
ŝŶĂĐƚŝǀĞ 'W ďŽƵŶĚ ' ƉƌŽƚĞŝŶƐ ĂŶĚ ƚŚĞ ɴ ?Z ŝŶƚƌĂĐĞůƵůĂƌ ĚŽŵĂŝŶ ? ǁŚŝĐŚ ŵĂǇ
reconcile with the constitutive activity of a fraction of receptors in the absence of
agonist. ICL2 has also been proposed to be important for determining the
selectivity of GPCR-G protein interactions. For the thyrotropin receptor (TSHR) for
example, residues 525-527 of ICL2 drive agonist induced coupling to GɲƐ, but
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residues 528-532 direct GɲƋ coupling (Kosugi et al., 1994). Additionally the
protease activated receptor 1 (PAR1) has been shown to couple to multiple G
protein subtypes Gq/11, Gi/o or G12/13 (see section 1.5.1) However mutagenesis
studies have shown that five key residues within ICL2 direct coupling to the G(q/11)
subtype exclusively (McCoy et al., 2012).
Multiple studies have also implied the importance of ICL3 for G protein coupling.
In rhodopsin, mutation of several hydrophobic residues in this region reduced the
activation rate of the cognate G protein transducin, by 90% (Acharya et al., 1997).
For TSHR, ICL3 in conjunction with the intracellular domain of TM6, has been
shown to directly interact with multiple residues within the G protein structure
(Huang et al., 2005). However to date no clearly defined G protein consensus
motif within ICL3 has been identified. Moreira (2014) has suggested that this may
be a consequence of ICL3 being one of the least conserved regions of Class A
GPCRs meaning that coupling selectivity would be impossible to detect from the
primary structure alone. In addition even closely related GPCR subtypes show
notable discrepancies in the secondary structure adopted by ICL3 (reviewed in
(Moreira, 2014)).
1.5 The G protein cycle
There are two principle classes of G proteins  the small monomeric class which
are comprised of 3 main branches Ras, Raf and Rap which act as GTPases (Cherfils
and Zeghouf, 2013) and the larger heterotrimeric G proteins.
Heterotrimeric G proteins are historically the principle mechanism by which GPCR
activation, through binding of extracellular stimuli, results in the initiation of
intracellular signalling cascades (Oldham and Hamm, 2008). These G proteins are
ĐŽŵƉƌŝƐĞĚ ŽĨ ƚŚƌĞĞ ƐƵďƵŶŝƚƐ ƚĞƌŵĞĚ ɲ ? ɴ ĂŶĚ ɶ  ?&ŝŐƵƌĞ  ? ? ? Z ? /Ŷ ƚŚĞ ŝŶĂĐƚŝǀĞ '
protein these subunits are complexed together as a heterotrimer with Gɲ bound
to guanosine diphosphate (GDP). Following ligand binding, the now activated
GPCR can in turn activate its cognate G protein via the exchange of GDP for
guanosine triphosphate (GTP) at Gɲ. The G protein heterotrimer then dissociates
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into Gɲ-GTP and Gɴɶ subunits, which are able to positively and negatively regulate
downstream effectors, leading to the regulation of second messenger molecules
such as cyclic AMP, cyclic GMP, inositol trisphosphate, diacylglycerol and
intracellular calcium. Cessation of G protein activation comes via the hydrolysis of
GTP for GDP at the Gɲ subunit, facilitated by the intrinsic GTPase activity of Gɲ,
meaning that G protein dependent signalling is self limiting. Amplification is
inbuilt as a single agonist molecule binding to a single receptor is capable of
activating a large pool of G proteins and inducing the production of a cascade of
second messenger molecules, which can lead to pharmacological properties such
as receptor reserve (Chabre and le Maire, 2005).
1.5.1 G protein dependent signalling
There are at least 20 subtypes of GD subunit, which group G proteins into four
main classes  Gs, Gi/o, Gq and G12 (Premont and Gainetdinov, 2007). These
classes are, to a greater or lesser extent, activated selectively by different GPCRs.
ZĞĐĞƉƚŽƌƐ ƚŚĂƚ ƉƌĞĨĞƌĞŶƚŝĂůůǇ ĐŽƵƉůĞ ƚŽ ƚŚĞ 'ɲs ƐƵďƚǇƉĞ ŝŶĐůƵĚĞ ĂĐƚŝǀĂƚĞĚ ɴ ?Z
(Gilman, 1984), which has been implicated in the control of vascular and airway
smooth muscle relaxation, blood vessel dilation and bronchodilation (Johnson,
 ? ? ? ? Z ?'ɲs activation stimulates adenylyl cyclase leading to the production of the
second messenger molecule cyclic AMP (cAMP). cAMP itself activates cAMP
dependent protein kinase (PKA) which phosphorylates cytosolic targets such as
ion channels (Gray et al., 1998), nuclear targets such as the transcription factor
cAMP response element binding protein (CREB), leading to changes in gene
ƚƌĂŶƐĐƌŝƉƚŝŽŶ ?ĂŶĚŝŶƚŚĞĐĂƐĞŽĨƚŚĞɴ ?Z ?ƉƌŽƚĞŝŶƐƚŚĂƚƌĞŐƵůĂƚĞƐŵŽŽƚŚŵƵƐĐůĞ
tone. cAMP can also inhibit the release of Ca2+ ions from intracellular stores and
ŝŶƚŚĞĐĂƐĞŽĨɴ ?ZĂĐƚŝǀĂƚŝŽŶƚŚŝƐĂůƐŽůĞĂĚƐƚŽƚŚĞƌĞůĂǆĂƚŝŽŶŽĨĂŝƌǁĂǇƐŵŽŽƚŚ
muscle (Johnson et al., 2005). The novel cAMP mediators, termed Epac1 and
Epac2 can act alone or in concert with PKA. They are guanine nucleotide
exchange factors for Ras-like small GTPases, which catalyse the exchange of GDP
for GTP and can regulate multiple processes including ion transport, neuronal
responses and ve
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,ŽǁĞǀĞƌ ĞǀŝĚĞŶĐĞ ŝƐ ŶŽǁ ĞŵĞƌŐŝŶŐ ƚŚĂƚ ŝŶƚĞƌŶĂůŝƐĞĚ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ  ?ƐĞĞ
section 1.6.2) can continue to signal within endosomes with a more sustained
profile of cAMP production observed (Vilardaga et al., 2014).
Conversely receptors signalling through the Gi subunit, such as the NPY receptor
family, adenosine A1 and A3ƌĞĐĞƉƚŽƌƐĂŶĚƚŚĞŽƉŝŽŝĚƌĞĐĞƉƚŽƌƐA? ?ɷĂŶĚʃ ?ŝŶĚƵĐĞ
inhibition of adenylyl cyclase and subsequent cAMP production, ultimately
inhibiting protein kinase A activation (Michel et al., 1998). Additionally receptors
of the Neuropeptide Y family have been shown to signal via Gi to activate
inwardly rectifying potassium GIRK ion channels in rat thalamic neurons (Sun et
al., 2001).
The Gq subunits are modulated by receptors including the muscarinic M1,M3 and
M5 leading to activation of phospholipase Cɴ and subsequent production of the
second messengers diacylglycerol (DAG) and inositol trisphosphate (IP3). IP3
released into the cytosol can act on IP3 ligand gated calcium channels located on
the membrane of the endoplasmic reticulum, leading to release of calcium from
intracellular stores (Ferris and Snyder, 1992). DAG chiefly activates protein kinase
C, which can regulate receptor desensitisation. Physiological effects include
vasoconstriction in the circulatory system and contraction of smooth muscle cells
in the digestive and urinary systems via various effectors (Rang, 2003).
The G12/13 subunits regulate actin cytoskeletal rearrangement via Rho guanine
exchange factors (GEFs) activating the small G protein Rho (Wang et al., 2006). An
example of this is the activation of G12/13 via stimulation of the thrombin receptor
results in platelet shape changes (Offermanns et al., 1994).
1.6 Termination of GPCR activation  the classical role of arrestins
The regulation of processes involved in GPCR activation right through to receptor
recycling or degradation allows spatial and temporal control of GPCR signalling.
Regulation can occur at several points in the pathway but here I will focus on
those mechanisms that directly affect GPCRs.
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Cessation of signalling induced by the activation of GPCRs occurs by a process
called desensitisation. Heterologous desensitisation occurs independently of
ligand binding, with phosphorylation of receptor intracellular loop and C terminal
residues by protein kinases A and C (Luttrell and Gesty-Palmer, 2010).
Homologous desensitisation is targeted to ligand activated receptors and is the
ĐůĂƐƐŝĐĂů ĨƵŶĐƚŝŽŶ ŽĨ ƚŚĞ ĂĐĐĞƐƐŽƌǇ ƉƌŽƚĞŝŶ ɴ ?ĂƌƌĞƐƚŝŶ ? <ĞǇ ƐĞƌŝŶĞ ĂŶĚ ƚŚƌĞŽŶŝŶĞ
residues in the receptor C terminus and the third intracellular loop are
phosphorylated by G protein-coupled receptor kinases (GRKs) (Luttrell and
Lefkowitz, 2002), with GRKs showing greater affinity for activated GPCRs
(Premont and Gainetdinov, 2007). GRK phosphorylation alone is not enough to
ĚƌŝǀĞ ƌĞĐĞƉƚŽƌ ĚĞƐĞŶƐŝƚŝƐĂƚŝŽŶ ? ŝƚ ŝŶƐƚĞĂĚ ĐŚŝĞĨůǇŝŶĐƌĞĂƐĞƐ ƚŚĞ ĂĨĨŝŶŝƚǇ ŽĨ ɴ ?
arrestins for receptors (Luttrell and Lefkowitz, 2002). These rapidly translocate
from the cytosol to dock at the receptor phosphorylated residues, sterically
blocking receptor coupling to additional G proteins even in the continued
presence of agonist (Premont and Gainetdinov, 2007), leading to receptor
ĚĞƐĞŶƐŝƚŝƐĂƚŝŽŶ ĂŶĚ ĞŶĚŽĐǇƚŽƐŝƐ ŝŶƚŽ ŝŶƚƌĂĐĞůůƵůĂƌ ǀĞƐŝĐůĞƐ ?  dŚĞ ŝŶƚĞƌĂĐƚŝŽŶ ŽĨɴ ?
ĂƌƌĞƐƚŝŶƐǁŝƚŚ'WZƐǁĂƐĨŝƌƐƚǀŝƐƵĂůŝƐĞĚƵƐŝŶŐ'&WƚĂŐŐĞĚɴ ?ĂƌƌĞƐƚŝŶ ?ƌĞĐƌƵŝƚŵĞŶƚ
ƚŽƚŚĞɴ ?Z ?ĂƌĂŬĞƚĂů ? ? ? ? ? ?ď Z ?ZĞĂůƚŝŵĞŵĞĂƐƵƌĞƐŽĨƚŚŝƐŝŶƚĞƌĂĐƚŝŽŶ ?ĨƵƌƚŚĞƌ
discussed in Chapter 3) have been made using resonance energy transfer
methods, for thyrotropin releasing hormone receptors or vasopressin V2
receptors (Kocan et al., 2008), dopamine D2 (Masri et al., 2008), orexin (OXR2)
(Hasbi et al., 2004) and angiotensin AT1 receptors (Hansen et al., 2004).
Additionally BRET was used to investigate the kinetics of this interaction following
agonist stimulation for the NPY receptor subtypes Y1, Y2, Y4 and Y5 (Berglund et
al., 2003b).
There are 4 subtypes of arrestin - arrestin 1 (visual) and 4 (cone) are
predominantly expressed in visual tissue (Luttrell and Gesty-Palmer, 2010). The
function of arrestins was first identified in rhodopsin, whereby visual arrestin,
alongside rhodopsin targeted GRK1, was shown to be crucial to desensitisation of
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photon activated rhodopsin (Wilden et al., 1986) and steric inhibition of the
specialised G protein transducin (Krupnick et al., 1997b). Lohse et al identified a
molecule analogous to visual arrestin (E-arrestin) that was also involved in the
desensitisation of other activated GPCRs following their phosphorylation by
'Z< ?Ɛ ?ƵƐŝŶŐɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌĂƐĂŵŽĚĞůƐǇƐƚĞŵ ?>ŽŚƐĞĞƚĂů ? ? ? ? ? ? Z ?K^ ? ?ĐĞůůƐ
ƚƌĂŶƐĨĞĐƚĞĚ ǁŝƚŚ ƚŚŝƐ ƉƌŽƚĞŝŶ ŝŶŚŝďŝƚĞĚ ĨƵŶĐƚŝŽŶ ŽĨ 'Z< ƉŚŽƐƉŚŽƌǇůĂƚĞĚ ɴ ? ?
adrenoceptor compared to control cells. This inhibition was 20-40 times more
ĞĨĨĞĐƚŝǀĞ Ăƚ 'Z< ƉŚŽƐƉŚŽƌǇůĂƚĞĚ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ƚŚĂŶ ŶŽŶƉŚŽƐƉŚŽƌǇůĂƚĞĚ
ƌĞĐĞƉƚŽƌƐ  ?>ŽŚƐĞ Ğƚ Ăů ? ?  ? ? ? ? Z ? ^ƵďƐĞƋƵĞŶƚůǇ ɴ ?ĂƌƌĞƐƚŝŶ ?  ?ĂƌƌĞƐƚŝŶ ? Z ĂŶĚ ɴ ?
arrestin2 (arrestin3) isoforms have been identified which are ubiquitously
expressed (Luttrell and Gesty-Palmer, 2010) and share 78% sequence homology
with one another (DeWire et al., 2007) as well as sequence and structural
homology with the two visual arrestins (Kendall and Luttrell, 2009). Observations
ŚĂǀĞƐƵŐŐĞƐƚĞĚƚŚĂƚ'WZƐŵĂǇƐŚŽǁĂďŝĂƐĨŽƌɴ ?ĂƌƌĞƐƚŝŶƐƵďƚǇƉĞ ?ĨŽƌĞǆĂŵƉůĞ
ƚŚĞĂĐƚŝǀĂƚĞĚɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌƉƌĞĨĞƌĞŶƚŝĂůůǇďŝŶĚƐɴ ?ĂƌƌĞƐƚŝŶ ?ŽǀĞƌ ? ?DŽŽƌĞĞƚ
al., 2007). Both subtypes have been implicated in regulating GPCR endocytosis,
ĨŽƌ ĞǆĂŵƉůĞ ƚŚƌŽƵŐŚ ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ůĞĂĚŝŶŐ ƚŽ ŝŶĐƌĞĂƐĞĚ ĂŐŽŶŝƐƚ
ŝŶĚƵĐĞĚ ƐĞƋƵĞƐƚƌĂƚŝŽŶ ŽĨ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĂŶĚ ĐŽŶǀĞƌƐĞůǇ ĞǆƉƌĞƐƐŝŽŶ ŽĨ Ă
ĚŽŵŝŶĂŶƚ ŶĞŐĂƚŝǀĞ ĨŽƌŵ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ŝŶŚŝďŝƚŝŶŐ ƚŚŝƐ ƉƌŽĐĞƐƐ  ?&ĞƌŐƵƐŽŶ Ğƚ Ăů ? ?
1996).
 ? ? ? ? ?dŚĞŵŽůĞĐƵůĂƌŝŶƚĞƌĂĐƚŝŽŶƐĨĂĐŝůŝƚĂƚŝŶŐɴ ?ĂƌƌĞƐƚŝŶďŝŶĚŝŶŐƚŽ'WZƐ
Crystal structures have revealed that E-arrestins show structural similarities with
ŽŶĞĂŶŽƚŚĞƌ ?dŚŝƐĐŽŵŵŽŶĚŽŵĂŝŶƐƚƌƵĐƚƵƌĞŝƐĂůƐŽƐŚĂƌĞĚƚŽĂŶĞǆƚĞŶƚďǇƚŚĞɲ ?
ĂƌƌĞƐƚŝŶ ƉƌŽƚĞŝŶƐ ? ǁŚŝĐŚ ĂƌĞ ĂŶ ĂŶĐĞƐƚƌĂů ƌĞůĂƚŝǀĞŽĨ ɴ ?ĂƌƌĞƐƚŝŶƐ ?  ɲ ?ĂƌƌĞƐƚŝŶƐ ĂƌĞ
involved in intracellular trafficking processes, but their ability to regulate GPCRs
remains largely unclear(Puca and Brou, 2014). This suggests that the shared
motifs are likely to reflect the similar roles of these proteins in intracellular
trafficking (Gurevich and Gurevich, 2013).
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Arrestins are comprised of two concave domains; the N domain (8-180 residues)
ĐŽŵƉƌŝƐĞĚŽĨĂƐŝŶŐůĞɲŚĞůŝǆĂŶĚƚŚĞĚŽŵĂŝŶ ? ? ? ? ? ? ? ?ƌĞƐŝĚƵĞƐ ZŵĂĚĞƵƉŽĨ ?
short helices and an extended C tail connected by a flexible linker (Gurevich and
'ƵƌĞǀŝĐŚ ?  ? ? ? ? Z ? sŝƐƵĂů ĂŶĚ ɴ ?ĂƌƌĞƐƚŝŶƐ ĂƌĞ ĐŽŶƐƚƌĂŝŶĞĚ ŝŶ ƚŚĞ ďĂƐĂů ƐƚĂƚĞ ďǇ Ă
series of intramolecular interactions. The polar core primarily stabilises the
inactive conformation via electrostatic attractions between a series of highly
conserved charged residues Asp27, Arg170, Lys171, Asp292, Asp299 and Arg394
 ?ƌĂƚ ɴ ?ĂƌƌĞƐƚŝŶ  ? Z ƚŚĂƚ ŵĂŬĞ ƵƉ ƚŚĞ ƉŽůĂƌ ĐŽƌĞ  ?yŝĂŽ Ğƚ Ăů ? ?  ? ? ? ? Z ? ůĂŶŝŶĞ
substitution of any of these residues resulted in an arrestin mutant that is able to
bind to unphosphorylated receptor (Vishnivetskiy et al., 2000). Additionally
charge reversal of the Arg170 residue disrupted the delicate balance of the polar
core leading to an arrestin form that is able to bind unphosphorylated active
receptor. These observations suggested that the polar core of arrestin is
responsible for recognising the phosphorylation status of the receptor, and drives
conformational change when it is disrupted on binding negatively charged
phosphorylated receptor residues. This has recently been demonstrated in the
ĐƌǇƐƚĂů ƐƚƌƵĐƚƵƌĞ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ŝŶ ĐŽŵƉůĞǆ ǁŝƚŚ Ăs ? ƌĞĐĞƉƚŽƌ  ƚĂŝů
phosphopeptide (Shukla et al., 2013). An additional feature of inactive arrestin
ƐƚƌƵĐƚƵƌĞŝƐŚǇĚƌŽƉŚŽďŝĐŝŶƚĞƌĂĐƚŝŽŶƐƚŚĂƚŽĐĐƵƌďĞƚǁĞĞŶƚŚĞEƚĞƌŵŝŶĂůɴƐƚƌĂŶĚ
 ? ?ƌĞƐŝĚƵĞƐ ? ? ? ? ? ? ? Z ?ɲŚĞůŝǆ ? ? ? ? ? ? ZĂŶĚƚŚĞůĂƐƚɴƐƚƌĂŶĚ ŽĨ ŚĞƚĞƌŵŝŶƵƐ ? ? ? ? ?
380) (Xiao et al., 2007), (Gurevich and Gurevich, 2004) termed the 3 element
interaction.
The agonist induced activation of GPCRs and the subsequent phosphorylation of
their C terminal domain by GRKs, facilitates arrestin recruitment and engagement
with the intracellular face of the receptor. Arrestin has been shown to exhibit
highest affinity binding for active phosphorylated receptors (Bayburt et al.,
2011),(Vishnivetskiy et al., 2011). For example studies on visual arrestin in vitro
have shown low affinity binding to unphosphorylated active receptors or inactive
phosphorylated receptors, with 20 fold increased binding observed for active
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phosphorylated receptors (Gurevich and Gurevich, 2004). Initial studies involving
 ƚĞƌŵŝŶĂů ƚƌƵŶĐĂƚŝŽŶƐ ŽĨ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ  ?ŽƵǀŝĞƌ Ğƚ Ăů ? ?  ? ? ? ? Z ? ƌĞƐƵůƚĞĚ ŝŶ
receptors with delayed agonist induced desensitisation. The authors postulated
that this was due to the receptor being sensitive to phosphorylation of residues
within this receptor domain by GRKs. Further C terminal truncation studies in
other GPCRs such as complement 5A (Braun et al., 2003), rhodopsin (Kisselev et
al., 2004), prostagladin EP4 (Neuschafer-Rube et al., 2004) have supported this
assertion. Removal of the Y1 receptor C terminal, alongside mutation studies
identified a region within the rat Y1 (Ser352 to Lys360; (Holliday et al., 2005)) and
human Y1 sequences (Met355 to Thr362; (Ouedraogo et al., 2008)) that contains
Ă ƉƵƚĂƚŝǀĞ  RƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ŵŽƚŝĨ ? ƚŚĂƚ ĨĂĐŝůŝƚĂƚĞƐ ĚĞƐĞŶƐŝƚŝƐĂƚŝŽŶ ? ɴ ?ĂƌƌĞƐƚŝŶ ?
ďŝŶĚŝŶŐ ĂŶĚ ƵůƚŝŵĂƚĞůǇ z ? ƌĞĐĞƉƚŽƌ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ? ĚĚŝƚŝŽŶĂůůǇ ƐƚƵĚŝĞƐ ŽĨ ɴ ?
arrestin recruitment to the NPY Y1 receptor have implied that mutation of these
ƐŝƚĞƐ ůĞĚ ƚŽ ƐĞǀĞƌĞůǇ ŝŵƉĂŝƌĞĚ ɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚ  ?<ŝůƉĂƚƌŝĐŬ Ğƚ Ăů ? ?  ? ? ? ? Z ?
Interestingly for both the Y1 receptor and rhodopsin, there does not seem to be a
single magic bullet residue that when phosphorylated drives internalisation,
rather a minimum number of residues must be phosphorylated (Kilpatrick et al.,
2010) (Doan et al., 2006) (Shukla et al., 2013).
KďƐĞƌǀĂƚŝŽŶƐ ĨƌŽŵ ƚŚĞ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ŚĂǀĞ ĂůƐŽ ƐƵŐŐĞƐƚĞĚ ƚŚĂƚ ĚŝĨĨĞƌĞŶƚ 'Z<
subtypes can phosphorylate distinct receptor sites (Nobles et al., 2011). These
phosphorylation barcodes might lead to distinct signalling outcomes, by
ƐƚĂďŝůŝƐŝŶŐ ĚŝĨĨĞƌĞŶƚ ɴ ?ĂƌƌĞƐƚŝŶ ĐŽŶĨŽƌŵĂƚŝŽŶƐ ? ^ŝŵŝůĂƌ ŽďƐĞƌǀĂƚŝŽŶƐ ĨƌŽŵ 'q/11
coupled M3-muscarinic receptors have suggested that phosphorylation profiles
may be tissue/cell specific and might contribute to the differential effects of the
same receptor observed in different tissues (Butcher et al., 2011).
NMR spectroscopy studies have indicated that visual arrestin binding to inactive
phosphorylated rhodopsin results in small movements of the polar core and the 3
element interaction described above (Zhuang et al., 2013). However the arrestin
C tail remains constrained. Binding of visual arrestin to active unphosphorylated
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rhodopsin, resulted in conformational changes of the 3 element interaction alone
resulting in increased local mobility of this region. No changes in the
conformation of the C terminal tail were observed. However in this context,
arrestin is not fully activated, suggesting further global conformational changes
are required. All these observations indicated that arrestin has two independent
sensors recognising the phosphorylation and activation states of the receptor
(Gurevich and Gurevich, 2004), (Nobles et al., 2007) (Zhuang et al., 2013) with
both elements needed for transition of arrestin to the fully active state (discussed
further in Chapter 5).
Binding to active phosphorylated receptors, results in major global
conformational changes in both the N and C domain of arrestin (Zhuang et al.,
2013), (Hanson et al., 2006), (Vishnivetskiy et al., 2011). The elucidation of the
ĐƌǇƐƚĂů ƐƚƌƵĐƚƵƌĞ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ďŽƵŶĚ ƚŽ Ă 'WZ ƚĞƌŵŝŶĂů ƉŚŽƐƉŚŽƉĞƉƚŝĚĞ
(consisting of a B2AR chimera containing the vasopressin V2 receptor C terminus
ǁŚŝĐŚ ƐƚĂďůǇ ŝŶƚĞƌĂĐƚƐ ǁŝƚŚ ɴ ?ĂƌƌĞƐƚŝŶ ĚƵĞ ƚŽ Ă ĐůƵƐƚĞƌ ŽĨ ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ƐŝƚĞƐ Z
has supported many of the previous indications of structural changes inherent to
activation (Shukla et al., 2013). The burying of charged residues in the arrestin
polar core is energetically unfavourable. Phosphate residues attached to the
activated GPCR C terminal tail by GRKs, are guided by lysine residues 10 and 11
to the phosphate sensor of the polar core (Gurevich and Gurevich, 2004) where
upon engagement disrupts the delicate balance of the core. These lysine residues
ĨĂĐĞŽƉƉŽƐŝŶŐĚŝƌĞĐƚŝŽŶƐŽŶƚŚĞɴ ?ƐƚƌĂŶĚ/ ?ƐŽƚŚĂƚǁŚĞŶƚŚĞǇŵŝŐƌĂƚĞƚŚĞǇĚŝƐƌƵƉƚ
the hydrophobic 3 element interactions. This leads to a pronounced movement
of the arrestin C tail (Palczewski et al., 1991), (Hanson et al., 2006), (Vishnivetskiy
et al., 2010), (Zhuang et al., 2013), (Kim et al., 2012) that has also been observed
in crystal structures of receptor bound visual arrestin (Kim et al., 2012) and GPCR
ƉŚŽƐƉŚŽƉĞƉƚŝĚĞďŽƵŶĚɴ ?ĂƌƌĞƐƚŝŶ ? ?^ŚƵŬůĂĞƚĂů ? ? ? ? ? Z ?dŚĞĂƌƌĞƐƚŝŶƚĂŝůŝƐƚŚĞŶ
available to interact with accessory partners such as clathrin and adaptin. In
addition an extensive 20° rotation of the N and C terminal domains relative to
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ŽŶĞĂŶŽƚŚĞƌǁĂƐƐĞĞŶŝŶƚŚĞĂĐƚŝǀĞɴ ?ĂƌƌĞƐƚŝŶ ?ƐƚƌƵĐƚƵƌĞĂŶĚĚƌŝǀĞŶďǇƚŚĞŚŝŶŐĞ
ĚŽŵĂŝŶďĞƚǁĞĞŶƚŚĞEĚŽŵĂŝŶĂŶĚɲŚĞůŝǆ/ ?^ŚƵŬůĂĞƚĂů ? ? ? ? ? ? ZŚĂǀĞƐƵŐŐĞƐƚĞĚ
that this rearrangement may expose large interaction interfaces in the arrestin
structure for binding signalling partners ((Shukla et al., 2013)).
Additional interactions also occur between arrestin residues and regions of the
receptor also implicated in G protein binding. Hydrogen-deuterium exchange
ŵĂƐƐ ƐƉĞĐƚƌŽƐĐŽƉǇ  ?,y ?D^ Z ŚĂƐ ƐƵŐŐĞƐƚĞĚ ƚŚĂƚ ƚŚĞ ĨŝŶŐĞƌ ůŽŽƉ ĚŽŵĂŝŶ ŽĨ ɴ ?
ĂƌƌĞƐƚŝŶ ?ĐĂŶĚŝƌĞĐƚůǇĞŶŐĂŐĞǁŝƚŚĂɴ ?ZĐŚŝŵĞƌĂĐŽŶƚĂŝŶŝŶŐƚŚĞǀĂƐŽƉƌĞƐƐŝŶs ?
receptor C terminus (Shukla et al., 2013). The finger loop is inserted into the
ƐƉĂĐĞďĞƚǁĞĞŶdD ? ? ?ĂŶĚ ?ĐƌĞĂƚĞĚďǇɴ ?ZĂĐƚŝǀĂƚŝŽŶĂŶĚƚŚĞƌĞƐŝĚƵĞ>ǇƐ  ? ?
crosslinks with a fellow lysine reside in ICL3 of the receptor.
ƌƌĞƐƚŝŶ ƌĞƐŝĚƵĞƐ ŝŶ ƚŚĞ E ƚĞƌŵŝŶĂů ĚŽŵĂŝŶ ɴ ƐƚƌĂŶĚƐ s ĂŶĚ s/  ? ? ? ? ? ? Z ĂŶĚ 
ƚĞƌŵŝŶĂůɴƐƚƌĂŶĚƐysĂŶĚys/ ? ? ? ? ? ? ? ? ZŚĂǀĞďĞĞŶŝŵƉůŝĐĂƚĞĚŝŶĚĞƚĞƌŵŝŶŝŶŐƚŚĞ
difference in specificity of visual arrestin or E-arrestin1 binding to GPCRs
(Vishnivetskiy et al., 2011). Of these only 35 residues differ between the two
subtypes, but visual arrestin shows almost exclusive preference for binding
rhodopsin, whereas E-arrestin1 shows more promiscuity for GPCRs. Simultaneous
swapping of these regions switched the receptor binding preference of E-
arrestin1 to that of visual arrestin (Vishnivetskiy et al., 2004). Selective mutation
studies implicated 5 specific N terminal and 9 specific C terminal residues as
being largely responsible for this arrestin-GPCR specificity by directly contacting
the receptor (Vishnivetskiy et al., 2011). BRET measurements showed that
alanine substitution of these residues abolished binding of E-arrestin1 to
ĚŽƉĂŵŝŶĞ ? Žƌ ŵƵƐĐĂƌŝŶŝĐ D ? ƌĞĐĞƉƚŽƌƐ ? ďƵƚ ŽŶůǇ ĚĞĐƌĞĂƐĞĚ ďŝŶĚŝŶŐ ƚŽɴ ?Z ?
This discrepancy suggested that interface between arrestin and GPCR cytosplamic
domains may vary with GPCR.
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&ŝŐƵƌĞ ? ? ? PdŚĞŬĞǇƐƚƌƵĐƚƵƌĂůĞůĞŵĞŶƚƐŽĨɴ ?ĂƌƌĞƐƚŝŶ ŚŽǁŝŶŐƌĞƐŝĚƵĞƐǁŚŝĐŚŵĞĚŝĂƚĞ
GPCR trafficking
 ƌŝďďŽŶ ĚŝĂŐƌĂŵ ŝƐ ƐŚŽǁŶ ŽĨ ƚŚĞ ƐƚƌƵĐƚƵƌĞ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ? ǁŝƚŚ E ĂŶĚ  ĚŽŵĂŝŶƐ
identified alongside the polar core. Motifs implicated in the binding of G protein,
ƉŚŽƐƉŚŽŝŶŽƐŝƚŝĚĞƐ ?ĐůĂƚŚƌŝŶ ?ĂŶĚɴ ?ĂĚĂƉƚŝŶĂƌĞĂůƐŽƐŚŽǁŶ ? Z ?WĂŶĞůƐĂŶĚƐŚŽǁƚŚĞ
 RŝŶĂĐƚŝǀĞ ?  ?ĂƉŽ ?ɴ ?ĂƌƌĞƐƚŝŶ ? Z ĂŶĚ  RĂĐƚŝǀĞ ?  ?ɴ ?Z ?s ?Z ƉŚŽƐƉŚŽƉĞƉƚŝĚĞ ďŽƵŶĚ Z ɴ ?ĂƌƌĞƐƚŝŶ ?
structures. Engagement of the phosphopeptide (shown in blue), disrupts the charge
ďĂůĂŶĐĞŽĨƚŚĞƉŽůĂƌĐŽƌĞĐĞŶƚƌĞĚĂƌŽƵŶĚƌŐ ? ? ? ?ĐĂƵƐŝŶŐĚŝƐƉůĂĐĞŵĞŶƚŽĨƚŚĞɴ ?ĂƌƌĞƐƚŝŶ
C tail and global rearrangement of both N and C terminal domains. The C tail is then free
to bind members of the endocytic machinery.
Figure taken from (Kang et al., 2014).
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1.6.2 The role of arrestins in receptor trafficking
Intracellular trafficking is a homeostatic mechanism by which cells regulate
signalling and functional responses to stimuli through the transit of receptor
proteins between the cell surface and various intracellular vesicular
compartments.. This process is particularly significant for GPCRs due to the wide
range of structurally diverse ligands to which they bind and the diverse
physiological functions they regulate (Hanyaloglu and von Zastrow, 2008).
Typically in response to agonist, receptors are rapidly removed from the cell
surface and internalised into intracellular compartments. This process is termed
ĞŶĚŽĐǇƚŽƐŝƐ ?ĂŶĚĐĂŶƚĂŬĞĚŝƐƚŝŶĐƚĨŽƌŵƐ ?&ŽƌƚŚĞŵĂũŽƌŝƚǇŽĨ'WZƐŝŶĐůƵĚŝŶŐ ?ɴ ? ?
adrenoceptors and the NPY Y receptor family, this process is dependent on the
protein clathrin and E-arrestins (see below 1.6.2.1).
However it should also be noted that clathrin independent endocytosis has been
observed for a range of membrane proteins including but not limited to
ƚƌĂŶƐĨŽƌŵŝŶŐ ŐƌŽǁƚŚ ĨĂĐƚŽƌ ɴ ƌĞĐĞƉƚŽƌƐ ? ĂƵƚŽĐƌŝŶĞ ŵŽƚŝůŝƚǇ ĨĂĐƚŽƌ ƌĞĐĞƉƚŽƌƐ ĂŶĚ
interleukin-2 receptors (reviewed in (Le Roy and Wrana, 2005)). One mechanism
of this is the formation of membrane buds termed caveolae (60-80nm in
diameter) that consist of the cholesterol binding protein caveolin 1 and
glycolipids (Doherty and McMahon, 2009). The GTPase dynamin mediates the
fission of these caveolar vaginations from the plasma membrane into the cell
where they can fuse with endosomes.
dŚĞŝŵƉŽƌƚĂŶĐĞŽĨɴ ?ĂƌƌĞƐƚŝŶƌĞĐƌƵŝƚŵĞŶƚŝŶƌĞĐĞƉƚŽƌĞŶĚŽĐǇƚŽƐŝƐĐĂŶĂůƐŽĚŝĨĨĞƌ
ǁŝƚŚ ƐƵďƚǇƉĞ ? &Žƌ ĞǆĂŵƉůĞ ɴ ?ĂƌƌĞƐƚŝŶ ? ŝƐ ĐƌƵĐŝĂů ƚŽ ƚŚĞ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŽĨ ɴ ? ?
adrenoceptors (Tsao and von Zastrow, 2001). However for PAR1 receptors,
ĂůƚŚŽƵŐŚƚŚĞǇĂƌĞĚĞƉĞŶĚĞŶƚŽŶɴ ?ĂƌƌĞƐƚŝŶĨŽƌĚĞƐĞŶƐŝƚŝƐĂƚŝŽŶ ?ďŽƚŚĐŽŶƐƚŝƚƵƚŝǀĞ
ĂŶĚ ĂŐŽŶŝƐƚ ŝŶĚƵĐĞĚ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŝƐ ŝŶĚĞƉĞŶĚĞŶƚ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ  ?WĂŝŶŐ Ğƚ Ăů ? ?
2002).
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Following endocytosis, receptors are sorted and either recycled back to the cell
surface or degraded in lysosomes. Here I will focus on the mechanism of
ĞŶĚŽĐǇƚŽƐŝƐƚŚĂƚƌĞƋƵŝƌĞƐɴ ?ĂƌƌĞƐƚŝŶƌĞĐƌƵŝƚŵĞŶƚĂŶĚŝƐĐůĂƚŚƌŝŶŵĞĚŝĂƚĞĚ ?
1.6.2.1 Clathrin mediated endocytosis and receptor sorting
Upon activation, the C tail of arrestin is released allowing arrestin to act as a
molecular scaffold for adaptor proteins involved in the internalisation of
ƌĞĐĞƉƚŽƌƐ ? ɴ ?ĂƌƌĞƐƚŝŶ ? ĐĂŶ ŝŶƚĞƌĂĐƚ ĚŝƌĞĐƚůǇ ǁŝƚŚ ĐůĂƚŚƌŝŶ ĂŶĚ ĚŝƌĞĐƚ ƌĞĐĞƉƚŽƌƐ ƚŽ
clathrin coated pits (approximately 100nm in diameter) for their subsequent
endocytosis (Goodman et al., 1996) via the engagement of a clathrin binding
ŵŽƚŝĨ  ?>/& Z ĨŽƵŶĚ ŝŶ ƚŚĞ ɴ ?ĂƌƌĞƐƚŝŶ ?  ƚĂŝů  ?<ĂŶŐ Ğƚ Ăů ? ?  ? ? ? ? Z ? dŚĞ ĞŶĚŽĐǇƚŝĐ
ĂĚĂƉƚĞƌ W ? ? ĂůƐŽ ŝŶƚĞƌĂĐƚƐ ǁŝƚŚ ƚŚĞ ɴ ?ĂƌƌĞƐƚŝŶ ? ?'WZ ĐŽŵƉůĞǆ  ?>ĂƉŽƌƚĞ Ğƚ Ăů ? ?
 ? ? ? ? Z ǀŝĂ Ă  ƚĂŝů ŵŽƚŝĨ  ? ? ? ?ǆǆ&ǆǆ Z ŝŶ ɴ ?ĂƌƌĞƐƚŝŶ ? ƚŚĂ  ŝŶƚĞƌĂĐƚƐ ǁŝƚŚ ƚŚĞ ɴ ?
subunit of AP-2. AP-2 promotes the recruitment of clathrin and the targeting of
receptors to pits composed of a polyhedral lattice of clathrin heavy and light
ĐŚĂŝŶƐ ?&ŝŐƵƌĞ ? ? ? Z ?dŚĞƌĞĐƌƵŝƚŵĞŶƚŽĨW ? ?ŝƐĂŝĚĞĚďǇŝŶƚĞƌĂĐƚŝŽŶŽĨɴ ?ĂƌƌĞƐƚŝŶ ?
with phosphoinositides (IP6) with both high and low affinity binding sites found in
the N and C terminal arrestin domains respectively (Kang et al., 2014) (Figure
1.4).
dŚĞƐĞ ĂĐĐĞƐƐŽƌǇ ƉƌŽƚĞŝŶƐ ďŽƵŶĚ ƚŽ ɴ ?ĂƌƌĞƐƚŝŶ ? ĚƌŝǀĞ ƚŚĞ ƐĞƋƵĞƐƚƌĂƚŝŽŶ ŽĨ
receptors inside the cell via clathrin coated pits (Figure 1.5). These pits enable
receptors to be sequestered into the cell by the small G protein dynamin,
whereupon they enter the endosomal trafficking network (Kendall and Luttrell,
2009). The longevity of the GPCR-arrestin interaction can determine the fate of
the sequestered receptor (Kendall and Luttrell, 2009). Receptors with greater
ĂĨĨŝŶŝƚǇĨŽƌɴ ?ĂƌƌĞƐƚŝŶ ? ?ƐƵĐŚĂƐƚŚĞɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ZƌĂƉŝĚůǇĚŝƐƐŽĐŝĂƚĞĨƌŽŵĞĂĐŚ
other following internalisation, due to arrestin de-ubiquitination (see 1.6.2.2
below) (Wolfe and Trejo, 2007), (Kendall and Luttrell, 2009). They then re-
sensitise and recycle back to the plasma membrane (Kendall and Luttrell, 2009).
dŚŽƐĞ ƌĞĐĞƉƚŽƌƐ ǁŝƚŚ ĞƋƵĂů ĂĨĨŝŶŝƚǇ ĨŽƌ ɴ ?ĂƌƌĞƐƚŝŶ ? ĂŶĚ  ?  ?ƐƵĐŚ ĂƐ ƚŚĞ s ?
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Vasopressin receptor) remain in complex due to the continued presence of
stabilising ubiquitin (Luttrell and Lefkowitz, 2002), (Kendall and Luttrell, 2009),
(Shenoy and Lefkowitz, 2003). Following early endosomal sorting (Moore et al.,
2007), receptors are then slowly recycled or sorted and degraded in lysosomes
(Kendall and Luttrell, 2009). This downregulation decreases the proportion of
receptors at the plasma membrane and is a process allowing longer term
modulation of receptor signal duration and magnitude (Kendall and Luttrell,
2009) (Moore et al., 2007).
1.6.2.2 The role of post translational modifications in trafficking
GPCR trafficking is also regulated by post translational modifications and binding
ƚŽ ŽƚŚĞƌ ƚƌĂĨĨŝĐŬŝŶŐ ƉƌŽƚĞŝŶƐ ? &Žƌ ĞǆĂŵƉůĞ ďŽƚŚ ɴ ?ĂƌƌĞƐƚŝŶ ? ĂŶĚ ɴ ?Z ĂƌĞ
ubiquitinated by the E3 ubiquitin ligase Mdm2 which increases GPCR
internalisation (Shenoy and Lefkowitz, 2003), (Kommaddi and Shenoy, 2013).
DĚŵ ?ďŝŶĚŝŶŐŝƐĂůƐŽĨĂĐŝůŝƚĂƚĞĚďǇƚŚĞďŝŶĚŝŶŐŽĨƚŚĞƐŵĂůůƉƌŽƚĞŝŶƉĂƌŬĞŶƚŽɴ ?
arrestin2 (Ahmed et al., 2011). The covalent attachment of a Small Ubiquitin-like
DŽĚŝĨŝĞƌƉƌŽƚĞŝŶ ?^hDK ZƚŽ>ǇƐ ? ? ?ŝŶƚŚĞɴ ?ĂƌƌĞƐƚŝŶ ?ƚĂŝůŚĂƐĂůƐŽďĞĞŶƐŚŽǁŶ
ƚŽ ŝŶĐƌĞĂƐĞ ɴ ?Z ĞŶĚŽĐǇƚŽƐŝƐ  ?tǇĂƚƚ Ğƚ Ăů ? ?  ? ? ? ? Z ?ĚĚŝƚŝŽŶĂůůǇ ŶŝƚƌŽƐǇůĂƚŝŽŶ Ăƚ
ǇƐ ? ? ? ?ŚĂƐďĞĞŶƐŚŽǁŶƚŽĞŶŚĂŶĐĞƚŚĞ ĂƐƐŽĐŝĂƚŝŽŶŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ?ǁŝƚŚĐůĂƚŚƌŝŶ
heavy chains leading to accelerating the rate of sequestration (Ozawa et al.,
 ? ? ? ? Z ?  ^ŽŵĞ 'WZƐ ƐƵĐŚ ĂƐ ŚƵŵĂŶ ɴ ?Z ? ďŽǀŝŶĞ ƌŚŽĚŽƉƐŝŶ ĂŶĚ ƚŚĞ D ?
muscarinic receptors are also subject to palmitolylation (Escriba et al., 2007)
whereby one or more palmitate molecule is covalently attached to C terminal
receptor cysteine residues. Palmitoylation has been suggested to aid the delivery
of some GPCRs to the plasma membrane. For example mutation of
palmitoylation sites in the follicle stimulating hormone receptor have been shown
to decrease receptor surface expression by 10-30% (Uribe et al., 2008).
Figure 1.5: The molecular machinery in
Agonist binding to its cognate GPCR
activation. G protein coupled recepto
key serine or threonine residues in its
ŽĨɴ ?ĂƌƌĞƐƚŝŶƚŽƚŚĞƌĞĐĞƉƚŽƌ ?ɴ ?arrest
ɴ ?arrestin can then act as a molecular
2. Following sequestration into the ce
ĂƐƐŽĐŝĂƚŝŽŶǁŝƚŚĂƌƌĞƐƚŝŶ ?ůĂƐƐƌĞĐĞƉƚŽƌƐ ?ƐƵĐŚĂƐɴ ?
the plasma membrane. Class B recepto
then slowly recycle or are degraded.
Figure adapted from (Kendall and Lutt
31
volved in GPCR desensitisation and internalisation
leads to conformational changes within the GPCR helical domains
r kinases (GRKs) are recruited to the activated receptor and phosph
C terminal domain. These phosphates can act as docking sites to fa
in desensitises the receptor by sterically hindering further G protein
scaffold for a variety of molecules essential to GPCR in ternalisation
ll the internalised receptor has one of two fates , partly influenced
 ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ?ƌĞĂĚŝůǇĚŝƐƐŽĐŝĂƚĞĨƌŽŵɴ ?ĂƌƌĞstin
rs, such as the V2 vasopressin receptor ?ĨŽƌŵƐƚĂďůĞĐŽŵƉůĞǆĞƐǁŝƚŚɴ
Preferential pathways are shown in bold.
rell, 2009)
that facilitate receptor
orylate the receptor at
cilitate the recruitment
coupling to the GPCR.
such as clathrin and AP-
by the strength of its
and rapidly recycle to
-arrestin which are
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 ? ? ?dŚĞƌŽůĞŽĨɴ ?ĂƌƌĞƐƚŝŶŝŶƐŝŐŶĂůůŝŶŐ
dŚĞ ƌŽůĞ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ŝŶ 'WZ ĚĞƐĞŶƐŝƚŝƐĂƚŝŽŶ ĂŶĚŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŝƐ ŶŽǁ ǁĞůů
ĞƐƚĂďůŝƐŚĞĚ ?,ŽǁĞǀĞƌĞǀŝĚĞŶĐĞŶŽǁƐƵŐŐĞƐƚƐƚŚĂƚɴ ?ĂƌƌĞƐƚŝŶƐƚŚĞŵƐĞůǀĞƐĐĂŶĂůƐŽ
act as signalling components in their own right (Rajagopal et al., 2010) and can
interact with a wide range of signalling partners including but not limited to
protein kinases such as c-Src, p38 and ERK1/2 (Xiao et al., 2007), (Shukla et al.,
2008),(Song et al., 2009), phosphodiesterase (PDE) 4 to accelerate cAMP
degradation (Baillie et al., 2003) and diacylglycerol kinases to assist the quenching
of diacylglycerol dependent signalling (such as PKC) (Nelson et al., 2007).
ɴ ?ĂƌƌĞƐƚŝŶĂĐƚŝǀĂƚĞĚZ<ŚĂƐďĞĞŶƐƵŐŐĞƐƚĞĚƚŽŝŵƉĂĐƚƚƌĂŶƐůĂƚŝŽŶĂůƌĞŐƵůĂƚŝŽŶĂƐ
it is sequestered in the cytoplasm unlike G protein dependently activated ERK
which translocates to the nucleus and activates transcription factors (Gesty-
Palmer et al., 2006), reviewed in (Musnier et al., 2010). This suggests that G
protein dependent and G protein independent activation of ERK can result in
distinct functional outcomes via the stabilisation of different receptor active
conformations or ligand selective states (Shukla et al., 2008). The concept of
biased agonism offers the potential to be able to pharmacologically separate and
direct signalling pathways depending on the ligand used and could represent a
ŶŽǀĞů ƚŚĞƌĂƉĞƵƚŝĐ ĂŐĞŶƚ  ?^ŚƵŬůĂĞƚĂů ? ?  ? ? ? ? Z ?dŚĞƌŽůĞ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ŝŶ ƐŝŐŶĂůůŝŶŐ
has driven the interest in the identification of ligands that selectively bias
signalling towards these G protein independent pathways. For example ligands
ƚŚĂƚ ŚĂǀĞ ŝŶǀĞƌƐĞ ĂŐŽŶŝƐƚ ĂĐƚŝǀŝƚǇ Ăƚ ƚŚĞ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĨŽƌ ĂĚĞŶǇůǇů ĐǇĐůĂƐĞ
activation (ie. inhibit Gs coupling) are capable of activating MAPK (Azzi et al.,
2003) with increased ERK phosphorylation following propranolol stimulation and
// ? ? ? ? ? ? ?hƐŝŶŐĂĚŽŵŝŶĂŶƚŶĞŐĂƚŝǀĞŵƵƚĂŶƚŽĨɴ ?ĂƌƌĞƐƚŝŶĂŶĚŵŽƵƐĞĞŵďƌǇŽŶŝĐ
ĨŝďƌŽďůĂƐƚɴ ?ĂƌƌĞƐƚŝŶŬŶŽĐŬŽƵƚƐ ?ƚŚŝƐƉĂƌƚŝĂůĂĐƚŝǀĂƚŝŽŶŽĨZ<ǁĂƐƐŚŽǁŶƚŽďĞ'ɲ
ŝŶĚĞƉĞŶĚĞŶƚďƵƚɴ ?ĂƌƌĞƐƚŝŶĚĞƉĞŶĚĞŶƚ ?dŚĞĂƵƚŚŽƌƐƉƌŽƉŽƐĞƚŚĂƚƚŚĞƉŚĞŶŽŵĞŶĂ
of G protein independent activation of MAPK occurs when GPCR-G protein
coupling is ablated or inhibited by particular ligands, suggesting that different
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ligands can stabilise different active states of the receptor and bias signalling
ƚŽǁĂƌĚƐ Ă ' ƉƌŽƚĞŝŶ ĚĞƉĞŶĚĞŶƚ Žƌ ŝŶĚĞƉĞŶĚĞŶƚ ƉĂƚŚǁĂǇ ? dŚĞ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ
ligand carvedilol has been shown to bias signalling to G protein independent
ƉĂƚŚǁĂǇƐ ?tŝƐůĞƌĞƚĂů ? ? ? ? ? ? Z ?&ŽƌĞǆĂŵƉůĞ ?ƐƚŝŵƵůĂƚŝŽŶŽĨƚŚĞɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ
with carvedilol led to a distinct receptor phosphorylation profile to that seen for
the unbiased agonist isoprenaline indicative of a differential recruitment of GRK
subtypes (Nobles et al., 2011). The phosphorylation barcode resulting from
ĐĂǀĞĚŝůŽůďŝŶĚŝŶŐƉƌŽŵŽƚĞƐĂĐŽŶĨŽƌŵĂƚŝŽŶŽĨƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ?ƚŚĂƚĨĂǀŽƵƌƐ'
protein independent signalling pathways.
Parathyroid hormone receptor (PTH1R) ligands can activate Gs and also Gq/11, and
ŝŶƚĞƌŶĂůŝƐĞ ŝŶ Ă ɴ ?ĂƌƌĞƐƚŝŶ ĚĞƉĞŶĚĞŶƚ ŵĂŶŶĞƌ ? WĂƌĂƚŚǇƌŽŝĚ ŚŽƌŵŽŶĞ ƐƚŝŵƵůĂƚŝŽŶ
induces MAPK activation with a rapid G protein dependent phase followed by a
prolonged G protein independent phase (Gesty-Palmer et al., 2006). RNA
silencing and the use of G protein inhibitors showed that this prolonged MAPK
ĂĐƚŝǀĂƚŝŽŶ ǁĂƐ ɴ ?ĂƌƌĞƐƚŝŶ ĚĞƉĞŶĚĞŶƚ ĂŶĚ ǁŚŽůůǇ ĚŝƐƚŝŶĐƚ ĨƌŽŵ ' ƉƌŽƚĞŝŶ
involvement. Biased agonism was also observed at the PTH1R, as the inverse
agonist for Gs and Gq, PTH-1A, can still stimulate prolonged MAPK activity in
,< ? ? ?ĐĞůůƐĂŐĂŝŶĐŽŶĨŝƌŵĞĚďǇZEƐŝůĞŶĐŝŶŐƚŽďĞɴ ?ĂƌƌĞƐƚŝŶĚĞƉĞŶĚĞŶƚ ?
The impact of biased agonism, therefore requires greater elucidation to tease out
potential effects of signalling crosstalk, however it does provide the potential to
improve therapeutic selectivity. For example the angiotensin II receptor ligand
TRV027 has been shown in vitro ƚŽƐĞůĞĐƚŝǀĞůǇďŝĂƐƐŝŐŶĂůůŝŶŐ ƚŽǁĂƌĚƐɴ ?ĂƌƌĞƐƚŝŶ
dependent pathways (Violin et al., 2010). This bias was translated to early clinical
studies in humans where TRV027 treatment was shown to have cardioprotective
effects in both healthy volunteers and those suffering from systolic heart failure
which was selective for the renin-angiotensin system (Violin et al., 2014). TRV027
is currently in phase IIb clinical trials in acute heart failure.
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1.8 The NPY Y receptor family
1.8.1 Peptide ligands
The endogenous ligands of the NPY receptors are neuropeptide Y (NPY), peptide
YY (PYY) and pancreatic polypeptide (PP). They are all 36 amino acid peptides
with an amidated C terminal tyrosine (Figure 1.6A; (Babilon et al., 2013).
Although PYY and PP only share 70% and 50% sequence homology with NPY
(Cerda-Reverter and Larhammar, 2000) they have been proposed to share a
common defined U shaped tertiary structure comprising of an extended N
ƚĞƌŵŝŶĂů ƉŽůǇƉƌŽůŝŶĞ ŚĞůŝǆ ĨŽůůŽǁĞĚ ďǇ Ă ĂŵƉŚŝƉĂƚŚŝĐ ɲ ŚĞůŝǆ ? ĐŽŶŶĞĐƚĞĚ ďǇ Ă ɴ
turn (Michel et al., 1998). This structure has been derived from the crystal
structure of avian PP resolved in 1981 (Blundell et al., 1981). An alternative
structure has also been proposed based on the nuclear magnetic resonance
(NMR) structure of human NPY in the presence of membrane mimicking micelles
(composed of dodecylphosphocholine) (Bader et al., 2001). This structure also
contains the alpha helical regions as before, but the N terminus shows greater
flexibility and lacks the U shaped fold. The authors propose that this model may
more likely reflect the physiological status of NPY and other related peptides.
NPY is the most abundant neuropeptide in the brain, with greatest expression
found in the hypothalamus (Bai et al., 1985) where it is primarily produced in the
arcuate nucleus (Morris, 1989) (Fetissov et al., 2004). NPY is also expressed in the
periphery as a co-transmitter in postganglionic sympathetic neurones and the
adrenal medulla, with circulating human plasma levels estimated to be 5-
19pmol/L (Onuoha et al., 2000). Additionally NPY and noradrenaline are co-
released from central catecholamine neurons during nerve stimulation (Illes and
Regenold, 1990).
In contrast to NPY, peptide YY (PYY) and pancreatic polypeptide (PP) are both
hormones, with PYY released from endocrine L cells most widespread in the distal
ileum and colon, but present throughout the gastrointestinal tract (Ekblad and
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Sundler, 2002). PP is exclusively expressed by pancreatic F type cells (Adrian et
al., 1978). Both NPY and PYY can be cleaved by endogenous dipeptidyl peptidase
IV in the periphery to generate the truncated forms NPY3-36 and PYY3-36 (Borowsky
et al., 1998).
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1.8.2 NPY Y receptor family
The NPY Y receptor subtypes are Class A GPCRs, withFour functional subtypes in
man termed the Y1,Y2,Y4 and Y5 (Michel et al., 1998). A further subtype, the y6,
has been identified but is a truncated form that is not expressed in primates
(Rose et al., 1997). Structural domains are relatively consistent between
subtypes, with the exception of the Y5 subtype which has a short C terminal
domain and a larger ICL3. All 5 receptor subtypes couple to Gi/o proteins, and are
capable of binding to a similar array of ligands. However subtypes differ in their
endogenous and synthetic ligand selectivity, which is likely a reflection of the
relatively low sequence homology of 27-32% (Michel et al., 1998, Sjodin et al.,
2006).
1.8.2.1 Y1 receptor
The Y1 receptor is expressed in a wide range of species, with more than 92%
sequence homology observed for human, rat, pig, guinea pig, mouse and cattle
(Michel et al., 1998) (see Figure 1.7). The Y1 subtype shows a wide distribution
throughout the body, but the greatest concentrations are found within regions of
the hypothalamus, namely the arcuate nucleus, paraventricular and dorsomedial
nuclei (Fetissov et al., 2004). Y1 receptors are also expressed in vascular smooth
muscle cells, adipose tissue, kidney and the gastrointestinal tract (Michel et al.,
1998). Y1 receptors are able to bind both NPY and PYY with high affinity (Cabrele
and Beck-Sickinger, 2000), but show reduced affinity for PP (Gehlert and
Gackenheimer, 1997). This subtype is also able to bind the NPY analogue Leu31,
Pro34 NPY (Fuhlendorff et al., 1990) with high affinity
BIBO3304 is a highly selective Y1 antagonist exhibiting 2600 fold selectivity over
Y2, Y4 and Y5 receptors (Wieland et al., 1998). The closely related non peptide
antagonist BIBP3326 also shows high selectivity for the Y1 subtype over other Y
receptors but also shows relatively high affinity binding (Ki 79nM) for
neuropeptide FF receptors (Mollereau et al., 2001). The dimeric C terminal NPY
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analogue GR231118 has also been suggested to be a highly potent antagonist at
the Y1 receptor (Ishihara et al., 1998), however it is worth noting that this was
when compared to selectivity at the Y2 subtype. Additionally GR231118 has been
shown to be a potent agonist at human Y4 (Parker et al., 1998) and to a lesser
extent rat Y5 and Y2 receptors as well showing affinity for neuropeptide FF
receptors (Mollereau et al., 2001). Caution should therefore be taken when
assuming the selectivity of these antagonists in assays where multiple subtypes
may be present.
Figure 1.7: The rat Y1 receptor sequence
A snake plot showing the structure of the rat Y1 receptor. Amino acids are numbered
according to cDNA sequence. The presence of a disulphide bridge between TM3 and
ECL2 is predicted residues Cys112 to Cys197) in addition to receptor palmitoylation at
Cys337.
Figure courtesy of Dr Nick Holliday.
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1.8.2.2 Y2 receptor
The Y2 receptor subtype is predominantly expressed in the central nervous
system, particularly within the arcuate nucleus of the hypothalamus (Dumont et
al., 1998), whereby their activation at presynaptic junctions can inhibit the
release of the neurotransmitters NPY and glutamate (Klapstein and Colmers,
1993). The Y2 receptor is also expressed in spleen, liver, blood vessels, white and
brown adipose tissue and the gastrointestinal tract (Michel et al., 1998).
The Y2 receptor shows similar affinities for NPY and PYY and lower affinity for PP
(Michel et al., 1998). However unlike the Y1 receptor, the Y2 receptor is also
capable of binding the truncated forms NPY3-36 and PYY3-36 with high affinity
(Keire et al., 2000) and has low affinity for Leu31, Pro34 NPY (Gerald et al., 1995).
1.8.2.3 NPY Y4
Expression of the Y4 receptor subtype is largely localised to the gastrointestinal
tract, but has also been documented in the hippocampus and hypothalamus
(Dumont et al., 1998), (Lindner et al., 2008). Like the Y2 receptor, the Y4 subtype
has been suggested to mediate the satiety effects of PP and perhaps also PYY
(Sainsbury et al., 2003). The Y4 receptor is a PP-selective receptor, binding PP
with high affinity (Gehlert et al., 1997) (Tough et al., 2006) and showed reduced
affinity for NPY and PYY and Leu31, Pro34 NPY (Gehlert et al., 1996b). The NPY C
terminal analogue GR231118 has also been shown to be a potent agonist at
human Y4 receptors (Parker et al., 1998).
1.8.2.4 NPY Y5
The highest expression for the Y5 subtype is seen in the brain, specifically the
hippocampus and hypothalamus (Parker and Herzog, 1999). Both the mRNA and
protein expression of the Y5 receptor overlaps with that of the Y1 receptor in
these regions of rat brains (Parker and Herzog, 1999) with immunohistochemistry
further confirming distinct receptor co-expression within the same cells and
nerve fibres of this brain region (Wolak et al., 2003). Additionally both receptors
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are located on chromosome 4q31-q32, and share an overlapping gene structure
(Nguyen et al., 2012).
dŚĞƌĂŶŬŽƌĚĞƌŽĨƉŽƚĞŶĐǇŽĨz ?ƌĞĐĞƉƚŽƌƐĨŽƌĞŶĚŽŐĞŶŽƵƐůŝŐĂŶĚƐŝƐEWzA?WzzA?WW
(Michel et al., 1998). However this subtype is relatively non-selective, and is
capable of responding to both NPY3-36 and PYY3-36 (Gerald et al., 1996) and also
[Leu31,Pro34] NPY (Balasubramaniam, 1997), analogues traditionally used to
define Y1 versus Y2 receptor pharmacology. However synthetic ligands have also
been created that selectively target the Y5 subtype with high affinity, in
comparison to other Y receptors such as the agonists cPP(1-17)(Ala31,Aib32) (17-
36) NPY (Dumont et al., 2003) and DTrp32NPY (Balasubramaniam et al., 1994) and
antagonists such as CGP71683 (Criscione et al., 1998), NPY5RA972 (Block et al.,
2002) and L152,804 (Kanatani et al., 2000) (see chapter 6).
1.8.3 Peptide binding to NPY receptor subtypes
The Y1, Y2 and Y5 subtypes differ the most in sequence homology, but yet share
high affinity binding to the same ligand NPY, suggesting that the small proportion
of conserved residues are important to ligand binding (Sjodin et al., 2006). All 3
subtypes have been shown to interact with the amidated C terminal domain of
NPY and PYY, but differ in their interaction with the N terminus. The Y1 subtype
requires a complete N terminal domain of NPY (Larhammar et al., 1992) reflected
in its lack of affinity for the N terminal truncated forms NPY3-36 and PYY3-36.
However the Y2 and Y5 receptor subtypes have equal affinity for NPY, PYY and
NPY3-36 and PYY3-36, suggesting the N terminal portion of the peptide is not as
crucial.
Ligand binding to NPY receptor subtypes has been suggested to occur within the
transmembrane helical bundle and also involve extracellular loop residues.
Extensive mutagenesis of the human Y1 receptor was used to characterise
residues important to binding both peptide agonists and non peptide antagonists
(Kannoa et al., 2001, Sjodin et al., 2006). Mutation of the highly conserved Tyr100
to alanine led to a complete loss of NPY binding (Kannoa et al., 2001, Sautel et al.,
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1995). This residue is a tyrosine or serine in the Y2 and Y5 receptors respectively,
and the hydroxyl group both thes amino acids contain has been proposed to
interact with the amidated C terminus of the peptide ligand directly (Sjodin et al.,
2006). The TM6 residues F286 and His298 have also been implicated in ligand
binding (Kannoa et al., 2001). Mutation of the Y1 receptor specific residue
Asn116 (TM3) has also been shown to produce a 35 fold decrease in binding of
the Y1 selective antagonist SR120819A (Sjodin et al., 2006). Asp286 at the
interface of TM6 and ECL3 of Y1 and Y4 receptors has also been shown to form a
salt bridge with Arg35 of NPY and PP (Merten et al., 2007). This residue in Y2 and
Y5 receptors is also conserved but instead interacts with Arg33 of the peptide,
and requires an additional interaction of Asp199 in ECL2 to Arg25 of the peptide
for high affinity binding (Lindner et al., 2008). This suggests that some residues
have a shared importance for ligand binding across the subtypes, but subtype
specific residues are also involved. Babilon et al. (2013) have suggested that the
Y1 and Y4 subtypes may have distinct ligand binding modes to that seen for the
Y2 and Y5 subtypes based on these mutation studies and may reflect the closer
sequence homology of this receptor pairing (Babilon et al., 2013).
1.8.4 Physiological implication of NPYergic peptide signalling
The NPY receptor subtypes have been implicated in a range of physiological
processes such as feeding responses, energy expenditure, anxiolysis, nociception,
circadian rhythms, bone metabolism, inflammation, and cognitive impairment
(reviewed in (Holzer et al., 2012)). NPY can also act in conjunction with
noradrenaline in perivascular sympathetic neurons to promote vasoconstriction
(Wahlestedt et al., 1990b). In addition, aberrations in receptor expression have
also been seen in cancer. Overexpression of NPY receptor subtypes have been
implicated in ERK signalling driven proliferation and migration of a variety of
tumours, with overexpression of Y1 and Y2 receptors seen in human breast
carcinomas, and glioblastomas respectively and Y5 receptors in a range of cancer
cell lines (Sheriff et al., 2010). Both Y1 and Y5 subtypes have also been shown to
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mediate NPY effects on stimulating vascular endothelial growth factor secretion
from endothelial cells and subsequent angiogenesis in breast cancer cell lines
(Medeiros and Jackson, 2013).
However the physiological role of the NPY receptor subtypes that has historically
attracted the most pharmacological interest is their control of appetite, (Zhang et
al., 2011) - specifically the regulation of centrally mediated food intake and
satiety, and processes such as lipid metabolism, and insulin secretion.
The arcuate nucleus, a major hypothalamic centre for appetite regulation, is
responsible for innervating the majority of the hypothalamus, with chemical and
neuronal signals generated in the periphery also integrated here. As well as
expressing all 4 of the functional NPY receptor subtypes, (Dumont et al., 1998),
the arcuate nucleus also expresses receptors for the orexigenic hormone ghrelin
(Willesen et al., 1999), the satiety adipose hormone leptin (Elmquist et al., 1998)
and insulin (Marks et al., 1990). NPY release from arcuate neurons can be
temporally controlled by these receptors depending on the energy expenditure
balance, with insulin and leptin able to inhibit NPY secretion and ghrelin stimulate
it (Zhang et al., 2011). NPY is a potent stimulator of hyperphagia, with its release
correlated with food intake in rodents (Clark et al., 1984), (Kalra et al., 1991) in a
circadian fashion (Akabayashi et al., 1994). Direct injection of NPY into
hypothalamic regions of rats results in a dose dependent increase in food intake
(Stanley and Leibowitz, 1985), (Stanley et al., 1986), (Leibowitz et al., 1988),
(Zarjevski et al., 1993). Through both its central actions and peripheral
sympathetic nerve release, increased NPY signalling is also implicated in other
processes of energy homeostasis which result in weight gain and increased fat
storage, such as hyperinsulinemia, insulin hyper responsiveness, insulin
resistance in skeletal muscle, increased de novo lipogenesis in white adipose
tissue and suppressed thermogenesis in brown adipose tissue (reviewed in
(Zhang et al., 2011)). Therefore increased NPYergic tone has been implicated as
one of the signalling pathways in the development and persistence of obesity.
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Elevation in circulating NPY levels have been observed in obese women
(Baranowska et al., 2005) when compared to healthy women. Obese rats fed a
high fat diet for 22 weeks have increased mRNA expression of NPY in the
hypothalamus (Huang et al., 2003). Similar increases have also been seen for
obese rats with defective leptin signalling (Stephens and Caro, 1998) in keeping
with the inhibitory role of leptin on NPY secretion previously documented.
Both PYY and PP have been shown to be secreted following food ingestion and
act in the periphery as satiety factors. Once secreted, PYY is cleaved to its
predominant form PYY3-36, allowing selective binding to Y2 receptors and to a
lesser extent Y5 (Holzer et al., 2012). PYY and PYY3-36 binding to Y2 receptors in
the enteric nervous system have been shown to inhibit colonic transit in mice
(Wang et al., 2010). PYY and PYY3-36, together with co-released peptides from
ileal and colonic cells, such as GLP-1, inhibit gastric acid secretion and mediate
the ileal brake that slows gastric emptying in response to food entering the
small intestine (Field et al., 2010). PP can also inhibit gastric emptying via the
vagus nerve (Field et al., 2010) , peristalsis (Fujimiya and Inui, 2000) and
intestinal electrolyte and water secretion via binding to Y4 receptors expressed
on the intestinal epithelium (Tough et al., 2006).
Therefore the control of central feeding responses is a delicate balance between
the brain-gut axis involving multiple signalling inputs that can have both
synergistic and opposing physiological effects. which are partly mediated by the Y
family of receptors.
1.8.4.1 Y1 and Y5 receptor roles in stimulating food intake
Interestingly Y receptor subtypes can be grouped based on their roles in feeding
responses. The Y1 and Y5 subtypes mediate NPY induced orexigenic responses,
with both originally identified as feeding receptors (Haynes et al., 1998).
Significantly reduced mRNA expression levels of Y1 and Y5 receptors in the
hypothalamus have been observed for rodents that are resistant to diet induced
obesity (compared to control obese animals)(Huang et al., 2003) suggesting the
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role of both receptors in obesity development. Direct administration of NPY into
the hypothalamus of Y1 receptor knock out mice led to decreases in feeding
responses. However germline knock out models of the Y1 receptor in mice
surprisingly do not show substantial changes in spontaneous feeding (Kushi et al.,
1998), (Howell et al., 2003) but more subtle reductions in hyperphagia compared
to wildtype controls (Pedrazzini et al., 1998).
However paradoxically, Y1 receptor germline knock outs developed late onset
obesity suggested to be due to decreased metabolic rate. This was also
associated with hyperinsulinemia with increased circulating insulin suggested to
increase adipose tissue glucose storage (Kushi et al., 1998). Similar development
of late onset obesity have also been seen Y5 receptor knock out mice (Marsh et
al., 1998), (Higuchi et al., 2008), suggesting they may be a degree of
compensation between the Y1 and Y5 subtypes in respect to feeding responses
(Nguyen et al., 2012). However significant reductions in feeding were seen in Y1
receptor deficient ob/ob mice (Pralong et al., 2002) in addition to a significant
decrease in body weight, suggesting that deficiency in Y1 receptor mediated
effects is more pronounced in physiological conditions of high NPY
concentrations.
The intravenous administration of a range of Y1 receptor agonists in rats, such as
[DArg25]NPY, stimulates increased food intake (Mullins et al., 2001). Prolonged
stimulation led to significant increases in body weight and fat gain (Mullins et al.,
2001), increased lipogenesis (Henry et al., 2005), and circulating insulin levels
(Gao et al., 2004). Similar effects have also been observed when using Y5
receptor selective agonists such as [Ala31, Aib34] NPY which were able to
significantly increase feeding behaviour in rats (Cabrele et al., 2000). The Y5
receptor chimeric agonist 2-36 [K4,RYYSA19-23]PP (McCrea et al., 2000) also was
able to dramatically increase food intake in a rat model.
Therefore activation of both Y1 and Y5 receptor subtypes has both been
implicated in the stimulation of food intake in vivo. Potential compensatory
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effects between these two subtypes have been proposed instead to be due to
coregulation of feeding responses. In support of this concurrent germline and
hypothalamic knock out of both Y1 and Y5 receptors in mice, resulted in
decreased spontaneous and fast induced food intake when fed a high fat diet
suggesting a coordination between these subtypes (Nguyen et al., 2012). This
coordination has also been suggested to be via the Y1 and Y5 receptors forming
heterodimers that are able to modulate one another (Gehlert et al., 2007) and
result in altered pharmacology compared to either receptor acting alone (see
Chapter 6).
1.8.4.2 Y2 and Y4 receptor roles in satiety
Conversely the activation of Y2 and Y4 receptor subtypes has been implicated in
the induction of satiety. Gut derived peptides such as PYY and PP, are satiety
signals that can trigger the termination of feeding via binding to both receptor
subtype (Batterham et al., 2003b, Batterham et al., 2002). Therefore agonist
therapies that target either subtype were attractive targets for anti obesity
treatments (see section 1.8.6.2).
Mice models with germline knock out of Y2 receptors show increased food intake
(Naveilhan et al., 1999), (Sainsbury et al., 2002). Knock out studies have shown
discrepancies in respect to effects on body weight, with both increases
(Naveilhan et al., 1999) and no changes observed (Sainsbury et al., 2002) but is
likely due to either differences in the mice model used, experimental stress
affecting typical mice feeding behaviour or differential effects seen in the central
or periphery (Zhang et al., 2011). For example, hypothalamic deletion in adult
mice has resulted in significant increases in food intake, weight gain and fat
deposition (Shi et al., 2010). This group also showed by deleting Y2 receptors only
expressed on NPYergic neurons, that the Y2 receptors can regulate NPY
expression in an autocrine manner in the arcuate nucleus (Shi et al., 2010).
Knock out studies of the ligand PYY, resulted in mice developing an obese
phenotype with (Batterham et al., 2006) or without any significant change in
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feeding (Wortley et al., 2007). Another study suggested that PYY knock out may
result in hyperinsulinemia (Boey et al., 2006) similar to effects after Y1 receptor
ideletion. Conversely, overexpression of PYY in mice models leads to marked
inhibition of diet induced obesity (Boey et al., 2006). Crossing this line with an
ob/ob line can rescue the obese phenotype with significant reductions on weight
gain, adiposity and improved glucose tolerance observed. These in vivo models
therefore suggest that PYY and PYY derivatives play a substantial role in the
control of feeding responses via activation of the Y2 receptor.
Although Y4 receptors are expressed in the brain regions implicated in appetite
regulation, its primary endogenous agonist, PP is exclusively expressed in the
pancreas and is released prior to PYY via vagal cholinergic mechanisms (Schwartz
et al., 1978). The extent of PP release is in proportion to the calorific load, leading
to inhibition of exocrine function, stimulation of gastric motility and gastric
secretion (Zhang et al., 2011). However Zhang et al., 2011, have suggested that
many of the anorexigenic effects in the CNS attributed to PP are actually due to
binding of NPY to the Y4 subtype (Zhang et al., 2011) , although this seems
unlikely based on the reduced affinity of the Y4 receptor for NPY (Chapter 3,
Figure 3.9) (Gehlert et al., 1997).
Germline deletion of Y4 receptors in mice resulted in a lean phenotype with
reduction in body weight and adiposity but no change in food intake (Sainsbury et
al., 2003). The authors suggest reduction in body weight is driven by changes in
energy expenditure and metabolic rate. A synergistic effect on reduced adiposity
and increased energy expenditure was observed when both the Y4 and Y2
receptors were ablated (Zhang et al., 2010). Therefore as for the Y1-Y5 receptors
in respect to orexigenic effects, coregulation between Y2 and Y4 receptors may
be involved in anorexigenic effects.
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1.8.5 Obesity the health and socioeconomic implications
As of 2013, it was estimated that 61.9% of adults and 28% of children aged 2-15
in the UK are overweight or obese 2. Obesity rates have also vastly increased
globally over the past three decades (Finucane et al., 2011) with suggestions that
prevalence is correlated to socioeconomic state. Obesity is typically defined by
an individual having a body mass index (BMI) in excess of 30 kg/m2, compared to
18.5-25 kg/m2 for a healthy individual (Mitchell et al., 2011). Measurements of
waist circumference are also used to evaluate individual health risks. Medical
complications associated with obesity cost the NHS more than £5 billion pounds
each year and include higher incidences and morbidity rates of coronary heart
disease, hypertension, type 2 diabetes, cognitive dysfunction, sleep apnea, non
alcoholic liver disease and many forms of cancer including thyroid, colorectal,
renal, pancreatic, oesophageal, ovarian and breast (reviewed in (Mitchell et al.,
2011)).
A gap exists in the market for pharmacotherapies targeting obesity, as social
drives by governments and health officials in promoting healthier lifestyles and
exercise have been largely unsuccessful. Diet and exercise programmes are also
often ineffective for maintaining long term weight loss. Surgical intervention in
the form of bariatic surgery is not only costly (private health care estimates range
from £5000-£15,000) but carries a high risk of internal bleeding, thrombosis and
pulmonary embolism 3 with mortality rates in the USA estimated at 1:1000
patients. Additionally the NHS will only consider patients with a BMI in excess of
35 as eligible.
In order to obtain food and drug administration (FDA) approval in the USA, drug
treatments in phase trials must show a sustained weight loss of approximately 5%
of total body weight, which could significantly improve the quality of life for
2 https://www.gov.uk/government/policies/reducing-obesity-and-improving-diet authored by the
Department of Health and Jane Ellison MP, March 25th 2013. Accessed 01-09-2014.
3 http://www.nhs.uk/conditions/weight-loss-surgery/Pages/Introduction.aspx; page last
reviewed 05-11-2013. Accessed 01-09-2014.
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obese individuals. However as obese individuals are likely to require these
therapies chronically, their safety profiles must be beyond dispute. Currently the
majority of anti obesity agents have been withdrawn from market due to a lack of
efficacy or concerns over safety. Only orlistat, a pancreatic lipase inhibitor, is
currently approved for long term use, however many patients cannot tolerate its
gastrointestinal side effects. The noradrenaline and dopamine stimulators
diethylpropion and benzphetamine have been approved for short term use (12
weeks) in the USA, but there are concerns over potential drug abuse in longer
term use (Cheung et al., 2013). Sibutramine, a noradrenaline/5-HT reuptake
blocker was withdrawn from the market in 2010 due to major cardiovascular
effects (Cheung et al., 2013). Rimonabant, a cannabinoid 1 receptor antagonist
was also withdrawn worldwide due to significant psychiatric side effects such as
suicide. As of June 2014, the FDA had postponed the approval of the combined
therapy Contrave following phase III trials, due to worries over long term
cardiovascular risks. Therefore there is a large currently unmet demand for anti
obesity therapies that are effective and safe.
1.8.6 Targeting the NPY receptor subtypes in anti obesity therapies
1.8.6.1 The Y1 and Y5 subytpes
The primary aim of many pharmacotherapies to treat obesity was in inducing
reductions in food intake. Historically, the first focus on anti-obesity agents
targeted at Y receptors was on inhibiting NPY orexigenic effects modulated
through the Y1 and Y5 receptors, by the use of highly subtype selective
antagonists. A number of Y1 receptor selective antagonists have been developed,
which bind with high affinity. Direct injection of BIBO3304 or 1229U91 into the
paraventricular nucleus of lean or obese rats inhibited NPY induced hyperphagia
(Kanatani et al., 1996). However the therapeutic use of these Y1 receptor
antagonists in the clinic was limited due to their poor bioavailability in both oral
and peripheral administration (Kanatani et al., 2001) restricting their use to
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pharmacological research. An orally active compound J-104870 when
administered via the intracerebroventricular and intraperitoneal route was able
to inhibit hypothalamic NPY induced food intake in Zucker fatty rats (Kanatani et
al., 1999) leading to significant reduction in weight gain and lipid accumulation in
the liver (Ishihara et al., 2002). A similar antagonist, J-115814 also showed similar
effects on NPY induced feeding (Kanatani et al., 2001), however its therapeutic
use has been limited due to cardiovascular toxicity (Fermini and Fossa, 2003).
A range of Y5 selective antagonists have also been developed that have shown
high selectivity and the ability to inhibit NPY and/or Y5 agonist induced
hyperphagia in rats. Of these CGP71683A showed high efficacy in both acute and
chronic administration, however it also showed cross reactivity with muscarinic
and serotonin 5-HT receptors raising the potential for physiological side effects
(Criscione et al., 1998). Additionally GW438014A showed high efficacy, but poor
oral bioavailability (Daniels et al., 2002). MK-0557 showed promise in mice
studies with chronic administration suppressing high fat diet and DTrp32NPY
induced obesity in mice (Erondu et al., 2006). However this efficacy did not
translate to human clinical trials, where a 1 year trial with MK-0557 treatment
induced no meaningful clinical weight loss. Clinical trials with Velneperit (S-2367)
in 656 patients also showed limited human efficacy with no clinically significant
weight loss observed compared to placebo (George et al., 2014). Therefore both
Y1 and Y5 selective antagonists showed promise as inhibitors of agonist induced
hyperphagia in rodent studies, but translating this to human trials has so far been
unsuccessful. The potential coregulation of Y1 and Y5 receptors in the control of
central feeding responses in rats (Nguyen et al., 2012) suggests pharmacological
targeting of both subtypes simultaneously, may provide a therapeutic alternative
(discussed further in chapter 6).
1.8.6.2 The Y2 and Y4 subtypes
The roles of Y2 and Y4 receptors in satiety, also suggest that agonists targeting
either subtype may have therapeutic potential in treating obesity. Administration
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of PYY3-36 in rats, mice and humans (Batterham et al., 2002), (Batterham et al.,
2003a) reduced food intake and/or body weight. These effects were abolished in
Y2 deficient mice (Batterham et al., 2002) or in the presence of the Y2 selective
antagonist BIIE0246 (Abbott et al., 2005), suggesting the anorexic effects of PYY3-
36 are driven by activation of Y2 receptors. Long term 7-56 day administration of
PYY3-36 or another Y2 peptide agonist produced sustained reductions in body
weight and adiposity but transient changes in feeding in obese rodents whether
given daily (Ortiz et al., 2007) or continuously (Pittner et al., 2004). This suggested
that long term changes in weight are driven by alterations in energy expenditure
as opposed to long term decreases in feeding (Zhang et al., 2011). Unlike leptin
administration, where obese patients tended to develop resistance to treatment
over time, PYY3-36 appeared to remain effective in clinical trials (Batterham et al.,
2003a). However the therapeutic use of PYY3-36 in humans is currently limited as
i.v. administration of high doses has been documented to cause nausea and
vomiting (Sloth et al., 2007), but well tolerated doses appear to have decreased
efficacy in decreasing food intake. Additionally Allison et al., 2006, have also
suggested that PYY3-36 treatment may have long term effects on bone mass
(Allison and Herzog, 2006).
Peripheral administration of physiological doses of PP also produces rapid satiety
in fasted normal weight mice (Asakawa et al., 1999). Administration in Y4 knock
out mice abolishes the anorexic effects of PP confirming the specific role of Y4
receptors in these responses (Balasubramaniam et al., 2006). Peripheral
administration of physiological doses of PP in healthy men decreased rapid and
transient food intake (Batterham et al., 2003b). Repeated treatment in ob/ob
mice leads to decreased body weight and food intake (Asakawa et al., 1999).
Circulating PP levels in humans have been correlated with some disease states.
Patients with Prader Willi syndrome who are morbidly obese, with hyperphagia
have very low concentrations of PP (Zipf et al., 1981), but peripheral
administration of PP can result in decreased food intake (Berntson et al., 1993)
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for these patients, suggesting a potential therapeutic option if issues of
bioavailability and peptide life span can be improved.
Whilst combination treatments of PYY3-36 and PP have shown no additive effects
on reducing food intake in mice or humans, the shared roles of Y2 and Y4
receptors in satiety mechanisms suggests that other methods of co-targeting this
pairing may be effective (McGavigan and Murphy, 2012). One such compound
was obinepitide, a synthetic dual analogue of PYY3-36 and PP. The poor
bioavailability of obinepitide, whereby daily or twice daily subcutaneous
injections were required, made it unsuited to long term use (McGavigan and
Murphy, 2012), however improved anoretic effects were observed suggesting
that Y2/Y4 complexes (potentially in the form of heterodimers) might still be a
valid target for anti obesity therapies.
Y receptor family targeted therapies in anti obesity treatment, have therefore
shown potential but there is a need to increase efficacy in vivo whilst retaining
bioavailability. Suggested coregulation, potentially reflecting receptor
dimerisation, between subtypes also increases the complexity of developing
selective therapies due to the potential impact of compensatory mechanisms or
novel signalling. Therefore investigating the pharmacological consequences of
dimerisation would be of benefit to potentially improve therapeutic targeting.
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1.9 Aims of this thesis:
Whilst the preferential coupling of all Y receptor subtypes to the Gi class of G
proteins is well established, less is known of their relative abilities to interact with
ɴ ?ĂƌƌĞƐƚŝŶƐĂŶĚƚŚĞƌŽůĞ ƚŚŝƐ ŝŶƚĞƌĂĐƚŝŽŶƉůĂǇƐ ŝŶƌĞŐƵůĂƚŝŶŐƌĞĐĞƉƚŽƌ ŝŶƚƌĂĐĞůůƵůĂƌ
trafficking, which may underlie substantive functional differences between the
subtypes. To this end, Chapter 3ŵĂŬĞƐĂƐǇƐƚĞŵĂƚŝĐĐŽŵƉĂƌŝƐŽŶŽĨzƌĞĐĞƉƚŽƌɴ ?
arrestin association and intracellular trafficking, developing high content imaging
assays to quantify agonist and antagonist pharmacology. In particular it will
ĐŚĂƌĂĐƚĞƌŝƐĞ ƚŚĞ ĂƐƐŽĐŝĂƚŝŽŶ ŽĨ z ƌĞĐĞƉƚŽƌ ƐƵďƚǇƉĞƐ ǁŝƚŚ ɴ ?ĂƌƌĞƐƚŝŶƐ ƵƐŝŶŐ Ă
technique known as bimolecular fluorescence complementation (BiFC), which is
capable of identifying receptor signalling complexes of precise composition.
Chapter 4 develops these methods further in conjunction with single molecule
imaging techniques, such as fluorescence correlation spectroscopy (FCS), to
characterise the mobilities and stoichiometry of Y receptor complexes, and the
influence of ligand occupancy. For the first time, the combination of FCS and BiFC
approaches is used to describe the behaviour of molecular Y receptor-arrestin
complexes at the plasma membrane.
The potential of GPCRs to form dimers is now widely accepted, but the functional
importance in respect to signalling protein interaction, modified receptor
trafficking and signalling is still in debate. This evidence is discussed in detail in
Chapters 5 and 6, in which a novel BiFC based imaging system is described which
constrains GPCRs as dimers of precise composition, allowing pharmacological
responses to be directly attributable to defined GPCR dimer populations. Chapter
5 will explore the influence of Y receptor and E2AR homodimerisation on one
functional readout  receptor endocytosis. Selective protomer mutagenesis will
be used to investigate the functional requirements for ligand binding site
occupancy, receptor activation and phosphorylation within the dimer  allowing
ĐŽŶĐůƵƐŝŽŶƐ ƚŽ ďĞ ĚƌĂǁŶ ĂďŽƵƚ ƚŚĞ ƐƚŽŝĐŚŝŽŵĞƚƌǇ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚ ƚŽ
the dimer interface. Chapter 6 extends this technique to investigations of Y1
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receptor heterodimer pharmacology, demonstrating that heterodimerisation
between Y1 and Y5 receptors, the key co-expressed feeding receptors,
selectively influences both agonist and antagonist pharmacology.
54
Chapter 2: Materials and methods
2.1 Materials
pcDNA3.1zeo(+) and pcDNA4/TO(+) DNA vectors, HEK293T/TR cells, OptiMEM,
lipofectamine and the selection antibiotics zeocin and blasticidin were from
Invitrogen (Paisley, UK). pCMV FLAG vector was from Agilent (Santa Clara, CA,
USA). All oligonucleotide primers were synthesised by Eurogentec (Seraing,
Belgium). The GenEluteTM gel extraction, PCR purification, miniprep and maxiprep
kits were purchased from Sigma Aldrich (Gillingham, UK). Restriction enzymes,
fast shrimp alkaline phosphatase, T4 DNA ligase and pJET cloning kit were
obtained from Fermentas (St Leon-Rot, Germany). 1kb DNA ladder was
purchased from Promega (Madison, WI). Additional molecular biology reagents
were also purchased from Sigma Aldrich (Gillingham, UK). DNA sequencing was
carried out by the DNA sequencing laboratory, School of Life Sciences, University
of Nottingham.
All cell culture plasticware was purchased from Fisher Scientific (Loughborough,
UK) with all medium reagents from Sigma (Gillingham, UK). The SNAPSurfaceTM
Alexa Fluor 647 was obtained from New England Biolabs (Hitchen, UK). The
compounds Neuropeptide Y (NPY), peptide YY (PYY), pancreatic polypeptide (PP),
Pro NPY ((Leu 31, Pro 34) NPY), NPY 3-36 and cPP (1-17)(Ala
31, Aib32) NPY (18-36)
were purchased from Bachem (Bubendorf, Switzerland). The compounds DTrp32
NPY, BIBO3304 trifluoroacetate, CGP71683 hydrochloride, NPY5RA972, L182,504,
isoproterenol hydrochloride (isoprenaline), salmeterol, salbutamol hemisulphate,
propranolol hydrochloride, ICI 118,551 and forskolin were all obtained from
Tocris Cookson (Avonmouth, Bristol, UK). Both [3H] Adenine and [14C] cAMP were
purchased from Amersham Biosciences UK (Buckinghamshire, UK), the poly prep
columns and Dowex AC 50 50W-4X resin from Bio-Rad (Hercules, CA), and
imidazole was from Applichem (Darmstadt, Germany), [125I] PYY and scintillation
fluid from Perkin Elmer (Groningen, Netherlands) and scintillation vials from
55
Sarstedt (Nümbrecht, Germany). Whatman GF/B filters (Size 21/4 x 121/4 inches)
were purchased from Brandel Inc (Maryland, USA).
All compounds were stored as single use aliquots at -20°C diluted in aqueous
stock with the exception of the Y receptor antagonists BIBO3304, CGP71683,
EWz ?Z ? ? ? ? > ? ? ? ? ? ? ? ĂŶĚ ƚŚĞ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĂŐŽŶŝƐƚƐ ĨŽƌŵŽƚĞƌŽů ĂŶĚ
salmeterol which were diluted in DMSO. Non-dissolved stock compounds were
ƐƚŽƌĞĚ ĂƐ ŝŶƐƚƌƵĐƚĞĚ ĞŝƚŚĞƌ Ăƚ ƌŽŽŵ ƚĞŵƉĞƌĂƚƵƌĞ  ?ɴ ? ĂĚƌĞŶŽĐĞƉƚŽƌ ůŝŐĂŶĚƐ ĞŐ ?
isoprenaline), 4°C (non peptide Y receptor ligands eg. L182,504) or -20°C (peptide
ligands eg. NPY, PP).
All other chemicals if not directly stated were obtained from Sigma Aldrich
(Gillingham, UK).
2.2 Methods
2.2.1 Molecular biology
ƐƵŵŵĂƌǇŽĨĂůůĐŽŶƐƚƌƵĐƚƐƵƐĞĚŝƐƉƌŽǀŝĚĞĚŝŶdĂďůĞ ? ? ? ?ZĂƚz ?ƌĞĐĞƉƚŽƌĂŶĚɴ ? ?
adrenoceptor cDNAs were provided by Professor T Schwartz of the University of
Copenhagen, Denmark. Human Y2, Y4 and Y5 receptor, D2L dopamine and
human arrestin cDNAs were obtained from the Missouri S&T cDNA resource
centre (www.cDNA.org)
.2.2.1.1 Amplification of DNA
2.2.1.1.1 Using sited directed mutagenesis to generate a C terminal phospho-
site negative mutant of the NPY Y1 receptor
PCR-based site directed mutagenesis (Quikchange) was used to selectively
mutate specific serine and threonine residues in the C terminal domain of the rat
NPY Y1 receptor cDNA sequence (Genbank reference number: Z11504). This
phospho-site deficient mutant was termed Y15A after the number of alanine
mutations that were introduced. Mutagenesis reactions were performed using
Accuzyme, a 5-3 DNA polymerase (Bioline, London, UK). This enzyme also has 3-
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5 exonuclease proofreading activity whereby nucleotide mismatches identified in
the newly synthesised DNA are excised and the correct base pair inserted.
Accuzyme can amplify large regions of DNA (up to 5kbp) with high fidelity
producing blunt ended products.
2.2.1.1.1.2 Mutagenesis primer design
Two sets of complementary primers were designed to introduce 5 amino acid
changes into the template cDNA strand in succession. The specific amino acid
codons were identified and mutated to a codon used frequently in human cells to
account for species specific codon usage bias. Primer sequences contained 12-15
conserved bases either side of the mutated codons and both forward and reverse
primers recognised the same sequence on opposite template DNA strands. The
forward primer sequence was identical to the coding strand of the template DNA
(except for the introduced mutations), with the reverse primer the reversed and
complemented sequence of this (see Table 1). A further consideration in primer
design was GC base content, with a figure of 40-60% desirable for stable binding
of primer sequences to template DNA. Where possible, primer sequences ended
with a GC clamp to promote specific primer binding (due to the stronger triple
hydrogen bonding of G and C bases). The melting point of primers was also
considered (dependent on the degree of GC content and primer length) with
temperatures of 58-62°C preferred in order to minimise the chance of secondary
annealing. When generating the Y15A mutant, sequential rounds of mutagenesis
were required. 3 mutations were introduced in the first round. This mutant
(when confirmed as correct with sequencing) was used as the template for the
second round of mutagenesis to introduce the 2 additional mutations. The same
protocol was followed for both rounds. All primers were purchased from
Eurogentec and are detailed in Table 2.1.
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2.2.1.1.1.3 PCR-based site directed mutagenesis protocol
Reactions were prepared in 200µl PCR tubes consisting of 25ng template DNA
(pCMV FLAG Y1-Yc first round), 125ng of forward and reverse primers (1µl each),
200µM dNTPs (2µl), AccuBuffer buffer (5µl; supplied with enzyme; 60mM Tris-
HCl, 6mM (NH4)2SO4, 10mM KCl, 2mM MgSO4; pH 8.3) and 2.5 units of Accuzyme
(not added to the starting mix) in double distilled water (ddH20) to give a total
volume of 50µl. A negative control reaction was also set up containing all
components except Accuzyme. Reactions were carried out using a thermocycler
block (Mastercycler gradient, Eppendorf, UK). The initial step, whereby double
stranded template DNA was denatured to single stranded DNA, was performed at
95°C for 30 s (see Figure 2.1). The temperature was then decreased (typically to
58-60°C for mutagenesis reactions; for 1min), and Accuzyme added at this point.
This HotStart procedure, following the first round of denaturation and primer
annealing to the template, minimised non specific DNA amplification by
Accuzyme. The annealing temperature was varied depending on the primer used
but was typically 5°C less than the melting temperature of the primer to allow
specific primer hybridisation. Finally the extension step was performed (68°C for
10min; equating to approximately 1.5min per kbp) whereby the DNA polymerase
synthesised a new complementary DNA strand from the primer sequence in a 5
to 3 direction. This sequence of cycles (denaturation, annealing and elongation)
was repeated 18 times, with the newly synthesised fragment DNA (containing the
region to be amplified) now also acting as the template DNA. Following
completion of all cycles, tubes were cooled and held at 4°C.
Samples were then treated with the restriction enzyme Dpn I for 2hr at 37°C, 20
min at 60°C. Dpn I can only cleave methylated DNA (ie the original template
DNA), therefore digestion with this enzyme will leave the unmethylated mutated
DNA intact as a circular plasmid for efficient transformation. 2µl of each Dpn I
digested sample was then transformed into XL-1 competent cells (see section
2.2.1.7.1), grown on a small scale and purified (miniprep; section 2.2.1.8) before
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being screened using restriction enzyme digestion (section 2.2.1.3). If the isolated
DNA was of an expected size, the sample was then sequenced to confirm the
presence or absence of the desired mutations. (Figure 2.2; section 2.2.1.2).
If correct, the DNA was ligated into fresh plasmid vector. This was to prevent
unwanted mutations that may have been introduced elsewhere during the
mutagenesis process being carried over into the DNA. DNA in fresh vector was
then transformed into XL-1 cells and then grown up on a larger scale (maxiprep;
section 2.2.1.9).
Figure 2.1: The principles of using polymerase chain r
PCR begins with an initial high temperature step
(denaturation). The reaction is then cooled to facili
sequences in the two DNA strands (hybridisation). D
direction (elongation). This entire cycle is repeated w
be amplified) now acting as the template. Every cycle
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2.2.1.1.1.4 Amplification of the Human NPY Y5 receptor using polymerase chain
reaction (PCR)
In this case, the polymerase chain reaction (PCR) was used to amplify the entire
human NPY Y5 receptor cDNA (residues 2-444). The PCR protocol was similar to
that used for site directed mutagenesis with some modifications. Here a different
high fidelity DNA polymerase, PWO (Roche, Burgess Hill, UK) was used. PWO is
also a 5-3 DNA polymerase with 3-5 exonuclease proofreading activity.
2.2.1.1.1.5 Primer design
Two complementary primers (34-40 bases) were designed to anneal to the start
and end of the human NPY Y5 receptor sequence (Genbank Reference number:
NM_006174.2). They were also designed to introduce a Bam HI (GGATCC) and a
Not I (GCGGCCGC) restriction enzyme site prior to the start and after the end of
the Y5 sequence respectively (Figure 2.3). The initiation methionine codon was
removed from the start of the Y5 sequence so that the receptor could ultimately
be inserted continuously into the pCMV vector downstream of a FLAG tag (Figure
2.5; see section 2.2.1.3.2.1). The stop codon was also removed to allow C
terminal fluorescent protein fragment tags to be added, and the position of the
NotI site was designed so that it located the Y5 sequence in frame with the
fluorescent protein tag in the vector on cloning
Forward: 5 G AGT GGA TCC GAT TTA GAG CTC GAC GAG TAT TAT AAC 3
Receptor codons: Bam HI D L E L D E Y Y N
Reverse: 5 ATT AGC GGC CGC CAT ATG AAG ACA GTG TAT AAG G
Receptor codons: Not I M H L C H I L
Figure 2.3: PCR primer design for amplifying the human NPY Y5 receptor
The forward primer sequence is detailed in the top section, alongside the corresponding
Y5 receptor codon sequence. The initiation methionine codon has been omitted. The
second section shows the reverse primer reversed and complemented to the final part of
the Y5 sequence, excluding the STOP codon. Restriction enzyme consensus sites are
underlined.
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2.2.1.1.1.6 PCR protocol
Reactions were prepared in 200µl PCR tubes, comprised of 25ng template cDNA
(p3.1neo human Y5 receptor), 600nM each of forward and reverse primers,
200µM dNTPs (final concentration), PWO buffer (5µl; supplied with enzyme;
10mM Tris-HCl, 25mM KCl, 5mM (NH4)SO4, 2mM MgSO4; pH 8.9) and 0.5µl PWO
enzyme (added at a later point) in ddH20 to make a total volume of 50µl. Using
the thermocycler block, a similar protocol was followed as for site directed
mutagenesis, with PWO polymerase following an initial HotStart primer annealing
step. 25 cycles of PCR were performed, with an annealing temperature of 58°C
and an extension step at 72°C for 90sec. (for the last 15 cycles, 5 sec was added
to the extension time each cycle). Following the completion of all cycles, tubes
were cooled and held at 4°C.
Following the completion of the PCR cycles, the DNA was visualised using gel
electrophoresis, and the size of the fragment accessed (section 2.2.1.4). If
correct, the fragment band was excised and purified (section 2.2.1.5.1).
2.2.1.1.1.7 Ligation of PCR generated human NPY Y5 receptor cDNA into pJET
vector
The PCR Y5 receptor cDNA fragment was first subcloned into the vector pJET1.2
(CloneJET PCR cloning kit, Fermentas). Ligation of the PCR cDNA blunt-ended
product into the pJET vector disrupts the expression of a gene encoding the
restriction endonuclease enzyme eco46/R. This enzyme is typically lethal to host
E coli cells therefore only bacterial clones with insert containing plasmids are
capable of growth.
pJET ligation reactions were performed in 0.5ml Eppendorf tubes consisting of
10µl 2x pJET ligation buffer containing polyethylene glycol to improve the
efficiency of blunt end ligations (supplied with enzyme), 1µl pJET vector (50ng),
1µl purified PCR product and 1µl T4 DNA Ligase in nuclease free water to give a
total volume of 20µl. Reactions were incubated for 30min at 22°C, before being
transformed into XL-1 cells (section 2.2.1.7.1). DNA was then grown up on a small
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scale and purified (miniprep; section 2.2.1.8), before being screened using
restriction enzymes (section 2.2.1.3) and gel electrophoresis (section 2.2.1.4).
PCR derived DNA was then sequenced and if correct, ligated into fresh vector
(firstly pcDNA3.1 zeo or pcDNA4 TO containing (between KpnI and BamH1) a
Kozak sequence prior to the initiation methionine residue and FLAG tag) using a
restriction digest (Bam HI/Not I; sections 2.2.1.3 and 2.2.1.6) before fluorescent
protein tags could be inserted downstream (using a Not I / Xba I restriction
digest; section 2.2.1.3). Complete constructs were then cultured on a larger scale
(maxiprep; section 2.2.1.9) to be used in mammalian cell transfections (section
2.2.2.1).
2.2.1.2 DNA sequencing
The sequences of all engineered DNA were checked for any alterations that may
have been erroneously introduced, and that mutations purposely introduced
were present (Figure 2.2). The appropriate forward and reverse primers for that
particular construct (dependent on the vector cDNA used; see Table 1) were
used. All sequencing was undertaken by the DNA sequencing laboratory at the
University of Nottingham.
2.2.1.3 Restriction digestion
Restriction enzymes recognise and bind to a specific small sequence of
nucleotides (termed restriction sites) and subsequently cleave DNA into
fragments. Typically constructs were digested with two different restriction
enzymes (a double digest) at either end of the insert DNA (eg. receptor,
fluorescent protein tag). The same enzyme pair was used to digest the vector
DNA ultimately receiving the insert (eg. pCMV FLAG, pcDNA3.1 zeo Snap). The
enzymes chosen also produced complementary sticky ends, whereby an
overhang stretch of unpaired nucleotides was left following digestion. The
different sticky ends left by double enzyme digestion of both insert and vector
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DNA are complementary and can subsequently be joined together in only one
orientation using T4 DNA ligase (see section 2.2.1.6).
When performing a restriction digest, 2µg of DNA (in a total volume of 20µl) was
added to a sterile 0.5ml Eppendorf tube along with 2µl of 10x fast digest buffer
(supplied with enzyme) and digested with 1µl of each restriction enzyme (Fast
Digest; Fermentas). This reaction was incubated for 1hr at 37°C, followed by
20min at 65°C and 5min at 80°C to heat inactivate the restriction enzymes.
Digested DNA was then identified and isolated using gel electrophoresis (Figure
2.8; see section 2.2.1.4).
2.2.1.3.1 Generation of a Snap tagged receptor construct
Receptor cDNA was inserted into a pcDNA 3.1zeo plasmid already containing the
Snap tag sequence (181 amino acids; see Table 2.3). This vector was previously
made by Dr Holliday. A short sequence derived from 5HT3 receptor derived signal
sequence (amino acids MRLCIPQVLLALFLSMLTGPGEGSRK) was added upstream of
the Snap tag sequence to facilitate insertion of the receptor protein into the
membrane during translation. This construct was also tagged at the C terminus
with an N terminal fragment of Venus YFP (Yn; residues 2-173).
This p3.1zeo Snap vector (see Figure 2.4) contained a human cytomegalovirus
(CMV) promoter, which is a strong promoter that expresses well in a variety of
mammalian cell lines and allowed for a high level of receptor expression. This
vector also contained a polyadenylation signal (bovine growth hormone derived;
bGH poly A) which is a transcription termination sequence that aids expression in
eukaryotic cells as well as sites for sequencing primers (T7 promoter and bGHrev;
see section 2.2.1.2). Sites of antibiotic resistance for the selection of both
transformed bacterial cells (ampicillin) and transfected mammalian cell lines
(zeocin; see Table 2.2 for details) were also included.
All cDNAs of interest were inserted into the vector in frame downstream of the
Snap tag, via the multiple cloning site (MCS) which contained several restriction
enzyme sites (Figure 2.4). Receptor cDNAs were placed between BamHI and XhoI
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internal Xho I site in the Y1 sequence. Inserted receptor cDNA sequences lacked
the initiation methionine codon and the 3 STOP codon to allow the addition of a
Venus Yellow Fluorescent Protein (vYFP) fragment (N terminal 2-173 termed Yn;
these numbers equated to the native Green Fluorescent Protein (GFP) sequence
(Kilpatrick and Holliday, 2012) ). This fragment was placed between Not I / Xho I
ĂŶĚyďĂ/ƌĞƐƚƌŝĐƚŝŽŶƐŝƚĞƐǇŝĞůĚŝŶŐ>ZW> ?z ? ZŽƌ> ?ɴ ?Z ZĂŵŝŶŽĂĐŝĚůŝŶŬĞƌƐ ?
AB
Figure 2.4 pcDNA
Panel A shows a sc
generate receptor
map of the pcDNA
inserted into the pc
fragment tag (Yn;
Snap-receptor-Yn
included and key s
66
3.1 zeo Snap Y1-Yn construct
hematic of the multiple cloning site restriction
-Yn constructs in pcDNA3.1 zeo Snap vector. P
3.1 zeo Snap Y1-Yn. NPY Y1 receptor cDNA
DNA 3.1 zeo vector downstream of a Snap seque
purple) was inserted downstream of the rece
in frame cDNA. Additional features contained
ingle and remaining double cut restriction enzym
enzyme sites used to
anel B shows a vector
(shown in yellow) was
nce (purple). A BiFC
ptor cDNA, giving the
in the vector are also
e sites indicated.
67
2.2.1.3.1.2 Exchanging C terminal fluorescent protein fragment tags on FLAG
tagged receptor constructs
2.2.1.3.1.2.1 pCMV FLAG Receptor-Yc / Gc
Enzymatic digestion was used to ultimately insert receptor cDNAs into a pCMV
FLAG vector also containing a C terminal fragment of Venus YFP (termed Yc
throughout). This vector contained a FLAG tag epitope (MDYKDDDDK), which
gave the option to identify this receptor construct by techniques such as antibody
live labelling (Figure 2.5). This vector also contained a pCMV promoter to allow
for high receptor expression, and polyadenylation signals (Simian1 virus 40 (SV40)
derived) to aid eukaryotic protein expression.
The NotI enzyme could not be used when cloning receptor cDNA in the correct
orientation into the pCMV FLAG vector, because of an additional NotI site
upstream of the FLAG tag. To account for this receptor cDNA was first inserted
ŝŶƚŽ Ă Ɖ ? ? ?ǌĞŽ ǀĞĐƚŽƌ ďĞƚǁĞĞŶ Ăŵ ,/ ĂŶĚ EŽƚ /  ?EWz z ? Z Žƌ yŚŽ /  ?ɴ ?Z Z
restriction sites (see figure 2.5). Receptor cDNA sequences lacked the initiation
methionine codon and the 3 STOP codon to allow the addition of a C terminal
vYFP fragment (173-238; termed Yc) or a C terminal superfolder GFP fragment
(173-238; Gc) between Not I / Xho I and Xba I restriction sites using a LRPLE
linker. The GFP sequence used had previously been engineered to contain
superfolder mutations S30R, F99S, N105T, M153T and V163A (Pedelacq et al.,
2006). The entire receptor-Yc construct was then inserted into the pCMV FLAG
vector, downstream of the vector FLAG tag via a Bam HI and Apa I digest.
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2.2.1.3.1.2.1.2 pcDNA4 TO FLAG Receptor-GFP
Receptor cDNA tagged with a full length superfolder GFP tag (GFP) was inserted
into the pcDNA4 TO vector downstream of a FLAG tag epitope (MDYKDDDDK).
The pcDNA4 TO vector contains a pCMV promoter in conjunction with two
tetracycline operator sequences (see figure 2.6) inserted between the TATA box
and the transcription initiation start site. This sequence was identical to that of
pcDNA 3.1zeo with the exception of the tetracycline operon sequence. As for
pCDNA3.1zeo, the vector used for cloning contained a Kozak sequence, start
methionine and FLAG tag placed between KpnI and BamH1 of the multiple
cloning sequence.
Receptor cDNA sequences lacked the initiation methionine codon and the 3
STOP codon to allow the C terminal addition of full length superfolder GFP placed
between Not I and Xba I restriction sites after an LRPLE linker (see Figure 2.6).
2.2.1.3.3 ĚĚŝŶŐƚĞƌŵŝŶĂůĨƌĂŐŵĞŶƚƚĂŐƐƚŽɴ ?ĂƌƌĞƐƚŝŶ ?ĐŽŶƐƚƌƵĐƚƐ
,ƵŵĂŶɴ ?ĂƌƌĞƐƚŝŶ ?Žƌ ?ĐE ?'ĞŶďĂŶŬƌĞĨĞƌĞŶĐĞED Y ? ? ? ? ? ?ŽƌED Y ? ? ? ? ? ? Z ?
containing a Kozak sequence (GCCACC) prior to the initiation methionine residue
and no STOP codon (as described in Kilpatrick et al 2010), was inserted into the
pcDNA3.1zeo vector using enzymatic digestion with EcoRI and Not I (Figures 2.7).
The pcDNA3.1zeo vector was previously described in section 2.2.1.3.1. A N
terminal vYFP fragment (residues 2-173; Yn) or an N terminal GFP fragment (2-
 ? ? ? ? 'Ŷ Z ǁĂƐ ĂĚĚĞĚ ŝŶ ĨƌĂŵĞ ĚŽǁŶƐƚƌĞĂŵ ŽĨ ƚŚĞ ɴ ?ĂƌƌĞƐƚŝŶ ? ĐE  ?ĐƌĞĂƚŝŶŐ Ă
QRPLE linker] and placed between Not I and Xba I restriction sites.
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2.2.1.4 Visualisation and isolation of DNA using agarose gel electrophoresis
Gel electrophoresis allows the separation of DNA molecules based upon their size
by applying an electric field through an agarose gel matrix. Smaller negatively
charged DNA molecules move faster through the pores of the gel, towards the
positive electrode of the electric field, than larger DNA molecules.
A gel was prepared consisting of 1% agarose (Sigma Aldrich) dissolved in TBE
buffer (89mM Tris HCl, 89mM Boric acid, 2mM EDTA (ethylenediaminetetraacetic
acid); pH 7.6). The mixture was allowed to cool to touch whereupon ethidium
bromide (0.1µg ml-1) was added. Ethidium bromide is a chemical agent which
intercalates into DNA. Upon exposure to ultraviolet light, ethidium bromide
bound to DNA is intensely fluorescent, allowing DNA to be visualised as discrete
bands on the gel. The gel was then left to set, prior to being placed into an
electrophoresis tank and covered entirely with TBE buffer. DNA samples were
mixed with blue loading buffer (0.25% w/v bromophenol blue, 50% v/v glycerol in
TBE) and loaded. 5µl of 1kb DNA ladder (Promega) was also added as a molecular
weight marker. The gel was run at 80V for 30-45 minutes until sufficient
migration of the DNA was achieved to separate the bands of interest..
DNA was visualised using an UV light box (Syngene GVS-30 transilluminator) and
if required the DNA band of the correct size excised. A representative gel showing
a variety of constructs used throughout this thesis and the DNA bands obtained
following their restriction digestion can be seen in figure 2.8.
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2.2.1.5 Preparation of insert and vector cDNA for ligation
2.2.1.5.1 Gel extraction of insert DNA
Restriction digested DNA fragments for ligation were separated by agarose gel
electrophoresis and isolated using a gel extraction kit (Sigma Aldrich). This
method of DNA purification is a silica gel-based which uses column
chromatography. The gel slice containing the desired DNA fragment was weighed
in a sterile Eppendorf and 3 gel volumes of gel solubilisation solution added and
the tube incubated for 10 min at 60°C. The chaotropic salts in the solubilisation
solution disrupt the ordered structure of water molecules surrounding the DNA.
This creates a hydrophobic environment that promotes the binding of the DNA
phosphate backbone to the silica of the spin column whilst proteins and other
contaminants do not bind and are washed away. One gel volume of isopropranol
was then added to the solubilised gel solution to increase specific binding of the
DNA to the column. Column preparation solution was added to the binding
column and the column centrifuged for 1min at 12,000rpm. The solubilised gel
solution was then added and centrifuged for1 min at 12,000rpm facilitating the
binding of the DNA to the silica filter of the column. A solvent based wash
solution, containing 70% ethanol was added to remove any contaminants without
affecting DNA binding (DNA does not dissolve in ethanol solution). A further 2min
centrifuge at 12,000rpm removed any excess ethanol. The DNA was then
unbound from the silica of the column upon addition of 40µl ddH2O and a 1min
centrifugation at 12,000rpm. The DNA was now in solution and ready to use in
ligation reactions.
2.2.1.5.2 Preparation of vector DNA
Following double digest with restriction enzymes, 2 µg vector DNA was treated
with shrimp alkaline phosphatase (SAP; 2µl SAP buffer (supplied with enzyme ;
100mM Tris-HCl, 50mM MgCl2, 1M KCl, 0.2% Triton-X-100, 1mg ml
-1; pH 8.0) and
2µl SAP) for 2hr at 37°C. The purpose of SAP treatment is to remove phosphates
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from exposed nucleotides at the ends of the linearised plasmid DNA in order to
prevent self-ligation. In order to be used in ligation reactions, the vector DNA
was purified using a PCR clean up kit (Sigma Aldrich) following the manufacturers
instructions. Like the gel extraction kit (as described in section 2.2.1.5.1) it uses
silica spin columns to remove contaminants such as excess salts and protein.
Vector DNA was eluted in 40µl ddH2O.
2.2.1.6 Ligations
The insert and vector preparations (as described in sections 2.2.1.5.1 and
2.2.1.5.2.1) were ligated together in a 3:1 insert:vector molar ratio. DNA
concentrations in both preparations were calculated assuming an 80% yield from
the gel purification (insert; I) and PCR clean up (vector; V) protocol, and starting
from 2µg of DNA:
2µg DNA x (size of isolated I or V/ size of original plasmid in its entirety) x 0.8
= concentration of I or V DNA isolated in the 40µl elution.
50ng of vector DNA was deemed optimal for use in ligations to produce single
circular plasmids. A 1:3 ratio of vector to insert was used, therefore assuming
50ng of vector contains x moles, the following equation was used to calculate the
correct amount of insert DNA required:
ng of insert needed = 3x 50ng x (size of I/size of V)
The actual volume in µl of vector and insert to be added was then calculated
(based on the number of moles required and the actual concentration present in
the eluate). Positive and negative ligations were set up in 0.5ml Eppendorf tubes,
with ddH2O added in place of insert to the negative control (but all other
components present). 1µl of 10x T4 Ligase buffer (supplied with the enzyme) and
1µl T4 DNA ligase were added to give a total volume in ddH2O of 10µl per ligation
reaction. Reactions were performed at 16°C for 16 hours.
5µl of both positive and negative ligations were transformed in XL-1 competent
cells as described in section 2.2.1.7.1.
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2.2.1.7 Preparation of competent cells
The XL-1 strain of E.coli is suitable for making chemically competent cells as
mutations have been introduced that make it more amenable for DNA uptake.
Mutations in recA recombinase minimises recombination of the introduced
plasmid DNA with host DNA and increases the stability of inserts. The lack of
endA nuclease improves the quality of purified plasmid DNA isolates. A hsdR17
mutation knocks out EcoK 1 methylase, which prevents cleavage of transformed
plasmid DNA by endogenous endonucleases. The gene encoding tetracycline
resistance (on the F episome) has also been introduced.
Agar plates were produced using 35 grams of Luria Bertani (LB) agar powder
(Sigma Aldrich) dissolved in 1L of ddH20 which was sterilised by autoclaving. The
mixture was allowed to cool to hand hot and tetracycline was added at a
concentration of 10 µg ml-1 before being poured into Petri dishes and allowed to
set. The XL-1 strain E.coli cells were streaked out onto these LB agar plates using
sterile apparatus with the aim of obtaining single colonies. Plates were incubated
overnight at 37°C. The next day a single colony was inoculated into 5ml of sterile
LB broth containing 10µg/ml-1 tetracycline and grown overnight at 37°C with
shaking at 225rpm. On the third day this 5ml preparation was added to 20ml of
2YT medium and incubated at 225rpm until cell growth had reached a density of
OD600 = 0.2-0.8. The entire 20ml preparation was then poured into a 1L flask
containing 80ml 2YT medium plus 10µg ml-1 tetracycline. This solution was
further agitated until OD600 = 0.5-0.9 before being diluted to 250ml using 2YT
medium. Cells were grown until a precise density of OD600 = 0.6 was obtained and
the solution rapidly cooled in ice water to arrest further growth. The solution
was centrifuged for 15 min at 4,000rpm at 4°C and the subsequent pellet was
resuspended in 50ml TfB I solution (30mM potassium acetate, 50mM MnCl2,
64mM KCl, 10mM CaCl2 and 15% glycerol; pH 5.8) on ice with gentle shaking. The
solution was further centrifuged for 8min at 4,000 rpm at 4°C, the supernatant
poured off and the pellet resuspended in 10ml cold TfB II buffer (10mM 3-(N-
77
morpholino) propanesulphonic acid (MOPS), 1mM KCl, 75mM CaCl2 and 15%
glycerol; pH 7.4) on ice with gentle shaking. 400µl resuspension was aliquoted
into pre chilled microcentrifuge tubes, snap frozen in liquid nitrogen and stored
at -80°C until required.
2.2.1.7.1 Transformation of DNA into competent E.coli cells
Transformation is the process of introducing plasmid DNA into E coli cells. By
treating cells using a heat shock process and with chemicals, they become
competent to take up DNA.
Aliquots of competent cells (described in section 2.2.1.7) were gently thawed on
ice and 100µl of cell suspension per transformation was added to pre-chilled
ƉƉĞŶĚŽƌĨ ƚƵďĞƐ ?  ? ? ?A?ů ŽĨ ɴ ?ŵĞƌĐĂƉƚŽĞƚŚĂŶŽů  ? ? ? ?D ŝŶ ,2O) was then added to
ĞĂĐŚƚƵďĞ ?ɴ ?ŵĞƌĐĂƉƚŽĞƚŚĂŶŽůŝƐĂƌĞĚƵĐŝŶŐĂŐĞŶƚǁŚŝĐŚŝŶĐƌĞĂƐĞƐƚŚĞĞĨĨŝĐŝĞŶĐǇ
of transformations by inactivating surface nucleases and making the cell wall
permeable to nucleic acids (Brzobohaty and Kovac, 1986). Cells were incubated
on ice for 10min before 5µl of a ligation reaction or 10ng circular plasmid DNA
was added to the tube and mixed by swirling. The reaction mix was then
incubated on ice for 30min, to allow the DNA to associate with the competent
cells. Following this, cells were heat shocked for 45 s at precisely 42°C to facilitate
uptake of DNA by the competent cells. The length of time and the temperature
used are critical to the efficiency of the transformation. Reaction tubes were then
returned to ice for 2min before 400µl LB broth was added to each tube. Tubes
were then incubated for 1hr at 37°C with gentle shaking at 225rpm. Following
this 100µl transformation mix was plated onto LB agar plates containing the
correct selection antibiotic for the specific plasmid being transformed (eg. 75µg
ml-1 ampicillin or 30µg ml-1 kanamycin). Plates were then grown overnight at 37°C
and the next day colony growth assessed. Only those cells that have taken up the
introduced plasmid DNA express the appropriate antibiotic resistance protein
required to grow. 2 single colonies were then picked and each inoculated into
5ml of LB broth containing the appropriate selection antibiotic (75µg ml-1
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ampicillin or 30µg ml-1 kanamycin). These miniprep cultures were then grown
overnight at 37°C with gentle shaking at 225rpm.
2.2.1.8 Small scale (miniprep) isolation and purification of cDNA
The purpose of performing a miniprep is to further amplify and then isolate the
plasmid vector from the transformed bacteria. Purification of the DNA was
performed using a silica binding spin column protocol using alkaline-SDS lysis
according to the manufacturers instructions (Sigma Aldrich). A 3ml sample of the
overnight preparation was pelleted by centrifugation for 5 min at 5,000rpm. The
resulting pellet was resuspended in hyperosmotic sucrose resuspension buffer
containing RNase that degrades RNA in the preparation.
The cells were then lysed using an alkaline solution containing sodium dodecyl
sulphate (SDS), a very strong detergent, which solubilises the lipid bilayer of the
cells and denatures any proteins that may be bound to the desired plasmid DNA.
This lysis solution contains NaOH, a strong base that disrupts the hydrogen bond
network intrinsic to DNA base pairing of chromosomal DNA essentially denaturing
it into single stranded DNA. However the supercoiled nature of the plasmid DNA
means it is not irreversibly affected. The solution was then neutralised using a
buffer containing potassium acetate (KOAc). The larger chromosomal DNA,
proteins and cell debris do not renature correctly and instead aggregate into an
insoluble precipitate, whereas the plasmid DNA remains soluble. This
neutralisation step also added chaotropic binding salts that facilitated plasmid
DNA binding to the silica of the spin column. The solution was then centrifuged
for 10min at 12,000rpm to form a pellet to remove any contaminants.
The binding column was prepared by being placed into a centrifuge tube and
500µl column preparation solution added before centrifugation at 12,000rpm for
1min. The neutralised lysate was then added to the column and centrifuged again
at 12,000rpm to promote binding of the plasmid DNA to the silica filter of the
column. The filter was then washed using a solution containing solvent (80%
ethanol) which dissolves residual salts and other contaminants from the
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preparation (then eluted in the supernatant). The plasmid DNA is unaffected and
remains bound to the column. The column was re-spun again for 2min at
12,000rpm to remove any residual ethanol. The plasmid DNA was then eluted
from the column using 100µl ddH2O or Tris-EDTA (TE; 10mM Tris HCl, 0.1mM
EDTA; pH 8.0). The resulting miniprep (approximate concentration of 50ng/µl)
was then digested using restriction enzymes in order to screen whether they
contained the correct plasmid DNA, or stored at -20°C for later use.
2.2.1.9 Large scale (maxiprep) isolation and purification of DNA
If screening of a miniprep produces a correct result, a larger yield of cDNA may be
required for use in cellular transfections. This was achieved using a maxiprep kit
(Sigma Aldrich) according to the manufacturers instructions. Many of the buffer
solutions are of a similar composition to those used in the miniprep kit.
A starter culture consisting of 20µl of the correct miniprep clone (not purified)
was placed in a 20ml tube containing 5ml LB broth plus the required antibiotic
(75µg ml-1 ampicillin or 30µg ml-1 kanamycin) and grown for eight hours during
the course of the day at 37°C with gentle shaking (225rpm). This starter culture
was then added to a 500ml conical flask containing 120ml sterile LB broth
containing the appropriate antibiotic (75µg ml-1 ampicillin or 30µg ml-1
kanamycin) and grown overnight at 37°C with gentle shaking (225rpm).
The following day, the overnight culture was centrifuged for 15 min at 4,000rpm
at 4°C. The pellet was then resuspended in a resupension buffer, a hyperosmotic
sucrose solution containing RNase to degrade any RNA that may be present in the
preparation. An alkaline detergent solution composed of NaOH and SDS, was
added and centrifuge tubes inverted 6 times to mix the contents. The lysis
solution was left on for 3min, until the solution was clear and viscous.
The solution was then neutralised using a chilled solution containing potassium
acetate. The larger chromosomal DNA, proteins and cell debris precipitate into an
insoluble cluster, whereas the plasmid DNA remains soluble in the supernatant. A
binding solution was then added and centrifuge tubes inverted once before the
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contents were immediately poured into the barrel of a prepared filter syringe and
left to sit for 5min, whilst binding columns were prepared. Half of the lysate was
expelled into the tube, before centrifugation at 4,000rpm and the eluate
discarded. The second half of the lysate was then added to the binding column
and the process repeated. This resulted in the plasmid DNA becoming bound to
the filter of the column. The filter was washed with two wash solutions, the first
for 2 min at 4,000rpm and the second with a solution containing solvent (80%
ethanol) for 5min at 4,000rpm. This second solution removes residual salts and
other contaminants from the purified DNA which remains in the filter.
The binding column was then removed and placed in a clean 50ml collection
tube. 3ml of elution solution was then added and the tube centrifuged for 5min
at 4,000rpm. Ethanol precipitation was then performed to further concentrate
and purify the eluted DNA. 3M sodium acetate (pH 5.0) was added in a 1:10 ratio
(300µl, giving a final concentration of 0.3M) to the 3ml DNA elute. The Na+ ions
neutralise the negative charges on the DNA sugar phosphate backbone and
subsequent addition of chilled 100% ethanol as a 2.2 x volume (7.2ml) displaces
the less polar water molecules surrounding the DNA phosphates. The plasmid
DNA precipitates out of this solution, and can be collected following
centrifugation for 20min at 4,000rpm. This was followed by adding 1ml of chilled
70% ethanol and the solution centrifuged for 10min at 4,000rpm, to remove any
residual salt from the precipitated DNA. The resulting supernatant was removed
and the pellet re-centrifuged to remove residual ethanol. The pellet was then left
to air dry for approximately 20min. The pellet was then resuspended in TE buffer
(10mM Tris-HCl, 1mM EDTA; pH 7.4) and concentration and purity determined
using a spectrophotometer (BioPhotometer, Eppendorf) with absorbance read at
260nm (the wavelength at which double stranded DNA absorbs light). This
absorbance was converted to a DNA concentration using the calibration for
double stranded DNA (1 AU = 50 ng / ml). Protein peak absorption was also
measured at 280nm, and the ratio between these two values (260/280nm)
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indicated the purity of the sample DNA. A ratio of 1.7-1.9 was desired, as it was
indicative of relatively pure double stranded DNA. The volume of the preparation
was then adjusted to a stock DNA concentration of 1µg/µl in TE buffer.
2.2.2 Cell culture
2.2.2.1 Cell lines and passaging
The base cell line typically used for bimolecular fluorescence complementation
(BiFC) studies of constrained GPCR dimers, were HEK293T cells stably expressing
clonal Snap modified receptor fused to a N terminal fragment of Venus YFP (2-
172; Yn) (see Figure 2.4). Additionally cell lines were also generated using this
Snap receptor-Yn cell line, co-transfected with a mixed population of FLAG tagged
receptor cDNA (lacking the STOP codon) within the pCMV FLAG vector (see Figure
2.5). The complete dual transfect cell line is therefore referred to as Snap
receptor-Yn / FLAG receptor-Yc.
dŚĞĐĞůů ůŝŶĞƐƵƐĞĚ ĨŽƌŝ& ƐƚƵĚŝĞƐ ŽĨ ƌĞĐĞƉƚŽƌ P ɴ ?ĂƌƌĞƐƚŝŶ ĂƐƐŽĐŝĂƚŝŽŶǁĞƌĞ ĂůƐŽ
dual transfects stably expressed in HEK293T cells, as described previously
 ? ?<ŝůƉĂƚƌŝĐŬĞƚĂů ? ? ? ? ? ? Z Z ?dŚĞƐĞĐŽŶƐŝƐƚĞĚŽĨĂĐůŽŶĂůƉŽƉƵůĂƚŝŽŶŽĨɴ ?ĂƌƌĞƐƚŝŶ ? ?zŶ
ɴ ?ĂƌƌĞƐƚŝŶ ? ?'Ŷ Žƌ ɴ ?ĂƌƌĞƐƚŝŶ ? ?'Ŷ  ?&ŝŐƵƌĞ  ? ? ? Z ? ĐŽ ?ĞǆƉƌĞƐƐĞĚ ǁŝƚŚ Ă ŵŝǆĞĚ
population of FLAG receptor -Yc or -Gc(Figure 2.5).
Additionally HEK293TR tetracycline inducible cell lines were also used in some
experiments. Here receptor-GFP cDNA sequences were placed in the pcDNA4/TO
vector downstream of the FLAG epitope (Figure 2.6). Receptor expression was
induced following treatment with tetracycline (see section 2.2.2.4).
All cell lines were grown in Dulbeccos modified Eagles medium (DMEM)
supplemented with 10% foetal bovine serum (FBS) in 75 cm2 tissue culture flasks
(T75s) at 37°C and 95% O2/5% CO2. Medium was supplemented with
maintenance concentrations of the appropriate antibio-tic required for the
transfected constructs in that cell line (see Table 2.2). Cells were only grown up
to 80% confluency prior to passaging to prevent cell detachment. When
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passaging cellsthe presence of residual FBS can deactivate trypsin, therefore cells
were first washed with PBS followed by treatment with 1ml trypsin (0.25% w/v in
Versene; Lonza Wokingham Ltd (Wokingham, UK)). Trypsin is a serine protease
that facilitates cell detachment by hydrolysing proteins that enable cells to
adhere to the culture flask. Washing the flask surface with 10ml DMEM
prevented trypsin from further proteolysis and allowed detached cells to be
collected. Cells were then centrifuged then resuspended in 5ml DMEM. For cell
passaging, and an appropriate volume of cell suspension added to a T75 flask to
give a required dilution ratio typically of 1:5-1:20. Maintenance concentrations of
appropriate antibiotic were also included (see Table 2.2).
For experiments, 100µl cell suspension was loaded onto a haemocytometer and
the number of cells within a 1mm2 area counted (25x0.04mm2 squares totalling
0.1µl volume). The average number of cells per ml was calculated by multiplying
the number of cells by 10,000. This cell suspension was then resuspended in an
appropriate volume of DMEM to give the required cell density. Prior to seeding,
the wells of an appropriate plate were coated with poly-D-lysine (10 µg ml-1 in
double distilled H2O; filter sterilised using a 0.2µm filter) for 30min at room
temperature before being aspirated and washed with DMEM.
Typically cells were seeded the day before experimentation with the exception of
cells under the tetracycline repressor system (eg. HEK293TR Y1-GFP) or cells used
for cAMP accumulation experiments (see Table 4 for details).
2.2.2.2 Transfection
Transfection is the process of introducing DNA into a recipient eukaryotic cell
and, for stable transfection, the integration of this DNA into the host cells
genome. Stable transfections were undertaken using lipofectamine (Invitrogen)
and the appropriate cell line (HEK293T or HEK293TR cells) to generate mixed
populations. Cells were grown to 70% confluence in T25 flasks and the media
replaced with 1.2 ml OptiMEM (Invitrogen). Mixtures of 2 µg DNA in 200µl
OptiMEM and 18 µl lipofectamine also in 200µl OptiMEM, were prepared
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separately and then combined to allow lipofectamine:DNA complexes to form
over 1hr at room temperature. At the end of the incubation, a further 800µl
OptiMEM was added to the DNA-lipofectamine reaction, which was then mixed
by vortexing. The entire 1.2 ml DNA-lipofectamine mixture was then carefully
added to the T25 flask of cells and left for 24 h at 37°C and 95% O2/5% CO2. The
next day, cells were passaged using the standard protocol described (in section
2.2.2.3) and seeded at a 1:5 ratio. The appropriate antibiotic was also added at
concentration required for selection (Table 2.2).
2.2.2.3 Dilution cloning
Dilution cloning was used to generate HEK293T clonal cell lines expressing Snap
modified receptor constructs, namely Snap Y1-Yn, Snap Y1Y99A-Yn and Snap
ɴ ?ZzŶ ? ĂŶĚ ƚŚĞ ɴ ?ĂƌƌĞƐƚŝŶ ? ?'Ŷ Žƌ ɴ ?ĂƌƌĞƐƚŝŶ ? ?'Ŷ ďĂƐĞ ůŝŶĞƐ dŚĞƐĞ ĐůŽŶĂů ĐĞůů
lines were then either expressed alone or used to create a dual stably transfected
cell line for use in BiFC dimer experiments. Mixed populations of cell lines
generated by stable transfection (2.2.2.1) were passaged (2.2.2.3) and counted
(2.2.2.1). Serial dilutions were created whereby an appropriate aliquot of cell
suspension was added to a universal containing 20ml DMEM and the appropriate
antibiotic required to give dilutions of ~200 cells per 20ml and ~20 cells per 20ml.
Of each dilution, 200µl per well was seeded onto a clear flat bottomed 96 well
plate with the aim to place 1 cell per well. Cells were left to grow until they had
reached approximately 50% confluency, with growth medium (containing the
required antibiotic for selection) replaced regularly. Only wells containing
colonies grown from a single foci were selected, with growth medium removed
and cells washed with 100µl PBS followed by treatment with 50µl trypsin. Gentle
pipetting was used to detach and collect cells, which were added to an individual
well of a 24 well plate containing 1.5ml DMEM. Cells were then grown to
approximately 70% confluency with cell morphology assessed, before being
moved to 6 well plates. Additionally 100µl cell suspension of each clone was
seeded onto 2 wells of a poly-D-lysine coated 96 well plate to allow clones to be
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screened for receptor expression. Screening was achieved using Snap tag
labelling (see section 2.2.5.4) and imaging using an IX Ultra confocal plate reader.
The growth of positive clones was expanded in T75 flasks before being frozen.
The clone showing appropriate levels of receptor expression was either used
alone in experiments, or co-transfected with FLAG and Yc tagged receptor
constructs to generate mixed population BiFC dimer cell lines (eg. Snap Y1-Yn
(clone) / FLAG Y1-Yc (mixed)).
2.2.2.4 Induction of receptor expression using tetracycline
For receptor constructs expressed in HEK293TR cells (e.g. Y1-GFP), receptor
expression was induced following treatment with tetracycline (1µg ml-1) 24 h
prior to experimentation. The promoter of pcDNA4/TO contained two operon
sites (see figure 2.6) that are typically bound by the repressor protein co-
expressed in HEK293TR cells. This repressor control mechanism subsequently
prevents receptor transcription initiation. Treatment with tetracycline led to a de-
repression process, whereby the repressor protein is now bound by tetracycline.
This leads to the dissociation of the repressor protein from the tetracycline
operon sites, allowing receptor transcription to commence from the pCMV
promoter (Yao et al., 1998).
2.2.3 [
125
I] PYY competition binding studies
2.2.3.1 Membrane preparation
Crude membranes were freshly prepared from HEK293T or 293TR (following
tetracycline induction) cell lines, grown to 70% confluent in T75 flasks. All
equipment and buffers were kept on ice whilst membranes were prepared.
Medium was aspirated from flasks, and cells washed using PBS. 15ml of
membrane preparation buffer (25mM HEPES, 10mM Na2EDTA and 0.1mM AEBSF;
pH 7.4) was fired at the cells to detach them from the flask. The cell suspension
was added to a Dounce homogeniser. A further 5ml of membrane preparation
buffer was used to wash the surface of the T75 flask to collect any remaining
85
cells. This 5ml of suspension was also added to the homogeniser. The entire
suspension was then homogenised 15 times using a pestle to break down cell
architecture. The suspension was then centrifuged for 20min at 40,000x g and
the resulting pellet resupended in 15ml of membrane resupension buffer (25mM
HEPES, 1mM Na2EDTA and 0.1mM AEBSF; pH 7.4) and added to the homogeniser.
A further 5ml was used to wash the centrifuge tube and collect any remaining
cells. The homogenisation process was repeated and the resulting suspension
centrifuged again for 20min at 40,000x g. The resulting pellet was resuspended in
4ml of membrane resuspension buffer and placed in a homogeniser. The
suspension was homogenised 50 times, before being placed on ice until needed.
2.2.3.2 Assay protocol
Experimental incubation buffer consisted of 25mM HEPES, 2.5mM CaCl2 and
1.0mM MgCl2, 0.1% BSA and 0.01% bacitracin (pH7.4). Bacitracin was included in
the assay buffer as a metallopeptidase inhibitor.
&Žƌ'dWɶ^ĚŝƐƉůĂĐĞŵĞŶƚƐ ?ƐĂƉŽŶŝŶǁĂƐĂůƐŽŝŶĐůƵĚĞĚŝŶƚŚĞĂƐƐĂǇďƵĨĨĞƌĂƚĂĨŝŶĂů
concentration of 30µg/ml-1, in order to permeabilise cell membranes and allow
access of the GTPyS to micelles (Cohen et al., 1996).
400µl of assay incubation buffer was added first to each experimental tube. Serial
dilutions of competing non radioactive ligands (at 10x final concentration) were
made up in assay incubation buffer and then added as a 50µl aliquot in duplicate
ƚŽƚŚĞĂƉƉƌŽƉƌŝĂƚĞƚƵďĞĂŶĚƚƵďĞƐǀŽƌƚĞǆĞĚ ?'dWɶ^ĚŝůƵƚŝŽŶƐǁĞƌĞŶŽƚŵĂĚĞƵƉ
until needed due to its instability. A stock volume of [125I] PYY was diluted in
incubation buffer to give a final experimental concentration per tube of 15pM.
The volume for dilution was determined for each experiment, to account for the
decreasing activity of the radioligand as it decays. Firstly the activity of stock (in
Bq) was calculated using the equation:
1. ቀ ୱ୲୭ୡ୩ ୳ୱୣୢ (ஜ୪)୲୭୲ୟ୪ ୴୭୪୳୫ୣ ୱ୲୭ୡ୩ (ஜ୪)ቁ . stock size(in Bq). eି஽. ೗೙మ೟భ/మ
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where D is the difference in days between the assay date and the reference date,
and t1/2 is the half life of Iodine-125
Radioactive activity required per tube (500 µl) was then calculated using the
equation:
2. Assay concentration (15pM)/2*specific activity of radioligand (81.4
Bq/fmol).
The dilution volume was finally calculated using the equation:
3. (Equation 1/ Equation 2)*volume of radioligand per tube (25µl)
This 25µl aliquot of diluted [125I] PYY was added to the side of each assay tube (ie.
not directly to the assay buffer to avoid cross contamination with the competing
ligands) and tubes vortexed. 10µl aliquots of [125I] PYY were saved for later
calibration of the gamma counter counting efficiency. A 25µl aliquot of diluted
cell membranes was then added to all assay tubes (except the designated blanks),
and tubes vortexed. The stock volume of diluted membranes was vortexed every
6 tubes to prevent settling. Therefore each assay tube contained a total volume
of 500µl consisting of:
400µl assay incubation buffer
50µl cold ligand
25µl diluted [125I] PYY
25µl diluted membranes
Competition binding assays were carried out for 90 minutes at 21°C with gentle
shaking. Membrane bound ligand was then separated by filtration through
Whatman GF/B filters pre-soaked in 0.3% polyethyleneimine solution using a
Brandel cell harvester. Retained radioactivity was quantified using a gamma
counter (Packard Cobra II, Perkin Elmer, Waltham, MA, USA).
2.2.4 [3H]cAMP accumulation assay
Typically in response to receptor activation, the enzyme adenylyl cyclase converts
ATP to cAMP and pyrophosphate. Therefore the production of cAMP can be used
as a readout of the activity of adenylyl cyclase. To facilitate this [3H] adenine can
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be used to label pools of intracellular adenine nucleotides, such as ATP ([3H]ATP)
which is then converted to [3H]cAMP. In response to the activation of receptors
coupled to the Gi class of G proteins, such as Y receptors, the Gɲsubunit inhibits
adenylyl cyclase and subsequent [3H]cAMP production. Measuring [3H]cAMP
production in response to agonist stimulation gives an indication of the degree of
receptor induced inhibition with sequential column chromatography used to
recover [3H] cAMP from [3H] ATP (Donaldson et al., 1989).
2.2.4.1.1 Dowex columns
A slurry of Dowex AC 50 50W-4X resin mesh 200-400 (1:1 (v/v)) with distilled
water was mixed under constant stirring and 2.4ml of this suspension was added
to each Bio-Rad Poly-prep column. Columns were regenerated prior to each
experiment using 10ml 1M HCL, followed by 2 washes of 10ml distilled water.
Columns were cleaned after each experiment using 10ml 1M NaOH followed by 2
washes of 10ml distilled water.
2.2.4.1.2 Alumina columns
Columns were prepared when 0.6g of Neutral alumina WN-3 was added to each
Bio-Rad Poly-prep column. Both prior to and after each experiment, columns
were washed twice with 10ml 0.1M imidazole.
2.2.4.2 Assay protocol
The assay protocol was adapted from (Donaldson et al., 1989). Due to the large
number of cells required for each assay, HEK293T cells were cultured in 175cm2
flasks (T175). Cells were seeded onto poly-D-lysine coated 24 well plates two days
prior to experimentation at a density of 100,000 cells per well in a total volume of
500µl (see section 2.2.2.3). On the day of the experiment, cells were loaded with
100µl of serum free DMEM containing 1µl [3H] adenine per well (2 µCi/ml; ie.
25µl [3H] adenine in 2.5ml DMEM per plate) added using a 10ml Eppendorf
combitip. Plates were incubated for 2hr at 37°C/5% CO2 to allow incorporation of
[3H]adenine into intracellular pools of adenine nucleotides. Following this,
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extracellular [3H]adenine was removed by washing once with 400µl of serum free
DMEM and replaced with 400µl DMEM/0.1% BSA containing 1mM rolipram (a
phosphodiesterase IV inhibitor). Antagonists, where used, were added at this
stage at an appropriate concentration, and plates incubated for 30 min at
37°C/5% CO2. Serial dilutions of desired agonist were made up in a vehicle buffer
of DMEM/0.1% BSA. A 50µl aliquot of agonist was added to designated wells,
along with a negative control of vehicle alone. Cells were preincubated with
agonist for 10min at 37°C/5% CO2, before the addition of 50µl per well of
forskolin (final concentration 30 µM) in serum free DMEM. Plates were then
incubated for a further 1hr at 37°C/5% CO2. Reactions were terminated using
50µl concentrated HCL added to all wells, followed by the addition of 100µl of
[14C] cAMP solution per well (0.25µl [14C] cAMP in 2.5ml ddH2O per plate). The
addition of [14C] cAMP, allowed the percentage recovery sample cAMP during
column chromatography to be estimated and corrected for. Therefore 3 vials
containing 100µl of [14C] cAMP alone from the day of the assay, representing
100% recovery controls, were saved to be read at a later date alongside the
corresponding plate. Assay plates were frozen and stored at -20°C in a
radioactivity designated freezer prior to recovery of [3H]cAMP and [14C]cAMP
using sequential column chromatography.
2.2.4.3 [
3
H] cAMP and [
14
C] cAMP recovery
Sequential chromatography using prepared Dowex and Alumina Biorad columns,
was used to isolate [3H] cAMP from [3H] ATP. This method was based on that
described by (Salomon et al., 1974). Columns were prepared as described above
(2.2.7.1), during which time assay plates were thawed at room temperature. The
whole well contents, totalling 650µl, was transferred to Dowex columns and left
to drip through. The resin of the Dowex columns, though negatively charged
themselves absorb the negatively charged nucleotides, cAMP, AMP, ADP and ATP
delaying their passage through the column. Upon washing the columns with 3ml
distilled water, the more negatively charged molecules, ATP and ADP are repelled
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by the negatively charged Dowex and forced through the column. The less
negatively charged AMP and cyclic AMP are retained in the Dowex column. The
Dowex columns were then placed over the alumina columns. The addition of 6ml
distilled water per Dowex column facilitated the elution of cAMP ([3H] cAMP,
[14C] cAMP and unlabelled cAMP) into the alumina column. Alumina columns
were then placed directly over scintillation vials, with 5ml 0.1M imidazole added
to each column to allow the elution of cAMP from the column into the vial (due
to the induced rise in pH). 8ml of scintillation fluid was added to each vial, in
addition to the 3 100% recovery vials saved from the day of the experiment. All
ǀŝĂůƐ ǁĞƌĞ ƚŚĞŶ ĐŽƵŶƚĞĚ ƵƐŝŶŐ Ă ɴ ƐĐŝŶƚŝůůĂƚŝŽŶ ĐŽƵŶƚĞƌ ĐĂƉĂďůĞ ŽĨ ƐŝŵƵůƚĂŶĞŽƵƐ
dual counting of [3H] and [14C].
The scintillation fluid added to each vial contains phosphors which have
luminescence properties. Upon decay [3H] and [14 ? ƌĂĚŝŽŝƐŽƚŽƉĞƐ Ğŵŝƚ ɴ ?
particles, which transfer energy absorbed by the phosphor. They then re-emit
this as photons, which are counted to give counts per minute (cpm). The use of a
control radioactive sample alongside each vial, allowed the efficiency of the mix
of scintillation fluid/elution to be determined. From this cpm values were
corrected to give estimated disintegrations per minute (dpm) values. The use of
dual counting of samples relies on the two radioisotopes decaying with different
ĞŶĞƌŐŝĞƐĨƌŽŵĞĂĐŚŽƚŚĞƌ ?dŚĞɴ ?ƉĂƌƚŝĐůĞƐĞŵŝƚƚĞĚďǇ ?14C] have more energy than
those produced by [3H], and are therefore recognised as distinct species by the
scintillation counter producing a separate value for each isotopes disintegration.
2.2.5 Automated platereader assays
2.2.5.1 Agonist induced internalisation of HEK293TR GFP tagged receptors
HEK293TR cells stably expressing FLAG-tagged receptor-GFP constructs were
seeded onto poly-D-lysine coated 96 well clear flat bottomed black sided plates
(Greiner 655090, Greiner Bio-One, Stonehouse, UK) two days prior to assay at a
density of 20,000 cell per well. The next day cells were treated with 1 µg/ml
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tetracycline to induce receptor expression (see section 2.2.2.4). On the day of
experiment, cells were washed once with medium consisting of HEPES buffered
saline solution (HBSS; 147mM NaCl, 5 mM KCl, 1.3mM CaCl2, 1mMMgSO4, 10mM
HEPES, 2mM NaCH3COCO2; pH 7.45) supplemented with 0.1% bovine serum
albumin (BSA). This was then replaced with 100µl per well of HBSS. BSA was
included in the assay vehicle to prevent the peptide ligands from sticking to the
plasticware. Vehicle (HBSS) or agonist additions were made to triplicate wells and
incubated at 37°C for times as indicated. Following this, cells were washed with
phosphate buffered saline (PBS) and fixed in 3% paraformaldehyde (PFA)/PBS for
10min at room temperature. Cells were then washed with PBS for 5min followed
by nuclei staining using H33342 (bisbenzimide H 33342 trihydrochloride; Sigma
Aldrich; 2µg ml-1 in PBS) for 15min at room temperature. Wells were then washed
twice with PBS before being imaged using an IX Ultra confocal plate reader
(Molecular Devices). A Plan Fluor 40x NA0.6 extra long working distance air
objective with a pinhole set to 4 was used to image four central sites per well.
405nm (DAPI; cell nuclei) and 488nm (GFP) laser excitation were used. Laser
powers and gains were kept constant for all experiments (see Table 2.6).
2.2.5.2 Bimolecular fluorescence complementation (BiFC)
Bimolecular fluorescence complementation (BiFC) is a fluorescence based
technique which can be used to investigate defined protein-protein interactions.
A fluorescent protein is split into 2 non fluorescent halves N and C terminal
fragments. These fragments can be covalently fused to proteins of interest eg.
ƌĞĐĞƉƚŽƌ ?zĐ ĂŶĚ ɴ ?ĂƌƌĞƐƚŝŶ ? ?zŶ  ?<ŝůƉĂƚƌŝĐŬ Ğƚ Ăů ? ? ? ? ? ? Z ? hƉŽŶ ŝŶƚĞƌĂĐƚŝŽŶ ŽĨ ƚŚĞ
tagged proteins, the two fragment tags are brought into close proximity
facilitating their association and refolding into the full length vYFP. The
chromophore matures, which then produces a fluorescent signal that acts as a
readout of the interaction of the two tagged proteins (Kerppola, 2009).
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Figure 2.9: The principle of bimolecular fluorescence complementation (BiFC)
Two proteins of interest can be covalently tagged with complementary fragments of vYFP. Following interaction of the tagged proteins, these
fragments re-associate and re-fold to form full length vYFP. Following chromophore maturation, observed fluorescence acts as a readout of
protein-protein interaction.
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 ? ? ? ? ? ? ?DĞĂƐƵƌŝŶŐƚŚĞŝŶƚĞƌĂĐƚŝŽŶŽĨɴ ?ĂƌƌĞƐƚŝŶ ?ǁŝƚŚEWzzƌĞĐĞƉƚŽƌƐƵƐŝŶŐŝ&
HEK293T cells stably co-expressing a mixed population of FLAG-NPY Y receptor-Yc
ĂŶĚĐůŽŶĂůɴ ?ĂƌƌĞƐƚŝŶ ? ?zŶ ?z ? ? ? ZŽƌɴ ?ĂƌƌĞƐƚŝŶ ?'Ŷ ?z  ? ?' ?z ? ? ?' ZǁĞƌĞƐĞĞĚĞĚ
the day prior at a density of 40,000 cells per well onto poly-D-lysine coated 96
well clear bottomed black sided plates (Greiner 655090). Cells were washed with
serum free DMEM/0.1% BSA (vehicle) and replaced with 100µl per well. Plates
were incubated for 20min at 37°C/5% CO2. Agonists or vehicle control were
added to the appropriate-triplicate wells to give a final concentration range of 10-
10 to 10-6M and incubated for 60min at 37°C/5% CO2. Cells were then washed,
fixed and nuclei stained as described in section 2.2.3.1. Plates were also imaged
using an IX Ultra confocal platereader, fitted with a Plan Fluor 40x NA0.6 extra
long working distance air objective, with 405nm (DAPI; cell nuclei) and 488nm
(YFP; BiFC signal) laser lines used for excitation. A larger pinhole diameter of 7
was used for imaging recomplemented YFP to improve the signal to noise ratio.
2.2.5.4 Receptor visualisation of Snap tagged receptors
The Snap tag is a 20 kDa mutated version of the human DNA repair protein O6-
alkylguanine transferase (hAGT). Physiologically this enzyme removes alkyl
groups on the O6 position of guanine bases of DNA and covalently transfers them
to an internal cysteine residue (Pegg, 2011). This property has been exploited for
use in tagging recombinant proteins by engineering hAGT to react with
exogeneous benzylguanine substrates covalently bound to a fluorophore (BG-
AF647 throughout). This leads to irreversible labelling of the Snap tag with the
fluorescent probe allowing direct visualisation of N terminally Snap modified
receptors. Snap surface labels are membrane impermeant, therefore only
receptors that have been successfully trafficked from the endoplasmic reticulum
or Golgi apparatus and are subsequently expressed at the cell surface (with
extracellular Snap tag) are labelled.
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Figure 2.11: The principle of combining Snap labelling and BiFC to study the interaction
of two receptor protomers.
The schematic illustrates how HEK293T cells were stably transfected with a clonal GPCR
protomer (A) expressing an N terminal Snap tag. The Snap tag is a small polypeptide
based on a mammalian DNA repair protein, which irreversibly transfers the alkyl group of
a membrane impermeant fluorophore conjugated substrate (AF-647) to a cysteine
residue of the tag sequence allowing the surface expression of Snap labelled receptor to
be imaging using the Cy5 filter settings of a confocal platereader (B). To investigate the
internalisation of receptor dimers, Snap-protomer A can be co-expressed with an
additional FLAG labelled protomer B. Both protomers (A and B) are tagged at their C
terminus with a fragment of YFP. Receptor dimerisation brings the two fragments into
close proximity whereupon they can refold into recomplemented YFP. This produces a
fluorescent signal that identifies a discrete interaction between receptors of known
composition (BiFC dimer).
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2.2.5.5 Agonist induced internalisation of BiFC constrained GPCR dimers
For BiFC dimer experiments, Snap 647 labelling of Snap-Receptor-Yn (termed
protomer A; Figure 2.11) allowed the simultaneous imaging of this population
with the BiFC dimer population (complementation between Snap Receptor-Yn /
FLAG Receptor-Yc protomers A+B; recomplemented YFP) in the same cell. This
allowed the responses of the BiFC dimer population to be compared with the
protomer A population (be that monomers, dimers or oligomers).
HEK293T cells stably co-expressing Snap-receptor protomer A-Yn alongside a
mixed population of FLAG-tagged receptor protomer B-Yc were seeded onto
poly-D-lysine coated 96 well clear flat bottomed black sided plates (Greiner
655090) on the day before experiment at a density of 40,000 cells per well. On
the day of experiment, cells were treated with serum supplemented DMEM
containing 0.2µM Snap AF647 for 30min at 37°C/5% CO2. Wells were then
washed with HBSS/0.1% BSA before being replaced with 100µl per well of HBSS /
0.1% BSA. Vehicle or agonist were added as a 20µl aliquot typically at a final
concentration range of 10-10 to 10-6M to triplicate wells and incubated at 37°C for
times as indicated. Cells were then fixed and nuclei stained as described
previously (2.2.3.1). Plates were imaged using an IX Ultra confocal platereader,
fitted with a Plan Fluor 40x NA0.6 extra long working distance air objective, with
a pinhole set to 7 using 405nm (DAPI; H33342 cell nuclei) and 488nm (FITC; YFP
BiFC signal) and 647nm (Cy5; Snap AF647 label) laser excitation.
2.2.6 Specific platereader assay methods
2.2.6.1 Assays requiring pretreatment with antagonist
Where antagonist pre-treatment was required after the initial wash, the contents
of wells of even numbered columns was replaced with 100µl of HBSS/0.1% BSA
containing the appropriate concentration of antagonist (see Figure 2.10, plate
layout B). To the wells of odd numbered columns, 100µl of medium alone was
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added. Plates were incubated for 30min at 37°C/5% CO2, prior to agonist
addition. From this point on the assay protocol followed that of section 2.2.3.1.
2.2.6.2 Timecourse assays
To assess the timecourse of agonist induced internalisation of receptor
constructs, the same protocol as for section 2.2.5.3 or 2.2.5.5 was followed until
the replacement of well volumes with 100µl per well of HBSS/0.1% BSA. 100nM
NPY was then added as a 20µl aliquot to the centre of wells in rows B D and F at
an appropriate time point, such that incubations finished concurrently The time
intervals chosen were 30, 20, 15, 12, 10, 8, 6, 4, 2, and 1min (see plate layout).
Assay medium was quickly removed, by flicking the well contents into a sink. Cells
were immediately fixed as described in 2.2.3.1.
2.2.7 Confocal microscopy
HEK293T Snap-receptor cell lines were seeded onto poly-D-lysine coated 8 well
clear plates (Nunc Lab-Tek, Thermo-Fisher Scientific, UK) at a density of 50,000
cells per well. The next day, live cells were labelled with 0.2µM Snap AF647 as
previously described (see section 2.2.3.4), washed twice with HBSS/0.1% BSA
(vehicle) and treated with either 300µl vehicle or 100nM NPY in HBSS/0.1% BSA
for 30 min at 37°C. Images were taken using a Zeiss LSM 510 (Carl Zeiss Ltd.,
Welwyn, UK) fitted with a 63x Plan Apochromat NA 1.4 oil objective using Argon
488nm (Recomplemented vYFP) and HeNe 633nm (SNAP-surface AF647) laser
lines for excitation.
Multitrack settings were utilised, so that the sample was illuminated sequentially
with the distinct laser excitations to prevent bleed-through from one to the
other. Long pass and band pass emission spectra are detailed in Table 2.5.
A pinhole diameter of 1.5 Airy units was set for the longest wavelength acquired
(633 nm / long pass 650nm) and the optical slice subsequently matched for the
shorter wavelength (488nm / BP 505  550 nm). This pinhole size was larger than
the optimal pinhole size of 1 Airy unit in order to improve the signal to noise ratio
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when imaging BiFC fluorescence. Microscope detector gains and amplifier offsets
were consistently adjusted within data groups to enable comparison between
control and treated samples and prevent oversaturation. All images were taken
at 1024x1024 pixels per frames with 8 averages limiting total laser exposure per
acquisition to approximately one minute.
When using HEK293TR receptor-GFP cell lines, cells were seeded two days prior
to assay at a density of 20,000 cells per well. The next day receptor expression
was induced following the addition of 1µg ml-1 tetracycline (see section 2.2.2.4).
Cells were also imaged using a Zeiss LSM 510 fitted with a 63x Plan Apochromat
NA 1.4 oil objective using an Argon 488nm laser line for excitation and emitted
light collected via a 505-550nm bandpass filter, using a pinhole diameter of 1 Airy
unit. Gains and offsets were consistently adjusted within data groups to prevent
oversaturation. All images were taken at 1024x1024 pixels per frame with 8
averages.
2.2.8 Fluorescence correlation spectroscopy (FCS)
Fluorescence correlation spectroscopy (FCS) is a technique which measures the
diffusion of fluorescently tagged moieties through a fixed confocal volume of
approximately 0.25µm3. As fluorescent particles pass through this volume, they
produced time dependent fluctuations in intensity which were analysed to
generate information concerning the mobility, concentration and molecular
brightness of these particles (Figure 2.12; see Chapter 4).
2.2.8.1 Calibration
FCS measurements were performed using a Zeiss Confocor 2 fluorescence
microscope fitted with a c-Apochromat 40x NA 1.2 water immersion objective
lens. Calibration was required to ensure the optimal position of the beam path
and to confirm a detection volume of Gaussian shape. Calibration was first
performed using rhodamine 6G (Invitrogen, DR6G; known diffusion coefficient, D =
3x10-6 cm2 s-1). 10-2M stock solutions of Rhodamine 6G was diluted to 10-6M and
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10-8M aliquots in ultrapure fluorescence free water. 300µl of each dilution was
placed into separate wells of an 8 well plate and left for 5min before calibration.
The plate was placed over the objective, and firstly centred on the well containing
the 10-6M solution. Both the lower then upper surface of the 8 well plate were
determined using the reflection beampath and the focal position set 200µm
above the upper surface as the defined well bottom.
A beampath was then selected which gave the correct laser excitation, dichroic
mirror and emission filter for detecting GFP tagged receptors. An Argon laser set
to 25% output, with a pinhole diameter of 1 Airy unit was used. When calibrating
using 10-6M rhodamine, a laser power of 0.3% was used and the collar correction
adjusted to give a count rate of 200-250 kHz. The position of the pinhole was
then scanned and automatically optimised by the machine in both the x and y
axis alongside adjustment of the collimator position (z axis). The x,y and z values
were recorded for each experiment, with the x and y values not expected to
widely vary. The objective was then centred over the well containing the 10-8M
rhodamine solution and the laser power increased to give a count rate of
approximately 50-70 counts per molecule. Rhodamine calibration measures of 3
x 15 seconds reads were then carried out using a range of laser powers (5-1%).
The first read was used to bleach immobile species within the sample in order to
obtain a more stable trace in the absence of systematic decreases in mean
intensity over the recording time. However in reality, bleaching for rhodamine is
minimal (due to its fast diffusion), and was therefore included as a control for
measurements of fluorescent protein tagged cells where bleaching is much more
prevalent. The calibration autocorrelation curves were then fitted using the
inbuilt analysis software (Zeiss AIM, Jena, Germany) to a one component 3D
diffusion model with the structural parameter set to free (see section 2.2.11.1 for
further details of equations used). All counts per molecule and structural
parameters for each laser power used were recorded in order to confirm that the
system was calibrated correctly and to calculate the parameters required for
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analysis post experiment. The structural parameter is a value that is extremely
sensitive to correct calibration as it is the ratio of the height to waist radius of the
confocal volume. For correct rhodamine calibration this value should be
approximately 5 for a Gaussian detection volume (independent of the laser
power used).
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Figure 2.12: The principles of fluorescence correlation spectroscopy (FCS)
The confocal volume was positioned on the upper membrane of the cell (A) and the diffusion of fluorescently tagged molecules through the
confocal volume was detected. These time dependent fluctuations in fluorescent intensity were measured (B) and analysed to give quantitative
data concerning the mobility and concentration of these fluorescent particles (C).
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2.2.8.2 Measuring the diffusion of superfolder GFP tagged receptors using FCS
HEK293TR cells expressing FLAG receptor-GFP were seeded on poly-D-lysine
coated 8 well plates (Nunc Lab-Tek, Thermo Fisher Scientific, UK) at a density of
20,000 cells per well. The next day receptor expression was induced upon
tetracycline addition (1µg ml-1 see section 2.2.2.4). FCS experiments were
performed two days post seeding. On the day of the assay, cells were washed
with HBSS/0.1% BSA. Well contents were then replaced with 400µl per well
vehicle and cells pretreated with either vehicle or 100nM NPY for 15min at
37°C/5% CO2. Following this plates were placed over the objective (previously
calibrated as detailed in section 2.2.5.1) and fluorescent cells (of approximately
equivalent brightness) were selected from live imaging using a Zeiss Axiocam HR
camera with GFP exposure set to 700ms. To prevent bleaching, a low laser power
(0.1%) was used to place the xy position of the focal volume over the centre of a
nucleus. The z position of the confocal volume was determined by performing a z
scan which, for plasma membrane limited tagged receptors, produced 2 peaks
defining the upper and lower membranes of the cell. The focal volume was then
placed at the z position on the upper membrane. When recording
autocorrelation fluctuations, the laser power was increased to 0.3% (0.61
kW/cm2) and a 15sec prebleach was performed followed by 2 x 15sec reads.
 ? ? ? ? ? ? ? DĞĂƐƵƌŝŶŐ ƚŚĞ ĚŝĨĨƵƐŝŽŶ ŽĨ &>' ƌĞĐĞƉƚŽƌ ?'Đ ĂŶĚ ɴ ?ĂƌƌĞƐƚŝŶ ? ?'Ŷ
complexes using FCS
HEK293T cells co-expressing a mixed population of FLAG receptor-Gc and clonal
ɴ ?ĂƌƌĞƐƚŝŶ ? ?'ŶǁĞƌĞƐĞĞĚĞĚŽŶƉŽůǇ ?D-lysine coated 8 well plates at a density of
50,000 cells per well the day before experimentation.
On the day of the assay, cells were washed with HBSS/0.1% BSA (vehicle). Well
contents were then replaced with 400µl per well of vehicle and cells pretreated
with 100nM NPY for 1 h at 37°C/5% CO2.
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Fluorescent cells were again selected from live imaging using a Zeiss Axiocam HR
camera. However GFP exposure during selection was increased to 1000 ms, to
account for the reduced signal to noise ratio of recomplemented GFP. A defined
plasma membrane was difficult to identify for GFP BiFC cells, therefore the xy
position of the confocal volume was placed over an area of high intensity
fluorescence corresponding to internalised receptor within perinuclear recycling
compartments. Following cell selection, a z scan was performed as before but the
confocal volume was now placed slightly offset of the fluorescence intensity peak
representing the upper membrane. From this point, the same assay protocol was
followed as for full length GFP tagged receptors (section 2.2.8.2).
2.2.9 Fluorescence recovery after photobleaching (FRAP)
Fluorescence recovery after photobleaching (FRAP) is a technique that can be
used to quantify the 2D diffusion of fluorescently tagged molecules. Additionally
FRAP can also provide estimates on the respective proportions of mobile and
immobile fluorescent molecules present. In FRAP the fluorescent molecules
present on a small region of interest (ROI) on a cell, are irreversibly
photobleached using a high intensity laser power. Subsequent recovery of
fluorescence due to the lateral diffusion of non bleached fluorescent molecules
into the bleached area are recorded and estimates of diffusion coefficients
calculated (Ishikawa-Ankerhold et al., 2012).
2.2.9.1 Using FRAP to measure the diffusion of GFP tagged receptors
HEK293TR cells expressing native or mutant Y1 receptor-GFP were seeded on
poly-D-lysine coated 8 well plates (Nunc Lab-Tek) at a density of 20,000 cells per
well. The next day receptor expression was induced using tetracycline addition
(1µg ml-1 see section 2.2.2.4). FRAP experiments were performed two days post
seeding.
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 ? ? ? ? ? ? ? hƐŝŶŐ &ZW ƚŽ ŵĞĂƐƵƌĞ ƚŚĞ ĚŝĨĨƵƐŝŽŶ ŽĨ z ? ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ? ŝ&
complexes
&Žƌ &ZW ŝŶǀĞƐƚŝŐĂƚŝŽŶƐ ƵƐŝŶŐ ,< ? ? ?d ĐĞůůƐ ĐŽĞǆƉƌĞƐƐŝŶŐ z ? ƌĞĐĞƉƚŽƌ ĂŶĚ ɴ ?
arrestin constructs tagged with superfolder GFP complementary fragments (e.g.
Y1/A2G) cells were seeded on poly-D-lysine coated 8 well plates (Nunc Lab-Tek)
at a density of 40,000 cells per well. FRAP experiments were performed the
following day.
2.2.9.3 FRAP experimental protocol
FRAP experiments were performed using a Zeiss LSM710 laser scanning
microscope using a 63x Plan-Apochromat NA 1.4 oil objective. Argon 488nm (full
length or recomplemented GFP) laser excitation was used with emitted light
collected between 493 -558nm. On the day of the assay, cells were washed with
HBSS/0.1% BSA. Well contents were then replaced with 400µl per well of vehicle
and cells pretreated with either vehicle or 100nM NPY for 15min (GFP tagged
constructs) or 60min (GFP fragment tagged constructs) at 37°C/5% CO2. Slides
were then transferred to a heated stage and left to equililbrate at 37°C. A 1.4µm2
ROI (radius 0.66µm; red circle in Figure 2.13) was placed on the lower plasma
membrane adjacent to the coverglass. 10 images were then acquired at 0.5sec
intervals (512x512 pixels) to provide a baseline value of fluorescence intensity for
the ROI. The region of interest was then bleached using 50 iterations of 100%
laser power. Fluorescence recovery was then measured for 90 (full length GFP) to
120 sec (recomplemented GFP). Following this ROIs were also placed on an area
of the coverslip containing no cells (background ROI; blue circle) and an adjacent
cell of comparable fluorescence intensity to the cell investigated (representative
cell; green circle). These representative ROIs allowed background fluorescence
and the amount of non bleached fluorescent signal lost during imaging
(background bleaching) to be corrected for in recovery curves. A one phase
exponential model was used to fit FRAP recovery curves (see section 2.12).
Figure 2.13: Repres
Representative im
circular area on the
is shown in red (P
spot (bleach pane
(green) and backg
2.2.10 Data analy
2.2.10.1 [
125
I] PY
As each ligand c
count was used.
binding was su
molecule (dpm)
Specific cpm * (1
Where 60 is the
Where CE = co
aliquot, protein
activity (81.4 Bq
IC50 values were
squares regressi
used to convert I
104
entative images showing the placement of RO
ages show a FRAP experiment being performe
lower plasma membrane approximately 1.3µm
rebleach panel). Following bleaching, this area
l). Following the recording of fluorescence re
round (blue) references ROIs are drawn (recover
sis
Y competition binding
oncentration was performed in duplicate,
Non specific binding, comprising less than
btracted from the data. Specific disinteg
were converted to fmol/mg using the formul
/60) * (100 / CE) * 1000 / protein * (1 / SA)
factor to convert counts per minute to count
unting efficiency (%), based on the days
= amount of protein (µg) in membrane aliqu
/ fmol).
calculated from displacement curves fitted u
on in GraphPad Prism 5.02. The Cheng P
C50measurements to pKi values where appro
I used in FRAP
d on Y1-GFP cells. The
to be photobleached
is now seen as a black
covery, representative
y panel).
the average gamma
5% of total specific
rations per minute
a:
s per second.
reference [125I] PYY
ot, and SA = specific
sing non linear least
rusoff equation was
priate:
105
x Ki = IC50/ (1+[L]/Kd)
where [L] is the concentration of free radioligand and Kd the dissociation constant
of the radioligand derived from homologous displacements of PYY for the
receptor.
Homologous PYY displacements were used to derive approximate estimates of
Bmax values (in pmol mg-1 membrane protein) using the equation:
x Bmax = TSBxIC50/[L]
where TSB is the total specific binding in the absence of agonist and [L] the
radioligand concentration used.
To convert disintergration counts to fmol/mg the counting efficiency of the
gamma counter was firstly determined using the equation:
1. = ୓ୠୱୣ୰୴ୣୢ ୡ୭୳୬୲ୱ ୤୰୭୫ ୰ୣ୤ୣ୰ୣ୬ୡୣ ୴୭୪୳୫ୣ (୆୯)ୟୡ୲୧୴୧୲୷ ୭୤ ୰ୟୢ୧୭୪୧୥ୟ୬ୢ ୭୬ ୡ୭୳୬୲ ୢୟ୷ ݔ 100
The concentration of radioligand per assay in fmol/mg was then calculated using
the equation:
2. = ቀଵ୅ቁ . Equation 1. ቀଵ଴଴଴୆ ቁ . ቀଵେቁ
where A = the half life of the radioligand
B = protein amount within the assay volume used (µg/tube).
C = the known specific activity of the radiolabel (81.4 Bq/fmol).
All values are quoted as means ± s.e.m throughout.
2.2.10.2 Inhibition of cAMP accumulation
To determine the efficiency of the column chromatography, the average of the 3x
100% recovery vials per experiment was used to give the expected [14C]-cAMP
dpm values assuming 100% column efficiency (the 100% recovery dpm). To
correct for column efficiency, the [14C] dpm value from each individual column
was divided by this 100% recovery dpm to give the fraction recovered from that
column (the recovery fraction). The corrected [3H] dpm value for each column
was then determined by dividing the [3H] dpm obtained from the counter by this
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recovery fraction. All cAMP data presented in this thesis are expressed as
corrected [3H] dpm values obtained from raw data which has been normalised
using negative (unstimulated cells representing 0% basal values) and positive
controls (wells stimulated with 30µM forskolin only representing 100% values) to
allow different assay plates to be compared. Normalised dpm values from
multiple experiments were pooled and then plotted against agonist
concentration with bottom values constrained to 100% and Hill slopes set equal
to 1. Antagonist Kb values were calculated as for section 2.2.9.1.2.
2.2.10.3 Automated image analysis of plate reader images
The images acquired using the IX Ultra confocal platereader (see section 2.2.3;
Figure 2.14) can be analysed using various algorithms (MetaXpress 2.0, Molecular
Devices) to provide quantitative data of receptor internalisation. All images
acquired were 16 bit greyscale, meaning each pixel is represented as a number
from 0 (black) to 65535 (white). Images of receptor internalisation (Example
images from Y1-GFP receptor internalisation are shown in Figure 2.14; panel A
ĂŶĚ  Z Žƌ ŝ& ŝŵĂŐĞƐ ŽĨ EWz z ƌĞĐĞƉƚŽƌƐ ŝŶƚĞƌĂĐƚŝŶŐ ǁŝƚŚ ɴ ?ĂƌƌĞƐƚŝŶ ǁĞƌĞ
analysed using a granularity algorithm which identified regions of internalised
fluorescence as granules of 3-15 µm in diameter (Figure 2.14 panel C; white
spots). Additionally fluorescence intensity thresholds were set to negative
(vehicle) and positive plate controls (top concentration of full agonist used). The
addition of a nuclear stain H33342 identified nuclei, allowing all data to be
expressed on a per cell basis (Figure 2.14 panel C; green masks). Internalised
vesicles were assigned to an identified nucleus based on proximity.
All values were averaged from triplicate wells (4 sites imaged per well; ie. 12 sites
of data obtained per point). Granularity analysis gives several parameters such as
granule count, intensity and area which all produced similar results. All data
presented derived from measurements of granule count per cell. BiFC receptor
dimer images were also analysed using the granularity algorithm.
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ƉŽƐŝƚŝǀĞ  ? ?A?D EWz ĨŽƌ EWz z ƌĞĐĞƉƚŽƌƐ ĂŶĚ  ? ?A?D /ƐŽƉƌĞŶĂůŝŶĞ ĨŽƌ ɴ ?Z
receptors) plate controls.
All automated image analysis data was exported as an Excel spreadsheet and
analysed using GraphPad Prism 5 (Prism 5.02; GraphPad Software Inc, San Diego,
CA).
2.2.10.3.1 Concentration response curves measured using plate reader assays
Data was normalised to the top concentration of the specific full agonist used (eg.
 ?A?D EWz ĨŽƌ EWz z ? ƌĞĐĞƉƚŽƌƐ Žƌ  ? ?A?D /ƐŽƉƌĞŶĂůŝŶĞ ĨŽƌ ɴ ?Z Z ? ŽŶĐĞŶƚƌĂƚŝŽŶ
response curves were fitted to pooled data from at least 3 individual experiments
using non linear least squares regression (Prism 5.02; GraphPad). Additionally
some data sets were expressed where appropriate as percentage fold increase
over basal with all data constrained at basal values to 100%. Hill slopes were
fitted freely but constrained to a maximum of 2. If a maximum response could be
defined agonist pEC50 values were stated (expressed as log EC50; pEC50) as mean
± standard error of the mean and responses fitted as defined by the equation:
Response = = Rmax.[Agonist]n/([Agonist]n+EC50
n)
Where Rmax is the maximum response and n is the Hill Slope.
2.2.10.3.2 Antagonist pretreatment
Responses following antagonist pretreatment were analysed using the Gaddum
equation to determine the affinity of the competitive antagonist used. Firstly the
concentration ratio (CR) was determined as the ratio of the agonist EC50 value in
the absence and presence of a particular concentration of antagonist ([B]). The
antagonist equilibrium dissociation constant (Kb) was then calculated using the
equation: Kb = [B] / (CR-1)
The Kb, equilibrium dissociation constant represents the concentration of
antagonist required at equilibrium to occupy 50% of receptors. Each individual Kb
value from independent experiments was pooled and expressed as mean ±
standard error of the mean.
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2.2.10.3.4 Timecourse of stimulation
Timecourse experimental data were analysed using single phase association
kinetics using Prism 5. A latency period (typically of 2 minutes) was included
where appropriate to account for the delay between agonist addition and initial
response, as indicated in the relevant Figure legends.
2.2.11 FCS
2.2.11.1 Autocorrelation analysis
In FCS the pinhole of the microscope objective can be positioned to create a
Gaussian shaped confocal detection volume (~0.25fl) on a region of interest, such
as the plasma membrane of a cell. As fluorescently tagged moieties diffuse
through this volume they produce time dependent fluctuations in detected
fluorescent intensities. Autocorrelation analysis compares the size of a
ĨůƵĐƚƵĂƚŝŽŶ ?ɷ/ ZǁŝƚŚƚŚĞŵĞĂŶĨůƵŽƌĞƐĐĞŶƚŝŶƚĞŶƐŝƚǇ ?AM/AN ZĂƚƚŝŵĞdǁŝƚŚƚŚĂƚŽĨĂ
ƐƵďƐĞƋƵĞŶƚ ĨůƵĐƚƵĂƚŝŽŶ Ăƚ ƚŝŵĞ dA?ʏ ?  hƐŝŶŐ ƚŚĞ ǁŚŽůĞ ƌĂŶŐĞ ŽĨ ʏ ǀĂůƵĞƐ ? ƚŚĞ
ĂƵƚŽĐŽƌƌĞůĂƚŝŽŶ ĨƵŶĐƚŝŽŶ  ?' ?ʏ Z Z ĐĂŶ ďĞ ĚĞƌŝǀĞĚ ? ǁŚŝĐŚ ŝƐ ƚŚĞŶ ŶŽƌŵĂůŝƐĞĚ ƚŽ ƚŚĞ
square of the mean intensity measured (<I>). The autocorrelation function is
ƚŚƵƐ P' ?ʏ ZA? ?A?AMɷ/ ?d Z ?ɷ/ ?dA?ʏ ZAN ?AM/AN2 (Figure 2.12C).
Non linear curve fitting of data derived from the autocorrelation function using a
biophysical model, was used to produce an autocorrelation decay curve (see
Figure 2.12, panel C). From this curve, specific parameters of the fluorescent
particles within the confocal detection volume can be defined, namely the
ĂǀĞƌĂŐĞĚǁĞůůƚŝŵĞ ?ʏ ZƌĞƉƌĞƐĞŶƚŝŶŐƚŚĞŚĂůĨǁĂǇƉŽŝŶƚŽĨƚŚĞ' ?ʏ ZĚĞĐĂǇ ?ƌŝĚĚŽŶ
and Hill, 2007) and the average particle number N, from its inverse relationship to
the autocorrelation function at time zero (G0).
Experimental calibration using a fluorophore with a known diffusion coefficient,
in this case rhodamine 6G (D = 3x10-6 cm2 s-1), alongside the structural parameter
obtained in calibration, allowed the volume and waist radius of the confocal
ǀŽůƵŵĞ ƚŽ ďĞ ĚĞƚĞƌŵŝŶĞĚ ƉĞƌ ĞǆƉĞƌŝŵĞŶƚ  ?ʘ0=(4D ?ʏ Z1/2). This volume, in
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ĐŽŶũƵŶĐƚŝŽŶǁŝƚŚŝŶĚŝǀŝĚƵĂůʏǀĂůƵĞƐĂůůŽǁĞĚƚŚĞĚŝĨĨƵƐŝŽŶĐŽĞĨĨŝĐŝĞŶƚƐ ?D) of the
fluorescently tagged receptor or complex to be calculated using the equation
DA?ʘ20 ? ?ʏ ? dŚĞ ĐŽŶĐĞŶƚƌĂƚŝŽŶ ŽĨ  ? ůŝŵŝƚĞĚ ĨůƵŽƌĞƐĐĞŶƚ ƉĂƌƚŝĐůĞƐ  ?ŝĞ ? ƌĞĐĞƉƚŽƌƐ
expressed in plasma membranes) within the confocal detection volume, was
derived using the equation N ? ?ʋʘ20).
The model chosen for curve fitting of calibration reads was 1x3D free, as it
incorporates movement in x,y and z dimensions. Very rapid fluctuations (< 10 µs)
were also recorded of excited fluorophore electrons exhibiting delayed decay and
emission. This property, termed the triplet factor, was accounted for by a pre-
exponential term (not shown) in the 1x3D model chosen (1x3D + Triplet):ܩ (߬) = 1 + ଵே .σ . ݂݅. ቀ1 + ఛఛವ೔ቁିଵ . ቀ1 + ఛௌమ.ఛವ೔ቁିభమ௠௜ୀଵ
In addition to components already described, m is the total number of
components (in this case m=1), fi is the fractional contribution that component i
attributes to the curve (in this case 1), and S is the structural parameter related to
the shape of the confocal volume.
A 2D model, was used to fit traces of GFP tagged receptors and BiFC complexes as
this model only incorporates diffusion in x and y within the plasma membrane.
This model also incorporates a fast pre-exponential component (<10µs) that
accounts for on-off transitions in fluorescence, termed blinking, that is a
consequence of the photophysics of GFP. In this fit, the number of components
(m) was 2. The following equation was used for fitting traces to a 2D model:ܩ(߬) = 1 + 1ܰ .෍. ݂݅. ൬1 + ߬߬஽௜൰ିଵ௠௜ୀଵ
dŚŝƐŵŽĚĞů ƚǇƉŝĐĂůůǇŐĂǀĞ ƚǁŽĚǁĞůů ƚŝŵĞƐ ?ʏ1ĂŶĚʏ2, as well as fi in terms of
the percentage each component contributes to the overall amplitude of the
autocorrelation curve at G(0)  ?ʏ1 A?ĂŶĚʏ2%).
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2.2.11.2. Photon counting histogram (PCH)
In a subset of FCS experiments, the raw fluctuation measurements were also
exported and analysed using photon counting histogram (PCH) analysis (Chen et
al., 1999). Unlike autocorrelation analysis which describes the temporal
behaviour of fluorescence fluctuations, PCH analysis is concerned with the
variations that occur in the amplitude of excitation intensity in different parts of
the confocal volume. PCH analysis can provide information on molecular
ďƌŝŐŚƚŶĞƐƐ  ?ɸ Z ĂŶĚ ĂŶ ĂůƚĞƌŶĂƚŝǀĞ ĐĂůĐƵůĂƚŝŽŶ ŽĨ ƉĂƌƚŝĐůĞ ĐŽŶĐĞŶƚƌĂƚŝŽŶ ? tŚĞŶ
performing PCH analysis, the fluorescence trace is divided into bins of a specific
time. For diffusion of receptor GFP (dwell time ~40 ms) for example, a bin time of
1 ms was chosen throughout to be less than the dwell time of the fluorescent
species but to exclude more rapid time dependent fluctuations attributed to the
photophysics of the fluorophore.
The photon counts in each bin were counted, with a frequency histogram
generated with the x axis representing the number of photon counts k and the y
axis the number of bins containing those counts k. This histogram deviates from
an expected Poisson distribution due to the uneven illumination of the confocal
volume, whereby the greatest excitation is found in the centre of the volume.
This deviation from the ideal Poisson distribution can be measured in PCH
ĂŶĂůǇƐŝƐ ?ĂŶĚĂĨŝƚŵŽĚĞůůĞĚŽŶƚŚĞŶƵŵďĞƌ ?E ZĂŶĚƚŚĞŵŽůĞĐƵůĂƌďƌŝŐŚƚŶĞƐƐ ?ɸ ZŽĨ
fluorescent species.
PCR calibration reads (rhodamine) were fitted to a 1 component model. The
purpose of this calibration was to provide a first order correction value (F), which
accounts for deviation from a Gaussian observation volume when using single
photon rather than 2 photon excitation (Huang et al., 2004). This value was then
used in the analysis of experimental data, using 1 or 2 component PCH models
with a bin time set to 1msec.
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2.2.12 Calculating diffusion coefficients from FRAP recovery curves
A one phase exponential model was used to fit FRAP recovery curves using data
previously corrected for background fluorescence and global bleaching of the
image (Zen 2010 software, Zeiss, Jena, Germany). The following equation was
used:
x I(t) = I0-I1.e-t/T1
I0 is the final intensity value of recovered fluorescence, I1 is the amplitude of the
recovered fraction, T1 is an exponential decay time and t equals time.
t1/2 times of recovery were calculated using the equation:
x t1/2 = T1 In0.5
Percentage of mobile fractions (F1) were calculated using:
x = F1 = 100.I1/(IB-IA)
where IB is the initial fluorescence intensity pre bleaching and IA is the
fluorescence intensity recorded post bleaching.
Diffusion coefficients of fluorescence recovery were calculated using the
equation:
x D= radius of bleached area2/4.t1/2
2.2.13 Statistical analysis
Multiple comparisons between data sets were compared using GraphPad Prism
one way analysis of variance (ANOVA) and Dunnetts post tests to determine
statistical significance (Chapters 3, 5 and 6). For FCS, PCH and FRAP
measurements (Chapter 4), a normal distribution of diffusion co-efficient data
was not assumed, and the non parametric Kruskal-Wallis test followed by Dunns
post test was used to determine statistical significance between groups.
Students unpaired t tests were used to test significance in all other experiments.
All data throughout is expressed as mean ± standard error of the mean (s.e.m).
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Table 2.1: Oligonucleotide primers used for polymerase chain reactions and mutagenesis reactions
Receptor Primer sequence Tm (°C) % GC Length
PCR
Human Y5 - Forward GAGTGGATCCGATTTAGAGCTCGACGAGTATTATAAC 70 43 37
Human Y5 - Reverse ATTAGCGGCCGCCATATGAAGACAGTGTATAAGG 73 47 34
Mutagenesis rat Y1 Phosneg (Y15A)
First round forward (3 mutations) GCATACGGACGTGGCCAAGGCTGCTTTGAAGC 79 59 32
First round reverse GCTTCAAAGCAGCCTTGGCCACGTCCGTATGC
Second round forward (2 mutations) CTATAGCCATGGCAGCCATGCATAC 68 52 25
Second round reverse GTATGCATGGCTGCCATGGCTATAG
Bolded regions show restriction enzyme sites.
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Table 2.2: The use of antibiotics in maintaining cells in culture
Antibiotic resistance
Parent cell line Cell line cDNA Construct Receptor plasmid Concentration Experimental use
,< ? ? ?d ĞŽĐŝŶ ^ŶĂƉz ? ?zŶ ?ɴĂƌƌĞƐƚŝŶ ? ?zŶ ƉĐE ? ? ?ǌĞŽĐŝŶ  ? ? ?A?Őŵů-1 ŝ&ĐŽŶƐƚƌĂŝŶĞĚĚŝŵĞƌƐ ?ɴ ?ĂƌƌĞƐƚŝŶ ?
association
HEK293T Neomycin
(G418)
z ? ?zĐ ?ɴ ?Z ?zĐ ƉDs&>'  ? ? ?ŵŐŵů-1 ŝ&ĐŽŶƐƚƌĂŝŶĞĚĚŝŵĞƌ ?ŝ&ɴ ?
arrestin2 association
HEK293TR Blasticidin For tetracycline operon pcDNA4/TR 5µg ml-1 Internalisation, FCS
A table summarising the antibiotics used in routine cell culture, the parent cell line plasmid they select for and the selection concentration used.
115
Table 2.3: Table of tagged constructs used throughout this thesis.
Host vector N terminal
tag
cDNA insert C terminal
tag
Bacterial
resistance
Mammalian
resistance
Tetracycline
inducible
Plasmid
map
pcDNA3.1
zeocin
Snap Y1 (rat) Yn Ampicillin Zeocin No Figure 2.4
Snap Y15A (rat) Yn Ampicillin Zeocin No
Snap ɴ ?Z ?ŚƵŵĂŶ Z Yn Ampicillin Zeocin No
ɴ-arrestin2 Yn Ampicillin Zeocin No Figure 2.7
ɴ-arrestin2 Gn (sf)* Ampicillin Zeocin No
ɴ-arrestin2LIEFD Gn (sf) Ampicillin Zeocin No
ɴ-arrestin1 Gn (sf) Ampicillin Zeocin No
pCMV FLAG Y1 (rat) Yc Kanamycin Neomycin No Figure 2.5
FLAG Y1 Gc (sf) Kanamycin Neomycin No
FLAG Y16A Yc Kanamycin Neomycin No
FLAG Y16A Gc (sf) Kanamycin Neomycin No
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FLAG Y15A (rat) Yc Kanamycin Neomycin No
FLAG Y1Y199A(rat) Yc Kanamycin Neomycin No
FLAG Y4 (human) Yc Kanamycin Neomycin No
FLAG Y5 (human) Yc Kanamycin Neomycin No
FLAG ɴ ?Z ?ŚƵŵĂŶ Z Yc Kanamycin Neomycin No
FLAG ɴ ?ZE ? ? ?(human) Yc Kanamycin Neomycin No
FLAG ɴ ?Zz ? ? ? ?ŚƵŵĂŶ Z Yc Kanamycin Neomycin No
pcDNA4/TO FLAG Y1 (rat) GFP (sf) Ampicillin Zeocin Yes Figure 2.6
FLAG Y4 (human) GFP (sf) Ampicillin Zeocin Yes
FLAG Y5 (human) GFP (sf) Ampicillin Zeocin Yes
FLAG Y2 (rat) GFP (sf) Ampicillin Zeocin Yes
FLAG Y2H155P (rat) GFP (sf) Ampicillin Zeocin Yes Figure 2.6
*sf abbreviation refers to superfolder GFP
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Table 2.4: Table detailing the parameters required for seeding of cells depending on the experimental use.
Cell seeding
Plate layout Cell density/cell Volume/well Day plated Experimental use
96 well
HEK293T 40, 000 100 µl Day prior Platereader experiments
HEK293TR 20, 000 100 µl 2 days prior Platereader experiments
24 well
HEK293T 100, 000 500 µl 2 days prior Inhibition of cAMP accumulation
8 well
HEK293T 50, 000 300 µl Day prior Confocal microscopy, FCS, FRAP
HEK293TR 25, 000 300 µl 2 days prior Confocal microscopy, FCS, FRAP
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Table 2.5: Laser excitation and emission spectra for use with the IX Ultra confocal platereader
Laser excitation Fluorophore emission Laser power Laser gain
H33342 (cell nuclei) 405nm 447/60nm 40% 500
BiFC (recomplemented YFP or GFP) 488nm 525/50nm 50% 550
Receptor-GFP (superfolder) 488nm 525/50nm 30% 500
Snap receptor 647nm 685/40nm 35% 500
Table 2.6: Laser excitation and emission spectra for use with a confocal Zeiss LSM 510
Laser excitation Laser type Emission filter Laser power Gain
BiFC (recomplemented YFP or GFP) 488nm Argon BP 505-530nm 3% 850-1000
Receptor-GFP (superfolder) 488nm Argon BP 505-530nm 3% 800-900
Snap receptor 633nm Helium-Neon LP650nm 15% 800-900
BP = band pass filter; LP = long pass filter
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ŚĂƉƚĞƌ  ? PDĞĂƐƵƌĞŵĞŶƚŽĨɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚĂŶĚ
endocytosis of fluorescently tagged NPY Y receptors
using high content imaging and automated analysis
3.1 Introduction
3.1.1 The importance of fluorescence based imaging techniques
Fluorescence based imaging techniques provide the opportunity to visualise
cellular proteins, such as GPCRs, in their native environment at a single cell
level. Recent advances in both the fluorescence proteins themselves and
imaging techniques have allowed the spatial and temporal resolution of
protein-protein interactions in living and fixed cells. This is particularly
important as many of these interactions are involved in the regulation of a
ǁŝĚĞ ƌĂŶŐĞ ŽĨ ƉŚǇƐŝŽůŽŐŝĐĂů ƉƌŽĐĞƐƐĞƐ ? &Žƌ ĞǆĂŵƉůĞƚŚĞ ƌĞĐƌƵŝƚŵĞŶƚ ŽĨ ɴ ?
arrestins has been implicated in regulating GPCR desensitisation, endocytosis,
and subsequent trafficking (see Chapter 1; section 1.6) as well as directing
signalling in their own right to produce therapeutically relevant outcomes
(Chapter 1, section 1.7).
A variety of techniques have been used to selectively visualise receptors and
other proteins in cells. Some of these are theoretically applicable to receptors
in their native environment. For example antibodies conjugated to
fluorophores offer potentially high labelling as they selectively recognise a
small receptor peptide epitope expressed on the target protein. However this
epitope must be of high enough selectivity to minimise non specific binding
and antibodies (particularly those that are monoclonal) are expensive. In
respect to GPCRs, fluorescent ligands are an alternative label as they both
identify receptor expression and act as a pharmacological probe (Kuder and
Kiec-Kononowicz, 2008). However a caveat of this technique is that the
addition of a fluorescent label can adversely affect the affinity of a ligand for
its target receptor, and the localisation of ligands and their receptors may
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differ during intracellular trafficking. However fluorescent imaging of proteins
within a cell, more often requires genetic modifications to target proteins.
Snap tagging can be used to attach a fluorophore to the protein itself. This is a
modified form of a DNA repair enzyme, which covalently binds a synthetic
probe (most often a fluorophore) transferred from a benzyl guanine
substrate, and can be inserted as genetically engineered tag attached to the
target protein (see Chapter 5 for further details on Snap tag labelling). This
technique minimises non specific labelling as the probe is chemically inert in
respect to other proteins. Genetically encoded full length fluorescent protein
tags also offer an alternative method of labelling, and do not require the
addition of exogenous substrates. Both fluorescent protein (typically 27 kD)
and the Snap tag enzyme (20 kD) represent substantive modifications to the
labelled receptor, which may potentially affect function. As the fluorescent
protein is encoded alongside that of the target protein, labelling is
theoretically of a 1:1 stoichiometry. However to improve their effectiveness
as biological labels, naturally occurring fluorescent proteins have required
engineering.
3.1.2 The engineering of fluorescent proteins for use in biological assays
The isolation and subsequent cloning of green fluorescent protein (GFP) from
the jellyfish species Aequorea Victoria (Prasher et al., 1992) combined with
advances in microscopy, has revolutionised the imaging of biological
processes in single cells. Fluorescent proteins have also been isolated from
other species, such as DsRed from the sea anemone Discosoma (Patterson,
2007). The elucidation of the crystal structure of GFP revealed a 11 stranded
beta barrel wrapped around a central alpha helix (Figure 3.1, A; (Ormo et al.,
1996)). Each strand consists of 9-13 residues linked by inter-strand loops.
During maturation the chromophore is buried inside the beta barrel,
ultimately resulting in the production of fluorescence. A photon hitting the
chromophore excites an electron from its ground state to an excited energy
state. When the electron falls back to its lower state, it loses energy either by
emitting a photon or from heat or vibration (Figure 3.1B). This emitted
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photon is of lower energy and therefore a longer wavelength than the excited
photon. This is manifested as a difference (in terms of the frequency or
wavelength) in the maximum peaks observed for the fluorescence absorption
and emission spectra. This difference is termed the Stokes shift (Figure 3.1C).
Figure 3.1: The tertiary structure of G
The tertiary structure of GFP is shown
(A). dŚĞ  ? ? ɴ ƐƚƌĂŶĚƐ ƐƵƌƌŽƵŶĚŝŶŐ ƚŚ
Absorption of light by the chromopho
returning to a relaxed state is emitted
of light is illustrated in C and is termed
Figure A was taken from (Tsien, 1998)
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FP
in A, with the central residues that form the chromophore shown
e chromophore are also shown. Panel B shows the principle of
re excites an electron from a ground state of energy to a higher e
as photons of a longer wavelength than that originally absorbed. Th
the Stokes shift.
.
as a ball and stick representation
electron excitation and emission.
nergy state. The energy lost upon
is shift in frequency or wavelength
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Maturation of the chromophore in GFP and GFP derived polypeptides is a
multistep process consisting of a folding step, followed by the formation of
the native conformation of the protein and finally oxidation of an internal
tripeptide which becomes the core of the chromophore (Ser65-Tyr66-Gly67;
(Heim et al., 1995)). However wildtype GFP has some properties that make its
use as a biological label in mammalian cells unsuitable, such as a relatively low
quantum yield and poor folding and maturation at 37°C (Patterson, 2007).
To address some of these limitations, selective mutations were introduced
into the wildtype GFP sequence. An initial mutation at serine residue 65 to
threonine resulted in GFP with increased quantum yield and crucially a single
excitation peak which lessens potential ultraviolet excitation, avoiding
damage to living cells (Heim et al., 1995). An additional mutation was then
introduced at F64L which resulted in accelerated chromophore maturation at
37°C and was termed eGFP (Cormack et al., 1996). The rate of folding,
chromophore maturation, fluorescence intensity and thermostability of the
protein at 37°C was further improved by additional mutation of the eGFP
sequence. These included the cycle 3 mutations (F99S, M153T and V164A)
which increased fluorescence intensity compared to wildtype GFP due to
improved folding efficiency (Crameri et al., 1996) as well as substitutions at
residues S30R, Y39N, N105T, Y145F, I171V and A206V. All wildtype GFP
derived fluorescent proteins have a tendency to form dimers, albeit at high
(µM) concentrations. This property is undesirable in biological assays, as it can
lead to the atypical localisation and disrupted function of any labelled
proteins. Therefore a lysine substitution was also introduced at alanine
residue 206 (A206K) which inhibited the formation of GFP dimers (Zacharias
et al., 2002). These 11 mutations resulted in a GFP variant, that was more
suitable for use in fluorescence based biological assays and was termed
superfolder GFP (Pedelacq et al., 2006). As for A206K, the A206V substitution
was introduced, based upon theoretical modelling of dimeric GFP, to hinder
the probability of superfolder GFP forming dimers (Pedelacq et al., 2006). The
S30R substitution is the greatest contributor to increasing folding rate and
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efficiency at 37°C by mediating the formation of an electrostatic network of
ƌĞƐŝĚƵĞƐŝŶɴƐƚƌĂŶĚƐ ? ? ? ? ?ĂŶĚ ? ?dŚŝƐŝŶĐƌĞĂƐĞĚƚŚ ŝŶŚĞƌĞŶƚƐƚĂďŝůŝƚǇŽĨƚŚĞ
structure even when fused to a poorly folding protein partner. These
mutations ultimately resulted in the fluorescence intensity of GFP being 60%
greater than that of eGFP with no changes to either excitation or emission
spectra.
Both the eGFP and GFP forms can be used as biological tags to label proteins
of interest, such as GPCRs, in order to investigate the pharmacological
properties of these receptors.
3.1.3 GFP variants  Yellow Fluorescent Protein
The eGFP sequence has been further engineered to produce coloured variants
with different excitation and emission spectra (from blue to orange). This is
typically done by substituting residues in the immediate environment
surrounding the chromophore with residues that are spatially similar. Of these
the yellow variant (eYFP) was produced by a substitution of a threonine
residue that lies close to the chromophore at position 203 with tyrosine
(T203Y). However eYFP has a relatively slow folding and maturation rate at
37°C, as well as being sensitive to pH and halides. Therefore additional
mutations were introduced to address these limitations resulting in the
variant form Venus YFP (vYFP) (Nagai et al., 2002). The principle mutation,
F46L is responsible for increasing the rate of folding and chromophore
maturation at 37°C by accelerating the oxidation of Tyr66 residue within the
internal tripeptide at the core of the chromophore. This F46L mutation is
specific to YFP, as the same mutation introduced into eGFP and other GFP
variants had no effect upon maturation. 4 additional folding mutations were
also introduced; F64L. M153T, V163A S175G which are also shared with other
GFP variants. All enhanced folding and maturation at 37°C by introducing
ŚŝŐŚůǇ ĨůĞǆŝďůĞ ƐŵĂůůĞƌ ƐŝĚĞ ĐŚĂŝŶƐ ŽƵƚƐŝĚĞ ƚŚĞ ɴ ďĂƌƌĞů ƐƚƌƵĐƚƵƌĞ ǁŝƚŚŝŶ ƚŚĞ
connecting loop regions. These 4 mutations were also effective at decreasing
pH and halide sensitivity of vYFP. However they did not have any significant
effect upon fluorescent intensities, when compared to eGFP (100%), with
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relative brightness values being 151% for eYFP and 156% for vYFP
respectively.
3.1.4 The use of fluorescent proteins
Full length fluorescent proteins have been expressed in a wide range of
species including mammalian, nematode, plant, insect, fungi and yeast cells
(reviewed in (Tsien, 1998) ). Theoretically GFP derived proteins can be
expressed in any cell amenable to genetic modification (Hu et al., 2002). The
intrinsic fluorescence of these proteins means there is no requirement for
external substrates. Additionally unlike immunolabelling techniques (such as
antibody conjugates) no cell permeabilisation or fixation is required.
Fluorescent protein expression appears to be well tolerated by live cells, and
is easily detected using standard FITC excitation and emission filters (for GFP)
on a fluorescence microscope.
Arguably the most successful use of fluorescent proteins has been in directly
labelling proteins of interest in order to visualise their subcellular location.
The gene encoding the fluorescent protein is fused in frame with that of the
gene encoding the target protein, (Kallal and Benovic, 2000). The resulting
chimera is then expressed in the cell, effectively in a 1:1 stoichiometry.
Protein-GFP fusions have been successfully identified in a range of organelles
including secretory vesicles, the endoplasmic reticulum, Golgi apparatus,
mitochondria, peroxisomes and nucleus (reviewed in (Tsien, 1998)). They have
also been used to label plasma membrane spanning proteins, including
'WZƐ ? dŚĞ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ǁĂƐ ƚŚĞ ĨŝƌƐƚ 'WZ ƚŽ ďĞ ƐƵĐĐĞƐƐĨƵůůǇ ůĂďĞůůĞĚ
with eGFP (Barak et al., 1997a) and was then followed by labelling of GPCRs
spanning all classes of the superfamily (reviewed in (Kallal and Benovic,
2000)). For example, both N terminal eGFP (Gicquiaux et al., 2002) and C
terminal vYFP (Kilpatrick et al., 2010) tags have been used to investigate the
agonist induced internalisation of NPY Y1 receptors.
Fluorescent proteins tags have also been used to study the real time dynamics
of protein-protein interactions, such as the recruitment of proteins from the
cytosol to the plasma membrane. For example the desensitisation and
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endocytosis of many activated GPCRs, has been shown to be dependent upon
ŝŶƚĞƌĂĐƚŝŽŶǁŝƚŚɴ ?ĂƌƌĞƐƚŝŶ ?ŚĂƉƚĞƌ ? ?ƐĞĐƚŝŽŶ ? ? ? Z ?dŚŝƐĂƐƐŽĐŝĂƚŝŽŶŚĂƐďĞĞŶ
ǀŝƐƵĂůŝƐĞĚĂƚĂĚŝƐƚŝŶĐƚƌĂŶŐĞŽĨ'WZƐƐƵĐŚĂƐƚŚĞɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ?ĚŽƉĂŵŝŶĞ
D1 and angiotensin II type 1A receptors by imaging the fluorescence
ƌĞĚŝƐƚƌŝďƵƚŝŽŶ ŽĨ '&W ƚĂŐŐĞĚ ɴ ?ĂƌƌĞƐƚŝŶ ? ĨƌŽŵ ƚŚĞ ĐǇƚŽƐŽů ƚŽ ƚŚĞ ƉůĂƐŵĂ
membrane following receptor activation (Barak et al., 1997b, Zhang et al.,
 ? ? ? ? Z ? dŚŝƐ ƚĞĐŚŶŝƋƵĞ ǁĂƐ ĂůƐŽ ƐĞŶƐŝƚŝǀĞ ĞŶŽƵŐŚ ƚŽƐŚ ǁ ƚƌĂĨĨŝĐŬŝŶŐ ŽĨ ɴ ?
arrestin2-GFP to distinct subcellular locations depending on the stability of its
interaction with specific GPCRs (Zhang et al., 1996).
3.1.5 Protein Complementation Assays
The use of fluorescent tags to label proteins can provide useful information on
their cellular distribution and co-localisation with other structures (for
ĞǆĂŵƉůĞ ɴ ?ĂƌƌĞƐƚŝŶ ?'&W ǁŝƚŚ 'WZƐ Z ? ,ŽǁĞǀĞƌ ĐŽůŽĐĂůŝƐĂƚŝŽŶ ĐĂŶ ŽŶůǇ ŝŵƉůǇ
but not resolve protein-protein interactions. Standard light microscopy is
limited in spatial resolution by Abbes limit which states that a point source of
light must form a diffraction limited spot 150 - 250 nm in diameter, depending
on wavelength and the numerical aperture of the lens .
However there are a range of fluorescence based techniques that can be used
to investigate protein-protein interactions indirectly including fluorescence
resonance energy transfer (FRET), fluorescence lifetime imaging microscopy
(FLIM), bioluminescence resonance energy transfer (BRET) which can be used
singularly or in conjunction with each other (Ciruela et al., 2014). Protein
complementation assays (PCA) offer a further option for discretely identifying
the molecular composition of protein complexes (Diekmann and Hoischen,
2014). A reporter protein is split into its complementary N and C terminal
fragments, which are both fused to proteins of interest. Upon close
association of the two proteins, the fragment tags are able to re-fold and
produce a readout indicative of specific protein-protein interactions
(Kerppola, 2008b, Hu and Kerppola, 2003). Initial assays produced an
ĞŶǌǇŵĂƚŝĐ ƌĞĂĚŽƵƚ ? ǁŝƚŚ ĨƌĂŐŵĞŶƚƐ ŽĨ ɴ ?ŐĂůĂĐƚŽƐŝĚĂƐĞ Žƌ ĚŝŚǇĚƌŽĨŽůĂƚĞ
reductase used (reviewed in (Kerppola, 2008a, Michnick et al., 2011)).
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However in order to visualise many of these interactions an exogenous
chromogenic or fluorogenic substrate is required, which can risk disrupting
the environment surrounding the PCA complex, for example through cell lysis.
Therefore PCAs utilising fluorescent protein fragments were developed which
exploit the intrinsic fluorescence produced when fluorescently tagged
proteins interact within living cells (Kerppola, 2013, Ghosh et al., 2000). This
modification was termed bimolecular fluorescence complementation (BiFC).
3.1.6Bimolecular Fluorescence Complementation (BiFC)
In bimolecular fluorescence complementation (BiFC), fluorescent proteins (for
example vYFP) are split into their complementary N and C terminal fragments.
WƌŽƚĞŝŶƐ ŽĨ ŝŶƚĞƌĞƐƚ  ?ƐƵĐŚ ĂƐ ƌĞĐĞƉƚŽƌ ĂŶĚ ɴ ?ĂƌƌĞƐƚŝŶ ? Z ĂƌĞ ĐŽǀĂůĞŶƚůǇ ƚĂŐŐĞĚ
with these fragments (see Figure 2.2) which themselves are not fluorescent
(Hu et al., 2002). However upon protein association, the fragments are
brought into close proximity and refold to reform the full length fluorescent
protein (Rose RH, 2010). The resulting fluorescent signal acts as a readout of
tagged protein-protein interaction. Fluorescence complementation was
initially demonstrated using split eGFP fused to leucine zippers of
transcription regulatory proteins both in vitro and in E coli (Ghosh et al.,
2000). This assay was then modified using eYFP fragments to successfully
visualise the interaction of Fos and Jun transcription factors in vitro and in
living transfected mammalian COS cells (Hu et al., 2002). BiFC has now been
successfully used in a wide range of cell systems such as bacteria, yeast,
insect, plant and mammalian (Kerppola, 2009, Vidi and Watts, 2009) using a
wide variety of fluorescent protein fragments (Kodama and Hu, 2012).
As the beta barrel of the fluorescent protein must be present in order to
maintain the complex network of polar residues surrounding the
chromophore (Ormo et al., 1996), the location of the split point, typically
ǁŝƚŚŝŶ ƚŚĞ ůŽŽƉƐ ĐŽŶŶĞĐƚŝŶŐ ŝŶĚŝǀŝĚƵĂů ɴ ?ƐƚƌĂŶĚƐ ŽĨ ƚŚĞ ďĂƌƌĞů ? ŝƐ ĐƌƵĐŝĂů ƚŽ
successful complementation. In this work, the fluorescent protein tags
generated from vYFP or superfolder GFP (see Chapter 4), contained an
ŽǀĞƌůĂƉƉŝŶŐƌĞŐŝŽŶŽĨƌĞƐŝĚƵĞƐŵĞĂŶŝŶŐ ƚŚĂƚɴƐƚƌĂŶĚ  ?ǁĂƐƌĞƉĞĂƚĞĚĂƚƚŚŝƐ
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break point in both the N (residues 2-172 termed Yn or Gn) and C terminal
(residues 155-238 termed Yc or Gc) fragments. For both vYFP and GFP this
ďƌĞĂŬƉŽŝŶƚǁĂƐďĞƚǁĞĞŶɴƐƚƌĂŶĚƐ ? ? ? ?ĂŵŝŶŽĂĐŝĚƐ ? ? ? ? ? ? ? ZŽƌɴƐƚƌĂŶĚƐ ? ? ?
(amino acids 172/173). The use of BiFC fragments with an overlapping region
has been shown to aid the refolding process (Hu and Kerppola, 2003) and
increase the kinetics of BiFC development when compared to using fragments
that lack this overlap (Kilpatrick et al., 2010).
Figure 3.2: The principle of using BiFC to investigate the interaction of Y receptor
ƐƵďƚǇƉĞƐǁŝƚŚɴ ?ĂƌƌĞƐƚŝŶ ? ?
Y receptor subtypes were tagged at the C terminal domain with a fragment of Venus
YFP (Yc). The complimentary vYFP fragment (Yn) was covalently attached to the C
ƚĞƌŵŝŶƵƐ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ? &ŽůůŽǁŝŶŐ ĂĚĚŝƚŝŽŶ ŽĨ ƚŚĞĂŐŽŶŝƐƚ EWz ? ƚŚĞ ƌĞĐĞƉƚŽƌ ƚŚĞŶ
ĂƐƐŽĐŝĂƚĞƐ ǁŝƚŚ ɴ ?ĂƌƌĞƐƚŝŶ ? ? ďƌŝŶŐŝŶŐ ƚŚĞ ƚǁŽ ĨůƵŽƌĞƐĐĞŶƚ ĨƌĂŐŵĞŶƚƐ ŝŶƚŽ ĐůŽƐĞ
proximity allowing them to refold to form the full length YFP. Following a period of
maturation, the chromophore then matures to produce a fluorescent signal which
ĐĂŶĂĐƚĂƐĂƌĞĂĚŽƵƚŽĨƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ?ĂƐƐŽĐŝĂƚŝŽŶ ?<ŝůƉĂƚƌŝĐŬĞƚĂů ? ? ? ? ? ? Z ?ƐĞĞ
Chapter 2, 2.2.5.3).
One of the reasons for using BiFC in this thesis, as opposed to other PCAs or
&Zd ŝƐ ƚŚĂƚ ƚŚĞ ƐƵďĐĞůůƵůĂƌ ůŽĐĂůŝƐĂƚŝŽŶ ŽĨ ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ? ĐŽŵƉůĞǆĞƐ
could be visualised directly using single wavelength measurements on a
standard confocal platereader. Quantification of this fluorescent BiFC signal
using automated analysis provided an indirect measure of the recruitment of
ɴ ?ĂƌƌĞƐƚŝŶ ?ƚŽĂĐƚŝǀĂƚĞĚƌĞĐĞƉƚŽƌƐ ?<ŝůƉĂƚƌŝĐŬĞƚĂů ? ? ? ? ? ? Z ?
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3.2 Aims of this chapter
The mains aims of this chapter are to undertake a quantitative comparison of
ƚŚĞƌĞůĂƚŝǀĞĂďŝůŝƚŝĞƐŽĨĚŝĨĨĞƌĞŶƚzƌĞĐĞƉƚŽƌƐƵďƚǇƉĞƐƚŽƌĞĐƌƵŝƚɴ ?ĂƌƌĞƐƚŝŶ ?ĂŶĚ
undergo regulatory endocytosis. This will be achieved by using GFP tagging of
Y receptor subtypes, or YFP BiFC fragment tagging of Y receptor (receptor-Yc)
ĂŶĚ ɴ ?ĂƌƌĞƐƚŝŶ ?  ?zŶ Z ?  dŚĞ ĞǆƚĞŶƚ ƚŽ ǁŚŝĐŚ ƚŚĞƐĞ ƚǁŽ ƉƌŽĐĞƐƐĞƐ  ?z ƌĞĐĞƉƚŽƌ
ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶĂŶĚɴ ?ĂƌƌĞƐƚŝŶ ?ďŝŶĚŝŶŐ ZĂƌĞĐŽƌƌĞůĂƚĞĚǁŝůůďĞŝŶǀĞƐƚŝŐĂƚĞĚďǇ
quantifying agonist and antagonist pharmacology using high content imaging
techniques and automated analysis.
Targeted amino acid substitutions in both the Y1 and Y2 receptor sequences
ŽĨ ƉŽƚĞŶƚŝĂů ɴ ?ĂƌƌĞƐƚŝŶ ŝŶƚĞƌĂĐƚŝŽŶ ŵŽƚŝĨƐ ? ǁŝůů ďĞ ƉĞƌĨŽƌŵĞĚ ƚŽ ŝŶǀĞƐƚŝŐĂƚĞ
ǁŚĞƚŚĞƌ ƚŚĞ ŵŽůĞĐƵůĂƌ ŵĞĐŚĂŶŝƐŵƐ ŝŶǀŽůǀĞĚ ŝŶ ɴ ?ĂƌƌĞƐƚŝŶ ? ďŝŶĚŝŶŐ ĂŶĚ
receptor endocytosis are comparable.
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3.3 Results
3.3.1 The use of full length fluorescent protein tags to investigate the
agonist induced internalisation of Y1 and Y2 receptors.
Y1 or Y2 receptor-GFP cDNA was expressed in HEK293TR cells with receptor
expression induced using tetracycline 18hr prior to experimentation (see
Chapter 2, section 2.2.2.4). To verify expression of Y1-GFP and Y2-GFP
constructs, competition [125I] PYY binding was initially performed.
Displacements of specific binding for Y1-GFP membranes are shown in Figure
3.3. Both agonist (PYY; A) or a non peptide Y1 antagonist (BIBO3304; B) were
able to displace specific [125I] PYY binding. Compared to the Y1 subtype, Y2-
GFP exhibited increased PYY binding affinities, consistent with its documented
higher affinity (Gehlert et al., 1996a, Krause et al., 1992). For both Y1 and Y2-
'&W ?'dWɶ^ǁĂƐĂďůĞƚŽŝŶŚŝďŝƚ ?125I] PYY binding by disrupting the formation of
the high affinity Y receptor-G protein complex (Figure 3.3, C) (Kilpatrick et al.,
2012). Additionally Bmax estimates indicated that expression levels were
comparable between both cell lines. This validation of receptor function (in
respect to ligand binding and G protein coupling) was important as the
addition of the relatively large GFP tag may adversely affect receptor function.
The expression of receptor-GFP constructs was also confirmed using confocal
fluorescent imaging. In the absence of tetracycline treatment, no GFP
fluorescence was observed for any cell line (Figure 3.4). Following treatment
with vehicle (HBSS/0.1% BSA; 30min at 37°C) predominantly plasma
membrane localised GFP fluorescence was observed for both native and
mutant Y1 (A) and Y2-GFP tagged receptors (B). Cells were then stimulated
with the endogenous agonist NPY (1µM; 30min at 37°C) and the same region
of cells imaged. Marked receptor internalisation was observed for the Y1
receptor-GFP, represented as highly intense punctuate regions of internalised
GFP fluorescence (granules). Internalisation was also observed for Y2-GFP
receptors following this high concentration of NPY. However detecting more
subtle differences in agonist potency between these subtypes required more
quantitative automated imaging of receptor internalisation.
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Figure 3.3: [
125
I] PYY competition binding experiments in HEK293TR cell membranes stably expressing Y1-GFP receptors
Membranes freshly prepared from HEK293TR cell lines stably expressing Y1-GFP were incubated with [125I] PYY (15pM) and increasing concentrations of
ƵŶůĂďĞůůĞĚWzz ? Z ?/K ? ? ? ? ? ZŽƌ'dWɶ^ ? ZĨŽƌ ? ?ŵŝŶĂƚ ? ? ? ?DĞŵďƌĂŶĞďŽƵŶĚƌĂĚŝŽůŝŐĂŶĚǁĂƐƐĞƉĂƌĂƚĞĚƵƐŝŶŐĨŝůƚƌĂƚŝŽŶĂŶĚƋƵĂŶƚŝĨŝĞĚƵƐŝŶŐĂŐĂŵŵĂ
counter. Competition displacement curves were generated using GraphPad Prism, with pooled data representing 4 independent experiments. Data was
expressed as mean ± s.e.m (Hill slope range 0.72-1.0).
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Table 3.1: [
125
I] PYY membrane competition binding parameters derived from Y receptor-GFP and BiFC HEK293T cell lines
Cell line PYY BIBO3304 'dWɶ^ Bmax
pIC50 pIC50 pIC50 % inhibition fmol/mg
-1
Y1 9.5 ± 0.2 9.0 ± 0.2 68.6 ± 6.7 1500 ± 700
Y16A 9.2 ± 0.1 8.8 ± 0.2 72.9 ± 7.0 2300 ± 100
Y2 10.8 ± 0.1 8.8 ± 0.1 69.2 ± 5.4 2200 ± 300
Y2H155P 10.6 ± 0.1 8.7 ± 0.2 46.9 ± 10.2 2100 ± 200
Y1/A2 9.8 ± 0.1 9.0 ± 0.1 9.1 ± 0.2 58.6 ± 4.1 350 ± 60
Y16A/A2 9.6 ± 0.1 9.1 ± 0.2 9.0 ± 0.1 63.2 ± 1.2 340 ± 30
Y2/A2 11.1 ± 0.1 9.2 ± 0.1 73.8 ± 3.5 1190 ± 120
All parameters were obtained from [125I] PYY competition membrane binding experiments as described in Chapter 2, section 2.2.3.
Details of receptor mutations are given in the text.
% inhibition of TSB refers to the displacement by 1µM competing ligand, as a % of the total specific binding (TSB) defined in the absence / presence of 1 µM
PYY.
n =3-4 independent experiments
Table was reproduced from (Kilpatrick et al., 2010, Kilpatrick et al., 2012).
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Firstly a timecourse of NPY stimulation was used to determine an appropriate
assay timepoint (Figure 3.5). Both Y1-GFP (A) and Y2-GFP (B) were stimulated
over a 30min timecourse with 100nM NPY (37°C) with the same region of cells
imaged at 5min intervals. By 10min noticeable internalisation was observed
for Y1-GFP that was maintained until 30min. Y2-GFP internalised at a slower
rate with noticeable internalisation only seen from 20min stimulation.
Additionally timecourse experiments using YFP tagged Y1 receptor, have
illustrated rapid NPY induced internalisation (t1/2 2.4min ± 0.3; n=3) that
reaches saturation at 20min (timecourse length 1-120min) (Kilpatrick et al.,
2010). A 30min time period was therefore chosen for all future investigations
of agonist induced internalisation of both subtypes. Y2-GFP receptor
internalisation responses in particular, were noticeably less with 100nM NPY
compared to 1µM NPY (Figure 3.4, B) suggesting that quantification of
responses could reveal subtle differences in subtype specific ligand potencies.
3.3.1.2 The use of automated high content imaging to quantify Y receptor
subtype specific ligand pharmacology
Manual imaging of HEK293T cells expressing Y1 or Y2-GFP constructs using a
confocal microscope (Figure 3.4) provided visual validation of receptor
expression and internalisation. However this is of relatively low throughput
and qualitative images cannot quantify the degree of receptor internalisation
without further manual image analysis. In order to address this, fluorescently
tagged constructs were imaged in a 96 well plate format using an automated
confocal platereader (IX Ultra, MDC). Like a standard confocal microscope,
this provided qualitative images that revealed the subcellular location of
receptor GFP tagged constructs following vehicle and agonist treatment
(Figure 3.6, 3.7A). After stimulation with vehicle (HBSS/0.1% BSA; 37°C), all
receptor constructs were localised predominantly to the plasma membrane
with a small degree of constitutive internalisation observed for both
receptors. Following treatment with NPY, pronounced intracellular regions of
highly intense internalised GFP fluorescence were observed for both
receptors.
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A granularity algorithm was then applied to paired nuclei and GFP images.
Internalised GFP fluorescent compartments were defined on the basis of
diameter (3-15µm) and threshold intensity (see Chapter 2, section 2.2.10.3 for
more detail). These punctuate regions termed granules were identified as
white spots (Figure 3.6; Analysis). Cell nuclei were identified according to a set
diameter range (shown as green spots). This analysis was then used to derive
full NPY concentration response courses for Y1 and Y2 receptors (Figure 3.7, B
and C). Data was expressed as fold over basal to allow responses of cell lines
to be compared. The endogenous agonist NPY was a full agonist stimulating
the internalisation of Y1-GFP receptors with a pEC50 value of 8.4 ± 0.2 (30min
at 37°C; n=4; Figure 3.7, B). However NPY was 63 fold less potent in inducing
the internalisation of Y2-GFP receptors (n=4) with appreciable internalisation
only seen at concentrations in excess of 100nM NPY (Figure 3.7, C). This was
in keeping with the noticeable difference in the extent of Y2-GFP
internalisation observed in confocal imaging performed using 100nM (Figure
3.5) or 1µM NPY (Figure 3.4).
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3.3.1.3 Subtype selective pharmacology of agonist stimulated Y receptor
internalisation
High content imaging was then used to investigate the potency of a panel of
ligands at inducing the internalisation of the four cloned Y receptor subtypes
(Figures 3.7 and 3.8). Subtype specific ligands were also used to ensure that
selectivity was maintained in respect to potency and efficacy following GFP
tag addition. The Y4 and Y5 subtypes were also tagged with full length GFP
and stably expressed in HEK293TR cells. Receptor expression for all cell lines
was induced using tetracycline (1µg/ml) 18hr prior to the assay. All responses
were normalised to the reference 1µM NPY for Y1-GFP, Y2-GFP and Y5-GFP
and 100nM PP for Y4-GFP respectively. Figure 3.9 shows the initial
comparisons for key agonists using these cell lines (with Figure 3.7 NPY data
for Y1-GFP (A) and Y2-GFP (B) also included for comparison, normalised this
time to the reference concentration). A overall summary of potency data for
each receptor-GFP is found in Table 3.2.
Compared to the reference NPY (Figure 3.9, A), pancreatic polypeptide (PP)
showed reduced efficacy at inducing Y1 receptor internalisation with a
maximal response of 18.3 ± 3.3 % (n=4) when normalised to 1µM NPY
responses. A Y1 peptide antagonist GR231118, reported previously to
increase Y1 receptor internalisation (Pheng et al., 2003) showed no activity at
inducing Y1-GFP internalisation (n=3). In contrast PP was the most potent
agonist at promoting Y4 receptor internalisation, with NPY showing
comparatively lower potency and efficacy (Figure 3.9, C). The Y4 selective
agonist GR231118 showed partial agonism in respect to PP, with a maximal
responses of 28.4 ± 7.4 % (pEC50 of 7.1 ± 0.3; n=5).
Y5-GFP internalisation proceeded at a somewhat slower rate compared to
other Y receptor subtypes. Therefore a 60min incubation time, rather than
30min, was used when measuring Y5-GFP agonist concentration response
curves in order to increase response windows. NPY stimulated internalisation
of Y5-GFP receptors with a pEC50 8.0 ± 0.1 (D; n=6). PP also showed maximal
responses similar to NPY. The Y5 selective agonist cPP (1-17)(Ala,Aib) 18-36
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NPY (referred to as cPP-Aib NPY (Cabrele et al., 2000)), was a potent
stimulator of Y5-GFP internalisation, maximum responses 94.6 ± 1.1 % (n = 4)
relative to that of the positive reference ligand (1µM NPY).
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Figure 3.9: Quantification of the agonist induced internalisation of GFP tagged NPY
receptors in response to a panel of ligands.
Y1, Y2, Y4 and Y5 GFP tagged receptors were stably transfected into HEK293TR cells,
with expression induced following pretreatment with tetracycline (1µg ml-1) for 18 hr
prior to assay. Cells were treated with a panel of subtype selective ligands for 30min
for Y1, Y2 and Y4 receptors and 60min for the Y5 subtype. All assays were performed
at 37°C, prior to fixation, nuclei staining and imaging using an IX Ultra confocal
platereader. Granularity analysis of these images allowed for quantification of
agonist induced internalisation. All data were normalised to vehicle (basal) and
maximal 1µM NPY responses for Y1 (A), Y2 (B) and Y5 receptors (D) and 100nM PP for
Y4 receptor responses (C). Data were pooled from 3-9 individual experiments.
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Table 3.2: Summary of potencies and efficacies of a panel of ligands for stimulating internalisation of GFP tagged NPY receptor subtypes
Y1-GFP Y2-GFP Y4-GFP Y5-GFP
Ligand pEC50 Emax (%) pEC50 Emax (%) pEC50 Emax (%) pEC50 Emax (%)
NPY 8.2 ± 0.1 100 N.D / N.D 61.4 ± 6 8.0 ± 0.1 100
PP 7.0 ± 0.1 18.3 ± 3.3 9.0 ± 0.2 100 8.1 ± 0.1 94.6 ± 1.1
GR231118 N.D N.D 7.1 ± 0.3 28.4 ± 7.4
cPP (Aib ) NPY N.D N.D 9.0 ± 0.1 87.8 ± 10.7
All data were expressed as ± standard error of the mean. pEC50 values were obtained from pooled concentration response curves presented in Figure 3.6.
Emax responses to each ligand were calculated as a percentage of 1µM NPY responses for Y1 and Y5-GFP, and as a percentage of 100nM PP responses for
Y4-GFP.
N values for all data 3-4.
N.D = not determined
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Figure 3.10: The effect of antagonist treatment on Y1-GFP and Y5-GFP receptors
HEK293TR cells stably expressing Y1-GFP (A) or Y5-GFP (B) were pretreated for 30min
(37°C) with subtype selective antagonists BIBO3304 or CGP71683 (both 30nM)
respectively. Both cell lines were then stimulated with a concentration response
course of NPY (30min for Y1-GFP and 60min for Y5-GFP; 37°C/5% CO2). Cells were
then washed, fixed, nuclei stained with H33342 prior to being imaged using a IX Ultra
confocal platereader. Granularity analysis allowed the quantification of agonist
induced internalisation. All data were normalised to vehicle (basal) and maximal 1µM
NPY responses from a minimum of 4 experiments.
Antagonist pharmacology was then investigated for Y1-GFP and Y5-GFP
receptors using subtype selective non-peptide antagonists. Cells were
pretreated for 30min at 37°C with BIBO3304 (Y1) or CGP71683 (Y5) (Dumont
et al., 2000), prior to stimulation with a concentration response course of NPY
(30min for Y1-GFP; 60min for Y5-GFP). Both BIBO3304 and CGP71683
exhibited expected rightward parallel shifts of NPY induced receptor
internalisation indicative of surmountable antagonism (Figure 3.10; A and B).
pKb values were estimated at 8.8 ± 0.2 (n=4) and 8.2 ± 0.1 (n=3) for BIBO3304
and CGP71683 respectively.
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 ? ? ? ? ? ? ? DĞĂƐƵƌŝŶŐ ƚŚĞ ĂŐŽŶŝƐƚ ŝŶĚƵĐĞĚ ĂƐƐŽĐŝĂƚŝŽŶ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ǁŝƚŚ z ?
receptors using automated imaging of BiFC responses
Quantification of the internalisation of GFP tagged NPY receptors is only an
ŝŶĚŝƌĞĐƚ ŝŶĚŝĐĂƚŝŽŶ ŽĨ ƚŚĞ ĞĨĨĞĐƚƐ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚ ƉƌĞĚŝĐƚĞĚ ƚŽ
underlie their endocytosis (Ouedraogo et al., 2008, Holliday et al., 2005,
Berglund et al., 2003b, Kilpatrick et al., 2010). Therefore, BiFC was used to
ĚŝƌĞĐƚůǇŵĞĂƐƵƌĞƚŚĞĂƐƐŽĐŝĂƚŝŽŶďĞƚǁĞĞŶɴ ?ĂƌƌĞƐƚŝŶ ?ĂŶĚzƌĞĐĞƉƚŽƌƐ ?ŝŶŝƚŝĂůůǇ
focussing on the Y1 subtype. YFP C (Yc) and N terminal (Yn) fragments were
ĨƵƐĞĚ ƚŽ ƚŚĞ  ƚĞƌŵŝŶƵƐ ŽĨ z ? ƌĞĐĞƉƚŽƌƐ ĂŶĚ ɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞƐƉĞĐƚŝǀĞůǇ  ?&ŝŐƵƌĞ
 ? ? ? Z ?^ƚĂďůĞ,< ? ? ?dĐĞůůƐǁĞƌĞŐĞŶĞƌĂƚĞĚƚŚĂƚĐŽĞǆƉƌĞƐƐĞĚĐůŽŶĂůɴĂƌƌĞƐƚŝŶ ? ?
Yn with mixed population Y1-Yc (cell line termed Y1/A2). [125I] competition
PYY binding in Y1/A2 membranes (Kilpatrick et al., 2010) verified that PYY,
/K ? ? ? ? ĂŶĚ 'dWɶ^ ĂĨĨŝŶŝƚŝĞƐ ǁĞƌĞ ĐŽŵƉĂƌĂďůĞ ƚŽ ƚŚŽƐĞ ŽďƐĞƌǀĞĚ ĨŽƌ z ? ?
GFP. The generation of completed YFP fluorescence, indicative of an agonist
stimulated association between Y1 receptors and E-arrestin2, was then
imaged using an automated confocal platereader (Figure 3.11, A).
120 min timecourse stimulations using 100nM NPY indicated a t1/2 value of
10.4min ± 1.0 (n=3) in respect to Y1/A2 BiFC development, with responses
reaching a sustained plateau at 60min (Kilpatrick et al., 2010). A 60min assay
length was therefore chosen to assess the responses to a panel of agonists
using the BiFC cell lines. Stimulation with the endogenous agonist NPY lead to
a substantial increase in the accumulation of Y1/A2 BiFC complexes localised
to intracellular compartments (Figure 3.11; A). Responses to PYY and the
selective analogue [Leu31, Pro34] NPY were equipotent with NPY (Figure 3.11,
B; Table 2.3). PP and the metabolite NPY3-36 showed reduced potency and
efficacy in respect to NPY. GR231118, reported previously to increase Y1
receptor internalisation (Pheng et al., 2003) showed no activity in Y1/A2 cells.
Figure 3.11: Quantitative analysis of Y1/A2 BiFC agon
HEK293T cells stably expressing Y1/A2 BiFC construct
confocal platereader. Representative images followin
assessed by applying a granularity algorithm to acq
expressed as mean ± s.e.m (B). Data were pooled from
Pro NPY refers to [Leu31, Pro34] NPY.
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3.3.2.2 The use of BiFC to compare Y receptor subtype specific recruitment
ŽĨɴ ?ĂƌƌĞƐƚŝŶ ?
Following the validation of the BiFC assay at the Y1/A2 cell line, it was then
used to investigate the agonist selectivity of other NPY receptor subtypes in
respect to potency and relative maximal responses. HEK293T cells were stably
co-transfected with mixed populations of Y2-Yc or Y4-Yc on top of a clonal
ƉŽƉƵůĂƚŝŽŶ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ?zŶ ? dŚĞ z ? ? ? ĐĞůů ůŝŶĞ ƌĞƋƵŝƌĞĚ ĚŽƵďůĞ ĚŝůƵƚŝŽŶ
cloning as expressing the Y5-Yc receptor as a mixed population resulted in low
numbers of cells expressing both BiFC components.
Cell lines were treated with a panel of ligands (60min at 37°C/5%CO2) and
concentration response curves derived following the quantification of
internalised BiFC fluorescence (Figure 3.12). All responses were normalised to
a reference compound 1µM NPY for Y1/A2 (A) Y2/A2 (B) and Y5/A2 (D) BiFC
and 100nM PP for Y4/A2 (C) BiFC respectively. An overall summary of
potencies for each Y receptor subtype is found in Table 2.3.
For the Y1/A2 cell line a rank order of potency of PYY>Leu31, Pro34 NPY>NPY>
was observed (Figure 3.11, 3.12A). NPY was also a full agonist at Y2/A2 BiFC
but with a reduced potency when compared to Y1/A2 (26 fold less). The rank
order of potency observed for Y2/A2 BiFC was PYY>PYY3-36>NPYب Leu31, Pro34
NPY (Figure 3.12, B).
PP was a full agonist at Y4/A2 as expected based on its documented potency
(Lundell et al., 1995, Tough et al., 2006) with a 1000 fold increased potency
and an increased efficacy compared to PP activity at Y1/A2. Y4/A2 showed a
rank order of potency of PP>GR231118> PYY>NPY. Subtype selective activity
was observed, in respect to the Y4 selective ligand GR231118 which was able
to induce partial BiFC responses at Y4/A2 BiFC cells.
The Y5 subtype selective ligand cPP-Aib-NPY was equipotent to NPY at Y5/A2
cells as expected from its selectivity for this receptor subtype (Dumont et al.,
2003). Furthermore PP and NPY3-36 were also potent agonist.
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&ŝŐƵƌĞ ? ? ? ? PŐŽŶŝƐƚŝŶĚƵĐĞĚEWzƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ?ŝ&ŝŶƌĞƐƉŽŶƐĞƚŽĂƉĂŶĞůŽĨůŝŐĂŶĚƐ ?
,< ? ? ?d ĐĞůůƐ ƐƚĂďůǇ ĐŽ ?ĞǆƉƌĞƐƐŝŶŐ z ƌĞĐĞƉƚŽƌ ?zĐ ĂŶĚ ɴ ?ĂƌƌĞƐƚŝŶ ? ?zŶ ǁĞƌĞ ƐƚŝŵƵůĂƚĞĚ ǁŝƚŚ ůŝŐĂŶĚ ĨŽƌ  ? ?ŵŝŶ Ăƚ  ? ? ? ? ?A? K2. Ligand responses were
measured by performing granularity analysis of images acquired using an automated confocal platereader. All data were normalised to plate controls of
vehicle (basal responses) and maximal reference agonist concentration (1µM NPY for receptor subtypes Y1 (panel A), Y2 (panel B) and Y5 (D) and 100nM PP
for the Y4 subtype (C)). All data were pooled from a minimum of 3 independent experiments, and expressed as mean ± s.e.m.
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Table 3.3: Summary of potencies and efficacies of a panel of ligands for stimulating the internalisation of NPY receptor/A2 BiFC complexes
Y1/A2 Y2/A2 Y4/A2 Y5/A2
Ligand pEC50 Emax (%) pEC50 Emax (%) pEC50 Emax (%) pEC50 Emax (%)
NPY 8.3 ± 0.1 100 7.1 ± 0.1 100 <6.5 70.6 ± 7.2 7.9 ± 0.1 100
PYY 8.5 ± 0.1 95.4 ± 3.4 7.8 ± 0.1 94.8 ± 1.5 6.8 ± 0.1 59.1 ± 9.8
[Leu
31
,Pro
34
] NPY 8.5 ± 0.1 89.9 ± 4.5 N.D 8.6 ± 6.3
PYY3-36 6.4 ± 0.4 45.5 ± 10.4 7.7 ± 0.1 119.3 ± 14.7
PP 6.3 ± 0.1 40.1 ± 5.8 / / 9.5 ± 0.3 100 7.5 ± 0.2 105.7 ± 18.0
NPY3-36 <6.5 64.5 ± 5.5 / / 7.5 ± 0.2 110.3 ± 6.9
GR231118 / / / / 7.5 ± 0.4 23.9 ± 5.3
cPP (Aib ) NPY / / / / / / 7.4 ± 0.1 90.5 ± 11.5
All data were expressed as ± standard error of the mean. pEC50 values were obtained from pooled concentration response curves presented in Figure 3.9.
Emax responses to each ligand were calculated as a percentage of 1µM NPY responses, which the exception of responses at Y4/A2 whereby they were
expressed as a percentage of 100nM PP responses.
N values for all data 3-11.
N.D = not determined
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Figure 3.13: The effect of pretreatment with antagonist on NPY stimulated Y1 / A2
BiFC
Y1/A2 cells were pretreated with the antagonist BIBO3304 at the concentrations
indicated for 30min at 37°C/5% CO2. Cells were then stimulated with NPY for 60min
at 37°C/5% CO2. Granularity analysis was performed on images obtained using an
automated confocal platereader. Concentration response curves in the presence and
absence of BIBO3304 were fitted (A), with a shared minimum, maximum and Hill
slope constraints. Concentration ratios in respect to derived EC50 values were used to
construct a Schild plot (B) to determine the pA2 value.
Y1/A2 BiFC responses in respect to antagonist pharmacology were also
investigated. The Y1 selective antagonist BIBO3304, was able to inhibit the
NPY induced Y1/A2 BiFC responses, showing rightward parallel shifts in the
NPY concentration response curve indicative of surmountable antagonism
(Figure 3.13, A). Schild analysis was used to calculate a pA2 value of 9.0 ± 0.1
(n=5; B).
3.3.3.1 Y1 and Y2 receptor mutants that alter agonist induced internalisation
ĂůƐŽĂĨĨĞĐƚɴ ?ĂƌƌĞƐƚŝŶ ?ĂƐƐŽĐŝĂƚŝŽŶƚŽƚŚĞƐĞƐƵďƚǇƉĞƐ
Point mutations were selectively introduced into the Y1 and Y2 receptor
sequences (as described in section 2.2.1.1.1.2-3). For the Y1 receptor, an
alanine substitution was introduced at Tyr 99 (Y99; see Figure 3.14, A; residue
highlighted in blue) located at the top of TM2. This mutation has previously
been shown to inhibit NPY binding (Sautel et al., 1995, Sautel et al., 1996).
This receptor construct was termed Y1Y99A. Another set of mutations were
151
also separately introduced into the C terminal domain of the Y1 receptor.
Alanine substitutions were made of 6 serine and threonine residues (S352A,
T353A, T356A, S359A, T361A, S362A) previously implicated as sites
phosphorylated by GRKs in receptor desensitisation (see Figure 3.14, A;
residues highlighted in red). Mutation of these residues resulted in a
 RƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ŶĞŐĂƚŝǀĞ ? ƌĞĐĞƉƚŽƌ ƚŚĂƚ ŝƐ ŝŶĐĂƉĂďůĞ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ?
dependent agonist induced internalisation (Holliday et al., 2005, Ouedraogo
et al., 2008, Kilpatrick et al., 2010). This receptor was termed the Y16A
receptor. A point mutation was also introduced into the Y2 receptor sequence
with histidine residue 155 in the second intracellular loop being substituted
with proline (see Figure 3.14, B; residue shown in red). The H155P mutation
ŚĂƐ ďĞĞŶ ƉƌĞǀŝŽƵƐůǇ ƐŚŽǁŶ ƚŽ ĞŶŚĂŶĐĞ ƌĞĐƌƵŝƚŵĞŶƚ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ƚŽ z ?
receptors (Marion et al., 2006, Ouedraogo et al., 2008) by reconstructing a
ŶĞĐĞƐƐĂƌǇ ƌĞĐŽŐŶŝƚŝŽŶ ŵŽƚŝĨ ŝŵƉůŝĐĂƚĞĚ ŝŶ ƌĞŐƵůĂƚŝŶŐ ɴ ?ĂƌƌĞƐƚŝŶ ? ďŝŶĚŝŶŐ ĂŶĚ
ɴ ?ĂƌƌĞƐƚŝŶ ? ŵĞĚŝĂƚĞĚ ƌĞĐĞƉƚŽƌ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ĨŽƌ Ă ǀĂƌŝĞƚǇ ŽĨ ůĂƐƐ  'WZƐ ?
This receptor construct was termed Y2H155P.
Competition binding experiments using [125I] PYY were performed in
membranes derived from HEK293TR cells stably expressing either Y16A-GFP
or Y2H155P-GFP. Receptor expression was induced using tetracycline
treatment 18hr prior to assay. At both receptor constructs, PYY and BIBO3304
were able to displace specific [125I] PYY binding with comparable affinities to
that seen for native Y1-GFP and Y2-GFP respectively (Kilpatrick et al., 2012).
ŽƚŚƌĞĐĞƉƚŽƌƐ ǁĞƌĞ ĂůƐŽƐĞŶƐŝƚŝǀĞ ƚŽ'dWɶ^ ƚƌĞĂƚŵĞŶƚ ? ĂŶĚŵĂǆ ĞƐƚŝŵĂƚĞƐ
of receptor expression were comparable to Y1-GFP and Y2-GFP preparations.
Confocal imaging was then performed to investigate the agonist induced
internalisation of Y16A-GFP and Y2H155P-GFP receptors. For the
phosphorylation negative Y16A mutant, no internalisation was observed in
response to 1µM NPY following 30min stimulation (Figure 3.14, C).
Internalisation in response to high NPY concentrations (1µM) was observed
for mutant Y2H155P-GFP tagged receptors after 30min incubation at 37°C
(Figure 3.14, C; Figure 3.15).
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In order to determine if a 30min agonist incubation (as previously used for Y1-
GFP and Y2-GFP) was sufficient, cells were stimulated with 100nM NPY at
37°C with the same region of cells imaged at 2.5min intervals. No
internalisation was seen for Y16A-GFP at any timepoint imaged. Noticeable
internalisation was observed for Y2H155P-GFP cells from 2.5min incubation
times onwards (Figure 3.15 compared to Figure 3.5). Automated imaging
using a confocal platereader, in conjunction with a granularity algorithm,
allowed NPY induced internalisation to be quantified and compared with
those obtained for native Y1 and Y2-GFP. No NPY induced internalisation
(30min at 37°C) was observed for Y16A-GFP even at higher concentrations
(Figure 3.16, A and B). Conversely the H155P mutation introduced into the Y2
sequence enhanced agonist-stimulated endocytosis of Y2H155P-GFP
receptors (A and C), with NPY potencies 18 fold greater when compared to
responses at the wildtype Y2 receptor (pEC50 7.8 ± 0.1, n=4; p < 0.01).
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3.3.3.2 Using automated imaging of BiFC responses to investigate the effect
ŽĨƐĞůĞĐƚŝǀĞŵƵƚĂƚŝŽŶƐŽŶƚŚĞĂƐƐŽĐŝĂƚŝŽŶŽĨz ?ƌĞĐĞƉƚŽƌƐǁŝƚŚɴ ?ĂƌƌĞƐƚŝŶ ?
Studies using GFP tagged mutant Y16A and Y2H15PP-GFP suggested that
these mutations could confer changes in the nature of Y receptor
internalisation. The BiFC assay was then used to quantify whether selective
ŝŶƚƌŽĚƵĐƚŝŽŶƐŽĨƚŚĞƐĞŵƵƚĂƚŝŽŶƐĐŽƵůĚĂůƐŽĂůƚĞƌɴ ?ĂƌƌĞƐƚŝŶ ?ƌĞĐƌƵŝƚŵĞŶƚ ?
Firstly, the effect of substituting a tyrosine at residue 99 for alanine (Y99A) in
the Y1 receptor sequence was investigated (Y1Y99A/A2; Figure 3.14, A;
residue highlighted in blue). This residue has been shown to inhibit agonist
binding at the Y1 receptor preventing the use of radioligand binding
measurements to estimate ligand affinity and receptor expression (Sautel et
al., 1995). The Y16A mutation (previously described in section 3.4.3.1) was
also investigated to assess the relative importance of these phosphorylated
ƌĞƐŝĚƵĞƐ ŝŶɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚ  ?z ? ? ? ? Z ?ŝƐƉůĂĐĞŵĞŶƚŽĨ ƐƉĞĐŝĨŝĐ  ?125I]
Wzz ďŝŶĚŝŶŐ ďǇ Wzz ĂŶĚ /K ? ? ? ? ? ĂŶĚ ƐĞŶƐŝƚŝǀŝƚǇ ŽĨ ƚŚŝƐ ďŝŶĚŝŶŐ ƚŽ 'dWɶ^
suggested that Y16A/A2 constructs were functional in respect to ligand
binding with Bmax values comparable to native Y1/A2 (Kilpatrick et al., 2010).
,< ? ? ?dĐĞůůůŝŶĞƐƐƚĂďůǇĐŽ ?ĞǆƉƌĞƐƐŝŶŐz ? ?ɴ ?ĂƌƌĞƐƚŝŶ ?ŵƵƚĂŶƚŝ&ĐŽŶƐƚƌƵĐƚƐ
were stimulated with NPY for 60min at 37°C/5% CO2 (Figure 3.17). NPY
induced BiFC responses were abolished for both Y1Y99A/A2 and Y1Y6A/A2
mutant cell lines.
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Figure 3.17: Investigating the effect of selectively introduced mutations on Y1
ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ?ŝ&
HEK293T cells stably co-expressing native or mutant Y1/A2 were stimulated with a
concentration range of NPY (60min at 37°C/5% CO2). Granularity analysis of images
acquired using an automated confocal platereader, allowed the effects on receptor
internalisation of mutations affecting ligand binding (Y1Y99A) and receptor
phosphorylation (Y16A) to be determined. All data was normalised to wildtype Y1
receptor repsonses to plate controls (vehicle and 1µM NPY) and expressed as means
± s.e.m. Data were pooled from at least 4 independent experiments.
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3.4 Discussion
3.4.1 Summary of main findings
High content imaging of fluorescently tagged Y receptor subtypes or Y
ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ? ŝ& ĐŽŵƉůĞǆĞƐ ŝŶ ĐŽŶũƵŶĐƚŝŽŶǁŝƚŚ ĂƵƚŽŵĂƚĞĚ ĂŶĂůǇƐŝƐ
allowed quantitative pharmacology to be derived from qualitative images. The
ƵƐĞ ŽĨ ŝ& ĚĞĨŝŶĞĚ ƚŚĞ ĂƐƐŽĐŝĂƚŝŽŶ ŽĨ z ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ? ĂƐ ĚŝƐĐƌĞƚĞ
complexes, whose pharmacological responses could be compared to those
obtained in respect to Y receptor internalisation. Consistent agonist and
antagonist pharmacology was observed for these distinct signalling endpoints,
across all 4 Y receptor subtypes investigated, with affinity estimates also
comparable with those previously documented for each subtype using
alternative assay methodologies.
Quantification of BiFC fluorescence was here able to distinguish between
ƌĞĐĞƉƚŽƌ ŵƵƚĂƚŝŽŶƐ ƚŚĂƚ ĂůƚĞƌ ƚŚĞ ĞŶŐĂŐĞŵĞŶƚ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ĂĐƚŝǀĂƚŝŽŶ
(Y1H155P) or phosphorylation sensors (Y16A) with the receptor. The use of
these selective mutations further supported a shared molecular mechanism
ƵŶĚĞƌůǇŝŶŐ ďŽƚŚ ƌĞĐĞƉƚŽƌ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ĂŶĚ ɴ ?ĂƌƌĞƐƚŝŶ ƌĞĐƌƵŝƚŵĞŶƚ ƚŽ z
receptors. As supported by previous studies, Y receptor internalisation is
ƚŚĞƌĞĨŽƌĞ ůŝŬĞůǇ ƚŽ ƌĞĨůĞĐƚ ĂŶ ĂŐŽŶŝƐƚ ŝŶĚƵĐĞĚ ƌĞĐƌƵŝƚŵĞŶƚ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ƚŚĂƚ
subsequently facilitates receptor endocytosis.
3.4.2.1 Y receptor-GFP fusion proteins are functional in respect to ligand
binding and cell surface expression
The addition of C terminal fluorescent protein tags to receptor constructs
required validation to ensure receptor expression and function was
conserved. The large size of GFP (27kDa) has the potential to alter the
expression and function of tagged proteins.. However the addition of
superfolder GFP tags to the C terminus of Y1-GFP did not adversely affect
ligand binding or receptor expression. [125I] PYY competition binding assays
(Figure 3.3) confirmed that ligand affinities were comparable to that
previously documented for cloned rat Y1 receptors in respect to PYY (Gehlert
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et al., 1997) and BIBO3304 (Dumont and Quirion, 2000) binding. The activity
ŽĨ 'dWɶ^ ŝŶ ƌĞƐƉĞĐƚ ƚŽ ŝƚƐ ƉŽƚĞŶĐǇ ĂŶĚ ĚĞŐƌĞĞ ŽĨ ŝŶŚŝďŝƚŝŽŶ ǁĂƐ ĂůƐŽ
comparable to previous measures of N terminally HA-tagged Y1 receptors
(Holliday and Cox, 2003). Additionally confocal imaging confirmed that Y1-
GFP receptors were expressed at the plasma membrane of HEK293T cells
(Figure 3.4, A). A small degree of constitutive Y1 receptor internalisation was
observed, which was consistent with untagged Y1 receptors using antibody
live labelling techniques (Holliday et al., 2005, Lundell et al., 2011).
Observations from the Y receptor subtypes Y1, Y2, Y4 and Y5 with full length
eGFP or eYFP, showed that receptor expression and ligand binding was
unchanged (Bohme et al., 2008). GFP tagging of other Class A GPCRs such as
ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ? ɲ1A ĂŶĚ ɲ1B, vasopressin V2 and thyrotropin releasing
hormone receptors also resulted in receptors with unaltered ligand binding
and second messenger generation (reviewed in (Kallal and Benovic, 2000)).
Rapid agonist induced internalisation of Y1-GFP in response to agonist was
comparable to that previously observed for Y1 receptors containing no
fluorescent tag and measured using alternative methods. Labelling cloned
guinea pig Y1 receptors expressed in CHO cells using [125I] peptide ligands
revealed a marked decrease in the proportion of cell surface receptors in
response to agonist challenge(Parker et al., 2001, Parker et al., 2002). This was
also consistent with observations for endogenously expressed human Y1
receptor internalisation following labelling with a fluorescent NPY derivative
and observed using confocal microscopy in SK-N-MC cells (Fabry et al., 2000),
C terminal FLAG epitope labelling of human Y1 receptors in HEK derived
EBNA-293 cells (Lundell et al., 2011) and HA tagged rat Y1 receptors in
HEK293T cells (Holliday et al., 2005, Pheng et al., 2003). Y1-GFP receptor
agonist induced internalisation was also comparable to that previously
observed for this receptor when containing alternative C terminal (Bohme et
al., 2008, Lindner et al., 2009, Kilpatrick et al., 2010) or N terminal (Gicquiaux
et al., 2002, Ouedraogo et al., 2008, Lecat et al., 2011) fluorescent protein
tags. These comparisons are important, because for example, tagging of the
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ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌǁŝƚŚĞ'&WŚĂƐƉƌĞǀŝŽƵƐůǇďĞĞŶƐŚŽǁŶƚŽĚĞĐƌĞĂƐĞƚŚĞƌĂƚĞ
of Isoprenaline induced internalisation compared to untagged receptor
(McLean and Milligan, 2000). Therefore the addition of a C terminal GFP tag
to the Y1 receptor did not appear to adversely affect Y1 receptor expression,
ligand binding potency or agonist induced internalisation suggesting this
technique was suitable for use in further investigations of Y receptor
pharmacology aligned to the internalisation response.
3.4.2.2 Agonist and antagonist pharmacology of Y1-GFP internalisation
responses revealed by quantitative imaging and analysis
Here for the first time, the use of automated confocal imaging and analysis
allowed quantitative data of agonist (pEC50) and antagonist (pKb) potencies to
be extracted from confocal imaging of Y1-GFP internalisation (Figure 3.6).
Previous observations of Y1 receptor agonist induced internalisation have
derived ligand potencies from alternative measures of Y1 internalisation, for
example the use of radiolabelled peptides (Parker et al., 2001, Parker et al.,
2002) and anti GFP antibodies (Ouedraogo et al., 2008, Lecat et al., 2011,
Gicquiaux et al., 2002) to measure the decrease in surface receptor
expression. Using this technique agonist pharmacology for Y1-GFP
internalisation could then be compared with previous estimates of Y1
pharmacology, which were broadly similar (Table 3.1) (Krause et al., 1992,
Gehlert et al., 1997, Lindner et al., 2009, Kilpatrick et al., 2010). For example,
the decreased potency of PP, compared to NPY, at inducing Y1-GFP
internalisation was similar to previous observations of the inability of PP to
decrease cell surface expression of GFP-Y1 receptors (Gicquiaux et al., 2002)
and was expected based on its decreased affinity for the Y1 receptor (Gehlert
et al., 1997). Functional antagonism was also observed for Y1-GFP receptor
endocytosis. The Y1 selective antagonist BIBO3304 was able to competitively
inhibit NPY induced Y1-GFP internalisation with affinity estimates consistent
with those from other studies (Michel et al., 1998, Wieland et al., 1998) and
reconcilable with the affinity of BIBO3304 at Y1-GFP receptors measured
using [125I] PYY radioligand binding (Table 3.1).
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Therefore automated confocal microscopy and analysis of Y1-GFP
internalisation allowed agonist and antagonist pharmacology to be
investigated and compared to previous measurements. This same technique
was therefore validated for use in quantifying ligand pharmacology using both
z ƌĞĐĞƉƚŽƌ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ĂŶĚ z ? ?ɴ ?ĂƌƌĞƐƚŝŶ ? ŝ&ƌĞƐƉŽŶƐĞƐ ĂƐ ĨƵŶĐƚŝŽŶĂů
readouts.
3.4.2.3 Advantages and limitations of the platereader approach to
measuring Y1 receptor internalisation
The use of standard confocal microscopy allowed the sub-cellular localisation
of GFP tagged Y1 receptors to be visualised at high magnification and
resolution (Figure 3.4, A). The internalisation of these labelled receptors could
be observed in response to receptor activation with agonist. However
quantification of internalisation from these images requires manual analysis
which can be time consuming and risks unintended experimenter bias. The
use of automated confocal image acquisition and analysis addressed both of
these caveats, in addition to also providing high resolution qualitative data of
the sub-cellular localisation of GFP tagged receptors (Figure 3.6) and
ŵĞĂƐƵƌŝŶŐ ƚŚĞ ĂĐĐƵŵƵůĂƚŝŽŶ ŽĨ ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ?ŝ& ĐŽŵƉůĞǆĞƐ  ?&ŝŐƵƌĞ
3.11, A). For example when using the granularity algorithm, although the
fluorescent intensity threshold to detect internalised granules is subjectively
defined by the experimenter, these were consistently applied to all images
acquired across the entire plate. This allowed quantification of
pharmacological responses to both full and partial agonists. The addition of a
nuclei stain also allowed results to be expressed on a per cell basis.
Additionally automated imaging allowed a greater number of cells to be
imaged per field assays can be performed in 96-1536 plate well formats (Auld
et al., 2006). However it is worth noting that the granularity algorithm
method is to some extent an indirect measure of endocytosis, as although it
measures an increase in intracellular receptor-GFP fluorescence as
endocytosis proceeds, it does not specifically measure decreases in the cell
surface receptor expression. However, automated detection and monitoring
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of receptors at the cell surface, using images of confluent cell lines such as
HEK293, is very difficult without a separate specific fluorescent marker to
define the plasma membrane. Thus granularity represents the most
convenient and rapid option to measure receptor endocytosis from
automated platereader images.
Additionally in common with manual microscopy there are spatiotemporal
limits to the confocal resolution possible. For example both are unable to
resolve structures such as clathrin coated pits and can only infer that
internalised receptors accumulate in perinuclear recycling compartments.
There are also differences between the spatial resolutions possible between
the confocal and plate reader formats due to the differences in numerical
aperture of the objectives used. The numerical aperture of the 40x objective
used in the plate reader format is lower (NA 0.6) than that of the 63x time
objective (NA 1.4) used in manual confocal imaging, meaning that some finer
details are less likely to be resolved using platereader imaging. Additionally
the choice of medium used between the objective and cover glass/plate can
account for these differences in resolution, as the immersion oil used at the
63x objective in confocal imaging creates an interface with a greater refractive
index which increases the possible resolution of cellular structures.
However despite these factors, automated image acquisition and analysis,
was able to generate both qualitative and quantitative data on the
internalisation of fluorescently tagged Y receptors and the interaction of Y
ƌĞĐĞƉƚŽƌ ǁŝƚŚ ɴ ?ĂƌƌĞƐƚŝŶ ? ƵƐŝŶŐ ŝ& ĂŶĚ ĐŽƵůĚ ŝŶĚŝĐĂƚĞ ƚŚĞ ĐĞůůƵůĂƌ
localisation of these fluorescent species.
3.4.3 Correspondence between Y receptor internalisation pharmacology and
BiFC measurements of E-arrestin2 association
The successful use of automated analysis to quantify agonist induced Y1-GFP
receptor internalisation, suggested that this technique could be applied to
quantify the upstream signalling process such as the agonist induced
ƌĞĐƌƵŝƚŵĞŶƚŽĨɴ ?ĂƌƌĞƐƚŝŶ ?ƚŽz ?ƌĞĐĞƉƚŽƌƐŵĞĂƐƵƌĞĚďǇŝ& ?
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3.4.3.1 Characteristics of Y1 receptor-barrestin2 recruitment measured using
BiFC
The same imaging system and analysis algorithm used to quantify Y receptor-
GFP internalisation was used in conjunction with BiFC to quantify ligand
ƉŚĂƌŵĂĐŽůŽŐǇŽĨzƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ?ĂƐƐŽĐŝĂƚŝŽŶƐ ?dŚĞz ? ? ?ŝ&ĐĞůůůŝŶĞ
was functional in respect to [125I] PYY ligand binding and GTPJS sensitivity,
with PYY and BIBO3304 binding affinities similar to those of Y1-GFP (Table 1)
and to previous observations (Kilpatrick et al., 2010, Gehlert et al., 1997,
Dumont and Quirion, 2000, Holliday and Cox, 2003). Translocation of cytosolic
'&WƚĂŐŐĞĚɴ ?ĂƌƌĞƐƚŝŶ ?ƚŽĂĐƚŝǀĂƚĞĚz ?ƌĞĐĞƉƚŽƌƐŚĂƐďĞĞŶƐŚŽǁŶŝŶ,< ? ? ?d
cells (Holliday et al., 2005, Ouedraogo et al., 2008). BRET assays have also
ƐŚŽǁŶ ƚŚĂƚ EWz ƌĞĐĞƉƚŽƌ ƐƵďƚǇƉĞƐ ĂƐƐŽĐŝĂƚĞ ǁŝƚŚ ɴ ?ĂƌƌĞƐƚŝŶ ? ŝŶ Ă
concentration dependent manner (Berglund et al., 2003b). However whilst
BRET, and other techniques such as FRET, have the advantage of providing a
ƌĞĂů ƚŝŵĞ ƌĞĂĚŽƵƚ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ƌĞĐƌƵŝƚŵĞŶƚ ? ƚŚĞǇ ĂƌĞ ƌĞůĂƚŝǀĞůǇ ĐŽŵƉůĞǆ
requiring exogenous substrates (BRET) or dual wavelength measurements
(FRET). The irreversibility of BiFC and the time required for chromophore
maturation prevents real time measurements of responses using this
technique (Kerppola, 2009, Kerppola, 2013). However the irreversibility of
BiFC can be advantageous as it constrains associated proteins (in this case Y
ƌĞĐĞƉƚŽƌ ĂŶĚ ɴ ?ĂƌƌĞƐƚŝŶ ? Z ĂƐ ƐƚĂďůĞ ŵŽůĞĐƵůĂƌ ĐŽŵƉůĞǆĞƐ ŽĨ ƉƌĞĐŝƐĞ
composition, generating long lived recomplemented YFP fluorescence
indicative of an interaction. This is reflected in the stimulation time used here,
ĂƐ ĂůƚŚŽƵŐŚ ƚŚĞ ŝŶŝƚŝĂů z ? ?ɴ ?ĂƌƌĞƐƚŝŶ ? ŝŶƚĞƌĂĐƚŝŽŶŝƐ ƌĂƉŝĚ ? ƚŚĞ  ? ? ŵŝŶƵƚĞ
incubation time allowed the fluorophore to fully mature resulting in a more
stable and intense fluorescent readout. Previous observation using these BiFC
fragments suggested that incubation time had no effect on derived agonist
potencies, and that longer stimulations only increased the proportion of
fluorescent recomplemented YFP observed (Kilpatrick et al., 2010). Analysis of
this fluorescence using the granularity algorithm allowed quantification of
ĂŐŽŶŝƐƚ ĂŶĚ ĂŶƚĂŐŽŶŝƐƚ ƉŚĂƌŵĂĐŽůŽŐŝĐĂů ƌĞƐƉŽŶƐĞƐ ŽĨ z ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ?
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complexes (Figure 3.11). The derivation of pEC50 potencies also allowed
comparisons to be made between BiFC and receptor-GFP internalisation
readouts using the same assay format. The use of this same granularity
algorithm in conjunction with the same set of BiFC fragments has previously
illustrated the agonist induced association of GPR120S and 120L splice
ǀĂƌŝĂŶƚƐǁŝƚŚɴ ?ĂƌƌĞƐƚŝŶ ? ?tĂƚƐŽŶĞƚĂů ? ? ? ? ? ? Z ?ůƚĞƌŶĂƚŝǀĞĂŶĂůǇƐŝƐƚĞĐŚŶŝƋƵĞƐ
ŚĂǀĞĂůƐŽƋƵĂŶƚŝĨŝĞĚƚŚĞŝŶƚĞƌĂĐƚŝŽŶŽĨɴ ?ĂƌƌĞƐƚŝŶ ?ǁŝƚŚɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ?ƵůĚ
et al., 2006) (also using a larger scale 1536 well plate format) and angiotensin
1 receptors (Porrello et al., 2011). Quantitative analysis of BiFC fluorescence
ǁĂƐƚŚĞƌĞĨŽƌĞĂǀĂůŝĚĂƉƉƌŽĂĐŚƚŽŝŶǀĞƐƚŝŐĂƚĞƚŚĞƉŚĂƌŵĂĐŽůŽŐǇŽĨɴ ?ĂƌƌĞƐƚŝŶ ?
recruitment to Y receptor subtypes.
Much of the success of BiFC assays is linked to the appropriate choice of BiFC
fragment used (Kilpatrick and Holliday, 2012). This factor was previously
optimised for vYFP fragments (Kilpatrick et al., 2010), which suggested that C
terminal tagging of the Y1 receptor with the 155-238 Yc fragment was most
appropriate for sufficient receptor expression. The use of a complementary N
ƚĞƌŵŝŶĂůĨƌĂŐŵĞŶƚƚĂŐŽĨɴ ?ĂƌƌĞƐƚŝŶ ? ? ? ? ? ? ? ZǁĂƐĨŽƵŶĚ ƚ ŵĂǆŝŵŝƐĞƌĞĨŽůĚŝŶŐ
rates at 37°C (Kilpatrick et al., 2010, Nagai et al., 2002, Hu and Kerppola,
 ? ? ? ? Z ?dŚŝƐ ŝƐ ůŝŬĞůǇĚƵĞ ƚŽƚŚĞŽǀĞƌůĂƉƉŝŶŐƌĞŐŝŽŶƌĞƉĞĂƚŝŶŐĂɴƐƚƌĂŶĚ  ? ? ? ? ?
 ? ? ? ZǁŝƚŚŝŶďŽƚŚĨƌĂŐŵĞŶƚƐƚŚĂƚĨĂĐŝůŝƚĂƚĞƐƌĞĨŽůĚŝŶŐŽĨƚŚĞĐŽŵƉůĞƚĞɴďĂƌƌĞů
structure. Timecourse experiments using both these overlapping and non-
overlapping YFP fragments, revealed differences in the rates of
complementation (Kilpatrick et al., 2010), with the overlapping pairs showing
significantly faster t1/2 values for BiFC development compared to other
fragment pairs (10 min ± 1.0 versus 17.5-20.9min). However it is worth noting
that the choice of fragment pair had no effect on observed agonist potencies
(Kilpatrick et al., 2010), indicating that the different affinities of these
fragments for each other did not alter the agonist driven receptor-arrestin
association Additionally the kinetics of Y1/A2 with overlapping BiFC
fragments was slower than that observed for Y1-vYFP internalisation (2.4min
± 0.3) (Kilpatrick et al., 2010), confirming that NPY stimulation results in the de
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novo formation of new BiFC complexes rather than altering trafficking of
existing complexes. The use of a series of wash steps supported this assertion
in addition to illustrating the irreversible nature of BiFC complementation
(comparable results are observed for GFP complementation, see Chapter 4,
Figure 4.8) (Kilpatrick et al., 2010). An inevitable consequence of using
overlapping BiFC fragments with more efficient folding is the increased
propensity for bystander collisions that can lead to higher background levels
of fluorescence (Kerppola, 2008b, Kodama and Hu, 2010). There is also a risk
in using BiFC assays that the strength of the affinity of the two tags is driving
the association of the tagged proteins as opposed to representing a genuine
interaction (Kerppola, 2013)  but as indicated above, changing the affinity of
the fragments for each other had no effect on the observed agonist
pharmacology (15). Under control conditions, some constitutive Y1/A2
fluorescence was observed (Figure 3.11, A), however this reconciled with the
constitutive activity previously observed for Y1-YFP receptors, suggesting it is
not as a consequence of intrinsic fragment affinity. The lack of basal
fluorescence observed for Y16A/A2 BiFC using the same overlapping BiFC
fragments (see below) (Kilpatrick et al., 2012), also suggested that constitutive
BiFC fluorescence may be receptor, not BiFC, dependent.
3.4.3.2 Agonist and antagonist pharmacology of Y1 receptor-arrestin
association closely resembles the profile seen for Y1-GFP receptor
internalisation
EWz ǁĂƐ ĂďůĞ ƚŽ ŝŶĚƵĐĞ ƚŚĞ ĂƐƐŽĐŝĂƚŝŽŶ ŽĨ z ? ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ? ŝ&
complexes with a potency comparable to that observed for Y1-GFP receptor
internalisation (Table 3.2 and 3.3). Confocal images obtained (Figure 3.11, A)
ǁĞƌĞŽĨŚŝŐŚĞŶŽƵŐŚƌĞƐŽůƵƚŝŽŶƚŽƐƵŐŐĞƐƚƚŚĂƚĨŽůůŽǁŝŶŐŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ?z ? ?ɴ ?
arrestin2 complexes were present in perinuclear compartments within the
cytosol. This is reconciled with previous observations for Y1 receptor
ĂƐƐŽĐŝĂƚŝŽŶƐǁŝƚŚɴ ?ĂƌƌĞƐƚŝŶ ?ŝŶ,< ? ? ?dĐĞůůƐ ?'ŝĐƋƵ ĂƵǆĞƚĂů ? ? ? ? ? ? ?WŚĞŶŐĞƚ
al., 2003). However no real conclusions can be made on the endocytic
ƚƌĂĨĨŝĐŬŝŶŐ ŽĨ ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ? ŝ& ĐŽŵƉůĞǆĞƐďĞǇŽŶĚ ƚŚŝƐ ƉŽŝŶƚ ĚƵĞ ƚŽ
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the risk that the irreversibility of complementation is adversely affecting
receptor trafficking.
Y1/A2 BiFC responses showed agonist potencies and maximal responses
consistent with that observed for NPY at inducing fluorescently tagged Y1
receptor internalisation (Tables 3.2 and 3.3) (Gicquiaux et al., 2002, Lecat et
al., 2011, Ouedraogo et al., 2008). Similar to the Y1-GFP receptor, the typically
z ?ƐĞůĞĐƚŝǀĞůŝŐĂŶĚ'Z ? ? ? ? ? ?ĚŝĚŶŽƚŝŶĚƵĐĞƚŚĞĂƐƐŽĐŝĂƚŝŽŶŽĨɴ ?ĂƌƌĞƐƚŝŶ ?ĂŶĚ
Y1 receptors (Pheng et al., 2003). Responses to PP were also comparable in
ŵĞĂƐƵƌĞƐŽĨďŽƚŚz ?ƌĞĐĞƉƚŽƌŝŶƚĞƌŶĂůŝƐĂƚŝŽŶĂŶĚɴ ?ĂƌƌĞƐƚŝŶ ?ƌĞĐƌƵŝƚŵĞŶƚ ?dŚĞ
low potency and efficacy of the N terminal truncated ligands NPY3-36 and PYY3-
36 reflected the importance of N terminal peptide residues in Y1 receptor
binding and activation (reviewed in (Pedragosa-Badia et al., 2013)). BIBO3304
exhibited the expected surmountable antagonism of Y1 / A2 BiFC responses,
with affinity estimates consistent with those determined for Y1-GFP and
previous affinity measurements for BIBO3304 (Michel et al., 1998, Wieland et
al., 1998).
Therefore the BiFC assay gives expected pharmacology for agonist induced
ƌĞĐƌƵŝƚŵĞŶƚ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ƚŽ z ? ƌĞĐĞƉƚŽƌƐ ƚŚĂƚ ǁĂƐ ĂůƐŽ ĐŽŵƉĂƌĂďůĞ ƚŽ z ? ?
GFP responses and suggested that the presence of the BiFC tags did not have
an adverse effect on measuring the pharmacology of Y1 receptor  arrestin
recruitment. The quantification of two assay endpoint measurements
 ?ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ĂŶĚ ɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚ Z ŐĞŶĞƌĂƚĞĚ ĐŽŵƉĂƌĂďůĞ ůŝŐĂŶĚ
ƉŚĂƌŵĂĐŽůŽŐǇ ? ƐƵŐŐĞƐƚŝŶŐ ƚŚĂƚ ƐŝŵŝůĂƌ ŵŽůĞĐƵůĂƌ ŵĞĐŚĂŶŝƐŵƐ ƵŶĚĞƌůŝĞ ɴ ?
arrestin recruitment and Y1 receptor internalisation.
 ? ? ? ? ? ^ŝŵŝůĂƌŝƚŝĞƐ ďĞƚǁĞĞŶ ɴ ?ĂƌƌĞƐƚŝŶ ƌĞĐƌƵŝƚŵĞŶƚ ĂĚ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ
pharmacology are preserved for other Y receptor subtypes
3.4.4.1 The Y2 receptor
As previously described the Y1 receptor rapidly internalised in response to
stimulation with the agonists NPY, PYY and [Leu31, Pro34] NPY (Y1-GFP, Figure
3.12A). However observations of human (Gicquiaux et al., 2002) and guinea
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pig Y2 receptors (Parker et al., 2001) expressed in heterologous cell lines,
showed comparatively decreased internalisation in response to agonist. Here
NPY induced internalisation of GFP tagged Y2 receptors, and stimulated the
ĨŽƌŵĂƚŝŽŶ ŽĨ z ? ?ɴ ?ĂƌƌĞƐƚŝŶ ? ŝ& ĐŽŵƉůĞǆĞƐ ? ǁŝƚŚ ĐŽŵƉĂƌĂďůĞ ƉŽƚĞŶĐŝĞƐ
obtained for both assay formats (Figure 3.12, B; Table 3.3). However both of
these processes only occurred with NPY concentrations in excess of 50nM.
This is in accordance with previous observations of Y2 receptor internalisation
using N terminal GFP tagged (Ouedraogo et al., 2008), C terminal tagged eYFP
(Bohme et al., 2008, Walther et al., 2010) and FLAG tag immunolabelling
(Lundell et al., 2011). These groups observed Y2 receptor internalisation only
with NPY concentrations of 50-100nM, suggesting that internalisation
required a high degree of receptor occupancy (Kilpatrick et al., 2010).
However Lundell et al (2011) (Lundell et al., 2011) have suggested that the Y2
receptor internalisation observed in response to high concentrations of NPY is
less relevant at the physiological levels of NPY observed in vivo. Interestingly
the Y2 receptor showed comparable affinity to that of the Y1 receptor for NPY
and radiolabelled NPY (Lundell et al., 2011) even though both receptor
subtypes share only 30% sequence homology (Akerberg et al., 2010) and
substantial different residues implicated in ligand binding (Lindner et al.,
 ? ? ? ? ? yƵ Ğƚ Ăů ? ?  ? ? ? ? Z ?  EWz ǁĂƐ ƐƵďƐƚĂŶƚŝĂůůǇ ůĞƐƐ ƉŽƚĞŶƚ ŝŶ ƐƚŝŵƵůĂƚŝŶŐ ɴ ?
arrestin2 recruitment to Y2 receptors when using the BiFC assay (Y2/A2) with
responses 26 fold less than observed at Y1/A2. This phenomena was also
mirrored when quantifying Y2 receptor internalisation, with NPY responses 63
fold lower than that seen for Y1-GFP (Table 3.2 and 3.3).
The reduction in potency of NPY at inducing the formation of Y2/A2 BiFC
complexes or Y2-GFP internalisation does not appear to be due to a complete
ůĂĐŬ ŽĨ ŝŶƚĞƌĂĐƚŝŽŶ ǁŝƚŚ ɴ ?ĂƌƌĞƐƚŝŶ ? ? ŽůŽĐĂůŝƐĂƚŝŽŶ ŽĨ z ? ƌĞĐĞƉƚŽƌƐ ĂŶĚ ɴ ?
arrestin2 has been observed using BRET (Berglund et al., 2003b, Walther et
al., 2010). Monitoring reductions in Y2 receptor plasma membrane expression
ŵĞĂƐƵƌĞĚ ďǇ >/^ ƐŚŽǁĞĚ ƚŚĂƚ ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ ŽĨ ŵŚĞƌƌǇ ?ɴ ?ĂƌƌĞƐƚŝŶ ?
further enhanced Y2 receptor internalisation. Therefore the decreased
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potency for Y2/A2 and Y2-GFP is likely to be a consequence of Y2 receptors
ŚĂǀŝŶŐĂĚĞĐƌĞĂƐĞĚĂĨĨŝŶŝƚǇĨŽƌɴ ?ĂƌƌĞƐƚŝŶ ?ĐŽŵƉĂƌĞĚƚŽƚŚĂƚŽďƐĞƌǀĞĚĨŽƌƚŚĞ
Y1 receptor. This has been implied from BRET studies whereby recruitment of
ɴ ?ĂƌƌĞƐƚŝŶ ?ƚŽz ?ƌĞĐĞƉƚŽƌƐǁĂƐďŽƚŚĚĞĐƌĞĂƐĞĚŝŶƚĞƌŵƐŽĨĞǆƚĞŶƚĂŶĚŬŝŶĞƚŝĐƐ
when compared to the Y1 subtype (t1/2 23min for Y2 and 3.4min for Y1
respectively) (Berglund et al., 2003b). The reason for this reduced arrestin
affinity may lie in the sequence differences between the Y1 and Y2 receptors.
Surprisingly interaction does not appear dependent on the Y1 and Y2 receptor
C terminal tails, the traditional site for phosphorylation by G protein receptor
and other kinases. For example the Y2 receptor contains a region analogous
to the Y1 receptor phosphorylation motif (Ouedraogo et al., 2008, Walther
ĞƚĂů ? ? ? ? ? ? ZƚŚŽƵŐŚƚƚŽƉůĂǇĂŬĞǇƌŽůĞŝŶƚŚĞƌĞĐƌƵŝƚŵĞŶƚŽĨɴ ?ĂƌƌĞƐƚŝŶ ? ?EWz
receptor chimeras consisting of the Y1 receptor substituted with the Y2
receptor C terminal domain, showed significantly increased NPY induced
internalisation when compared to wildtype Y1 receptors (Lundell et al., 2011).
dŚŝƐ ŝŶĚŝĐĂƚĞĚ ƚŚĂƚ ƚŚĞ z ? ƌĞĐĞƉƚŽƌ  ƚĞƌŵŝŶƵƐ ŝƐ ĐĂƉĂďůĞ ŽĨ ƐƵƉƉŽƌƚŝŶŐ ɴ ?
arrestin2 recruitment, so that other Y2 receptor intracellular domains may be
affecting the strength of this interaction.
Both PYY and the amino truncated form of PYY3-36 induced the formation of
Y2/A2 BiFC with higher potencies than that observed for NPY. This is in line
with previous observations of the rank order of potency at the Y2 receptor
(Gerald et al., 1995, Matthews et al., 1997, Akerberg et al., 2010). The
differences in potency of PYY3-36 at Y1 versus Y2 receptors likely reflects the
differing requirements of each receptor subtype for the N terminal domain of
the peptide (Michel et al., 1998). Ligand binding affinity observations
suggested that unlike the Y1 receptor, the C terminal peptide portion from
residue 13 onwards is sufficient for binding to the Y2 subtype (Lindner et al.,
2008). As expected the Y1 selective peptide [Leu31, Pro34] NPY (Fuhlendorff et
al., 1990) showed very low potency at the Y2 receptor, reconcilable with
previous measurements of its low binding affinity at this subtype (Matthews
et al., 1997, Lindner et al., 2008, Akerberg et al., 2010).
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3.4.4.2 Y4 receptor
Stimulation with agonist resulted in internalisation of Y4-GFP receptors and
ƚŚĞ ĨŽƌŵĂƚŝŽŶ ŽĨ z ? ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ? ŝ& ĐŽŵƉůĞǆĞƐ  ?&ŝŐƵƌĞƐ  ? ? ? ?ĂŶĚ
3.12, C). Conflicting reports exist on the ability and kinetics of Y4 receptor
internalisation. Initial observations in CHO cells showed no desensitisation or
internalisation for C terminal FLAG tag labelled Y4 receptors (Voisin et al.,
2000). However observations from several other groups have shown rapid
internalisation of Y4 receptors in response to agonist (Tough et al., 2006,
Bohme et al., 2008), which were largely comparable to Y1 responses (Parker
et al., 2001, Parker et al., 2005). The greatest degree of responses for both
endpoint measurements were observed following stimulation with PP. This
was expected based on the known high selectivity of Y4 receptors for PP (Bard
et al., 1995, Berglund et al., 2001) in contrast to responses observed for the
Y1 receptor (Tables 3.2 and 3.3). Observations of HA tagged Y4 receptor
internalisation in HEK293 cells in response to PP was also less than observed
for Y1 receptors in response to NPY (Tough et al., 2006). BRET observations
have also shown that PP can induce concentration dependent recruitment of
ɴ ?ĂƌƌĞƐƚŝŶ ? ƚŽ z ? ƌĞĐĞƉƚŽƌƐ  ?ĞƌŐůƵŶĚ Ğƚ Ăů ? ?  ? ? ? ?ď Z ŚŽǁĞǀĞƌ ǁŝƚŚ Ă
significantly reduced potency compared to that observed using BiFC (pEC50 7.4
± 0.1 for BRET2 versus 9.5 ± 0.3 for Y4/A2 BiFC). It is worth noting however in
the aforementioned BRET study, agonist potencies were consistently lower for
all subtypes than their respective binding estimates (Berglund et al., 2003b).
The authors postulate that this may be due to an overexpression of GFP-
arrestin2 in these studies changing the stoichiometry of receptor-arrestin
ŝŶƚĞƌĂĐƚŝŽŶƐ ?,ŽǁĞǀĞƌɴ ?ĂƌƌĞƐƚŝŶ ?ǁĂƐĂůƐŽŽǀĞƌĞǆƉƌĞƐƐĞĚŝŶƚŚŝƐŝ&ƐǇƐƚĞŵ
 ?ĂƐƚŚĞɴ ?ĂƌƌĞƐƚŝŶ ? ?zŶŝƐĂƐƚĂďůǇĞǆƉƌĞƐƐĞĚĐůŽŶĂůůŝŶĞ ZĂŶĚĂŐŽŶŝƐƚƉŽƚĞŶĐŝĞƐ
for all Y subtypes were relatively consistent with those seen for the
internalisation of GFP tagged receptors expressed in HEK293T (expressing
ĞŶĚŽŐĞŶĞŽƵƐ ůĞǀĞůƐ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? Z ĂŶĚ ƉƌĞǀŝŽƵƐ ĞƐƚŝŵĂƚĞƐ ŽĨ ůŝŐĂŶĚ
potencies. However observations from BRET are useful as an indicator of the
ƌĞĂůƚŝŵĞƌĂŶŬŽƌĚĞƌŽĨĂƐƐŽĐŝĂƚŝŽŶŽĨɴ ?ĂƌƌĞƐƚŝŶ ?ǁŝƚŚzƌĞĐĞƉƚŽƌƐƵďƚǇƉĞƐ ?ŝŶ
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terms of t1/2 values), which can only be inferred by BiFC studies from changes
in agonist potency.
NPY and PYY showed reduced maximal responses, compared to PP, at
inducing Y4/A2 BiFC responses and Y4-GFP receptor internalisation. This is
consistent with the reported decreased affinity of these ligands at the Y4
receptor when [125I] PP is used as the radioligand (Lundell et al., 1995, Lundell
et al., 1996, Parker et al., 1998), in comparison to relative affinities at the Y1
and Y5 receptor subtypes (Lindner et al., 2008), and their reduced ability to
stimulate Y4 receptor G protein coupling and inhibition of cAMP formation
(Tough et al., 2006). GR231118 was a low efficacy agonist at both Y4-GFP and
Y4/A2 cell lines. Partial agonism of GR231118 at Y4 receptors has also been
ĚŽĐƵŵĞŶƚĞĚ ŝŶ ĨƵŶĐƚŝŽŶĂů ĂƐƐĂǇƐ ƐƵĐŚ ĂƐ ƐƚŝŵƵůĂƚŝŽŶ ŽĨ 'dWɶ ?35S] binding
(Tough et al., 2006) and is consistent with previous observations implying it is
high affinity Y4 receptor agonist (Parker et al., 1998). Interestingly although
GR231118 has similar binding affinities for both Y4 and Y1 receptor subtypes
(Matthews et al., 1997, Parker et al., 1998), GR231118 showed no activity at
Y1-GFP or Y1/A2 BiFC (Figures 3.9, A and 3.12, A) consistent with its previously
documented activity as a Y1 receptor antagonist (Daniels et al., 1995).
GR231118 is a dimeric analogue of the C terminal domain of NPY (Tough et al.,
2006). The contrasting effects of GR231118 at Y4 and Y1 receptors, suggests
that the C terminal portion of NPY is capable of activating the Y4 receptor.
However the Y1 receptor requires further engagement with the NPY N
terminus , which reconciles with the previous partial efficacy observed at
Y1/A2 for NPY3-36 and PYY3-36 (Table 3.3) and the Y1 selective antagonism
observed for the NPY C terminal dipeptide mimic BIBO3304 for Y1-GFP
internalisation and Y1/A2 BiFC formation (Lindner et al., 2008).
Both Y4-GFP and Y4/A2 BiFC cell lines therefore showed expected ligand
selectivity based on previous observations. The presence of either tag did not
ĂĚǀĞƌƐĞůǇ ĂĨĨĞĐƚ ƉŽƚĞŶĐǇ ǀĂůƵĞƐ ŝŶ ƌĞƐƉĞĐƚ ƚŽ ƌĞĐĞƉƚŽƌ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ Žƌ ɴ ?
arrestin recruitment.
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3.4.4.3 Y5 receptor
Both NPY and PP were able to induce the formation of Y5/A2 BiFC complexes
and the internalisation of Y5-GFP receptors within a 60 minute time period
(Figure 3.6, C) with comparable potencies observed between the different
endpoint measurements (Tables 3.2 and 3.3). These NPY potencies were also
comparable to those previously observed for this receptor for inositol
phosphate accumulation assay in COS-7 cells (Lindner et al., 2008). NPY3-36
also exhibited high potency in stimulating Y5/A2 BiFC complexes, consistent
with the previously documented affinity of N terminal truncated peptides for
this receptor subtype (Gerald et al., 1996). The Y5 selective ligand cPP(1-
17)(Ala31,Aib32) (17-36) NPY showed subtype selectivity for Y5 receptors,
whereby it was able to induce Y5/A2 BiFC with high potency and efficacy, but
showed no activity at inducing Y1/A2 BiFC complex formation. This was
expected based on previous observations of the subnanomolar affinity of
Ala31, Aib32 containing PP/NPY hybrid peptides at Y5 receptors when
compared to other NPY receptor subtypes (Cabrele and Beck-Sickinger, 2000),
with this motif crucial for promoting selectivity. The Y5 selective antagonist
CGP71683 also showed expected surmountable antagonism at Y5-GFP
receptors, suggesting that the presence of the fluorescent protein tag was
well tolerated. The only discrepancy in ligand responses observed between
ŵĞĂƐƵƌĞƐŽĨɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚĂŶĚz ?ƌĞĐĞƉƚŽƌ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶǁĂƐ ƚŚĞ
43 fold increase in potency seen for cPP(1-17)(Ala31,Aib32) (17-36) NPY at Y5-
GFP.
All stimulations of the Y5 receptor required a 60min assay stimulation in order
for sufficient responses to be determined. Similar to the Y4 receptor, the
extent and rate of Y5 receptor internalisation has been disputed. Y5-GFP
receptors have previously been shown to translocate in a time dependent
manner to intracellular compartments following stimulation with PYY (Gehlert
et al., 2007) and with internalisation assays using radiolabelled ligand
suggested this receptor does undergo internalisation but at a slower rate
when compared to Y1 receptors (Parker et al., 2003, Bohme et al., 2008).
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Zd ƐƚƵĚŝĞƐ ŚĂǀĞ ƐŚŽǁŶ ƚŚĂƚ ƚŚĞ z ? ƌĞĐĞƉƚŽƌ ƌĂƉŝĚůǇ ĂƐƐŽĐŝĂƚĞƐ ǁŝƚŚ ɴ ?
arrestin2 in response to stimulation with NPY with kinetics comparable to that
observed for the Y1 receptor (t1/2 values 4.6minand 3.4min respectively).
However BRET maximum responses were decreased for Y5 receptors
compared to that of the Y1, suggesting that the Y5 receptor is capable of
ƌĂƉŝĚůǇ ƌĞĐƌƵŝƚŝŶŐ ɴ ?ĂƌƌĞƐƚŝŶ ? ? ďƵƚ ƚŽ Ă ůŽǁĞƌ ĞǆƚĞŶƚ  W ĂŶĚ ƚŚĂƚ ĚŽĞƐ ŶŽƚ
translate to rapid receptor internalisation as seen for the Y1 receptor.
One explanation for this discrepancy is the structure of the Y5 receptor, in
that it is relatively distinct from other NPY receptor subtypes, with a short C
terminus consisting of only 17 amino acids (versus 64 amino acids for the Y1
receptor) and a long intracellular loop 3 over 100 residues longer than the Y1
receptor (Gerald et al., 1996). The ability of the Y5 receptor to internalise,
suggests that for this subtype, the third intracellular loop may fulfil the typical
role of the C terminus for the other NPY receptor subtypes, particularly as it
contains a stretch of serine residues that are potential kinase phosphorylation
sites (Berglund et al., 2003b). As a change in potency was only observed for
the Y5 selective ligand c cPP(1-17)(Ala31,Aib32) (17-36) NPY, this ligand may
stabilise a particular conformation of Y5-GFP that is capable of rapidly
recruiting E-arrestin2 (Berglund et al., 2003b), might also recruit other
mechanisms to drive internalisation.
This phenomenon has been suggested to account for the constitutive
internalisation of C terminal truncated Y1 receptors (Holliday et al., 2005) and
muscarinic M2 receptors (Pals-Rylaarsdam et al., 1997). Although further
work is required to confirm this, it is possible that the selective change in cPP-
Aib-NPY potency reflects that all forms of Y5-GFP receptor internalisation are
ŵĞĂƐƵƌĞĚ ?ďĞ ƚŚĂƚ ɴ ?ĂƌƌĞƐƚŝŶ ? ĚĞƉĞŶĚĞŶƚ Žƌ ŝŶĚĞƉĞŶĚĞŶƚ ? ǁŚĞƌĞĂƐ ƚŚĞ ŝ&
ĂƐƐĂǇ ŝƐ ĚŝƌĞĐƚůǇ ŵĞĂƐƵƌŝŶŐ ƚŚĞ ĂƐƐŽĐŝĂƚŝŽŶ ŽĨ z ? ƌĞĐĞƉƚŽƌƐ ǁŝƚŚ ɴ ?ĂƌƌĞƐƚŝŶ ?
only.
3.4.4.4 Summary of responses at Y receptor subtypes
Measurements of ligand pharmacology derived from the quantification of two
ĚŝƐƚŝŶĐƚ ĨƵŶĐƚŝŽŶĂů ŽƵƚƉƵƚƐ  ?ƌĞĐĞƉƚŽƌ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ĂŶĚ ɴ ?ĂƌƌĞƐƚŝŶ
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recruitment) were relatively consistent across all 4 Y receptor subtypes
ƐƵŐŐĞƐƚŝŶŐƚŚĂƚƚŚĞĂŐŽŶŝƐƚŝŶĚƵĐĞĚƌĞĐƌƵŝƚŵĞŶƚŽĨɴ ?ĂƌƌĞƐƚŝŶ ?ƚŽzƌĞĐĞƉƚŽƌƐ
facilitates receptor endocytosis.
3.4.5 The relationship between Y receptor internalisation and arrestin
association is supported by the effects of Y1 and Y2 receptor mutations
Mutations were selectively introduced into the Y1 and Y2 receptor sequences
in order to investigate the role of residues implicated in ligand binding
 ?z ?z ? ? Z Žƌ ŝŶ ƚŚĞ ŵŽůĞĐƵůĂƌ ŵĞĐŚĂŶŝƐŵƐ ƚŚĂƚ ĨĂĐŝůŝƚĂƚĞ ɴ ?ĂƌƌĞƐƚŝŶ ?
recruitment (Y16A, Y2H155P).
3.4.5.1 The effect of mutating a residue implicated in ligand binding
(Y1Y99A)
Mutation studies have implicated 3 hydrophobic residues in transmembrane
domains 2 (Y99), 6 (F286) and 7 (H298) that facilitate ligand binding at the Y1
receptor (Walker et al., 1994, Sautel et al., 1995, Sautel et al., 1996, Sjodin et
al., 2006, Akerberg et al., 2010). Substitution of these residues with alanine
has been shown to abolish binding of peptide ligands. These residues have
been proposed to form a hydrophobic binding pocket essential for peptide
binding (Sjodin et al., 2006). In this study, mutant Y1Y99A/A2 BiFC complexes
did not show agonist induced endocytosis in response to stimulation with NPY
(Figure 3.17). This was in marked contrast to responses of wildtype Y1/A2,
supporting the importance of this residue in peptide binding at the Y1
receptor. Interestingly this Tyr99 residue is highly conserved across all NPY
receptor subtypes, with the exception of the Y5 receptor (Akerberg et al.,
2010). Mutation of this residue to alanine in both the Y2 (Akerberg et al.,
2010) and the Y4 receptor (Pedragosa-Badia et al., 2013) sequences led to
marked alterations in the affinity of the receptor for binding peptide agonists.
This suggests Tyr99 may be a crucial contributor to ligand binding for the
majority of the NPY receptor family, with a potential hydrogen bond being
formed between the hydroxyl group of this tyrosine to the carboxyl terminal
amide of peptide ligands such as NPY, PYY and their metabolites (Sautel et al.,
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1995, Akerberg et al., 2010, Pedragosa-Badia et al., 2013). The Phe286 and
His298 residues are much less conserved across receptor subtypes and the
extent of their importance in ligand binding is disputed, with other subtype
specific residues thought to be required. The agonist selectivity of Y receptor
subtypes may partly be a reflection of this, with specific residues interacting
with different residues of each peptide ligand.
3.4.5.2 Mutation of Y1 receptor carboxyl terminal residues implicated in the
ƌĞĐƌƵŝƚŵĞŶƚŽĨɴ ?ĂƌƌĞƐƚŝŶ ? ?z ? ? ?
A lack of agonist induced responses were observed for both Y16A-GFP
internalisation and Y16A/A2 BiFC responses (Figures 3.16 and 3.17).
Radioligand competition binding experiments showed that Y16A constructs
were expressed at the cell surface and bound agonist and antagonist peptides
normally,. The C terminal domain of many GPCRs has been implicated in
ƌĞŐƵůĂƚŝŶŐ ƌĞĐĞƉƚŽƌ ĚĞƐĞŶƐŝƚŝƐĂƚŝŽŶ ĂŶĚ ĂƐ Ă ŵĂũŽƌ ƐŝƚĞ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ
recruitment. The six alanine substitutions sequentially introduced into the C
terminal domain of the Y16A (Figure 3.14, A) were located within the Y1
receptor phosphorylation motif that has been proposed to aid high affinity
ďŝŶĚŝŶŐŽĨɴ ?ĂƌƌĞƐƚŝŶ ? ?,ŽůůŝĚĂǇĞƚĂů ? ? ? ? ? ? ?KƵĞĚƌĂŽŐŽĞƚĂů ? ? ? ? ? ? ?<ŝůƉĂƚƌŝĐŬ
ĞƚĂů ? ?  ? ? ? ? Z ?Ɛɴ ?ĂƌƌĞƐƚŝŶ ?ŚĂƐƉƌĞǀŝŽƵƐůǇďĞĞŶƐŚŽǁŶƵƐŝŶŐZdƚŽƌĞĂĚŝůǇ
be interact with agonist activated Y receptors (Berglund et al., 2003b), the
abolition of NPY responses for Y16A-GFP and Y16A/A2 indirectly suggested
ƚŚĂƚ ɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚ ŝƐ ƌĞƐƉŽŶƐŝďůĞ ĨŽƌ z ?ƌĞĐĞƉƚŽƌ ĞŶĚŽĐǇƚŽƐŝƐ ? dŚŝƐ
also reconciles with the shared agonist and antagonist profiles seen for Y
receptor internalisation and Y receptor/A2 BiFC responses.
Mass spectrometry experiments have been used to directly identify C terminal
residues phosphorylated upon agonist stimulation in vasopressin (Wu et al.,
 ? ? ? ? Z ?yZ ? ?ƵƐŝůůŽĞƚĂů ? ? ? ? ? ? ZĂŶĚɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ?E ďůĞƐĞƚĂů ? ? ? ? ? ? Z ?
Interestingly for the Y1 receptor, it seems to be the number of residues
phosphorylated is more important than the location of these residues. When
sequential alanine mutations were introduced into the Y1 receptor C terminal,
ĚƌĂŵĂƚŝĐ ƌĞĚƵĐƚŝŽŶƐ ŝŶ ɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚ ǁĞƌĞ ŽŶůǇ ƐĞĞŶ ǁŚĞŶ Ă
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combination of 4/6 residues were mutated (Ouedraogo et al., 2008, Kilpatrick
et al., 2010). Two separate mutant Y1 receptor cell lines containing a
different combination of 4 mutated residues, showed similar reductions
 ?ĂƉƉƌŽǆŝŵĂƚĞůǇ Ă  ? ?A? ĚĞĐƌĞĂƐĞ Z ŝŶ ɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚ  ?<ŝůƉĂƚƌŝĐŬ Ğƚ Ăů ? ?
2010). Only marginal reductions (approximately 20%) were observed with
single substitutions, suggesting there are no magic bullet residues that
ŬŶŽĐŬŽƵƚ z ? ?ɴ ?ĂƌƌĞƐƚŝŶ ? ŝŶƚĞƌĂĐƚŝŽŶ ĂŶĚ ƚŚĂƚ ĚŝĨĨĞƌĞŶƚ ĐůƵƐƚĞƌƐ ŽĨ
phosphorylated residues can support this association. This redundancy within
the phosphorylation motif was also observed for rhodopsin receptors (Doan
et al., 2006) where activity was correlated to the number of C terminal
phosphorylation sites as opposed to the identity of the specific residue, and
chemokine receptor 5 (Huttenrauch et al., 2005). Interestingly the importance
ŽĨ ƚĞƌŵŝŶĂůƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ŝŶĚƌŝǀŝŶŐƌĞĐƌƵŝƚŵĞŶƚŽĨɴ ?ĂƌƌĞƐƚŝŶ ?ƐĞĞŵƐƚŽ
differ within the GPCR superfamily with muscarinic M2 (Gimenez et al., 2012)
and neurokinin receptors (Richardson et al., 2003) both capable of
desensitising and internalising in a phosphorylation independent manner. The
conservation of this phosphorylation barcode may also change with cell type,
receptor subtype and the ligand used to activate the receptor (possibly
providing a mechanism for signalling pathway bias; (Nobles et al., 2011, Chen
et al., 2013). Additional sites distinct from the receptor carboxyl terminal
ŚĂǀĞĂůƐŽďĞĞŶŝŵƉůŝĐĂƚĞĚŝŶŚŝŐŚĂĨĨŝŶŝƚǇďŝŶĚŝŶŐŽĨɴ ?ĂƌƌĞƐƚŝŶ ? ?ƐƵĐŚĂƐƐŝƚĞƐ
in the second (Marion et al., 2006) and third intracellular loop (for example
the muscarinic M2 and M3 receptors; (Gimenez et al., 2012, Poulin et al.,
2010, Butcher et al., 2011).
3.4.5.3 Mutation of an intracellular loop 2 mutation implicated in the
ƌĞĐƌƵŝƚŵĞŶƚŽĨɴ ?ĂƌƌĞƐƚŝŶ ? ?z ?, ? ? ?W ?
The H155P mutation selectively introduced into the Y2 receptor sequence
ĞŶŚĂŶĐĞĚ ďŽƚŚ ɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚ  ?<ŝůƉĂƚƌŝĐŬ Ğƚ Ăů ? ?  ? ? ? ? Z ĂŶĚ z ?
receptor internalisation in response to NPY (Figure 3.16) with potency values
substantially greater than those observed for the wildtype Y2 receptor (Table
3.2). In the Y1 receptor sequence this residue is a proline that is conserved in
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64% of class A GPCRs (Marion et al., 2006, Shan et al., 2010) and has been
ŝŵƉůŝĐĂƚĞĚ ĂƐ ŽŶĞ ŽĨ ƚŚĞ ĞůĞŵĞŶƚƐ ǁŝƚŚŝŶ ƚŚĞ ƌĞĐĞƉƚŽƌ ƌĞĐŽŐŶŝƐĞĚ ďǇ ɴ ?
arrestin2 to determine the receptor activation state (Marion et al., 2006, Shan
et al., 2010). Therefore the H155P mutation appears to confer a Y1 like
phenotype on the Y2 receptor in respect to agonist induced internalisation,
ŵŽƐƚ ůŝŬĞůǇ ďǇ ĞŶŚĂŶĐŝŶŐ ɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚ ? dŚĞ ŝŶĐƌĞĂƐĞĚ ƉŽƚĞŶĐǇ ŽĨ
NPY at the Y2H155P vs Y2 receptor is a consequence of this. Additionally this
conclusion is supported by previous substitutions of the equivalent proline
ƌĞƐŝĚƵĞ  ŝŶ ƌŚŽĚŽƉƐŝŶ  ?ZĂŵĂŶ Ğƚ Ăů ? ?  ? ? ? ? Z ? ƐĞƌŽƚŽŶŝŶ  ? ĂŶĚ ɴ ? ?
ĂĚƌĞŶŽĐĞƉƚŽƌƐ  ?DĂƌŝŽŶ Ğƚ Ăů ? ?  ? ? ? ? Z ǁŚŝĐŚ ůĞĚ ƚŽ ĂŵĂƌŬĞĚ ĚĞĐƌĞĂƐĞĚ ŝŶ ɴ ?
ĂƌƌĞƐƚŝŶ ?ďŝŶĚŝŶŐĂŶĚƐƵďƐĞƋƵĞŶƚɴ ?ĂƌƌĞƐƚŝŶ ?ŵĞĚŝĂƚĞĚŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ?
3.4.6 Final conclusions
Here automated imaging was used to successfully quantify the agonist and
antagonist pharmacology of internalisation responses across Y receptor
subtypes for the first time. These responses largely corresponded with those
ŽďƐĞƌǀĞĚ ĨŽƌ ƵƉƐƚƌĞĂŵ ɴĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚ ƚŽ ƚŚĞ ƐĂŵĞ z ƌĞĐĞƉƚŽƌ
subtypes. Quantification of BiFC fluorescence was here able to distinguish
ďĞƚǁĞĞŶ ƌĞĐĞƉƚŽƌ ŵƵƚĂƚŝŽŶƐ ƚŚĂƚ ĂůƚĞƌ ƚŚĞ ĞŶŐĂŐĞŵĞŶƚ ŽĨ ƚŚĞ ɴ ?ĂƌƌĞƐƚŝŶ
activation (Y1H155P) or phosphorylation sensors (Y16A) with the receptor,
with complementary effects in respect to receptor-GFP internalisation
observed. This suggested shared molecular machinery was involved in both
these processes, in that internalisation of Y receptor subtypes is likely to be
ůĂƌŐĞůǇĚƌŝǀĞŶďǇƚŚĞƌĞĐƌƵŝƚŵĞŶƚŽĨɴ ?ĂƌƌĞƐƚŝŶ ? ?
The irreversibility of BiFC effectively constrains protein-protein interactions as
complexes of precise composition. Subsequent chapters exploit this to allow
the investigation of responses that can be directly attributable to this defined
ĐŽŵƉůĞǆ ? ƐƵĐŚ ĂƐ ŝŶƚĞƌĂĐƚŝŽŶƐ ŽĨ 'WZƐ ǁŝƚŚ ɴ ?ĂƌƌĞƐƚŝŶ ?  ?ŚĂƉƚĞƌ  ? Z Žƌ
receptor-receptor homo (Chapter 5) or heterodimerisation (Chapter 6).
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Chapter 4  The use of fluorescence correlation
spectroscopy alongside bimolecular fluorescence
ĐŽŵƉůĞŵĞŶƚĂƚŝŽŶƚŽ ŝŶǀĞƐƚŝŐĂƚĞƚŚĞĞĨĨĞĐƚƐŽĨɴ ?ĂƌƌĞƐƚŝŶ
recruitment on the membrane mobility of NPY receptors
4.1 Introduction
The Y receptor family has previously been shown in Chapter 3 to be able to
ŝŶƚĞƌŶĂůŝƐĞ ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ ĂŐŽŶŝƐƚ ? ǁŚŝĐŚ ĐŽƌƌĞůĂƚĞĚ ǁŝƚŚ ɴ ?ĂƌƌĞƐƚŝŶ ?
ĂƐƐŽĐŝĂƚŝŽŶ  ?&ŝŐƵƌĞƐ  ? ? ? ?  ? ? ? ? Z ? dŚĞ ƌŽůĞ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶƐ ŝŶ ĨĂĐŝůŝƚĂƚŝŶŐ ƚŚĞ
endocytosis of many GPCRs (Chapter 1, section 1.6) by interacting with
components of the endocytic machinery such as clathrin and AP-2 is well
ĞƐƚĂďůŝƐŚĞĚ ? ,ŽǁĞǀĞƌ ɴ ?ĂƌƌĞƐƚŝŶƐ ŚĂǀĞ ĂůƐŽ ďĞĞŶ ƐŚŽǁŶ ƚŽ ĂĐƚ ĂƐ ƐŝŐŶĂůůŝŶŐ
adaptors in their own right, with ligands able to selectively bias signalling
ƚŽǁĂƌĚƐ ɴ ?ĂƌƌĞƐƚŝŶ ĚĞƉĞŶĚĞŶƚ ƉĂƚŚǁĂǇƐ  ?<ĞŶĂŬŝŶ ĂŶĚŚƌŝƐƚŽƉŽƵůŽƐ ?  ? ? ? ? ?
Wisler et al., 2007), though the intracellular or plasma membrane location of
such signalling complexes is currently unclear. At the plasma membrane for
example, the spatial organisation of GPCRs into discrete membrane
microdomains, through interactions with the cytoskeleton or the lipid
environment (Cordeaux et al., 2008, Padgett and Slesinger, 2010, Insel et al.,
2005), may organise intracellular signalling components in close proximity
(Corriden et al., 2014). However due to the heterogeneity of these
microdomains, and their small size, it is often difficult to study specific
ĐŽŵƉůĞǆĞƐ ? ĨŽƌ ĞǆĂŵƉůĞ ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ? ŝŶ ŵŝĐƌŽĚŽŵĂŝŶƐ ǁŝƚŚŝŶ ƐŝŶŐůĞ
cells. One way in which this might be overcome is through the use of single
cell imaging techniques such as fluorescence correlation spectroscopy (FCS),
photon counting histogram analysis (PCH) and fluorescence recovery after
photobleaching (FRAP). Potentially these techniques have great enough
spatial resolution to investigate microdomain organisation of GPCR signalling
domains, but the drawback has often been to define what is present in the
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complex. Application of BiFC in combination with such methods provides one
approach, which is explored in this Chapter.
4.1.2 Fluorescence correlation spectroscopy (FCS)
FCS is a live cell imaging technique used to measure the diffusion of
fluorescent species through a defined confocal volume (Schwille, 2001,
Diekmann and Hoischen, 2014, Briddon and Hill, 2007) (Figure 4.1, A). As
fluorescent species traverse the detection volume they generate time
dependent fluctuations in fluorescence intensity that can be analysed to give
quantitative data on the nature of fluorescent particles present, including the
ĂǀĞƌĂŐĞƉĂƌƚŝĐůĞŶƵŵďĞƌĂŶĚ ƚŚĞ ĂǀĞƌĂŐĞĚǁĞůů ƚŝŵĞǁŝƚŚŝŶ ƚŚĞ ǀŽůƵŵĞ  ?ʏ Z
 ?ŚĂƉƚĞƌ ? ?ƐĞĐƚŝŽŶ ? ? ? ? ? Z ?ʏŝŶĐŽŶũƵŶĐƚŝŽŶǁŝƚŚƚŚĞ ĐĂůŝďƌĂƚĞĚĚŝŵĞŶƐŝŽŶƐŽĨ
the confocal volume can be used to determine diffusion coefficients (D) for
the fluorescent species (For equations see Chapter 2, section 2.2.11).
&ƵƌƚŚĞƌŵŽƌĞŵƵůƚŝƉůĞʏĐŽŵƉŽŶĞŶƚƐŝƐŽůĂƚĞĚŝŶĂƵƚŽĐŽƌƌĞůĂƚŝŽŶĂŶĂůǇƐŝƐĐĂŶ
provide quantitative information about different complexes involving the
fluorescent species, where they are distinguished by sufficiently different
diffusion rates (for example, free and receptor bound fluorescent ligands
(Corriden et al., 2014). This information is extracted from within the
detection volume used in FCS (~0.25fl), comprising cellular regions containing
only ~0.1µm2 of plasma membrane consisting of typically 1-100 fluorescent
particles. The diffusional behaviour of fluorescent ligands or GPCRs can then
provide insights into the signalling events within these microdomains. For
example FCS has been used to study the diffusion of adenosine receptors
 ?ƌŝĚĚŽŶĞƚĂů ? ?  ? ? ? ?Ă ?ŽƌĚĞĂƵǆĞƚĂů ? ?  ? ? ? ? Z ?ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ  ?,ĞŐĞŶĞƌĞƚ
al., 2004) somatostatin receptors (Patel et al., 2002) and GABAA receptors
(Meissner and Haberlein, 2003).
There are limitations that need to be considered when using FCS to measure
the diffusion of membrane bound receptors and signalling complexes. Firstly
the 2D model used to fit the recorded fluctuations assumes a 2D plasma
membrane when in reality it contains topographical 3D features such as
clathrin coated pits. Additionally the use of changes in D to identify alterations
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in molecular mass, indicative of events such as receptor dimerisation or
clustering of signalling complexes, can often be problematic due to the cube
root relationship that exists between changes in mass causing a change in D
(Briddon and Hill, 2007). For example whilst the formation of a GPCR dimer
from a monomer is a 2 fold change in mass, this only equates to a 1.25 fold
change in D.
However FCS is sensitive enough to be used where receptor expression is low
(such as in native tissues), as the amplitude of the autocorrelation curve is
inversely proportional to the concentration of fluorescent particles present
within the confocal volume (Diekmann and Hoischen, 2014). The largest
limitation to using FCS is that only mobile fluorescent species will produce
fluctuations that can be recorded. Therefore immobilised species will not be
detected (Diekmann and Hoischen, 2014), for example receptors bound to the
cytoskeleton (Lenne et al., 2006) or limited by other membrane components
such as caveolae (Insel et al., 2005) and lipid rafts (Padgett and Slesinger,
2010).
4.1.3 Photon counting histogram analysis (PCH)
The same fluorescent fluctuations recorded in FCS readings can be
alternatively analysed in respect to variation in amplitude rather than time.
PCH analysis generates an alternative estimate of particle concentration than
that determined by autocorrelation analysis, in addition to estimates of
ŵŽůĞĐƵůĂƌďƌŝŐŚƚŶĞƐƐ ?੣ ZŽĨĨůƵŽƌĞƐĐĞŶƚƐƉĞĐŝĞƐ ?ŚĞŶĞƚĂů ? ? ? ? ? ? ?<ĂƐŬĞƚĂů ? ?
1999). PCH is therefore a more sensitive indicator of changes in the
stoichiometry of fluorescent complexes as molecular brightness is
proportional to the number of fluorescent molecules within a complex as for
example, the transition of a fully labelled GPCR from a monomer to dimer
ƐŚŽƵůĚƚŚĞŽƌĞƚŝĐĂůůǇƌĞƐƵůƚŝŶĂĚŽƵďůŝŶŐŽĨ੣ (assuming a 1:1 stochiometry of
protein to fluorescent label).
Therefore FCS and PCH can provide complementary information on the
diffusion characteristics and molecular composition of fluorescently tagged
complexes such as adenosine A3 receptors (Cordeaux et al., 2008), serotonin
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5-HT2C ƌĞĐĞƉƚŽƌƐ  ?,ĞƌƌŝĐŬ ?ĂǀŝƐ Ğƚ Ăů ? ?  ? ? ? ? Z ĂŶĚ ƚŚĞ ďŝŽŐĞŶŝĐ ĂŵŝŶĞ ɲ1b-
ĂĚƌĞŶŽĐĞƉƚŽƌƐ ? ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ? ŵƵƐĐĂƌŝŶŝĐ D1 and M3 and dopamine D1
receptors (Herrick-Davis et al., 2013).
4.1.4 Fluorescence recovery after photobleaching (FRAP)
FRAP is a technique that can also measure the mobility and molecular
dynamics of fluorescently tagged molecules within the membranes of living
cells (Bancaud et al., 2009, Axelrod et al., 1976, Dorsch et al., 2009). Since its
development in the 1970s, FRAP has now become commonplace to study the
dynamics of a wide range of cellular processes such as protein recycling,
cytoskeletal dynamics, vesicle transport, cell adhesion and signal transduction
(reviewed in (Diekmann and Hoischen, 2014)). Typically in a FRAP assay,
fluorescent molecules within a small region of the cell are photobleached
using a high power focused laser beam. Photobleaching causes irreversible
damage to the chromophore by interrupting the cycle of repetitive excitation
and emission so that these molecules can no longer fluoresce. The recovery of
fluorescence within the bleached region is attributable to an inward diffusion
of unbleached bright fluorescent molecules which are exchanged for their
bleached counterparts. This process is recorded over time at a low intensity
laser power (Lippincott-Schwartz et al., 2003, McNally, 2008).
FRAP analysis can also provide additional information on the underlying
molecular dynamics of the cellular environment, by giving estimates of the
proportion of fluorescently tagged receptors that are mobile. This fraction can
be significantly affected by the interaction of fluorescently tagged receptors
of interest with other intracellular components and microdomains leading to
restrictions on free diffusion (Diekmann and Hoischen, 2014). Both the mobile
and immobile fractions can be calculated directly from the ratios of
fluorescence intensities recorded pre and post bleaching (see Chapter 2,
2.12). The use of representative and background ROIs in addition to the
experimental ROI monitors background bleaching over time, and facilitates
the calculation of accurate diffusion coefficients (D) (Figure 4.4, A; see
Chapter 2, 2.12 for further details). .
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In contrast to FCS, FRAP measurements are made over a larger membrane
area (Briddon and Hill, 2007) and are more likely to be influenced by the
heterogeneity of the membrane surface. However unlike FCS, FRAP can
estimate the proportion of fluorescent molecules which are mobile compared
to immobile, providing information on the influence of stable cellular barriers
to free diffusion within membrane regions. Therefore both techniques can
complement one another to provide information on the micro (FCS) and
macro (FRAP) diffusion of cellular complexes.
4.1.5 The development of a novel BiFC pairing using superfolder GFP
fragments
BiFC using YFP fragments has been used previously in FCS studies to
investigate the diffusion of adenosine receptor dimers (Briddon et al., 2008),
serotonin 5-HT2C homodimers (Herrick-Davis et al., 2012) and histamine H1
receptors (Rose et al., 2010). The irreversible nature of BiFC is potentially
advantageous when investigating such interactions as it defines the precise
composition of molecular complexes (Kerppola, 2008a, Kilpatrick et al., 2010).
However, although YFP BiFC fragments were previously used successfully in
ŚĂƉƚĞƌ  ? ƚŽ ŝŶǀĞƐƚŝŐĂƚĞ ƚŚĞ ɴ ?ĂƌƌĞƐƚŝŶ ? ĂƐƐŽĐŝĂƚŝŽŶ ǁŝƚŚ z ƌĞĐĞƉƚŽƌƐ ? ƚŚĞƐĞ
same constructs are less suited to single molecule imaging techniques. This is
due to the high propensity of YFP molecules to spot bleach as they diffuse
through the confocal volume (Schwille, 2001). YFP tagged molecules
effectively disappear from the confocal volume during the recording leading
to artificially reduced dwell times and consequently faster observed diffusion
coefficients (Rose et al., 2010, Briddon et al., 2004b, Schwille et al., 2000). This
property has been illustrated in assessments of myc tagged H1-YFP receptors,
using YFP fluorescence directly, where a steep linear relationship was
observed between laser power and D (Rose et al., 2012).
GFP variants do not show as great an inclination to bleach at low laser powers
and would therefore be better suited to FCS assays (Diekmann and Hoischen,
2014), as well as showing other improved photophysical characteristics for
measurements (such as a reduced contribution to the autocorrelation trace
182
from fluorescent protein blinking at high frequencies). However the use of
split eGFP fragments in complementation assays is problematic, as they show
relatively poor complementation efficiencies in living cells under physiological
conditions (Hu and Kerppola, 2003). The superfolder variant of GFP has also
been developed for BiFC, but the fragments previously chosen (split point
ďĞƚǁĞĞŶ ďĞƚǁĞĞŶ ɴ ƐƚƌĂŶĚƐ  ? ? ĂŶĚ  ? ? Z ǁĞƌĞ ĚĞƐŝŐŶĞĚĨŽƌ ƐƉŽŶƚĂŶĞŽƵƐ ƐĞůĨ
assembly (Cabantous and Waldo, 2006). Therefore we proposed that the split
point used previously in this (Chapter 3) and other YFP BiFC studies (Kilpatrick
et al., 2010, Hu and Kerppola, 2003, Kerppola, 2008a, Rose RH, 2010) could be
ƌĞƉůŝĐĂƚĞĚƚŽŐĞŶĞƌĂƚĞŽǀĞƌůĂƉƉŝŶŐƐƵƉĞƌĨŽůĚĞƌ'&WE ?ɴƐƚƌĂŶĚƐ ? ? ? ZĂŶĚ ?ɴ
strands 7-8) terminal fragments with BiFC properties suitable for monitoring
agonist induced Y receptor-arrestin complexes using FCS, FRAP or PCH
analysis.
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4.2 Aims of this chapter:
The overarching aim of this chapter was to use single molecule imaging
techniques to probe the diffusion characteristics of Y1 and Y2 receptor
complexes and investigate how these were affected by agonist stimulation,
and the differing propensities of these subtypes to undergo agonist induced
internalisation. We then aimed to characterise and use the novel superfolder
GFP BiFC system to relate these data to defined Y receptor-E-arrestin
signalling complexes, using E-arrestin mutants to manipulate their interaction
with clathrin coated pits.
Finally, in addition to FCS autocorrelation analysis and FRAP, we used PCH to
obtain estimates of molecular brightness, in order to provide information on
the molecular stoichiometry of Y1 receptors and E-arrestin complexes.
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4.3 Results
4.3.1 The use of FCS and FRAP to investigate the plasma membrane diffusion
of agonist stimulated NPY receptors
Initial FCS recordings were performed on unstimulated Y1-GFP receptors
expressed in 293TR cells (GFP cell lines as previously described in Chapter 3)
(Figure 4.1, B), with the confocal volume placed on the upper plasma
membrane All FCS recordings were performed at 22°C, rather than the 37°C
incubation used for internalisation assays, as this decreased temperature is
necessary to minimise cell membrane movements and consequent fluctuation
artefacts. Fluctuations were fitted to a 2 dimensional model with two
components of similar proportions (WD1, WD2 see Table 4.1), which also
contains a pre-exponential term (not shown) to correct for rapid (< 5 µs)
fluctuations arising from photophysics of the fluorophore. The first
ĐŽŵƉŽŶĞŶƚ ǇŝĞůĚĞĚ Ă ƐŚŽƌƚ ĚǁĞůů ƚŝŵĞ  ?ʏ ? Z ŽĨ  ? ? ? ? ?  A?Ɛ ? ǁŚŝĐŚ ǁĂƐ ĂůƐŽ
interpreted as a consequence of the photophysics of the GFP protein as
highlighted in previous studies (Schwille, 2001, Briddon et al., 2004b, Briddon
Ğƚ Ăů ? ?  ? ? ? ? ? >ŝĐŚƚ Ğƚ Ăů ? ?  ? ? ? ? Z ? dŚĞ ƐĞĐŽŶĚ ůŽŶŐĞƌ ĚǁĞůů ƚŝŵĞ  ?ʏ ? Z ǁĂƐ
therefore interpreted as representing the dwell time and mobility of
unstimulated Y1-GFP receptor proteins. Diffusion coefficients were derived
from these dwell times normalised to the dimensions of the confocal volume
calibrated with Rhodamine 6G on each experimental day.
Y1-GFP expressing cells were then pretreated with vehicle or 100nM NPY for
15min at 37°C, prior to FCS measurements being made at 22°C (Figure 4.1, C).
During the initial 37°C period agonist-stimulated internalisation was observed,
comparable to that seen previously for the Y1-GFP receptor in manual or
automated confocal imaging (Chapter 3, Figures 3.4, 3.7A). Room
temperature FCS recordings were made for up to 60min after control or
agonist treatments, and no time dependent changes in either particle
concentration or D were observed for Y1-GFP receptors, under control or NPY
stimulated conditions, in traces obtained at different points over this period
(Figure 4.2, A and B). The data presented henceforth were therefore pooled
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over this recording time. FCS reads from the plasma membrane revealed no
change in the concentration of Y1-GFP particles after NPY stimulation
compared to controls (Figure 4.2, C), despite evident receptor internalisation .
However a significant slowing of Y1-GFP lateral mobility was detected with
NPY occupancy (Figure 4.2, D, see Table 4.1).
FCS measurements performed here utilised the superfolder variant of GFP
previously used to measure the agonist induced internalisation of NPY
receptor subtypes in platereader assays (Chapter 3, Figure 3.9). This
engineered variant contained mutations that increased the efficiency and rate
of chromophore maturation resulting in a 60% increase in fluorescence
intensity when compared to standard enhanced (e)GFP (Pedelacq et al., 2006)
As this is the first documented set of FCS experiments using the superfolder
GFP variant, its properties were verified by comparing the diffusion of
HEK293TR Y1-eGFP receptors to that previously observed for Y1-GFP
(superfolder). Using identical acquisition settings, comparable measurements
ŽĨʏ ? ?ʏ ? ? ?dĂďůĞ ? ? ? ZĂŶĚƉĂƌƚŝĐůĞĐŽŶĐĞŶƚƌĂƚŝŽŶƐ ? ? ? ? ?A? ? ? ?A?ŵ-2 and 62.3
± 5.0 µm-2; n=46-53) were observed for Y1-eGFP in control and NPY
stimulated conditions (Figure 4.2, C and D). This was expected given that the
addition of superfolder mutations, whilst enhancing GFP folding efficiency, do
not alter chromophore photophysics (Pedelacq et al., 2006).
The Y1 antagonist BIBO3304 (Wieland et al., 1998) was previously
demonstrated to competitively inhibit NPY induced internalisation of Y1-GFP
receptors (Chapter 3, Figure 3.10, A). Pretreatment with BIBO3304 (1µM;
15min at 37°C) did not significantly change the membrane mobility of Y1-GFP
under control conditions (Figure 4.3, B; D= 2.32 ± 0.22 x 10-9 cm2 s-1; n=28).
However BIBO3304 pretreatment was able to inhibit the effect of 100nM NPY
treatment on the slowing of Y1-GFP diffusion. BIBO3304 treatment did not
significantly affect the particle concentrations of Y1-GFP receptors under
control or NPY stimulated conditions (A).
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Table 4.1: Summary of FCS parameters for GFP tagged NPY receptor subtypes
Receptor Condition ʏ ? ʏ ? ŽŶĐĞŶƚƌĂƚŝŽŶ ?ʏ ? ? D n cells
µs % ms N µm
-2
(x 10
-9
cm
2
s
-1
)
Y1-eGFP (5) Control 144 ± 5 46.3 ± 1.6 40.4 ± 2.2 63.7 ± 4.2 2.05 ± 0.2 53
100nM NPY 190 ± 10 49.5 ± 2.1 59.3 ± 5.1 62.3 ± 5.0 1.64 ± 0.2 46
Y1-GFP (16) Control 250 ± 9 41.6 ± 1.1 40.0 ± 1.6 102.5 ± 5.2 2.22 ± 0.2 148
100nM NPY 258 ± 9 39.6 ± 1.2 60.4 ± 3.4 117 ± 6.5 1.48 ± 0.1 117
Y16A-GFP (7) Control 230 ± 8 41.6 ± 1.4 33.9 ± 1.8 90.7 ± 5.4 2.45 ± 0.1 87
100nM NPY 244 ± 8 42.6 ± 1.2 40.0 ± 2.0 89.3 ± 5.1 2.09 ± 0.1 95
Y2-GFP (4) Control 223 ± 11 52.2 ± 0.6 37.5 ± 2.2 77.3 ± 5.7 2.15 ± 0.2 50
100nM NPY 265 ± 12 51.6 ± 0.6 46.4 ± 4.8 83.0 ± 6.0 1.99 ± 0.2 47
Y2H155P-GFP (4) Control 213 ± 11 53.4 ± 0.6 31.6 ± 2.1 68.4 ± 4.8 2.55 ± 0.1 51
100nM NPY 260 ± 16 53.1 ± 1.3 53.0 ± 6.2 70.5 ± 7.3 1.78 ± 0.2 35
ǀĂůƵĞƐǁĞƌĞĐĂůĐƵůĂƚĞĚĨƌŽŵŵĞĂƐƵƌĞŵĞŶƚƐŽĨĚǁĞůůƚŝŵĞ ?ʏ ? ZƵƐŝŶŐĂ ?ĚŝĨĨƵƐŝŽŶŵŽĚĞůǁŝƚŚ ?ǆĚǁĞůůĐŽŵƉŽŶĞŶƚƐ ?dŚĞA?ʏ ?ƌĞĨĞƌƐƚŽƚŚĞƉĞƌĐĞŶƚĂŐĞ
ĐŽŶƚƌŝďƵƚŝŽŶŽĨƚŚĞʏ ?ĚǁĞůůƚŝŵĞĐŽŵƉŽŶĞŶƚƚŽƚŚĞĂƵƚŽĐŽƌƌĞůĂƚŝŽŶĐƵƌǀĞ ?
n numbers in parenthesis refers to the number of independent experiments performed, whilst n values in the table refer to the total number of cell
recordings. Pooled data are expressed as mean ± s.e.m..
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Figure 4.3: Changes in agonist stimulated membrane Y1-GFP receptor mobility are
inhibited by the Y1 selective antagonist BIBO3304
Histograms showing pooled data for FCS measurements of particle concentrations
(A) and diffusion coefficients (B) observed in HEK293TR Y1-GFP cells. Cells were
pretreated with BIBO3304 (1µM; 15min at 37°C) followed by incubation with vehicle
(control; open bars) or NPY (100nM; solid bars) for 15min at 37°C. FCS measurements
were then obtained at 22°C (n=20-29 cells). Significant differences between control
and NPY stimulated data groups are indicated by *** p<0.001 (Kruskal-Wallis,
followed by Dunns post hoc test). Data was pooled from 4 independent
experiments.
Previous investigation of HEK293TR cells stably expressing native (Y1 or Y2) or
mutant (Y16A, Y2H155P) GFP tagged Y receptor subtypes revealed differences
in the extent of their agonist induced endocytosis. Y1 receptors showed rapid
internalisation in response to agonist, which was abolished by the selective
introduction of 6 alanine mutations (6A) into the Y1 C terminus (Chapter 3,
Figure 3.7, B; Figure 3.16). Y2-GFP receptors showed reduced NPY induced
internalisation when compared to Y1-GFP (Figure 3.7, A), however the
Y2H155P mutation was able to enhance the potency of NPY at inducing Y2
receptor internalisation (Y2H155P; Figure 3.7,C and Figure 3.16). We
therefore used these mutants to test whether the observed changes in Y
receptor diffusion following agonist exposure could be accounted for by
predicted interaction with the endocytosis machniery. In order to maximise
the difference in the extent of agonist-stimulated endocytosis by the different
receptors, pretreatment with 100nM NPY was used throughout (Chapter3,
Figure 3.9). In FCS measurements of Y16A-GFP, NPY pretreatment had no
effect on membrane motility, unlike the significant reduction in D observed
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for the wildtype Y1 receptor (Figure 4.2, D). Additionally NPY pretreatment did
not alter the lateral diffusion of wildtype Y2-GFP, however a significant
decrease in the rate of diffusion was introduced by the Y2H155P mutation.
However NPY pretreatment had no effect on cell surface particle
concentrations of native or mutant Y1 or Y2-GFP receptors (Figure 4.2, C). This
was surprising for native Y1-GFP or Y2H155P-GFP receptors given the receptor
internalisation previously seen (Chapter 3, Figures 3.7,B, 3.16,C). This
observation might be explained by NPY increasing the proportion of the
mobile fraction of receptor complexes present at the plasma membrane,
particularly as immobile fractions are undetectable by FCS (Briddon and Hill,
2007). This might compensate for the overall loss of Y receptor-GFP from the
cell surface as endocytosis proceeds.
In order to investigate the role of the mobile receptor fraction, FRAP
experiments were perfomed on HEK293TR Y1-GFP or Y16A-GFP cells at 37°C
(Figure 4.4). A high fraction (approximately 80%) of mobile receptors was
observed for unstimulated Y1-GFP, which did not change with NPY stimulation
or following the introduction of the 6A mutations (Figure 4.5, B). Similar to
observations using FCS, FRAP studies revealed a significant slowing in the rate
of Y1-GFP diffusion following NPY stimulation (C; D= 0.68 ± 0.04 x10-10 cm2 s-1;
**p<0.01; n=23) when compared to vehicle (control; D= 0.99 ± 0.06 x10-10 cm2
s-1; n=19). These D values were considerably lower (approximately 10 fold)
than those obtained using FCS. No effect of agonist on the diffusion of Y16A-
GFP receptors was observed using FRAP.
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4.3.2 The use of superfolder GFP BiFC to detect Y receptor-arrestin
complexes using FCS
A clear correlation was revealed from FCS and FRAP investigations between
the agonist induced changes in Y1 or Y2 receptor mobility and the ability of
these receptors to undergo agonist induced endocytosis. However the
molecular composition of species diffusing through the confocal volume, for
example the receptor-E-arrestin complexes that might be involved in this
pathway, are difficult to define using standard FCS measurements using GFP-
tagged receptors.
Therefore methods that identify the actual molecular complexes present
within the confocal volume will potentially improve the interpretation of D
measurements and their changes. To this end, a novel version of BiFC utilising
ƐƵƉĞƌĨŽůĚĞƌ '&W ĨƌĂŐŵĞŶƚƐ ǁĂƐ ĐƌĞĂƚĞĚ ƚŽ ĚĞĨŝŶĞ z ? ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ
complexes of defined composition in FCS studies. The use of a mutant form of
ɴ ?ĂƌƌĞƐƚŝŶ ? ůĂĐŬŝŶŐ Ă ƉƌŽƉŽƐĞĚ ĐůĂƚŚƌŝŶ ďŝŶĚŝŶŐ ƐŝƚĞ  ?>/& ? ƌĞƐŝĚƵĞƐ  ? ? ? ? ? ? ?
deleted; termed A2LIEFD throughout (ter Haar et al., 2000, Krupnick et al.,
1997a)) was also used to investigate the potential influence of clathrin
ŝŶƚĞƌĂĐƚŝŽŶŽĨĚŝĨĨƵƐŝŽŶƌĂƚĞƐŽĨz ? ?ɴ ?ĂƌƌĞƐƚŝŶ ? ?ƐĚĞƐĐƌŝďĞĚŝŶŚĂƉƚĞƌ ? ?ĚƵĂů
stably transfected HEK293T cells lines were established that coexpressed Y1
ƌĞĐĞƉƚŽƌ ?'ĐĂŶĚĐůŽŶĂůɴ ?ĂƌƌĞƐƚŝŶ ? ? ? Z ?ɴ ?ĂƌƌĞƐƚŝŶ ? ? ? ZŽƌɴ ?ĂƌƌĞƐƚŝŶ ?A?>/&
(A2LIEFD) tagged with the complementary Gn fragment. These cell lines were
termed Y1/A1G, Y1/A2G or Y1/A2LIEFDG respectively, with the G representing
the superfolder GFP BiFC variant.
[125/ ? Wzz ďŝŶĚŝŶŐ ĐŽŶĨŝƌŵĞĚ ƚŚĂƚ Ăůů z ? ?ɴ ?ĂƌƌĞƐƚŝŶ '&W ŝ& ĐĞůů ůŝŶĞƐ ǁĞƌĞ
able to specifically bind PYY and BIBO3304 with high affinity and were
sensitive to GTPJS (Kilpatrick et al., 2012). Bmax values derived from [125I] PYY
displacements confirmed similar expression levels for Y1/A2G, Y1/ A2G and
Y1/A2LIEFD G BiFC cell lines (Table 4.2). Confocal and platereader imaging
experiments were then performed using these lines, as described for the YFP
BiFC system to detect receptor-arrestin association (Chapter 3, Figure 3.4.2.1).
NPY stimulated complementation of the superfolder GFP fragments was
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indicated by fluorescence in live transfected HEK293T cells (Figure 4.6),
ĨŽůůŽǁŝŶŐ ĂƐƐŽĐŝĂƚŝŽŶ ŽĨ ƚŚĞ z ? ƌĞĐĞƉƚŽƌ ǁŝƚŚ ɴ ?ĂƌƌĞƐƚŝŶ ? &Žƌ ƚŚĞ z ? ? ?' ĐĞůů
line, minimal intracellular fluroescence was observed under control
conditions, however stimulation with 100nM NPY (60min, 37°C/5%CO2)
ŐĞŶĞƌĂƚĞĚ ŶŽǀĞů z ? ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ? ŝ& ĐŽŵƉůĞǆĞƐ ƚŚĂƚ ǁĞƌĞ
predominantly localised to intracellular perinuclear compartments and to a
lesser extent the plasma membrane (A; Y1/A2G). However under basal
conditions some pre existing Y1/A1G BiFC complexes were observed at the
plasma membrane (B). After NPY stimulation of Y1/A1G lines, brighter
intracellular fluorescent compartments were observed, suggesting both
redistribution of pre-existing complexes and de novo complementation.
The specificity of the GFP BiFC signal for both arrestin isoforms was verified
using control Y16A receptors, which do not recuit arrestin (Chapter 3; Figure
3.17). No BiFC was detected under basal or agonist stimulated conditions for
Y16A/A2G or Y16A/A1G (C or D). In these confocal experiments, incorporation
of the clathrin binding deletion 'LIEFD into E-arrestin2 also resulted in more
cell surface BiFC in the Y1/A2LIEFDG cell line, when compared to Y1/A2G cells,
under basal or agonist stimulated conditions (E). However substantial
ůŽĐĂůŝƐĂƚŝŽŶ ŽĨ z ? ? ?A?>/&' ŝ& ĐŽŵƉůĞǆĞƐ ĂĨƚĞƌ EWz ƐƚŝŵƵůĂƚŝŽŶ ŝŶ
intracellular compartments was still observed.
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Table 4.2: [
125/ ?WzzŵĞŵďƌĂŶĞĐŽŵƉĞƚŝƚŝŽŶďŝŶĚŝŶŐƉĂƌĂŵĞƚĞƌƐĚĞƌŝǀĞĚĨƌŽŵz ? ?'Đ ?ɴ ?ĂƌƌĞƐƚŝŶ ?'ŶĐŽŶƐƚƌƵĐƚƐ
Cell line PYY BIBO3304 'dWɶ^ Bmax
pIC50 pIC50 pIC50 % inhibition pmol/mg
-1
Y1/A1G 9.5 ± 0.2 9.6 ± 0.1 8.6 ± 0.3 68.5 ± 13.9 0.7 ± 0.2
Y1/A2G 9.2 ± 0.1 9.7 ± 0.1 8.5 ± 0.2 66.7 ± 7.0 0.9 ± 0.4
Y1/A2LIEFDG 9.4 ± 0.1 9.8 ± 0.2 8.5 ± 0.1 54.9 ± 7.0 1.1 ± 0.3
Table taken from (Kilpatrick et al., 2012).
All parameters were obtained from [125I] PYY competition membrane binding experiments (using 16pM [125I] PYY) as described in Chapter 2, section 2.2.3.
% inhibition of TSB refers to the displacement by 1µM competing ligand, as a % of the total specific binding (TSB) defined in the absence / presence of 1 µM
PYY.
ĞƚĂŝůƐŽĨƚŚĞɴ ?ĂƌƌĞƐƚŝŶ ?>/&ĚĞůĞƚŝŽŶĂƌĞŐŝǀĞŶŝŶƚŚĞƚĞǆƚ ?
n =3+ independent experiments
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Figure 4.6: Confocal microscopy images identifying the association of Y1 receptors
ǁŝƚŚɴ ?ĂƌƌĞƐƚŝŶ ?ƵƐŝŶŐƐƉůŝƚƐĨ'&Wŝ&
>ŝǀĞ ,< ? ? ?d ĐĞůůƐ ƐƚĂďůǇ ĐŽĞǆƉƌĞƐƐŝŶŐ z ? ƌĞĐĞƉƚŽƌ ?'Đ ĂŶĚ ĞŝƚŚĞƌ ɴ ?ĂƌƌĞƐƚŝŶ ? ?'Ŷ
 ?ƚĞƌŵĞĚ z ? ? ?' Z ? ɴ ?ĂƌƌĞƐƚŝŶ ? ?'Đ  ?z ? ? ?' Z Žƌ ɴ ?ĂƌƌĞƐƚŝŶ ?A >/& ?'Ŷ  ?z ? ? ?>/&' Z
were imaged using confocal microscopy. Equivalent images were also obtained for
ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶĚĞĨŝĐŝĞŶƚŵƵƚĂŶƚz ? ?ƌĞĐĞƉƚŽƌ ?'ĐĐŽĞǆƉƌĞƐƐĞĚǁŝƚŚɴ ?ĂƌƌĞƐƚŝŶ ?'Ŷ
(Y16A/A2G or Y16A/A1G). BiFC fluorescence was investigated under both control or
agonist simulated conditions (100nM NPY, 60min at 37°C). Acquisition settings were
kept consistent across all cell lines from all experiments (from n=3-5).
The kinetics of the agonist stimulated development of Y1/A1G and Y1/A2G
BiFC, were quantified using automated confocal platereader images and
granularity analysis (Figure 4.7, A and B). Cells expressing Y1/A1G or Y1/A2G
constructs were stimulated with 100nM NPY (60min at 37°C) with t1/2 values
for BiFC responses of 3.0 ± 0.8 min (n=4) and 5.2 ± 1.4 min (n=5) respectively
(Figure 4.8 A and B). The reversibility of superfolder BiFC responses was also
investigated, by washing plates twice after the intial 100nM NPY timecourse
stimulation and then leaving cells in media minus agonist for 60min at 37°C
prior to fixation. This protocol has previously been shown to be sufficient to
enable Y1 receptor-YFP recycling to the plasma membrane after
internalisation (Kilpatrick et al., 2010). For both Y1/A1G (A) and Y1/A2G cells
(B), the formation of endosomal BiFC complexes was largely irreversible. NPY
ǁĂƐ ĞƋƵŝƉŽƚĞŶƚ  ? ? ?ŵŝŶ Ăƚ  ? ? ? Z ŝŶ ƌĞĐƌƵŝƚŝŶŐ ɴ ?ĂƌƌĞƐƚŝŶ ? Žƌ  ? ƚŽ ƚŚĞ z ?
receptor (Figure 4.7 C), with pEC50 values of 8.3 ± 0.1 (n=4) and 8.6 ± 0.1 (n=4).
Overall these values were also similar to previous potency estimates of
ĂŐŽŶŝƐƚ ŝŶĚƵĐĞĚz ?ƌĞĐĞƉƚŽƌ  ?ɴ ?ĂƌƌĞƐƚŝŶĂƐƐŽĐŝĂƚŝŽŶŵĞĂƐƵƌĞĚƵƐŝŶŐƐƉůŝƚz&W
complementation (Chapter 3, Figure 3.11, B) or internalisation of Y1 receptors
tagged with full length YFP (Kilpatrick et al., 2010).
.
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Figure 4.7: Representative
images of Y1/A1G and Y1/A2G
cell lines taken using an IX Ultra
confocal platereader
HEK293T cells stably
coexpressing Y1/A1G or Y1/A2G
were treated with either vehicle
or 100nM NPY (60min at 37°C)
prior to fixation, nuclear staining
and imaging using a IX Ultra
confocal platereader. The
analysis panel shows the use of a
granularity algorithm which
identified nuclei (green spots;
original H33342 images not
shown) and BiFC fluorescent
compartments (red spots; >3µm
diameter). This algorithm
allowed the measurement of the
average granule intensity on a
per cell basis for each image.
The quantified pooled data of
this data is shown in Figure 4.8 .
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Figure 4.8: Timecourse, reversibility and concentration response relationships for
ƚŚĞĂƐƐŽĐŝĂƚŝŽŶŽĨz ?ƌĞĐĞƉƚŽƌĂŶĚɴ ?ĂƌƌĞƐƚŝŶŵĞĂƐƵƌĞĚƵƐŝŶŐ'&Wŝ&
ŝ&ƌĞƐƉŽŶƐĞƐƌĞƐƵůƚŝŶŐĨƌŽŵŝŶƚĞƌĂĐƚŝŽŶƐŽĨz ?ƌĞĐĞƉƚŽƌƐǁŝƚŚɴ ?ĂƌƌĞƐƚŝŶ ? ?z ? ? ?' ?
A) or-2 (Y1/A2G; B) were determined from quantitative analysis of automated
platereader images. Timecourses of stimulation (n=4-5) were performed over 120min
at 37°C with either 100nM NPY (closed circles) or vehicle controls (open circles.
Estimated half times were determined from curve fitting to a one phase association
and are stated in the text. In reversibility experiments 100nM NPY timecourses were
performed as before, but then agonist was removed by washing (2x rinse, 1x60min at
37°C). Cells were then fixed, nuclei stained and imaged using a IX Ultra confocal
platereader. BiFC responses from pooled data of washed cells were compared with
the original curve fits without agonist removal (dotted line; taken from A or B).
Additionally, NPY concentration response curves (C; 60min at 37°C; n=4) were
performed for both Y1/A1G and Y1/A2G complexes with pEC50 values quoted in the
text.
4.3.3 Molecularly defined Y1 receptor-arrestin BiFC complexes show slow
lateral mobility
Y1/A1G and Y1/A2G BiFC cells lines were then used to relate whether the NPY
induced changes observed in the diffusion of Y1-GFP receptors could be
correlated with the properties of molecular Y receptor-arrestin complexes.
FCS measurements were recorded from Y1/A1G and Y1/A2G cell lines
following a 60min NPY prestimulation to generate BiFC (100nM; 37°C).
Although NPY induced BiFC complexes were predominantly localised to
intracellular compartments, the plasma membrane localisation was sufficient
to allow FCS recordings to be made. Similar to FCS measurements of GFP
tagged Y receptors, a 2 dimensional 2 component model was sufficient to fit
ƌĞĐŽƌĚĞĚ ĨůƵŽƌĞƐĐĞŶĐĞ ĨůƵĐƚƵĂƚŝŽŶƐ ? ŽŵƉĂƌĂďůĞ ʏ ?ǀĂůƵĞƐ  ?ƌĞƉƌĞƐĞŶƚŝŶŐ
fluorophore photophysics) were observed for recomplemented superfolder
GFP when compared to full length superfolder GFP (Tables 4.1 and 4.3).
Particle concentrations observed for GFP Y1 receptor arrestin BiFC
complexes (Y1/A1G, Y1/A2G and Y1/A2LIEFDG) were substantially decreased
compared to the higher expressing Y1-GFP receptors (Figure 4.9, A). Similar
rates of mobility were observed for NPY stimulated Y1 receptors complexed
ǁŝƚŚ ĞŝƚŚĞƌ ɴĂƌƌĞƐƚŝŶ ? Žƌ ɴ ?ĂƌƌĞƐƚŝŶ ?  ?ƐĞĞ &ŝŐƵƌĞ  ? ?  ?  ? dĂďůĞ  ? Z ?  dŚĞƐĞ
diffusion coefficients were also comparable to those observed for Y1-GFP
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receptors stimulated by NPY and were significantly slower than those
observed for Y1-GFP under basal conditions (p<0.01 ** or p<0.001 ***).
,ŽǁĞǀĞƌĚĞůĞƚŝŽŶŽĨƚŚĞ>/&ŵŽƚŝĨǁŝƚŚŝŶɴ ?ĂƌƌĞƐƚŝŶ ?ŚĂĚŶŽĞĨĨĞĐƚŽŶƚŚĞ
ĚŝĨĨƵƐŝŽŶ ƌĂƚĞƐ ŽĨ z ? ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ? '&W ŝ& ĐŽŵƉůĞǆĞƐ ? &Žƌ z ? ? ?'
and Y1/A2LIEFDG BiFC complexe, preformed BiFC fluorescence was also
observed at the plasma membrane under basal conditions (Figure 4.6),
allowing FCS measurements under unstimulated conditions to be recorded.
There was evidence for a reduction in diffusion compared to unstimulated Y1-
GFP receptors, however this change was not significant (Figure 4.9, B).
Likewise, FRAP analysis revealed that the fraction of mobile Y1/A2G and
Y1/A2LIEFDG particles formed following 60min 100nM NPY stimulation (37°C)
were consistent with that observed for Y1-GFP (80.0% ± 2.6 and 79.6% ± 2.6
respectively; n=26-31, Figure 4.5, B). Diffusion rates of Y1/A2G and
Y1/A2LIEFDG, derived from FRAP analysis, were also comparable to NPY
stimulated Y1-GFP expressing cells (D=0.63 ± 0.03 x 10-10 cm2 s-1 and 0.67 ±
0.08 x 10-10 cm2 s-1 respectively; n=26-31).
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&ŝŐƵƌĞ ? ? ? PdŚĞƵƐĞŽĨ&^ƚŽĚĞƚĞƌŵŝŶĞƚŚĞĚŝĨĨƵƐŝŽŶŽĨz ?ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ?'&W
BiFC complexes
FCS measurements were taken from the upper membrane of Y1/A1G (control n=21;
NPY n=49 cells), Y1/A2G (NPY n=64) or Y1/A2LIEFDG cells (control n=35; NPY n=22).
Cells were pretreated with control (open bars) or 100nM NPY (closed bars) for 60min
at 37°C prior to FCS measurements at 22°C. Data was pooled for both particle
ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ  ? ?ƐƉĞĐŝĨŝĐƚŽʏ ?ĐŽŵƉŽŶĞŶƚ ZĂŶĚĚŝĨĨƵƐŝŽŶĐŽĞĨĨŝĐŝĞŶƚƐ  ? ?ĚĞƌŝǀĞĚ
ĨƌŽŵ ʏ ? Z ?  ZĞƐƉŽŶƐĞƐ ǁĞƌĞ ĐŽŵƉĂƌĞĚ ǁŝƚŚ ŵĞĂƐƵƌĞŵĞŶƚƐ ŽĨ z ? ?'&W ƌĞĐĞƉƚŽƌƐ
acquired under identical conditions. Plasma membrane fluorescence in Y1/A2G cells
under control conditions was negligible with no fluctuations able to be recorded.
Significant differences in responses refer to comparison with Y1/A2G NPY data (for A)
or Y1-GFP control data (for B) using the Kruskal-Wallis test with Dunns post test
(p<0.01 ** or p<0.001 ***).
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dĂďůĞ ? ? ? P^ƵŵŵĂƌǇŽĨ&^ƉĂƌĂŵĞƚĞƌƐĨŽƌz ?ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ'&Wŝ&ĐŽŵƉůĞǆĞƐ
Receptor Condition ʏ ? ʏ ? ŽŶĐĞŶƚƌĂƚŝŽŶ ?ʏ ? ? D n cells
µs % ms N µm
-2
(x 10
-9
cm
2
s
-1
)
Y1/A1G (4) Control 246 ± 20 52.1 ± 0.8 48.4 ± 3.7 14.2 ± 1.1 1.57 ± 0.1 21
100nM NPY 279 ± 29 60.3 ± 1.4 72.3 ± 5.6 10.9 ± 0.8 1.33 ± 0.1 49
Y1/A2G (9) 100nM NPY 278 ± 17 63.3 ± 1.4 72.6 ± 6.2 9.5 ± 0.8 1.26 ± 0.1 64
Y1/A2LIEFDG (4) Control 259 ± 17 60.0 ± 1.6 48.8 ± 2.3 30.6 ± 4.8 1.51 ± 0.1 35
100nM NPY 254 ± 11 57.8 ± 3.4 77.1 ± 7.0 28.1 ± 6.1 1.20 ± 0.1 22
ǀĂůƵĞƐǁĞƌĞĐĂůĐƵůĂƚĞĚĨƌŽŵŵĞĂƐƵƌĞŵĞŶƚƐŽĨĚǁĞůůƚŝŵĞ ?ʏ ? ZƵƐŝŶŐĂ ?ĚŝĨĨƵƐŝŽŶŵŽĚĞůǁŝƚŚ ?ǆĚǁĞůůĐŽŵƉŽŶĞŶƚƐ ?
Pooled data are expressed as mean ± s.e.m.
dŚĞA?ʏ ?ƌĞĨĞƌƐƚŽƚŚĞƉĞƌĐĞŶƚĂŐĞĐŽŶƚƌŝďƵƚŝŽŶŽĨƚŚĞʏ ?ĚǁĞůůƚŝŵĞĐŽŵƉŽŶĞŶƚƚŽƚŚĞĂƵƚŽĐŽƌƌĞůĂƚŝŽŶĐƵƌǀĞĂŵƉůŝƚƵĚĞ ?
n numbers in parenthesis refers to the number of independent experiments performed, whilst n values in the table refer to the total number of cell
recordings.
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4.3.4 The use of PCH analysis to investigate the stoichiometry of Y1-GFP and
z ? ?ɴ ?ƌƌĞƐƚŝŶŝ&ĐŽŵƉůĞǆĞƐ
The formation of GPCR dimers, higher order oligomers or signalling clusters
microdomains, has the potential to significantly impact GPCR signalling events
(addressed in greater detail in chapters 5 and 6). However standard FCS
measurements of mobility are relatively insensitive to detecting small changes
in molecular mass. (Schwille, 2001). In practice changes in D need to be more
pronounced to reliably reflect changes in molecular mass. However the same
fluorescence fluctuations can be analysed using PCH, to generate information
ŽŶƚŚĞŵŽůĞĐƵůĂƌďƌŝŐŚƚŶĞƐƐ  ?੣ ZŽĨĞĂĐŚƐƉĞĐŝĞƐ ? ŝŶĂĚĚŝƚŝŽŶƚŽĂŶĂůƚĞƌŶĂƚŝǀĞ
measure of particle concentration to that derived from autocorrealtion (FCS)
analysis.
Fluorescence fluctuations recorded from HEK293TR Y1-GFP and HEK293T
Y1/A2G BiFC were analysed using PCH (Figure 4.10). Frequency histograms
were generated from Y1-GFP data, using a 1ms bin time chosen to be below
the dwell time (WD2) of the diffusing receptors. This distribution was fitted
sufficiently with a 1 component model, under basal (A) and 100nM NPY
stimulated conditions (B). Stimulation of Y1-GFP with NPY resulted in an
increase (albeit not significant) of particle concentrations when compared to
basal conditions (350 ± 19 µm-2 (n=57) and 441 ± 37 µm-2 (n=47) for vehicle or
100nM NPY stimulations respectively). A significant 1.5 fold increase in
particle brightness was observed for Y1-GFP following NPY stimulation (C; P<
0.01 **; Table 4.4). This was consistent with NPY inducing the formation of
particles containing more fluorescent receptors. Pretreatment with the Y1
selective antagonist BIBO3304 (1µM; 15min at 37°C) abolished the NPY
ŝŶĚƵĐĞĚŝŶĐƌĞĂƐĞŝŶŵŽůĞĐƵůĂƌďƌŝŐŚƚŶĞƐƐƉƌĞǀŝŽƵƐůǇŽďƐĞƌǀĞĚ ?ďƌŝŐŚƚŶĞƐƐɸŽĨ
5412 ± 502 counts per molecule (cpm) sAL ?in cells treated with BIBO3304 alone
versus 5740 ± 388 cpm sAL ?for BIBO3304 followed by 100 nM NPY, n=2428).
Under basal conditions, PCH analysis revealed that Y16A-GFP showed similar
particle concentrations and molecular brightness to that seen for
unstimulated Y1-GFP (Table 4.4). However following NPY treatment, Y16A-
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GFP cells did not show a similar increase in molecular brightness or particle
number to that observed for native Y1-GFP.
W,ĂŶĂůǇƐŝƐƉĞƌĨŽƌŵĞĚŽŶĨůƵĐƚƵĂƚŝŽŶƐŽďƚĂŝŶĞĚĨƌŽŵz ?ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ
BiFC complexes (using Y1/A2G or Y1/A2LIEFDG cell lines) required a model
with 2 components for effective fitting (Figure 4.10, D). The predominant
species observed for both NPY stimulated Y1/A2G and Y1/A2LIEFDG had
particle concentrations of 97.2 ± 20.3 µm-2 (n=18) and 97.6 ± 27.5 µm-2 (n=14)
respectively. The molecular brightness of this component for both Y1/A2G
and Y1/A2LIEFDG was similar to that observed for unstimulated Y1-GFP
(Figure 4.10, E; Table 4.4). PCH analysis also revealed a second component for
z ? ? ?' ĂŶĚ z ? ? ?>/&' ? dŚŝƐ ĐŽŵƉŽŶĞŶƚ ŚĂĚ Ă  ? ? ? ĨŽůĚ ŝŶĐƌĞĂƐĞĚ ੣
compared to the first component, and likely represented aggregated BiFC
complexes. However component 2 only constituted 12.7 ± 2.4 % (Y1/A2G) or
8.6 ± 1.2 % (Y1/A2LIEFDG) of the total particle population (F).
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Figure 4.10: The use of PCH analysis to determine the molecular brightness of Y1-
'&WŽƌz ? ?ɴ ?ĂƌƌĞƐƚŝŶ ?'&Wŝ&ĐŽŵƉůĞǆĞƐ
Panels A and B show representative traces of 1 component PCH fits (red line) of
single recordings of Y1-GFP cells following control or 100nM NPY stimulation (from at
least 3 individual experiments). Photon counting frequency histograms were created
using a bin time of 1ms, from a 15sec read. Pooled data for Y1-GFP (n=47-57) or
Y16A-GFP (n=30-43) receptors (C) showed the effect of NPY treatment on particle
ďƌŝŐŚƚŶĞƐƐ ?੣ Z ?ƉAM ? ? ? ? ? ?ĐŽŶƚƌŽůǀƐEWz ? ?ĐŽŵƉŽŶĞŶƚĨŝƚǁĂƐŶŽƚĂĚĞƋƵĂƚĞůǇĂďůĞ
to model PCH data from Y1/A2G NPY treated cells (D; red line). Fitting was improved
by using a 2 component model (green line) with the proportion of each component
determined in the analysis. Both component 1 and 2 (Cp 1, Cp2) showed substantially
different molecular brightness values (pooled data shown in E) for NPY stimulated
z ? ? ?' Žƌ z ? ? ?A?>/&' ĐĞůůƐ  ?ŶA? ? ? ? ? ? ĨƌŽŵ  ? ŝŶĚŝǀŝĚƵĂů ĞǆƉĞƌŝŵĞŶƚƐ Z ? EŽ
significant difference was found in the proportion of component 2, respresenting
very bright aggregated particles, between Y1/A2G or Y1/A2LIEFDG cells (p=0.051).
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dĂďůĞ ? ? ? P^ƵŵŵĂƌǇŽĨW,ƉĂƌĂŵĞƚĞƌƐĨŽƌz ? ?'&WĂŶĚz ? ?ɴ ?ĂƌƌĞƐƚŝŶ ?'&Wŝ&ĐŽŵƉůĞǆĞƐ
Receptor Condition Concentration (N µm
-2
) Brightness (੣ ? n cells
Component 1 Component 2 Component 1 Component 2
Y1-GFP (7) Control 349.9 ± 18.8 / 5299 ± 291.4 / 57
100nM NPY 450.1 ± 36.9 / 7238 ± 476.5 / 44
Y16A-GFP (3) Control 351.2 ± 29.0 / 5110 ± 359.1 / 30
100nM NPY 382.6 ± 30.3 / 5799 ± 340.6 / 43
Y1/A2G (3) 100nM NPY 97.2 ± 20.3 7.6 ± 1.2 4477 ± 103.7 23217 ± 4291 18
Y1/A2LIEFDG (3) Control 98.0 ± 19.9 9.8 ± 1.6 3051 ± 462.9 12503 ± 2338 23
100nM NPY 72.0 ± 6.9 7.5 ± 1.7 3190 ± 690 23349 ± 4649 14
n numbers in parenthesis refers to the number of independent experiments performed, whilst n values in the table refer to the total number of cell
recordings.
/ indicates that traces were fit to a 1 component fit PCH model, therefore a 2 component was not resolved
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4.4 Discussion
4.4.1 Summary of main findings
Here we used FCS and FRAP analysis to investigate the motility of Y receptor
complexes at the single cell level. The use of native and mutant Y1 or Y2
receptors revealed that reduced receptor motility at the plasma membrane in
response to agonist occupancy was correlated with the relative abilities of
these receptors to undergo agonist induced internalisation (see Chapter 3).
A novel superfolder GFP complementation system was then developed to
define the specific properties of the signalling complex most likely to be
responsible for Y receptor endocytosis namely Y receptor-arrestin complexes
 using FCS and FRAP techniques. The improved photophysical properties of
superfolder GFP BiFC allowed its effective use in FCS measurements, and
ĚĞŵŽŶƐƚƌĂƚĞĚƚŚĂƚƚŚĞŽďƐĞƌǀĞĚůĂƚĞƌĂůŵŽďŝůŝƚŝĞƐŽĨz ? ?ɴ ?ĂƌƌĞƐƚŝŶĐŽŵƉůĞǆĞƐ
were correlated, as expected with NPY-stimulated Y1-GFP mobility. Although
the most likely explanation for the reduced complex mobility is an association
with clathrin coated pits, this was not confirmed by the use of the LIEFD
mutation to disrupt clathrin binding by E-arrestin2.
PCH analysis allowed the investigation of the molecular brightness of Y1
receptor complexes, suggesting a clustering of receptors occurs following
agonist stimulation and prior to endocytosis. The lack of change in molecular
brightness seen for Y16A-GFP suggested that this process was driven by
ĂƐƐŽĐŝĂƚŝŽŶŽĨɴ ?ĂƌƌĞƐƚŝŶ ? ?  dŚŝƐ ǁĂƐ ĂůƐŽ ĐŽŶĨŝƌŵĞĚ ĨƌŽŵ ƚŚĞƌĞƐŽůƵƚŝŽŶŽĨ Ă
clustered second component in PCH analysis of Y1/A2G BiFC, potentially
ƌĞĨůĞĐƚŝŶŐƌĞĐƌƵŝƚŵĞŶƚŽĨƐĞǀĞƌĂůz ? ?ɴ ?ĂƌƌĞƐƚŝŶ ?ĐŽŵƉůĞǆĞƐ ŝŶĐůĂƚŚƌŝŶĐŽĂƚĞĚ
pits. Comparable molecular brightness values obtained for Y1-GFP and the
first component of Y1/A2G provides some evidence that the mode of binding
ŽĨɴ ?ĂƌƌĞƐƚŝŶ ?ƚŽƚŚĞz ?ƌĞĐĞƉƚŽƌŝƐƐǇŵŵĞƚƌŝĐĂů ?
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4.4.2 Superfolder GFP showed improved photophysics when compared to
YFP, validating its suitability for use in single cell imaging techniques
The overall aim of this work was for the first time to use a novel version of
BiFC utilising split superfolder GFP fragments in combination with FCS. The
split YFP BiFC previously used to characterise the association of Y receptors
ǁŝƚŚɴ ?ĂƌƌĞƐƚŝŶ ? ?ŚĂƉƚĞƌ ? ?&ŝŐƵƌĞ ? ? ? ? ZŝƐůĞƐƐƐƵŝƚĂďůĞĨŽƌƵƐĞŝŶ&^ĚƵĞƚŽ
the increased propensity of YFP to spot bleach. This has been shown to yield
ĂƌƚŝĨŝĐŝĂůůǇƐŚŽƌƚĚǁĞůůƚŝŵĞƐ ?ʏ ? ZŐĞŶĞƌĂƚŝŶŐŝŶĂĐĐƵƌĂƚĞŝŶĐƌĞĂƐĞƐŝŶĚŝĨĨƵƐŝŽŶ
coefficients, which are less evident for GFP (Herrick-Davis et al., 2013). For
example FCS measurements of the diffusion of adenosine A3 receptors tagged
with GFP yielded a slower D of 1.3 x 10-9cm2 s-1 (Corriden et al., 2014) when
compared to the corresponding YFP tagged A3 receptor (D of 2.1 x 10-9cm2 s-1,
unpublished observations by Kilpatrick, LE., 2014). The use of split GFP
complementation would therefore be more advantageous in single imaging
ƐƚƵĚŝĞƐ ? ,ŽǁĞǀĞƌ ƉƌĞǀŝŽƵƐ ƵƐĞ ŽĨ Ğ'&W  ?ƐƉůŝƚ ƉŽŝŶƚƐ ɴ ƐƚƌĂŶĚƐ  ? ? ? Z Žƌ
ƐƵƉĞƌĨŽůĚĞƌ'&WĨƌĂŐŵĞŶƚƐ ?ƐƉůŝƚƉŽŝŶƚɴƐƚƌĂŶĚƐ ? ?  ? ? ZŝŶĐŽŵƉůĞŵĞŶƚĂƚŝŽŶ
assays have shown relatively poor complementation in physiological
conditions (eGFP) or were designed for spontaneous self assembly
respectively (Hu and Kerppola, 2003, Cabantous and Waldo, 2006). Therefore
here BiFC fragments were generated from superfolder GFP using the same
split point as previously used successfully for YFP complementation (Chapter
3). As this was the first documented use of superfolder GFP in FCS recordings,
its use was initially validated in pilot studies by comparison to eGFP widely
used in FCS studies , (Corriden et al., 2014, Skakun et al., 2012, Haupts et al.,
1998). No significant changes were observed between Y1-GFP (superfolder) or
z ? ?Ğ'&W ŝŶ ƌĞƐƉĞĐƚ ƚŽ ŬĞǇ ƉĂƌĂŵĞƚĞƌƐ ƐƵĐŚ ĂƐ ƚŚĞ ʏ ? ƉŚŽƚŽƉŚǇƐŝĐĂů
ĐŽŵƉŽŶĞŶƚ ? ʏ ? ? ƚŚĞ ƉƌŽƉŽƌƚŝŽŶ ŽĨ ƚŚĞ ʏ ? ĐŽŵƉŽŶĞŶƚ ŵĂŬŝŶŐ ƵƉ ƚŚĞ
autocrrelation curve or diffusion coefficients (Table 1) - for control or NPY
stimulated cells recorded under identical acquisition settings. This indicated
that superfolder GFP was a valid alternative to eGFP in FCS recordings.
ĚĚŝƚŝŽŶĂůůǇ ƌĞĐŽŵƉůĞŵĞŶƚĞĚ '&W ƐŚŽǁĞĚ ĐŽŵƉĂƌĂďůĞ ʏD1 values to that of
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ĨƵůů ůĞŶŐƚŚ '&W  ?ʏ ? ǀĂůƵĞƐ ? dĂďůĞƐ  ? ? ? ĂŶĚ  ? ? ? Z ŝŶĚŝĐĂƚŝŶŐ ƐŝŵŝůĂƌ
photophysical characteristics of the native and complemented fluorescent
proteins. This has also been observed for full length YFP versus
recomplemented YFP in FCS (Herrick-Davis et al., 2012).
4.4.3 FCS and FRAP revealed selective agonist induced slowing in the lateral
ĚŝĨĨƵƐŝŽŶŽĨzƌĞĐĞƉƚŽƌƐǁŚŝĐŚĞĨĨŝĐŝĞŶƚůǇƌĞĐƌƵŝƚɴ ?ĂƌƌĞƐƚŝŶƐ
Diffusion coefficients measured by FCS for unstimulated Y1 -GFP or Y2 -GFP
were broadly comparable to previous estimates of GPCR diffusion measured
using FCS and/or FRAP for adenosine A1 (Briddon et al., 2004b, Briddon et al.,
2008), A2A (Briddon et al., 2008), A3  ?ŽƌĚĞĂƵǆ Ğƚ Ăů ? ?  ? ? ? ? Z ƌĞĐĞƉƚŽƌƐ ? ɴ ? ?
adrenoceptor (Hegener et al., 2004, Barak et al., 1997b), histamine H1 (Rose
RH, 2010), type 2 bradykinin (Philip et al., 2007), complement C5a (Licht et
al., 2003), neurokinin 2 (Cezanne et al., 2004) and µ opioid receptors
(Golebiewska et al., 2011, Sauliere et al., 2006). Both FCS and FRAP
observations showed NPY was able to slow the lateral mobility of Y1-GFP
receptors similar to FCS observations of YFP tagged complement C5a
receptors (Licht et al., 2003), and the identification of 2 populations of
fluorescent agonist species with differing diffusion characteristics when bound
to adenosine A3 receptors  ?ŽƌĚĞĂƵǆ Ğƚ Ăů ? ?  ? ? ? ? Z Žƌ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ
(Hegener et al., 2004). However this agonist effect does not seem to be
universal for all GPCRs as agonist occupancy has been shown to have no effect
on the membrane motility of adenosine A1 receptors (Briddon et al., 2008).
Additionally observations of the µ opioid receptor have suggested that the
impact of agonist occupancy on diffusion rates may differ with experimental
setup with unchanged effects seen with FCS (Golebiewska et al., 2011) and
increases seen with FRAP (Sauliere et al., 2006) (see FCS and FRAP comparison
below).
The degree to which native and mutant Y1 or Y2 GFP tagged receptors
undergo endocytosis correlated with the extent to which NPY could induce
changes in their lateral diffusion characteristics. Both Y1-GFP and Y2H155P-
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GFP receptors have been previously shown to readily undergo endocytosis in
response to NPY (Chapter 3, Figure 3.7, A and Figure 3.16, C). This is here
mirrored in a slowing of their rates of diffusion measured using FCS (Figure
4.2, D) or FRAP (Figure 4.5, C) following agonist stimulation, which was in the
case of the Y1 receptor able to be inhibited by antagonist pretreatment. No
change was observed for receptors that are less capable (Y2) or unable (Y16A)
to undergo agonist mediated internalisation suggesting agonist induced
slowing of diffusion is selective to receptors which readily internalise.
However the lack of concomitant changes in the surface particle
concentrations of Y1 or Y2H155P-GFP measured by FCS, despite observed NPY
induced endocytosis, was surprising. We hypothesised that a simultaneous
change in mobile receptor fraction following agonist stimulation might be
responsible for preserving FCS particle concentration, but FRAP
measurements of Y1 or Y16A-GFP receptors showed no such changes. In fact
the high proportion of mobile Y1 or Y16A-GFP receptors was similar to
ŽďƐĞƌǀĂƚŝŽŶƐ ƵƐŝŶŐ &ZW ĨŽƌ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ĞǆƉƌĞƐƐĞĚ ŝŶ ,< ? ? ?d ĐĞůůƐ
(Barak et al., 1997b, Kaya et al., 2011) and both lipid raft and non raft
associated membrane proteins (such as H-Ras and K-Ras) (Kenworthy et al.,
2004). One issue that complicates comparison between such measurements is
the different spatial scales over which FCS and FRAP investigate fluorescent
protein mobility. The circular bleaching area used in FRAP in these
experiments (1.4µm2) was approximately 14 times larger than the confocal
volume used in FCS. Similarly the estimates of Y receptor diffusion co-
efficients made by FRAP supported the key finding that NPY stimulation
selectively slowed diffusion of Y1-GFP but not Y16A-GFP phosphorylation
deficient receptors. However FRAP derived measurements of D for Y1
receptors (based on fluorescence recovery half times) were an order of
magnitude lower than those recorded using FCS.
A larger experimental volume will increase the potential impact of limitors of
diffusion, particularly cytoskeletal networks (Kenworthy et al., 2004, Fujiwara
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et al., 2002). They can form corrals which effectively divide the plasma
membrane into 0.5-1µm regions that can limit the mobility of a diffusing
species at the scale of FRAP (and result in the lower measure of D from FRAP),
but will show little effect at the shorter diffusion scale used in FCS. This
phenomena has been observed using single particle tracking of gold tagged µ
opioid receptors (Suzuki et al., 2005). These experiments showed the
receptors undergo diffusion largely confined into membrane domains by
cytoskeleton fences, but are occasionally able to hop over these
compartments (covering distances of 210-730nm). These distinct states of
diffusion would thus influence FRAP measurements that cover an area of
several corrals , but FCS recordings might simply sample the diffusion within a
corral (due to the smaller size of the confocal volume used), and the limiting
fence and hop diffusion is therefore missed.
Equally using the smaller area sampled by FCS we observed a wide range of
individual D estimates for Y1-GFP controls ranging from 0.60 to 15.36 x10-9
cm2 s-1, although 90% of values were within 1.02-3.58 x10-9 cm2 s-1. With the
small confocal volume, a high degree of heterogeneity of the membrane
regions sampled is expected, in respect to other components present
(Kenworthy et al., 2004, Philip et al., 2007, Briddon and Hill, 2007, Licht et al.,
2003, Corriden et al., 2014, Lenne et al., 2006). .
4.4.4 The use of superfolder GFP BiFC to pharmacologically characterise the
ŝŶƚĞƌĂĐƚŝŽŶŽĨz ?ƌĞĐĞƉƚŽƌƐǁŝƚŚɴ ?ĂƌƌĞƐƚŝŶ
Agonist stimulated reductions in Y receptor mobility correlated with the
relative abilities of such receptors to undergo endocytosis, indicating that the
interactions of receptors with slow moving clathrin coated pits (CCP) might be
responsible. Though these stably associated complexes might be invisible to
FCS due to their lack of mobility, it is more likely these interactions occur
transiently, relative to the dwell time used in FCS measurements. Thus, CCP
trapping might immobilise tagged receptors for part of the dwell time within
the volume, resulting in a reduction of the diffusion coefficient D, rather than
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disappearance of the immobile component (Briddon and Hill, 2007, Schwille,
2001, Licht et al., 2003). As Chapter 3 illustrated, it is predicted that Y
receptor-E-arrestin signalling complexes would be the species associated with
CCPs. However the identification of this complex as the responsible
component is almost impossible using standard single channel FCS using Y
receptor GFP measurements.
For example, changes in molecular mass, such as GPCR-arrestin association,
have a limited impact on FCS derived measurements of diffusion alone, as a 2
fold change in D requires a 8 fold change in molecular mass (Briddon and Hill,
2007). Thus we used thenovel superfolder GFP BiFC system to identify Y1
ƌĞĐĞƉƚŽƌƐ ĐŽŵƉůĞǆĞĚ ǁŝƚŚ ĞŝƚŚĞƌ ɴ ?ĂƌƌĞƐƚŝŶ ? Žƌ  ? ? /Ŷ ŚŝŐŚ ĐŽŶƚĞŶƚ ĂŶĚ
confocal imaging assays, NPY stimulated receptor-arrestin association with
similar kinetics, irreversibility (demonstrating de novo complementation;
(Kilpatrick et al., 2010)) and potency expected based on the YFP BiFC system
ĐŚĂƌĂĐƚĞƌŝƐĞĚŝŶŚĂƉƚĞƌ  ? ?  dŚĞĞƋƵŝǀĂůĞŶĐǇŝŶɴ ?ĂƌƌĞƐƚŝŶ ?Žƌ  ?ƌĞĐƌƵŝƚŵĞŶƚ
ǁĂƐƐŝŵŝůĂƌƚŽƉƌĞǀŝŽƵƐŝŶĚŝƌĞĐƚŵĞĂƐƵƌĞƐŽĨƚŚĞĨŽƌŵĂƚŝŽŶŽĨɴ ?ĂƌƌĞƐƚŝŶ ?Žƌ ?
complexes with AP-2 following Y1 receptor agonist induced activation
(Ouedraogo et al., 2008).
^ŽŵĞĚŝĨĨĞƌĞŶĐĞƐďĞƚǁĞĞŶɴ ?ĂƌƌĞƐƚŝŶ ?Žƌ ?ŝ&ǁĞƌŽďƐĞƌǀĞĚ ?/ŶƉĂƌƚŝĐƵůĂƌ ?
some preformed cell surface and intracellular fluorescence was more evident
ƵŶĚĞƌ ďĂƐĂů ĐŽŶĚŝƚŝŽŶƐ ĨŽƌ z ? ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ?ŝ&  ?ďƵƚ ůĞƐƐ ƐŽE-
arrestin2). While this may represent non specific bystander fluorescence
driven by the affinity of the two GFP tags for one another (Kerppola, 2008a),
this is unlikely as the background fluorescence was significantly inhibited was
ŽďƐĞƌǀĞĚ ƵŶĚĞƌ ďĂƐĂů ĐŽŶĚŝƚŝŽŶƐ ĨŽƌ ƚŚĞ '&W ŝ& z ? ? ?ɴ ?ĂƌƌĞƐƚŝŶ ? Žƌ  ? ĐĞůů
lines, using the phosphorylation deficient receptor mutant that does not
recruit arrestins. Basal levels of BiFC fluorescence are therefore likely to be
ĚƵĞƚŽĂĚĞŐƌĞĞŽĨĂŐŽŶŝƐƚ ŝŶĚĞƉĞŶĚĞŶƚƌĞĐƌƵŝƚŵĞŶƚŽĨɴ ?ĂƌƌĞƐƚŝŶƐƚŽ ƚŚĞz ?
receptor in keeping with observations suggesting that for some GPCRs this
interaction can occur in the absence of ligand (Kocan et al., 2009, Halls and
ŽŽƉĞƌ ?  ? ? ? ? Z ? /Ŷ ĂĚĚŝƚŝŽŶ ĨŽƌĐĞĚ ƌĞĐƌƵŝƚŵĞŶƚ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ƚŽ s ?Ă Žƌ s ?
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vasopressin receptors in the absence of agonist, resulted in endocytosis of
these complexes, suggesting that agonist occupancy of receptors is not
ĞƐƐĞŶƚŝĂůĨŽƌŝŶĚƵĐŝŶŐƚŚĞĨŽƌŵĂƚŝŽŶŽĨz ? ?ɴ ?ĂƌƌĞƐƚŝŶĐŽŵƉůĞǆĞƐ ?dĞƌƌŝůůŽŶĂŶĚ
Bouvier, 2004).
dŚĞ ĂďŝůŝƚǇ ŽĨ z ? ?ɴ ?ĂƌƌĞƐƚŝŶ ?>/&' ĐŽŵƉůĞǆĞƐ ƚŽ ƵŶĚĞƌŐŽ EWz ŝŶĚƵĐĞĚ
endocytosis was consistent with additional compensatory clathrin binding
ƐŝƚĞƐǁŝƚŚŝŶɴ ?ĂƌƌĞƐƚŝŶ ? ?<ĂŶŐĞƚĂů ? ? ? ? ? ? ?<ĞƌŶĞƚ Ăů ? ? ? ? ? ? ?<ĂŶŐĞƚĂů ? ? ? ? ? ? Z
(Chapter 1, Figure 1.4 ) and the contribution of adaptor proteins such as AP-2
binding scaffolding with arrestins during endocytosis (Chapter 1, section
1.6.2.1) (Kim and Benovic, 2002, Kang et al., 2014). However in confocal
microscopy experiments, there was some evidence of an inhibitory effect of
the LIEFD mutation, because increased plasma membrane localisation of the
Y1/A2LIEFDG complexes was observed compared to Y1/A2G cells.
Comparable FCS and FRAP derived diffusion rates and proportions of mobile
particles were obtained for all agonist stimulated BiFC cell lines investigated,
and these were matched with NPY stimulated Y1-GFP measurements. Thus
the use of GFP BiFC can define the diffusion of the known molecular receptor-
arrestin complex and so support the hypothesis that similar complexes are
associated with Y1-GFP receptors following NPY stimulation. D estimates of
unstimulated Y1/A1G and Y1/A2LIEFDG complexes on the plasma membrane
were also obtained, with similarly slow D measurements compared to
unstimulated Y1-GFP receptors. Therefore, agonist occupancy is potentially
not required for these complexes to engage the structures (presumably CCPs)
limiting their diffusion.
4.4.5 PCH analysis can provide clues in respect to the molecular composition
of NPY stimulated Y1-GFP receptors
PCH measurements of molecular brightness were also obtained to provide
information on the stoichiometry of Y1-GFP receptors under different
conditions. Such measurements might reveal the oligomerisation state of
these receptors under unstimulated conditions. However this relies on an
accurate reference for the brightness of monomeric membrane associated
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GFP, which is technically challenging (Kilpatrick et al. 2012). In addition the
incomplete maturation of GFP in practice limits the expectation that a 2 fold
change in brightness would accompany receptor dimerization. For example,
estimates for eGFP or sfGFP constructs expressed in HEK293T cells range from
53-68% maturation (Hallworth and Nichols, 2012, McGuire et al., 2012).
Therefore the transition from monomeric to constitutive dimeric Y1-GFP
might result only in a 1.3  1.5 fold increase in molecular brightness as not all
receptor protomers would be tagged with a fully mature GFP molecule that
produces fluorescence. However a previous study on a number of other
GPCRs has indicated constitutive dimerisation for a range of GPCRs based on a
doubling of molecular brightness values when compared to monomeric
control in PCH analysis (Herrick-Davis et al., 2013). Given the incomplete
maturation of GFP, it is surprising that Herrick-Davis et al (2013) saw such
ĐůĞĂƌ ĐƵƚ ĚŽƵďůŝŶŐ ŽĨ ੣ ǁŚĞŶ ŝĚĞŶƚŝĨǇŝŶŐ  ŽůŝŐŽŵĞƌŝƐĂƚŝŽŶ ŽĨ Ă ƌĂŶŐĞ ŽĨ
fluorescently labelled GPCRs (Herrick-Davis et al., 2013). It is also worth
pointing out that the bin time used by Herrick-Davis is smaller than that used
here (10µs versus 1ms here) therefore it is likely a second contribution to the
ŽǀĞƌĂůů੣ĚĂƚĂŵĂǇďĞďĞŝŶŐĚĞƚĞĐƚĞĚĨƌŽŵƚŚĞ ĨĂƐƚĞƌʏ ?ĐŽŵƉŽŶĞŶƚǁŝƚŚŝŶ
the fluctuation trace. This is an important consideration, particularly as
Herrick-Davis et al used both YFP and GFP tagging when investigating
oligomerisation of GPCRs and as described previously, YFP shows an increased
ƉƌŽƉĞŶƐŝƚǇƚŽďůĞĂĐŚǁŚŝĐŚŝƐŽĨƚĞŶƌĞĨůĞĐƚĞĚŝŶĂĨĂƐƚʏ ?ĐŽŵƉŽŶĞŶƚ ? ? ? ? ?A?Ɛ
detected by (Briddon et al., 2004a) at the A1 receptors tagged with Topaz (a
ǇĞůůŽǁ ƐŚŝĨƚĞĚ ǀĂƌŝĂŶƚ ŽĨ '&W Z ĂŶĚ ŝŶ ƚŚĞ ĚĂƚĂ ĨƌŽŵ ƚŚŝƐ ŐƌŽƵƉ ʏ ? ĨŽƌ z&W
ranges from 70-100µs. It would therefore be interesting to see if increasing
ƚŚĞďŝŶƚŝŵĞǁŽƵůĚƌĞƐƵůƚŝŶƐƵĐŚĐůĞĂƌĐŚĂŶŐĞƐŝŶ੣ĂŶĚƐƵďƐĞƋƵĞŶƚĐŚĂŶŐĞƐ
in assumed oligomeric states in their data.
Nevertheless, even with the caveat of GFP maturation being incomplete,
there was a clear 1.5 fold increase in Y1-GFP brightness seen in PCH analysis
following NPY stimulation, and this is consistent with receptor clustering.
Agonist induced changes in brightness were sensitive to antagonist treatment,
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thus demonstrating the requirement for Y1 receptor activation. This effect
may be due to agonist driving oligomerisation of Y1 receptors, a phenomena
observed for other Class A GPCRs (see Chapter 4) and reconcilable with a
decreased maturation of GFP resulting in not all Y1-GFP dimers representing
ƚǁŽ ŵŽůĞĐƵůĞƐ ŽĨ '&W  ?ŝĞ ŶŽƚ Ă ĐůĞĂƌ ĐƵƚ ĚŽƵďůŝŶŐ ŽĨ ੣ Z ? ,ŽǁĞǀĞƌ &Zd
observations on Y1 receptor dimerisation suggest that oligomerisation is not
ligand dependent (Dinger et al., 2003). Additionally under basal conditions
Y16A-GFP and Y1-GFP receptors had similar particle concentrations and
brightness values, but only the Y1-GFP showed significant changes following
NPY stimulation. The location of the 6 alanine mutations, introduced into the
Y1 receptor C terminus, are unlikely to affect potential Y1 receptor
oligomerisation per se, particularly when the sites of GPCR dimer interfaces
have been largely been predicted to be within the transmembrane helical
bundle (Johnston et al., 2012) (see Chapter 4). As the 6A mutation has also
ďĞĞŶ ƐŚŽǁŶ ƚŽ ƐƵďƐƚĂŶƚŝĂůůǇ ŝŶŚŝďŝƚ ɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚ ? ƚŚĞƐĞ ĚĂƚĂ
suggest that the increased molecular brightness of NPY stimulated Y1-GFP
particles, in common with their slower diffusion, is an indirect consequence of
ɴ ?ĂƌƌĞƐƚŝŶĚĞƉĞŶĚĞŶƚĐůƵƐƚĞƌŝŶŐŽĨƌĞĐĞƉƚŽƌƐƉƌŝŽƌƚŽĞŶƚĞƌŝŶŐƚŚĞĞŶĚŽĐǇƚŽƐŝƐ
pathway.
This conclusion was supported by the 5-8 fold brighter second component
that was resolved in PCH analysis of BiFC complexes that was not observed for
z ? ?'&W ? dŚŝƐ ůŝŬĞůǇ ƌĞƉƌĞƐĞŶƚƐ z ? ?ɴ ?ĂƌƌĞƐƚŝŶ '&W ŝ& ĐŽŵƉůĞǆĞƐ ĨŽƌŵŝŶŐ
clusters that interact with components of the endocytic machinery such as
clathrin coated pits (Krupnick et al., 1997a, Goodman et al., 1996, Kim and
Benovic, 2002, Holliday et al., 2005, Gicquiaux et al., 2002, Ouedraogo et al.,
2008) (Chapter 1, section 1.6.2.1). The approximate waist diameter of the
confocal volume used (300nm) suggests that measurements are detecting
single clathrin coated pits (approximate 100nm diameter), and that such pits
ŵĂǇƚŚĞƌĞĨŽƌĞĐŽŶƚĂŝŶŵƵůƚŝƉůĞzƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶĐŽŵƉůĞǆĞƐ ?
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4.4.6 Reconciling discrepancies in diffusion characteristics seen in FCS and
PCH measurements
Whilst data obtained using FCS and PCH analysis can often complement each
another, there are limitations inherent to each technique. For example the
very bright second component resolved using PCH for Y1/A2G and
Y1/A2LIEFDG BiFC aggregates, whilst only representing a small proportion of
the total particles, may have have the greatest influence on overall dwell
times seen in FCS. This is partly due to each particle within component 2 (~10
% of the particle number) containing approximately 10 times the unit H of
component 1, meaning ~50% of the unit Y receptor-arrestin BiFC
fluorescent complexes at the membrane are actually represented by
component 2. In addition the relative contribution of these individual particles
ƚŽƚŝŵĞĚĞƉĞŶĚĞŶƚĨůƵĐƚƵĂƚŝŽŶƐŝŶ&^ ?ŝƐǁĞŝŐŚƚĞĚďǇ੣2 (Schwille, 2001), and
so brighter particles have a disproportionetly greater influence on
measurements of WD
A caveat to PCH analysis that may account for discrepancies with FCS
measurements is the use of a 3D model of diffusion when fitting in
comparison to the 2D model used in FCS autocorrelation analysis. The
complex membrane environment of living cells complicates the use of either
model. For example a 2D lipid bilayer will inevitability contain 3D features
such as clathrin coated pits, which can differentially affect the absolute
measurements. The size of bin time used may also explain some of the PCH
ĚŝƐĐƌĞƉĂŶĐŝĞƐ ŝŶ ƉĂƌƚŝĐůĞ ŶƵŵďĞƌ ? ĚƵĞ ƚŽ ƉŽƚĞŶƚŝĂůĐŽŶƚƌŝďƵƚŝŽŶƐ ŽĨ ƚŚĞ ʏ ?
photophysical component to overall data. However this is unlikely to be
exerting a significant influence here, as repeating the analysis on the same
data set but using a longer bin time (50ms, data not shown) did not change
ŽǀĞƌĂůůĞƐƚŝŵĂƚĞƐŽĨEŽƌ੣ŽďƚĂŝŶĞĚĨŽƌz ? ?'&WŽƌz ? ? ?'ŝ& ?&ŝŶĂůůǇĚĞƐƉŝƚĞ
the requirement of both FCS and PCH techniques for particles to be mobile in
order to produce fluorescent fluctuations, the sensitivity threshold of this
mobility is lower for PCH analysis. It is therefore likely that some slowly
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moving particles that are detected by PCH are not observed in FCS
autocorrelation measurements.
 ? ? ? ? ?W,ĂŶĂůǇƐŝƐƌĞǀĞĂůĞĚĂƐǇŵŵĞƚƌŝĐĂůŵŽĚĞŽĨƌĞĐƌƵŝƚŵĞŶƚŽĨɴ ?ĂƌƌĞƐƚŝŶ
to Y1 receptors
The precise stoichiometry of GPCR interactions with G proteins is still in
debate and is further complicated by the increasingly accepted concept of
GPCR oligomerisation (see Chapters 5 and 6 for more detailed discussion).
Compelling evidence has suggested that G protein binding can be either
symmetric (ie 1:1) (Whorton et al., 2007, Chabre and le Maire, 2005) or
asymmetric (2 receptors :1 G protein) (Jastrzebska et al., 2013, Damian et al.,
 ? ? ? ? ?ĂŶĞƌĞƐĂŶĚWĂƌĞůůŽ ?  ? ? ? ? Z ŝŶŶĂƚƵƌĞ ?,ŽǁĞǀĞƌƚŚĞŵŽĚĞŽĨɴ ?ĂƌƌĞƐƚŝŶ
binding is even more uncertain (Hanson et al., 2007a, Tsukamoto et al., 2010,
Sommer et al., 2011, Sommer et al., 2012) and may even change with the
proportion of activated receptors that are present (Sommer et al., 2011).
dŚĞ ďŝůŽďĞĚ ƐƚƌƵĐƚƵƌĞ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ  ?ŚĂƉƚĞƌ  ? ? &ŝŐƵƌĞ  ? ? ? ? ƐĞĐƚŝŽŶ  ? ? ? ? ? Z
suggests an asymmetric 2:1 recruitment to GPCR dimers, with both the
ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ĂŶĚ ĂĐƚŝǀĂƚŝŽŶ  RƐĞŶƐŽƌƐ ? ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ĞŶŐĂŐŝŶŐ ǁŝƚŚ Ă
different receptor protomer within the dimer (Fotiadis et al., 2006, Sommer et
al., 2011). However a symmetric 1:1 (or 2:2) stoichiometry has also been
suggested based on experimental studies of rhodopsin (Hanson et al., 2007a,
ĂǇďƵƌƚ Ğƚ Ăů ? ?  ? ? ? ? Z ? W, ĐŽŵƉĂƌŝƐŽŶƐ ďĞƚǁĞĞŶ z ? ?'&W ĂŶĚ z ? ?ɴ ?ĂƌƌĞƐƚŝŶ
ŝ&ĐŽŵƉůĞǆĞƐŵĂǇƉƌŽǀŝĚĞĂĐůƵĞƚŽƚŚĞŵŽĚĞŽĨɴ ?ĂƌƌĞƐƚŝŶďŝŶĚŝŶŐ ?dŚŝƐŝƐ
ďĞĐĂƵƐĞĞƋƵŝǀĂůĞŶƚŵŽůĞĐƵůĂƌďƌŝŐŚƚŶĞƐƐ੣ǁĂƐŽďƐĞƌǀĞĚĨŽƌz ? ?'&WĂŶĚƚŚĞ
ŶŽŶ ĐůƵƐƚĞƌĞĚ ĐŽŵƉŽŶĞŶƚ  ?ĐŽŵƉŽŶĞŶƚ  ? Z ŽĨ z ? ?ɴ ?ĂƌƌĞƐƚŝŶ ĐŽŵƉůĞǆĞƐ ?
suggesting that each fluorescent complex contained similar numbers of GFP
particles. Of the available stoichiometries, this is less supported by a model
ǁŝƚŚ ĞǆĐůƵƐŝǀĞ ĂƐǇŵŵĞƚƌŝĐ ɴ ?ĂƌƌĞƐƚŝŶ ďŝŶĚŝŶŐ ƚŽ Ă ƌĞĐĞƉƚŽƌ ĚŝŵĞƌ ?  /Ŷ ƚŚŝƐ
model, a single recomplemented GFP molecule per two receptors (ie a dimer)
would be predicted in Y receptor-arrestin BiFC particles, and theoretically this
would generate a halved brightness compared to two Y1-GFP protomers
participating in the same complex. Instead the equivalent brightness is more
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ĞĂƐŝůǇƌĞĐŽŶĐŝůĞĚǁŝƚŚĂƐǇŵŵĞƚƌŝĐĂůŵŽĚĞŽĨɴ ?ĂƌƌĞƐƚŝŶƌĞĐƌƵŝƚŵĞŶƚ ?,ŽǁĞǀĞƌ
there are several limitations placed on this conclusion, including the
confounding effects on incomplete maturation for GFP (described in 4.5.5). It
also makes the assumption that with the exception of receptor clustering
prior to endocytosis, Y1-GFP oligomerisation is not affected by agonist
stimulation, which is in keeping with previous FRET based observations for Y1
dimers (Dinger et al., 2003).
Although the PCH data in this chapter provides some indications of the mode
ŽĨƌĞĐƌƵŝƚŵĞŶƚŽĨɴ ?ĂƌƌĞƐƚŝŶƚŽ'WZƐ ?ŽƚŚĞƌĂƉƉƌŽĂĐŚĞƐĂƌĞƌĞƋƵŝƌĞĚƚŽƉƌŽďĞ
the stoichiometry of this interaction, particularly when considering dimeric
receptors. With this goal in mind, Chapter 5 describes the development of
ways to measure the function and pharmacology of BiFC constrained GPCR
homodimers, with the roles of individual protomers within the dimer
investigated using selective mutagenesis.
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Chapter 5  The combined use of Snap labelling and BiFC
to discretely constrain GPCRs as homodimers of precise
composition in order to probe the pharmacological
consequences of dimerisation
5.1 Introduction
The introduction to this chapter explores the evidence that GPCRs form
dimers, or higher order oligomers, and considers their functional relevance -
which is still much in debate. Dimerisation can take the form of homodimers,
whereby protomers of the same receptor subtype associate, or heterodimers
which represent the association of closely or distantly related GPCR family
members. Dimerisation may offer new pharmacological targets, with novel
pharmacology potentially arising from interaction between the promoter
binding sites or modified coupling to downstream effector proteins such as G
ƉƌŽƚĞŝŶƐ ĂŶĚ ɴ ?ĂƌƌĞƐƚŝŶ  ?^ŵŝƚŚ ĂŶĚ DŝůůŝŐĂŶ ?  ? ? ? ? Z ? WƌĞĐĞĚĞŶĐĞ ĨŽƌ ƌĞĐĞƉƚŽƌ
dimerisation exists for some non GPCR mammalian receptor systems such as
receptor tyrosine kinases (RTKs) and transcription factors (Helsen and
Claessens, 2014, Reich, 2007). Robust agonist induced dimerisation of RTKs
leads to their activation by bringing the receptor cytoplasmic tyrosine kinase
domains into close proximity to facilitate trans autophosphorylation (Hubbard
and Miller, 2007). Both ligand induced homodimerisation, and to a lesser
extent heterodimerisation, has also been observed for the non-catalytic Toll
like receptor superfamily involved in the innate immune response (Reuven et
al., 2014).
5.1.1 The evidence for the existence of GPCR dimerisation
Evidence for the existence and function of GPCR dimerisation has largely
been derived from a number of biochemical, functional and fluorescence
approaches.
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5.1.1.1 Biochemical and ligand binding evidence
Biochemical evidence for GPCR dimerisation is abundant in the Class C
subclass of GPCRs such as metabotropic glutamate receptor (mGlu5) and
GABAB receptors (Pierce et al., 2002). For example, mGlu5 receptors have
been shown under non reducing conditions to migrate through SDS-PAGE gels
with a higher molecular mass than predicted from the monomer, suggesting
the formation of larger receptor complexes (Romano et al., 1996). In
accordance with this a disulphide bridge has been shown to crosslink two
class C receptor subunits at the N terminal extracellular Venus fly trap dimer
interface for ligand binding. The monomeric form of Class C receptors is only
seen following reduction of this bond (Romano et al., 1996),(Pin et al., 2007).
Co-immunoprecipitation experiments confirmed that mGlu5 receptors
selectively form homodimers, as no association was observed with the
mGluR1a subtype even though they share 60% sequence homology (Romano
et al., 1996). A yeast two hybrid screen of another class C receptor, the
ƌĞĐĞƉƚŽƌ ĨŽƌ '  ?ɶ ?ĂŵŝŶŽďƵƚǇƌŝĐ ĂĐŝĚ Z ? ƐƵŐŐĞƐƚĞĚĂ ƐƉĞĐŝĨŝĐ ŝŶƚĞƌĂĐƚŝŽŶ
between the GABABR1 and R2 subtypes via an interaction between coiled coil
domains in their C terminus (White et al., 1998). Co-immunoprecipitation
experiments (Kaupmann et al., 1998, White et al., 1998) confirmed specific
heterodimers of co-expressed tagged GABABR1 with GABABR2 detected
together.
However biochemical evidence for functional dimerisation of Class A GPCRs
remains much more inconclusive. Early evidence came from photoaffinity
labelling of muscarinic receptors (Avissar et al., 1983), whereby a potent
muscarinic reagent specifically labelled muscarinic binding sites in the brain
and heart. Gel electrophoresis suggested these native muscarinic receptors
were found to exist as dimers or even higher order oligomers. Co-
immunoprecipitation experiments in baculovirus Sf9 cells demonstrated the
ĞǆŝƐƚĞŶĐĞŽĨƐƉĞĐŝĨŝĐɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌŵŽŶŽŵĞƌƐĂŶĚŚŽŵŽĚŝŵĞƌƐ ?,ĞďĞƌƚĞƚ
al., 1996). Hebert et al (Hebert et al., 1998) used [3H] palmitate labelling to
ƉƌŽǀĞ Ă ƉŚǇƐŝĐĂů ŝŶƚĞƌĂĐƚŝŽŶ ďĞƚǁĞĞŶ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ĂŶĚ Ă ŵƵƚĂŶƚ ĨŽƌŵ ?
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C341G that cannot be palmitoylated at the conserved cysteine. This mutant
was still immunoprecipitated with the [3H] palmitoylated wildtype receptor.
However, as acknowledged by the authors, and in common with most co-
immunoprecipitation approaches in recombinant cells, this does not imply
ƚŚĂƚ ƚŚĞĚŝŵĞƌ ŝƐ ƚŚĞƉƌĞĚŽŵŝŶĂŶƚĨƵŶĐƚŝŽŶĂů ĨŽƌŵŽĨɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ?dŚĞ
first evidence of GPCR Class A homodimerisation between two fully functional
receptor subtypes came from crosslinking and immunoprecipitation
ĞǆƉĞƌŝŵĞŶƚƐŽĨɷŽƉŝŽŝĚƌĞĐĞƉƚŽƌƐƚĂŐŐĞĚǁŝƚŚĞŝƚŚĞƌ&>'ŽƌĐ ?ŵǇĐĞƉŝƚŽƉĞƐ
 ?ǀĞũŝĐ ĂŶĚ Ğǀŝ ?  ? ? ? ? Z ? dŚĞ ƉƌŽƉŽƌƚŝŽŶ ŽĨ ɷ ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌƐ ĞǆŝƐƚŝŶŐ ĂƐ
dimers was seen to be modulated by ligand, with agonist inducing conversion
ƚŽŵŽŶŽŵĞƌƐ ?ŽŶǀĞƌƐĞůǇŚŽŵŽĚŝŵĞƌƐŽĨʃŽƉŝŽŝĚƌĞĐĞƉƚŽƌƐ ?ǁŚŽƐĞĞǆŝƐƚĞŶĐĞ
was confirmed by Jordan and Devi in 1999 (Jordan and Devi, 1999), do not
monomerise following agonist stimulation, suggesting dimerisation can have
different modes of regulation even within closely related receptor subtypes. A
limitation of coimmunoprecipitation approaches that must be considered is
the solubilisation of receptors required for protein gel loading may
inadvertently promote oligomerisation.
For homodimers, binding of an orthosteric ligand to protomer A or B has been
suggested to induce a conformational change within the dimer that can
positively or negatively affect the affinity of the same ligand binding to the
second orthosteric binding site. This phenomenon has been termed
cooperativity (Smith and Milligan, 2010, Casado et al., 2009b). This is allosteric
in nature as the second protomer binding site, although identical, is
topographically distinct from the first. Modulation of ligand binding affinities
or responses of the dimer are therefore driven by interactions occurring
across the dimer interface (Kenakin and Miller, 2010). Cooperativity at dimers
suggests they may be behaving as a single entity whereby the two binding
sites are allosterically linked, seen for thyrotropin (TSH) and lutropin (LH)
receptor heterodimers (Urizar et al., 2005). A chimeric receptor unable to
bind TSH but capable of binding LH was created and coexpressed with the TSH
receptor (unable to bind LH) Under these conditions, LH was able to displace
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radiolabelled thyrotropin ligand, suggestive of strong negative cooperativity
between the two ligand binding sites of the co-expressed receptors (Urizar et
al., 2005).
Chabre has argued that negative cooperativity in binding assays is not
necessarily indicative of dimer formation, but could be an artefact of assays
performed from membrane preparations in the absence of GTP and G
proteins (Chabre et al., 2009). However negative cooperativity has still been
observed in the excess of both (Smith and Milligan, 2010). Additionally
evidence for negative cooperativity has also been observed in living cells by
measuring dissociation kinetics with fluorescent ligands at native adenosine
A3 receptors in CHO K1 cells (May et al., 2011) or in native tissues measured
using TR-FRET with fluorescent agonists at oxytocin receptors (Albizu et al.,
2010).
5.1.1.2 Altered initial expression
The formation of constitutive dimers has been suggested to occur soon after
receptor biosynthesis in order to facilitate correct receptor endoplasmic
reticulum export and transport to the plasma membrane by acting as a
molecular chaperone (Angers et al., 2002). This is supported by evidence from
Class C GPCRs. For example, the GABAB receptor splice variants (GABABR1a
and GABABR1b) are retained intracellularly as immature glycoproteins due to
a C terminal intracellular retention signal preventing them being trafficked to
the cell surface (Margeta-Mitrovic et al., 2000). Three separate research
groups (Jones KA, 1998), (White et al., 1998), (Kaupmann et al., 1998) each
used expressed sequence tags from the GABABR1 sequence to identify
another subtype termed GABABR2 with 35% identity. Flow cytometry
confirmed that the addition of GABABR2 facilitates surface expression of
mature glycosylated GABABR1 (White et al., 1998) with in situ hybridisation
showing co-localisation of GABABR1 and R2 in the rat cerebellar cortex (Jones
KA, 1998).The GABABR2 subunit masks the intracellular retention signal on the
GABABR1 subunit (summarised in (Kniazeff et al., 2002)) so that only via
dimerisation is the GABAB receptor able to be expressed.
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For the Class A group, the requirement for dimerisation for correct receptor
expression is less clear. Some evidence of dimers forming during biosynthesis
has been obtained, for example for the E2-adrenoceptor (Hebert et al., 1998),
but more research is needed before firm conclusions can be drawn.
5.1.1.3 Evidence from effector protein coupling stoichiometries
The stoichiometry of effector protein binding to GPCR can provide insight into
the minimal functional receptor unit that is required to support signalling. The
mode of binding of G proteins is beginning to be elucidated, however the
ƌĞĐƌƵŝƚŵĞŶƚŽĨɴ ?ĂƌƌĞƐƚŝŶŝƐƐƚŝůůƵŶĐůĞĂƌ ?ŝŶĚŝŶŐĐĂŶƚĂŬĞƚŚĞĨŽƌŵŽĨĂƌĂŶŐĞ
of modes including one effector molecule binding to a single GPCR monomer
within a dimer (1:2), two molecules bound to each monomer (2:2), both
monomers bind to a single effector protein (2:1) or active receptor is only
found in its monomeric form bound to one effector (1:1) (Gurevich and
Gurevich, 2008). Gurevich and Gurevich suggest that a single model may not
be appropriate for all GPCRs and that dimer coupling may differ even over
the course of the same receptors life cycle (Gurevich and Gurevich, 2008).
Using Class C GPCR dimerisation as a model it is worth noting that in GABAB
receptor dimers only one subunit couples to the G protein alpha subunit,
(however these studies did not exclude that binding to the second protomer
could occur) (Kniazeff J, 2004, Kniazeff et al., 2002). The model class A GPCR,
rhodopsin has been consistently shown by many groups to be monomeric in
its dark, unactivated state when detergent solubilised (summarised in (Chabre
and le Maire, 2005)). However atomic force microscopy has indicated that
rhodopsin is found as highly organised rows of dimers or higher order
oligomers in retinal rod outer membrane segments (Fotiadis et al., 2003).
Isolation of rhodopsin monomers in nanodiscs, a synthetic model membrane
bilayer, or reconstituted high density lipid (HDL) vesicles illustrated that the
monomeric form was capable of functionally coupling to its cognate G protein
transducin (Bayburt et al., 2007, Whorton et al., 2008). Similar results have
ďĞĞŶƐĞĞŶĨŽƌŵŽŶŽŵĞƌŝĐɴ ?Z ?tŚŽƌƚŽŶĞƚĂů ? ?  ? ? ? ? ZŽƌɷŽƉŝŽŝĚƌĞĐĞƉƚŽƌƐ
(Kuszak et al., 2009) reconstituted in HDL vesicles alongside the Gs subunit of
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their cognate G protein. These results indicate that, like rhodopsin the
monomeric form is the minimal functional unit required for G protein
dependent signalling and high affinity agonist binding (Whorton et al., 2007).
Similar results were observed for mGluR, whereby isolated monomers in HDL
vesicles could functionally couple to G protein when activated by a synthetic
allosteric ligand (that binds to the TM bundle) (El Moustaine et al., 2012).
However the reconstituted dimeric form was required for glutamate
activation, via (the class C specific) venus fly trap ligand binding domains.
Therefore even for well documented constitutive dimers, such as mGluRs,
monomeric receptor is sufficient to support functional G protein coupling.
However these results do not disprove the presence of dimer formation in
intact membranes of living cells as for example only one protomer may be
fully activated within the dimer (Pellissier et al., 2011). The second protomer
also may not directly couple to G protein (as in the GABABR1 subunit) but
exert some degree of cooperativity when also ligand bound. A further
scenario is that binding of ligand A to a dimer might be different than if it
were binding to a monomeric receptor (Birdsall, 2010). The stoichiometry of
one G protein binding to a GPCR dimer could arise from altered pharmacology
due to allosterism, or competition between the two ligand occupied
monomers in the dimer for a shared pool of G protein molecules (Birdsall,
2010).
5.1.1.4 Evidence from GPCR crystal structures
The recently solved high resolution crystal structures of a range of Class A
GPCRs have provided some insight into the potential structural basis of
oligomerisation. A range of conformational states have been crystallised for
ƚŚĞɴ ?Z ?ZŽƐĞŶďĂƵŵĞƚĂů ? ? ? ? ? ? ?ZĂƐŵƵƐƐĞŶĞƚĂů ? ? ? ? ? Ă ?ZĂƐŵƵƐƐĞŶĞƚĂů ? ?
 ? ? ? ?Ă ZŝŶĚŝĐĂƚŝŶŐƚŚĞƌĞĐĞƉƚŽƌďŝŶĚƐƚŽ'ɲŝŶĂŵŽŶŽŵĞƌŝĐƐƚĂƚĞ ?ZĂƐŵƵƐƐĞŶ
et al., 2011b). However this does not necessarily imply a 1:1 receptor: G
protein stoichiometry in vivo, as asymmetric binding could still occur whereby
ŽŶĞ ƉƌŽƚŽŵĞƌ ŽĨ ƚŚĞ ĚŝŵĞƌ ĞŶŐĂŐĞƐ ǁŝƚŚ ƚŚĞ 'ɲ ƐƵďƵŶŝƚ ? ǁŚŝůƐƚ ƚŚĞ ŽƚŚĞƌ
ƉƌŽƚŽŵĞƌ ďŝŶĚƐ ƚŽ 'ɴJ ?  ĚĚŝƚŝŽŶĂůůǇ ƚŚĞ ůĂƐƐ  'WZƐ ƐƵĐŚ ĂƐ ƚŚĞ A? ĂŶĚ ʃ
227
opioid (Wu et al., 2012, Manglik et al., 2012), the chemokine CXCR4 (Wu et al.,
 ? ? ? ? Z ? ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ  ?,ƵĂŶŐ Ğƚ Ăů ? ?  ? ? ? ? Z ĂŶĚ ƚŚĞ ƐŵŽŽƚŚĞŶ Ě ƌĞĐĞƉƚŽƌ
(Wang et al., 2013) have all crystallised as parallel dimers and/ or tetramers.
These structures have indicated the existence of relatively conserved dimer
ŝŶƚĞƌĨĂĐĞƐ ďĞƚǁĞĞŶ ƉƌŽƚŽŵĞƌƐ ? &Žƌ ĞǆĂŵƉůĞ ƚŚĞ ŝŶĂĐƚŝǀĞ ɴ ?Z ĚŝŵĞƌŝĐ
structure suggests that it has two main interfaces, the first involving TM1,
TM2, helix 8 and ECL1 and the second TM4, TM5, ICL2 and ECL2 (Huang et al.,
2013). TM5 and 6, and to a lesser extent TM1,TM2 and helix 8 have been
suggested to be the interfaces of the symmetrical dimers observed for µ
opioid receptors (Manglik et al., 2012). These multiple interfaces may also
facilitate the higher order oligomerisation observed for some GPCRs such as
ƚŚĞ ɴ ?Z ǁŚŝĐŚ ƐƉŽŶƚĂŶĞŽƵƐůǇ ĨŽƌŵƐ ƚĞƚƌĂŵĞƌƐ ǁŚĞŶ ƌĞĐŽŶƐƚŝƚƵƚĞĚ ŝŶ
membranes (Fung JJ, 2009). Care needs to be taken when interpreting the
physiological implications of structures seen from crystallisation as they may
reflect artefacts of crystal packing (particularly as it is the lowest energy state
that is typically most amenable to successful crystallisation), reflect only the
conformational state captured during crystallisation, or may be a
consequence of the modifications/additions required to stabilise the receptor
for crystallisation away from its natural lipid environment (such as the use of
nanobodies (Rasmussen et al., 2011a). Nevertheless many of the sites
identified in crystal structures have also been previously implicated from
biochemical studies (see 5.1.1.5. below) suggesting they may be
physiologically relevant.
5.1.1.5 Mutagenesis and functional complementation assays
Much of the early evidence investigating the functional significance of GPCR
dimerisation came from studies of Class C receptors, and in particular the
GABAB receptor. Both GABABR1 variants can bind GABAB ligands but with 100
fold less affinity than the physiological receptor (Kaupmann et al., 1998),
while the GABABR2 subtype expressed alone exhibited no affinity for GABAB
receptor radioligands (Kaupmann et al., 1998). Only when GABABR1 and
GABABR2 were co injected into Xenopus oocytes (alongside GIRK subunits),
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could GIRK channel activation be observed in response to GABA (Jones KA,
1998), (Kaupmann et al., 1998), (White et al., 1998)). Subsequent studies have
revealed that agonist binding occurs only at the GABABR1 Venus fly trap
domain (Kniazeff J, 2004) but that it is the GABABR2 subunit responsible for G
protein coupling (summarised in (Kniazeff et al., 2002)). This implied
communication between the two subunits with conformational changes
transmitted through to the GABABR2 subunit following agonist binding
(Milligan, 2009). This transactivation is a theme that has been subsequently
been explored further by targeted mutagenesis in the mGluR (Brock et al.,
2007) and GABAB receptor family (Monnier et al., 2011).
Intermolecular trans complementation has been observed for some Class A
GPCRs in respect to ligand binding, receptor activation and downstream
signalling. Functional complementation has been observed for dopamine D2
receptor dimers in respect to G protein coupling (Han et al., 2009). D2
ƉƌŽƚŽŵĞƌƐ ĨƵƐĞĚ ƚŽ ƚŚĞ ĐŚŝŵĞƌŝĐ 'ɲƋ ŝ ? ƉƌŽƚĞŝŶ ǁĞƌĞ ŶŽŶ ?ĨƵŶĐƚŝŽŶĂů ƵŶůĞƐƐ
they were also expressed with wildtype D2 protomers, suggesting this system
required dimeric D2 receptors and allosteric cooperativity across the dimer
interface. For the Angiotensin II receptor, co-expression of two ligand binding
defective mutants with distinct mutations in TM3 or 5, were able to restore a
functional ligand binding site (Monnot et al., 1996). However it is worth
noting that this reconstituted angiotensin mutant receptor could not correctly
ĐŽƵƉůĞ ƚŽ ' ƉƌŽƚĞŝŶƐ ?  ƉĞƉƚŝĚĞ ĐŽŶƐŝƐƚŝŶŐ ŽĨ ƚŚĞ ŵĂũŽƌŝƚǇ ŽĨ dD ? ŽĨ ɴ ?Z
(implicated to be involved in the intermolecular interactions at the postulated
adrenoceptor dimer interface(Huang et al., 2013)) when introduced, can
ƐƵďƐƚĂŶƚŝĂůůǇ ĚĞĐƌĞĂƐĞ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĚŝŵĞƌ ĨŽƌŵĂƚŝŽŶ ĂŶĚ ŝƐŽƉƌĞŶĂůŝŶĞ
stimulated adenylyl cyclase activity (ie. functional coupling) (Hebert et al.,
1996). The authors suggested that this peptide formed a pseudodimer with
receptor monomers mimicking receptor  receptor interactions that could
occur in receptor dimerisation. Hebert et al followed up this observation in
 ? ? ? ? ƵƐŝŶŐ ƚŚĞ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ  ? ? ?' ŵƵƚĂŶƚ  ?ŵĞŶƚŝŽŶ Ě ĂďŽǀĞ Z  ƚŚĂƚ
signals less efficiently than wildtype receptor and is constitutively internalised
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(Hebert et al., 1998). Co-expression of the mutant and wild type receptors led
to a rescue of function for the mutant with the wildtype receptor having a
positive complementary effects in terms of restoring wildtype levels of
desensitisation and adenylyl cyclase activity (Hebert et al., 1998). However it
is unwise to rely on functional complementation assays alone to confirm
dimer formation, because the results of many of the studies above might
purely be a consequence of co-expression regenerating a functional
monomeric unit.
Funally, crosslinking experiments using a range of substituted cysteines have
implicated TM4 as a particularly crucial interface in dopamine D2 (Guo et al.,
 ? ? ? ? Z ? ɷ ŽƉŝŽŝĚ  ?ŝŶ ĂĚĚŝƚŝŽŶ ƚŽ dD ? Z  ?:ŽŚŶƐƚŽŶ Ğƚ Ăů ? ?  ? ? ? ? Z ĂŶĚ  ? ?,d ?
receptors (Berthouze et al., 2007) and an interaction between TM5 and the N
terminus of ICL3 in muscarinic M3 receptors (Hu et al., 2012). Selective
mutagenesis of ICL2 has also been implicated in partially promoting the
dissociation of melanocortin 4 receptors (Piechowski et al., 2013), implying
that sites distinct from the helical bundle may also influence dimerisation.
5.1.1.6 Fluorescence based techniques
Förster Resonance Energy Transfer (FRET) and Bioluminescence Resonance
Energy Transfer (BRET) assays can visualise protein-protein interactions
occurring in cells, including GPCR dimer formation, at high resolution and
sensitivity. They are both real time assays which utilise variants of fluorescent
proteins with overlapping emission and excitation spectra (Krasel et al., 2004)
to allow almost instantaneous detection and localisation of cellular
interactions. In FRET proteins of interest (eg. a receptor monomer) can be
tagged with cyan fluorescent protein (CFP) which is excited with 436nm light
leading to emission at 480nm wavelength. This energy can be transferred to
excite a yellow fluorescent protein (YFP) tagged to another protein of interest
with light being emitted at a wavelength of 535nm, provided the distance
between the two fluorophores is less than 10nm. The ratio of CFP to YFP
emission can be used as an indicator of the degree of interaction between the
two tagged proteins of interest, although it is still not possible to determine
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the proportion of FRET dimers compared to the total receptor population.
BRET is a similar technique to FRET but the CFP donor fluorophore is replaced
with a light emitting luciferase (typically derived from Renilla reniformis). BRET
produces less background fluorescence than FRET but has decreased temporal
resolution and requires the addition of the exogenous substrate
coelenterazine (Lohse et al., 2008).
For FRET and BRET the orientation and distance of the fluorophores joined to
the two interaction partners is crucial, with the spatial detection limit of 10nm
or less (Kerppola, 2009) equating to the distance of approximately twice that
of GPCR protomer dimensions (Milligan, 2009). As most RET studies simply
imply that some GPCR protomers interact, rather than identifying the
functional behaviour of the discrete dimer, it can be difficult to use these
techniques to identify any altered pharmacology that may arise with
dimerization.. It is therefore also difficult to infer the relative proportions of
dimers present compared to the total receptor population.
RET based techniques have been used to imply the constitutive dimerisation
of receptors such as GABAB1 and GABAB2 ?DĂƵƌĞůĞƚĂů ? ? ? ? ? ? Z ?ɴ ?Z ?ŶŐĞƌƐĞƚ
al., 2000), adenosine A2A (Canals et al., 2004), and the Y receptor subtypes Y1,
Y2 and Y5 (Dinger et al., 2003). Large variations have been observed for these
techniques in respect to dimer stability with ligand stimulation. For example,
agonist-stimulated association of somatostatin (Patel et al., 2002) and
melatonin MT1 and MT2 (Ayoub et al., 2002) receptors, contrasts with
ĚŝƐƐŽĐŝĂƚŝŽŶŽĨɴ ?Z ?ŶŐĞƌƐĞƚĂů ? ? ? ? ? ? Z ?A?ŽƉŝŽŝĚ ǀĞũŝĐĂŶĚĞǀŝ ? ? ? ? ? ZĂŶĚ
Y4 receptors (Dinger et al., 2003). Such studies also do not exclude other
clustering events at the plasma membrane, for example prior to endocytosis
(see Chapter 4).
FRET techniques have also been used in native tissues. Albizu et al (2010)
used time resolved (TR)-FRET in mammary gland tissue, which has a high
natural expression of oxytocin receptors (Albizu et al., 2010). In TR-FRET the
donor fluorophore europium lanthanide has an improved signal to noise ratio
with longer lasting fluorescence so that measurements can be taken after
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cellular autofluorescence decays. FRET was observed between the donor-
labelled receptor antibody and either fluorescent antagonist, or to a lesser
extent, agonist treatment.
Dual colour fluorescence recovery after photobleaching (FRAP) microscopy
has also been used to probe the mobility of potential GPCR complexes
laterally through the plasma membrane. Anti-YFP antibodies were used to
ŝŵŵŽďŝůŝƐĞ Ă ĚĞĨŝŶĞĚ ƉƌŽƉŽƌƚŝŽŶ ŽĨ ĞǆƚƌĂĐĞůůƵůĂƌ z&W ?ɴ ?Z Žƌ z&W ?ɴ ?Z ?Ɛ Ăƚ
the plasma membrane (Dorsch et al., 2009), tracking whether the diffusion of
a co-expressed receptor population (tagged only with C terminal intracellular
CFP that did not bind the antibody directly) was also retarded. The authors
suggested that although both adrenoceptor subtypes appeared to form
homodimers, the lifespan of dimer stability was markedly different with
ƚƌĂŶƐŝĞŶƚ ĂƐƐŽĐŝĂƚŝŽŶƐ ŽďƐĞƌǀĞĚ ĨŽƌ ɴ ?Z ǁŚŝůƐƚ ɴ ?Z ƐŚŽǁĞĚ ŵŽƌĞ ƐƚĂďůĞ
ŝŶƚĞƌĂĐƚŝŽŶƐ ?  dŚŝƐ ŝƐ ĐŽŶƐŝƐƚĞŶƚ ǁŝƚŚ ƐƵŐŐĞƐƚŝŽŶƐŽĨ ĞǀĞŶ ŚŝŐŚĞƌ ŽƌĚĞƌ ɴ ?Z
oligomer formation as stable tetramers in reconstituted systems (Fung JJ,
2009).
Single molecule imaging using total internal reflection microscopy (TIRF) with
fluorescent receptors and ligands has identified transient dimerisation of
muscarinic M1 (Hern et al., 2010) and N formyl peptide receptors (Kasai et al.,
2011), which both show dynamic association and dissociation (lifetime 0.5 and
5 s respectively). TIRF combined with Snap labelling also revealed transient
ŚŽŵŽ ƚĞƚƌĂŵĞƌ ĨŽƌŵĂƚŝŽŶ ŽĨ ɴ ? ĂŶĚ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ?ůŝĨĞƚŝŵĞ  ? ?ƐĞĐƐ Z ? ƚŚĞ
propensity of which differed with receptor subtype and expression levels
(Calebiro et al., 2013). Molecular brightness estimates derived from PCH
analysis (see Chapter 4), have also implicated that a range of Class A GPCRs
ŝŶĐůƵĚŝŶŐ ɴ ?Z ĂŶĚ ɲ1B adrenoceptors, muscarinic M1 and M2, dopamine D1
and 5-HT2A and 2B receptors that have been implied to be stable over a 10 fold
expression level (Herrick-Davis et al., 2013).
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5.1.2 The use of BiFC to constrain GPCRs as defined dimers of precise
composition
dŚĞɴ ?ZŝƐĂƉƌŝŵĞĞǆĂŵƉůĞŽĨŚŽǁĚŝĨĨĞƌĞŶƚĨůƵŽƌĞƐĐĞŶĐĞďĂƐĞĚƚĞĐŚŶŝƋƵĞƐ
can generate discrepancies in measurements of the extent, stability and
influence of agonist on dimerisation. Some of these differences are likely to
arise from the precise molecular composition of dimeric complexes during the
receptor lifespan being unknown. The use of BiFC to constrain receptors as
dimers is therefore advantageous as it unambiguously defines an interacting
protein-protein complex, which can then be studied functionally, as previously
ĚĞŵŽŶƐƚƌĂƚĞĚĨŽƌƚŚĞŝŶǀĞƐƚŝŐĂƚŝŽŶŽĨzƌĞĐĞƉƚŽƌĂŶĚɴ ?ĂƌƌĞƐƚŝŶ ?ŝŶƚĞƌĂĐƚŝŽŶƐ
using quantitative platereader imaging or FCS (Chapters 3 and 4).
BiFC has been used previously to indicate the existence and localisation of
adenosine A2A receptor dimers in a specialised neuronal cell line (Vidi et al.,
2008b). Additionally multicolour BiFC, using YFP and CFP tags, has also implied
the coexistence of dopamine D2 homodimers and A2A homodimers in
neuronal cell lines (Przybyla and Watts, 2010). Higher order oligomers of D2
receptors (comprising a minimum of 4 D2 receptor protomers) have also been
observed in HEK293T using combined fluorescence (BiFC) and luminescence
(BiLC) complementation (Guo et al., 2008), together with BRET. BiFC has also
been used in combination with both FRET (Vidi et al., 2008b) and BRET
(Gandia et al., 2008) to identify higher order complexes of A2A receptors.
In this and the following chapter, BiFC was used to identify the
ƉŚĂƌŵĂĐŽůŽŐŝĐĂů ĂŶĚ ĨƵŶĐƚŝŽŶĂů ƉƌŽƉĞƌƚŝĞƐ ŽĨ ƐƉĞĐŝĨŝĐ z ? ƌĞĐĞƉƚŽƌ Žƌ ɴ ?Z
dimerisation. The irreversible nature of BiFC was exploited in order to
constrain receptors as dimers of precise composition due to the requirement
for both tagged protomers (protomer A tagged with Yn; protomer B tagged
with Yc; Figure 5.1) to contribute to producing a fluorescent signal identifying
a defined interaction between known receptors (a BiFC dimer; protomer
A+B). This allowed the quantification of the agonist induced internalisation of
these BiFC dimer complexes to be used as a readout of dimer function.
Details of the system are described below.
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5.2 Chapter aims
The first aim of this chapter was to ascertain whether the function and
pharmacology of example class A GPCRs constrained as BiFC dimers (the NPY
z ? ƌĞĐĞƉƚŽƌ ĂŶĚ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ? ɴ ?Z Z ĐŽƵůĚ ďĞ ĂƐƐĞƐƐĞĚ ďǇ ƋƵĂŶƚŝĨǇŝŶŐ
their agonist-promoted internalisation. Secondly the roles of ligand binding
sites and intracellular domains of individual protomers governing BiFC dimer
internalisation were assessed by targeted site directed mutagenesis. Given
previous results seen for the Y1 receptor (Chapter 3) (Ouedraogo et al., 2008,
<ŝůƉĂƚƌŝĐŬĞƚĂů ? ?  ? ? ? ? ZĂŶĚɴ ?Z  ?DŽŽƌĞĞƚĂů ? ?  ? ? ? ? Z ? ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶŽĨŝ&
ĚŝŵĞƌƐŝƐĞǆƉĞĐƚĞĚƚŽďĞĂɴ ?ĂƌƌĞƐƚŝŶĚĞƉĞŶĚĞŶƚƉƌŽĐĞƐƐ ?,ŽǁĞǀĞƌƵŶůŝŬĞƚŚĞ
many studies that have probed the stoichiometry of G protein recruitment to
'WZ ĚŝŵĞƌƐ ? ƚŚĞ ŶĂƚƵƌĞ ŽĨ ƚŚĞŝƌ ŝŶƚĞƌĂĐƚŝŽŶ ǁŝƚŚ ɴ ?ĂƌƌĞƐƚŝŶƐ ŝƐ Ɛƚŝůů ůĂƌŐĞůǇ
unknown even in respect to the model Class A GPCR rhodopsin (Hanson et
al., 2007a, Tsukamoto et al., 2010, Sommer et al., 2011).
Therefore the use of targeted mutations within individual receptor protomers,
ƚŚĂƚ ƐĞůĞĐƚŝǀĞůǇ Ăŝŵ ƚŽ ĚŝƐƌƵƉƚ ƚŚĞ ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ? ŝŶƚĞƌĨĂĐĞ ? ƐŚŽƵůĚ
ƉƌŽǀŝĚĞƐŽŵĞŝŶĚŝƌĞĐƚŝŶƐŝŐŚƚŝŶƚŽƚŚĞŵŽĚĞŽĨɴ ?ĂƌĞƐƚŝŶ ?ƌĞĐƌƵŝƚŵĞŶƚƚŽŝ&
ĐŽŶƐƚƌĂŝŶĞĚz ?Žƌɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌĚŝŵĞƌƐ ?
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5.3 Results
5.3.1 Snap and BiFC fragment tagged Y1 receptors are functional in respect
to ligand binding and G protein coupling
Competition binding experiments using the radiolabelled agonist [125I] PYY
were first performed in order to verify the expression and functional
properties of HEK293T cell lines expressing either Snap Y1 receptor-Yn alone
(clonal line, termed Snap Y1 throughout) or co-expressing both Snap Y1-Yn
and FLAG Y1-Yc constructs (termed Snap Y1/Y1 throughout) (Figure 5.1).
Membranes were freshly prepared from both cell lines following the assay
protocol detailed in Chapter 2, section 2.2.3). Both membrane preparations
isolated from Snap Y1 or Snap Y1/Y1 cell lines showed specific [125I] PYY
binding which was inhibited by competition with the unlabelled agonist (PYY;
A) and antagonist (BIBO3304; B) co-incubation (Figure 5.2). Functional
estimates of ligand binding affinities (pKi) were calculated using the Cheng-
Prusoff equation (Chapter 2, section 2.2.10.1). The affinities of PYY (estimated
pKi 9.4-9.5 ± 0.1; n=3-4; Table 1) were comparable for both cell lines.
Observed affinities for BIBO3304 were also comparable for both cell lines.
Additionally [125/ ?WzzďŝŶĚŝŶŐǁĂƐƐĞŶƐŝƚŝǀĞƚŽ'dWɶ^ƚƌĞĂƚŵĞŶƚŝŶďŽƚŚĐĂƐĞƐ
(C), indicating functional coupling of the expressed receptors to G proteins.
Bmax estimates for both cell lines were also comparable in respect to
receptor expression.
The Y1 receptor subtype preferentially couples to the Gi class of G proteins
(Herzog et al., 1992), with agonist activation leading to the inhibition of
adenylyl cyclase. The resultant decrease in cAMP production acts as a
functional readout of this inhibition. The effect of Y1 receptor stimulation on
adenylyl cyclase activity was measured by a [3H]cAMP accumulation assay
(Chapter 2, section 2.2.4), in the presence of forskolin. Forskolin has been
shown to activate adenylyl cyclase directly in a receptor independent manner
by binding to a hydrophobic pocket close to the enzymes catalytic site
(Tesmer et al., 1997, Tang and Hurley, 1998). The optimal concentration of
forskolin was determined in the Y1/Y1 cell line in the presence and absence of
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100nM NPY stimulation (Figure 5.3; A), with a control forskolin pEC50 of 4.8 ±
0.1 (n=2). NPY inhibited these forskolin responses, therefore 30µM forskolin
was chosen for use in all subsequent experiments as it produced a sufficient
experimental window to measure Y1 mediated inhibitory responses.
237
Figure 5.2: [
125
I] PYY competition binding experiments performed in membranes
isolated from HEK293T cell lines expressing Snap Y1 or Snap Y1/Y1
Membranes were freshly prepared from HEK293T cell lines stably expressing Snap Y1
or Y1/Y1 BiFC dimer constructs (Chapter 2, section 2.2.3). These were incubated with
[125I] PYY (15pM) and increasing concentrations of unlabelled competing ligand (PYY
 ? Z ? /K ? ? ? ?  ? Z Žƌ 'dWɶ^  ? Z Z ? Ăƚ  ? ? ? ĨŽƌ  ? ?ŵŝŶ ? ďĞĨŽƌĞ ŵĞŵďƌĂŶĞ ďŽƵŶĚ
radioligand was separated using filtration. Retained radioactivity was quantified
using a gamma counter and competition displacement curves generated using
GraphPad Prism. Pooled data represent a minimum of 3 independent experiments
with data expressed as mean ± S.E.M. (Hill slopes 0.9-1.1 ± 0.2).
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Table 5.1: Summary of binding parameters for Snap Y1 and Y1 receptor BiFC homodimers
All parameters were obtained from [125I] PYY competition binding experiments described in the Chapter 2, section 2.2.3.
% inhibition of TSB refers to the displacement by 1µM competing ligand, as a % of the total specific binding (TSB) defined in the absence / presence of 1µM
PYY.
Details of Y1 receptor mutations are described in the text.
n =3-4
Cell line PYY BIBO3304 'dWɶ^ Bmax
pIC50 pIC50 pIC50 % [
125
I]PYY inhibition pmol/mg
-1
Snap Y1 9.4 ± 0.1 8.3 ± 0.1 8.4 ± 0.1 52.6 ± 1.4 2.9 ± 0.4
Snap Y1/Y1 9.5 ± 0.1 8.4 ± 0.1 8.5 ± 0.1 53.2 ± 5.4 3.2 ± 0.8
Snap Y1/Y1Y99A 9.2 ± 0.1 8.4 ± 0.1 8.8 ± 0.1 58.9 ± 6.2 2.7 ± 0.2
Snap Y1/Y15A 9.4 ± 0.1 8.1 ± 0.1 8.3 ± 0.1 47.0 ± 2.2 4.5 ± 0.8
Snap Y1Y5A/Y199A 9.4 ± 0.1 8.4 ± 0.1 8.5 ± 0.2 53.5 ± 6.2 2.7 ± 0.6
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Figure 5.3: Y1 receptor mediated inhibition of forskolin-stimulated 3H cAMP
accumulation in the Snap Y1 and Y1 / Y1 cell lines
HEK293T cells stably expressing Snap Y1-Yn with or without co-expression of the Y1-
Yc receptor construct were loaded with [3H] adenine for 2 hours at 37°C/5% CO2,
before treatment with a range of forskolin concentrations in the presence or absence
of 100nM NPY costimulation (A; 1 h). Snap Y1 (B) or Y1/Y1 BiFC cell lines (C) were
loaded with [3H] adenine and stimulated with NPY in the presence of 30µM forskolin
(1 h at 37°C/5% CO2). Y1/Y1 cells were also preincubated with either 30 or 100nM of
the Y1 selective antagonist BIBO3304 (30min at 37°C/5% CO2), compared to vehicle,
prior to stimulation with NPY and forskolin co-stimulation. Double column
chromatography was used to isolate [3H] cAMP (Chapter 2; section 2.2.4). All
responses were normalised to those obtained for forskolin alone (100%) or with
100nM NPY (0%), and are presented as mean ± s.e.m. of n=2-4.
For both Snap Y1 and Snap Y1/Y1 expressing cell lines, stimulation with NPY
inhibited the forskolin-stimulated accumulation of [3H] cAMP in a
concentration dependent manner (Figure 5.3; B and C; open circles) with
pEC50 values of 9.7 ± 0.1 and 9.8 ± 0.1 respectively (n=3-4). Surmountable
antagonism of NPY responses in the Snap Y1/Y1 BiFC cell line was observed
for BIBO3304 (estimated pKb value 7.8-7.9, from shifts in the presence of
30nM or 100nM antagonist; n=2).
240
5.3.2 Y1 receptors constrained as dimers using BiFC internalise in response
to agonist stimulation
Confocal imaging, both manual (Figure 5.4) and automated (Figure 5.5),
allowed the expression and localisation of both Snap Y1-Yn receptors and
Snap Y1-Yn/Y1-Yc BiFC dimers to be further validated. This was particularly
important for the constrained Snap Y1/Y1 BiFC dimers, as both of the previous
techniques used (radioligand binding and 3H-cAMP accumulation assays) did
not distinguish between this population and other complexes formed by
either the Snap-Y1-Yn or FLAG Y1-Yc promoters within these cells.
Receptor localisation was initially assessed using standard confocal
microscopy, labelling the Snap Y1 receptor-population with the membrane
impermeant SNAPsurface 647 fluorophore, which is spectrally distinct from
the YFP BiFC fluorescence. For both receptor cell lines, under control
conditions Snap labelled Y1 receptors (total protomer A; Figure 5.1) and Snap
Y1/Y1 receptor BiFC dimers (specifically A+B) were localised predominantly to
the plasma membrane (Figure 5.4; A and B). A small amount of constitutive
internalisation was observed for both receptor populations. Treatment with
the Y1 selective agonist NPY (100nM; 30min at 37°C) resulted in rapid
internalisation of both receptor populations with extensive colocalisation
(yellow) observed when images were overlayed (Figures 5.4). Similar cellular
distribution, and NPY-stimulated internalisation of the Snap-Y1 receptor Yn
and BiFC dimer populations, was observed when these cells were imaged
using the automated confocal platereader (Figure 5.5 A, B). This method
allowed the agonist induced internalisation of both Snap labelled and Y1/Y1
BiFC dimers to be quantified on a per cell basis (see Chapter 2, section
2.2.10.3). A granularity algorithm was applied to either the Snap 647 labelled
receptor, or BiFC dimer images, to identify punctuate regions of internalised
receptor fluorescence termed granules (Figure 5.5; white spots, analysis
panel).
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Figure 5.6: Kinetics of NPY induced internalisation of Snap Y1-Yn receptors and
Y1/Y1 BiFC dimers
Stably transfected HEK293T cells expressing either Snap Y1 (A) or Snap Y1/Y1 BiFC
dimers (B) were prelabelled with SNAPsurface 647 (30min at 37°C/5% CO2). Cells
were then stimulated with either vehicle or 100nM NPY at set time intervals, before
responses were terminated by fixation. H33342 labelling, image acquisition and
granularity analysis was carried out as described previously. Pooled data (mean ±
s.e.m, n = 3-4) were normalised to NPY responses observed at 30 min, and fitted to a
1 site exponential association including a 2min latency period.
A timecourse of agonist stimulated internalisation (NPY, 100nM; Figure 5.6),
measured on the IX Ultra platereader was performed on both Snap Y1
receptor (A) and Y1/Y1 BiFC cell lines (B) to ascertain the optimal length of
time required for future assays. Snap Y1-Yn receptors expressed alone (Figure
5.6, A; Snap Y1) or within the Snap Y1/Y1 BiFC cell line (Figure 5.6; B; Snap
Y1/Y1), showed comparable kinetics in respect to NPY induced internalisation
(t1/2 values of 5.4 ± 1.1 and 4.2 ± 0.4min respectively, n=4). Additionally no
significant difference was observed when comparing to the BiFC dimer
populations (t1/2 4.4 ± 0.9min) of constrained Y1/Y1 BiFC dimers, and these
kinetics were also comparable to observations for Y1-YFP internalisation
(Kilpatrick et al., 2010). Maximum internalisation responses in both cell lines
reached a stable plateau between 20-30 minutes stimulation. An assay length
of 30min treatment was therefore deemed optimal for use in subsequent
agonist stimulation assays.
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Figure 5.7: Quantification of the agonist induced internalisation of Snap Y1 or Y1/Y1 BiFC dimers following stimulation with a panel of agonist ligands
HEK293T cells stably expressing Snap Y1 (A) or Snap Y1/Y1 BiFC dimers (B and C) were prelabelled with Snap 647 (30min at 37°C/5% CO2), before
stimulation with a panel of ligands (30min at 37°C). Receptor internalisation in response to ligands (including [Leu31, Pro34]NPY, Pro NPY) was
determined following granularity analysis of images acquired using an automated confocal platereader. All data were normalised to negative
(basal) and positive (1µM NPY) plate controls. Pooled data shown represented a minimum of 3 independent experiments and are expressed as
mean ± s.e.m.
245
Table 5.2: Summary of potencies and efficacies of a panel of ligands for stimulating the internalisation of Snap Y1 receptors and Y1/
BiFC dimers
All data were expressed as ± standard error of the mean. pEC50 values were obtained from pooled concentration response curves presented in Figure 5.7.
Emax responses to each ligand were calculated as a percentage of 1µM NPY responses. n
values for all data 3-20.
/ = responses unable to determined
Snap Y1 Snap Y1/Y1
Snap 647 labelled receptor BiFC dimer Snap 647 labelled receptor
Ligand pEC50 Emax (%) pEC50 Emax (%) pEC50 Emax (%)
NPY 8.1 ± 0.1 100 8.0 ± 0.1 100 8.1 ± 0.1 100
PYY 8.2 ± 0.1 99.4 ± 2.9 8.0 ± 0.2 114.2 ± 7.6 7.8 ± 0.1 105.7 ± 0.6
Leu31, Pro34
NPY
8.0 ± 0.1 86.7 ± 2.4 7.5 ± 0.1 101.7 ± 4.9 7.7 ± 0.1 97.9 ± 3.4
PP / 29.1 ± 4.1 7.3 ± 0.1 26.4 ± 8.4 7.1 ± 0.1 25.2 ± 3.
NPY 3-36 / 59.5 ± 10.9 / 56.3 ± 11.8 / 65.3 ± 14.5
246
5.3.3 Using BiFC to constrain Y1 receptors as dimers does not result in
altered receptor agonist or antagonist pharmacology
HEK293T cells expressing Snap Y1 or Snap Y1/Y1 BiFC dimers were treated
with a panel of agonist ligands (30min at 37°C; Figure 5.7), and the functional
internalisation responses were compared. Pooled concentration response
curves revealed that the endogenous agonists NPY and PYY were equipotent
at Snap Y1 receptors expressed alone (Figure 5.7, A; see Table 5.2), and these
potencies were also comparable to those obtained for Snap labelled protomer
A (Figure 5.7,C) and BiFC dimer populations in the Snap Y1/Y1 cells (Figure 5.7,
B). The selective analogue [Leu31, Pro34] NPY was a full agonist, with respect to
NPY, at both cell lines (see Table 2), with no significant difference observed for
Snap labelled protomer A receptor or Snap Y1/Y1 BiFC dimer populations.
Both NPY3-36 and PP showed low potency and efficacy in inducing
internalisation of Snap Y1 and Snap Y1/Y1 receptor populations for both cell
lines. The rank order of potency for all ligands, both in terms of actual pEC50
values and relative efficacies was comparable to those previously observed
for endocytosis of Y1-GFP receptors (NPY, PP; see chapter 3, Table 3.2) and
z ? ?ɴ ?ĂƌƌĞƐƚŝŶ ?ĂƐƐŽĐŝĂƚŝŽŶŵĞĂƐƵƌĞĚƵƐŝŶŐŝ& ?ĐŚĂƉƚĞƌ ? ?dĂďůĞ ? ? ? Z ?
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Figure 5.8: The effect of pretreatment with the Y1 selective antagonist BIBO3304 on
the agonist induced internalisation of Snap Y1 or Snap Y1/Y1 BiFC dimers
HEK293T cells stably expressing Snap Y1 (A) or Snap Y1/Y1 BiFC dimers (B) were pre
labelled with SNAPsurface 647 (30min at 37°C/5% CO2). Cells were then pretreated
with BIBO3304 (30 or 300nM; 30min at 37°C), before being stimulated with NPY
(30min at 37°C). Granularity analysis was performed on images obtained using an
automated confocal platereader. Concentration response curves in the presence and
absence of BIBO3304 were fitted using GraphPad Prism with shared minimum (basal
responses), maximum (1µM NPY responses) and Hill slope constraints. All data were
pooled from a minimum of 3 independent experiments, and expressed as mean ±
s.e.m
In order to investigate whether constrained Y1 receptor dimers show altered
antagonist pharmacology, Snap Y1 receptor and Snap Y1/Y1 BiFC dimer cell
lines were pretreated with BIBO3304 (30nM or 300nM for 30min at 37°C).
This was followed by stimulation with a concentration response course of NPY
(30min at 37°C).
BIBO3304 produced parallel rightward shifts of NPY response curves for Snap
Y1 receptors indicative of surmountable antagonism (Figure 5.8, A; estimated
pKb 7.8 ± 0.1 and 8.1 ± 0.1; n=5.) Comparable effects were observed for both
Snap protomer A and Snap Y1/Y1 constrained BiFC dimer populations (B and
C; pKb 7.9 - 8.1; n = 4).
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5.3.4 Selective mutagenesis of individual protomers, to disrupt ligand
binding or phosphorylation, does not prevent agonist induced
internalisation of Y1 receptor BiFC dimers.
The Y1 receptor mutation Y99A has been previously shown to inhibit NPY
binding and subsequent receptor internalisation (Sautel et al., 1995, Kilpatrick
et al., 2010) (Chapter 3, Figure 3.8). Selective introduction of this mutation
into protomer B of Y1 BiFC dimers allowed determination of whether one or
both NPY binding sites needed to be occupied for BiFC dimer internalisation
(Figure 5.9, A). Additionally, mutations of five C terminal serine/threonine
phosphorylation residues in the C terminal domain (Ouedraogo et al., 2008)
were also separately introduced into protomer B (Y15A [containing mutations
S352A, T353A, S359A, T361A, S362A]; B). This mutant prevents agonist
ŝŶĚƵĐĞĚŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ?ƚŚƌŽƵŐŚŝŶŚŝďŝƚŝŽŶŽĨɴ ?ĂƌƌĞƐƚŝŶƌĞĐƌƵŝƚŵĞŶƚ ?<ŝůƉĂƚƌŝĐŬ
et al., 2010), equivalent to the Y16A mutant (also including T356A) discussed
in Chapter 3 (Figures 3.5, 3.6, 3.8). Expression of the Y15A mutant within a
BiFC dimer therefore allowed the number of phosphorylated protomers
required for internalisation of BiFC dimers to be investigated.
Figure 5.9: Schematic detailing the position of mutations selectively introduced into
Y1 receptor BiFC dimers
Mutations were selectively introduced into protomer B of Y1/Y1 BiFC dimers. The Y99
residue located at the top of TM2 is involved in NPY binding to the receptor, and was
here mutated to alanine (Y1Y99A; A, blue cross). Five serine or threonine residues (B;
red spots) located in the Y1 receptor C terminal domain and previously implicated in
ƌĞĐƌƵŝƚŵĞŶƚ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ƚŽ ƚŚĞ ƌĞĐĞƉƚŽƌ ? ǁĞƌĞ ŵƵƚĂƚĞĚ ƚŽ ĂůĂŶŝŶĞ ?  ĚŽƵďůĞ
mutant receptor dimer was created by simultaneously introducing both the Y15A and
Y1Y99A mutations into protomer A and B respectively (C).
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Figure 5.10: Representative images of Y1/Y1 mutant BiFC dimers taken using a IX
Ultra confocal platereader
HEK293T cells stably expressing Snap Y1/Y1Y99A (A) Snap Y1/Y15A (B) or Snap
Y15A/Y1Y99A (C) were prelabelled with SNAPsurface 647 (30min at 37°C/5% CO2)
before stimulation with vehicle (HBS/0.1% BSA) or 100nM NPY (30min at 37°C).
Representative images (cropped as 300x300 pixel regions, from at least 3
experiments) taken using an IX Ultra confocal platereader showed that in control
conditions Snap labelled protomer A and BiFC receptor populations for all mutant
Snap Y1/Y1 BiFC dimers were localised predominantly to the plasma membrane.
Following stimulation with NPY, rapid internalisation was observed for both Snap
labelled and BiFC dimer populations of Snap Y1/Y1Y99A and Snap Y1/Y15A BiFC
dimers. No discernable internalisation was seen for the double mutant Snap
Y1Y5A/Y1Y99A.
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Competition binding assays using [125I] PYY confirmed expression of both
Y1/Y199A and Y1/Y15A cell lines, with binding affinities for PYY and BIBO3304
comparable to those obtained for the Snap Y1/Y1 or Snap Y1-Yn cell lines (see
dĂďůĞ ? ? ? Z ?ĂŶĚďŝŶĚŝŶŐƐĞŶƐŝƚŝǀĞƚŽ'dWɶ^ƚƌĞĂƚŵĞŶƚ ? ?ƐƚŝŵĂƚĞĚŵĂǆǀĂůƵĞƐ
derived from PYY displacements were also comparable. Automated confocal
images, of both Snap Y1/Y1Y99A and Snap Y1/Y15A mutant BiFC homodimers,
showed that under control conditions both the Snap labelled and BiFC dimer
receptor populations showed predominant plasma membrane expression
with some constitutive internalisation (Figure 5.10; A, B), and both
populations internalised to colocalised intracellular compartments in response
to 100nM NPY. Comparable kinetics of agonist induced internalisation were
observed for both populations of Snap Y1/Y199A or Snap Y1/Y15A cell lines
(t1/2 values 4.2 - 5.7 min; Figure 5.11). These half times obtained for both
mutant BiFC dimer cell lines were also comparable to those seen for Snap Y1
receptors expressed alone (Figure 5.6, A) and Snap Y1/Y1 BiFC dimers (Figure
5.6, B).
Figure 5.11: Kinetics of agonist induced internalisation of Snap tagged mutant Y1
receptor BiFC dimers
Stably transfected HEK293T cells expressing either Snap labelled Y1/Y1Y99A (A) or
Y1/Y15A mutant BiFC dimers (B) were prelabelled with SNAPsurface 647 and
stimulated with either vehicle or 100nM NPY for different times, as for Figure 6.8.
Following image acquisition and data analysis, pooled data (mean ± s.e.m, n = 3-4)
were normalised to NPY responses observed at 30 min, and fitted to a 1 site
exponential association including a 2 min latency period. Graphs represent data from
at least 3 independent experiments and are expressed as mean ± s.e.m.
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Neither mutation inhibited agonist induced internalisation of the mutant BiFC
dimers. The Y1 selective agonists NPY and PYY were equipotent at both
mutant BiFC dimers (pEC50 values 7.8-8.4; n=3-4), with no significant
difference observed when comparing mutant BiFC dimer internalisation to
that of wildtype Snap Y1/Y1 BiFC dimers or Snap labelled Y1 receptors
expressed alone (2 way ANOVA; p>0.05). Quantitative comparison of the
maximum degree of internalisation (Rmax) was not possible in the normalised
data (with 1µM NPY set to 100 % in each case). However there was no
qualitative difference between the NPY-stimulated cell lines based on
inspection the images. In order to investigate whether internalisation of the
Snap Y1/Y15A and Snap Y1/Y1Y99A mutant BiFC dimers was due to protomer
functional compensation, both mutations were simultaneously introduced
into protomer A and B respectively (Snap Y15A/Y1Y99A). [125I] PYY
competition binding assays confirmed the ability of this Snap Y15A/Y1Y99A
mutant BiFC dimer to bind both agonist and antagonist, with binding affinities
comparable to those obtained for Snap Y1/Y1 BiFC dimers or Snap labelled Y1
receptors expressed alone (Table 1), and specific [125I] PYY binding was also
sensitive to GTPyS treatment. However stimulation with NPY or PYY was
unable to induce internalisation of either the Snap labelled protomer A or
BiFC dimer receptor populations (Figure 5.12, C).
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Figure 5.12: Quantitative analysis of the agonist induced internalisation of Snap
tagged Y1 receptor mutant BiFC dimers.
DƵƚĂƚŝŽŶƐ ĂĚǀĞƌƐĞůǇ ĂĨĨĞĐƚŝŶŐ ůŝŐĂŶĚ ďŝŶĚŝŶŐ  ?^ŶĂƉz ? ?z ?z ? ? ?  Z Žƌ ɴ ?ĂƌƌĞƐƚŝŶ
dependent internalisation (Snap Y1/Y15A; B) were selectively introduced into
protomer B only of Snap Y1/Y1 mutant BiFC dimers. Pooled concentration response
curves for internalisation, normalised to 1µM NPY, show that neither set of
mutations inhibited the internalisation of mutant BiFC dimers in response to the
agonists NPY or PYY (37°C for 30min). Equivalent agonist potencies were obtained for
Snap labelled protomer A receptor population (Snap 647, red) and mutant BiFC dimer
populations (pEC50 values stated in the text). Simultaneous introduction of the Y15A
and Y1Y99A mutations into protomers A and B respectively (Snap Y15A/Y1Y99A)
prevented internalisation of the Snap-Y15A-Yn population and Y15A/Y1Y99A BiFC
dimer populations in response to either NPY or PYY. As a consequence, data for the
Snap Y15A/Y1Y99A BiFC cell line are expressed as fold response over basal (100 %).
Data represent n=3-4 experiments.
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 ? ? ? ? ? ŽŵƉĂƌŝƐŽŶ ǁŝƚŚ ŝ& ĚŝŵĞƌ ďĞŚĂǀŝŽƵƌ ĨŽƌ Ă ƐĞĐŽŶĚ 'WZ  ? ƚŚĞ ɴ ? ?
adrenoceptor
In order to investigate whether observations on Y1 receptor BiFC homodimers
were common to other Class A GPCRs, we established a similar BiFC system to
ĐŽŶƐƚƌĂŝŶ ƚŚĞ ƉƌŽƚŽƚǇƉŝĐĂů ůĂƐƐ  'WZ ? ƚŚĞ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĂƐ ĚŝŵĞƌƐ ? 
ƐƚĂďůĞ ĐůŽŶĂů ƉŽƉƵůĂƚŝŽŶ ŽĨ ^ŶĂƉ ɴ ?Z ƚĂŐŐĞĚ ǁŝƚŚ ƚŚĞ zŶ ĨƌĂŐŵĞŶƚ ? ǁĂƐ
ĞǆƉƌĞƐƐĞĚ ŝŶ ,< ? ? ?d ĐĞůůƐ ĞŝƚŚĞƌ ĂůŽŶĞ ? Žƌ ŝŶ ĐŽŶũƵ ĐƚŝŽŶ ǁŝƚŚ &>' ɴ ? ?Z
tagged with the complementary Yc fragment.
Automated confocal imaging revealed the expression and localisation of Snap
ɴ ?Z ƉŽƉƵůĂƚŝŽŶƐ  ?&ŝŐƵƌĞ  ? ? ? ? ?  Z ĂŶĚ ^ŶĂƉ ɴ ? ?ɴ ?Zŝ& ĚŝŵĞƌƐ  ? Z ǁŝƚŚŝŶ
the same cells. Representative images showed that under control conditions
all receptor populations were localised to the plasma membrane with regions
of localisation shown in yellow (Overlay). Stimulation with the agonist
Isoprenaline (10µM; 30 min at 37°C) resulted in rapid internalisation of Snap
ůĂďĞůůĞĚɴ ?ZĂŶĚŝ&ĚŝŵĞƌƉŽƉƵůĂƚŝŽŶƐ ?ƐďĞĨŽƌĞ ?ĂƵƚŽŵĂƚĞĚĂŶĂůǇƐŝƐǁĂƐ
performed on both sets of images to allow for the quantification of
pharmacological responses of both receptor populations.
A timecourse was performed to compare the kinetics of 10µM isoprenaline
ŝŶĚƵĐĞĚ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŽĨ ^ŶĂƉ ɴ ?Z ƌĞĐĞƉƚŽƌƐ ĞǆƉƌĞƐƐĞĚ ĂůŽŶĞ ĂŶĚ ^ŶĂƉ
ɴ ?Z ?ɴ ?Zŝ&ĚŝŵĞƌƐ ?&ŝŐƵƌĞ ? ? ? ? Z ?&ŽƌƚŚĞ^ŶĂƉɴ ?Zŝ&ĚŝŵĞƌĐĞůůůŝŶĞ ?
a small difference was observed for the half time values of the Snap labelled
ɴ ?ZƌĞĐĞƉƚŽƌ  ?ƚ1/2 values 13.6 ± 2.1 min; n = 4) and BiFC dimer populations
(t1/2 values 6.9 ± 2.3 min; n = 4) however this was not significant (Students t
ƚĞƐƚ Ɖ AN  ? ? ? ? Z ? ŽŵƉĂƌĂďůĞ ŬŝŶĞƚŝĐƐ ǁĞƌĞ ŽďƐĞƌǀĞĚ ĨŽƌ ^ŶĂƉ ɴ ?Z ǁŚĞŶ
expressed alone (t1/2 values 7.1 ± 1.5 min; n = 6). Timecourse data for Snap
ɴ ? ?ɴ ?Z ŝ& ĚŝŵĞƌƐ ǁĂƐ ƉƌŽǀŝĚĞĚ ďǇ ƌ EŝĐŚŽůĂƐ ,ŽůůŝĚĂǇ  ?hŶŝǀĞƌƐŝƚǇ ŽĨ
Nottingham, UK).
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&ŝŐƵƌĞ ? ? ? ? PZĞƉƌĞƐĞŶƚĂƚŝǀĞŝŵĂŐĞƐŽĨɴ ?ZĐŽŶƐƚƌĂŝŶĞĚĂƐĚŝŵĞƌƐƵƐŝŶŐŝ&ƚĂŬĞŶ
using a IX Ultra confocal platereader
,< ? ? ?dĐĞůůƐ ƐƚĂďůǇĞǆƉƌĞƐƐŝŶŐĞŝƚŚĞƌ^ŶĂƉɴ ?Z ?zŶĂůŽŶĞ  ? ZŽƌ^ŶĂƉɴ ?Z ?ɴ ?Z
BiFC dimers (B), were prelabelled with Snap 647 (30min at 37°C/5% CO2) before
stimulation with vehicle control (HBS/0.1% BSA) or 10µM isoprenaline (30min at
37°C). Representative images (cropped as 300x300 pixel regions) taken using a IX
hůƚƌĂ ĐŽŶĨŽĐĂů ƉůĂƚĞƌĞĂĚĞƌ ƐŚŽǁĞĚ ƚŚĂƚ ŝŶ ĐŽŶƚƌŽů ĐŽŶĚŝƚŝŽŶƐ ^ŶĂƉ ɴ ?Z ?zŶ
expressed alone (A) showed predominant plasma membrane localisation. Rapid
internalisation was observed following stimulation with isoprenaline. A similar
ƉĂƚƚĞƌŶ ŽĨ ĞǆƉƌĞƐƐŝŽŶ ǁĂƐ ŽďƐĞƌǀĞĚ ĨŽƌ ďŽƚŚ ^ŶĂƉ ɴ ?Z ƉƌŽƚŽŵĞƌ  ĂŶĚ ƚŚĞ ŝ&
ĚŝŵĞƌƌĞĐĞƉƚŽƌƉŽƉƵůĂƚŝŽŶƐŽĨ^ŶĂƉɴ ?Z ?ɴ ?Zŝ&ĚŝŵĞƌƐ ?ǁŝƚŚĞǆƚĞŶƐŝǀĞĂƌĞĂƐŽĨ
colocalisation observed (Yellow; overlay panel). The use of a granularity algorithm on
these images allowed the internalisation of all receptor populations to be quantified
on a per cell basis (granularity panel), with nuclei shown in green and 2-15µm
granules identified as white spots.
&ŝŐƵƌĞ  ? ? ? ? P <ŝŶĞƚŝĐƐ ŽĨ ŝƐŽƉƌĞŶĂůŝŶĞ ŝŶĚƵĐĞĚ ŝŶƚĞƌĂůŝƐĂƚŝŽŶ ŽĨ ^ŶĂƉ ƚĂŐŐĞĚ ɴ ?Z
ĂŶĚƐŶĂƉƚĂŐŐĞĚɴ ?Z ?ɴ ?Zŝ&ĚŝŵĞƌƐ
^ƚĂďůǇ ƚƌĂŶƐĨĞĐƚĞĚ ,< ? ? ?d ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ĞŝƚŚĞƌ^ ŶĂƉ ɴ ?Z ?zŶ  ? Z Žƌ ^ŶĂƉ
ɴ ?Z ?ɴ ?Z ŝ& ĚŝŵĞƌƐ  ? Z ǁĞƌĞ ƉƌĞůĂďĞůůĞĚ ǁŝƚŚ ^EWƐƵƌĨĂĐĞ  ? ? ?  ? ? ?ŵŝŶ Ăƚ
37°C/5% CO2). Cells were then stimulated with either vehicle or 10µM isoprenaline at
set time intervals, before reactions were terminated using PBS. Cells were then fixed
and imaged using an IX Ultra confocal platereader as previously described. Data were
normalised to Isoprenaline responses observed at 60min, with a 5min latency period
also included during curve fitting. Graphs represent data pooled from at least 3
ŝŶĚĞƉĞŶĚĞŶƚ ĞǆƉĞƌŝŵĞŶƚƐ ĂŶĚ ĂƌĞ ĞǆƉƌĞƐƐĞĚ ĂƐ ŵĞĂŶ A? Ɛ ?Ğ ?ŵ ? ^ŶĂƉ ɴ ?Z ?ɴZ
timecourse data were provided by Dr Nicholas Holliday (University of Nottingham,
UK).
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 ? ? ? ? ?^ƚŝŵƵůĂƚŝŽŶŽĨ^ŶĂƉɴ ?Z ?ɴ ?Zŝ&ĚŝŵĞƌƐǁŝƚŚĂƉĂŶĞůŽĨůŝŐĂŶĚƐ
^ŶĂƉɴ ?Z ?zŶŽƌ^ŶĂƉɴ ?Z ?zŶ ?ɴ ?Z ?zĐŝ&ĐĞůů ůŝŶĞƐǁĞƌĞƚŚĞŶƐƚŝŵƵůĂƚĞĚ
with a panel of agonist ligands (30min at 37°C). Pooled concentration
response curves showed isoprenaline was equipotent at inducing
internalisation at all receptor populations (pEC50 values 7.1-7.4; n=8-10; Figure
5.15, Table 3). The rank order of potency of ligands was unchanged in each
case, being formoterol = salmeterol > isoprenaline > salbutamol. Both
salmeterol and salbutamol were partial agonists compared to isoprenaline,
and there was no significant change in their relative efficacy for the BiFC
ĚŝŵĞƌŝŶƚĞƌŶĂůŝƐĂƚŝŽŶƌĞƐƉŽŶƐĞĐŽŵƉĂƌĞĚƚŽ^ŶĂƉ ?ɴ ?Z ?zŶůĂďĞůůĞĚƌĞĐĞƉƚŽƌƐ ?
/Ŷ ŽƌĚĞƌ ƚŽ ŝŶǀĞƐƚŝŐĂƚĞ ǁŚĞƚŚĞƌ ĐŽŶƐƚƌĂŝŶŝŶŐ ɴ ?Z ĂƐ ĚŝŵĞƌƐ ƌĞƐƵůƚĞĚ ŝŶ
ĂůƚĞƌĞĚĂŶƚĂŐŽŶŝƐƚƉŚĂƌŵĂĐŽůŽŐǇ ?^ŶĂƉɴ ?ƌĞĐĞƉƚŽƌĂŶĚ^ŶĂƉɴ ?Zŝ&ĚŝŵĞƌ
ĐĞůů ůŝŶĞƐ ǁĞƌĞ ƉƌĞƚƌĞĂƚĞĚ ǁŝƚŚ ƚŚĞ ɴ ?Z ĂŶƚĂŐŽŶŝƐƚ ƉƌŽƉƌĂŶŽůŽů  ? ? ?ŶD ĨŽƌ
30min at 37°C). This was followed by stimulation with a concentration
response course of isoprenaline (30min at 37°C). Propranolol treatment had
no effect alone (Figure 5.16), but resulted in parallel rightward shifts of
ŝƐŽƉƌĞŶĂůŝŶĞ ƌĞƐƉŽŶƐĞ ĐƵƌǀĞƐ ĨŽƌ ^ŶĂƉ ɴ ?Z ĞǆƉƌĞƐƐĞĚ ĂůŽŶĞ ? ŝŶĚŝĐĂƚŝǀĞ ŽĨ
surmountable antagonism (Figure 5.16, A; estimated pKb 8.9 ± 0.1; n=4).
Comparable responses were also observed for both the Snap labelled and
ŝ& ĚŝŵĞƌ ƉŽƉƵůĂƚŝŽŶƐ ŽĨ ĐŽŶƐƚƌĂŝŶĞĚ ^ŶĂƉ ɴ ?Z ?ɴ ?Z ŝ& ĚŝŵĞƌƐ  ? ?
estimated pKb values 8.8 ± 0.1 - 9.1 ± 0.1; n = 4).
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&ŝŐƵƌĞ ? ? ? ? PYƵĂŶƚŝĨŝĐĂƚŝŽŶŽĨƚŚĞĂŐŽŶŝƐƚ ŝŶĚƵĐĞĚŝŶƚĞƌŶĂůŝƐĂƚŝŽŶŽĨ^ŶĂƉɴ ?Z ?Žƌ^ŶĂƉɴ ?Z ?ɴ ?Zŝ&ĚŝŵĞƌƐĨŽůůŽǁŝŶŐƐƚŝŵƵůĂƚŝŽŶǁŝƚŚĂƉĂŶĞůŽĨ
ligands
,< ? ? ?dĐĞůůƐƐƚĂďůǇĞǆƉƌĞƐƐŝŶŐĞŝƚŚĞƌ^ŶĂƉɴ ?Z ?zŶĂůŽŶĞ ? ZŽƌ^ŶĂƉůĂďĞůůĞĚɴ ?Z ?ɴ ?Zŝ&ĚŝŵĞƌƐ ? ZǁĞƌĞůĂďĞůůĞĚǁŝƚŚ ? ? ?A?D^EWƐƵƌĨĂĐĞ ? ? ?ĨŽƌ
30min at 37°C/5% CO2, before stimulation with a panel of ligands (30min at 37°C). Differential responses to ligand were determined following granularity
analysis of images acquired using an automated confocal platereader. All data were normalised to negative (basal responses) and positive (10µM
isoprenaline) plate controls. All data were pooled from a minimum of 3 independent experiments, and expressed as mean ± s.e.m.
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dĂďůĞ  ? ? ? P^ƵŵŵĂƌǇŽĨƉŽƚĞŶĐŝĞƐĂŶĚĞĨĨŝĐĂĐŝĞƐŽĨĂƉ ŶĞůŽĨ ůŝŐĂŶĚƐ ĨŽƌ ƐƚŝŵƵůĂƚŝŶŐ ƚŚĞ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶŽĨ^ŶĂƉɴ ?Z ƌĞĐĞƉƚŽƌƐĂŶĚɴ ?Z ?ɴ ?Zŝ&
dimers
^ŶĂƉɴ ?Z ^ŶĂƉɴ ?Z ?ɴ ?Z
Snap 647 labelled receptor BiFC dimer Snap 647 labelled receptor
Ligand pEC50 Emax (%) pEC50 Emax (%) pEC50 Emax (%)
Isoprenaline 7.4 ± 0.1 100 7.1 ± 0.1 100 7.3 ± 0.1 100
Formoterol 8.4 ± 0.1 84.2 ± 6.8 8.2 ± 0.2 82.8 ± 2.5 8.2 ± 0.1 80.0 ± 2.9
Salbutamol 6.4 ± 0.1 63.3 ± 9.7 6.2 ± 0.1 46.3 ± 8.8 6.2 ± 0.2 50.5 ± 3.2
Salmeterol 8.6 ± 0.1 16.5 ± 6.1 8.6 ± 0.1 8.8 ± 5.6 8.6 ± 0.8 15.2 ± 1.9
All data were expressed as ± standard error of the mean. pEC50 values were obtained from pooled concentration response curves presented in Figure 5.15.
Emax responses to each ligand were calculated as a percentage of 1µM NPY responses.
n values for all data 4-10
/ = responses unable to determined
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Figure 5.16: The effect of preincubation with the antagonist propranolol on the
ĂŐŽŶŝƐƚ ŝŶĚƵĐĞĚ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŽĨ ^ŶĂƉ ɴ ?Z ƌĞĐĞƉƚŽƌƐ ĂŶĚ ɴ ?Z ?ɴ ?Z ŝ&
dimers
,< ? ? ?dĐĞůůƐƐƚĂďůǇĞǆƉƌĞƐƐŝŶŐ^ŶĂƉɴ ?Z ?zŶ ? ZŽƌ^ŶĂƉɴ ?Z ?ɴ ?Zŝ&ĚŝŵĞƌƐ ? Z
were labelled with SNAPsurface 647 (30min at 37°C/5% CO2). Cells were then
pretreated with the antagonist propranolol (10nM; 30min at 37°C), followed by
stimulation with the agonist isoprenaline (ISO) for 30min at 37°C. Granularity analysis
was performed on images obtained using an automated confocal platereader.
Concentration response curves in the presence and absence of propranolol were
fitted using GraphPad Prism with shared minimum (basal responses), maximum
(10µM isoprenaline responses) and Hill slope constraints. All data were pooled from
a minimum of 3 independent experiments, and expressed as mean ± s.e.m.
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5.3.7 Introduction of receptor activation mutations selectively introduced
ŝŶƚŽ ƉƌŽƚŽŵĞƌ  ĚŽĞƐ ŶŽƚ ƉƌĞǀĞŶƚ ĂŐŽŶŝƐƚ ŝŶĚƵĐĞĚ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŽĨ ɴ ?Z
BiFC dimers
The NPxxY motif (Asn-Pro-X-X-Tyr) motif is a highly conserved sequence across
all Class A GPCRs (Chapter 1, section 1.2.3.2) found at the junction between
TM7 and helix 8 (Figure 5.17). This motif has been implicated in maintaining
the inactive state of the receptor in addition to influencing receptor
expression, sequestration and ligand affinity (Fritze et al., 2003).
Figure 5.17: Schematic showing the location of mutations of the NPxxY motif of the
ŚƵŵĂŶɴ ?Z
dŚĞƉŽƐŝƚŝŽŶŽĨƚŚĞEWǆǆzŵŽƚŝĨŽĨɴ ?ZŝƐŚŝŐŚůŝŐŚƚĞĚ ?ǁŝƚŚƚŚĞE ? ? ?ƐŚŽǁŶŝŶƌĞĚ
and the Y326 shown in green. Both residues were mutated to alanine when
ŝŶǀĞƐƚŝŐĂƚŝŶŐ ŵƵƚĂŶƚ ɴ ?Z ŝ& ĚŝŵĞƌƐ ? ^ƋƵĂƌĞ ďŽǆĞƐ ŝŶĚŝĐĂƚĞ ƌĞƐŝĚƵĞƐ ŚŝŐŚůǇ
conserved in the Class A GPCR family. Figure courtesy of Dr Nick Holliday.
Alanine mutations of the asparagine (N322) and tyrosine (N326) residues of
the NPxxY motif were introduced into protomer B alone of potential Snap
ɴ ?Z ?ɴ ?Zŝ&ĚŝŵĞƌƐ ? ƚŽ ĞǆĂŵŝŶĞ ƚŚĞ ĞĨĨĞĐƚ ŽĨ ŝŶĂĐƚŝǀĂƚŝŶŐ ŽŶĞ ƉƌŽŵŽƚĞƌ
within the BiFC dimer. As mutation of the tyrosine mutation has already been
ƐŚŽǁŶ ƚŽ ĂĚǀĞƌƐĞůǇ ĂĨĨĞĐƚ ɴ ?Z ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ  ?ĂƌĂŬ Ğƚ Ăů ? ?  ? ? ? ? Z ? ĂŐŽŶŝƐƚ
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ŝŶĚƵĐĞĚŝŶƚĞƌŶĂůŝƐĂƚŝŽŶŽĨ^ŶĂƉɴ ?Z ?ɴ ?ZE ? ? ?ĂŶĚ^ŶĂƉɴ ?Z ?ɴ ?Zz ? ? ?
mutant dimers was used as a readout of BiFC dimer function.
/ŶŽƌĚĞƌƚŽŝŶǀĞƐƚŝŐĂƚĞƚŚĞƉŽƚĞŶƚŝĂůĞĨĨĞĐƚƐŽĨEWǆǆzŵƵƚĂƚŝŽŶƐŽŶɴ ?Zŝ&
dimer function, these mutations were first expressed separately and their
internalisation assessed. Mutated receptors containing a N terminal Snap
label, but lacking any C terminal modification (ie. the Yn BiFC fragment) were
stably expressed in HEK293T cells (Figure 5.18; A, B). Neither the Snap N322A
or Snap Y326A mutant receptors were able to internalise in response to
stimulation with isoprenaline (30min at 37°C). Responses were 80
 ?ɴ ?ZE ? ? ? Z ĂŶĚ  ? ? ĨŽůĚ  ?ɴ ?Zz ? ? ? Z ůŽǁĞƌ ƚŚĂŶ ƚŚŽƐĞ ŽďƐĞƌǀĞĚ ĨŽƌ
ǁŝůĚƚǇƉĞ^ŶĂƉɴ ?ZŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ?dŚĞƐĞĚĂƚĂǁĞƌĞƉƌŽǀŝĚĞĚďǇƌEŝĐŚŽůĂƐ
,ŽůůŝĚĂǇ ? ^ŶĂƉ ɴ ?Z ?ɴ ?ZE ? ? ? ĂŶĚ ^ŶĂƉ ɴ ?Z ?ɴ ?Zz ? ? ? ŝ& ĚŝŵĞƌƐ
were stimulated with a panel of ligands (30min at 37°C) and agonist induced
internalisation was quantified using the granularity algorithm. Both mutant
BiFC dimers were able to internalise, with the same rank order of agonist
ƉŽƚĞŶĐǇ ŽďƐĞƌǀĞĚ ĨŽƌ ďŽƚŚ ^ŶĂƉ ɴ ?Z ƉƌŽƚŽŵĞƌ  ĂŶĚ ŝ& ĚŝŵĞƌ
populations, and preservation of salbutamol and salmeterol partial agonist
responses. This ligand selectivity was also the same as observed for Snap
ɴ ?Z ?zŶĞǆƉƌĞƐƐĞĚĂůŽŶĞĂŶĚ^ŶĂƉɴ ?Z ?ɴ ?Zŝ&ĚŝŵĞƌƐ ?&ŝŐƵƌĞ ? ? ? ? Z ?
Surprisingly neither mutation introduced into protomer B affected the
isoprenaline timecourse (t1/2 values 4.0-5.2min; n=4) or relative agonist
ƉŽƚĞŶĐǇĂŶĚĞĨĨŝĐĂĐǇŽĨ^ŶĂƉɴ ?Zŝ&ĚŝŵĞƌŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ?&ŝŐƵƌĞ ? ? ? ? Z ?
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Figure 5.18: Quantification of the agonist
induced internalisation of mutant Snap
ɴ ?Z Žƌ ŵƵƚĂŶƚ ^ŶĂƉ ɴ ?Z ?ɴ ?Z ŝ&
dimers
,< ? ? ?dĐĞůůƐƐƚĂďůǇĞǆƉƌĞƐƐŝŶŐ^ŶĂƉɴ ?Z
receptor constructs were prelabelled with
Snap 647 (30min at 37°C/5% CO2)
ǆƉƌĞƐƐŝŽŶ ŽĨ ĞŝƚŚĞƌ ŵƵƚĂŶƚ ^ŶĂƉ ɴ ?Z
alone (A) allowed the impact of selective
NPxxY mutations on receptor
internalisation following isoprenaline
stimulation (30min at 37°C/5% CO2) to be
determined. These mutations were then
selectively introduced into protomer B of
^ŶĂƉɴ ?Z ?ɴ ?Zŝ&ĚŝŵĞƌƐĂŶĚƌĞĐĞƉƚŽƌ
internalisation was quantified following
stimulation with a panel of ligands (30min
at 37°C; B). Pooled data are representative
of a minimum of 4 independent
experiments, expressed as mean ± s.e.m.
^ŶĂƉɴ ?ZE ? ? ?Žƌ^ŶĂƉɴ ?Zz ? ? ?ĚĂƚĂ
(A) were provided by Dr Nicholas Holliday.
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dĂďůĞ ? ? ? PWŽƚĞŶĐŝĞƐĂŶĚĞĨĨŝĐĂĐŝĞƐŽĨĂƉĂŶĞůŽĨůŝŐĂŶĚƐĨŽƌƐƚŝŵƵůĂƚŝŶŐƚŚĞŝŶƚĞƌŶĂůŝƐĂƚŝŽŶŽĨɴ ?ZŵƵƚĂŶƚŝ&ĚŝŵĞƌƐ
^ŶĂƉɴ ?Z ?ɴ2ARN322A ^ŶĂƉɴ ?Z ?ɴ ?Zz ? ? ?
BiFC dimer Snap 647 labelled receptor BiFC dimer Snap 647 labelled receptor
Ligand pEC50 Emax (%) pEC50 Emax (%) pEC50 Emax (%) pEC50 Emax (%)
Isoprenaline 7.0 ± 0.1 100 7.1 ± 0.1 100 7.0 ± 0.1 100 7.0 ± 0.1 100
Formoterol 8.1 ± 0.1 103.1 ± 6.1 8.2 ± 0.2 89.7 ± 3.1 8.2 ± 0.2 93.7 ± 4.4 8.6 ± 0.1 91.9 ± 5.2
Salbutamol 6.3 ± 0.1 32.3 ± 4.2 6.2 ± 0.1 42.4 ± 3.5 7.0 ± 0.2 26.2 ± 2.5 6.9 ± 0.2 38.1 ± 8.3
All data were expressed as ± standard error of the mean. pEC50 values were obtained from pooled concentration response curves presented in Figure 5.18
Emax responses to each ligand were calculated as a percentage of 1µM NPY responses.
n values for all data 4-8
/ = responses unable to determined
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Figure 5.19: Comparison of the kinetics of the agonist induced internalisation of
ŵƵƚĂŶƚ^ŶĂƉɴ ?Z ?ɴ ?Zŝ&ĚŝŵĞƌƐ
^ƚĂďůǇ ƚƌĂŶƐĨĞĐƚĞĚ ,< ? ? ?d ĐĞůůƐ ĞǆƉƌĞƐƐŝŶŐ ĞŝƚŚĞƌ^ŶĂƉ ɴ ?Z ?ɴ ?ZE ? ? ?  ? Z Žƌ
^ŶĂƉ ɴ ?Z ?ɴ ?Zz ? ? ?  ? Z ŝ& ĚŝŵĞƌƐ ? ǁĞƌĞ ƉƌĞůĂďĞůůĚ ǁŝƚŚ ^EWƐƵƌĨĂĐĞ  ? ? ?
(30min at 37°C/5% CO2). Cells were then stimulated with either vehicle or 10µM
isoprenaline (ISO) at set time intervals. Cells were then fixed, nuclei stained using
Hoescht prior to imaging using a IX Ultra confocal platereader. Data were normalised
to isoprenaline responses observed at 60min, with a 5min latency period also
included Graphs represent data pooled from at least 4 independent experiments and
are expressed as mean ± s.e.m.
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5.4 Discussion
5.4.1 Summary of main findings
/Ŷ ƚŚŝƐ ĐŚĂƉƚĞƌ ? ŝ& ǁĂƐ ƵƐĞĚ ƚŽ ĐŽŶƐƚƌĂŝŶ ďŽƚŚ z ? ƌĞĐĞƉƚŽƌƐ ĂŶĚ ɴ ? ?
adrenoceptors as homodimers of precise composition. This allowed a
functional readout (agonist-stimulated internalisation) of quantitative
pharmacology for these dimers, in a multiplex assay which also monitored in
the same cells (using the Snap tag system) the behaviour of the total
population of one promoter (A - be that monomers, dimers or higher order
ŽůŝŐŽŵĞƌƐ Z ?  &Žƌ ďŽƚŚ ^ŶĂƉ z ? ?z ? ĂŶĚ ^ŶĂƉ ɴ ?Z ?ɴ ?Z ŝ& ĐŽŶƐƚƌĂŝŶĞĚ
dimers, agonist-promoted internalisation was unaffected and the properties
of agonists (potency, relative efficacy) and antagonists (affinity) were
ƵŶĂůƚĞƌĞĚ ĐŽŵƉĂƌĞĚ ƚŽ ƌĞĨĞƌĞŶĐĞ ^ŶĂƉ z ? Žƌ ^ŶĂƉ ɴ ?Z ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ
responses. We were able to selectively introduce mutations that disrupt
ligand binding, receptor activation, or phosphorylation into one protomer of a
BiFC dimer only. These experiments indicated that one ligand binding site,
and one functioning receptor protomer was sufficient to induce agonist
internalisation of the BiFC dimer. Moreover the lack of functional rescue
between ligand binding and phosphorylation mutants in different promoters
of the Y1/Y1 BiFC dimer provides indirect evidence against asymmetric
ƌĞĐƌƵŝƚŵĞŶƚŽĨƚŚĞŝŶƚĞƌŶĂůŝƐĂƚŝŽŶĂĚĂƉƚŽƌɴ ?ĂƌƌĞƐƚŝŶƚŽƚŚĞĚŝŵĞƌ ?
 ? ? ? ? ? z ? Žƌ ɴ ?Z ƌĞĐĞƉƚŽƌƐ ǁŚĞŶ ĐŽŶƐƚƌĂŝŶĞĚ ĂƐ ƉƌĞĐŝƐĞ ŚŽŵŽĚŝŵĞƌƐ ŽĨ
defined composition, are able to internalise in response to ligand
The nature of complementation assays is artificial in that it essentially creates
an irreversible fusion protein between the tagged proteins of interest.
However this property was successfully exploited here to constrain the Class A
'WZ ?ƐƐƵďƚǇƉĞƐŽĨŶĂƚŝǀĞz ?Žƌɴ ?ZĂƐĚŝŵĞƌƐŽĨƉƌĞĐŝƐĞĐŽŵƉŽƐŝƚŝŽŶ ?ĚƵĞ
to the need for both Yn and Yc fluorescently tagged receptor protomers to
associate in order to reform full length YFP (Kerppola, 2009). Observed YFP
fluorescence (BiFC Figure 5.4, 5.5) was therefore considered a marker of
protomer dimerisation, with the quantitative measurement of BiFC dimer
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internalisation acting as a readout of dimer function. It is worth emphasising
that due to the irreversible trapping of what may be transient protomer
interactions, BiFC formation cannot be used in this context as a measure of
the extent such receptors form dimers  the purpose instead was to obtain a
specific readout of the function (and hence pharmacology) of a particular
dimer combination. It is likely that the proportion of BiFC dimers formed is
small relative to the total receptor population (discussed further in Chapter
6). Therefore, unlike measurements of whole population responses (such as
radioligand binding or cAMP accumulation), in which particular dimer
contributions to signalling might be obscured, measurements of BiFC dimer
endocytosis uniquely defined responses attributable to this population.
The combined use of Snap labelling also allowed the simultaneous
investigation of responses of the total receptor protomer A population (be
that monomers, dimers or higher order oligomers) to be compared within the
same cell (Figure 5.4, 5.5). Although this is a useful multiplex format, there
are limitations to the degree to which the Snap protomer A and BiFC
dimer responses are separated. The first is that the Snap labelling will also
label the BiFC dimer under investigation, as well as all other protomer A
species. The second is that the use of mixed receptor-Yc (protomer B)
populations means that the expression of this protomer varied on a cell by cell
basis  with some cells (a minority) within the line expressing only the
protomer A at detectable levels. Finally the system does not exclude the
possibility of higher order oligomers,, in which the BiFC dimers might
participate..
The formation of BiFC dimers did not adversely affect cell surface receptor
expression, consistent with previous uses of BiFC to investigate adenosine A2A
homodimers (Vidi et al., 2008b). As indicated above, the presence of plasma
membrane BiFC dimers demonstrates that these complexes are not retained
in the ER during synthesis and are expressed successfully, but does not
exclude trapping of transient, rather than constitutive, interactions by the
complementing YFP tags. However techniques with a real time reversible
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readout such as BRET, have supported the idea that Y1 receptors (Dinger et
Ăů ? ?  ? ? ? ? ZĂŶĚɴ ?ZƐ  ?ŶŐĞƌƐĞƚĂů ? ?  ? ? ? ? ZĐĂŶĨŽƌŵĐŽŶƐƚŝƚƵƚŝǀĞĚŝŵĞƌƐƉƌŝŽƌ
to membrane expression or ligand stimulation.
dŚĞ ƵŶĂĨĨĞĐƚĞĚ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŽĨ ^ŶĂƉ z ? ?z ? ĂŶĚ ^ŶĂƉ ɴ ?Z ?ɴ ?Z ŝ&
dimers demonstrated that dissociation of these protomers was not a
prerequisite for their endocytosis. Observations from coimmunoprecipitation
ĂŶĚZdƐƚƵĚŝĞƐŽĨɴ ?Z ?ŶŐĞƌƐĞƚĂů ? ? ? ? ? ? ?,ĞďĞƌƚĞƚĂů ? ?  ? ? ? ? Z ?ĚŽƉĂŵŝŶĞ
D2 receptors (Guo et al., 2008) and serotonin 5-HT2C receptors (Mancia et al.,
2008) have suggested that for these receptors, agonist stimulation has little
effect on the dissociation of dimers. However the effect of agonist can vary
substantially with GPCR subtype investigated and the experimental approach
carried out (Grant et al., 2004). Agonist stimulation has been shown to induce
ƚŚĞ ĚŝƐƐŽĐŝĂƚŝŽŶ ŽĨ ƉƌĞĨŽƌŵĞĚ ĚŝŵĞƌƐ ŽĨ ɴ ?Z  ?>ĂŶ Ğƚ Ăů ? ?  ? ? ? ? Z ? ɷ ŽƉŝŽŝĚ
(Cvejic and Devi, 1997), human thyrotropin (Latif et al., 2002), the Class B
GPCR type A cholecystokinin receptor (Cheng and Miller, 2001), and
interestingly the NPY Y4 receptors (Berglund et al., 2003a).
Lambert (2010) has suggested that these discrepancies on the influence of
agonist, may be due to Class A GPCRs existing in a dynamic equilibrium
(Lambert, 2010), with dimers being essentially transient. The recruitment of
ĂĨĨŝŶŝƚǇ ƚĂŐŐĞĚ ɴ ?Z Žƌ A? ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌƐ ŝŶƚŽ ĂŶĂƌƚŝĨŝĐŝĂů ŵĞŵďƌĂŶĞ
microdomain has suggested they are unable to corecruit untagged receptors
(Gavalas et al., 2013) compared to mGluR constitutive dimer controls. This
was consistent with FRAP studies of dopamine D2 protomers indicating that
they are unable to influence each one anothers lateral diffusion within the
membrane (Fonseca and Lambert, 2009). These data suggest that Class A
GPCR dimerisation is unstable, with the monomer:dimer equilibrium
favouring dissociation implying that protomer-protomer interactions are
ƌĞůĂƚŝǀĞůǇ ǁĞĂŬ ? ,ŽǁĞǀĞƌ &ZW ƐƚƵĚŝĞƐ ŽĨ ƚŚĞ ĚŝĨĨƵƐŝŽŶ ŽĨ ƐƵďƚǇƉĞƐ ŽĨ ɴ ?
adrenoceptors has disputed this, as the equilibrium of monomers:dimers for
ɴ ?Z ŚĞƌĞ ĨĂǀŽƵƌĞĚ ĂƐƐŽĐŝĂƚŝŽŶ ĞǀĞŶ Ăƚ ƐƵďƉŚǇƐŝŽůŽŐŝĐĂů ĞǆƉƌĞƐƐŝŽŶ ůĞǀĞůƐ
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 ?ŽƌƐĐŚ Ğƚ Ăů ? ?  ? ? ? ? Z ? dŚŝƐ ƌĞĐŽŶĐŝůĞƐ ǁŝƚŚ ƐƚƵĚŝĞƐ ŽĨ ɴ ?Z ŚŽŵŽĚŝŵĞƌƐ
 ?^ĂƌƚĂŶŝĂĞƚĂů ? ?  ? ? ? ? ZĂŶĚǇĞĂƐƚɲĨĂĐƚŽƌƉŚĞƌŽŵŽŶĞŚŽŵŽĚŝŵĞƌƐ  ?zĞƐŝůĂůƚĂǇ
and Jenness, 2000) showing they are capable of undergoing agonist induced
internalisation. BiFC studies have also shown that stimulation of D2/D2
homodimers in a neuronal cell model, with the D2 select agonist quinpirole
resulted in internalisation of both dimeric populations (Vidi et al., 2008a).
A2A/A2A homodimers also present were unaffected by D2 stimulation as
expected. Equally there is evidence that GPCR heterodimers can result in
unique modifications to the endocytosis and trafficking or receptors (see
Chapter 6).
Dimer stability has been suggested to differ with receptor subtype (Dorsch et
al., 2009, Calebiro et al., 2013) while single fluorescent molecule imaging
using fluorescent proteins or ligands has also implied that the half life of
dimers may vary from 0.5secs for M1 muscarinic receptors. (Hern et al., 2010)
ƚŽ  ?ƐĞĐƐĨŽƌɴ ?Z ?ĂůĞďŝƌŽĞƚĂů ? ?  ? ? ? ? ZǁŝƚŚĚŝŵĞƌƐ ŽŶůǇŵĂŬŝŶŐƵƉĂƐŵĂůů
proportion of the total receptor population expressed (estimated as 30% for
muscarinic M1 receptors (Hern et al., 2010)). Interestingly there are
suggestions that the predominant receptor form may also be influenced by
receptor expression levels (Kasai et al., 2011, Calebiro et al., 2013), with
dimers the prevalent form at high receptor expression, most likely due to
greater receptor proximity increasing the likelihood of associations.
Additionally the plasticity of the plasma membrane could facilitate any
dynamic dimer association/dissociation events (Casado et al., 2009a).
Plasticity for receptors in respect to their oligomer state in combination with
the point in receptor life cycle that measurements are made could impact
observations on agonist affects.
dŚĞƌĞĨŽƌĞĂůƚŚŽƵŐŚŽďƐĞƌǀĂƚŝŽŶƐŚĞƌĞƐŚŽǁƚŚĂƚ^ŶĂƉz ?Žƌɴ ?Zŝ&ĚŝŵĞƌƐ
ĐĂŶ ŝŶƚĞƌŶĂůŝƐĞ ? ƚŚŝƐ ĚŽĞƐ ŶŽƚ ĞǆĐůƵĚĞ ƚŚĞ ƉŽƐƐŝďŝůƚǇ ƚŚĂƚ z ? Žƌ ɴ ?Z
monomers could also internalise. However it does clearly demonstrate that
using BiFC to irreversibly constrain the dimeric state had no effect on
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ĞŶĚŽĐǇƚŽƐŝƐ ĂŶĚ ƚŚĂƚ ĚŝƐƐŽĐŝĂƚŝŽŶ ŽĨ z ? Žƌ ɴ ?Z ĚŝŵĞƌƐ ŝƐ ƚŚĞƌĞĨŽƌĞ ŶŽƚ Ă
prerequisite for their internalsation.
5.4.4: BiFC constrained Class A GPCR dimers do not show altered
pharmacology in respect to agonists or antagonists.
5.4.4.1 Unaltered agonist and antagonist pharmacology
Competitive [125I] PYY binding showed confirmed that Snap Y1/Y1 cell lines
were functional in respect to agonist and antagonist ligand binding affinities
and G protein coupling (Table 5.1). Affinity estimates for PYY were
comparable to those previously obtained for human and rhesus monkey Y1
receptors in radioligand competition binding assays (Berglund et al., 2003b,
'ĞŚůĞƌƚĞƚĂů ? ? ? ? ? ? ?>ĂƌŚĂŵŵĂƌĞƚĂů ? ? ? ? ? ? ZĂŶĚƚŚĞz ? ?'&WŽƌz ? ?ɴ ?ĂƌƌĞƐƚŝŶ ?
cell lines previously characterised in chapter 3 (Kilpatrick et al., 2010).
Additionally the kinetics and agonist rank potencies in respect to
ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŽĨ ^ŶĂƉ z ? ?z ? Žƌ ^ŶĂƉ ɴ ?Z ŝ& ĚŝŵĞƌ ĐĞůů ůŝŶĞƐ ǁĞƌĞ
comparable to their Snap Receptor-Yn counterparts and were consistent with
previous observations of Y1 receptor (Chapter 3, Tables 3.2 and 3.3)
 ?tĂŚůĞƐƚĞĚƚ Ğƚ Ăů ? ?  ? ? ? ? ? tĂŚůĞƐƚĞĚƚ Ğƚ Ăů ? ?  ? ? ? ?Ă Z Žƌ ɴ Z ƉŚĂƌŵĂĐŽůŽŐǇ
(Baker, 2010, Baker, 2005). NPY potencies (as pEC50) determined by cAMP
accumulation assays were increased compared to internalisation assays for
Snap Y1-Yn/Y1-Yc cell lines, likely reflecting the reduced receptor reserve for
receptor internalisation compared to the downstream amplification that
occurs in cAMP assays. Potencies in cAMP assays were comparable with
previous observations for the Y1 receptor (Mullins et al., 2001).
hƐŝŶŐ ŝ& ƚŽ ƚƌĂƉ ɴ ?Z ĚŝŵĞƌƐ ŚĂĚ ŶŽ ĞĨĨĞĐƚ ŽŶ ƚŚĞ ĂĨĨŝŶŝƚǇ ŽĨ ƉƌŽƉƌĂŶŽůŽů
ǁŚĞŶĐŽŵƉĂƌĞĚƚŽƚŚĞƚŽƚĂů^ŶĂƉɴ ?ZĞǆƉƌĞƐƐĞĚŝŶƚŚĞƐĂŵĞĐĞůůƐŽƌŵŽƌĞ
ŐĞŶĞƌĂů ɴ ?Z ŵĞĂƐƵƌĞŵĞŶƚƐ  ?ĂŬĞƌ ?  ? ? ? ? Z ? ƋƵĂůůǇ /K ? ? ? ? ǁĂƐ Ă
competitive reversible antagonist of NPY induced inhibition of cAMP
accumulation in Snap Y1/Y1 cells and internalisation of Y1/Y1 BiFC dimers.
However estimated pKb values for both assays, although comparable, were
lower than expected based on previous observations (Wieland et al., 1998)
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and results obtained from the Y1/A2 cell line (chapter 3, Figure 3.10).
However this reduction was also seen for Snap Y1 receptors expressed alone,
suggesting that this was not an exclusive consequence of the formation of
BiFC dimers and more likely a due to internalisation assays not being
performed at receptor-ligand equilibrium.
5.4.4.2 No functional evidence for co-operativity between homo-dimer
binding sites.
Dimerisation of GPCRs may present new pharmacological targets that could
be exploited in drug therapies. Altered pharmacology distinct from that
typically ascribed to the monomeric form of the receptor, has been observed
for some Class A GPCRs (4.1.3). As homodimers are composed of two
identical protomers they, unlike heterodimers, have two identical orthosteric
binding sites each with theoretically the same selectivity for the same ligand.
The apparent transient nature of dimerisation (Lambert, 2010) therefore
suggests that potential interactions across the dimer interface may contribute
to alterations in signalling an pharmacology.
No changes in agonist and antagonist pharmacology were generally observed
for BiFC dimers, but this also raises a question. If cooperativity is occurring for
homodimers what would be expected in internalisation data? The only way in
which this might be revealed by comparison between Snap receptor and BiFC
dimer responses, would bes if BiFC were to change the proportion of dimers
ƚŚĂƚ ĂƌĞ ƉƌĞƐĞŶƚ ? /Ĩ ^ŶĂƉ z ? ?z ? Žƌ ɴ ?Z ?ɴ ?Z ĚŝŵĞƌƐ ǁĞƌĞ ƐƚĂďůĞ ĂŶǇǁĂǇ ?
without the presence of the BiFC tags, then there would be no difference
observed between measurements for BiFC dimer versus those of Snap Y1-Yn
Žƌ ɴ ?Z ? ĞǆƉƌĞƐƐĞĚ ŝŶ ƚŚĞ ƐĂŵĞ ĐĞůůƐ Žƌ ŝŶĚĞƉĞŶĚĞŶƚůǇ ? ,ŽǁĞǀĞƌ ĂƐ
dimerisation is proposed to be a dynamic process (Lambert, 2010, Hern et al.,
2010), it is not unreasonable to suggest that dimer formation might be
promoted using the BiFC system. If positive cooperativity were occurring
between the respective protomer ligand binding sites this would therefore
manifest in internalisation data as increases in potency and/or increases in Hill
Slopes of curve fits for the BiFC dimer population relative to the Snap
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receptor-Yn population. None of the BiFC dimers investigated showed
evidence for this, or increases in the relative efficacies of partial agonists such
ĂƐWW ?z ? ZŽƌƐĂůŵĞƚĞƌŽů ?ɴ ?Z Z ?
Negative cooperativity across dimer interfaces implies that only one agonist
binding site can be occupied at any one time and has been observed for
dopamine D2 (Vivo et al., 2006) and glycoprotein hormone receptors (Urizar
et al., 2005). However this would likely be undetectable in internalisation
assays in terms of changes in ligand potency or efficacy.
No evidence was seen for cooperativity in respect to changes in antagonism,
with surmountable antagonism explained largely by classical pharmacology.
Although BIBO3304 affinity measures were lower at both Snap Y1 and Snap
Y1/Y1 BiFC dimers, this is likely to be a consequence of non equilibrium
conditions. Therefore the influence of cooperativity on BiFC homodimer
pharmacology is largely inconclusive, and will be revisited in respect to Y
receptor BiFC heterodimer pharmacology in Chapter 6. The BiFC system here
has the advantage that, unlike radioligand binding and cAMP accumulation
assays, it can distinguish responses of the distinct dimeric population from
that of the whole receptor population within the same cell. Therefore the
quantification of internalisation as a readout of receptor function is robust as
it allowed responses to be directly attributed to this small defined population
that are typically hidden in whole population measures (see Chapter 6 for
further detail).
5.4.5 The use of selective mutations to probe ligand binding site
stoichiometry required to facilitate BiFC dimer internalisation
^ŝŵŝůĂƌ ƚŽ ' ƉƌŽƚĞŝŶƐ ? ɴ ?ĂƌƌĞƐƚŝŶƐ ĂƌĞ ĂůůŽƐƚĞƌŝĐ ĞĨĨĞĐƚŽƌƐ ǁŚŝĐŚ ĐĂŶ ƐƚĂďŝůŝƐĞ
the high affinity state of the agonist bound receptor. Although evidence
suggests that the minimal functional unit for G protein binding is largely
believed to be a 1:1 stoichiometry (ie. bound to a receptor
monomer(Whorton et al., 2007, Rasmussen et al., 2011a)), this cannot be
ĂƐƐƵŵĞĚĂƐƚƌƵĞĨŽƌďŝŶĚŝŶŐŽĨĂůůĞĨĨĞĐƚŽƌƉƌŽƚĞŝŶƐ ?ƐƵĐŚĂƐɴ ?ĂƌƌĞƐƚŝŶ ?
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Binding could occur in a 4 potential modes 1:1 (receptor monomer:arrestin
monomer), 2:2 (receptor dimer:dimeric arrestin), 2:1a (Asymmetric whereby
arrestin interacts across the receptor dimer) and 2:1b (Asymmetric whereby
both arrestin domains interact with the same protomer) (Figure 5.20). The use
ŽĨƐĞůĞĐƚŝǀĞŵƵƚĂƚŝŽŶƐǁŚŝĐŚƚĂƌŐĞƚƚŚĞĚŝƐƚŝŶĐƚƌĞŐŝŽŶƐŽĨƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ
association were used to probe the nature of this interaction.
5.4.5.1 A mutation affecting ligand binding
The Y99 residue implicated in ligand binding at the Y1 receptor was selectively
mutated in protomer B only of a potential BiFC dimer (Figure 5.9), allowing
the stoichiometry of ligand binding site occupancy required to induce dimer
internalisation to be investigated. The extent of ligand occupancy of a GPCR
dimer is important, as ligand binding at one site may have cooperative effects
upon binding to the orthosteric site of the second protomer (Birdsall, 2010).
The Y99A mutation at the Y1 receptor has been shown to abolish agonist
ďŝŶĚŝŶŐĂŶĚƐŽŝŶŚŝďŝƚƚŚĞĂďŝůŝƚǇŽĨƚŚŝƐŵƵƚĂŶƚƌĞĐĞƉƚŽƌƚŽƌĞĐƌƵŝƚɴ ?ĂƌƌĞƐƚŝŶ ?
(Chapter 3; Figure 3.16). However the Y1/Y1Y99A mutant BiFC dimer, was
capable of internalising to agonist with kinetics and potencies comparable to
those observed for Y1/Y1 BiFC dimers, Snap Y1-Yn expressed alone or
superfolder GFP tagged receptors (Chapter 3). Coexpression of the Y1Y99A-Yc
mutant receptor did not alter the ability of Snap Y1/Y1Y99A cells to bind
ligand and couple to G protein with pIC50 values as expected. However the
small proportion of Y199A-Yc expressed in these cells relative to the Snap Y1-
Yn clonal population might mean that potential changes indicating altered co-
operativity  for example in Hill slopes  were unlikely to be detectable in
these assays.
These results suggested that only one functional agonist binding site was
required to support endocytosis with the wildtype agonist bound protomer
providing the necessary active conformation and or C terminal
phosphorylated residues required. WƌĞǀŝŽƵƐŽďƐĞƌǀĂƚŝŽŶƐŽĨɴ ?Z ?^ĂƌƚĂŶŝĂĞƚ
al., 2007) or complement 5a receptors (Rabiet et al., 2008) have supported
this conclusion, whereby coexpression of a binding deficient mutant receptor
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alongside a wildtype protomer, resulted in a dimer still capable of undergoing
agonist induced internalisation. Additionally BRET observations of angiotensin
1 receptor (AT1) dimers, whereby a wild type protomer was coexpressed
alongside a ligand binding deficient mutant, resulted in a BRET dimer that
ǁĂƐĂďůĞƚŽƌĞĐƌƵŝƚɴ ?ĂƌƌĞƐƚŝŶ ? ŝŶƌĞƐƉŽŶƐĞƚŽĂŐŽŶŝƐƚƐƚŝŵƵůĂƚŝŽŶ ?,ĂŶƐĞŶĞƚ
al., 2004). Asymmetrical ligand occupancy has also been observed for
dopamine D2 receptor homodimers, with maximal activation occurring with
agonist binding to a single protomer only (Han et al., 2009).
 ? ? ? ? ? ? ?DƵƚĂƚŝŽŶƐƚĂƌŐĞƚŝŶŐɴ ?ĂƌƌĞƐƚŝŶ ?ƌĞĐƌƵŝƚŵĞŶƚ
Although the mode of G protein binding to GPCR dimers is beginning to be
ĞůƵĐŝĚĂƚĞĚ ?  ƚŚĞ ƐƚŽŝĐŚŝŽŵĞƚƌǇ ĂŶĚ ƐǇŵŵĞƚƌǇ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ƌĞĐƌƵŝƚŵĞŶƚ ŝƐ
much less clear, with the bi-lobed structure of arrestin suggesting the
possibility of multiple modes of binding (Figure 5.20 ;(Chapter 1, 1.6.1)
(Gurevich and Gurevich, 2004, Nobles et al., 2007). Selective mutations of
ƌĞƐŝĚƵĞƐĞǆƉĞĐƚĞĚƚŽĂĨĨĞĐƚŝŶƚĞƌĂĐƚŝŽŶǁŝƚŚƚŚĞɴ ?ĂƌƌĞƐƚŝŶ ?ĂĐƚŝǀĂƚŝŽŶƐĞŶƐŽƌ
 ?ɴ ?ZE ? ? ?Žƌɴ ?Zz ? ? ? ZǁĞƌĞƵƐĞĚƚŽƉƌŽďĞƚŚŝƐ ?EŽŶĞŽĨƚŚĞŵƵƚĂƚŝŽŶƐ
prevented agonist induced internalisation of BiFC dimers, indicative of an
ĂƐǇŵŵĞƚƌŝĐ ƌĞĐƌƵŝƚŵĞŶƚ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ƚŽ ƚŚĞ ĚŝŵĞƌ ? ƐŽ ƚŚĂƚ ŽŶůǇ ŽŶĞ
functional protomer within a dimer was needed for internalisation. The
phosphorylation negative mutant Y15A that targets the phosphorylation
ƐĞŶƐŽƌ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ĂůƐŽ ĚŝĚ ŶŽƚ ƉƌĞǀĞŶƚ ĂŐŽŶŝƐƚŝŶĚƵĐĞĚ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŽĨ
^ŶĂƉ z ? ?z ? ? ŝ& ĚŝŵĞƌƐ ? dŚŝƐ ĂůƐŽ ƐƵŐŐĞƐƚĞĚ Ă  ? P ? ƐƚŽŝĐŚŝŽŵĞƚƌǇ ŽĨ ɴ ?
arrestin2 binding. Similar results have been observed for complement 5a
receptor dimers, whereby a phosphorylation deficient protomer did not
internalise when individually expressed, but was able to when coexpressed
with a wildtype protomer (Rabiet et al., 2008). This conclusion also assumes
that GRKs are able to be recruited to and phosphorylate the unmodified
protomer. Additional binding modes utilising the mutated protomer may still
ĂůƐŽďĞƉŽƐƐŝďůĞ ?ĂƐĂůƚŚŽƵŐŚ'Z<ƐŝŶĐƌĞĂƐĞƚŚĞĂĨĨŝŶŝƚǇŽĨɴ ?ĂƌƌĞƐƚŝŶĨŽƌ'WZƐ
(Luttrell and Lefkowitz, 2002), internalisation can still occur in the absence of
phosphorylation.
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&ŝŐƵƌĞ ? ? ? ? PWŽƚĞŶƚŝĂůŵŽĚĞƐŽĨďŝŶĚŝŶŐŽĨɴ ?ĂƌƌĞƐƚŝŶ ?ƚŽĚŝŵĞƌŝĐ'WZƐ
^ƚǇůŝƐĞĚƐĐŚĞŵĂƚŝĐƐŚŽǁƐƚŚĞƉŽƚĞŶƚŝĂůŵŽĚĞƐŽĨďŝŶĚŝŶŐƉŽƐƐŝďůĞĨŽƌɴ ?ĂƌƌĞƐƚŝŶ ?ƌĞĐƌƵŝƚŵĞŶƚƚŽ'WZƐ ?ǁŝƚŚƐƚŽŝĐŚŝŽŵĞƚƌŝĞƐŝŶƌĞƐƉĞĐƚƚŽƌĞĐĞƉƚŽƌ PĂƌƌĞƐƚŝŶ
ŝŶĚŝĐĂƚĞĚ ?/ŶĂ ? P ?ƐƚŽŝĐŚŝŽŵĞƚƌǇŵŽŶŽŵĞƌŝĐƌĞĐĞƉƚŽƌŝŶƚĞƌĂĐƚƐǁŝƚŚŵŽŶŽŵĞƌŝĐɴ ?ĂƌƌĞƐƚŝŶŝŶƚĞƌĂĐƚƐǁŝƚŚƌĞĐĞƉƚŽƌƐŽƚŚĂƚďŽƚŚŝƚƐĂĐƚŝǀĂƚŝŽŶ ?ƌĞĚĐŝƌĐůĞ ZĂŶĚ
phosphate (P) are engaged simultaneously. 2:2 refers to dimeric receptor (blue and pink protomers) binding 2 molecules (or dimeric) arrestin. A 2:1a
conformation is whereby dimeric receptor interacts with one molecule of arrestin which bridges the dimer interface to engage both its domains with
individual receptor protomers. Finally in a 2:1b stoichiometry, one arrestin binds exclusively to one protomer of the dimer. Respective size of proteins is not
to scale.
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dŚĞďŝ ?ůŽďĞĚƐƚƌƵĐƚƵƌĞŽĨĂƌƌĞƐƚŝŶ ?ŵĂǇƐƵƉƉŽƌƚɴ ?ĂƌƌĞƐƚŝŶďŝŶĚŝŶŐƚŽĂĚŝŵĞƌ
by interacting with the 2 monomers across its 70 Ångstrom span (Fotiadis et
al., 2006) (Gurevich and Gurevich, 2006) (Figure 5.20; stoichiometry 2:1a).
&ŽƚŝĂĚŝƐĞƚ Ăů  ? ? ? ? ? ZŚĂǀĞƵƐĞĚ ŵŽĚĞůůŝŶŐƐƚƵĚŝĞƐ ƚŽƉƌĞĚŝĐƚ ƚŚĞŶĂƚƵƌĞŽĨɴ ?
arrestin2 recruitment to an assumed rhodopsin dimer (Fotiadis et al., 2006).
dŚĞǇƐƵŐŐĞƐƚ ƚŚĂƚ ƚŚĞĚŝŵĞŶƐŝŽŶĂŶĚƐƚƌƵĐƚƵƌĞ ŽĨɴ ?ĂƌƌĞƐƚŝŶ ?ǁŽƵůĚƐƵƉƉŽƌƚ
binding of one molecule to a rhodopsin dimer via dual engagement of the
ĂĐƚŝǀĂƚŝŽŶ ĂŶĚ ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ĚŽŵĂŝŶƐ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ? ,ŽǁĞǀĞƌ ƚŚĞƐĞ
conclusions are largely based on molecular models of inactive arrestin and
may not reflect physiological events, particularly with the recently resolved
ĐƌǇƐƚĂů ƐƚƌƵĐƚƵƌĞ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ?  ?ďŽƵŶĚ ƚŽ Ă ƉĞƉƚŝĚĞ ĨƌĂŐŵĞŶƚ ŽĨ ƚŚĞ 
terminus of Vasopressin V2 receptor stabilised with an Fab30 antibody
fragment) highlighting the profoundly different conformations between the
two states (Shukla et al., 2013).
The use of the BiFC system here allowed the direct investigation of the
binding model proposed by Fotiadis (Fotiadis et al., 2006) by combining
binding site and phosphorylation site mutants in individual Y1 protomers of a
BiFC dimer (Snap Y15A/Y1Y99A). If the model proposed by Fotiadis et al.,
(Fotiadis et al., 2006) is correct then a functional response would only be seen
ŝĨƚŚĞĂĐƚŝǀĂƚŝŽŶĚŽŵĂŝŶĂŶĚƉŚŽƐƉŚŽƌǇůĂƚŝŽŶƐĞŶƐŽƌƐŽĨɴ ?ĂƌƌĞƐƚŝŶĞŶŐĂŐĞƚŚĞ
phosphorylation deficient protomer (Y15A) and ligand binding deficient
protomer (Y1Y99A) respectively. However no functional rescue was seen for
Snap Y15A/Y1Y99A, suggesting that the Fotiadis 2:1 model is incorrect and
that at least one protomer within a dimer must be both agonist occupied and
phosphorylated. However this conclusion depends on the assumption that
GRK phosphorylation of the constrained BiFC dimer, and especially the C tail
of the Y1Y99A protomer, can proceed. Alternatively, the documented
preference of GRKs for agonist occupied receptors (Premont and Gainetdinov,
2007) might limit phosphorylation only to the agonist-occupied protomer  so
that the Snap Y15A/Y1Y99A dimer cannot then be phosphorylated. One way
to test whether the lack of functional rescue genuinely reveals information
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about E-arrestin binding stoichiometry would be to incorporate mutations in
the Y1Y99A protomer that also mimic the negative charges of C tail
phosphorylation (e.g. substitutions by Glu / Asp). This would reduce the need
to consider the intervening GRK step, and if such a mutant restored
internalisation of a Snap Y15A/Y1Y99A phosphorylated dimer, the Fotiadis 2:1
model could be re-evaluated.
5.4.6 Reconciling the data from selective mutagenesis of BiFC dimers with
ƉƌŽƉŽƐĞĚŵŽĚĞƐŽĨɴ ?ĂƌƌĞƐƚŝŶ ?ƌĞĐƌƵŝƚŵĞŶƚ
TŚĞ ƌĞĐĞŶƚůǇ ƐŽůǀĞĚ ĐƌǇƐƚĂů ƐƚƌƵĐƚƵƌĞ ŽĨ ĂĐƚŝǀĞ ɴ ?ĂƌĞƐƚŝŶ ? ďŽƵŶĚ ƚŽ Ă  ? ?
amino acid peptide of the Vasopressin C terminus, suggests that the extensive
ĐŽŶƚĂĐƚƐ ďĞƚǁĞĞŶ ƚŚĞ ƉĞƉƚŝĚĞ ĂŶĚ ɴ ?ĂƌƌĞƐƚŝŶ ? E ƚĞƌŵŝŶƵƐ ǁŽƵůĚ ůŝŬĞůǇ
sterically occlude binding of a second arrestin molecule to the same
protomer (Shukla et al., 2013). Evidence from the model Class A GPCR
rhodopsin isolated in nanodiscs has also indicated a 1:1 binding stoichiometry
of arrestin (visual) with phosphorylated active monomeric rhodopsin (Hanson
et al., 2007b, Bayburt et al., 2011, Tsukamoto et al., 2010) that occurs at low
nanomolar affinity (Bayburt et al., 2011). Additionally pull down studies of
rhodopsin isolated from bovine rod outer segments, as well as in vivo
transgenic mice studies, have also indicated 1:1 binding saturations even at
high arrestin:receptor expression ratios (Hanson et al., 2007a). Due to the
physiological role of rod photoreceptors they are advantageous for
investigating stoichiometries as both arrestin and rhodopsin are expressed at
very high levels. However whilst these observations dispute a 2:1
stoichiometry they do not rule out 2:2 or the formation of even larger
complexes (eg. 3:3 or 4:4 (Tsukamoto et al., 2010). Rhodopsin has historically
been viewed as the model Class A GPCR, however care must be taken when
applying observations derived from them to other Class A GPCRs as the all or
nothing activation of rhodopsin cannot necessarily describe the degrees of
activation and range of conformational states at other GPCRs (Rasmussen et
al., 2007b).
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Atomic force microscopy has also revealed that in vivo rhodopsin formed
dimers arranged in organised rows (Fotiadis et al., 2003) suggesting they may
support alternative modes of binding. Maurice et al (Maurice et al., 2011)
have suggested that the particular binding stoichiometry may change with the
receptor dimer and the presence of other effector proteins. A further
possibility is that the stoichiometry of binding changes with the activation
density of receptors. In native disc membranes at low photoactivation
densities stoichiometry was measured as 1:1 arrestin: receptor monomer.
Whereas at high photoactivation densities the stoichiometry increased to 2:1
(2 rhodopsin:1 arrestin) (Sommer et al., 2011, Satoh et al., 2010).
The ability of Snap Y1/Y1Y99A BiFC dimers to internalise but the failure of
Snap Y15A/Y1Y99A BiFC dimers does not support a 2:2 stoichiometry of 2
activated and or phosphorylated Y1 receptor protomers recruiting 2
ŵŽůĞĐƵůĞƐ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? /ŶƐƚĞĂĚ ƚŚĞǇ ĂƌĞ ŵŽƐƚ ĐŽŶƐŝƐƚĞŶƚ ǁŝƚŚ  ? ƌĞĐĞƉƚŽƌƐ
ďŝŶĚŝŶŐ ƚŽ  ? ɴ ?ĂƌƌĞƐƚŝŶ ŵŽůĞĐƵůĞ ? ǁŚĞƌĞďǇ ďŽƚŚ ƚŚĞĂĐƚŝǀĂƚŝŽŶ ĂŶĚ
ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ĚŽŵĂŝŶƐ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ďŝŶĚ ũƵƐƚ ŽŶĞ ŽĨ ƚŚĞ ƌĞĐĞƉƚŽƌ
protomers within the BiFC dimer (discounting the model of (Fotiadis et al.,
2006)). An equivalent mutant AT1 receptor dimer also consisting of a ligand
binding deficient protomer and an internalisation deficient protomer has been
ƐŚŽǁŶƚŽƌĞĐƌƵŝƚɴ ?ĂƌƌĞƐƚŝŶ ?ďƵƚŶŽƚ'ƉƌŽƚĞŝŶ ?^ǌĂůĂŝĞƚĂů ? ? ? ? ? ? Z ?dŚŝƐĂŐĂŝŶ
suggests that for some GPCR dimers, ligand binding to one protomer alone is
ƐƵĨĨŝĐŝĞŶƚ ƚŽ ŝŶĚƵĐĞ ɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚ ǁŝƚŚ ĐŽŽƉĞƌĂƚŝǀĞ ĞĨĨĞĐƚƐ ǁŚŝĐŚ
are propagated through the protomer-protomer interface and reconciles with
responses for Snap Y1/Y1Y99A BiFC dimers. However here the authors
ƉŽƐƚƵůĂƚĞĂŶĂƐǇŵŵĞƚƌŝĐŵŽĚĞŽĨ ? P ?ɴ ?ĂƌƌĞƐƚŝŶ ?ƌĞĐƌƵŝƚŵĞŶƚƚŽƚŚĞƉƌŽƚŽŵĞƌ
unoccupied by ligand (ie. to the ligand binding deficient protomer) which can
ƐƵƉƉŽƌƚɴ ?ĂƌƌĞƐƚŝŶ ?ƌĞĐƌƵŝƚŵĞŶƚǀŝĂŝƚƐŝŶƚĂĐƚƚĞƌŵŝŶƵƐ ?
Although the lack of internalisation of the Y15A/Y1Y99A mutant BiFC dimer
does not support this conclusion, a 2:1 a stoichiometry may represent the
ŵŽĚĞ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ďŝŶĚŝŶŐ ƚŽ ^ŶĂƉ z ? ?z ?z ? ? ? ɴ ?Z ?ɴ ?ZE ? ? ? Žƌ
ɴ ?Z ?ɴ ?Zz ? ? ?ŵƵƚĂŶƚŝ&ĚŝŵĞƌƐ ?,ŽǁĞǀĞƌƚŚĞƌĞĂƌĞƚǁŽ ůŝŵŝƚĂƚŝŽŶƐƚŽ
279
this conclusion. Firstly, the quantification of BiFC dimer internalisation is only
ĂŶŝŶĚŝƌĞĐƚŵĞĂƐƵƌĞŽĨɴ ?ĂƌƌĞƐƚŝŶ ?ƌĞĐƌƵŝƚŵĞŶƚ ?dŚĞƌĞĨŽƌĞĨƵƚƵƌĞƐƚƵĚŝĞƐĐŽƵůĚ
combine BiFC with BRET to directly measure this association (See Chapter 7,
Final discussion). Secondly the use of BiFC artificially constrains receptors as
ĚŝŵĞƌƐ ?ƚŚĞƌĞĨŽƌĞŝƚĐĂŶŶŽƚďĞƵƐĞĚƚŽƌĞƐŽůǀĞƚŚĞƐƚŽŝĐŚŝŽŵĞƚƌǇŽĨɴ ?ĂƌƌĞƐƚŝŶ
binding to native receptors and whether this reconciles with a 1:1 essentially
monomeric internalisation or a 2:1 mode for a dimer as suggested from these
results. Nevertheless, as indicated in the next chapter, application of this
system to Y receptor heterodimers can reveal interactions between the
promoters which result in novel pharmacological responses.
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Chapter 6  The use of BiFC to constrain GPCRs as
heterodimers of precise composition in order to
investigate potential dimer specific modified
pharmacology
6.1 Introduction
The pharmacological possibilities presented by GPCR homodimerisation are
potentially expanded further by heterodimer formation. As
heterodimerisation involves the association of two structurally discrete GPCR
subtypes (whether closely or distantly related), often with differing ligand
selectivity and downstream signalling outcomes, the pharmacological
properties of heterodimerisation may be distinct from that seen for either
monomer or homodimer forms (Ayoub and Pfleger, 2010). This raises the
possibilities that heterodimers may represent novel pharmacological targets,
and that therapies selectively targeting them may show greater selectivity and
efficacy.
6.1.1 The evidence for the existence of GPCR heterodimerisation
As for the GPCR Class A homodimerisation, there are many strands of
evidence suggesting the formation of heterodimers. Here is a summary of
some key examples from heterologous cell lines and in native tissue samples.
6.1.1.1 Coimmunoprecipitation assays
As for GPCR homodimerisation, many of the initial indications of
heterodimerisation have come from biochemical techniques, such as
coimmunoprecipitation using differentially epitope tagged receptor subtypes
coexpressed in heterologous cell lines. For the Class C GPCR receptors, which
must form obligate dimers to function, coimmunoprecipitation revealed the
association of GABABR1 and GABABR2 receptor subtypes (Kaupmann et al.,
1998) as well as heterodimer pairings of bitter and sweet taste receptor
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subtypes (Kuhn et al., 2010). For Class A GPCRs, coimmunoprecipitation has
implied heterodimer formation of a variety of closely related receptor
subtypes. For example within the opioid receptor family,
ĐŽŝŵŵƵŶŽƉƌĞĐŝƉŝƚĂƚŝŽŶ ŽĨ ɷ ĂŶĚ ʃ  ?:ŽƌĚĂŶ ĂŶĚ Ğǀŝ ? ? ? ? ? Z ĂŶĚ ɷ ĂŶĚ A?
(George et al., 2000) subtypes has been documented. Coimmunoprecipitation
ŚĂƐĂůƐŽďĞĞŶŽďƐĞƌǀĞĚ ĨŽƌɴ ?ĂŶĚɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ ?>ĂǀŽŝĞĞƚĂů ? ?  ? ? ? ? ZĂƐ
well as the dopamine receptor subtypes D2 and D3 (Scarselli et al., 2001) and
D1 and D3 (Zeng et al., 2006). Coimmunoprecipitation has also been seen for
distantly related GPCR subtypes, such as the chemokine R5 (CCR5) and µ
opioid receptors (Suzuki et al., 2002), the adenosine A2A and dopamine D2
receptors (Hillion et al., 2002), and the adenosine A1 receptor with multiple
ƌĞĐĞƉƚŽƌƐ ŝŶĐůƵĚŝŶŐ ƚŚƌŽŵďŽǆĂŶĞ  ?Zɲ ƌĞĐĞƉƚŽƌƐ  ?DŝǌƵŶŽ Ğƚ Ăů ? ?  ? ? ? ? Z ?
dopamine D1 receptors (Gines et al., 2000), purinergic P2Y1 receptors
 ?zŽƐŚŝŽŬĂ Ğƚ Ăů ? ?  ? ? ? ? Z ĂŶĚ ƚŚĞ ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ ƐƵďƚǇƉĞƐ ɴ ? ĂŶĚ ɴ ?
(Chandrasekera et al., 2013).
The majority of coimmunoprecipitation studies investigating GPCR
heterodimerisation have been performed in overexpressing heterologous cell
lines, such as HEK293T, COS-7 or a mouse derived fibroblast cell line (Gines et
al., 2000). However coimmunoprecipitation from native tissue samples has
identified GABABR1/R2 (Kaupmann et al., 1998) and dopamine D1/D3
heterodimers (Zeng et al., 2006). Human heart tissue lysate also revealed
ĚŝƐƚŝŶĐƚƉŽƉƵůĂƚŝŽŶƐŽĨĂĚĞŶŽƐŝŶĞ ?ĐŽŶƐƚŝƚƵƚŝǀĞŚĞƚĞƌŽĚŝŵĞƌƐǁŝƚŚĞŝƚŚĞƌɴ ?
Žƌɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌƐ  ?ŚĂŶĚƌĂƐĞŬĞƌĂĞƚĂů ? ?  ? ? ? ? Z ?ĚĚŝƚŝŽŶĂůůǇŚŽŵŽŐĞŶĂƚĞƐ
isolated from rat striatum have implicated the association of mGluR5, D2 and
A2A receptors as potential trimer complexes (Cabello et al., 2009).
For the majority of observations, specific heterodimeric complexes were
identified from membrane isolations where tagged receptors were initially
coexpressed, and not when two cell preparations expressing different
receptor subtypes were mixed prior to solubilisation. This indicates that
coimmunoprecipitation of complexes was not a consequence of the assay
protocol used. However coimmunoprecipitation still requires that receptor
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complexes are solubilised from the membrane during isolation, and this
process might lead to artificial aggregration of the receptor hydrophobic
membrane spanning domains. Thus such observations need to be supported
by additional techniques, particularly those which provide evidence for
heterodimerisation in living cells and in vivo.
6.1.1.2 Evidence from fluorescent based approaches
Observations using fluorescence based techniques, such as FRET and BRET,
have implied the association of coexpressed fluorescently tagged receptor
subtypes in living cells. These associations may be between closely or distantly
related subtypes and have been interpreted as evidence of heterodimer
formation.
BRET and FRET studies have indicated interactions between the closely
ƌĞůĂƚĞĚ 'WZ ůĂƐƐ  ƐƵďƚǇƉĞƐ z ? ĂŶĚ z ?  ?'ĞŚůĞƌƚ Ğƚ Ăů ? ?  ? ? ? ? Z ? ɴ ? ĂŶĚ ɴ ? ?
adrenoceptors (Mercier et al., 2002), melanatonin MT1 and MT2 (Ayoub et al.,
2002), vasopressin V1a and V2 (Terrillon et al., 2003), cannabinoid CB1 and
CB2 subtypes (Callen et al., 2012), the dopamine subtypes D1 and D3
(Marcellino et al., 2008), D2 and D3 (Pou et al., 2012), and D2 and D5 (So et
al., 2009) and chemokine CXCR1 and CXCR2 receptors (Wilson et al., 2005).
Both techniques have also implied heterodimerisation of distantly related
ƐƵďƚǇƉĞƐƐƵĐŚĂƐƚŚĞɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌĂŶĚɷŽƉŝŽŝĚ ?ƚŚĞɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌĂŶĚ
ʃ ŽƉŝŽŝĚ  ?tŝůƐŽŶ Ğƚ Ăů ? ?  ? ? ? ? Z ? ƚŚĞ ɲ1A adrenoceptor and µ opioid receptors
 ?sŝůĂƌĚĂŐĂ Ğƚ Ăů ? ?  ? ? ? ? Z ĂŶĚ ɲ ? ĂĚƌĞŶŽĐĞƉƚŽƌ ĂŶĚ ĚŽƉĂŵŝŶĞ  ? ƌĞĐĞƉƚŽƌƐ
(Gonzalez et al., 2012). FRET has also been used to identify heterodimers of
CB1 and orexin OX1 receptors in intracellular endosomes of HEK293TR cells
(Ellis et al., 2006). This was interpreted as reflecting post endocytic trafficking
of heterodimeric receptors from the cell surface, due to the constitutive
internalisation observed for CB1 receptors. In addition these compartments
may be a route to traffic complexes that are formed in the ER to the cell
surface. Follow up TR-FRET studies using combined SNAP and CLIP N terminal
protomer labelling confirmed stable cell surface expression of these
heterodimers (Ward et al., 2011). Additionally TR-FRET using N terminal SNAP
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and CLIP tagged receptors has identified specific ghrelin (GHSR1a) and D2
receptor heterodimers colocalised at the cell surface of HEK293T cells (Kern et
al., 2012).
Heterodimers of adenosine A2A and D2L receptors have also been identified
using both BRET and FRET (Canals et al., 2003). Additionally the use of BiFC
identified heterodimers were localised at the cell membrane and within
endosomes in a neuronal cell model (Vidi et al., 2008a). This study was also
the first to use BiFC to monitor the ligand induced modulation of GPCR
oligomerisation, with long term ligand exposure influencing the balance of
A2A/D2L heterodimers, A2A or D2L homodimers. Multicolour BiFC has also
illustrated interactions of CB1 and D2L receptors in a neuronal cell model,
which were regulated by CB1 selective ligands (Przybyla and Watts, 2010).
Complexes of this heterodimer pairing have also been identified using FRET
and BRET techniques in HEK293T cells (Navarro et al., 2008) in keeping with
previous observations of CB1 and D2L receptor colocalisation in situ in rat
striatum (reviewed in (Blume et al., 2013)). The combined use of BiFC and
BRET has also suggested the occurrence of higher order hetero-trimers of CB1,
D2 and A2A receptors (Navarro et al., 2008) and mGluR5, D2 and A2A receptors
(Cabello et al., 2009) in HEK293T cells. However the use of BiFC has largely
been limited to the identification of the existence of GPCR dimers, as opposed
to investigating their functional relevance.
Many fluorescence based techniques are difficult to implement in native
tissues, as in contrast to heterologous cell lines it is difficult to control
receptor expression levels or easily introduce engineered fluorescently tagged
receptors (Ferre et al., 2014). To circumvent this, techniques utilising GPCR
specific antibodies have been developed. A proximity ligation assay has
implied close association of A2A and D2 receptors in rat brain slices (Trifilieff et
al., 2011) and CB1 and CB2 subtypes in the rat brain pineal gland and nucleus
accumbens (Callen et al., 2012). Here primary antibodies recognising either
protomer of a proposed heterodimer, are labelled with secondary antibodies
conjugated to complementary oligonucleotide sequences. These sequences
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are then ligated, amplified and visualised using a fluorescent probe.
Heterodimer specific monoclonal antibodies have also been generated which
selectively recognise an epitope spanning both protomers of a heterodimer
but shows no specific binding when one of the protomers is removed (Gupta
et al., 2010). However designing such a selective epitope is in practice
difficult, and is particularly dependent on the GPCR region against which the
epitope is designed.
A less complicated use of antibodies is to conjugate them to fluorescentRET
partners. This has been used to identify CB1 and AT1 receptor heteromers in
isolated rat hepatic stellate cells (Rozenfeld et al., 2011) and morphine
ŝŶĚƵĐĞĚĐŚĂŶŐĞƐŝŶĞǆƉƌĞƐƐŝŽŶŽĨA? ?ɷŽƉŝŽŝĚŚĞƚĞƌŽŵĞƌƐŝŶƌĂƚďƌĂŝŶƐĞĐƚŝŽŶƐ
(Gupta et al., 2010). It is worth noting that antibody based techniques rely on
high expression levels of receptors and their bivalent nature may
inadvertently promote receptor associations (Ward et al., 2011). However if
highly selective, they are a potentially important tool to identify association of
receptor subtypes in native tissue. TR-FRET using fluorescent ligands has also
identified heterodimers of ghrelin (GHSR1a) and dopamine D2 receptors in
mouse hypothalamic neurons (Kern et al., 2012). Antibody tagged dopamine
D2 protomers were identified using a secondary antibody conjugated to
fluorescent terbium cryptate, which acted as the donor fluorophore to excite
the fluorescently labelled agonist ghrelin (acceptor).
Fluorescence based techniques, although useful in identifying receptor-
receptor interactions, are dependent on the proximity and orientation of the
probes used. Therefore close receptor proximity can only imply, not confirm,
the formation of specific heterodimers and should be used in conjunction with
other functional methods. Additionally these techniques (or
coimmunoprecipitation) cannot distinguish the proportion of heterodimers
present at the cell surface compared to other receptor species (be that
monomers, homodimers or higher order oligomers).
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6.1.1.3 Altered receptor trafficking during synthesis and maturation
The level of receptor expression at the cell surface is largely determined by
the balance of intracellular trafficking mechanisms such as export from the
endoplasmic reticulum, endocytosis and degradation. GPCR dimerisation has
been implicated as a mechanism to facilitate trafficking of receptors through
the endoplasmic reticulum and Golgi apparatus following biosynthesis and
assist plasma membrane expression. Evidence from obligate dimers of the
Class C GPCR family, such as the GABAB receptor, has supported this assertion.
As discussed in Chapter 5, the GABABR2 subunit effectively masks the
intracellular retention signal on the GABABR1 subunit (summarised in (Kniazeff
et al., 2002)) so that only via dimerisation is the GABAB receptor able to be
expressed at the cell surface.
This functional complementation has also been observed for heterodimers of
Class A GPCRs, when these receptors were engineered to contain ER retention
motifs. The chemokine receptor subtypes CXCR1 and CXCR2 have been shown
previously to form constitutive heterodimers that are expressed at the cell
surface (Wilson et al., 2005). In addition when expressed independently, both
subtypes reach the cell surface correctly. The addition of an ER retention
ƐŝŐŶĂůĨƌŽŵƚŚĞɲ2C adrenoceptor to a HA tagged CXCR1 sequence resulted in a
receptor that is not trafficked to the plasma membrane and is retained
intracellularly. Coexpression of this mutant with a FLAG tagged CXCR2 subtype
resulted in a heterodimer with decreased cell surface expression
(approximately a 50% decrease in expression when compared to CXCR2
alone). Additionally co-expression of receptor subtypes showing high cell
surface expression with subtypes that are poorly expressed has been shown
to promote the translocation of the second protomer to the cell surface. For
ĞǆĂŵƉůĞ ĐŽĞǆƉƌĞƐƐŝŽŶ ŽĨ ƚŚĞ ɲ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ? ǁŚŝĐŚ ŝƐ ĂůŵŽƐƚ ĞǆĐůƵƐŝǀĞůǇ
ŝŶƚƌĂĐĞůůƵůĂƌ ůŽĐĂůŝƐĞĚ ?ǁŝƚŚĞŝƚŚĞƌ ƚŚĞɲ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ  ?,ĂŐƵĞĞƚĂů ? ?  ? ? ? ? Z
Žƌ ƚŚĞ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ  ?hďĞƌƚŝ Ğƚ Ăů ? ?  ? ? ? ? Z ǁĂƐ ƐŚŽ Ŷ ƚŽ ŝŶĐƌĞĂƐĞ ŝƚƐ ĐĞůů
ƐƵƌĨĂĐĞ ĞǆƉƌĞƐƐŝŽŶ ŝŶ ůƵŵŝŶŽŵĞƚĞƌ ĂƐƐĂǇƐ ? ƋƵĂůůǇ ?ƚŚĞ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ŝƐ
able to act as a molecular chaperone facilitating cell surface expression of an
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intracellular localised olfactory receptor (Hague et al., 2004), although this
study, and other examples of rescued expression, might be a consequence
of receptor over expression.
6.1.1.4 Altered ligand binding
Evidence for potential allosteric communication across a heterodimer
interface can be inferred by investigating ligand binding. If the affinity of a
ligand binding to a receptor coexpressed within a dimer is significantly
modified from that seen for the receptor expressed alone, this would suggest
that the presence of the second protomer is influencing binding.
This allosteric modulation can be ligand dependent, whereby binding of ligand
at protomer A influences binding at the orthosteric binding site of protomer B
(Kenakin and Miller, 2010).. One of the earliest observations of modified
ligand binding affinities at GPCR complexes came from coexpression studies of
A2A and D2 receptors (Ferre et al., 1991). Here coincubation with the A2A
selective agonist CGS21680 decreased the ability of dopamine to compete
with [3H] raclopride for the D2 orthosteric binding site. The addition of an A2A
receptor antagonist was able to restore the binding affinity of dopamine,
suggesting that the A2A site was allosterically modulating binding at the D2
orthosteric site. Comparable changes in affinity at selective protomers have
been observed for some heterodimers including A2A/dopamine D3 (Torvinen
ĞƚĂů ? ?  ? ? ? ? Z ? ? ? ?  ?DĂƌĐĞůůŝŶŽĞƚĂů ? ?  ? ? ? ? Z ?ƚŚĞɴ ?ZŽƌɴ ?ZƉƌŽƚŽŵĞƌŽĨ
ɴ ?Z ? ? Žƌ ɴ ? ? ? ŚĞƚĞƌŽĚŝŵĞƌƐ  ?ŚĂŶĚƌĂƐĞŬĞƌĂ Ğƚ Ăů ? ?  ?  ? ? Z ĂŶĚ ƌĞĐŝƉƌŽĐĂů
ĐŚĂŶŐĞƐĨŽƌĞŝƚŚĞƌƉƌŽƚŽŵĞƌŽĨɷ ?A?ŽƉŝŽŝĚŚĞƚĞƌŽĚŝŵĞƌƐ ?'ŽŵĞƐĞƚĂů ? ? ? ? ? ? Z ?
Additionally modification of ligand affinities was also seen for adenosine
A1/A2 receptor heterodimers expressed both in heterologous cell lines and
endogenous receptors expressed in native pre and post synaptic neurons
(Ciruela et al., 2006). However it is worth pointing out that ligand based
studies are often dependent on the subtype selectivity of the ligands being
sufficient to assume that only one protomer binding site is occupied. For
closely related receptor subtypes, such as the opioid family, such distinct
selectivity is not always possible.
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Alternatively allosterism at GPCR heterodimers, may be ligand independent
whereby the unoccupied protomer A  the receptor itself - may act as an
allosteric modulator of protomer B via a direct physical interaction (Kenakin
and Miller, 2010). For example GPR50, an orphan GPCR, constitutively
heterodimerises with melatonin MT1 receptors leading to abolition of high
affinity binding and G protein coupling of the MT1 protomer (Levoye et al.,
2006). This negative modulation is suggested to be due to a steric inhibition of
MT1 by the large C terminal tail of the GPR50 receptor.
Alterations in ligand binding affinities have not been observed for all
documented GPCR heterodimers. Notable exceptions include association of
ƚŚĞEWzz ?ĂŶĚz ?ƌĞĐĞƉƚŽƌƐƵďƚǇƉĞƐ ?'ĞŚůĞƌƚĞƚĂů ? ? ? ? ? ? Z ?ɴ ?ZĂŶĚɷŽƉŝŽŝĚ
ƌĞĐĞƉƚŽƌƐ ? ɴ ?Z ĂŶĚ ʃ ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌƐ  ?:ŽƌĚĂŶ Ğƚ Ăů ? ?  ? ? ? ? Z ? ƚŚĞ ɴ ?Z ĂŶĚ
ɴ ?ZƐ  ?ƌĞŝƚ Ğƚ Ăů ? ?  ? ? ? ? Z ĂŶĚ A? ŽƉŝŽŝĚ ĂŶĚ ŶĞƵƌŽŬŝŶŝŶ  ? ƌĞĐĞƉƚŽƌ ƌĞĐĞƉƚŽƌƐ
(Pfeiffer et al., 2003). Affinity (Kd) is the ratio of ligand association and
dissociation rate constants at equilibrium. Therefore alterations in ligand
dissociation rates may better reflect dynamic heterodimer allosterism (May et
al., 2007). Insights from the chemokine receptor family, has supported this
assertion by using infinite dilution to measure the dissociation kinetics of a
radioligand specific to one protomer of a CCR2/CCR5 (Springael et al., 2006) or
CCR2/CXCR4 heterodimer (Sohy et al., 2007), and then demonstrating the
effects of an unlabelled ligand binding the second protomer. In both cases
radioligand dissociation kinetics from the CCR2 protomer were found to be
affected by ligand binding to partner protomer, but this allosteric effect was
only seen when both receptors were expressed. Comparison with infinite
dilution conditions also implied strong cooperativity between protomer
binding sites of adenosine A3 dimers, with the effects of competing ligands
manifested as changes in ligand dissociation rates at the single cell level (May
et al., 2011). This cooperativity was decreased when one of the protomers
contained a mutation to prevent ligand binding, suggesting that allosterism
was a consequence of communication between protomer othosteric binding
sites.
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Effects of ligand binding on GPCR dimers can often be difficult to extract from
measures of cell population binding studies, as it is difficult to ascribe affects
directly to a dimeric population that may be both transient and (particularly
for heterodimers) a small proportion of the overall receptor species. For
example as discussed in Chapter 5, TIRF studies of M1 muscarinic receptors
suggested that the homodimeric state of these receptors only represent up to
30% of the total population at any time (Hern et al., 2010).
In addition to using ligands selective for one protomer of a heterodimer to
probe function, heterodimer selective ligands have been suggested. These
ligands have been hypothesised to have greater affinity for binding the
heterodimer form than respective monomer or homodimers. Examples of
these include 6'-guanidinonaltrindole (6GNTI), which has been shown to
induce intracellular Ca2+ ƚŽ Ă ŐƌĞĂƚĞƌ ĞǆƚĞŶƚ ǁŚĞŶ ƐƚŝŵƵůĂƚŝŶŐ ɷ ?A? ŽƉŝŽŝĚ
heterodimers than either species expressed alone, and also have selective
analgesic effects in the spinal cord (Waldhoer et al., 2005). A purportedly
highly selective dopamine D1-D2 ligand that activates novel Gq/11 signalling by
acting as a full agonist at D1 and a partial at D2 receptors (Rashid et al., 2007)
has also been proposed. However the selectivity of this ligand has been
questioned, as paradoxical signalling effects have been observed in vivo and it
has been shown to have high affinity for other unrelated GPCR subtypes
(Chun et al., 2013). Bivalent ligands, whereby two distinct pharmacophores
are linked by a spacer, have also been developed which are proposed to
bridge the dimer and either target both orthosteric sites or bind one and a
distinct allosteric site (Hiller et al., 2013). Examples include those that target
ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌ ƐƵďƚǇƉĞƐ  ?ɷ ?A? ?  ?ĂŶŝĞůƐ Ğƚ Ăů ? ?  ? ? ? ?ď Z ĂŶĚ ʃ ?ɷ ƌĞƐƉĞĐƚŝǀĞůǇ
(Daniels et al., 2005a)). However the main issue of these heterodimer
selective bivalent ligands in addition to selectivity is their relatively large size
limits therapeutic uses and restricts them to in vitro tools.
6.1.1.5 Altered internalisation
Heterodimerisaion has been implicated in altering the endocytosis of one or
both protomers within the complex. Evidence suggests that for some
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heterodimer combinations binding of a single ligand to one protomer is
sufficient to support the co-internalisation of the entire heterodimeric
ĐŽŵƉůĞǆ ? &Žƌ ĞǆĂŵƉůĞ ? ƚƌĞĂƚŵĞŶƚ ŽĨ ɴ ?Z ?ɷ ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌ ŚĞƚĞƌŽĚŝŵĞƌƐ
ǁŝƚŚ ƚŚĞɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ĂŐŽŶŝƐƚ ŝƐŽƉƌĞŶĂůŝŶĞ ? ƌĞƐƵůƚĞĚ ŝŶ ŽĐĐƵƉĂŶĐǇ ŽĨ ƚŚĞ
ɴ ?Z ŽƌƚŚŽƐƚĞƌŝĐ ďŝŶĚŝŶŐ ƐŝƚĞ ĂŶĚ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŽĨ ďŽƚŚ ƌĞĐĞƉƚŽƌ
populations. Reciprocal responses were also observed following stimulation
ǁŝƚŚ ƚŚĞ ɷ ŽƉŝŽŝĚ ĂŐŽŶŝƐƚ ĞƚŽƌƉŚŝŶĞ  ?:ŽƌĚĂŶ Ğƚ Ăů ? ?  ? ? ? ? Z ? Ɛ ŝƐŽƉƌĞŶĂůŝŶĞ ŝƐ
structurally distinct from etorphine, this suggests that either ligand is
activating it cognate orthosteric site selectively.
^ŝŵŝůĂƌĞĨĨĞĐƚƐŚĂǀĞďĞĞŶƐĞĞŶǁŝƚŚĐŽĞǆƉƌĞƐƐŝŽŶŽĨɷŽƉŝŽŝĚĂŶĚŶĞƵƌŽŬŝŶŝŶ
NK1 ƌĞĐĞƉƚŽƌƐ ?ŝŶƌĞƐƉŽŶƐĞƚŽƐƚŝŵƵůĂƚŝŽŶǁŝƚŚƚŚĞɷƐĞůĞĐƚŝǀĞĂŐŽŶŝƐƚD'K
or the NK1 agonist substance P (Pfeiffer et al., 2003). Cointernalisation has
also been observed for orexin (OX1) and CB1 heterodimers, whereby
stimulation with orexin A was able to stimulate the internalisation of the CB1
receptor population even though it has no direct affinity for this receptor
(Ward et al., 2011). Interestingly this effect was only seen when these
receptors were coexpressed and orexin A was more potent at inducing the
internalisation of the CB1 population than the total OX1 receptor population
(which is presumed to be a mixture of monomers, homodimers and
oligomers). These data are consistent with the previous observation in this
thesis, that ligand occupancy at one protomer within a defined dimer is able
to drive agonist induced endocytosis of the dimeric complex (Snap Y1/Y1Y99A
BiFC dimer; Chapter 5, Figure 5.13).
Detrimental effects upon internalisation as a consequence of
heterodimerisation have also been observed. For example rapid
internalisation in response to agonist stimulation has been observed for the
ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ƐƵďƚǇƉĞ  ? ?ǀŽŶ ĂƐƚƌŽǁ ĂŶĚ <ŽďŝůŬĂ ? ?  ? ? Z  ? ƐĞĞ ŚĂƉƚĞƌ  ? ?
&ŝŐƵƌĞ  ? ? ? ? Z ǁŚĞŶ ĞǆƉƌĞƐƐĞĚ ŝŶĚĞƉĞŶĚĞŶƚůǇ ? ŽŶǀĞƌƐĞůǇ ďŽƚŚ ƚŚĞ ɴ ? ĂŶĚ ɴ ?
adrenoceptor subtypes both internalise to a much lesser extent. However
ĐŽĞǆƉƌĞƐƐŝŽŶŽĨƚŚĞɴ ?ƐƵďƚǇƉĞǁŝƚŚĞŝƚŚĞƌƚŚĞɴ ? ?>ĂǀŽŝĞĞƚĂů ? ? ? ? ? ? ZŽƌƚŚĞ
ɴ ? ĂĚƌĞŶŽĐĞƉƚŽƌ ƐƵďƚǇƉĞƐ  ?ƌĞŝƚ Ğƚ Ăů ? ?  ? ? ? ? Z ƌĞƐƵůƚĞĚ ŝŶ ŚĞƚĞƌŽĚŝŵĞƌƐ ƚŚĂƚ
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were unable to undergo agonist promoted endocytosis. A similar effect has
ďĞĞŶŽďƐĞƌǀĞĚǁŚĞŶƚŚĞɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌǁĂƐĐŽĞǆƉƌĞƐƐĞĚǁŝƚŚƚŚĞĚŝƐƚĂŶƚůǇ
ƌĞůĂƚĞĚ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ƌĞƐŝƐƚĂŶƚ ʃ ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌ ? EŽ ŚĞƚĞƌŽĚŝŵĞƌ
internalisation was observed following stimulation with either subtype
ƐĞůĞĐƚŝǀĞůŝŐĂŶĚƐƵŐŐĞƐƚŝŶŐƚŚĞɴ ?ZƐƵďƚǇƉĞŚĂƐĂĚŽƉƚĞĚƚŚĞŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ
ƉƌŽĨŝůĞŽĨƚŚĞʃƐƵďƚǇƉĞ  ?:ŽƌĚĂŶĞƚĂů ? ?  ? ? ? ? Z ?dŚĞƐĞĚĂƚĂƐƵŐŐĞƐƚĞĚ ƚŚĂƚŽŶĞ
ƉƌŽƚŽŵĞƌŽĨĂŚĞƚĞƌŽĚŝŵĞƌ ?ŝŶƚŚŝƐĐĂƐĞɴ ? ?ɴ ?ŽƌʃŽƉŝŽŝĚƐƵďƚǇƉĞƐ ZǁĂƐĂďůĞ
to act as a dominant negative modulator of agonist induced internalisation of
the other.
Interestingly ligand induced internalisation has also been used as a measure
of the dynamic equilibrium between heterodimer and homodimer species
within the same cells. Treatment of A2A/D2 heterodimers with the D2 receptor
agonist quinpirole resulted in cointernalisation of the heterodimer complex
(Hillion et al., 2002). However long term stimulation induced a change in the
proportion of A2A/D2 heterodimers relative to A2A/ A2A homodimers (Vidi et
al., 2008a). These observations do raise the question of whether
cointernalisation is directly attributable to a physical association between
coexpressed receptors. An alternative method could be that activation of one
protomer may lead to intracellular signalling pathways that induce an
independent internalisation of the second protomer driven by PKA or PKC
mediated phosphorylation.
6.1.1.6 Altered G protein coupling and signalling
Phenotypic changes in downstream signalling outcomes have been observed
for some heterodimer pairings. These changes may reflect modifications in
effector protein coupling to dimers, in conjunction with the intrinsic efficacy
of ligands for stabilising a particular receptor conformation which favours
coupling to distinct signalling pathways (Ferre et al., 2014). This phenomenon,
termed functional selectivity, has been observed for some heterodimer
ƉĂŝƌŝŶŐƐǁŚĞƌĞďǇĐŚĂŶŐĞƐŝŶƚŚĞŶĂƚƵƌĞŽĨ'ƉƌŽƚĞŝŶŽƌɴ ?ĂƌƌĞƐƚŝŶĐŽƵƉůŝŶŐĐĂŶ
result in distinct physiological outcomes  often assuming an asymmetric
mode of coupling (see Chapter 5, section 5.1.1.3).
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For some GPCR heterodimers, the G protein class to which protomer A
preferentially couples is modified so that it adopts the GD subunit
preferentially bound by protomer B. For example coexpression of the
dopamine D1 receptor with histamine H3 receptors in neuroblastoma cells
resulted in a switch from GɲƐ to Gɲŝ driven MAPK signalling for the D2
protomer, while H3 agonists allosterically inhibited dopamine D1 mediated G
ƉƌŽƚĞŝŶĂŶĚɴ ?ĂƌƌĞƐƚŝŶ ?ŵĞĚŝĂƚĞĚƐŝŐŶĂůůŝŶŐ ?DŽƌĞŶŽĞƚĂů ? ? ? ? ? ? Z ?ƉƌŽƉŽƐĞĚ
physiological consequence of this modified signalling is that this histamine
dimer is able to inhibit dopamine D1 receptor mediated cell death. This
ƐǁŝƚĐŚŝŶ'ƉƌŽƚĞŝŶĐŽƵƉůŝŶŐǁĂƐĂůƐŽŽďƐĞƌǀĞĚĨŽƌɴ ?Z ?ɴ ?ZŚĞƚĞƌŽĚŝŵĞƌƐ ?
whereby Gɲŝ coupling, typically observed in addition to GDs coupling for both
individual subtypes, was not seen for the heterodimer but GDs recruitment
was preserved (Breit et al., 2004). Similar effects have also been seen for
ĂŶŽƚŚĞƌĂĚƌĞŶĞƌŐŝĐŚĞƚĞƌŽĚŝŵĞƌ ?ƚŚĞɴ ?Z ?ɴ ?Z ?ďƵƚŚĞƌĞ'ƉƌŽƚĞŝŶĐŽƵƉůŝŶŐ
ƌĞĨůĞĐƚĞĚĂɴ ?ZůŝŬĞƉŚĞŶŽƚǇƉĞǁŝƚŚZ<ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶƵƐĞĚĂƐĂƌĞĂĚŽƵƚ
(Lavoie et al., 2002). This suggests that G protein coupling to a receptor
ƉƌŽƚŽŵĞƌ ?ĞŐ ?ƚŚĞɴ ?Z ZĐĂŶďĞĚŝƐƚĂŶƚůǇŵŽĚŝĨŝĞĚĚĞƉĞŶĚŝŶŐŽŶƚŚĞƐĞĐŽŶĚ
protomer coexpressed, which further increases the potential for novel
pharmacology arising from heterodimerisation.
Heterodimerisation has also been suggested to switch G protein coupling to a
class that is completely atypical for either protomer. For example dopamine
D1 and D2 receptors, typically couple to GɲƐ and Gɲŝ classes respectively.
However the D1/D2 heterodimer shows novel coupling to the GɲƋ class,
facilitating the elevation of intracellular calcium levels in transfected cells and
rat brain striatum (Rashid et al., 2007). However this change in G protein
coupling may not reflect physical heterodimer formation, but has been
suggested to instead be a consequence of the expression level of GɲƋ or
downstream signalling crosstalk (Chun et al., 2013).
Signalling switching has also been indicated for CB1/AT1 (Rozenfeld et al.,
 ? ? ? ? ZĂŶĚɷ ?A?ŽƉŝŽŝĚŚĞƚĞƌŽĚŝŵĞƌƐ ?ZŽǌĞŶĨĞůĚĂŶĚĞǀŝ ? ? ? ? ? Z ?ŶĂĚĚŝƚŝŽŶĂů
ŵŽĚŝĨŝĐĂƚŝŽŶ ŽĨ ɷ ĂŶĚ A? ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌ ŚĞƚĞƌŽĚŝŵĞƌŝƐĂƚŝŽŶ ƚŚĂƚ ŚĂƐ
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unwanted physiological effects is a switch in the nature of effector protein
coupling. When expressed alone µ opioid receptors stimulated with morphine
results in G protein dependent signalling and ultimately analgesia (Raehal et
Ăů ? ?  ? ? ? ? Z ? ŽĞǆƉƌĞƐƐŝŽŶ ŽĨ A? ĂŶĚ ɷ ŽƉŝŽŝĚ ƌĞĐĞƉƚŽƌƐ ŚŽǁĞǀĞƌ ƌĞƐƵůƚĞĚ ŝŶ
ŵŽƌƉŚŝŶĞ ĚŝƌĞĐƚĞĚ ɴ ?ĂƌƌĞƐƚŝŶ ? ĚĞƉĞŶĚĞŶƚ ƐŝŐŶĂůůŝŶŐĂŶĚ ůĞĂĚŝŶŐ ƚŽ ŐƌĞĂƚĞƌ
tolerance of chronic morphine induced analgesia (Rozenfeld and Devi, 2010).
dŚŝƐ ŽƵƚĐŽŵĞ ǁĂƐ ƐƉĞĐŝĨŝĐ ƚŽ ƚŚĞ ƉƌĞƐĞŶĐĞ ŽĨ ƚŚĞ ɷ ŽƉŝŽŝĚ ƐƵďƚǇƉĞ ĂƐ
ƚƌĞĂƚŵĞŶƚǁŝƚŚĂɷƐĞůĞĐƚŝǀĞĂŶƚĂŐŽŶŝƐƚƌĞƐƚŽƌĞĚ'ƉƌŽƚĞŝŶĚŝƌĞĐƚĞĚƐŝŐŶĂůůŝŶŐ
and morphine induced analgesia. The intrinsic affinity of the ligand used can
also allosterically influence the direction of signalling bias. The angiotensin AT1
ƌĞĐĞƉƚŽƌ ĂŐŽŶŝƐƚ  ?^Ăƌ ? ?/ůĞ ? ?/ůĞ ? ? ĂŶŐŝŽƚĞŶƐŝŶ // ? ƐŚŽǁƐ ɴ ?ĂƌƌĞƐƚŝŶ ? ƐŝŐŶĂůůŝŶŐ
bias at AT1 receptors expressed alone (Violin et al., 2010). By binding to the
AT1 receptor orthosteric ligand binding site of AT1/bradykinin B2
heterodimers, this agonist showed lateral allosteric modulation of signalling at
the B2 subtype by inhibiting Gɲŝ ?Ž ƐŝŐŶĂůůŝŶŐ ĂŶĚ ƉƌŽŵŽƚŝŶŐ ɴ ?ĂƌƌĞƐƚŝŶ ?
recruitment and heterodimer cointernalisation (Wilson et al., 2013). However
this heterodimer pairing has been difficult to replicate by other groups in both
the same and different cell systems (Hansen et al., 2009).
For some heterodimer pairings, allosteric modulation of protomer A by
protomer B results is able to potentiate signalling responses originating at
protomer B. An example of this which may have physiological implications in
the control of feeding responses is the ghrelin GHSR1a and dopamine D2
receptor heterodimer (Kern et al., 2012) implicated in the promotion of
anorexigenic effects. Stimulation of this heterodimer with the dopamine or
another D2 receptor agonist cabergoline, led to a PLC mediated increase in
ŝŶƚƌĂĐĞůůƵůĂƌ ĐĂůĐŝƵŵ ŵŽďŝůŝƐĂƚŝŽŶ ǀŝĂ 'ɴɶ ĂĐƚŝǀĂƚŝŽŶ ? dŚŝƐ ĞĨĨĞĐƚ ǁĂƐ ƐĞĞŶ ŝŶ
the absence of ghrelin costimulation or the presence of a neutral GHSR1a
antagonist, suggesting that it is the GHSR1a subtype itself that is allosterically
modulating binding to the D2 subtype. However a caveat to this is that the
ghrelin receptor has a high degree of constitutive activity in the absence of
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stimulation, which may complicate interpretations of dimer specific
pharmacology.
The orexin 1 (OX1) / CB1 heterodimer has also been suggested to mediate the
stimulation of food intake. The presence of the CB1 subtype increased the
potency of the agonist orexin A at the OX1 receptor in respect to
internalisation (10 fold increase; (Ward et al., 2011) and MAPK signalling (100
fold; (Hilairet et al., 2003)). This allosteric potentiation of OX1 signalling was
specifically blocked by the CB1 selective antagonist rimonabant, a known
inhibitor of food intake, suggesting the OX1 / CB1 heterodimer may be a valid
target for anti obesity therapies.
Dual antagonism has also been observed for many GPCR Class A
heterodimers. This is where antagonists targeting protomer A of the dimer
can inhibit signalling originating from agonist binding to the unrelated
protomer B and vice versa. This effect has been observed for heterodimers of
ɲ1B adrenoceptor and dopamine D4 receptors in respect to phosphorylation of
Akt (Gonzalez et al., 2012), and histidine H3 and dopamine D1 receptors
 ?&ĞƌƌĂĚĂ Ğƚ Ăů ? ?  ? ? ? ? Z ? dŚĞ ƉƌŽƉŽƐĞĚ ŚĞƚĞƌŽĚŝŵĞƌŝƐĂƚŝŽŶ ŽĨ ɴ ?Z ĂŶĚ d1
receptors in mouse cardiomyocytes and whole animals has suggested this
effect may have clinical relevance as here cross antagonism resulted in
inhibition of heart rate and cardiac contractility (Barki-Harrington et al., 2003).
This bidirectional antagonism has also been observed for CB1/CB2
heterodimers expressed in the neuroblastoma cell line SH-SY5Y (Callen et al.,
2012). Additionally when expressed individually both CB1 and CB2 subtypes
have been shown to increase the phosphorylation of Akt and stimulate
neurite growth. However coactivation of both protomers of the CB1/CB2
heterodimer inhibits this response, suggesting negative crosstalk is occurring
at this heterodimer in respect to Akt phosphorylation.
It is therefore likely that the functional consequences of GPCR
heterodimerisation vary greatly depending on the receptor pairing and
potentially the specific ligand stimulation (Ferre et al., 2014). The extent of
modification of responses due to allosteric interactions within the dimer can
294
therefore vary from subtle changes in the efficacy of existing responses to
profound changes in signal switching. There are also suggestions that
functional selectivity may give rise to novel pharmacological targets with
distinct physiological implications.
A caveat for many of these observations from whole population measures is
they do not define the molecular composition of discrete receptor complexes.
This makes it difficult to attribute functional responses directly to
heterodimeric populations. Altered pharmacology may therefore be due to
intracellular signalling crosstalk as opposed to the defined physical
interactions of receptors (see D1-D2 controversy described above). This has
been proposed to explain the GABAB receptor Gɲŝ potentiation of mGluR GɲƋ
signalling, whereby alteration in signalling is actually due to a temporal
integration of signalling at PLC rather than receptor association (Rives et al.,
 ? ? ? ? Z ?ĚĚŝƚŝŽŶĂůůǇŽǀĞƌĞǆƉƌĞƐƐŝŽŶŽĨŚŝƐƚĂŵŝŶĞŽƌɴ ?ZƌĞĐĞƉƚŽƌƐŝŶ,K< ?
cells attenuated the signalling of other Gs coupled receptors without physical
interactions occurring. Effects were ascribed instead to receptors
sequestering the pool of G protein away from other receptors present and
leading to changes in specificity (Prezeau et al., 2010).
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6.2 Aims of this chapter
Extensive evidence has therefore suggested that coexpression of two distinct
receptor subtypes can result in altered pharmacology. However it is often
difficult to identify responses directly attributable to heterodimerisation as
opposed to a consequence of signalling crosstalk arising from the co-
expressed, but physically independent receptors. Here HEK293T cells
coexpressing the NPY Y1 receptor with the related subtypes Y5 (Y1/Y5) or Y4
 ?z ? ?z ? Z Žƌ ƚŚĞ ƵŶƌĞůĂƚĞĚ ƌĞĐĞƉƚŽƌ ɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ  ?z ? ?ɴ ?Z Z ? ǁĞƌĞ ƵƐĞĚ ƚŽ
investigate potential novel pharmacology attributable to receptor
heterodimerisation. As highlighted in chapter 4, BiFC was used to irreversibly
constrain these receptor pairings as dimers of precise composition allowing a
readout of pharmacology for a molecular heterdimer. The combined use of
SNAPsurface 647 labelling of the Y1 receptor protomer only, allowed BiFC
heterodimer responses to be simultaneously compared to responses of the
total Y1 receptor population in the same cells. Quantification of the agonist
induced internalisation of both the Snap labelled Y1 and BiFC dimer
populations were used as a readout of function.
As both protomers of the heterodimer have discrete orthosteric ligand
binding sites, the use of subtype selective ligands facilitated the targeted
activation of either protomer within the dimer. This allowed potential
allosteric interactions between the two heterodimer orthosteric binding sites
in response to agonist or antagonist stimulation to be investigated.
Additionally, standard competition radioligand binding and inhibition of cAMP
accumulation assays were used to investigate potential changes in subtype
selective ligand binding affinities or downstream signalling for the co-
expressed receptors at the level of cell populations. Overall these experiments
demonstrated that the Snap Y1/Y5 heterodimer, implicated in the regulation
of feeding responses but not other pairings investigated, is associated with
modified agonist and antagonist pharmacology.
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6.3 Results
6.3.1 Cell surface expression and ligand binding of co-expressed BiFC
fragment tagged Y1 receptor-containing heterodimers.
HEK293T cells stably expressing clonal Snap Y1-Yn receptor (protomer A, see
Chapter 5, Figure 5.1) were stably cotransfected with a second FLAG tagged
z ? Žƌ z ? ƌĞĐĞƉƚŽƌ ƐƵďƚǇƉĞ ? Žƌ ƚŚĞ ůĞƐƐ ĐůŽƐĞůǇ ƌĞůĂƚĞĚ ĐůĂƐƐ  ɴ ?Z Žƌ
dopamine D2 receptor (long variant), each fused at the C terminus to the
complementary Yc BiFC fragment (Receptor-Yc; protomer B). This generated
z ? ?z ? ?z ? ?z ? ?z ? ?ɴ ?ZŽƌz ? ? ?ĐĞůůůŝŶĞƐ ?
Prelabelling with SNAPsurface 647 (0.2µM) allowed the Snap Y1-Yn receptor
population to be identified, representing the total receptor population. BiFC
fragment tags allowed the simultaneous identification of discrete populations
ŽĨ^ŶĂƉz ? ?z ? ?z ? ?z ? ? z ? ?ɴ ?Z Žƌz ? ? ? ƌĞĐĞƉƚŽƌŚĞƚƌŽĚŝŵĞƌƐ ŝŶ ƚŚĞƐĂŵĞ
cells, via imaging of recomplemented YFP fluorescence as previously
described in Chapter 5. Automated confocal imaging initially confirmed the
expression and localisation of these BiFC heterodimers. Under control
conditions both the Snap labelled Y1 receptor population and the BiFC dimer
ƉŽƉƵůĂƚŝŽŶƐŽĨ z ? ?z ?  ?&ŝŐƵƌĞ  ? ? ? ? Z z ? ?z ?  ? Z ĂŶĚz  ?ɴ ?Z  ? Z ƌĞĐĞƉƚŽƌĐĞůů
lines, were predominantly localised to the plasma membrane, with areas of
colocalisation observed. A small degree of constitutive internalisation was also
observed. Treatment with the Y1 receptor selective agonist NPY (100nM;
30min at 37°C) showed that both the Snap Y1 receptor population and three
ŝ&ŚĞƚĞƌŽĚŝŵĞƌƉĂŝƌŝŶŐƐ ?z ? ?z ? ?z ? ?z ?ĂŶĚz ? ?ɴ ?Z ZǁĞƌĞĐĂƉĂďůĞŽĨƌĂƉŝĚůǇ
internalising in response to agonist stimulation, with extensive regions of
colocalisation observed. However Snap Y1/D2 BiFC dimer expression did not
share this distribution, with predominant intracellular BiFC fluorescence
observed for both control and NPY stimulated conditions (D), despite
continued plasma membrane labelling of Snap-tagged Y1-Yn receptors. This
suggested that these Y1/D2 dimers were not correctly trafficked to the cell
surface and had been retained within the cell post synthesis. Following this
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observation, the Y1/D2 BiFC dimer pairing was not investigated further.
Standard confocal microscopy of Snap Y1/Y5 and Snap Y1/Y4 BiFC dimers also
revealed similar receptor distribution and NPY stimulated internalisation
(Figure 6.2, A and B).
The functional properties of HEK293T cell lines expressing Snap Y1/Y5, Y1/Y4
ĂŶĚ z ? ?ɴ ?Z ŝ& ŚĞƚĞƌŽĚŝŵĞƌƐ ? ǁĞƌĞ ĨƵƌƚŚĞƌ ǀĂůŝĚĂƚĞĚ ǁŝƚŚ ĐŽŵƉĞƚŝƚŝŽŶ
binding experiments using the radiolabelled agonist [125I] PYY, capable of
binding Y1, Y4 or Y5 receptors with high affinity (Lundell et al., 1995, Gerald et
al., 1996). Membranes were freshly prepared from these cell lines as
described in Chapter 2, section 2.2.4. Snap Y1/Y5 (Figure 5.2, A), Y1/Y4 (B)
ĂŶĚ z ? ?ɴ ?Z  ? Z ĐĞůů ůŝŶĞƐ Ăůů ƐŚŽǁĞĚ ƐƉĞĐŝĨŝĐ  ?125I] PYY binding which was
inhibited by co-incubation with the unlabelled agonist PYY (Figure 6.3).
Observed affinities of PYY were comparable across all three cell lines
(estimated pIC50 values in Table 6.1, A-C) and to those observed for Snap Y1-
Yn receptors expressed alone or when coexpressed with Y1-Yc cDNA (Y1/Y1
BiFC dimer; see chapter 5, Table 5.1). For the Snap Y1/Y5 cell line, co-
incubation with the Y5 selective agonist cPP (1-17)(Ala31, Aib32) NPY (18-36)
(referred to in all legends as cPP-Aib-NPY), resulted in marginal displacement
of [125I] PYY specific binding (defined by 1 µM PYY; Table 6.1, A), even at
competing ligand concentrations in excess of 300nM (Figure 6.4, A). This was
surprising as [125I] PYY has high affinity for both the Y1 and Y5 receptor
binding sites. Y5 receptor antagonist CGP71683 also showed minor inhibition
of specific [125I] PYY binding. However the Y1 selective antagonist BIBO3304
was able to almost fully inhibit specific [125I] PYY binding at the Snap Y1/Y5 cell
line (Figure 6.4, B; Table 6.1, A). This indicated that Y1 receptor binding was
the predominant receptor component labelled in Y1/Y5 cell lines (but not
Y1/Y4 membranes, see Figure 6.11). Additionally [125I] PYY binding was
ƐĞŶƐŝƚŝǀĞ ƚŽ 'dWɶ^ ƚƌĞĂƚŵĞŶƚ ŝŶ ďŽƚŚ z ? ?z ? ĂŶĚ z ? ?z  ĐĞůů ůŝŶĞƐ ? ŝŶĚŝĐĂƚŝŶŐ
functional coupling of expressed receptors to Gi.
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Table 6.1A: Summary of ligand binding
Figure 6.3: [
125
I] PYY competition
binding experiments in HEK293T cell
lines stably co-expressing BiFC
heterodimer constructs.
Membranes were freshly prepared
from HEK293T cell lines stably
expressing Snap Y1/Y5 (A), Y1/Y4 (B)
Žƌ z ? ?ɴ ?Z  ? Z ŝ& ĚŝŵĞƌ ĐŽŶƐƚƌƵĐƚƐ
(see Chapter 2, section 2.2.4). These
were incubated with [125I] PYY (15pM)
and increasing concentrations of
unlabelled competing agonist PYY or
'dWɶ^ ĨŽƌ  ? ?ŵŝŶ Ăƚ  ? ? ? ? DĞŵďƌĂŶĞ
bound radioligand was separated
using filtration and quantified using a
gamma counter. Competition
displacement curves were generated
using GraphPad Prism, with pooled
data representing a minimum of 3
independent experiments. pIC50 and
other data were expressed as mean ±
s.e.m (Table 6.1, A-C; Hill slope range
0.74-0.96).
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Table 6.1A: Summary of ligand binding affinities for HEK293T cells coexpressing Snap Y1-Yn/Y5-Yc
PYY cPP Aib NPY* BIBO3304 CGP71683 'dWɶ^
pIC50 9.1 ± 0.1 / 8.3 ± 0.1 / 8.7 ± 0.1
%inhibition of TSB 100 11.5 ± 1.1 92.3 ± 0.4 24.0 ± 6.2 60.7 ± 3.3
Table 6.1B: Summary of ligand binding affinities for HEK293T cells coexpressing Snap Y1-Yn/Y4-Yc
PYY BIBO3304 PP 'dWɶ^
pIC50 9.2 ± 0.1 8.4 ± 0.1 9.6 ± 0.4 (High affinity site); fraction = 41.8% ± 0.2
7.8 ± .0.4 (low affinity site); fraction = 58.2% ± 1.2
8.3 ± 0.1
% inhibition of TSB 100 59.5 ± 2.2 80.8 ± 2.2 45.0 ± 4.1
dĂďůĞ ? ? ? P^ƵŵŵĂƌǇŽĨůŝŐĂŶĚďŝŶĚŝŶŐĂĨĨŝŶŝƚŝĞƐĨŽƌ ,< ? ? ?dĐĞůůƐĐŽĞǆƉƌĞƐƐŝŶŐ^ŶĂƉz ? ?zŶ ?ɴ ?Z ?zĐ
PYY BIBO3304 Propranolol Isoprenaline
pIC50 9.2 ± 0.1 8.4 ± 0.1 / /
% inhibition of TSB 100 97.6 ± 0.5 13.6 ± 12.7 3.7 ± 8.7
% inhibition of TSB refers to the displacement by 1µM competing ligand, as a % of the total specific binding (TSB) defined in the absence / presence of 1 µM
PYY.
/ = responses unable to determined
n = 2-4
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Figure 6.4: [
125
I] PYY binding experiments in membranes isolated from HEK293T cell
lines expressing Snap Y1/Y5 BiFC dimers, and Y1 or Y5 selective competing ligands
Membranes were freshly prepared from HEK293T cell lines stably coexpressing Snap
Y1-Yn and Y5-Yc BiFC dimer constructs. These were incubated with [125I] PYY (15pM)
and increasing concentrations of unlabelled PYY, or Y1 (BIBO3304) or Y5 selective
ligands (cPP Aib NPY, CGP71683) for 90min at 22°C. Membrane bound radioligand
was separated using filtration and quantified using a gamma counter. Competition
displacement curves were generated using GraphPad Prism, with pooled data
representing a minimum of 3 independent experiments. pIC50 data were expressed as
mean ± s.e.m (Table 6.1, A; Hill slope range 0.78-0.92). PYY curve replicated from
Figure 6.3.
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6.3.2 Y1 and Y5 receptors BiFC heterodimers show altered pharmacology in
respect to Y5 agonist-stimulated internalisation
Using the automated platereader analysis, the kinetics of Snap Y1/Y5 BiFC
dimer internalisation in response to NPY were first investigated in timecourse
experiments (100nM; 37°C, Figure 6.5). No significant difference was
observed in respect to the rate of NPY induced internalisation between the
Snap Y1-Yn receptor and Snap Y1/Y5 BiFC dimer populations (t1/2 values of 4.7
± 1.0 min and 8.2 ± 1.8 min respectively n=3; unpaired t test P = 0.46).
Therefore although 60 min agonist incubations were required for the Y5-GFP
cell line (Chapter 3, Figure ), a 30min timecourse was used for Snap Y1/Y5 cells
to maintain consistency with other BiFC dimer cell lines.
Whole population studies, such as competition binding, did not identify
pharmacology specifically attributable to the Y1/Y5 BiFC dimer population
(Figure 6.2). Therefore in order to tease out any effects on agonist
pharmacology attributable to heterodimerisation, simultaneous quantification
of the internalisation of both Snap labelled Y1 receptor and BiFC Y1/Y5 dimer
populations in Snap Y1/Y5 cells was performed, and compared to either
receptor expressed alone (Snap Y1-Yn or Y5-GFP, described earlier in chapters
5 and 3 respectively). Pooled concentration response curves normalised to
1µM NPY responses, showed that NPY was a full agonist at both the Snap Y1-
Yn receptor and Y1/Y5 BiFC dimer populations, with comparable agonist
potencies observed (Figure 6.6, Table 6.2, n=14). NPY was also a potent
stimulator of Y5-GFP receptor internalisation (Figure 6.6, B).
To investigate this further, agonists showing selectivity for the Y5 receptor
subtype over the Y1 subtype were used, namely the endogenous NPY related
peptide pancreatic polypeptide (PP) and the Y5 selective agonist cPP (1-
17)(Ala31, Aib32) NPY (18-36). As described in chapter 3, both agonists were
potent at inducing the internalisation of Y5-GFP when compared to NPY (see
Table 3.2, n = 4). However, given that previous data has indicated that agonist
occupancy of a single protomer binding site is sufficient for internalisation of
the BiFC dimer (Chapter 4), the most striking observation was that both PP
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and cPP (1-17)(Ala31, Aib32) NPY (18-36) agonist responses were significantly
altered, relative to NPY in inducing Snap Y1/Y5 BiFC dimer endocytosis. These
ligands in addition to a third Y5 selective ligand [D-Trp32]NPY were all partial
agonists compared to NPY, rather than full agonists, in stimulating Snap Y1/Y5
dimer internalisation (Figure 6.6; Table 6.2). Furthermore these agonists were
significantly less potent for example the EC50 for cPP (1-17)(Ala
31, Aib32) NPY
(18-36) was over 300 fold lower in stimulating Snap Y1/Y5 BiFC dimer
responses than for Y5-GFP (Table 6.2; P < 0.001, Students t test).
Figure 6.5: Kinetics of NPY induced internalisation of Snap Y1/Y5 BiFC heterodimers
Stably transfected HEK293T cells coexpressing Snap Y1/Y5, were prelabelled with
SNAPsurface 647 (0.2µM). Cells were then stimulated with vehicle (circles) or 100nM
NPY (squares) at set time intervals. H33342 labelling, image acquisition and
granularity analysis were performed as previously described to compare
internalisation of the Snap-Y1-Yn population (Snap 647) and Y1/Y5 BiFC dimer Pooled
data (mean ± s.e.m; n= 4) were normalised to NPY responses observed at 30 min and
fitted to a 1 site exponential association including a 2 min latency period.
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Figure 6.6: Quantification of the agonist induced internalisation of Y1 or Y5
receptors when expressed alone or constrained as heterodimers using BiFC
HEK293T cells stably expressing Snap Y1-Yn receptors alone (A), Y5-GFP or Snap
Y1/Y5 BiFC dimers (C) were prelabelled with SNAPsurface 647 (0.2µM), before
stimulation with a panel of ligands (30min at 37°C). H33342 labelling, image
acquisition and granularity analysis of images was performed as previously. All
responses were normalised to negative (basal) and positive (1µM NPY) plate controls.
Pooled data shown represented a minimum of 3 independent experiments and are
expressed as mean ± s.e.m. The Y5-GFP data (60min agonist incubation) are repeated
from Figure 3.9 for clarity and comparison.
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Table 6.2: Summary of potencies and efficacies of a panel of ligands for stimulating the internalisation of Snap Y1/Y5
Snap Y1 / Y5 Y5-GFP
Agonist Snap Y1 Y1/Y5 BiFC dimer
pEC50 % NPY response pEC50 m % NPY response pEC50 % NPY response
NPY 8.0 ± 0.1 100 7.8 ± 0.1 100 8.0 ± 0.1 100
PP 21.4 ± 11.4 / 44.5 ± 11.6 8.1 ± 0.2 87.8 ± 10.7
cPP Aib NPY / / 7.2 ± 0.2 + 50.6 ± 9.1 9.0 ± 0.1 94.6 ± 1.1
DTrp 32 NPY / / 6.4 ± 0.3 56.5 ± 9.0 / /
+ = potency of cPP Aib NPY pEC50 value at Snap Y1/Y5 BiFC was significantly different to that for Y5-GFP (p<0.001 ***).
All data were expressed as ± standard error of the mean. pEC50 values were obtained from pooled concentration response curves presented in Figure 6.6.
Rmax responses to each ligand were calculated as a percentage of 1µM NPY responses
n= 4-15
/ not able to be determined
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6.3.3 NPY-induced internalisation of the constrained Y1/Y5 BiFC dimer
population is not inhibited by the Y1 receptor selective antagonist BIBO3304
The pharmacology of subtype selective antagonists was next investigated for
the Snap Y1/Y5 cell line, initially using [3H]cAMP accumulation assays.
Stimulation with NPY inhibited forskolin-stimulated accumulation in a
concentration dependent manner (Figure 6.7, A) comparable to that observed
for Snap Y1 or Snap Y1/Y1 cell lines (Chapter 5, Figure 5.3). Surmountable
antagonism of NPY responses was observed in response to pretreatment with
the BIBO3304 (estimated pKb value 7.6 ± 0.4, from shifts in the presence of
30nM antagonist; n=3). The estimated pKb obtained from this was also
consistent with previous observations for Snap Y1-Yn receptors expressed
alone and when coexpressed with Y1-Yc. Preincubation with CGP71683 had
no effect on NPY responses in this assay (B). Therefore in whole population
second messenger assays, the Snap Y1-Yn/Y5-Yc cell line showed Y1 receptor
like pharmacology in respect to both BIBO3304 and CGP71683.
Figure 6.7: The effect of pretreatment with receptor subtype selective antagonists,
on NPY inhibition of forskolin-stimulated [
3
H] cAMP accumulation in the Snap
Y1/Y5 cell line.
HEK293T cells stably coexpressing Snap Y1-Yn/Y5-Yc, were loaded with [3H] adenine
(2hr; 37°C/5% CO2). Cells were then pretreated with vehicle or the Y1 selective
antagonist BIBO3304 (A) or the Y5 selective antagonist CGP71683 (B) (30min at
37°C/5 % CO2) prior to NPY and 30µM forskolin costimulation. All responses were
normalised to those obtained for forskolin (100%) and 100nM NPY (0%) stimulations
and are shown as mean ± s.e.m of 3 independent experiments.
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Simultaneous measurement of the internalisation of both Snap Y1 and Snap
Y1/Y5 BiFC dimer populations following BIBO3304 pretreatment was then
used to investigate potential allosteric modulation of Y1 antagonist
pharmacology by Y1 and Y5 receptor association. Following pre-treatment
with BIBO3304 (30nM or 300nM; 30min at 37°C) cells were stimulated with
NPY (30min at 37°C). Pooled concentration response curves normalised to
1µM NPY responses showed that BIBO3304 produced rightward parallel shifts
of NPY induced responses for the Snap-Y1-Yn population indicative of
surmountable antagonism (Figure 6.8, Snap 647), and expected based on the
known affinity of BIBO3304 for the Y1 receptor subtype (Wieland et al., 1998).
Estimated pKb values (30nM BIBO3304 8.2 ± 0.1, n=5; 300nM BIBO3304 7.8 ±
0.3, n=4) were similar to those observed for Snap Y1-Yn receptors expressed
alone, Snap Y1/Y1 homodimers (Chapter 5, Figure 5.9) and Y1-GFP (Chapter 3,
section 3.10). However BIBO3304 did not inhibit NPY induced internalisation
of the Snap Y1/Y5 BiFC dimer population (Figure 6.8, BiFC dimer) even using
concentrations 100x greater (300nM) than the documented pKb of BIBO3304
at the Y1 receptor. Notably in the presence of BIBO3304, NPY potency and
maximum responses remained largely unchanged (NPY pEC50 values 7.3 ± 0.1,
n=4-5). Given that in the presence of excess BIBO3304, NPY responses might
be expected to be driven exclusively via the Y5 binding site, this also contrasts
with the markedly reduced potency and partial agonism of Y5 selective
agonists previously observed at the Snap Y1/Y5 BiFC dimer.
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Figure 6.8: The effect of pretreatment with the Y1 selective antagonist BIBO3304 on
the agonist induced internalisation of Snap Y1/Y5 BiFC heterodimers
HEK293T cells stably expressing Snap Y1/Y5 BiFC dimers were pre labelled with
SNAPsurface 647 (0.2µM). Cells were then pretreated with BIBO3304 (30 or 300nM;
30min at 37°C), followed by stimulation with NPY (30min at 37°C). H33342 labelling,
image acquisition and quantification of receptor internalisation was performed as
previously described. NPY concentration response curves in the presence and
absence of BIBO3304 were fitted using GraphPad Prism with shared minimum (basal
responses), maximum (1µM NPY responses) and Hill slope (1.0) constraints. All data
were pooled from a minimum of 3 independent experiments, and expressed as mean
± s.e.m.
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Figure 6.9: The effect of pretreatment with the Y5 selective antagonist CGP71683
on NPY induced internalisation of Snap Y1/Y5 BiFC heterodimers
HEK293TR cells stably expressing Y5-GFP (A), and HEK293T cells stably expressing
Snap Y1 (B) or Snap Y1/Y5 BiFC dimers (C), were pretreated with the Y5 receptor
selective antagonist CGP71683 (30 or 300nM; 30min at 37°C). Cells were then
stimulated with NPY (30min at 37°C). H33342 labelling, image acquisition and
quantification of receptor internalisation was performed as previously described.
NPY concentration response curves in the presence and absence of CGP71683 were
fitted using GraphPad Prism with shared minimum (basal responses) and maximum
(1µM NPY responses) constraints with Hill slopes set to 1. All data were pooled from
a minimum of 3 independent experiments, and expressed as mean ± s.e.m. ***
(P<0.001, 1 way ANOVA responses compared to 1 µM NPY).
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6.3.4 Y5 receptor selective antagonists produce insurmountable inhibition of
Snap Y1/Y5 BiFC dimer internalisation, contrasting with the expected
competitive pharmacology observed for Y5 receptors expressed alone
The specific pharmacology of Snap Y1/Y5 BiFC heterodimers was next
investigated in respect to the Y5 selective non peptide antagonist CGP71683.
As previously indicated in population studies using [125I]PYY binding and cAMP
assays, this antagonist had limited effects in Snap Y1/Y5 cells, presumably
reflecting the predominant expression overall of Snap-Y1-Yn compared to Y5-
Yc receptors. Thus, in order to probe potential dimer specific pharmacology
that may be masked in whole population studies for CGP71683, quantification
of the NPY induced internalisation of both the Snap Y1 receptor and Y1/Y5
BiFC dimer populations following pretreatment was next assessed.. For
comparison, CGP71683 (30nM or 300nM) showed surmountable competitive
antagonism of NPY stimulated Y5-GFP internalisation (Figure 5.9; estimated
pKb 7.8-8.2 ± 0.1; n=4; also see Chapter 3, Figure 3.10).
At these concentrations, CGP71683 had no significant effect on NPY induced
endocytosis of Snap Y1 receptors expressed alone (B) or when coexpressed
with Y5-Yc (Snap 647, C) as expected based upon the selectivity of CGP71683
for the Y5 receptor subtype over the Y1 receptor (Criscione et al., 1998).
However for the Y1/Y5 BiFC dimer receptor population, the nature of
CGP71683 antagonism had changed to non-surmountable inhibition with
significantly reduced maximal NPY responses (1 µM in the presence of 30nM
CGP71683 37.9 ± 8.0%; *** P < 0.001 1 way ANOVA compared to 1 µM NPY
control; n=4) but potencies remained comparable with control curves (NPY
pEC507.7-8.1; n=4-7). Similar results were observed when the concentration of
CGP71683 was increased to 300nM (NPY Rmax of 44.1 ± 2.8 %; pEC50 7.6-7.9;
n=4). Thus increasing the concentration of CGP71683 pre-treatment from 30
to 300 nM did not further reduce maximal NPY responses at the Y1/Y5 BiFC
dimer, showing that this insurmountable antagonism was saturable. In order
to ensure that this alteration in the nature of CGP71683 antagonism was not
due to a steric effect of a particular class of antagonist binding, two
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structurally unrelated Y5 selective antagonists, L-182,504 (Kanatani et al.,
2000) and NPY5RA972 (Block et al., 2002) were also investigated. Both
antagonists were unable to affect NPY induced internalisation of the Snap Y1
receptor population in Snap Y1/Y5 expressing cells. However both compounds
showed insurmountable inhibition of Y1/Y5 BiFC dimer internalisation with a
significant reduction in maximal NPY responses observed (Figure 6.10 A, B).
Figure 6.10: The effect of pretreatment with structurally distinct Y5 receptor
selective antagonists on NPY induced internalisation of Snap Y1/Y5 BiFC
heterodimers
HEK293T cells stably expressing Snap Y1/Y5 BiFC dimers were pre labelled with
SNAPsurface 647 (0.2µM), followed by pretreatment with L182,504 or NPY5RA972
(30nM; 30min at 37°C). Cells were then stimulated with NPY (30min at 37°C). H33342
labelling, image acquisition and quantification of receptor internalisation was
performed. NPY concentration response curves in the presence and absence of
antagonist were fitted using GraphPad Prism with shared minimum (basal responses)
and Hill slopes of 1. All data were pooled from a minimum of 3 independent
experiments, and expressed as mean ± s.e.m
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6.3.5 Y1 and Y4 receptors as BiFC heterodimers exhibit agonist responses
consistent with their binding sites acting independently
The unlabelled Y4 receptor selective agonist PP was able to displace specific
[125I] PYY binding in a concentration dependent manner in membranes
prepared from the Y1/Y4 receptor cell line (Figure 6.11, B, Table 6.1, B).
However, unlike displacement seen for the Snap Y1 cell line (A), displacement
at Snap Y1/Y4 preferentially fit to a 2 site model representing high (estimated
pIC50 9.6 ± 0.4; 41.8% ± 0.2 fraction of fit; n=4) and low affinity (7.8 ± 0.3;
58.2% fraction) PP binding sites within the whole population. Interestingly the
estimated pIC50 value of the lower affinity site corresponded to the pIC50 value
obtained for PP competition at Snap Y1-Yn receptors expressed alone (1 site
fit; 7.9 ± 0.3, n=3). BIBO3304 was able to displace only the Y1 receptor bound
[125I] PYY at the Snap Y1/Y4 cell line (C). This degree of displacement (Table
6.1, B) was consistent with the fraction of low affinity binding observed for
Snap Y1/Y4 in respect to PP induced displacement. This suggested that under
the conditions used, specific [125I] PYY binding to Snap Y1/Y4 membranes
represented relatively even labelling of the Y1 and Y4 receptor populations.
Figure 6.11: Competition binding experiments using [
125
I] PYY in membranes
isolated from HEK293T cells stably expressing Snap Y1-Yn alone or Snap Y1/Y4
Membranes freshly prepared from HEK293T cell lines stably expressing Snap
Y1-Yn alone (A) or Snap Y1-Yn/Y4-Yc (B and C) were incubated with [125I] PYY
(15pM) and increasing concentrations of unlabelled competing PP or
BIBO3304 for 90min at 22°C. Competition displacement curves were
generated using GraphPad Prism, with responses in the Snap Y1/Y4 cell line
for PP preferentially fitted to a 2 site binding model and Snap Y1 and Snap
Y1/Y4 BIBO3304 responses fitted to a 1 site model (Hill slopes 0.92-0.97).
Pooled data are presented representing a minimum of 3 independent
experiments with data expressed as mean ± s.e.m.
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Automated confocal imaging revealed Y1/Y4 BiFC dimers internalised in
response to either NPY or PP stimulation (Figure 6.12). However the Snap Y1-
Yn population within the same cells only did so in response to NPY.
Quantification of internalisation of the BIFC dimer population revealed that PP
responses were slightly reduced in respect to the NPY maximum (Figure 6.13,
C BiFC dimer; Table 6.3). Limited PP responses, at high concentration, were
observed for the Snap Y1 population measured at the same time in the Y1/Y4
cell line (Snap 647; 21.3% ± 5.3 of 1µM NPY responses) and Y1-GFP (A). These
responses were also similar to those obtained for the Snap Y1-Yn receptor
populations of Y1/Y1 (Chapter 5, Table 5.2) and Y1/Y5 BiFC dimers (Figure
6.6). The potency of PP responses at the BiFC population of Y1/Y4
heterodimers was significantly reduced (Table 6.3) compared to that seen for
inducible Y4-GFP receptor endocytosis, in which internalisation was observed
in response to PP (Figure 6.13, B; Table 6.3) but only with high concentrations
of NPY.
Figure 6.12: IX Ultr
HEK293T cells
HEK293T cells stab
647 (0.2µM) befo
37°C). Representat
taken using an IX Ul
regions. Extensive
populations are sh
315
a confocal images of Snap Y1/Y4 BiFC dimers
ly coexpressing Snap Y1/Y4 were prelabelled
re stimulation with vehicle, 100nM PP or 100
ive images from a minimum of 4 independent
tra confocal platereader and are shown as cro
areas of colocalisation between Snap Y1 recep
own in yellow (overlay panel).
stably expressed in
with SNAPsurface
nM NPY (30min at
experiments, were
pped 300x300 pixel
tor and BiFC dimer
316
Figure 6.13: Quantification of the agonist induced internalisation of Y1 or Y4
receptors when expressed alone or constrained as dimers using BiFC
HEK293T cells stably expressing Snap Y1-Yn (A), Y4-GFP (B) or Snap Y1/Y4 BiFC dimers
(C) were prelabelled with SNAPsurface 647 (0.2µM), before stimulation with NPY or
PP (30 min at 37°C). H33342 labelling, image acquisition and receptor internalisation
was determined following granularity analysis of images acquired using an
automated confocal platereader. All responses were normalised to negative (basal)
and positive (1µM NPY for Snap Y1 and Snap Y1/Y4 BiFC dimers; 100nM PP for Y4-
GFP) plate controls. Pooled data shown represented a minimum of 3 independent
experiments and are expressed as mean ± s.e.m. Data for Y4-GFP are repeated from
Figure 3.9 for comparison.
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Table 6.3: Summary of potencies and efficacies of a panel of ligands for stimulating the internalisation of Snap Y1/Y4
Snap Y1 / Y4 Y4-GFP
Agonist Snap Y1 Y1/Y4 BiFC dimer
pEC50 % NPY response pEC50 % NPY response pEC50 % NPY response
NPY 7.7 ± 0.1 100 7.8 ± 0.1 100 / 61.4 ± 6.9
PP / 21.3 ± 5.3 7.5 ± 0.2+ 75.9 ± 4.4 9.1 ± 0.2 100
+ = potency of PP pEC50 value at Snap Y1/Y4 BiFC was significantly different to that for Y4-GFP (p<0.001 ***).
All data were expressed as ± standard error of the mean. pEC50 values were obtained from pooled concentration response curves presented in Figure 6.13.
Rmax responses to each ligand were calculated as a percentage of 1µM NPY responses for Snap Y1/Y4 cell lines or 100nM PP for Y4-GFP
n= 4
/ not able to be determined
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6.3.6 Constrained NPY Y1/Y4 BiFC heterodimers show Y1 selective
antagonist pharmacology also consistent with the Y1 and Y4 orthosteric
binding sites acting independently.
In order to investigate whether constrained NPY receptor heterodimers
exhibited novel antagonist pharmacology, Snap Y1/Y4 expressing cells were
pre-treated with BIBO3304 (30nM; 30min at 37°C) followed by incubation
with NPY or PP (30min at 37°C). Pooled concentration response curves
quantifying receptor internalisation in Snap Y1/Y4 cells, (Figure 6.14, A),
showed that antagonist treatment produced a 10 fold rightward parallel shift
of NPY concentration response curves for both the Snap Y1 receptor-Yn and
Snap Y1/Y4 BiFC dimer populations. This was indicative of competitive
reversible antagonism (estimated pKb of BiFC dimer 8.5 ± 0.2; Snap Y1
population 8.4 ± 0.2, n=4) and was similar to results obtained for the inducible
GFP tagged Y1 receptor cell line (estimated pKb 8.6 ± 0.2, n=4), and the
documented affinity of BIBO3304 for the Y1 receptor (Kilpatrick et al., 2010).
However pre-treatment with BIBO3304 had no effect on PP induced
internalisation of the Snap Y1 receptor or Snap Y1/Y4 BiFC dimer populations
(B). The lack of BIBO3304 effect on PP responses observed in inducible Y4-GFP
receptors was consistent with a BIBO3304 Ki > 1µM for the Y4 receptor
subtype that has been previously reported (Wieland et al., 1998).
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Figure 6.14: The effect of pretreatment with
the antagonist BIBO3304 on the agonist
induced internalisation of Y1 and Y4 receptor
subtypes expressed alone or when
constrained as a heterodimer using BiFC
GFP tagged Y1 or Y4 receptor and Snap Y1/Y4
BiFC dimer cell lines were pretreated with the
Y1 selective antagonist BIBO3304 (30nM;
30min at 37°C) prior to stimulation with either
NPY (Snap Y1/Y4; Y1-GFP (A)) or PP (Snap
Y1/Y4; Y4-GFP (B)). H33342 labelling, image
acquisition and quantification of receptor
internalisation was performed as previously
described. NPY concentration response curves
in the presence and absence of BIBO3304 were
fitted using GraphPad Prism with shared Hill
slopes. Responses to NPY were normalised to
minimum (basal responses) and maximum
(1µM NPY responses), whilst responses to PP
were expressed as percentage fold over basal
(as PP had no effect on the Snap-Y1-Yn
populations). All data were pooled from a
minimum of 3 independent experiments, and
expressed as mean ± s.e.m.
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 ? ? ? ? ?dŚĞƉŚĂƌŵĂĐŽůŽŐǇŽĨEWzz ? ?ɴ ?Zŝ&ŚĞƚĞƌŽĚŝŵĞƌƐǁĂƐĐŽŶƐŝƐƚĞŶƚ
with independent orthosteric binding sites.
,< ? ? ?d ĐĞůůƐ ƐƚĂďůǇ ĐŽĞǆƉƌĞƐƐŝŶŐ ^ŶĂƉ z ? ?zŶ ĂŶĚ ɴ ?Z ?zĐ ƌĞĐĞƉƚŽƌ
constructs were used to investigate whether modified pharmacology was
observed when closely related GPCR subtypes were constrained as BiFC
ĚŝŵĞƌƐ ?  dŚĞ ƐƵďƐƚĂŶƚŝĂůůǇ ĚŝĨĨĞƌĞŶƚ ƐƚƌƵĐƚƵƌĞƐ ŽĨz ? ƉĞƉƚŝĚĞ ĂŶĚ ɴ ?Z
monoamine ligands meant that there was high confidence in the selectivity of
either ligand for its cognate orthosteric site.
In competition binding experiments using membranes freshly prepared from
these cells, specific [125I] PYY binding was competed by Y1 selective agonist
(PYY) or antagonist (BIBO3304; Figure 6.15, Table 6.1, C). Estimated pIC50
values were consistent with previous observations for Snap Y1 receptors
expressed alone or when coexpressed with Y1-Yc (Y1/Y1 BiFC dimer; Chapter
 ? ? dĂďůĞ  ? ? ? Z ? ,ŽǁĞǀĞƌ ĐŽ ?ŝŶĐƵďĂƚŝŽŶ ǁŝƚŚ Ă ɴ ?Z ƐĞůĞĐƚŝǀĞ ĂŐŽŶŝƐƚ
(isoprenaline) or antagonist (propranolol) did not inhibit specific [125I] PYY
binding, suggesting that in measurements accessing the whole receptor
population, as expected a Y1 receptor like phenotype was observed in
respect to ligand binding.
Representative images taken using an IX Ultra confocal platereader,
confirmed predominant plasma membrane expression of both the Snap Y1
ƌĞĐĞƉƚŽƌĂŶĚ^ŶĂƉz ? ?ɴ ?Zŝ&ƉŽƉƵůĂƚŝŽŶƐƵŶĚĞƌĐŽŶƚƌŽůĐŽŶĚŝƚŝŽŶƐ ?&ŝŐƵƌĞ
6.16, control). Stimulation with NPY was able to induce the internalisation of
ďŽƚŚ ƚŚĞ ^ŶĂƉ z ? ƌĞĐĞƉƚŽƌ ĂŶĚ z ? ?ɴ ?Z ŝ& ĚŝŵĞƌ ƉŽƵůĂƚŝŽŶ ŝŶ Ă
concentration dependent manner (Figure 6.17; BiFC dimer; Table 6.4). As
expected isoprenaline had no activity at the Snap Y1 receptor population, but
ǁĂƐĂďůĞƚŽ ŝŶĚƵĐĞƚŚĞŝŶƚĞƌŶĂůŝƐĂƚŝŽŶŽĨƚŚĞz ? ?ɴ ?Zŝ&ĚŝŵĞƌƉŽƉƵůĂƚŝŽŶ
(Figure 6.17; 10µM ISO panel) in a concentration dependent manner with a
pEC50ǀĂůƵĞĐŽŶƐŝƐƚĞŶƚǁŝƚŚƚŚĂƚŽďƐĞƌǀĞĚĨŽƌ^ŶĂƉɴ ?Z ?zŶĞǆƉƌĞƐƐĞĚĂůŽŶĞ
ŽƌǁŚĞŶĐŽĞǆƉƌĞƐƐĞĚǁŝƚŚɴ ?Z ?zĐ ?ŚĂƉƚĞƌ ? ?dĂďůĞ ? ? ? Z ?
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Figure 6.15: Competition binding assay using [
125
I] PYY and unlabelled receptor
subtype selective ligands in membranes derived from HEK293T cells stably
ĞǆƉƌĞƐƐŝŶŐ^ŶĂƉz ? ?ɴ ?ZƌĞĐĞƉƚŽƌĐŽŶƐƚƌƵĐƚƐ
Membranes were freshly prepared from HEK293T cell lines stably coexpressing Snap
z ? ?zŶĂŶĚɴ ?Z ?zĐŝ&ĚŝŵĞƌĐŽŶƐƚƌƵĐƚƐĂŶĚǁĞƌĞŝŶĐƵďĂƚĞĚǁŝƚŚ ?125I] PYY (15pM)
ĂŶĚŝŶĐƌĞĂƐŝŶŐĐŽŶĐĞŶƚƌĂƚŝŽŶƐŽĨƵŶůĂďĞůůĞĚĐŽŵƉĞƚŝŶŐz ? ?WzzŽƌ/K ? ? ? ? ZŽƌɴ ?Z
selective ligands (isoprenaline or propranolol) for 90min at 22°C. Membrane bound
radioligand was separated using filtration and quantified using a gamma counter.
Competition displacement curves were generated using GraphPad Prism, with pooled
data representing a minimum of 3 independent experiments. Data was expressed as
mean ± s.e.m (Hill slope range 0.70-1.1).
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&ŝŐƵƌĞ  ? ? ? ? P YƵĂŶƚŝĨŝĐĂƚŝŽŶ ŽĨ ^ŶĂƉ z ? ?ɴ ?Z ŝ& ĚŝŵĞƌ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ĨŽůůŽǁŝŶŐ
stimulation with receptor subtype selective agonists
^ŶĂƉz ? ?ɴ ?Zŝ&ŚĞƚĞƌŽĚŝŵĞƌƐǁĞƌĞƉƌĞůĂďĞůůĞĚǁŝƚŚ^EWƐƵƌĨĂĐĞ' ? ? ? ? ? ? ?A?D Z
prior to stimulation with NPY or isoprenaline (30min at 37°C). H33342 labelling,
image acquisition and quantification of receptor internalisation was performed as
previously described. Responses were normalised to minimum (basal) and maximum
(1µM NPY) with shared Hill slope constraints. All data were pooled from a minimum
of 4 independent experiments, and expressed as mean ± s.e.m..
/Ŷ ŽƌĚĞƌ ƚŽ ŝŶǀĞƐƚŝŐĂƚĞ ǁŚĞƚŚĞƌ ĐŽŶƐƚƌĂŝŶŝŶŐ z ? ?ɴ ?Z ĂƐ ĚŝŵĞƌƐ ƵƐŝŶŐ ŝ&
resulted in altered antagonist pharmacology, cells were pretreated with either
ƚŚĞz ?ƐĞůĞĐƚŝǀĞĂŶƚĂŐŽŶŝƐƚ/K ? ? ? ?  ? ? ?ŶDĨŽƌ  ? ?ŵŝŶĂƚ  ? ? ? ZŽƌƚŚĞɴ ?Z
selective propranolol (10nM for 30min at 37°C). This was followed by
stimulation with a concentration response course of NPY or isoprenaline (30
min at 37°C). BIBO3304 pretreatment was able to inhibit the NPY induced
ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŽĨ ďŽƚŚ ƚŚĞ ^ŶĂƉ z ? ƌĞĐĞƉƚŽƌ ĂŶĚ z ? ?ɴ ?Z ŝ& ĚŝŵĞƌ
populations indicative of surmountable antagonism (Figure 6.18, A; estimated
pKb  ? ? ? A?  ? ? ? ŝ& ĚŝŵĞƌ ?  ? ? ? A?  ? ? ? ^ŶĂƉ ɴ ?Z ? ŶA? ? Z ? ,ŽǁĞǀĞƌ /K ? ? ? ?
pretreatment was not able to inhibit isoprenaline induced internalisation of
ƚŚĞ z ? ?ɴ ?Z ŝ& ĚŝŵĞƌ ƉŽƉƵůĂƚŝŽŶ  ? ? ŝƐŽƉƌĞŶĂůŝŶĞƉ50 values 7.0 ± 0.1;
+30nM BIBO3304 7.2 ± 0.2; n=4).
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Figure 6.18: The effect of pretreatment with the antagonist BIBO3304 on the
ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŽĨ ^ŶĂƉ z ? ?ɴ ?Z ŝ& ĚŝŵĞƌƐ ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ ƐƵďƚǇƉĞ ƐĞůĞĐƚŝǀĞ
agonists
^ŶĂƉ z ? ?ɴ ?Z ŝ& ĚŝŵĞƌƐ ǁĞƌĞ ƉƌĞƚƌĞĂƚĞĚ ǁŝƚŚ ƚŚĞ z ? ƐĞůĞĐƚŝǀĞ ĂŶƚĂŐŽŶŝƐƚ
BIBO3304 (30nM; 30min at 37°C) prior to stimulation with either NPY or isoprenaline.
H33342 labelling, image acquisition and quantification of receptor internalisation was
performed as previously described. Concentration response curves in the presence
and absence of BIBO3304 were fitted using GraphPad Prism with shared Hill slopes
and normalised to 1µM NPY or 10µM isoprenaline. Responses for Snap Y1-Yn in
respect to isoprenaline were expressed as fold responses over basal (where basal is
100%). All data were pooled from 4 independent experiments, and expressed as
mean ± s.e.m.
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&ŝŐƵƌĞ  ? ? ? ? P dŚĞ ĞĨĨĞĐƚ ŽĨ ƉƌĞƚƌĞĂƚŵĞŶƚ ǁŝƚŚ ƚŚĞ ɴ ?Z ƐĞůĞĐƚŝǀĞ ĂŶƚĂŐŽŶŝƐƚ
ƉƌŽƉƌĂŶŽůŽů ŽŶ ƚŚĞ ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ŽĨ ^ŶĂƉ z ? ?ɴ ?Zŝ& ĚŝŵĞƌƐ ŝŶ ƌĞƐƉŽŶƐĞ ƚŽ
subtype selective agonists
^ŶĂƉ z ? ?ɴ ?Z ŝ& ĚŝŵĞƌƐ ǁĞƌĞ ƉƌĞƚƌĞĂƚĞĚ ǁŝƚŚ ƚŚĞ ɴ ?Z ƐĞůĞĐƚŝǀĞ ĂŶƚĂŐŽŶŝƐƚ
propranolol (10nM; 30min at 37°C) prior to stimulation with either NPY or
Isoprenaline. H33342 labelling, image acquisition and quantification of receptor
internalisation was performed as previously described. Concentration response
curves in the presence and absence of propranolol were fitted using GraphPad Prism
with shared Hill slopes and normalised to 1µM NPY or 10µM Isoprenaline Responses
for Snap Y1-Yn in respect to isoprenaline were expressed as fold responses over basal
(where basal is 100%). All data were pooled from 4 independent experiments, and
expressed as mean ± s.e.m.
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dĂďůĞ ? ? ? P^ƵŵŵĂƌǇŽĨƉŽƚĞŶĐŝĞƐĂŶĚĞĨĨŝĐĂĐŝĞƐŽĨĂƉ ŶĞůŽĨůŝŐĂŶĚƐĨŽƌƐƚŝŵƵůĂƚŝŶŐƚŚĞŝŶƚĞƌŶĂůŝƐĂƚŝŽŶŽĨ^ŶĂƉz ? ?ɴ ?Z
^ŶĂƉz ? ?ɴ ?Z
Agonist Snap Y1 z ? ?ɴ ?Zŝ&ĚŝŵĞƌ
pEC50 % NPY response pEC50 % NPY response
NPY 7.9 ± 0.1 100 7.8 ± 0.1 100
Isoprenaline / 3.5 ± 3.3 7.2 ± 0.1 109.7 ± 8.7
All data were expressed as ± standard error of the mean. pEC50 values were obtained from pooled concentration response curves presented in Figure 6.17.
Emax responses to each ligand were calculated as a percentage of 1µM NPY responses.
/ not able to be determined
n= 4
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ƋƵĂůůǇ ? ƉƌĞƚƌĞĂƚŵĞŶƚ ǁŝƚŚ ƚŚĞ ɴ ?Z ƐĞůĞĐƚŝǀĞ ĂŶƚĂŐŽŶŝƐƚ ƉƌŽƉƌĂŶŽůŽů ǁĂƐ ŶŽƚ
able to inhibit NPY induced internalisation of either the Snap Y1 receptor (NPY
pEC50 ǀĂůƵĞƐ  ? ? ? A?  ? ? ? Z Žƌ z ? ?ɴ ?Z ŝ& ĚŝŵĞƌ ƉŽƉƵůĂƚŝŽŶƐ  ?&ŝŐƵƌĞ  ? ? ? ? ?  ? EWz
pEC50 values 7.9 ± 0.1; n=4). Propranolol was able to selectively inhibit the
/ƐŽƉƌĞŶĂůŝŶĞŝŶĚƵĐĞĚŝŶƚĞƌŶĂůŝƐĂƚŝŽŶŽĨƚŚĞz ? ?ɴ ?Zŝ&ĚŝŵĞƌƉŽƉƵůĂƚŝŽŶ ?ǁŝƚŚ
rightward parallel shifts in responses seen indicative of surmountable antagonism
(B; estimated pKb 9.2 ± 0.2; n=4).
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6.4 Discussion
6.4.1 Summary of main findings
/ŶƚŚŝƐĐŚĂƉƚĞƌŝ&ǁĂƐƐƵĐĐĞƐƐĨƵůůǇƵƐĞĚƚŽĐŽŶƐƚƌĂŝŶz ? ?z ? ?z ? ?z ?ĂŶĚz ? ?ɴ ?Z
subtypes as heterodimers of precise composition, which were able to internalise
in response to selective agonist stimulation. In [125I]PYY competition binding
assays, Snap Y1/Y5 and Snap Y1/E2AR membranes showed profiles consistent
with a Y1 receptor like pharmacology, whilst a mixed profile, suggestive of both
Y1 and Y4 receptor components, was obtained from the Snap Y1/Y4 cell line.
Equally, cAMP assays in Snap Y1/Y5 cells indicated predominantly Y1 mediated
responses. Thus as expected, the trapped heterodimers visualised by BiFC
(especially for Snap Y1/Y5) represented a small proportion of the total receptor
population, and that as a consequence, cell population studies may mask dimer
specific responses. However the combined use of Snap labelling and BiFC allowed
the discrete quantification of responses of the constrained BiFC dimer or
reference Snap -Y1-Yn receptor populations simultaneously within the same cells,
with internalisation of both populations used as a readout of function. This
revealed modified agonist and antagonist pharmacology of Snap Y1/Y5 BiFC
dimers compared to the responses of either receptor expressed alone. The most
striking alteration observed for constrained Snap Y1/Y5 BiFC dimers, was a switch
in the nature of antagonism for Y5 receptor selective antagonists from
surmountable to insurmountable. Changes in pharmacology were also observed
at this dimer pairing in respect to the action of the Y1 selective antagonist
BIBO3304, and to the relative potency and efficacy of Y5 selective agonists. When
viewed in combination, these altered properties suggest allosteric interactions
occurring across the Snap Y1/Y5 receptor dimer interface. Furthermore, the
specificity of such interactions was suggested by the fact that modified
pharmacology was only seen for the Snap Y1/Y5 combination, with responses for
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^ŶĂƉ z ? ?z ? Žƌ ^ŶĂƉ z ? ?ɴ ?Z ŝ& ĚŝŵĞƌƐ ůĂƌŐĞůǇ ƌĞĐŽŶ ŝůĂďůĞ ǁŝƚŚ ƚŚĞŝƌ
orthosteric binding sites acting independently.
As altered pharmacology was only observed for the Y1/Y5 BiFC dimer alone,
formation of these dimers may have an impact on the control of central feeding
responses in vivo by the combined signalling of Y1 and Y5 subtypes, and the
limited efficacy of highly selective Y1 or Y5 receptor antagonists in inhibiting
these responses. Equally this system raises the possibility of screening for novel
Y1/Y5 heterodimer selective anti obesity therapies.
 ? ? ? ? ?zƌĞĐĞƉƚŽƌƐƵďƚǇƉĞƐĂŶĚz ? ?ɴ ?ZƌĞĐĞƉƚŽƌƐĐŽŶƐƚƌĂŝ ĞĚĂƐŚĞƚĞƌŽĚŝŵĞƌƐ
using BiFC were correctly expressed and capable of binding NPY ligands
In order to study Y receptor heterodimers, the subtypes Y1 and Y5 were chosen
as a primary focus, as this pairing has previously been implicated in co-promoting
central feeding responses (Chapter 1, section 1.8.4.1) and immunohistochemistry
showing coexpression of these subtypes within the same cells of the
hypothalamus (Wolak et al., 2003) raises the potential for functional
heterodimerisation.
The Y1 and Y4 pairing were also chosen as in contrast, these receptors have
opposing effects in the central control of appetite, where the Y4 receptor has
been implicated in inducing satiety (Chapter 1, section 1.8.4.2). However both Y1
and Y4 receptors are co-expressed in epithelial cells of the gastrointestinal tract,
where they bind PP and PYY released postprandially, and promote antisecretory
effects (Cox, 2007).
Additionally these subtypes have distinct ligand selectivity profiles, particularly in
respect to PP binding (Chapter 3, Table 3.2 and 3.3). For both Y receptor
heterodimers, the use of selective ligands with high affinities for the distinct
subtypes was exploited in order to selectively target orthosteric ligand binding
sites within the dimer. When combined with BiFC, this allowed potential
pharmacological effects of ligand occupancy and potential cooperativity to be
investigated at a constrained heterodimer complex of known composition. The
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current lack of a wholly Y1 selective agonist was unfortunate as it did not allow
reciprocal effects, particularly in respect to the Y1/Y5 BiFC dimer to be
investigated.
dŚĞ ɴ ?Z ǁĂƐ ĂůƐŽ ĐŚŽƐĞŶ ƚŽ ďĞ ĐŽŶƐƚƌĂŝŶĞĚ ǁŝƚŚ z ?ƌĞĐĞƉƚŽƌƐ ǁŝƚŚŝŶ Ă ŝ&
dimer, as both receptors are coexpressed at some sympathetic synapses and
have been implicated in co-regulating vasoconstriction in vascular smooth muscle
cells (Wahlestedt et al., 1990b). Additionally the ligands of both these subtypes
are structurally distinct (peptide vs monomamines) allowing selective orthosteric
ligand bind site targeting.
BiFC was successfully used to constrain these subtypes as heterodimers of precise
composition. As in Chapter 5, the intention here was not to identify to what
extent such dimers form, but instead to investigate the pharmacology of
complexes constrained in a defined 1:1 stoichiometry. All BiFC dimer heterodimer
combinations, with the exception of Snap Y1/D2L, were correctly expressed at
the cell surface and functional in respect to PYY binding with affinities consistent
with previous observations for Snap Y1-Yn alone, Snap Y1-Y1 homodimers
(Chapter 5, Table 5.1) and Y1-GFP (Chapter 3, Table 3.1).
Like Snap Y1/Y1 BiFC homodimers (Chapter 4), constrained Snap Y1/Y5, Y1/Y4
ĂŶĚ z ? ?ɴ ?Z ŝ& ĚŝŵĞƌ ƉŽƉƵůĂƚŝŽŶƐ ǁĞƌĞ Ăůů ĂďůĞ ƚŽ ƌĂƉŝĚůǇ ŝŶƚĞƌŶĂůŝƐĞ ŝŶ
response to NPY stimulation with comparable potencies to that observed for
unconstrained Snap labelled Y1-Yn receptors within the same cells. Extensive
areas of colocalisation were also observed, suggesting that both receptor
populations internalised to the same intracellular compartments. These
observations suggested that the use of BiFC to constrain GPCRs as heterodimers
did not adversely affect their expression or endocytosis, which was comparable
to Snap Y1/Y1 BiFC dimers, Y1 receptor oligomers (Dinger et al., 2003, Gehlert et
al., 2007) and previous uses of BiFC to identify D2L and A2A heterodimers in a
neuronal cell line (Vidi et al., 2008a). However as for previous observations of
BiFC constrained D1 and A2A heterodimers (Vidi et al., 2008a), Snap Y1/D2L BiFC
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dimers were retained within the cell. This suggests a degree of selectivity in that
where receptor pairings are not appropriate, BiFC dimers can form but fail to
reach to the cell surface.
In competition radioligand binding studies of Snap Y1-Yn/Y5-Yc derived
membranes, a predominantly Y1 receptor like pharmacology was observed in
respect to subtype selective agonists and antagonists. The lack of Y5 receptor
responses was not due to a lack of binding of the radioligand, as [125I] PYY has
been previously shown to bind to this subtype with an affinity comparable to that
seen for the Y1 receptor (Gerald et al., 1996). This implied that the expression of
the Snap Y1-Yn receptor population was substantially greater than the Y5-Yc
receptor. In whole population measures, the functional behaviour Snap Y1-Yn
population may therefore be masking any alterations in pharmacology
attributable to the formation of heterodimers.
For Y1-Yn/Y4-Yc coexpressing cells the preferential two site fit observed for PP
inhibition of specific [125I] PYY binding reflected the differing affinities of PP for
the co-expressed Y1 and Y4 protomer orthosteric binding sites (Chapter 3, Table
3.2, 3.3). This was further confirmed by selective BIBO3304 displacement of Y1
binding. The fraction of specific binding displaced, was almost identical to the
binding fraction of the high affinity site for PP. Therefore the high affinity site
likely represents PP binding to the Y4 receptor protomer as the IC50 value
obtained here is comparable to previous observations of PP binding affinity to
human Y4 receptors ((Gehlert et al., 1997)). Likewise the IC50 value obtained for
the low affinity site is similar to PP binding to rat Y1 receptors (Chapter 3, Table
3.1; (Gehlert et al., 1997)). This is consistent with the known order of selectivity
of PP for the Y receptor subtypes, and likely represents PP binding independently
to either the Y1 or Y4 orthosteric ligand binding sites of the whole expressed
receptor population. [125I] PYY binding assays in Y1/Y4 membranes therefore
appeared to reflect a relatively greater expression of the Y4 receptor when
compared to the Y5-Yc construct in this Snap Y1-Yn coexpressed system. The
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exact proportions are hard to assess, because the higher documented affinity of
Y4 receptors for [125I] PYY (Lundell et al., 1995) compared to the Y1 subtype
(Larhammar et al., 1992) (pKd values 9.8 vs 9.1 respectively),means that at the
concentration of radioligand used (15pM) a greater proportion of Y4 receptors
would be labelled than Y1 within the sample.
&ŽƌƚŚĞz ? ?ɴ ?ZĐĞůůůŝŶĞ ?Ă Rz ?ƌĞĐĞƉƚŽƌůŝŬĞ ?ƉŚĂƌŵĂĐŽůŽŐǇǁĂƐĂůƐŽŽďƐĞƌǀĞĚŝŶ
ƌĞƐƉĞĐƚ ƚŽĐŽŵƉĞƚŝƚŝŽŶďŝŶĚŝŶŐ ĂƐĞǆƉĞĐƚĞĚĚƵĞƚŽ ƚŚĞ ůĂĐŬŽĨ ĂĨĨŝŶŝƚǇ ƚŚĞ ɴ ?Z
orthosteric site has for [125/ ?Wzz ?ĂŶĚŶŽ ĂůůŽƐƚĞƌŝĐ ŝŶĨůƵĞŶĐĞŽĨĐŽŵƉĞƚŝŶŐɴ ?Z
agonists or antagonists was detected
6.4.3 Pharmacology consistent with the Y1 receptor subtype was observed in
inhibition of cAMP accumulation experiments for the Snap Y1/Y5 cell line
Similar to observations in [125I] PYY binding, a Y1 receptor like pharmacology was
also observed for the Y1/Y5 cell line in respect to inhibition of cAMP
accumulation. For example, BIBO3304 showed surmountable antagonism of NPY
responses. It is worth noting that BIBO3304 showed slightly reduced affinity (3 
10 fold) in cAMP accumulation, than expected from previous work (Wieland et
al., 1998). This might be attributed to a portion of the response being mediated
via BIBO-insensitive Y5 receptors. However as discussed in Chapter 5, similarly
lower affinity was also observed for BIBO3304 in radioligand binding assays, Snap
Y1/Y1 BiFC homodimers, and Snap Y1 receptors expressed alone (Chapter 5,
Figure 5.9), Y1-GFP and Y1/A2 (Chapter 3), suggesting BIBO3304 were relatively
internally consistent. Equally the lack of inhibition observed for CGP71683 in
cAMP accumulation assays reflected the reduced Y5 receptor expression in the
Snap Y1/Y5 cell line compared to the Snap Y1-Yn receptor as indicated by
radioligand binding.
Although modified pharmacology has been observed in cell systems for the Y1 /
Y5 receptor combination (Gehlert et al., 2007; see below), in this work, whole
population studies could not distinguish heterodimer specific responses from
those of monomeric receptor or homodimer populations likely also present.
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6.4.4 The combined use of Snap labelling and BiFC revealed altered ligand
pharmacology of constrained Y1/Y5 BiFC dimers previously unseen in whole
population measures
BRET studies have previously suggested Y1 and Y5 receptor can interact (Gehlert
et al., 2007), but this can only infer the formation of distinct functional
heterodimers. This is where the use of BiFC was advantageous as it discretely
identified the Y1 / Y5 complex s due to the need for both fragment tagged
protomers to contribute to fluorescence production. The irreversibility of BiFC
meant that both Y1 and Y5 receptors were constrained as dimers, in a defined 1:1
stoichiometry. Notably, because BiFC is an inefficient process (for example due to
the its proximity and orientation limits and the likelihood that not all
complemented YFP will be matured and fluorescent (Hallworth and Nichols,
2012)), and population studies established an significant excess of Snap-Y1-Yn
receptors, the levels of Snap Y1/Y5 BiFC dimers must represent a small
proportion of the total Y receptor contingent on the surface. Thus using agonist
induced receptor internalisation as a readout of function enabled responses of
the Y1/Y5 BiFC dimer to be assessed in a way which is impossible in population
experiments, and also allowed comparisons to responses of the Snap labelled
total Y1 receptor population simultaneously in the same cells. Therefore the
alterations in both agonist and antagonist pharmacology observed for the Snap
Y1/Y5 BiFC population could be assigned to the behaviour of the specific
molecular dimer.
First, constrained Snap Y1/Y5 BiFC dimers showed altered pharmacology for Y5
subtype selective agonists such as cPP(1-17)(Ala31,Aib32) NPY(18-36) or D-Trp32
NPY (Balasubramaniam et al., 1994) which became markedly less potent and had
lower ability to stimulate internalisation than NPY (compared to observations in
Y5-GFP cells). These altered responses for Snap Y1/Y5 BiFC heterodimers,
suggested that coexpression of the Snap Y1-Yn was adversely influencing the
binding of Y5 selective ligands to the Y5 receptor orthosteric binding site. This
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was not evident in previous results where the Y5 selective agonist cPP(1-17)
NPY(19-23, Ala31,Aib32) and Gln34 hPP showed greater efficacy in inhibiting
forskolin induced cAMP accumulation at a AV-12 cell line coexpressing both Y1
and Y5 receptors when compared to Y5 receptors expressed alone (Gehlert et al.,
2007). Taken alone however these data on Y5 agonists are not sufficient to
confirm an allosteric interaction. As determined in Chapter 5, agonist occupancy
of one binding site is sufficient to drive internalisation of Snap Y1/Y1 BiFC dimers,
supported by other studies (Rovira et al., 2009). Indeed Y5 agonist stimulated
internalisation of the Snap Y1/Y5 BiFC dimer must occur in this manner, since
these agonists were inactive at the Snap-Y1-Yn protomer. Conceivably, reduced
ability of Y5 receptors to undergo endocytosis compared to Y1 might confer these
agonist-selective properties on the Snap Y1/Y5 dimer, and the use of a 60min
agonist incubation period for Y5-GFP and previously observations of reduced
kinetics of endocytosis (Bohme et al., 2008, Parker et al., 2003) may suggest this.
However, the same low potency partial agonism of PP-Aib-NPY and PP, relative to
NPY, was still observed in Snap Y1/Y5 cells when internalisation was instead
measured at 60 min (Dr N Holliday, personal communication).
Therefore additional evidence for allosteric communication between Y1 and Y5
receptors was required, and provided by the modified antagonist pharmacology
that is directly attributable to the Snap Y1/Y5 BiFC dimer. The switch in the
nature of inhibition of structurally unrelated Y5 selective antagonists from
surmountable in single receptor systems (Y5-GFP) to insurmountable at the Snap
Y1/Y5 BiFC dimer population is strong evidence that the presence of the Y1
receptor was influencing the Y5 receptor orthosteric ligand binding site. For two
orthosteric sites acting independently, and given that only one binding site (e.g.
Y1) needs to be occupied by NPY for maximum Snap Y1/Y5 internalisation, the
prediction would be that antagonists such as CGP71683 would have become
inactive, because they had no effect on the Snap-Y1-Yn population. However
clearly this did not occur. Interestingly, a similar switch from reversible to
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irreversible antagonism was also observed for the Y5 selective antagonist,
Novartis-1, in AV-12 cell populations coexpressing both the Y1 and Y5 receptor
subtypes by (Gehlert et al., 2007)  the detection of this phenomenon in cell
populations may be because Y1 and Y5 receptor expression levels were better
matched (see section 6.4.3 on cAMP). In addition both receptors in that study did
possess a C terminal fluorescent protein tag to allow BRET identification of
potential dimers, but were not irreversibly constrained, ruling out an artefact
from the use of BiFC in this study. Instead identification of these antagonist
properties at the level of a molecularly defined dimer is new evidence that they
derive from physical association between the receptors, rather than indirectly via
signalling cross talk.
The modified pharmacology also observed for the Y1 selective antagonist
BIBO3304 again suggested that Y1 and Y5 receptor heterodimerisation has
functional implications for ligand binding. Surmountable antagonism was
observed for the Snap Y1-Yn receptor population alone, but BIBO3304 was
unable to inhibit the NPY induced internalisation of the Snap Y1/Y5 BiFC dimer
population in the same cells. Thus the behaviour of Y1 and Y5 receptor
antagonists is not reciprocal. BIBO3304 has very low affinity for the Y5 receptor
(Ki > 1uM) (Wieland et al., 1998), and so Snap Y1/Y5 BiFC dimer internalisation
could still be mediated by NPY binding the Y5 protomer. However if this was the
case, the behaviour of NPY in stimulating Snap Y1/Y5 BiFC dimer internalisation
might be expected to resemble the partial agonism of the Y5 selective agonists
(see above), which are equally efficacious in stimulating Y5-GFP receptor
endocytosis. Thus the lack of effect of BIBO3304 on NPY potency or maximum
response is hard to explain without allosteric modulation. Either the Y5 selective
agonists are indeed less active at the Snap Y1/Y5 dimer because of allosteric
communication, or co-expression of the Y5 receptor modifies the ability of the Y1
protomer to bind BIBO304. Again, this effect does not appear to be biased
ƚŽǁĂƌĚƐƌĞĐĞƉƚŽƌŝŶƚĞƌŶĂůŝƐĂƚŝŽŶƌĞĂĚŽƵƚƐ ?ĂŶĚŝŶĚŝƌĞĐƚůǇɴ ?ĂƌƌĞƐƚŝŶƌĞĐƌƵŝƚŵĞŶƚ Z ?
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or the BiFC approach, as similar results have been observed for the Y1 selective
antagonists BIBP3226 and LY366258 in respect to the agonist mediated inhibition
of cAMP synthesis by coexpressed Y1 and Y5 receptors when compared to Y1
receptors expressed alone (Gehlert et al., 2007). While in the Gehlert study it was
impossible to rule out the possibility that Y5 receptor stimulation by NPY was
maintaining responses in the presence of Y1 antagonists, this study again
pinpoints the lack of Y1 antagonist effect to the physical properties of the Snap
Y1/Y5 dimer. The extensive modified agonist and particularly antagonist
pharmacology observed for Snap Y1/Y5 BiFC heterodimers, was therefore likely
to be a consequence of the distinct association of Y1 and Y5 receptor subtypes.
Interestingly modified signalling for both Y1 and Y5 selective antagonists seen
here and by (Gehlert et al., 2007) exhibited a ceiling effect, whereby even using
concentrations of antagonist 100 fold that of their documented pKbs did not
result in further changes in responses. This phenomenon of saturation is
indicative of allosteric modulation (Langmead and Christopoulos, 2014). This
suggested that both the Y1 and Y5 orthosteric ligand binding sites of the
heterodimer were both amenable to allosteric modulation, whereby ligand
binding to one protomer (eg. the Y1), induces a conformational change within the
dimer so that the affinity of ligand binding to the second site (Y5) is either
positively or negatively modulated and vice versa. Observations from other GPCR
heterodimers, suggest that it is possible to obtain modified pharmacology that is
ĨƵŶĐƚŝŽŶĂůůǇƐƉĞĐŝĨŝĐ ?&ŽƌĞǆĂŵƉůĞĐŽĞǆƉƌĞƐƐŝŽŶŽĨɴ ? ?ɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌƐƌĞƐƵůƚĞĚ
ŝŶŵĂƌŬĞĚĐŚĂŶŐĞƐŝŶƚŚĞĂŐŽŶŝƐƚŝŶĚƵĐĞĚŝŶƚĞƌŶĂůŝƐĂƚŝŽŶŽĨƚŚĞɴ ?ĂĚƌĞŶŽĐĞƉƚŽƌ
protomer (Breit et al., 2004), but with no changes in respect to ligand binding
ĂĨĨŝŶŝƚŝĞƐ Ăƚ ĞŝƚŚĞƌ ƉƌŽƚŽŵĞƌ Žƌ ƚŚĞ ĂďŝůŝƚǇ ŽĨ ƚŚĞ ɴ ? ĂĚƌĞŶŽĐĞƉƚŽƌ ƉƌŽƚŽŵĞƌ ƚŽ
functionally couple to GɲƐ. It is therefore likely that the signalling pathway that is
modified can vary greatly depending with receptor pairing and potentially the
specific ligand stimulation used (Ferre et al., 2014)  this might be expected given
the distinct ways in which effectors (G proteins or arrestins for example) might
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interact with such heterodimers. As we have highlighted in this study, the caveat
in proposing functionally selective effects is the extent to which the specific
dimer pairing can be isolated from other receptor combinations for the different
signalling endpoints. Future investigations (see Chapter 7) might adapt the BiFC
system in combination with RET to examine signalling of the Snap Y1 / Y5 pairs
directly with G proteins or arrestins.
A potential mechanism to propagate allosteric effects across a GPCR Class A
dimer, such as the Y1/Y5 BiFC dimer, is physical interaction between the two
protomers of the dimer, such as that observed for the melatonin MT1 receptor
and GPR50 receptor. There are 3 main sites most likely to be the location of
ĚŝŵĞƌ ŝŶƚĞƌĨĂĐĞƐ ?  &ŝƌƐƚůǇ ƚŚĞ ĂŶĂůǇƐŝƐ ŽĨ y ?ƌĂǇ ƐƚƌƵĐƚƵƌĞƐ ƐƵĐŚ ĂƐ ƚŚĞ A? ĂŶĚ ʃ
opioid (Wu et al., 2012, Manglik et al., 2012), chemokine CXCR4 (Wu et al., 2010)
ĂŶĚɴ ? ?ĂĚƌĞŶŽĐĞƉƚŽƌ ?,ƵĂŶŐĞƚĂů ? ? ? ? ? ? ZǁŚŝĐŚĂůůĐƌǇƐƚ ůŝƐĞĚĂƐĚŝŵĞƌƐĂŶĚ ?Žƌ
tetramers, suggested that the transmembrane helices may be such sites (section
5.1.1.4). Interactions of TM1 with helix 8 and TM4 with TM56 appear to be
particularly conserved (Huang et al., 2013, Manglik et al., 2012). Many of these
observations are supportive of previous interaction candidates suggested from
biochemical studies (Johnston et al., 2012)(Section 5.1.1.5). The TM helices are
relatively rigid, so questions remain whether these regions would be sufficiently
influenced upon domain formation to propagate a conformational change that
would be sufficient to affect both protomer binding sites. A second potential
interface site is within the N terminus and/or extracellular loops. ECL2 has been
implicated as the primary region that defines ligand specificity by governing
access to the binding pocket (section 1.2.2.2). For example, for binding of
neuropeptides by Y receptors a critical highly conserved (in Y subtypes) Asp 6.59
of ECL3 binds to the amidated C terminus of NPY (Walker et al., 1994, Merten et
al., 2007) and for the Y1 receptor only an additional connection involving His7.31
of ECL3 (Akerberg et al., 2010) is also crucial. If dimerisation involved these ECL
regions, the high degree of influence they hold over ligand access and binding
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would likely allow conformational changes/cooperative effects to be propagated
from one protomer binding site to the other.
Lastly the intracellular regions govern the binding of effector proteins such as G
ƉƌŽƚĞŝŶƐĂŶĚɴ ?ĂƌƌĞƐƚŝŶƐ ?ƐƚŚĞƐĞĞĨĨĞĐƚŽƌƐĂƌĞĂůůŽƐƚĞƌŝĐŵŽĚƵůĂƚŽƌƐŝŶƚŚĞŝƌŽǁŶ
right, this means that if dimerisation were governed by the intracellular domains,
then these allosteric effects which influence ligand binding could be readily
transduced through the dimer structure. This reconciles with the observations of
Maurice et al., 2011 (Maurice et al., 2011) who suggested that some cooperative
effects ascribed to dimerisation, may instead be due to sequential or spatial
ďŝŶĚŝŶŐ ŽĨ ĞĨĨĞĐƚŽƌ ŵŽůĞĐƵůĞƐ ƐƵĐŚ ĂƐ ' ƉƌŽƚĞŝŶƐ ĂŶĚ ɴ ?ĂƌƌĞƐƚŝŶƐ ƚŽ ĚŝƐƚŝŶĐƚ
receptor populations. It is unlikely that the presence of the BiFC tags is affecting
ƚŚŝƐ ĂƐ ŽŶůǇ ƚŚĞ ^ŶĂƉ z ? ?z ? ŝ& ? ĂŶĚ ŶŽƚ ƚŚĞ z ? ?z ? Žƌ z ? ?ɴ ?Z ĚŝŵĞƌ ƉĂŝƌŝŶŐ
showed any modification of pharmacology when constrained. It is unlikely that
ƚŚĞ ^ŶĂƉ z ? ?z ? ŝ& ĚŝŵĞƌ ŝƐ ĂĚŽƉƚŝŶŐ Ă ĐŽŶĨŽƌŵĂƚŝŽŶ ƚŚĂƚ ƐƚĞƌŝĐĂůůǇ ĂĨĨĞĐƚƐ ɴ ?
arrestin2 binding affinity, as potencies for NPY at inducing internalisation of this
BiFC dimer population were comparable to Snap Y1-Yn expressed alone (Chapter
 ? ?dĂďůĞ ? ? ? ZŽƌǁŚĞŶŝ&ǁĂƐƵƐĞĚƚŽŝŶǀĞƐƚŝŐĂƚĞɴ ?ĂƌƌĞƐƚŝŶ ?ƌĞĐƌƵŝƚŵĞŶƚƚŽƚŚĞ
Y1 or Y5 receptor (Y1/A2; Chapter 3, Table 3.3). One consideration is that the
evidence from Y1 homodimer mutagenesis (Chapter 5) argues against
asymmetric binding of arrestin molecular sensors to different protomers of the
dimer (with caveats, for example the ability of GRKs to phosphorylate such
dimers)  a 1:2 stoichiometry would be the most plausible manner for modified
dimer properties to occur via this mechanism. However heterodimer specific
intracellular domains could still modify the way in which effectors are recuited to
individual protomers by other means. The use of selective mutagenesis of single
protomers within a BiFC dimer (Chapter 5) provides a unique mechanism to
investigate which regions of the receptor are responsible for communicating
allosteric effects (see Chapter 7).
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There is also the potential that observations of altered signalling for heterodimers
are actually a consequence of downstream signalling cross talk between
receptors in close proximity. This is a particular concern when studying receptors
expressed in heterologous cell lines, as receptor expression levels often exceed
those found physiologically, and use population measurements which derive
from the entire cohort of receptors on the cell surface. However as the modified
signalling observed here for Y1/Y5 has been seen using a constrained system
(BiFC) whereby protomer stoichiometries are defined (1:1) the impact of cross
talk, although not wholly eliminated, is certainly less likely.
 ? ? ? ? ? ^ŶĂƉ z ? ?z ? ĂŶĚ z ? ?ɴ ?Z ŝ& ĚŝŵĞƌƐ ƐŚŽǁĞĚ ĂŐŽŶŝƐƚ ĂŶĚ ĂŶƚĂŐŽŶŝƐƚ
pharmacology consistent with their orthosteric ligand binding sites acting
independently
The observations that Snap Y1/Y5 dimers showed allosterically modified
pharmacology were given greater weight in that these changes were specific to
that heterodimer. In general, the BiFC system applied to Snap Y1/Y4 or Snap
z ? ?ɴ ?ZŚĞƚĞƌŽĚŝŵĞƌƐĚŝĚŶŽƚƌĞǀĞĂůĂůƚĞƌĞĚƉŚĂƌŵĂĐŽůŽŐǇ ?
When using the Snap-BiFC system to quantify internalisation, agonist responses
for NPY and PP at the Snap Y1 or Snap Y1/Y4 BiFC dimer populations or
ŝƐŽƉƌĞŶĂůŝŶĞ Ăƚ ƚŚĞ ^ŶĂƉ z ? ?ɴ ?Z ŝ& ĚŝŵĞƌ ĐŽƵůĚ ďĞ ĞǆƉůĂŝŶĞĚ ďǇ ƚŚĞ ŬŶŽǁŶ
ůŝŐĂŶĚ ƐĞůĞĐƚŝǀŝƚǇ ?Ɛ ŽĨ z ? ? z ? Žƌ ɴ ?Z ĂŶĚ ǁĞƌĞ ůĂƌŐĞůǇ ĐŽŶƐŝƐƚĞŶƚ ǁŝƚŚ ƚŚŽƐĞ
previously seen for the Y1 (Y1-GFP; Chapter 3, Figure ), Y4 (Chapter 3, Figure 3.9)
Žƌɴ ?ZƌĞĐĞƉƚŽƌƐ ?ŚĂƉƚĞƌ ? ?&ŝŐƵƌĞ ? ? ? ? ZĞǆƉƌĞƐƐĞĚĂůŽŶĞ ?/ƚǁĂƐŽďƐĞƌǀĞĚƚŚĂƚ
PP was significantly less potent (more than 10 fold) for the Snap Y1/Y4 dimer than
might be expected from its effects in Y4-GFP expressing cells. However in the
absence of a greater range of Y4 selective ligands (both agonists and antagonists),
this finding alone cannot be sufficient evidence for an allosteric effect. Instead,
when considering the effects of antagonists (and in marked contrast to the Snap
z ? ?z ? ƐǇƐƚĞŵ Z ? ďŽƚŚ z ? ?z ? ĂŶĚ z ? ?ɴ ?Z ŝ& ĚŝŵĞƌƐ ĚƐƉůĂǇĞ  ƐƵƌŵŽƵŶƚĂďůĞ
antagonism to BIBO3304 and propranolol respectively, but only when the
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relevant orthosteric agonist (NPY or isoprenaline) was used, consistent with the
protomer binding sites acting independently.
6.4.6 Potential physiological implications of modified pharmacology of Y1/Y5
receptor heterodimers
The control of food intake in response to NPY is driven largely by the combined
action of Y1 and Y5 receptors in neurons of the paraventricular nucleus of the
hypothalamus. The modified pharmacology (particularly in respect to
antagonists) of these heterodimers seen both here and by other groups (Gehlert
et al., 2007), might explain the poor clinical efficacy of antagonist therapies that
are highly selective for either subtype (Chapter 1, section 1.8.6.1). Gehlert et al.,
2007 observed that only dual treatment with both Y1 and Y5 selective
antagonists resulted in significant decreases in the agonist induced internalisation
of coexpressed subtypes. This evidence suggests that a therapeutic agent which
co-targets both subtypes may have greater success.
This hypothesis is supported by the overlapping mRNA and protein expression of
both receptors in a range of brain regions (Parker and Herzog, 1999) with in situ
immunohistochemistry suggesting this coexpression is within the same cells and
nerve fibres (Wolak et al., 2003). The formation of Y1/Y5 heterodimers may
therefore be a mechanism by which these receptors co-regulate feeding.
Additionally the presence of functional Y1/Y5 heterodimers may explain some of
the paradoxical results seen in knockout studies of either subtype (Chapter 1,
section 1.8.4.1). For example, germline knock outs of either subtype in mice
resulted in late onset obesity with either no change or increases in food intake
(Kushi et al., 1998, Marsh et al., 1998). In the context of receptor dimerisation,
this may reflect changes in the proportion of homodimer or heterodimer species
present. Hypothalamic knock out of both subtypes in mice, resulted in decreased
spontaneous and fast induced food intake, increased body weight and adiposity
when fed a high fat diet, supporting the hypothesis that it is the combined action
of both receptors which drives hyperphagia in vivo (Nguyen et al., 2012, Lecklin et
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al., 2002). Additionally a series of experiments performed in wildtype and Y1
receptor knock mice fed a high fat diet have illustrated that co-administration of
Y1 and Y5 receptor antagonists resulted in greater anti obesity effects than when
either subtype was targeted alone (Mashiko et al., 2009). However the
documented poor bioavailability of many Y receptor antagonists suggests that
simultaneousadministration may not show as great an efficacy in human studies.
However care must be taken when interpreting in vivo observations of co-
regulation as direct evidence for dimerisation, as other explanations might be
sufficient. For example alterations in the action of antagonists, may simply be
explained by coexpression of both subtypes in close proximity without necessarily
implying the need for direct physical associations. Close proximity of receptors
does not necessarily imply co-regulation as signalling at both receptors may
instead be temporally regulated. For example the rate of agonist induced
ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ  ?ŽŚŵĞ Ğƚ Ăů ? ?  ? ? ? ? Z ĂŶĚ ɴ ?ĂƌƌĞƐƚŝŶ ? ƌĞĐƌƵŝƚŵĞŶƚ ŽĨ ƐŝŶŐƵůĂƌůǇ
expressed Y5 receptors are slower than that of Y1 (Berglund et al., 2003b).
Additionally both Y1 and Y5 receptors have been shown to individually regulate
multiple aspects of metabolism beyond the induction of feeding, and these
effects are not limited to the hypothalamus.
As we have shown, the Y1/Y5 BiFC constrained heterodimer exhibits modified
pharmacology. It is difficult to unambiguously identify heterodimer populations in
coexpression systems due to the likely mixture of monomer, homodimer and
higher order oligomers also present and the proposed transience of dimers
(Lambert, 2010). However designing heterodimer selective bivalent ligands which
bridge the dimer structure may provide an answer to this. Additionally bivalent
ligands have the potential to increase the potency, efficacy and/or selectivity of
pharmacotherapies. Such ligands have been developed for the opioid receptor
ƐƵďƚǇƉĞƐ ɷ ?A?  ?ĂŶŝĞůƐ Ğƚ Ăů ? ?  ? ? ? ?ď Z ĂŶĚ ʃ ?ɷ  ?ĂŶŝĞůƐ Ğƚ Ăů ? ?  ? ? ? ?Ă Z ? ǁŚŝĐŚ ŚĂǀĞ
been shown to promote greater analgesia than morphine. However as the
majority of these ligands are tested in coexpression systems, the actual dimeric
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complex responsible is not clearly defined. For example the dopamine D1-D2
heterodimer selective agonist SKF83959, was proposed to show heterodimer
selective pharmacology when receptors were coexpressed in HEK293T cells, but
subsequent screening revealed profound cross selectivity with other GPCRs (Chun
et al., 2013). The BiFC system provides a way to screen such compounds at clearly
defined heterodimers, allowing any selective responses that are identified to be
then further investigated.
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Chapter 7: Final discussion
The prevalence of obesity has increased globally over the past three decades
(Finucane et al., 2011) and has been implicated as a causative factor in a range of
health problems including cardiovascular disease, cancer and type II diabetes
(reviewed in (Mitchell et al., 2011)). There is therefore a largely unmet demand
for anti obesity therapies that are effective at delivering long term weight loss
and are safe.
The NPY Y receptor family of GPCRs has been shown to contribute to the central
control of feeding responses. In particular the subtypes Y1 and Y5 have been
shown to mediate NPY induced hyperphagia, lipogenesis and insulin resistance.
Immunohistochemistry techniques have implied that these subtypes are
coexpressed in the same cells of the paraventricular neurons (Wolak et al., 2003),
with knock out studies suggesting a co-regulation between subtypes in respect to
feeding responses (Nguyen et al., 2012). This co-regulation has been suggested to
be due to the formation of Y1/Y5 heterodimers (Gehlert et al., 2007), which may
account for the limited efficacy of antagonist therapies selective for either
subtype in clinical trials.
The functional role of GPCR dimerisation is still currently in debate particularly in
respect to physiological relevance. Dimerisation has the potential to offer novel
pharmacological targets, and account for pathway specific signalling by some
ligands both of which might increase the efficacy and selectivity of future GPCR
based therapies. A wide array of biochemical, fluorescence based and kinetic data
have suggested that the formation of dimers can alter the pharmacology of GPCR
subtypes in respect to expression, ligand binding, coupling of effector proteins
and downstream signalling. However many of these modifications might instead
be explained as consequences of receptor coexpression, such as intracellular
signalling cross talk, as opposed to representing a genuine physical interaction.
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There is therefore a need to unambiguously identify the precise molecular
makeup of signalling complexes.
This thesis explored the way this could be achieved using bimolecular
fluorescence complementation (BiFC) to constrain protein-protein interactions as
complexes of defined composition  either Y receptor dimers, or receptors and E-
arrestin. The use of BiFC in conjunction with high content imaging and selective
mutagenesis, initially allowed the quantification of the pharmacology of the
ĂƐƐŽĐŝĂƚŝŽŶŽĨzƌĞĐĞƉƚŽƌƐƵďƚǇƉĞƐǁŝƚŚɴ ?ĂƌƌĞƐƚŝŶ ? ZĞƐƉŽŶƐĞƐůĂƌŐĞůǇĐŽƌƌĞůĂƚĞĚ
with those observed for the pharmacology of Y receptor agonist induced
ŝŶƚĞƌŶĂůŝƐĂƚŝŽŶ ? ƐƵŐŐĞƐƚŝŶŐ ƚŚĂƚ ŝƚ ŝƐ ƚŚĞ ƌĞĐƌƵŝƚŵĞŶƚ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ƚŚĂƚ ůĂƌŐĞůǇ
drives endocytosis of Y receptors. This conclusion was supported by single
molecule imaging studies, such as FCS and PCH, whereby agonist occupancy
resulted in a slowing of receptor diffusion, interpreted as clustering of activated
receptors prior to their endocytosis. These FCS observations supported a well
ĞƐƚĂďůŝƐŚĞĚĞŶĚŽĐǇƚŝĐƉĂƚŚǁĂǇĚĞƉĞŶĚĞŶƚƵƉŽŶɴ ?ĂƌƌĞƐƚŝŶĂŶĚƚŚĞƌĞĐƌƵŝƚŵĞŶƚŽĨ
clathrin coated pits (Goodman et al., 1996, Luttrell and Gesty-Palmer, 2010).
Understanding the molecular mechanisms of receptor effector protein
ŝŶƚĞƌĂĐƚŝŽŶƐŝƐƉĂƌƚŝĐƵůĂƌůǇŝŵƉŽƌƚĂŶƚŝŶůŝŐŚƚŽĨƚŚĞĂďŝůŝƚǇŽĨɴ ?ĂƌƌĞƐƚŝŶ ?ƚŽĂĐƚĂƐ
a signalling components in its own right with potentially beneficial therapeutic
ŽƵƚĐŽŵĞƐ ?sŝŽůŝŶĞƚĂů ? ? ? ? ? ? Z ?dŽĨƵƌƚŚĞƌŝŶǀĞƐƚŝŐĂƚĞƚŚĞĞĨĨĞĐƚŽĨzƌĞĐĞƉƚŽƌ Wɴ ?
arrestin interactions, a novel version of BiFC using superfolder GFP fragments was
used for the first time in FCS. This revealed slow mobility of discretely defined Y1
ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ? ĐŽŵƉůĞǆĞƐ ĂŶĚ ƚŚĞŝƌ ĐůƵƐƚĞƌŝŶŐ ƉƌŝŽƌ ƚŽ ĞŶĚŽĐǇƚŽƐŝƐ ?
Molecular brightness analysis using PCH indicated a symmetrical mode of
ƌĞĐƌƵŝƚŵĞŶƚ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ? ƚŽ ŝŶĚŝǀŝĚƵĂů z ? ƌĞĐĞƉƚŽƌ ĐŽŵƉůĞǆĞƐ ǁŚŝĐŚ ǁĞƌĞ
potentially oligomeric in nature. Single molecule imaging using BiFC therefore
ĂůůŽǁĞĚ ƚŚĞ ŝŶǀĞƐƚŝŐĂƚŝŽŶ ŽĨ ĚĞĨŝŶĞĚ z ƌĞĐĞƉƚŽƌ ? ɴ ?ĂƌƌĞƐƚŝŶ ? ĐŽŵƉůĞǆĞƐ Ăƚ ƚŚĞ
plasma membrane prior to endocytosis. However questions remain as to the
downstream intracellular signalling properties of these discrete complexes (for
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example to ERK signalling). Investigating this is the key to understanding potential
agonist directed signalling bias. The use of two colour cross correlation FCS may
be an option. Here two detection channels separate the emission from two
spectrally distinct fluorophores, and the fluctuations from both can each be
autocorrelated (Briddon and Hill, 2007). Cross correlation between the two
channels can also be performed to give an indication of interaction between the
two distinctly labelled species (which does not rely on proximity rather co-
diffusion). Therefore this technique could use BiFC (ie receomplemented YFP)
alongside intracellular protein such as ERK, clathrin or caveolin labelled with
spectrally distinct fluorophores (such as Cy5) to investigate potential changes in
downstream signalling partners associated with discretely identified BiFC dimer
pairings or receptor-arrestin complexes based on co-diffusion. Additionally PCH
ŝĚĞŶƚŝĨŝĞĚ ďŽƚŚ ĐůƵƐƚĞƌĞĚ z ƌĞĐĞƉƚŽƌ ?ɴ ?ĂƌƌĞƐƚŝŶ ? ĐŽŵƉůĞǆĞƐ  ?ĐŽŵƉŽŶĞŶƚ  ? Z ďƵƚ
single units (ie. not clustered) complexes were also identified. These units were
presumably not associated with clathrin coated pits, therefore questions remain
as to what these complexes represent and what they are interacting with.
The use of conventional fluorescence microscopy is of too low spatial resolution
to adequately determine interactions of BiFC complexes with downstream
partners. This is due to the diffraction limit of light being comparable or larger
than the size of many subcellular proteins (Huang et al., 2009). However recent
advances in microscopy techniques, so called super resolution have
demonstrated order of magnitude improvements in spatial resolution. One of
these, termed photoactivated localisation microscopy (PALM) uses fluorophores
that switch between bright and dark states to allow these molecules to be
activated at different time points within a diffraction limited region, so that single
fluorescence molecules can be individually activated, imaged, localised and
deactivated allowing the fraction of molecules in the fluorescent state at any one
time to be controlled to increase optic resolution. The coordinates of many
individual fluorescent molecules can then be mapped and images reconstructed.
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Recently BiFC-PALM, using photactivatable recomplemented mCherry has been
used to visualise the nanoscale interaction and localisation of the GTPase Ras
with its downstream effector Raf and indicated clustering of these complexes
(Nickerson et al., 2014). A range of photoactivatable and photoconvertible
fluorescent proteins have been shown to be suitable for BiFC, suggesting that
super resolution imaging of BiFC complexes could provide more detailed
information on the localisation of these complexes following endocytosis and the
degree of clustering that occurs.
Quantification of internalisation using high content imaging was also used to
investigate the function of GPCR dimerisation, with Snap labelling also used to
allow comparison with responses of the total receptor population (be that
monomers, dimers or oligomers). This revealed that constrained BiFC dimers
were capable of undergoing agonist induced endocytosis, countering the notion
that GPCR dimers must dissociate prior to internalisation (Lambert, 2010).
Selective mutagenesis of one protomer of the dimer showed that occupation of
one ligand binding site (Y1/Y1Y99A) and the phosphorylation of one protomer C
terminus (Y1/Y15A) was sufficient to support this. The chief limitation to these
observations is that the inherent irreversibility of BiFC essentially creates a fusion
protein between the two protomers. Hence, it is difficult to exclude the
possibility that internalisation of the wildtype protomer drags the mutant
protomer with it Co-internalisation of wildtype/mutant Y1 homodimers in the
absence of BiFC tagging would go some way to answering this. Alternatively the
use of an unrelated well characterised monomeric receptor as the second
protomer, such as CD86, would allow this question to be further addressed,
provided that the differences in receptor structures (for example CD86 only has a
single TM domain) does not adversely affect expression of complexes.
The work of Chapters 4 and 5 indirectly suggested a single Y receptor protomer
was sufficient to recruit E-arrestins, whether or not the receptors were joined as
Ăŝ&ŚŽŵŽ ?ĚŝŵĞƌ ?dŚŝƐĂƌŐƵĞƐĂŐĂŝŶƐƚĂŶĂƐǇŵŵĞƚƌŝĐƌĞĐƌƵŝƚŵĞŶƚŽĨɴ ?ĂƌƌĞƐƚŝŶ
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ƚŽ Ă 'WZ ĚŝŵĞƌ ? ǁŚĞƌĞďǇ ƚŚĞ ĂĐƚŝǀĂƚŝŽŶ ĂŶĚ ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ƐĞŶƐŽƌƐ ŽĨ ɴ ?
arrestin engage with separate protomers of the dimer as proposed by Fotiadis et
al., (Fotiadis et al., 2006).
However it is worth noting that BiFC here identified two protomers in a dimer as
a unit, but that does not eliminate the possibility that higher order oligomers
(such as trimers or tetramers) are present. This higher order oligomerisation may
ĂĨĨĞĐƚ ƚŚĞ ƉŽƚĞŶƚŝĂů ŵŽĚĞ ŽĨ ɴ ?ĂƌƌĞƐƚŝŶ ƌĞĐƌƵŝƚŵĞŶƚ ?  ĚĚŝƚŝŽŶĂůůǇ ƚŚĞ ŵŽĚĞ ŽĨ
recruitment may change with experimental/physiological conditions. For example
this may be ligand dependent, particularly when the evidence of ligand induced
ƌĞĐĞƉƚŽƌ  RƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ďĂƌĐŽĚĞƐ ? ĂůƚĞƌŝŶŐ ɴ ?ĂƌƌĞƐƚŝŶ ƐŝŐŶĂůůŝŶŐ ŝƐ ĂůƐŽ
considered (Nobles et al., 2011). In addition there is also evidence from
rhodopsin studies, that the stoichiometry of arrestin recruitment changes with
the proportion of activated receptors (Sommer et al., 2011). This suggests there
ŵĂǇ ďĞ Ă ĚĞŐƌĞĞ ŽĨ ƐƚƌƵĐƚƵƌĂů ƉůĂƐƚŝĐŝƚǇ ŝŶ ɴ ?ĂƌƌĞƐƚŝŶ ƌĞĐƌƵŝƚŵĞŶƚ ǁŝƚŚ ŵƵůƚŝƉůĞ
modes possible.
ĚĚŝƚŝŽŶĂůůǇĂƐŝŶƚĞƌŶĂůŝƐĂƚŝŽŶŝƐĂŶŝŶĚŝƌĞĐƚŵĞĂƐƵƌĞŽĨɴ ?ĂƌƌĞƐƚŝŶƌĞĐƌƵŝƚŵĞŶƚƚŽ
BiFC constrained dimers, this assumes that GRKs are able to phosphorylate a non
ligand occupied receptor protomer. To address this issue mutations that mimic
phosphorylation could be introduced into the Y1Y99A protomer which would
remove the need for GRK phosphorylation. If this mutant (ie. Y1Y99A +
phosphorylation) when coexpressed with the Y15A (phosphorylation negative)
protomer was able to restore dimer internalisation, this would show an
ĂƐǇŵŵĞƚƌŝĐŵŽĚĞŽĨɴ ?ĂƌƌĞƐƚŝŶƌĞĐƌƵŝƚŵĞŶƚŝƐƉŽƐƐŝďůĞ ?
Combining BiFC with BRET would also provide a more accurate assessment of the
ĂƐƐŽĐŝĂƚŝŽŶŽĨɴ ?ĂƌƌĞƐƚŝŶ ? ?ŽƌŽƚŚĞƌĞĨĨĞĐƚŽƌƉƌŽƚĞŝŶƐ ?ǁŝƚŚĚŝƐĐƌĞƚĞ'WZĚŝŵĞƌƐ ?
dŚĞ ůƵŵŝŶĞƐĐĞŶƚ ĚŽŶŽƌ ĐĂŶ ďĞ ĂƚƚĂĐŚĞĚ ƚŽ ɴ ?ĂƌƌĞƐƚŝŶ ? ǁŝƚŚ ƚŚĞ ĨůƵŽƌĞƐĐĞŶĐĞ
acceptor being recomplemented YFP (ie. GPCR BiFC dimer). The advantage of
Zd ŝƐƚŚĂƚ ŝƚĐĂŶƉƌŽǀŝĚĞĂƌĞĂů ƚŝŵĞŵĞĂƐƵƌĞŵĞŶƚŽĨɴ ?ĂƌƌĞƐƚŝŶ ?ƌĞĐƌƵŝƚŵĞŶƚ ?
The fold change in fluorescence produced in BRET assays is typically small
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(Salahpour et al., 2012),which is a potential problem for sensitivity when the
relatively low expression of the BiFC dimer population in these cell lines is also
considered. A solution to this may be the use of the newer luminescent donors
with increased quantum yields and longer lifespans of emission, such as the
mutant form of luciferase RLuc8 (De et al., 2007) or the engineered luciferase
reporter NanoLuc (Hall et al., 2012). However a caveat to using these brighter
luciferase variants is that overexpression may make it very difficult to
differentiate a specific BRET from the general luciferase emission.
Quantification of BIFC Y1 heterodimer internalisation (Chapter 6), revealed
modified pharmacology for constrained Y1/Y5 BiFC dimers that was unseen in
whole receptor population studies, or for other Y1 heterodimer combinations The
most striking alteration was a switching in the nature of Y5 selective antagonism
from surmountable at single receptor expression systems to insurmountable at
the Y1/Y5 BiFC dimer. This alteration was independent of the structure of the Y5
antagonist used, and was not replicated by Y1 antagonist data, where BIBO3304
became ineffective. The fact that these effects were able to be measured from
the responses of a well defined BiFC dimer strongly suggests an allosteric
interaction occurring between the Y1 and Y5 protomers.
There is still a risk that allosteric effects are an artefact of BiFC complementation.
However this risk is minimised by the specificity of this allosterism, with no
ĐŚĂŶŐĞƐŽďƐĞƌǀĞĚĨŽƌz ?ĂŶĚz ?Žƌz ?ĂŶĚɴ ?ZƉĂŝƌŝŶŐƐ ?dŽĨƵƌƚŚĞƌĐŽŶĨŝƌŵƚŚĂƚ
altered Y1/Y5 pharmacology was not an artefact of BiFC, co-expression
experiments could be performed to investigate the internalisation of co-
expressed (but not BiFC joined) partners. However, similar to whole receptor
populations studies (Chapter 6) coexpression studies may still be unable to detect
the specific responses of a Y1/Y5 heterodimer from that of the other Y1 and Y5
receptor species that are likely to be present. For example, even if these
receptors were expressed at equivalent levels and showed an equal propensity to
form stable dimers, the heterodimer component would form only 50% of a
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population that also included Y1/Y1 and Y5/Y5 homodimers. This illustrates the
strength of the BiFC technique whereby responses can be attributed to a discrete
dimer population without the confounding influence of monomer or homodimer
internalisation responses.
It is also worth noting that Gehlert et al., (2007) observed comparable changes
that support those observed in this study, in the nature of Y1 and Y5 selective
antagonists in respect to cAMP accumulation using coexpressed untagged Y1 and
Y5 receptors (Gehlert et al., 2007), albeit these experiments were performed in
AV-12 cells, not HEK293T as here, with unknown levels of respective absolute
expression. The structure of the Y5 receptor is most divergent of all the Y
subtypes, in that it has a longer intracellular loop 3 and a shorter C terminal tail
(Michel et al., 1998), and historically this subtype (whether tagged or not) has
proven the most challenging to express recombinantly. Competition radioligand
binding assays indicated that the population of FLAG Y5-Yc receptors was
substantially lower than the Snap Y1-Yn population also expressed in the same
cells, and this potentially differed from the Y1/Y4 and Y1/E2AR (where E2AR
expression was not specifically measured) controls. In each case the presence of
the N terminal FLAG tag prior to the start of the receptor-Yc cDNA could facilitate
the monitoring of this receptor population using antibody live labelling
techniques. A primary antibody that selectively recognises the FLAG tag epitope is
added, followed by a secondary antibody conjugated to a fluorophore. This
technique could be used to give a qualitative indication of the membrane
localisation of these receptors and the differences in expression levels of
receptor-Yc between cell lines. The advantage of antibody labelling is that only
receptors that have successfully reached the cell surface are detected due to the
membrane impermenance of the antibody. In addition to this the granularity
algorithm is actually an indirect measure of internalisation as opposed to other
techniques which measure the actual loss of cell surface fluorescence. For
example the use of FLAG tag labelling may be a way to quantify the fraction of
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labelled receptor-Yc lost from the cell surface using enzyme linked
immunosorbent assays (ELISA), with anti-SNAP antibodies identifying the
receptor-Yn population. Although these approaches could allow measures of
receptor internalisation to be compared between subtypes and supplement
granularity data, unlike the BiFC technique used here they do not specifically
identify dimeric complexes. Additionally the work of Gehlert et al. (2007) has
indicated that coexpression of Y1 and Y5 receptor subtypes increased the rate of
Y5 receptor internalisation and can also change the trafficking fate. Again, these
data support the idea of a Y1/Y5 heterodimeric receptor complex with unique
pharmacology, arrestin recruitment and trafficking properties. However as
previously noted, coexpression systems can only imply specific associations of
receptors based on proximity. It would therefore be interesting to repeat aspects
of this study, using both the combined Snap-BiFC system where the dimeric state
is constrained, and the co-expressing Y1 and Y5 cell lines described above.
However a caveat to this is that the irreversible nature of BiFC may itself
influence trafficking, but it would be interesting to see whether localisation with
markers of the endocytic pathway (such as transferrin to identify recycling
compartments and lysotracker to identify lysosomes on the degradative pathway)
occurs and if trafficking of a known dimer differs from either subtype expressed
alone.
As previously detailed in Chapters 5 and 6, multiple regions have been proposed
as the site/sites of protomer-protomer interfaces. While transmembrane domain
regions might be responsible for determining the structural integrity and stability
of the dimer, the extracellular loops are promising (especially for peptide
receptors) as a mechanism for allosteric modulation due to their influence over
the ligand binding pocket and access of ligands to and from it. Equally the unique
intracellular domains of the Y5 receptor compared to the Y1 subtype (e.g. large
ICL3) might play a role in allosteric modulation of the dimer by effector proteins
such as arrestins  which would then impact on ligand pharmacology. The use of
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selective mutagenesis or chimeric receptors at BiFC constrained dimers may
allow the effect of particular domains on dimer pharmcology to be investigated.
For example exchanging the extracellular loops (e.g. ECL2) of the Y1 and Y5
receptor subtypes might reverse the effects of heterodimerisation on ligand
pharmacology observed. A challenge to this technique will be distinguishing
effects on dimer allosterism of these mutations from more general effects they
may bestow on ligand binding at the orthosteric site. Nevertheless such
investigations may be possible using the BiFC system as it would allow the
heterodimer specific pharmacology to be probed.
Ultimately, for validating the role of the Y1/Y5 heterodimer in native cells and
tissues (e.g. on feeding responses) and the potential therapeutic targeting of this
pairing in the future, the development of heterodimer selective ligands is
required. For some types of heterodimer ligands, selectivity could simply be
achieved because the ligand influences allosteric communication between the
receptor protomers. For example, this phenomenon has been recently observed
at functionally constrained dopamine D2 dimers, whereby binding of the bivalent
ligand SB269652 to one protomer othosteric ligand binding site allows it to
allosterically modulate the binding of dopamine to the second orthosteric site
(Lane et al., 2014). In order to do this SB269652 must bind at a secondary site
found at the extracellular end of TM2 and TM7. Interestingly the introduction of a
ligand binding mutation into the second protomer switched the nature of
SB269652 pharmacology in respect to dopamine signalling from allosteric to
competitive. Potential bivalent ligands are already identified for the Y receptor
family, such as. the dimeric C terminal NPY analogue GR231118, which is highly
potent Y1 receptor antagonist (Dumont and Quirion, 2000, Kilpatrick et al.,
2010), and of much greater affinity at this receptor than its monomeric
components. However the size of GR231118 makes it unlikely that it would be
able to simultaneously bridge both orthosteric binding sites of a Y1 receptor
dimer. However the does not mean that dimerisation does not impact GR231118
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pharmacology. The twin pharmacophores mean that when one C terminal
domain of GR231118 is docked at one protomer, it acts as a tethered ligand
increasing the local concentration of the second C terminal domain in the
environment of the second protomer. This mechanism could be tested using the
BiFC system and the Y1/Y99A dimer (with only one GR231118 binding site),
allowing the mode of GR231118 antagonism to be assessed at both Snap Y1/Y1 or
Y1/Y1Y99A homodimers, in a manner similar to the work of Lane et al., 2014
(Lane et al., 2014). If such a mechanism exists, the ability to synthesise chimeric
dimer GR231118 peptides (Mountford et al., 2014) in which one arm of the
peptide incorporates Y5 selective amino acids (e.g. Ala31, Aib32) (Cabrele et al.,
2000) may be a strategy to develop Y1/Y5 selective antagonists.
Although no indications of cooperativity were observed for the Snap Y1/Y1
homodimer pairings, this effect is typically difficult to observe using radioligand
binding techniques as both orthosteric sites are identical. The use of fluorescent
ligand single cell binding kinetics comparing infinite dilution with the presence of
potential allosteric modulators, may be a way to investigate this.. For example
both monovalent and bivalent fluorescent GR231118 based antagonists have
recently been developed with nanomolar affinity for the Y1 receptor (Mountford
et al., 2014). May et al (2007) has suggested that alterations in dissociation rates
may better reflect dimer allosterism with conformation changes of protomer A
occurring in response to ligand binding at protomer B, with the second site
effectively acting as an allosteric modulator (May et al., 2007). This technique
has previously been used to illustrate strong cooperative interactions between
orthosteric binding sites of adenosine A3 receptors (May et al., 2011), which was
manifested as changes in fluorescent ligand dissociation rates. For example
comparison between existing monomeric and dimeric ligand, and the use of the
Snap Y1/Y1Y99A co-expressing cells here would allow the potential extent of
cooperativity across the dimer interface to be investigated.
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Other Y receptor dimer combinations may also have future therapeutic benefit.
For example the Y2/Y4 receptor subtypes have been shown to work in concert to
regulate PP or PYY induced satiety. Currently the lack of truly subject selective
ligands for either protomer makes it difficult to investigate these dimers to the
same extent in vitro ? ĂůƚŚŽƵŐŚ ƚŚĞƌĞ ĂƌĞ ŝŶĚŝĐĂƚŝŽŶƐ ƚŚĂƚ ƚŚĞ ŝŶƚƌŽĚƵĐƚŝŽŶ ŽĨ ɴ ?
amino acids may lead to the synthesis of compounds with high Y4 selectivity in
the future (Berlicki et al., 2013). A more general issue for Y2/Y4 ligands (as
experienced for the Y2/Y4 obinepitde) is that they are agonists, and are thus
prone to limiting side effects such as nausea. Thus, in revealing modified
pharmacology observed for Y1/Y5 hetero-dimers, the work in this thesis may
offer one approach for re-evaluation of the role and targeting of these receptors
in the central control of appetite. Functional dimerisation may explain the failure
of current therapies that only target either subtype. The BiFC system therefore
offers opportunities to screen and identify Y1/Y5 heterodimer selective ligands in
the future, which if efficacious in animal models, may be a valid therapeutic
option for the treatment of obesity.
354
References
ABBOTT, C. R., SMALL, C. J., KENNEDY, A. R., NEARY, N. M., SAJEDI, A.,
GHATEI, M. A. & BLOOM, S. R. 2005. Blockade of the neuropeptide Y
Y2 receptor with the specific antagonist BIIE0246 attenuates the effect
of endogenous and exogenous peptide YY(3-36) on food intake. Brain
Res, 1043, 139-44.
ACHARYA, S., SAAD, Y. & KARNIK, S. S. 1997. Transducin-alpha C-terminal
peptide binding site consists of C-D and E-F loops of rhodopsin. J Biol
Chem, 272, 6519-24.
ADRIAN, T. E., BLOOM, S. R., HERMANSEN, K. & IVERSEN, J. 1978. Pancreatic
polypeptide, glucagon and insulin secretion from the isolated perfused
canine pancreas. Diabetologia, 14, 413-7.
AHMED, M. R., ZHAN, X., SONG, X., KOOK, S., GUREVICH, V. V. & GUREVICH,
E. V. 2011. Ubiquitin ligase parkin promotes Mdm2-arrestin interaction
but inhibits arrestin ubiquitination. Biochemistry, 50, 3749-63.
AKABAYASHI, A., LEVIN, N., PAEZ, X., ALEXANDER, J. T. & LEIBOWITZ, S. F.
1994. Hypothalamic neuropeptide Y and its gene expression: relation to
light/dark cycle and circulating corticosterone. Mol Cell Neurosci, 5,
210-8.
AKERBERG, H., FALLMAR, H., SJODIN, P., BOUKHARTA, L., GUTIERREZ-DE-
TERAN, H., LUNDELL, I., MOHELL, N. & LARHAMMAR, D. 2010.
Mutagenesis of human neuropeptide Y/peptide YY receptor Y2 reveals
additional differences to Y1 in interactions with highly conserved ligand
positions. Regul Pept, 163, 120-9.
ALBIZU, L., COTTET, M., KRALIKOVA, M., STOEV, S., SEYER, R., BRABET, I.,
ROUX, T., BAZIN, H., BOURRIER, E., LAMARQUE, L., BRETON, C.,
RIVES, M. L., NEWMAN, A., JAVITCH, J., TRINQUET, E., MANNING, M.,
PIN, J. P., MOUILLAC, B. & DURROUX, T. 2010. Time-resolved FRET
between GPCR ligands reveals oligomers in native tissues. Nat Chem
Biol, 6, 587-94.
ALLISON, S. J. & HERZOG, H. 2006. NPY and bone. EXS, 171-82.
ANGERS, S., SALAHPOUR, A. & BOUVIER, M. 2002. Dimerization: an emerging
concept for G protein-coupled receptor ontogeny and function. Annu
Rev Pharmacol Toxicol, 42, 409-35.
ANGERS, S., SALAHPOUR, A., JOLY, E., HILAIRET, S., CHELSKY, D., DENNIS,
M. & BOUVIER, M. 2000. Detection of beta 2-adrenergic receptor
dimerization in living cells using bioluminescence resonance energy
transfer (BRET). Proc Natl Acad Sci U S A, 97, 3684-9.
ASAKAWA, A., INUI, A., UENO, N., FUJIMIYA, M., FUJINO, M. A. & KASUGA, M.
1999. Mouse pancreatic polypeptide modulates food intake, while not
influencing anxiety in mice. Peptides, 20, 1445-8.
AULD, D. S., JOHNSON, R. L., ZHANG, Y. Q., VEITH, H., JADHAV, A., YASGAR,
A., SIMEONOV, A., ZHENG, W., MARTINEZ, E. D., WESTWICK, J. K.,
AUSTIN, C. P. & INGLESE, J. 2006. Fluorescent protein-based cellular
assays analyzed by laser-scanning microplate cytometry in 1536-well
plate format. Methods Enzymol, 414, 566-89.
AVISSAR, S., AMITAI, G. & SOKOLOVSKY, M. 1983. Oligomeric structure of
muscarinic receptors is shown by photoaffinity labeling: subunit
355
assembly may explain high- and low-affinity agonist states. Proc Natl
Acad Sci U S A, 80, 156-9.
AXELROD, D., KOPPEL, D. E., SCHLESSINGER, J., ELSON, E. & WEBB, W. W.
1976. Mobility measurement by analysis of fluorescence photobleaching
recovery kinetics. Biophys J, 16, 1055-69.
AYOUB, M. A., COUTURIER, C., LUCAS-MEUNIER, E., ANGERS, S., FOSSIER,
P., BOUVIER, M. & JOCKERS, R. 2002. Monitoring of ligand-
independent dimerization and ligand-induced conformational changes
of melatonin receptors in living cells by bioluminescence resonance
energy transfer. J Biol Chem, 277, 21522-8.
AYOUB, M. A. & PFLEGER, K. D. 2010. Recent advances in bioluminescence
resonance energy transfer technologies to study GPCR
heteromerization. Curr Opin Pharmacol, 10, 44-52.
AZZI, M., CHAREST, P. G., ANGERS, S., ROUSSEAU, G., KOHOUT, T.,
BOUVIER, M. & PINEYRO, G. 2003. Beta-arrestin-mediated activation of
MAPK by inverse agonists reveals distinct active conformations for G
protein-coupled receptors. Proc Natl Acad Sci U S A, 100, 11406-11.
BABILON, S., MORL, K. & BECK-SICKINGER, A. G. 2013. Towards improved
receptor targeting: anterograde transport, internalization and
postendocytic trafficking of neuropeptide Y receptors. Biol Chem, 394,
921-36.
BADER, R., BETTIO, A., BECK-SICKINGER, A. G. & ZERBE, O. 2001. Structure
and dynamics of micelle-bound neuropeptide Y: comparison with
unligated NPY and implications for receptor selection. J Mol Biol, 305,
307-29.
BAI, F. L., YAMANO, M., SHIOTANI, Y., EMSON, P. C., SMITH, A. D., POWELL,
J. F. & TOHYAMA, M. 1985. An arcuato-paraventricular and -
dorsomedial hypothalamic neuropeptide Y-containing system which
lacks noradrenaline in the rat. Brain Res, 331, 172-5.
BAILLIE, G. S., SOOD, A., MCPHEE, I., GALL, I., PERRY, S. J., LEFKOWITZ, R.
J. & HOUSLAY, M. D. 2003. beta-Arrestin-mediated PDE4 cAMP
phosphodiesterase recruitment regulates beta-adrenoceptor switching
from Gs to Gi. Proc Natl Acad Sci U S A, 100, 940-5.
BAKER, J. G. 2005. The selectivity of beta-adrenoceptor antagonists at the
human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol, 144,
317-22.
BAKER, J. G. 2010. The selectivity of beta-adrenoceptor agonists at human
beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol, 160, 1048-
61.
BALARAMAN, G. S., BHATTACHARYA, S. & VAIDEHI, N. 2010. Structural
insights into conformational stability of wild-type and mutant beta1-
adrenergic receptor. Biophys J, 99, 568-77.
BALASUBRAMANIAM, A., MULLINS, D. E., LIN, S., ZHAI, W., TAO, Z.,
DHAWAN, V. C., GUZZI, M., KNITTEL, J. J., SLACK, K., HERZOG, H. &
PARKER, E. M. 2006. Neuropeptide Y (NPY) Y4 receptor selective
agonists based on NPY(32-36): development of an anorectic Y4
receptor selective agonist with picomolar affinity. J Med Chem, 49,
2661-5.
BALASUBRAMANIAM, A., SHERIFF, S., JOHNSON, M. E., PRABHAKARAN, M.,
HUANG, Y., FISCHER, J. E. & CHANCE, W. T. 1994. [D-
TRP32]neuropeptide Y: a competitive antagonist of NPY in rat
hypothalamus. J Med Chem, 37, 811-5.
356
BALASUBRAMANIAM, A. A. 1997. Neuropeptide Y family of hormones: receptor
subtypes and antagonists. Peptides, 18, 445-57.
BALLESTEROS, J. & WEINSTEIN, H. 1995. Integrated methods for the
construction of three-dimensional models and computational probing of
structure-function relations in G protein-coupled receptors.
BALLESTEROS, J. A., JENSEN, A. D., LIAPAKIS, G., RASMUSSEN, S. G., SHI,
L., GETHER, U. & JAVITCH, J. A. 2001. Activation of the beta 2-
adrenergic receptor involves disruption of an ionic lock between the
cytoplasmic ends of transmembrane segments 3 and 6. J Biol Chem,
276, 29171-7.
BANCAUD, A., HUET, S., DAIGLE, N., MOZZICONACCI, J., BEAUDOUIN, J. &
ELLENBERG, J. 2009. Molecular crowding affects diffusion and binding
of nuclear proteins in heterochromatin and reveals the fractal
organization of chromatin. EMBO J, 28, 3785-98.
BANERES, J. L. & PARELLO, J. 2003. Structure-based analysis of GPCR
function: evidence for a novel pentameric assembly between the
dimeric leukotriene B4 receptor BLT1 and the G-protein. J Mol Biol,
329, 815-29.
BARAK, L. S., FERGUSON, S. S., ZHANG, J. & CARON, M. G. 1997a. A beta-
arrestin/green fluorescent protein biosensor for detecting G protein-
coupled receptor activation. J Biol Chem, 272, 27497-500.
BARAK, L. S., FERGUSON, S. S., ZHANG, J., MARTENSON, C., MEYER, T. &
CARON, M. G. 1997b. Internal trafficking and surface mobility of a
functionally intact beta2-adrenergic receptor-green fluorescent protein
conjugate. Mol Pharmacol, 51, 177-84.
BARAK, L. S., TIBERI, M., FREEDMAN, N. J., KWATRA, M. M., LEFKOWITZ, R.
J. & CARON, M. G. 1994. A highly conserved tyrosine residue in G
protein-coupled receptors is required for agonist-mediated beta 2-
adrenergic receptor sequestration. J Biol Chem, 269, 2790-5.
BARANOWSKA, B., WOLINSKA-WITORT, E., MARTYNSKA, L., CHMIELOWSKA,
M. & BARANOWSKA-BIK, A. 2005. Plasma orexin A, orexin B, leptin,
neuropeptide Y (NPY) and insulin in obese women. Neuro Endocrinol
Lett, 26, 293-6.
BARD, J. A., WALKER, M. W., BRANCHEK, T. A. & WEINSHANK, R. L. 1995.
Cloning and functional expression of a human Y4 subtype receptor for
pancreatic polypeptide, neuropeptide Y, and peptide YY. J Biol Chem,
270, 26762-5.
BARKI-HARRINGTON, L., LUTTRELL, L. M. & ROCKMAN, H. A. 2003. Dual
inhibition of beta-adrenergic and angiotensin II receptors by a single
antagonist: a functional role for receptor-receptor interaction in vivo.
Circulation, 108, 1611-8.
BATTERHAM, R. L., COHEN, M. A., ELLIS, S. M., LE ROUX, C. W., WITHERS, D.
J., FROST, G. S., GHATEI, M. A. & BLOOM, S. R. 2003a. Inhibition of
food intake in obese subjects by peptide YY3-36. N Engl J Med, 349,
941-8.
BATTERHAM, R. L., COWLEY, M. A., SMALL, C. J., HERZOG, H., COHEN, M. A.,
DAKIN, C. L., WREN, A. M., BRYNES, A. E., LOW, M. J., GHATEI, M. A.,
CONE, R. D. & BLOOM, S. R. 2002. Gut hormone PYY(3-36)
physiologically inhibits food intake. Nature, 418, 650-4.
BATTERHAM, R. L., HEFFRON, H., KAPOOR, S., CHIVERS, J. E., CHANDARANA,
K., HERZOG, H., LE ROUX, C. W., THOMAS, E. L., BELL, J. D. &
357
WITHERS, D. J. 2006. Critical role for peptide YY in protein-mediated
satiation and body-weight regulation. Cell Metab, 4, 223-33.
BATTERHAM, R. L., LE ROUX, C. W., COHEN, M. A., PARK, A. J., ELLIS, S. M.,
PATTERSON, M., FROST, G. S., GHATEI, M. A. & BLOOM, S. R. 2003b.
Pancreatic polypeptide reduces appetite and food intake in humans. J
Clin Endocrinol Metab, 88, 3989-92.
BAYBURT, T. H., LEITZ, A. J., XIE, G., OPRIAN, D. D. & SLIGAR, S. G. 2007.
Transducin activation by nanoscale lipid bilayers containing one and
two rhodopsins. J Biol Chem, 282, 14875-81.
BAYBURT, T. H., VISHNIVETSKIY, S. A., MCLEAN, M. A., MORIZUMI, T.,
HUANG, C. C., TESMER, J. J., ERNST, O. P., SLIGAR, S. G. &
GUREVICH, V. V. 2011. Monomeric rhodopsin is sufficient for normal
rhodopsin kinase (GRK1) phosphorylation and arrestin-1 binding. J Biol
Chem, 286, 1420-8.
BENOVIC, J. L. & VON ZASTROW, M. 2014. Editorial overview: Cell regulation:
The ins and outs of G protein-coupled receptors. Curr Opin Cell Biol,
27, v-vi.
BERGLUND, M. M., LUNDELL, I., ERIKSSON, H., SOLL, R., BECK-SICKINGER,
A. G. & LARHAMMAR, D. 2001. Studies of the human, rat, and guinea
pig Y4 receptors using neuropeptide Y analogues and two distinct
radioligands. Peptides, 22, 351-6.
BERGLUND, M. M., SCHOBER, D. A., ESTERMAN, M. A. & GEHLERT, D. R.
2003a. Neuropeptide Y Y4 receptor homodimers dissociate upon
agonist stimulation. J Pharmacol Exp Ther, 307, 1120-6.
BERGLUND, M. M., SCHOBER, D. A., STATNICK, M. A., MCDONALD, P. H. &
GEHLERT, D. R. 2003b. The use of bioluminescence resonance energy
transfer 2 to study neuropeptide Y receptor agonist-induced beta-
arrestin 2 interaction. J Pharmacol Exp Ther, 306, 147-56.
BERLICKI, L., KASKE, M., GUTIERREZ-ABAD, R., BERNHARDT, G., ILLA, O.,
ORTUNO, R. M., CABRELE, C., BUSCHAUER, A. & REISER, O. 2013.
Replacement of Thr32 and Gln34 in the C-terminal neuropeptide Y
fragment 25-36 by cis-cyclobutane and cis-cyclopentane beta-amino
acids shifts selectivity toward the Y(4) receptor. J Med Chem, 56,
8422-31.
BERNTSON, G. G., ZIPF, W. B., O'DORISIO, T. M., HOFFMAN, J. A. & CHANCE,
R. E. 1993. Pancreatic polypeptide infusions reduce food intake in
Prader-Willi syndrome. Peptides, 14, 497-503.
BERTHOUZE, M., RIVAIL, L., LUCAS, A., AYOUB, M. A., RUSSO, O., SICSIC, S.,
FISCHMEISTER, R., BERQUE-BESTEL, I., JOCKERS, R. & LEZOUALC'H,
F. 2007. Two transmembrane Cys residues are involved in 5-HT4
receptor dimerization. Biochem Biophys Res Commun, 356, 642-7.
BHATTACHARYA, S., HALL, S. E. & VAIDEHI, N. 2008. Agonist-induced
conformational changes in bovine rhodopsin: insight into activation of
G-protein-coupled receptors. J Mol Biol, 382, 539-55.
BIRDSALL, N. J. 2010. Class A GPCR heterodimers: evidence from binding
studies. Trends Pharmacol Sci, 31, 499-508.
BLOCK, M. H., BOYER, S., BRAILSFORD, W., BRITTAIN, D. R., CARROLL, D.,
CHAPMAN, S., CLARKE, D. S., DONALD, C. S., FOOTE, K. M., GODFREY,
L., LADNER, A., MARSHAM, P. R., MASTERS, D. J., MEE, C. D.,
O'DONOVAN, M. R., PEASE, J. E., PICKUP, A. G., RAYNER, J. W.,
ROBERTS, A., SCHOFIELD, P., SULEMAN, A. & TURNBULL, A. V. 2002.
358
Discovery and optimization of a series of carbazole ureas as NPY5
antagonists for the treatment of obesity. J Med Chem, 45, 3509-23.
BLUME, L. C., BASS, C. E., CHILDERS, S. R., DALTON, G. D., ROBERTS, D. C.,
RICHARDSON, J. M., XIAO, R., SELLEY, D. E. & HOWLETT, A. C. 2013.
Striatal CB1 and D2 receptors regulate expression of each other,
CRIP1A and delta opioid systems. J Neurochem, 124, 808-20.
BLUNDELL, T. L., PITTS, J. E., TICKLE, I. J., WOOD, S. P. & WU, C. W. 1981.
X-ray analysis (1. 4-A resolution) of avian pancreatic polypeptide:
Small globular protein hormone. Proc Natl Acad Sci U S A, 78, 4175-9.
BOCKENHAUER, S., FURSTENBERG, A., YAO, X. J., KOBILKA, B. K. &
MOERNER, W. E. 2011. Conformational dynamics of single G protein-
coupled receptors in solution. J Phys Chem B, 115, 13328-38.
BOEY, D., HEILBRONN, L., SAINSBURY, A., LAYBUTT, R., KRIKETOS, A.,
HERZOG, H. & CAMPBELL, L. V. 2006. Low serum PYY is linked to
insulin resistance in first-degree relatives of subjects with type 2
diabetes. Neuropeptides, 40, 317-24.
BOHME, I., STICHEL, J., WALTHER, C., MORL, K. & BECK-SICKINGER, A. G.
2008. Agonist induced receptor internalization of neuropeptide Y
receptor subtypes depends on third intracellular loop and C-terminus.
Cell Signal, 20, 1740-9.
BOROWSKY, B., WALKER, M. W., BARD, J., WEINSHANK, R. L., LAZ, T. M.,
VAYSSE, P., BRANCHEK, T. A. & GERALD, C. 1998. Molecular biology
and pharmacology of multiple NPY Y5 receptor species homologs. Regul
Pept, 75-76, 45-53.
BOUVIER, M., HAUSDORFF, W. P., DE BLASI, A., O'DOWD, B. F., KOBILKA, B.
K., CARON, M. G. & LEFKOWITZ, R. J. 1988. Removal of
phosphorylation sites from the beta 2-adrenergic receptor delays onset
of agonist-promoted desensitization. Nature, 333, 370-3.
BRAUN, L., CHRISTOPHE, T. & BOULAY, F. 2003. Phosphorylation of key serine
residues is required for internalization of the complement 5a (C5a)
anaphylatoxin receptor via a beta-arrestin, dynamin, and clathrin-
dependent pathway. J Biol Chem, 278, 4277-85.
BREIT, A., LAGACE, M. & BOUVIER, M. 2004. Hetero-oligomerization between
beta2- and beta3-adrenergic receptors generates a beta-adrenergic
signaling unit with distinct functional properties. J Biol Chem, 279,
28756-65.
BRIDDON, S. J., GANDIA, J., AMARAL, O. B., FERRE, S., LLUIS, C., FRANCO,
R., HILL, S. J. & CIRUELA, F. 2008. Plasma membrane diffusion of G
protein-coupled receptor oligomers. Biochim Biophys Acta, 1783, 2262-
8.
BRIDDON, S. J. & HILL, S. J. 2007. Pharmacology under the microscope: the
use of fluorescence correlation spectroscopy to determine the
properties of ligand-receptor complexes. Trends Pharmacol Sci, 28,
637-45.
BRIDDON, S. J., MIDDLETON, R. J., CORDEAUX, Y., FLAVIN, F. M.,
WEINSTEIN, J. A., GEORGE, M. W., KELLAM, B. & HILL, S. J. 2004a.
Quantitative analysis of the formation and diffusion of A1-adenosine
receptor-antagonist complexes in single living cells. Proc Natl Acad Sci
U S A, 101, 4673-8.
BRIDDON, S. J., MIDDLETON, R. J., YATES, A. S., GEORGE, M. W., KELLAM, B.
& HILL, S. J. 2004b. Application of fluorescence correlation
spectroscopy to the measurement of agonist binding to a G-protein
359
coupled receptor at the single cell level. Faraday Discuss, 126, 197-
207; discussion 245-54.
BROCK, C., OUESLATI, N., SOLER, S., BOUDIER, L., RONDARD, P. & PIN, J. P.
2007. Activation of a dimeric metabotropic glutamate receptor by
intersubunit rearrangement. J Biol Chem, 282, 33000-8.
BRZOBOHATY, B. & KOVAC, L. 1986. Factors enhancing genetic transformation
of intact yeast cells modify cell wall porosity. J Gen Microbiol, 132,
3089-93.
BUSILLO, J. M., ARMANDO, S., SENGUPTA, R., MEUCCI, O., BOUVIER, M. &
BENOVIC, J. L. 2010. Site-specific phosphorylation of CXCR4 is
dynamically regulated by multiple kinases and results in differential
modulation of CXCR4 signaling. J Biol Chem, 285, 7805-17.
BUTCHER, A. J., PRIHANDOKO, R., KONG, K. C., MCWILLIAMS, P., EDWARDS,
J. M., BOTTRILL, A., MISTRY, S. & TOBIN, A. B. 2011. Differential G-
protein-coupled receptor phosphorylation provides evidence for a
signaling bar code. J Biol Chem, 286, 11506-18.
CABANTOUS, S. & WALDO, G. S. 2006. In vivo and in vitro protein solubility
assays using split GFP. Nat Methods, 3, 845-54.
CABELLO, N., GANDIA, J., BERTARELLI, D. C., WATANABE, M., LLUIS, C.,
FRANCO, R., FERRE, S., LUJAN, R. & CIRUELA, F. 2009. Metabotropic
glutamate type 5, dopamine D2 and adenosine A2a receptors form
higher-order oligomers in living cells. J Neurochem, 109, 1497-507.
CABRELE, C. & BECK-SICKINGER, A. G. 2000. Molecular characterization of
the ligand-receptor interaction of the neuropeptide Y family. J Pept Sci,
6, 97-122.
CABRELE, C., LANGER, M., BADER, R., WIELAND, H. A., DOODS, H. N.,
ZERBE, O. & BECK-SICKINGER, A. G. 2000. The first selective agonist
for the neuropeptide YY5 receptor increases food intake in rats. J Biol
Chem, 275, 36043-8.
CALEBIRO, D., RIEKEN, F., WAGNER, J., SUNGKAWORN, T., ZABEL, U.,
BORZI, A., COCUCCI, E., ZURN, A. & LOHSE, M. J. 2013. Single-
molecule analysis of fluorescently labeled G-protein-coupled receptors
reveals complexes with distinct dynamics and organization. Proc Natl
Acad Sci U S A, 110, 743-8.
CALLEN, L., MORENO, E., BARROSO-CHINEA, P., MORENO-DELGADO, D.,
CORTES, A., MALLOL, J., CASADO, V., LANCIEGO, J. L., FRANCO, R.,
LLUIS, C., CANELA, E. I. & MCCORMICK, P. J. 2012. Cannabinoid
receptors CB1 and CB2 form functional heteromers in brain. J Biol
Chem, 287, 20851-65.
CANALS, M., BURGUENO, J., MARCELLINO, D., CABELLO, N., CANELA, E. I.,
MALLOL, J., AGNATI, L., FERRE, S., BOUVIER, M., FUXE, K., CIRUELA,
F., LLUIS, C. & FRANCO, R. 2004. Homodimerization of adenosine A2A
receptors: qualitative and quantitative assessment by fluorescence and
bioluminescence energy transfer. J Neurochem, 88, 726-34.
CANALS, M., MARCELLINO, D., FANELLI, F., CIRUELA, F., DE BENEDETTI, P.,
GOLDBERG, S. R., NEVE, K., FUXE, K., AGNATI, L. F., WOODS, A. S.,
FERRE, S., LLUIS, C., BOUVIER, M. & FRANCO, R. 2003. Adenosine
A2A-dopamine D2 receptor-receptor heteromerization: qualitative and
quantitative assessment by fluorescence and bioluminescence energy
transfer. J Biol Chem, 278, 46741-9.
CASADO, V., CORTES, A., MALLOL, J., PEREZ-CAPOTE, K., FERRE, S., LLUIS,
360
heteromers: a better choice as targets for drug development than
GPCR monomers? Pharmacol Ther, 124, 248-57.
CASADO, V., FERRADA, C., BONAVENTURA, J., GRACIA, E., MALLOL, J.,
CANELA, E. I., LLUIS, C., CORTES, A. & FRANCO, R. 2009b. Useful
pharmacological parameters for G-protein-coupled receptor
homodimers obtained from competition experiments. Agonist-
antagonist binding modulation. Biochem Pharmacol, 78, 1456-63.
CERDA-REVERTER, J. M. & LARHAMMAR, D. 2000. Neuropeptide Y family of
peptides: structure, anatomical expression, function, and molecular
evolution. Biochem Cell Biol, 78, 371-92.
CEZANNE, L., LECAT, S., LAGANE, B., MILLOT, C., VOLLMER, J. Y., MATTHES,
H., GALZI, J. L. & LOPEZ, A. 2004. Dynamic confinement of NK2
receptors in the plasma membrane. Improved FRAP analysis and
biological relevance. J Biol Chem, 279, 45057-67.
CHABRE, M., DETERRE, P. & ANTONNY, B. 2009. The apparent cooperativity of
some GPCRs does not necessarily imply dimerization. Trends Pharmacol
Sci, 30, 182-7.
CHABRE, M. & LE MAIRE, M. 2005. Monomeric G-protein-coupled receptor as a
functional unit. Biochemistry, 44, 9395-403.
CHANDRASEKERA, P. C., WAN, T. C., GIZEWSKI, E. T., AUCHAMPACH, J. A. &
LASLEY, R. D. 2013. Adenosine A1 receptors heterodimerize with
beta1- and beta2-adrenergic receptors creating novel receptor
complexes with altered G protein coupling and signaling. Cell Signal,
25, 736-42.
CHEN, Y., MULLER, J. D., SO, P. T. & GRATTON, E. 1999. The photon counting
histogram in fluorescence fluctuation spectroscopy. Biophys J, 77, 553-
67.
CHEN, Y. J., OLDFIELD, S., BUTCHER, A. J., TOBIN, A. B., SAXENA, K.,
GUREVICH, V. V., BENOVIC, J. L., HENDERSON, G. & KELLY, E. 2013.
Identification of phosphorylation sites in the COOH-terminal tail of the
mu-opioid receptor. J Neurochem, 124, 189-99.
CHENG, Z. J. & MILLER, L. J. 2001. Agonist-dependent dissociation of
oligomeric complexes of G protein-coupled cholecystokinin receptors
demonstrated in living cells using bioluminescence resonance energy
transfer. J Biol Chem, 276, 48040-7.
CHEREZOV, V., ROSENBAUM, D. M., HANSON, M. A., RASMUSSEN, S. G.,
THIAN, F. S., KOBILKA, T. S., CHOI, H. J., KUHN, P., WEIS, W. I.,
KOBILKA, B. K. & STEVENS, R. C. 2007. High-resolution crystal
structure of an engineered human beta2-adrenergic G protein-coupled
receptor. Science, 318, 1258-65.
CHERFILS, J. & ZEGHOUF, M. 2013. Regulation of small GTPases by GEFs,
GAPs, and GDIs. Physiol Rev, 93, 269-309.
CHEUNG, B. M., CHEUNG, T. T. & SAMARANAYAKE, N. R. 2013. Safety of
antiobesity drugs. Ther Adv Drug Saf, 4, 171-81.
CHIEN, E. Y., LIU, W., ZHAO, Q., KATRITCH, V., HAN, G. W., HANSON, M. A.,
SHI, L., NEWMAN, A. H., JAVITCH, J. A., CHEREZOV, V. & STEVENS, R.
C. 2010. Structure of the human dopamine D3 receptor in complex with
a D2/D3 selective antagonist. Science, 330, 1091-5.
CHUN, L. S., FREE, R. B., DOYLE, T. B., HUANG, X. P., RANKIN, M. L. &
SIBLEY, D. R. 2013. D1-D2 dopamine receptor synergy promotes
calcium signaling via multiple mechanisms. Mol Pharmacol, 84, 190-
200.
361
CHUNG, K. Y., RASMUSSEN, S. G., LIU, T., LI, S., DEVREE, B. T., CHAE, P. S.,
CALINSKI, D., KOBILKA, B. K., WOODS, V. L., JR. & SUNAHARA, R. K.
2011. Conformational changes in the G protein Gs induced by the beta2
adrenergic receptor. Nature, 477, 611-5.
CIRUELA, F., CASADO, V., RODRIGUES, R. J., LUJAN, R., BURGUENO, J.,
CANALS, M., BORYCZ, J., REBOLA, N., GOLDBERG, S. R., MALLOL, J.,
CORTES, A., CANELA, E. I., LOPEZ-GIMENEZ, J. F., MILLIGAN, G.,
LLUIS, C., CUNHA, R. A., FERRE, S. & FRANCO, R. 2006. Presynaptic
control of striatal glutamatergic neurotransmission by adenosine A1-
A2A receptor heteromers. J Neurosci, 26, 2080-7.
CIRUELA, F., VALLANO, A., CUFFI, M. L., CARBONELL, L., SANCHEZ, S.,
ARNAU, J. M., TASCA, C., FERNANDEZ-DUENAS, V. & GOMEZ-SOLER,
M. 2014. Deciphering G Protein-Coupled Receptor Biology With
Fluorescence-Based Methods. Curr Pharm Biotechnol.
CLARK, J. T., KALRA, P. S., CROWLEY, W. R. & KALRA, S. P. 1984.
Neuropeptide Y and human pancreatic polypeptide stimulate feeding
behavior in rats. Endocrinology, 115, 427-9.
COHEN, F. R., LAZARENO, S. & BIRDSALL, N. J. 1996. The effects of saponin
on the binding and functional properties of the human adenosine A1
receptor. Br J Pharmacol, 117, 1521-9.
CORDEAUX, Y., BRIDDON, S. J., ALEXANDER, S. P., KELLAM, B. & HILL, S. J.
2008. Agonist-occupied A3 adenosine receptors exist within
heterogeneous complexes in membrane microdomains of individual
living cells. FASEB J, 22, 850-60.
CORMACK, B. P., VALDIVIA, R. H. & FALKOW, S. 1996. FACS-optimized
mutants of the green fluorescent protein (GFP). Gene, 173, 33-8.
CORRIDEN, R., KILPATRICK, L. E., KELLAM, B., BRIDDON, S. J. & HILL, S. J.
2014. Kinetic analysis of antagonist-occupied adenosine-A3 receptors
within membrane microdomains of individual cells provides evidence of
receptor dimerization and allosterism. FASEB J.
COX, H. M. 2007. Neuropeptide Y receptors; antisecretory control of intestinal
epithelial function. Auton Neurosci, 133, 76-85.
CRAMERI, A., WHITEHORN, E. A., TATE, E. & STEMMER, W. P. 1996. Improved
green fluorescent protein by molecular evolution using DNA shuffling.
Nat Biotechnol, 14, 315-9.
CRISCIONE, L., RIGOLLIER, P., BATZL-HARTMANN, C., RUEGER, H.,
STRICKER-KRONGRAD, A., WYSS, P., BRUNNER, L., WHITEBREAD, S.,
YAMAGUCHI, Y., GERALD, C., HEURICH, R. O., WALKER, M. W.,
CHIESI, M., SCHILLING, W., HOFBAUER, K. G. & LEVENS, N. 1998.
Food intake in free-feeding and energy-deprived lean rats is mediated
by the neuropeptide Y5 receptor. J Clin Invest, 102, 2136-45.
CVEJIC, S. & DEVI, L. A. 1997. Dimerization of the delta opioid receptor:
implication for a role in receptor internalization. J Biol Chem, 272,
26959-64.
DAMIAN, M., MARY, S., MARTIN, A., PIN, J. P. & BANERES, J. L. 2008. G
protein activation by the leukotriene B4 receptor dimer. Evidence for an
absence of trans-activation. J Biol Chem, 283, 21084-92.
DANIELS, A. J., GRIZZLE, M. K., WIARD, R. P., MATTHEWS, J. E. & HEYER, D.
2002. Food intake inhibition and reduction in body weight gain in lean
and obese rodents treated with GW438014A, a potent and selective
NPY-Y5 receptor antagonist. Regul Pept, 106, 47-54.
362
DANIELS, A. J., MATTHEWS, J. E., SLEPETIS, R. J., JANSEN, M., VIVEROS, O.
H., TADEPALLI, A., HARRINGTON, W., HEYER, D., LANDAVAZO, A.,
LEBAN, J. J. & SPALTENSTEIN, A. 1995. High-affinity neuropeptide Y
receptor antagonists. Proc Natl Acad Sci U S A, 92, 9067-71.
DANIELS, D. J., KULKARNI, A., XIE, Z., BHUSHAN, R. G. & PORTOGHESE, P. S.
2005a. A bivalent ligand (KDAN-18) containing delta-antagonist and
kappa-agonist pharmacophores bridges delta2 and kappa1 opioid
receptor phenotypes. J Med Chem, 48, 1713-6.
DANIELS, D. J., LENARD, N. R., ETIENNE, C. L., LAW, P. Y., ROERIG, S. C. &
PORTOGHESE, P. S. 2005b. Opioid-induced tolerance and dependence
in mice is modulated by the distance between pharmacophores in a
bivalent ligand series. Proc Natl Acad Sci U S A, 102, 19208-13.
DE, A., LOENING, A. M. & GAMBHIR, S. S. 2007. An improved bioluminescence
resonance energy transfer strategy for imaging intracellular events in
single cells and living subjects. Cancer Res, 67, 7175-83.
DEUPI, X. & STANDFUSS, J. 2011. Structural insights into agonist-induced
activation of G-protein-coupled receptors. Curr Opin Struct Biol, 21,
541-51.
DEWIRE, S. M., AHN, S., LEFKOWITZ, R. J. & SHENOY, S. K. 2007. Beta-
arrestins and cell signaling. Annu Rev Physiol, 69, 483-510.
DIEKMANN, S. & HOISCHEN, C. 2014. Biomolecular dynamics and binding
studies in the living cell. Phys Life Rev, 11, 1-30.
DING, X., ZHAO, X. & WATTS, A. 2013. G-protein-coupled receptor structure,
ligand binding and activation as studied by solid-state NMR
spectroscopy. Biochem J, 450, 443-57.
DINGER, M. C., BADER, J. E., KOBOR, A. D., KRETZSCHMAR, A. K. & BECK-
SICKINGER, A. G. 2003. Homodimerization of neuropeptide y receptors
investigated by fluorescence resonance energy transfer in living cells. J
Biol Chem, 278, 10562-71.
DOAN, T., MENDEZ, A., DETWILER, P. B., CHEN, J. & RIEKE, F. 2006. Multiple
phosphorylation sites confer reproducibility of the rod's single-photon
responses. Science, 313, 530-3.
DOHERTY, G. J. & MCMAHON, H. T. 2009. Mechanisms of endocytosis. Annu
Rev Biochem, 78, 857-902.
DONALDSON, J., BROWN, A. M. & HILL, S. J. 1989. Temporal changes in the
calcium-dependence of the histamine H1-receptor-stimulation of cyclic
AMP accumulation in guinea-pig cerebral cortex. Br J Pharmacol, 98,
1365-75.
DORE, A. S., OKRASA, K., PATEL, J. C., SERRANO-VEGA, M., BENNETT, K.,
COOKE, R. M., ERREY, J. C., JAZAYERI, A., KHAN, S., TEHAN, B., WEIR,
M., WIGGIN, G. R. & MARSHALL, F. H. 2014. Structure of class C GPCR
metabotropic glutamate receptor 5 transmembrane domain. Nature,
511, 557-62.
DORE, A. S., ROBERTSON, N., ERREY, J. C., NG, I., HOLLENSTEIN, K., TEHAN,
B., HURRELL, E., BENNETT, K., CONGREVE, M., MAGNANI, F., TATE, C.
G., WEIR, M. & MARSHALL, F. H. 2011. Structure of the adenosine
A(2A) receptor in complex with ZM241385 and the xanthines XAC and
caffeine. Structure, 19, 1283-93.
DORSCH, S., KLOTZ, K. N., ENGELHARDT, S., LOHSE, M. J. & BUNEMANN, M.
2009. Analysis of receptor oligomerization by FRAP microscopy. Nat
Methods, 6, 225-30.
363
DUMONT, Y., CADIEUX, A., DOODS, H., FOURNIER, A. & QUIRION, R. 2000.
Potent and selective tools to investigate neuropeptide Y receptors in
the central and peripheral nervous systems: BIB03304 (Y1) and
CGP71683A (Y5). Can J Physiol Pharmacol, 78, 116-25.
DUMONT, Y., JACQUES, D., BOUCHARD, P. & QUIRION, R. 1998. Species
differences in the expression and distribution of the neuropeptide Y Y1,
Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. J
Comp Neurol, 402, 372-84.
DUMONT, Y. & QUIRION, R. 2000. [(125)I]-GR231118: a high affinity
radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors. Br J
Pharmacol, 129, 37-46.
DUMONT, Y., THAKUR, M., BECK-SICKINGER, A., FOURNIER, A. & QUIRION,
R. 2003. Development and characterization of a highly selective
neuropeptide Y Y5 receptor agonist radioligand: [125I][hPP1-17, Ala31,
Aib32]NPY. Br J Pharmacol, 139, 1360-8.
DUNHAM, T. D. & FARRENS, D. L. 1999. Conformational changes in rhodopsin.
Movement of helix f detected by site-specific chemical labeling and
fluorescence spectroscopy. J Biol Chem, 274, 1683-90.
EKBLAD, E. & SUNDLER, F. 2002. Distribution of pancreatic polypeptide and
peptide YY. Peptides, 23, 251-61.
EL MOUSTAINE, D., GRANIER, S., DOUMAZANE, E., SCHOLLER, P., RAHMEH,
R., BRON, P., MOUILLAC, B., BANERES, J. L., RONDARD, P. & PIN, J. P.
2012. Distinct roles of metabotropic glutamate receptor dimerization in
agonist activation and G-protein coupling. Proc Natl Acad Sci U S A,
109, 16342-7.
ELLIS, J., PEDIANI, J. D., CANALS, M., MILASTA, S. & MILLIGAN, G. 2006.
Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results
in both ligand-dependent and -independent coordinated alterations of
receptor localization and function. J Biol Chem, 281, 38812-24.
ELMQUIST, J. K., AHIMA, R. S., ELIAS, C. F., FLIER, J. S. & SAPER, C. B.
1998. Leptin activates distinct projections from the dorsomedial and
ventromedial hypothalamic nuclei. Proc Natl Acad Sci U S A, 95, 741-6.
ERONDU, N., GANTZ, I., MUSSER, B., SURYAWANSHI, S., MALLICK, M., ADDY,
C., COTE, J., BRAY, G., FUJIOKA, K., BAYS, H., HOLLANDER, P.,
SANABRIA-BOHORQUEZ, S. M., ENG, W., LANGSTROM, B.,
HARGREAVES, R. J., BURNS, H. D., KANATANI, A., FUKAMI, T.,
MACNEIL, D. J., GOTTESDIENER, K. M., AMATRUDA, J. M., KAUFMAN,
K. D. & HEYMSFIELD, S. B. 2006. Neuropeptide Y5 receptor antagonism
does not induce clinically meaningful weight loss in overweight and
obese adults. Cell Metab, 4, 275-82.
ESCRIBA, P. V., WEDEGAERTNER, P. B., GONI, F. M. & VOGLER, O. 2007.
Lipid-protein interactions in GPCR-associated signaling. Biochim
Biophys Acta, 1768, 836-52.
FABRY, M., LANGER, M., ROTHEN-RUTISHAUSER, B., WUNDERLI-
ALLENSPACH, H., HOCKER, H. & BECK-SICKINGER, A. G. 2000.
Monitoring of the internalization of neuropeptide Y on neuroblastoma
cell line SK-N-MC. Eur J Biochem, 267, 5631-7.
FERGUSON, S. S., DOWNEY, W. E., 3RD, COLAPIETRO, A. M., BARAK, L. S.,
MENARD, L. & CARON, M. G. 1996. Role of beta-arrestin in mediating
agonist-promoted G protein-coupled receptor internalization. Science,
271, 363-6.
364
FERMINI, B. & FOSSA, A. A. 2003. The impact of drug-induced QT interval
prolongation on drug discovery and development. Nat Rev Drug Discov,
2, 439-47.
FERRADA, C., MORENO, E., CASADO, V., BONGERS, G., CORTES, A., MALLOL,
J., CANELA, E. I., LEURS, R., FERRE, S., LLUIS, C. & FRANCO, R. 2009.
Marked changes in signal transduction upon heteromerization of
dopamine D1 and histamine H3 receptors. Br J Pharmacol, 157, 64-75.
FERRE, S., CASADO, V., DEVI, L. A., FILIZOLA, M., JOCKERS, R., LOHSE, M.
J., MILLIGAN, G., PIN, J. P. & GUITART, X. 2014. G protein-coupled
receptor oligomerization revisited: functional and pharmacological
perspectives. Pharmacol Rev, 66, 413-34.
FERRE, S., VON EULER, G., JOHANSSON, B., FREDHOLM, B. B. & FUXE, K.
1991. Stimulation of high-affinity adenosine A2 receptors decreases the
affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl
Acad Sci U S A, 88, 7238-41.
FERRIS, C. D. & SNYDER, S. H. 1992. IP3 receptors. Ligand-activated calcium
channels in multiple forms. Adv Second Messenger Phosphoprotein Res,
26, 95-107.
FETISSOV, S. O., KOPP, J. & HOKFELT, T. 2004. Distribution of NPY receptors
in the hypothalamus. Neuropeptides, 38, 175-88.
FIELD, B. C., CHAUDHRI, O. B. & BLOOM, S. R. 2010. Bowels control brain:
gut hormones and obesity. Nat Rev Endocrinol, 6, 444-53.
FINUCANE, M. M., STEVENS, G. A., COWAN, M. J., DANAEI, G., LIN, J. K.,
PACIOREK, C. J., SINGH, G. M., GUTIERREZ, H. R., LU, Y., BAHALIM, A.
N., FARZADFAR, F., RILEY, L. M. & EZZATI, M. 2011. National, regional,
and global trends in body-mass index since 1980: systematic analysis
of health examination surveys and epidemiological studies with 960
country-years and 9.1 million participants. Lancet, 377, 557-67.
FONSECA, J. M. & LAMBERT, N. A. 2009. Instability of a class a G protein-
coupled receptor oligomer interface. Mol Pharmacol, 75, 1296-9.
FOTIADIS, D., JASTRZEBSKA, B., PHILIPPSEN, A., MULLER, D. J.,
PALCZEWSKI, K. & ENGEL, A. 2006. Structure of the rhodopsin dimer:
a working model for G-protein-coupled receptors. Curr Opin Struct Biol,
16, 252-9.
FOTIADIS, D., LIANG, Y., FILIPEK, S., SAPERSTEIN, D. A., ENGEL, A. &
PALCZEWSKI, K. 2003. Atomic-force microscopy: Rhodopsin dimers in
native disc membranes. Nature, 421, 127-8.
FRITZE, O., FILIPEK, S., KUKSA, V., PALCZEWSKI, K., HOFMANN, K. P. &
ERNST, O. P. 2003. Role of the conserved NPxxY(x)5,6F motif in the
rhodopsin ground state and during activation. Proc Natl Acad Sci U S A,
100, 2290-5.
FUHLENDORFF, J., GETHER, U., AAKERLUND, L., LANGELAND-JOHANSEN, N.,
THOGERSEN, H., MELBERG, S. G., OLSEN, U. B., THASTRUP, O. &
SCHWARTZ, T. W. 1990. [Leu31, Pro34]neuropeptide Y: a specific Y1
receptor agonist. Proc Natl Acad Sci U S A, 87, 182-6.
FUJIMIYA, M. & INUI, A. 2000. Peptidergic regulation of gastrointestinal
motility in rodents. Peptides, 21, 1565-82.
FUJIWARA, T., RITCHIE, K., MURAKOSHI, H., JACOBSON, K. & KUSUMI, A.
2002. Phospholipids undergo hop diffusion in compartmentalized cell
membrane. J Cell Biol, 157, 1071-81.
FUNG JJ, D. X., PRADO L, YAO XJ, VELEZ-RUIZ GA, DEVREE BT, SUNAHARA
RK, KOBILKA BK 2009. Ligand-regulated oligomerization of E2-
365
adrenoceptors in a model lipid bilayer. The EMBO Journal, 28, 3315-
3328.
GANDIA, J., GALINO, J., AMARAL, O. B., SORIANO, A., LLUIS, C., FRANCO, R.
& CIRUELA, F. 2008. Detection of higher-order G protein-coupled
receptor oligomers by a combined BRET-BiFC technique. FEBS Lett,
582, 2979-84.
GAO, J., GHIBAUDI, L. & HWA, J. J. 2004. Selective activation of central NPY
Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms. Am
J Physiol Endocrinol Metab, 287, E706-11.
GARLAND, S. L. 2013. Are GPCRs still a source of new targets? J Biomol
Screen, 18, 947-66.
GAVALAS, A., LAN, T. H., LIU, Q., CORREA, I. R., JR., JAVITCH, J. A. &
LAMBERT, N. A. 2013. Segregation of family A G protein-coupled
receptor protomers in the plasma membrane. Mol Pharmacol, 84, 346-
52.
GEHLERT, D. R., BEAVERS, L. S., JOHNSON, D., GACKENHEIMER, S. L.,
SCHOBER, D. A. & GADSKI, R. A. 1996a. Expression cloning of a
human brain neuropeptide Y Y2 receptor. Mol Pharmacol, 49, 224-8.
GEHLERT, D. R. & GACKENHEIMER, S. L. 1997. Differential distribution of
neuropeptide Y Y1 and Y2 receptors in rat and guinea-pig brains.
Neuroscience, 76, 215-24.
GEHLERT, D. R., GACKENHEIMER, S. L., SCHOBER, D. A., BEAVERS, L.,
GADSKI, R., BURNETT, J. P., MAYNE, N., LUNDELL, I. & LARHAMMAR,
D. 1996b. The neuropeptide Y Y1 receptor selective radioligand,
[125I][Leu31,Pro34]peptide YY, is also a high affinity radioligand for
human pancreatic polypeptide 1 receptors. Eur J Pharmacol, 318, 485-
90.
GEHLERT, D. R., SCHOBER, D. A., GACKENHEIMER, S. L., BEAVERS, L.,
GADSKI, R., LUNDELL, I. & LARHAMMAR, D. 1997. [125I]Leu31, Pro34-
PYY is a high affinity radioligand for rat PP1/Y4 and Y1 receptors:
evidence for heterogeneity in pancreatic polypeptide receptors.
Peptides, 18, 397-401.
GEHLERT, D. R., SCHOBER, D. A., MORIN, M. & BERGLUND, M. M. 2007. Co-
expression of neuropeptide Y Y1 and Y5 receptors results in
heterodimerization and altered functional properties. Biochem
Pharmacol, 74, 1652-64.
GEORGE, M., RAJARAM, M. & SHANMUGAM, E. 2014. New and emerging drug
molecules against obesity. J Cardiovasc Pharmacol Ther, 19, 65-76.
GEORGE, S. R., FAN, T., XIE, Z., TSE, R., TAM, V., VARGHESE, G. & O'DOWD,
B. F. 2000. Oligomerization of mu- and delta-opioid receptors.
Generation of novel functional properties. J Biol Chem, 275, 26128-35.
GERALD, C., WALKER, M. W., CRISCIONE, L., GUSTAFSON, E. L., BATZL-
HARTMANN, C., SMITH, K. E., VAYSSE, P., DURKIN, M. M., LAZ, T. M.,
LINEMEYER, D. L., SCHAFFHAUSER, A. O., WHITEBREAD, S.,
HOFBAUER, K. G., TABER, R. I., BRANCHEK, T. A. & WEINSHANK, R. L.
1996. A receptor subtype involved in neuropeptide-Y-induced food
intake. Nature, 382, 168-71.
GERALD, C., WALKER, M. W., VAYSSE, P. J., HE, C., BRANCHEK, T. A. &
WEINSHANK, R. L. 1995. Expression cloning and pharmacological
characterization of a human hippocampal neuropeptide Y/peptide YY Y2
receptor subtype. J Biol Chem, 270, 26758-61.
366
GESTY-PALMER, D., CHEN, M., REITER, E., AHN, S., NELSON, C. D., WANG,
S., ECKHARDT, A. E., COWAN, C. L., SPURNEY, R. F., LUTTRELL, L. M.
& LEFKOWITZ, R. J. 2006. Distinct beta-arrestin- and G protein-
dependent pathways for parathyroid hormone receptor-stimulated
ERK1/2 activation. J Biol Chem, 281, 10856-64.
GHANOUNI, P., STEENHUIS, J. J., FARRENS, D. L. & KOBILKA, B. K. 2001.
Agonist-induced conformational changes in the G-protein-coupling
domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci U S A, 98,
5997-6002.
GHOSH, R. N., CHEN, Y. T., DEBIASIO, R., DEBIASIO, R. L., CONWAY, B. R.,
MINOR, L. K. & DEMAREST, K. T. 2000. Cell-based, high-content screen
for receptor internalization, recycling and intracellular trafficking.
Biotechniques, 29, 170-5.
GICQUIAUX, H., LECAT, S., GAIRE, M., DIETERLEN, A., MELY, Y., TAKEDA, K.,
BUCHER, B. & GALZI, J. L. 2002. Rapid internalization and recycling of
the human neuropeptide Y Y(1) receptor. J Biol Chem, 277, 6645-55.
GILMAN, A. G. 1984. G proteins and dual control of adenylate cyclase. Cell,
36, 577-9.
GIMENEZ, L. E., KOOK, S., VISHNIVETSKIY, S. A., AHMED, M. R., GUREVICH,
E. V. & GUREVICH, V. V. 2012. Role of receptor-attached phosphates in
binding of visual and non-visual arrestins to G protein-coupled
receptors. J Biol Chem, 287, 9028-40.
GINES, S., HILLION, J., TORVINEN, M., LE CROM, S., CASADO, V., CANELA, E.
I., RONDIN, S., LEW, J. Y., WATSON, S., ZOLI, M., AGNATI, L. F.,
VERNIERA, P., LLUIS, C., FERRE, S., FUXE, K. & FRANCO, R. 2000.
Dopamine D1 and adenosine A1 receptors form functionally interacting
heteromeric complexes. Proc Natl Acad Sci U S A, 97, 8606-11.
GOLEBIEWSKA, U., JOHNSTON, J. M., DEVI, L., FILIZOLA, M. & SCARLATA, S.
2011. Differential response to morphine of the oligomeric state of mu-
opioid in the presence of delta-opioid receptors. Biochemistry, 50,
2829-37.
GOMES, I., FUJITA, W., GUPTA, A., SALDANHA, S. A., NEGRI, A., PINELLO, C.
E., EBERHART, C., ROBERTS, E., FILIZOLA, M., HODDER, P. & DEVI, L.
A. 2013. Identification of a mu-delta opioid receptor heteromer-biased
agonist with antinociceptive activity. Proc Natl Acad Sci U S A, 110,
12072-7.
GONZALEZ, S., MORENO-DELGADO, D., MORENO, E., PEREZ-CAPOTE, K.,
FRANCO, R., MALLOL, J., CORTES, A., CASADO, V., LLUIS, C., ORTIZ,
J., FERRE, S., CANELA, E. & MCCORMICK, P. J. 2012. Circadian-related
heteromerization of adrenergic and dopamine D(4) receptors modulates
melatonin synthesis and release in the pineal gland. PLoS Biol, 10,
e1001347.
GOODMAN, O. B., JR., KRUPNICK, J. G., SANTINI, F., GUREVICH, V. V., PENN,
R. B., GAGNON, A. W., KEEN, J. H. & BENOVIC, J. L. 1996. Beta-
arrestin acts as a clathrin adaptor in endocytosis of the beta2-
adrenergic receptor. Nature, 383, 447-50.
GRACE, C. R., PERRIN, M. H., DIGRUCCIO, M. R., MILLER, C. L., RIVIER, J. E.,
VALE, W. W. & RIEK, R. 2004. NMR structure and peptide hormone
binding site of the first extracellular domain of a type B1 G protein-
coupled receptor. Proc Natl Acad Sci U S A, 101, 12836-41.
367
GRANDOCH, M., ROSCIONI, S. S. & SCHMIDT, M. 2010. The role of Epac
proteins, novel cAMP mediators, in the regulation of immune, lung and
neuronal function. Br J Pharmacol, 159, 265-84.
GRANIER, S., MANGLIK, A., KRUSE, A. C., KOBILKA, T. S., THIAN, F. S.,
WEIS, W. I. & KOBILKA, B. K. 2012. Structure of the delta-opioid
receptor bound to naltrindole. Nature, 485, 400-4.
GRANT, M., COLLIER, B. & KUMAR, U. 2004. Agonist-dependent dissociation of
human somatostatin receptor 2 dimers: a role in receptor trafficking. J
Biol Chem, 279, 36179-83.
GRAY, P. C., SCOTT, J. D. & CATTERALL, W. A. 1998. Regulation of ion
channels by cAMP-dependent protein kinase and A-kinase anchoring
proteins. Curr Opin Neurobiol, 8, 330-4.
GREASLEY, P. J., FANELLI, F., ROSSIER, O., ABUIN, L. & COTECCHIA, S. 2002.
Mutagenesis and modelling of the alpha(1b)-adrenergic receptor
highlight the role of the helix 3/helix 6 interface in receptor activation.
Mol Pharmacol, 61, 1025-32.
GUO, W., SHI, L. & JAVITCH, J. A. 2003. The fourth transmembrane segment
forms the interface of the dopamine D2 receptor homodimer. J Biol
Chem, 278, 4385-8.
GUO, W., URIZAR, E., KRALIKOVA, M., MOBAREC, J. C., SHI, L., FILIZOLA, M.
& JAVITCH, J. A. 2008. Dopamine D2 receptors form higher order
oligomers at physiological expression levels. EMBO J, 27, 2293-304.
GUPTA, A., MULDER, J., GOMES, I., ROZENFELD, R., BUSHLIN, I., ONG, E.,
LIM, M., MAILLET, E., JUNEK, M., CAHILL, C. M., HARKANY, T. & DEVI,
L. A. 2010. Increased abundance of opioid receptor heteromers after
chronic morphine administration. Sci Signal, 3, ra54.
GUREVICH, E. V. & GUREVICH, V. V. 2006. Arrestins: ubiquitous regulators of
cellular signaling pathways. Genome Biol, 7, 236.
GUREVICH, V. V. & GUREVICH, E. V. 2004. The molecular acrobatics of
arrestin activation. Trends Pharmacol Sci, 25, 105-11.
GUREVICH, V. V. & GUREVICH, E. V. 2008. GPCR monomers and oligomers: it
takes all kinds. Trends Neurosci, 31, 74-81.
GUREVICH, V. V. & GUREVICH, E. V. 2013. Structural determinants of arrestin
functions. Prog Mol Biol Transl Sci, 118, 57-92.
HAGA, K., KRUSE, A. C., ASADA, H., YURUGI-KOBAYASHI, T., SHIROISHI, M.,
ZHANG, C., WEIS, W. I., OKADA, T., KOBILKA, B. K., HAGA, T. &
KOBAYASHI, T. 2012. Structure of the human M2 muscarinic
acetylcholine receptor bound to an antagonist. Nature, 482, 547-51.
HAGUE, C., UBERTI, M. A., CHEN, Z., HALL, R. A. & MINNEMAN, K. P. 2004.
Cell surface expression of alpha1D-adrenergic receptors is controlled by
heterodimerization with alpha1B-adrenergic receptors. J Biol Chem,
279, 15541-9.
HALL, M. P., UNCH, J., BINKOWSKI, B. F., VALLEY, M. P., BUTLER, B. L.,
WOOD, M. G., OTTO, P., ZIMMERMAN, K., VIDUGIRIS, G., MACHLEIDT,
T., ROBERS, M. B., BENINK, H. A., EGGERS, C. T., SLATER, M. R.,
MEISENHEIMER, P. L., KLAUBERT, D. H., FAN, F., ENCELL, L. P. &
WOOD, K. V. 2012. Engineered luciferase reporter from a deep sea
shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem Biol,
7, 1848-57.
HALLS, M. L. & COOPER, D. M. 2010. Sub-picomolar relaxin signalling by a
pre-assembled RXFP1, AKAP79, AC2, beta-arrestin 2, PDE4D3 complex.
EMBO J, 29, 2772-87.
368
HALLWORTH, R. & NICHOLS, M. G. 2012. Prestin in HEK cells is an obligate
tetramer. J Neurophysiol, 107, 5-11.
HAN, Y., MOREIRA, I. S., URIZAR, E., WEINSTEIN, H. & JAVITCH, J. A. 2009.
Allosteric communication between protomers of dopamine class A GPCR
dimers modulates activation. Nat Chem Biol, 5, 688-95.
HANSEN, J. L., HANSEN, J. T., SPEERSCHNEIDER, T., LYNGSO, C.,
ERIKSTRUP, N., BURSTEIN, E. S., WEINER, D. M., WALTHER, T.,
MAKITA, N., IIRI, T., MERTEN, N., KOSTENIS, E. & SHEIKH, S. P. 2009.
Lack of evidence for AT1R/B2R heterodimerization in COS-7, HEK293,
and NIH3T3 cells: how common is the AT1R/B2R heterodimer? J Biol
Chem, 284, 1831-9.
HANSEN, J. L., THEILADE, J., HAUNSO, S. & SHEIKH, S. P. 2004.
Oligomerization of wild type and nonfunctional mutant angiotensin II
type I receptors inhibits galphaq protein signaling but not ERK
activation. J Biol Chem, 279, 24108-15.
HANSON, M. A., ROTH, C. B., JO, E., GRIFFITH, M. T., SCOTT, F. L.,
REINHART, G., DESALE, H., CLEMONS, B., CAHALAN, S. M.,
SCHUERER, S. C., SANNA, M. G., HAN, G. W., KUHN, P., ROSEN, H. &
STEVENS, R. C. 2012. Crystal structure of a lipid G protein-coupled
receptor. Science, 335, 851-5.
HANSON, S. M., FRANCIS, D. J., VISHNIVETSKIY, S. A., KOLOBOVA, E. A.,
HUBBELL, W. L., KLUG, C. S. & GUREVICH, V. V. 2006. Differential
interaction of spin-labeled arrestin with inactive and active
phosphorhodopsin. Proc Natl Acad Sci U S A, 103, 4900-5.
HANSON, S. M., GUREVICH, E. V., VISHNIVETSKIY, S. A., AHMED, M. R.,
SONG, X. & GUREVICH, V. V. 2007a. Each rhodopsin molecule binds its
own arrestin. Proc Natl Acad Sci U S A, 104, 3125-8.
HANSON, S. M., VAN EPS, N., FRANCIS, D. J., ALTENBACH, C.,
VISHNIVETSKIY, S. A., ARSHAVSKY, V. Y., KLUG, C. S., HUBBELL, W.
L. & GUREVICH, V. V. 2007b. Structure and function of the visual
arrestin oligomer. EMBO J, 26, 1726-36.
HANYALOGLU, A. C. & VON ZASTROW, M. 2008. Regulation of GPCRs by
endocytic membrane trafficking and its potential implications. Annu Rev
Pharmacol Toxicol, 48, 537-68.
HASBI, A., DEVOST, D., LAPORTE, S. A. & ZINGG, H. H. 2004. Real-time
detection of interactions between the human oxytocin receptor and G
protein-coupled receptor kinase-2. Mol Endocrinol, 18, 1277-86.
HAUPTS, U., MAITI, S., SCHWILLE, P. & WEBB, W. W. 1998. Dynamics of
fluorescence fluctuations in green fluorescent protein observed by
fluorescence correlation spectroscopy. Proc Natl Acad Sci U S A, 95,
13573-8.
HAYNES, A. C., ARCH, J. R., WILSON, S., MCCLUE, S. & BUCKINGHAM, R. E.
1998. Characterisation of the neuropeptide Y receptor that mediates
feeding in the rat: a role for the Y5 receptor? Regul Pept, 75-76, 355-
61.
HEBERT, T. E., LOISEL, T. P., ADAM, L., ETHIER, N., ONGE, S. S. & BOUVIER,
M. 1998. Functional rescue of a constitutively desensitized beta2AR
through receptor dimerization. Biochem J, 330 ( Pt 1), 287-93.
HEBERT, T. E., MOFFETT, S., MORELLO, J. P., LOISEL, T. P., BICHET, D. G.,
BARRET, C. & BOUVIER, M. 1996. A peptide derived from a beta2-
adrenergic receptor transmembrane domain inhibits both receptor
dimerization and activation. J Biol Chem, 271, 16384-92.
369
HEGENER, O., PRENNER, L., RUNKEL, F., BAADER, S. L., KAPPLER, J. &
HABERLEIN, H. 2004. Dynamics of beta2-adrenergic receptor-ligand
complexes on living cells. Biochemistry, 43, 6190-9.
HEIM, R., CUBITT, A. B. & TSIEN, R. Y. 1995. Improved green fluorescence.
Nature, 373, 663-4.
HELSEN, C. & CLAESSENS, F. 2014. Looking at nuclear receptors from a new
angle. Mol Cell Endocrinol, 382, 97-106.
HENRY, M., GHIBAUDI, L., GAO, J. & HWA, J. J. 2005. Energy metabolic profile
of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors.
Obes Res, 13, 36-47.
HERN, J. A., BAIG, A. H., MASHANOV, G. I., BIRDSALL, B., CORRIE, J. E.,
LAZARENO, S., MOLLOY, J. E. & BIRDSALL, N. J. 2010. Formation and
dissociation of M1 muscarinic receptor dimers seen by total internal
reflection fluorescence imaging of single molecules. Proc Natl Acad Sci
U S A, 107, 2693-8.
HERRICK-DAVIS, K., GRINDE, E., COWAN, A. & MAZURKIEWICZ, J. E. 2013.
Fluorescence correlation spectroscopy analysis of serotonin, adrenergic,
muscarinic, and dopamine receptor dimerization: the oligomer number
puzzle. Mol Pharmacol, 84, 630-42.
HERRICK-DAVIS, K., GRINDE, E., LINDSLEY, T., COWAN, A. &
MAZURKIEWICZ, J. E. 2012. Oligomer size of the serotonin 5-
hydroxytryptamine 2C (5-HT2C) receptor revealed by fluorescence
correlation spectroscopy with photon counting histogram analysis:
evidence for homodimers without monomers or tetramers. J Biol Chem,
287, 23604-14.
HERZOG, H., HORT, Y. J., BALL, H. J., HAYES, G., SHINE, J. & SELBIE, L. A.
1992. Cloned human neuropeptide Y receptor couples to two different
second messenger systems. Proc Natl Acad Sci U S A, 89, 5794-8.
HIGUCHI, H., NIKI, T. & SHIIYA, T. 2008. Feeding behavior and gene
expression of appetite-related neuropeptides in mice lacking for
neuropeptide Y Y5 receptor subclass. World J Gastroenterol, 14, 6312-
7.
HILAIRET, S., BOUABOULA, M., CARRIERE, D., LE FUR, G. & CASELLAS, P.
2003. Hypersensitization of the Orexin 1 receptor by the CB1 receptor:
evidence for cross-talk blocked by the specific CB1 antagonist,
SR141716. J Biol Chem, 278, 23731-7.
HILLER, C., KUHHORN, J. & GMEINER, P. 2013. Class A G-protein-coupled
receptor (GPCR) dimers and bivalent ligands. J Med Chem, 56, 6542-
59.
HILLION, J., CANALS, M., TORVINEN, M., CASADO, V., SCOTT, R., TERASMAA,
A., HANSSON, A., WATSON, S., OLAH, M. E., MALLOL, J., CANELA, E.
I., ZOLI, M., AGNATI, L. F., IBANEZ, C. F., LLUIS, C., FRANCO, R.,
FERRE, S. & FUXE, K. 2002. Coaggregation, cointernalization, and
codesensitization of adenosine A2A receptors and dopamine D2
receptors. J Biol Chem, 277, 18091-7.
HOLLENSTEIN, K., KEAN, J., BORTOLATO, A., CHENG, R. K., DORE, A. S.,
JAZAYERI, A., COOKE, R. M., WEIR, M. & MARSHALL, F. H. 2013.
Structure of class B GPCR corticotropin-releasing factor receptor 1.
Nature, 499, 438-43.
HOLLIDAY, N. D. & COX, H. M. 2003. Control of signalling efficacy by
palmitoylation of the rat Y1 receptor. Br J Pharmacol, 139, 501-12.
370
HOLLIDAY, N. D., LAM, C. W., TOUGH, I. R. & COX, H. M. 2005. Role of the C
terminus in neuropeptide Y Y1 receptor desensitization and
internalization. Mol Pharmacol, 67, 655-64.
HOLST, B., NYGAARD, R., VALENTIN-HANSEN, L., BACH, A., ENGELSTOFT, M.
S., PETERSEN, P. S., FRIMURER, T. M. & SCHWARTZ, T. W. 2010. A
conserved aromatic lock for the tryptophan rotameric switch in TM-VI
of seven-transmembrane receptors. J Biol Chem, 285, 3973-85.
HOLZER, P., REICHMANN, F. & FARZI, A. 2012. Neuropeptide Y, peptide YY
and pancreatic polypeptide in the gut-brain axis. Neuropeptides.
HOWELL, O. W., SCHARFMAN, H. E., HERZOG, H., SUNDSTROM, L. E., BECK-
SICKINGER, A. & GRAY, W. P. 2003. Neuropeptide Y is
neuroproliferative for post-natal hippocampal precursor cells. J
Neurochem, 86, 646-59.
HU, C. D., CHINENOV, Y. & KERPPOLA, T. K. 2002. Visualization of interactions
among bZIP and Rel family proteins in living cells using bimolecular
fluorescence complementation. Mol Cell, 9, 789-98.
HU, C. D. & KERPPOLA, T. K. 2003. Simultaneous visualization of multiple
protein interactions in living cells using multicolor fluorescence
complementation analysis. Nat Biotechnol, 21, 539-45.
HU, J., THOR, D., ZHOU, Y., LIU, T., WANG, Y., MCMILLIN, S. M., MISTRY, R.,
CHALLISS, R. A., COSTANZI, S. & WESS, J. 2012. Structural aspects of
M(3) muscarinic acetylcholine receptor dimer formation and activation.
FASEB J, 26, 604-16.
HUANG, B., BATES, M. & ZHUANG, X. 2009. Super-resolution fluorescence
microscopy. Annu Rev Biochem, 78, 993-1016.
HUANG, B., PERROUD, T. D. & ZARE, R. N. 2004. Photon counting histogram:
one-photon excitation. Chemphyschem, 5, 1523-31.
HUANG, J., CHEN, S., ZHANG, J. J. & HUANG, X. Y. 2013. Crystal structure of
oligomeric beta1-adrenergic G protein-coupled receptors in ligand-free
basal state. Nat Struct Mol Biol, 20, 419-25.
HUANG, W., OSMAN, R. & GERSHENGORN, M. C. 2005. Agonist-induced
conformational changes in thyrotropin-releasing hormone receptor type
I: disulfide cross-linking and molecular modeling approaches.
Biochemistry, 44, 2419-31.
HUANG, X. F., HAN, M. & STORLIEN, L. H. 2003. The level of NPY receptor
mRNA expression in diet-induced obese and resistant mice. Brain Res
Mol Brain Res, 115, 21-8.
HUBBARD, S. R. & MILLER, W. T. 2007. Receptor tyrosine kinases:
mechanisms of activation and signaling. Curr Opin Cell Biol, 19, 117-
23.
HUTTENRAUCH, F., POLLOK-KOPP, B. & OPPERMANN, M. 2005. G protein-
coupled receptor kinases promote phosphorylation and beta-arrestin-
mediated internalization of CCR5 homo- and hetero-oligomers. J Biol
Chem, 280, 37503-15.
ILLES, P. & REGENOLD, J. T. 1990. Interaction between neuropeptide Y and
noradrenaline on central catecholamine neurons. Nature, 344, 62-3.
INSEL, P. A., HEAD, B. P., PATEL, H. H., ROTH, D. M., BUNDEY, R. A. &
SWANEY, J. S. 2005. Compartmentation of G-protein-coupled receptors
and their signalling components in lipid rafts and caveolae. Biochem
Soc Trans, 33, 1131-4.
ISHIHARA, A., KANATANI, A., OKADA, M., HIDAKA, M., TANAKA, T.,
MASHIKO, S., GOMORI, A., KANNO, T., HATA, M., KANESAKA, M.,
371
TOMINAGA, Y., SATO, N. A., KOBAYASHI, M., MURAI, T., WATANABE,
K., ISHII, Y., FUKURODA, T., FUKAMI, T. & IHARA, M. 2002. Blockade
of body weight gain and plasma corticosterone levels in Zucker fatty
rats using an orally active neuropeptide Y Y1 antagonist. Br J
Pharmacol, 136, 341-6.
ISHIHARA, A., TANAKA, T., KANATANI, A., FUKAMI, T., IHARA, M. &
FUKURODA, T. 1998. A potent neuropeptide Y antagonist, 1229U91,
suppressed spontaneous food intake in Zucker fatty rats. Am J Physiol,
274, R1500-4.
ISHIKAWA-ANKERHOLD, H. C., ANKERHOLD, R. & DRUMMEN, G. P. 2012.
Advanced fluorescence microscopy techniques--FRAP, FLIP, FLAP, FRET
and FLIM. Molecules, 17, 4047-132.
JAAKOLA, V. P., GRIFFITH, M. T., HANSON, M. A., CHEREZOV, V., CHIEN, E.
Y., LANE, J. R., IJZERMAN, A. P. & STEVENS, R. C. 2008. The 2.6
angstrom crystal structure of a human A2A adenosine receptor bound
to an antagonist. Science, 322, 1211-7.
JAGER, S., PALCZEWSKI, K. & HOFMANN, K. P. 1996. Opsin/all-trans-retinal
complex activates transducin by different mechanisms than photolyzed
rhodopsin. Biochemistry, 35, 2901-8.
JASTRZEBSKA, B., ORBAN, T., GOLCZAK, M., ENGEL, A. & PALCZEWSKI, K.
2013. Asymmetry of the rhodopsin dimer in complex with transducin.
FASEB J, 27, 1572-84.
JOHNSON, J. D., CAMPISI, J., SHARKEY, C. M., KENNEDY, S. L., NICKERSON,
M. & FLESHNER, M. 2005. Adrenergic receptors mediate stress-induced
elevations in extracellular Hsp72. J Appl Physiol (1985), 99, 1789-95.
JOHNSON, M. 2006. Molecular mechanisms of beta(2)-adrenergic receptor
function, response, and regulation. J Allergy Clin Immunol, 117, 18-24;
quiz 25.
JOHNSTON, J. M., ABURI, M., PROVASI, D., BORTOLATO, A., URIZAR, E.,
LAMBERT, N. A., JAVITCH, J. A. & FILIZOLA, M. 2011. Making structural
sense of dimerization interfaces of delta opioid receptor homodimers.
Biochemistry, 50, 1682-90.
JOHNSTON, J. M., WANG, H., PROVASI, D. & FILIZOLA, M. 2012. Assessing
the relative stability of dimer interfaces in g protein-coupled receptors.
PLoS Comput Biol, 8, e1002649.
JONES KA, B. B., TAMM JA, CRAIG DA, DURKIN MM, DAI M, YAO W-J,
JOHNSON M, GUNWALDSEN C, HUANG L-Y, TANG C, SHEN Q, SALON
JA, MORSE K, LAZ T, SMITH KE, NAGARATHNAM D, NOBLE SA,
BRANCHEK TA, GERALD C 1998. GABAB receptors function as a
heteromeric assembly of the subunits GABABR1 and GABABR2. Nature
396, 674-678.
JONGEJAN, A., BRUYSTERS, M., BALLESTEROS, J. A., HAAKSMA, E., BAKKER,
R. A., PARDO, L. & LEURS, R. 2005. Linking agonist binding to
histamine H1 receptor activation. Nat Chem Biol, 1, 98-103.
JORDAN, B. A. & DEVI, L. A. 1999. G-protein-coupled receptor
heterodimerization modulates receptor function. Nature, 399, 697-700.
JORDAN, B. A., TRAPAIDZE, N., GOMES, I., NIVARTHI, R. & DEVI, L. A. 2001.
Oligomerization of opioid receptors with beta 2-adrenergic receptors: a
role in trafficking and mitogen-activated protein kinase activation. Proc
Natl Acad Sci U S A, 98, 343-8.
372
KALLAL, L. & BENOVIC, J. L. 2000. Using green fluorescent proteins to study
G-protein-coupled receptor localization and trafficking. Trends
Pharmacol Sci, 21, 175-80.
KALRA, S. P., DUBE, M. G., SAHU, A., PHELPS, C. P. & KALRA, P. S. 1991.
Neuropeptide Y secretion increases in the paraventricular nucleus in
association with increased appetite for food. Proc Natl Acad Sci U S A,
88, 10931-5.
KANATANI, A., HATA, M., MASHIKO, S., ISHIHARA, A., OKAMOTO, O., HAGA,
Y., OHE, T., KANNO, T., MURAI, N., ISHII, Y., FUKURODA, T., FUKAMI,
T. & IHARA, M. 2001. A typical Y1 receptor regulates feeding
behaviors: effects of a potent and selective Y1 antagonist, J-115814.
Mol Pharmacol, 59, 501-5.
KANATANI, A., ISHIHARA, A., ASAHI, S., TANAKA, T., OZAKI, S. & IHARA, M.
1996. Potent neuropeptide Y Y1 receptor antagonist, 1229U91:
blockade of neuropeptide Y-induced and physiological food intake.
Endocrinology, 137, 3177-82.
KANATANI, A., ISHIHARA, A., IWAASA, H., NAKAMURA, K., OKAMOTO, O.,
HIDAKA, M., ITO, J., FUKURODA, T., MACNEIL, D. J., VAN DER PLOEG,
L. H., ISHII, Y., OKABE, T., FUKAMI, T. & IHARA, M. 2000. L-152,804:
orally active and selective neuropeptide Y Y5 receptor antagonist.
Biochem Biophys Res Commun, 272, 169-73.
KANATANI, A., KANNO, T., ISHIHARA, A., HATA, M., SAKURABA, A., TANAKA,
T., TSUCHIYA, Y., MASE, T., FUKURODA, T., FUKAMI, T. & IHARA, M.
1999. The novel neuropeptide Y Y(1) receptor antagonist J-104870: a
potent feeding suppressant with oral bioavailability. Biochem Biophys
Res Commun, 266, 88-91.
KANG, D. S., KERN, R. C., PUTHENVEEDU, M. A., VON ZASTROW, M.,
WILLIAMS, J. C. & BENOVIC, J. L. 2009. Structure of an arrestin2-
clathrin complex reveals a novel clathrin binding domain that
modulates receptor trafficking. J Biol Chem, 284, 29860-72.
KANG, D. S., TIAN, X. & BENOVIC, J. L. 2014. Role of beta-arrestins and
arrestin domain-containing proteins in G protein-coupled receptor
trafficking. Curr Opin Cell Biol, 27, 63-71.
KANNOA, T., KANATANI, A., KEEN, S. L., ARAI-OTSUKI, S., HAGA, Y., IWAMA,
T., ISHIHARA, A., SAKURABA, A., IWAASA, H., HIROSE, M.,
MORISHIMA, H., FUKAMI, T. & IHARA, M. 2001. Different binding sites
for the neuropeptide Y Y1 antagonists 1229U91 and J-104870 on
human Y1 receptors. Peptides, 22, 405-13.
KASAI, R. S., SUZUKI, K. G., PROSSNITZ, E. R., KOYAMA-HONDA, I.,
NAKADA, C., FUJIWARA, T. K. & KUSUMI, A. 2011. Full characterization
of GPCR monomer-dimer dynamic equilibrium by single molecule
imaging. J Cell Biol, 192, 463-80.
KASK, P., PALO, K., ULLMANN, D. & GALL, K. 1999. Fluorescence-intensity
distribution analysis and its application in biomolecular detection
technology. Proc Natl Acad Sci U S A, 96, 13756-61.
KATRITCH, V., CHEREZOV, V. & STEVENS, R. C. 2012. Diversity and
modularity of G protein-coupled receptor structures. Trends Pharmacol
Sci, 33, 17-27.
KAUPMANN, K., MALITSCHEK, B., SCHULER, V., HEID, J., FROESTL, W., BECK,
P., MOSBACHER, J., BISCHOFF, S., KULIK, A., SHIGEMOTO, R.,
KARSCHIN, A. & BETTLER, B. 1998. GABA(B)-receptor subtypes
assemble into functional heteromeric complexes. Nature, 396, 683-7.
373
KAYA, A. I., UGUR, O., ALTUNTAS, O., SAYAR, K. & ONARAN, H. O. 2011.
Long and short distance movements of beta(2)-adrenoceptor in cell
membrane assessed by photoconvertible fluorescent protein dendra2-
beta(2)-adrenoceptor fusion. Biochim Biophys Acta, 1813, 1511-24.
KEIRE, D. A., MANNON, P., KOBAYASHI, M., WALSH, J. H., SOLOMON, T. E. &
REEVE, J. R., JR. 2000. Primary structures of PYY, [Pro(34)]PYY, and
PYY-(3-36) confer different conformations and receptor selectivity. Am
J Physiol Gastrointest Liver Physiol, 279, G126-31.
KENAKIN, T. & CHRISTOPOULOS, A. 2013. Measurements of ligand bias and
functional affinity. Nat Rev Drug Discov, 12, 483.
KENAKIN, T. & MILLER, L. J. 2010. Seven transmembrane receptors as
shapeshifting proteins: the impact of allosteric modulation and
functional selectivity on new drug discovery. Pharmacol Rev, 62, 265-
304.
KENDALL, R. T. & LUTTRELL, L. M. 2009. Diversity in arrestin function. Cell Mol
Life Sci, 66, 2953-73.
KENWORTHY, A. K., NICHOLS, B. J., REMMERT, C. L., HENDRIX, G. M.,
KUMAR, M., ZIMMERBERG, J. & LIPPINCOTT-SCHWARTZ, J. 2004.
Dynamics of putative raft-associated proteins at the cell surface. J Cell
Biol, 165, 735-46.
KERN, A., ALBARRAN-ZECKLER, R., WALSH, H. E. & SMITH, R. G. 2012. Apo-
ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons
and is essential for anorexigenic effects of DRD2 agonism. Neuron, 73,
317-32.
KERN, R. C., KANG, D. S. & BENOVIC, J. L. 2009. Arrestin2/clathrin interaction
is regulated by key N- and C-terminal regions in arrestin2.
Biochemistry, 48, 7190-200.
KERPPOLA, T. K. 2008a. Bimolecular fluorescence complementation (BiFC)
analysis as a probe of protein interactions in living cells. Annu Rev
Biophys, 37, 465-87.
KERPPOLA, T. K. 2008b. Bimolecular fluorescence complementation:
visualization of molecular interactions in living cells. Methods Cell Biol,
85, 431-70.
KERPPOLA, T. K. 2009. Visualization of molecular interactions using
bimolecular fluorescence complementation analysis: characteristics of
protein fragment complementation. Chem Soc Rev, 38, 2876-86.
KERPPOLA, T. K. 2013. Bimolecular fluorescence complementation (BiFC)
analysis of protein interactions in live cells. Cold Spring Harb Protoc,
2013, 727-31.
KILPATRICK, L. E., BRIDDON, S. J., HILL, S. J. & HOLLIDAY, N. D. 2010.
Quantitative analysis of neuropeptide Y receptor association with beta-
arrestin2 measured by bimolecular fluorescence complementation. Br J
Pharmacol, 160, 892-906.
KILPATRICK, L. E., BRIDDON, S. J. & HOLLIDAY, N. D. 2012. Fluorescence
correlation spectroscopy, combined with bimolecular fluorescence
complementation, reveals the effects of beta-arrestin complexes and
endocytic targeting on the membrane mobility of neuropeptide Y
receptors. Biochim Biophys Acta, 1823, 1068-81.
KILPATRICK, L. E. & HOLLIDAY, N. D. 2012. Dissecting the pharmacology of G
protein-coupled receptor signaling complexes using bimolecular
fluorescence complementation. Methods Mol Biol, 897, 109-38.
374
KIM, M., VISHNIVETSKIY, S. A., VAN EPS, N., ALEXANDER, N. S., CLEGHORN,
W. M., ZHAN, X., HANSON, S. M., MORIZUMI, T., ERNST, O. P.,
MEILER, J., GUREVICH, V. V. & HUBBELL, W. L. 2012. Conformation of
receptor-bound visual arrestin. Proceedings of the National Academy of
Sciences, 109, 18407-18412.
KIM, Y. M. & BENOVIC, J. L. 2002. Differential roles of arrestin-2 interaction
with clathrin and adaptor protein 2 in G protein-coupled receptor
trafficking. J Biol Chem, 277, 30760-8.
KIRCHBERG, K., KIM, T. Y., MOLLER, M., SKEGRO, D., DASARA RAJU, G.,
GRANZIN, J., BULDT, G., SCHLESINGER, R. & ALEXIEV, U. 2011.
Conformational dynamics of helix 8 in the GPCR rhodopsin controls
arrestin activation in the desensitization process. Proc Natl Acad Sci U S
A, 108, 18690-5.
KISSELEV, O. G., MCDOWELL, J. H. & HARGRAVE, P. A. 2004. The arrestin-
bound conformation and dynamics of the phosphorylated carboxy-
terminal region of rhodopsin. FEBS Lett, 564, 307-11.
KLAPSTEIN, G. J. & COLMERS, W. F. 1993. On the sites of presynaptic
inhibition by neuropeptide Y in rat hippocampus in vitro. Hippocampus,
3, 103-11.
KNIAZEFF J, B. A.-S., MAUREL D, ANSANAY H, PREZEAU L, PIN JP 2004.
Closed state of both binding domains of homodimeric mGlu receptors is
required for full activity. Nature Structural and Molecular Biology, 11,
706-713.
KNIAZEFF, J., GALVEZ, T., LABESSE, G. & PIN, J. P. 2002. No ligand binding in
the GB2 subunit of the GABA(B) receptor is required for activation and
allosteric interaction between the subunits. J Neurosci, 22, 7352-61.
KOBILKA, B. K. & DEUPI, X. 2007. Conformational complexity of G-protein-
coupled receptors. Trends Pharmacol Sci, 28, 397-406.
KOCAN, M., SEE, H. B., SAMPAIO, N. G., EIDNE, K. A., FELDMAN, B. J. &
PFLEGER, K. D. 2009. Agonist-independent interactions between beta-
arrestins and mutant vasopressin type II receptors associated with
nephrogenic syndrome of inappropriate antidiuresis. Mol Endocrinol,
23, 559-71.
KOCAN, M., SEE, H. B., SEEBER, R. M., EIDNE, K. A. & PFLEGER, K. D. 2008.
Demonstration of improvements to the bioluminescence resonance
energy transfer (BRET) technology for the monitoring of G protein-
coupled receptors in live cells. J Biomol Screen, 13, 888-98.
KODAMA, Y. & HU, C. D. 2010. An improved bimolecular fluorescence
complementation assay with a high signal-to-noise ratio.
Biotechniques, 49, 793-805.
KODAMA, Y. & HU, C. D. 2012. Bimolecular fluorescence complementation
(BiFC): a 5-year update and future perspectives. Biotechniques, 53,
285-98.
KOLINSKI, M. & FILIPEK, S. 2010. Study of a structurally similar kappa opioid
receptor agonist and antagonist pair by molecular dynamics
simulations. J Mol Model, 16, 1567-76.
KOMMADDI, R. P. & SHENOY, S. K. 2013. Arrestins and protein ubiquitination.
Prog Mol Biol Transl Sci, 118, 175-204.
KOSUGI, S., KOHN, L. D., AKAMIZU, T. & MORI, T. 1994. The middle portion
in the second cytoplasmic loop of the thyrotropin receptor plays a
crucial role in adenylate cyclase activation. Mol Endocrinol, 8, 498-509.
375
KRASEL, C., VILARDAGA, J. P., BUNEMANN, M. & LOHSE, M. J. 2004. Kinetics
of G-protein-coupled receptor signalling and desensitization. Biochem
Soc Trans, 32, 1029-31.
KRAUSE, J., EVA, C., SEEBURG, P. H. & SPRENGEL, R. 1992. Neuropeptide Y1
subtype pharmacology of a recombinantly expressed neuropeptide
receptor. Mol Pharmacol, 41, 817-21.
KRUPNICK, J. G., GOODMAN, O. B., JR., KEEN, J. H. & BENOVIC, J. L. 1997a.
Arrestin/clathrin interaction. Localization of the clathrin binding domain
of nonvisual arrestins to the carboxy terminus. J Biol Chem, 272,
15011-6.
KRUPNICK, J. G., GUREVICH, V. V. & BENOVIC, J. L. 1997b. Mechanism of
quenching of phototransduction. Binding competition between arrestin
and transducin for phosphorhodopsin. J Biol Chem, 272, 18125-31.
KRUSE, A. C., HU, J., PAN, A. C., ARLOW, D. H., ROSENBAUM, D. M.,
ROSEMOND, E., GREEN, H. F., LIU, T., CHAE, P. S., DROR, R. O.,
SHAW, D. E., WEIS, W. I., WESS, J. & KOBILKA, B. K. 2012. Structure
and dynamics of the M3 muscarinic acetylcholine receptor. Nature, 482,
552-6.
KUDER, K. & KIEC-KONONOWICZ, K. 2008. Fluorescent GPCR ligands as new
tools in pharmacology. Curr Med Chem, 15, 2132-43.
KUHN, C., BUFE, B., BATRAM, C. & MEYERHOF, W. 2010. Oligomerization of
TAS2R bitter taste receptors. Chem Senses, 35, 395-406.
KUSHI, A., SASAI, H., KOIZUMI, H., TAKEDA, N., YOKOYAMA, M. &
NAKAMURA, M. 1998. Obesity and mild hyperinsulinemia found in
neuropeptide Y-Y1 receptor-deficient mice. Proc Natl Acad Sci U S A,
95, 15659-64.
KUSZAK, A. J., PITCHIAYA, S., ANAND, J. P., MOSBERG, H. I., WALTER, N. G.
& SUNAHARA, R. K. 2009. Purification and functional reconstitution of
monomeric mu-opioid receptors: allosteric modulation of agonist
binding by Gi2. J Biol Chem, 284, 26732-41.
LAMBERT, N. 2010. GPCR Dimers Fall Apart. Science Signaling, 3, 1-3.
LAN, H., DURAND, C. J., TEETER, M. M. & NEVE, K. A. 2006. Structural
determinants of pharmacological specificity between D(1) and D(2)
dopamine receptors. Mol Pharmacol, 69, 185-94.
LAN, T. H., KURAVI, S. & LAMBERT, N. A. 2011. Internalization dissociates
beta2-adrenergic receptors. PLoS One, 6, e17361.
LANE, J. R., DONTHAMSETTI, P., SHONBERG, J., DRAPER-JOYCE, C. J.,
DENTRY, S., MICHINO, M., SHI, L., LOPEZ, L., SCAMMELLS, P. J.,
CAPUANO, B., SEXTON, P. M., JAVITCH, J. A. & CHRISTOPOULOS, A.
2014. A new mechanism of allostery in a G protein-coupled receptor
dimer. Nat Chem Biol, 10, 745-52.
LANGMEAD, C. J. & CHRISTOPOULOS, A. 2014. Functional and structural
perspectives on allosteric modulation of GPCRs. Curr Opin Cell Biol, 27,
94-101.
LAPORTE, S. A., OAKLEY, R. H., ZHANG, J., HOLT, J. A., FERGUSON, S. S.,
CARON, M. G. & BARAK, L. S. 1999. The beta2-adrenergic
receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during
endocytosis. Proc Natl Acad Sci U S A, 96, 3712-7.
LARHAMMAR, D., BLOMQVIST, A. G., YEE, F., JAZIN, E., YOO, H. &
WAHLESTED, C. 1992. Cloning and functional expression of a human
neuropeptide Y/peptide YY receptor of the Y1 type. J Biol Chem, 267,
10935-8.
376
LATIF, R., GRAVES, P. & DAVIES, T. F. 2002. Ligand-dependent inhibition of
oligomerization at the human thyrotropin receptor. J Biol Chem, 277,
45059-67.
LAVOIE, C., MERCIER, J. F., SALAHPOUR, A., UMAPATHY, D., BREIT, A.,
VILLENEUVE, L. R., ZHU, W. Z., XIAO, R. P., LAKATTA, E. G., BOUVIER,
M. & HEBERT, T. E. 2002. Beta 1/beta 2-adrenergic receptor
heterodimerization regulates beta 2-adrenergic receptor internalization
and ERK signaling efficacy. J Biol Chem, 277, 35402-10.
LE ROY, C. & WRANA, J. L. 2005. Clathrin- and non-clathrin-mediated
endocytic regulation of cell signalling. Nat Rev Mol Cell Biol, 6, 112-26.
LECAT, S., OUEDRAOGO, M., CHERRIER, T., NOULET, F., RONDE, P.,
GLASSER, N., GALZI, J. L., MELY, Y., TAKEDA, K. & BUCHER, B. 2011.
Contribution of a tyrosine-based motif to cellular trafficking of wild-type
and truncated NPY Y(1) receptors. Cell Signal, 23, 228-38.
LECKLIN, A., LUNDELL, I., PAANANEN, L., WIKBERG, J. E., MANNISTO, P. T. &
LARHAMMAR, D. 2002. Receptor subtypes Y1 and Y5 mediate
neuropeptide Y induced feeding in the guinea-pig. Br J Pharmacol, 135,
2029-37.
LEIBOWITZ, S. F., SLADEK, C., SPENCER, L. & TEMPEL, D. 1988. Neuropeptide
Y, epinephrine and norepinephrine in the paraventricular nucleus:
stimulation of feeding and the release of corticosterone, vasopressin
and glucose. Brain Res Bull, 21, 905-12.
LENNE, P. F., WAWREZINIECK, L., CONCHONAUD, F., WURTZ, O., BONED, A.,
GUO, X. J., RIGNEAULT, H., HE, H. T. & MARGUET, D. 2006. Dynamic
molecular confinement in the plasma membrane by microdomains and
the cytoskeleton meshwork. EMBO J, 25, 3245-56.
LEVOYE, A., DAM, J., AYOUB, M. A., GUILLAUME, J. L., COUTURIER, C.,
DELAGRANGE, P. & JOCKERS, R. 2006. The orphan GPR50 receptor
specifically inhibits MT1 melatonin receptor function through
heterodimerization. EMBO J, 25, 3012-23.
LICHT, S. S., SONNLEITNER, A., WEISS, S. & SCHULTZ, P. G. 2003. A rugged
energy landscape mechanism for trapping of transmembrane receptors
during endocytosis. Biochemistry, 42, 2916-25.
LINDNER, D., STICHEL, J. & BECK-SICKINGER, A. G. 2008. Molecular
recognition of the NPY hormone family by their receptors. Nutrition, 24,
907-17.
LINDNER, D., WALTHER, C., TENNEMANN, A. & BECK-SICKINGER, A. G. 2009.
Functional role of the extracellular N-terminal domain of neuropeptide Y
subfamily receptors in membrane integration and agonist-stimulated
internalization. Cell Signal, 21, 61-8.
LIPPINCOTT-SCHWARTZ, J., ALTAN-BONNET, N. & PATTERSON, G. H. 2003.
Photobleaching and photoactivation: following protein dynamics in
living cells. Nat Cell Biol, Suppl, S7-14.
LOHSE, M. J., BENOVIC, J. L., CODINA, J., CARON, M. G. & LEFKOWITZ, R. J.
1990. beta-Arrestin: a protein that regulates beta-adrenergic receptor
function. Science, 248, 1547-50.
LOHSE, M. J., HEIN, P., HOFFMANN, C., NIKOLAEV, V. O., VILARDAGA, J. P. &
BUNEMANN, M. 2008. Kinetics of G-protein-coupled receptor signals in
intact cells. Br J Pharmacol, 153 Suppl 1, S125-32.
LUNDELL, I., BLOMQVIST, A. G., BERGLUND, M. M., SCHOBER, D. A.,
JOHNSON, D., STATNICK, M. A., GADSKI, R. A., GEHLERT, D. R. &
LARHAMMAR, D. 1995. Cloning of a human receptor of the NPY
377
receptor family with high affinity for pancreatic polypeptide and peptide
YY. J Biol Chem, 270, 29123-8.
LUNDELL, I., RABE BERNHARDT, N., JOHNSSON, A. K. & LARHAMMAR, D.
2011. Internalization studies of chimeric neuropeptide Y receptors Y1
and Y2 suggest complex interactions between cytoplasmic domains.
Regul Pept, 168, 50-8.
LUNDELL, I., STATNICK, M. A., JOHNSON, D., SCHOBER, D. A., STARBACK, P.,
GEHLERT, D. R. & LARHAMMAR, D. 1996. The cloned rat pancreatic
polypeptide receptor exhibits profound differences to the orthologous
receptor. Proc Natl Acad Sci U S A, 93, 5111-5.
LUTTRELL, L. M. & GESTY-PALMER, D. 2010. Beyond desensitization:
physiological relevance of arrestin-dependent signaling. Pharmacol Rev,
62, 305-30.
LUTTRELL, L. M. & LEFKOWITZ, R. J. 2002. The role of beta-arrestins in the
termination and transduction of G-protein-coupled receptor signals. J
Cell Sci, 115, 455-65.
MANCIA, F., ASSUR, Z., HERMAN, A. G., SIEGEL, R. & HENDRICKSON, W. A.
2008. Ligand sensitivity in dimeric associations of the serotonin 5HT2c
receptor. EMBO Rep, 9, 363-9.
MANGLIK, A., KRUSE, A. C., KOBILKA, T. S., THIAN, F. S., MATHIESEN, J. M.,
SUNAHARA, R. K., PARDO, L., WEIS, W. I., KOBILKA, B. K. & GRANIER,
S. 2012. Crystal structure of the micro-opioid receptor bound to a
morphinan antagonist. Nature, 485, 321-6.
MARCELLINO, D., FERRE, S., CASADO, V., CORTES, A., LE FOLL, B.,
MAZZOLA, C., DRAGO, F., SAUR, O., STARK, H., SORIANO, A.,
BARNES, C., GOLDBERG, S. R., LLUIS, C., FUXE, K. & FRANCO, R.
2008. Identification of dopamine D1-D3 receptor heteromers.
Indications for a role of synergistic D1-D3 receptor interactions in the
striatum. J Biol Chem, 283, 26016-25.
MARGETA-MITROVIC, M., JAN, Y. N. & JAN, L. Y. 2000. A trafficking
checkpoint controls GABA(B) receptor heterodimerization. Neuron, 27,
97-106.
MARION, S., OAKLEY, R. H., KIM, K. M., CARON, M. G. & BARAK, L. S. 2006. A
beta-arrestin binding determinant common to the second intracellular
loops of rhodopsin family G protein-coupled receptors. J Biol Chem,
281, 2932-8.
MARKS, J. L., PORTE, D., JR., STAHL, W. L. & BASKIN, D. G. 1990.
Localization of insulin receptor mRNA in rat brain by in situ
hybridization. Endocrinology, 127, 3234-6.
MARSH, D. J., HOLLOPETER, G., KAFER, K. E. & PALMITER, R. D. 1998. Role of
the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med, 4,
718-21.
MASHIKO, S., MORIYA, R., ISHIHARA, A., GOMORI, A., MATSUSHITA, H.,
EGASHIRA, S., IWAASA, H., TAKAHASHI, T., HAGA, Y., FUKAMI, T. &
KANATANI, A. 2009. Synergistic interaction between neuropeptide Y1
and Y5 receptor pathways in regulation of energy homeostasis. Eur J
Pharmacol, 615, 113-7.
MASRI, B., SALAHPOUR, A., DIDRIKSEN, M., GHISI, V., BEAULIEU, J. M.,
GAINETDINOV, R. R. & CARON, M. G. 2008. Antagonism of dopamine
D2 receptor/beta-arrestin 2 interaction is a common property of
clinically effective antipsychotics. Proc Natl Acad Sci U S A, 105, 13656-
61.
378
MATTHEWS, J. E., JANSEN, M., LYERLY, D., COX, R., CHEN, W. J., KOLLER, K.
J. & DANIELS, A. J. 1997. Pharmacological characterization and
selectivity of the NPY antagonist GR231118 (1229U91) for different
NPY receptors. Regul Pept, 72, 113-9.
MAUREL, D., KNIAZEFF, J., MATHIS, G., TRINQUET, E., PIN, J. P. & ANSANAY,
H. 2004. Cell surface detection of membrane protein interaction with
homogeneous time-resolved fluorescence resonance energy transfer
technology. Anal Biochem, 329, 253-62.
MAURICE, P., KAMAL, M. & JOCKERS, R. 2011. Asymmetry of GPCR oligomers
supports their functional relevance. Trends Pharmacol Sci, 32, 514-20.
MAY, L. T., BRIDGE, L. J., STODDART, L. A., BRIDDON, S. J. & HILL, S. J.
2011. Allosteric interactions across native adenosine-A3 receptor
homodimers: quantification using single-cell ligand-binding kinetics.
FASEB J, 25, 3465-76.
MAY, L. T., LEACH, K., SEXTON, P. M. & CHRISTOPOULOS, A. 2007. Allosteric
modulation of G protein-coupled receptors. Annu Rev Pharmacol
Toxicol, 47, 1-51.
MCCOY, K. L., GYONEVA, S., VELLANO, C. P., SMRCKA, A. V., TRAYNELIS, S.
F. & HEPLER, J. R. 2012. Protease-activated receptor 1 (PAR1) coupling
to G(q/11) but not to G(i/o) or G(12/13) is mediated by discrete amino
acids within the receptor second intracellular loop. Cell Signal, 24,
1351-60.
MCCREA, K., WISIALOWSKI, T., CABRELE, C., CHURCH, B., BECK-SICKINGER,
A., KRAEGEN, E. & HERZOG, H. 2000. 2-36[K4,RYYSA(19-23)]PP a
novel Y5-receptor preferring ligand with strong stimulatory effect on
food intake. Regul Pept, 87, 47-58.
MCGAVIGAN, A. K. & MURPHY, K. G. 2012. Gut hormones: the future of
obesity treatment? Br J Clin Pharmacol, 74, 911-9.
MCGUIRE, H., AUROUSSEAU, M. R., BOWIE, D. & BLUNCK, R. 2012.
Automating single subunit counting of membrane proteins in
mammalian cells. J Biol Chem, 287, 35912-21.
MCLEAN, A. J. & MILLIGAN, G. 2000. Ligand regulation of green fluorescent
protein-tagged forms of the human beta(1)- and beta(2)-
adrenoceptors; comparisons with the unmodified receptors. Br J
Pharmacol, 130, 1825-32.
MCNALLY, J. G. 2008. Quantitative FRAP in analysis of molecular binding
dynamics in vivo. Methods Cell Biol, 85, 329-51.
MEDEIROS, P. J. & JACKSON, D. N. 2013. Neuropeptide Y Y5-receptor
activation on breast cancer cells acts as a paracrine system that
stimulates VEGF expression and secretion to promote angiogenesis.
Peptides, 48C, 106-113.
MEISSNER, O. & HABERLEIN, H. 2003. Lateral mobility and specific binding to
GABA(A) receptors on hippocampal neurons monitored by fluorescence
correlation spectroscopy. Biochemistry, 42, 1667-72.
MERCIER, J. F., SALAHPOUR, A., ANGERS, S., BREIT, A. & BOUVIER, M. 2002.
Quantitative assessment of beta 1- and beta 2-adrenergic receptor
homo- and heterodimerization by bioluminescence resonance energy
transfer. J Biol Chem, 277, 44925-31.
MERTEN, N., LINDNER, D., RABE, N., ROMPLER, H., MORL, K., SCHONEBERG,
T. & BECK-SICKINGER, A. G. 2007. Receptor subtype-specific docking
of Asp6.59 with C-terminal arginine residues in Y receptor ligands. J
Biol Chem, 282, 7543-51.
379
MICHEL, M. C., BECK-SICKINGER, A., COX, H., DOODS, H. N., HERZOG, H.,
LARHAMMAR, D., QUIRION, R., SCHWARTZ, T. & WESTFALL, T. 1998.
XVI. International Union of Pharmacology recommendations for the
nomenclature of neuropeptide Y, peptide YY, and pancreatic
polypeptide receptors. Pharmacol Rev, 50, 143-50.
MICHNICK, S. W., EAR, P. H., LANDRY, C., MALLESHAIAH, M. K. & MESSIER,
V. 2011. Protein-fragment complementation assays for large-scale
analysis, functional dissection and dynamic studies of protein-protein
interactions in living cells. Methods Mol Biol, 756, 395-425.
MILLIGAN, G. 2009. G protein-coupled receptor hetero-dimerization:
contribution to pharmacology and function. Br J Pharmacol, 158, 5-14.
MITCHELL, N. S., CATENACCI, V. A., WYATT, H. R. & HILL, J. O. 2011.
Obesity: overview of an epidemic. Psychiatr Clin North Am, 34, 717-32.
MIZUNO, N., SUZUKI, T., HIRASAWA, N. & NAKAHATA, N. 2012. Hetero-
oligomerization between adenosine A(1) and thromboxane A(2)
receptors and cellular signal transduction on stimulation with high and
low concentrations of agonists for both receptors. Eur J Pharmacol,
677, 5-14.
MOLLEREAU, C., GOUARDERES, C., DUMONT, Y., KOTANI, M., DETHEUX, M.,
DOODS, H., PARMENTIER, M., QUIRION, R. & ZAJAC, J. M. 2001.
Agonist and antagonist activities on human NPFF(2) receptors of the
NPY ligands GR231118 and BIBP3226. Br J Pharmacol, 133, 1-4.
MONKS, S. A., KARAGIANIS, G., HOWLETT, G. J. & NORTON, R. S. 1996.
Solution structure of human neuropeptide Y. J Biomol NMR, 8, 379-90.
MONNIER, C., TU, H., BOURRIER, E., VOL, C., LAMARQUE, L., TRINQUET, E.,
PIN, J. P. & RONDARD, P. 2011. Trans-activation between 7TM
domains: implication in heterodimeric GABAB receptor activation.
EMBO J, 30, 32-42.
MONNOT, C., BIHOREAU, C., CONCHON, S., CURNOW, K. M., CORVOL, P. &
CLAUSER, E. 1996. Polar residues in the transmembrane domains of
the type 1 angiotensin II receptor are required for binding and
coupling. Reconstitution of the binding site by co-expression of two
deficient mutants. J Biol Chem, 271, 1507-13.
MOORE, C. A., MILANO, S. K. & BENOVIC, J. L. 2007. Regulation of receptor
trafficking by GRKs and arrestins. Annu Rev Physiol, 69, 451-82.
MOREIRA, I. S. 2014. Structural features of the G-protein/GPCR interactions.
Biochim Biophys Acta, 1840, 16-33.
MORENO, E., MORENO-DELGADO, D., NAVARRO, G., HOFFMANN, H. M.,
FUENTES, S., ROSELL-VILAR, S., GASPERINI, P., RODRIGUEZ-RUIZ,
M., MEDRANO, M., MALLOL, J., CORTES, A., CASADO, V., LLUIS, C.,
FERRE, S., ORTIZ, J., CANELA, E. & MCCORMICK, P. J. 2014. Cocaine
disrupts histamine H3 receptor modulation of dopamine D1 receptor
signaling: sigma1-D1-H3 receptor complexes as key targets for
reducing cocaine's effects. J Neurosci, 34, 3545-58.
MORRIS, B. J. 1989. Neuronal localisation of neuropeptide Y gene expression
in rat brain. J Comp Neurol, 290, 358-68.
MOUNTFORD, S. J., LIU, M., ZHANG, L., GROENEN, M., HERZOG, H.,
HOLLIDAY, N. D. & THOMPSON, P. E. 2014. Synthetic routes to the
Neuropeptide Y Y1 receptor antagonist 1229U91 and related analogues
for SAR studies and cell-based imaging. Org Biomol Chem, 12, 3271-
81.
380
MULLINS, D., KIRBY, D., HWA, J., GUZZI, M., RIVIER, J. & PARKER, E. 2001.
Identification of potent and selective neuropeptide Y Y(1) receptor
agonists with orexigenic activity in vivo. Mol Pharmacol, 60, 534-40.
MUSNIER, A., BLANCHOT, B., REITER, E. & CRÉPIEUX, P. 2010. GPCR
signalling to the translation machinery. Cellular Signalling, 22, 707-
716.
NAGAI, T., IBATA, K., PARK, E. S., KUBOTA, M., MIKOSHIBA, K. & MIYAWAKI,
A. 2002. A variant of yellow fluorescent protein with fast and efficient
maturation for cell-biological applications. Nat Biotechnol, 20, 87-90.
NAVARRO, G., CARRIBA, P., GANDIA, J., CIRUELA, F., CASADO, V., CORTES,
A., MALLOL, J., CANELA, E. I., LLUIS, C. & FRANCO, R. 2008. Detection
of heteromers formed by cannabinoid CB1, dopamine D2, and
adenosine A2A G-protein-coupled receptors by combining bimolecular
fluorescence complementation and bioluminescence energy transfer.
ScientificWorldJournal, 8, 1088-97.
NAVEILHAN, P., HASSANI, H., CANALS, J. M., EKSTRAND, A. J., LAREFALK, A.,
CHHAJLANI, V., ARENAS, E., GEDDA, K., SVENSSON, L., THOREN, P. &
ERNFORS, P. 1999. Normal feeding behavior, body weight and leptin
response require the neuropeptide Y Y2 receptor. Nat Med, 5, 1188-93.
NELSON, C. D., PERRY, S. J., REGIER, D. S., PRESCOTT, S. M., TOPHAM, M. K.
& LEFKOWITZ, R. J. 2007. Targeting of diacylglycerol degradation to
M1 muscarinic receptors by beta-arrestins. Science, 315, 663-6.
NEUSCHAFER-RUBE, F., HERMOSILLA, R., REHWALD, M., RONNSTRAND, L.,
SCHULEIN, R., WERNSTEDT, C. & PUSCHEL, G. P. 2004. Identification
of a Ser/Thr cluster in the C-terminal domain of the human
prostaglandin receptor EP4 that is essential for agonist-induced beta-
arrestin1 recruitment but differs from the apparent principal
phosphorylation site. Biochem J, 379, 573-85.
NGUYEN, A. D., MITCHELL, N. F., LIN, S., MACIA, L., YULYANINGSIH, E.,
BALDOCK, P. A., ENRIQUEZ, R. F., ZHANG, L., SHI, Y. C.,
ZOLOTUKHIN, S., HERZOG, H. & SAINSBURY, A. 2012. Y1 and Y5
receptors are both required for the regulation of food intake and energy
homeostasis in mice. PLoS One, 7, e40191.
NICKERSON, A., HUANG, T., LIN, L. J. & NAN, X. 2014. Photoactivated
localization microscopy with bimolecular fluorescence complementation
(BiFC-PALM) for nanoscale imaging of protein-protein interactions in
cells. PLoS One, 9, e100589.
NOBLES, K. N., GUAN, Z., XIAO, K., OAS, T. G. & LEFKOWITZ, R. J. 2007. The
active conformation of beta-arrestin1: direct evidence for the
phosphate sensor in the N-domain and conformational differences in
the active states of beta-arrestins1 and -2. J Biol Chem, 282, 21370-
81.
NOBLES, K. N., XIAO, K., AHN, S., SHUKLA, A. K., LAM, C. M., RAJAGOPAL,
S., STRACHAN, R. T., HUANG, T. Y., BRESSLER, E. A., HARA, M. R.,
SHENOY, S. K., GYGI, S. P. & LEFKOWITZ, R. J. 2011. Distinct
phosphorylation sites on the beta(2)-adrenergic receptor establish a
barcode that encodes differential functions of beta-arrestin. Sci Signal,
4, ra51.
NYGAARD, R., ZOU, Y., DROR, R. O., MILDORF, T. J., ARLOW, D. H.,
MANGLIK, A., PAN, A. C., LIU, C. W., FUNG, J. J., BOKOCH, M. P.,
THIAN, F. S., KOBILKA, T. S., SHAW, D. E., MUELLER, L., PROSSER, R.
381
S. & KOBILKA, B. K. 2013. The dynamic process of beta(2)-adrenergic
receptor activation. Cell, 152, 532-42.
OFFERMANNS, S., LAUGWITZ, K. L., SPICHER, K. & SCHULTZ, G. 1994. G
proteins of the G12 family are activated via thromboxane A2 and
thrombin receptors in human platelets. Proc Natl Acad Sci U S A, 91,
504-8.
OLDHAM, W. M. & HAMM, H. E. 2008. Heterotrimeric G protein activation by
G-protein-coupled receptors. Nat Rev Mol Cell Biol, 9, 60-71.
ONUOHA, G. N., NUGENT, A. M., HUNTER, S. J., ALPAR, E. K., MCENEANEY, D.
J., CAMPBELL, N. P., SHAW, C., BUCHANAN, K. D. & NICHOLLS, D. P.
2000. Neuropeptide variability in man. Eur J Clin Invest, 30, 570-7.
ORMO, M., CUBITT, A. B., KALLIO, K., GROSS, L. A., TSIEN, R. Y. &
REMINGTON, S. J. 1996. Crystal structure of the Aequorea victoria
green fluorescent protein. Science, 273, 1392-5.
ORTIZ, A. A., MILARDO, L. F., DECARR, L. B., BUCKHOLZ, T. M., MAYS, M. R.,
CLAUS, T. H., LIVINGSTON, J. N., MAHLE, C. D. & LUMB, K. J. 2007. A
novel long-acting selective neuropeptide Y2 receptor polyethylene
glycol-conjugated peptide agonist reduces food intake and body weight
and improves glucose metabolism in rodents. J Pharmacol Exp Ther,
323, 692-700.
OUEDRAOGO, M., LECAT, S., ROCHDI, M. D., HACHET-HAAS, M., MATTHES,
H., GICQUIAUX, H., VERRIER, S., GAIRE, M., GLASSER, N., MELY, Y.,
TAKEDA, K., BOUVIER, M., GALZI, J. L. & BUCHER, B. 2008. Distinct
motifs of neuropeptide Y receptors differentially regulate trafficking and
desensitization. Traffic, 9, 305-24.
OZAWA, K., WHALEN, E. J., NELSON, C. D., MU, Y., HESS, D. T., LEFKOWITZ,
R. J. & STAMLER, J. S. 2008. S-nitrosylation of beta-arrestin regulates
beta-adrenergic receptor trafficking. Mol Cell, 31, 395-405.
PADGETT, C. L. & SLESINGER, P. A. 2010. GABAB receptor coupling to G-
proteins and ion channels. Adv Pharmacol, 58, 123-47.
PAGE, K. M., CURTIS, C. A., JONES, P. G. & HULME, E. C. 1995. The functional
role of the binding site aspartate in muscarinic acetylcholine receptors,
probed by site-directed mutagenesis. Eur J Pharmacol, 289, 429-37.
PAING, M. M., STUTTS, A. B., KOHOUT, T. A., LEFKOWITZ, R. J. & TREJO, J.
2002. beta -Arrestins regulate protease-activated receptor-1
desensitization but not internalization or Down-regulation. J Biol Chem,
277, 1292-300.
PALCZEWSKI, K. 2006. G protein-coupled receptor rhodopsin. Annu Rev
Biochem, 75, 743-67.
PALCZEWSKI, K., BUCZYLKO, J., IMAMI, N. R., MCDOWELL, J. H. &
HARGRAVE, P. A. 1991. Role of the carboxyl-terminal region of arrestin
in binding to phosphorylated rhodopsin. J Biol Chem, 266, 15334-9.
PALCZEWSKI, K., KUMASAKA, T., HORI, T., BEHNKE, C. A., MOTOSHIMA, H.,
FOX, B. A., LE TRONG, I., TELLER, D. C., OKADA, T., STENKAMP, R. E.,
YAMAMOTO, M. & MIYANO, M. 2000. Crystal structure of rhodopsin: A
G protein-coupled receptor. Science, 289, 739-45.
PALS-RYLAARSDAM, R., GUREVICH, V. V., LEE, K. B., PTASIENSKI, J. A.,
BENOVIC, J. L. & HOSEY, M. M. 1997. Internalization of the m2
muscarinic acetylcholine receptor. Arrestin-independent and -
dependent pathways. J Biol Chem, 272, 23682-9.
382
PARK, J. H., SCHEERER, P., HOFMANN, K. P., CHOE, H. W. & ERNST, O. P.
2008. Crystal structure of the ligand-free G-protein-coupled receptor
opsin. Nature, 454, 183-7.
PARKER, E. M., BABIJ, C. K., BALASUBRAMANIAM, A., BURRIER, R. E., GUZZI,
M., HAMUD, F., MUKHOPADHYAY, G., RUDINSKI, M. S., TAO, Z., TICE,
M., XIA, L., MULLINS, D. E. & SALISBURY, B. G. 1998. GR231118
(1229U91) and other analogues of the C-terminus of neuropeptide Y
are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y
Y4 receptor agonists. Eur J Pharmacol, 349, 97-105.
PARKER, M. S., SAH, R., SHERIFF, S., BALASUBRAMANIAM, A. & PARKER, S.
L. 2005. Internalization of cloned pancreatic polypeptide receptors is
accelerated by all types of Y4 agonists. Regul Pept, 132, 91-101.
PARKER, R. M. & HERZOG, H. 1999. Regional distribution of Y-receptor
subtype mRNAs in rat brain. Eur J Neurosci, 11, 1431-48.
PARKER, S. L., KANE, J. K., PARKER, M. S., BERGLUND, M. M., LUNDELL, I. A.
& LI, M. D. 2001. Cloned neuropeptide Y (NPY) Y1 and pancreatic
polypeptide Y4 receptors expressed in Chinese hamster ovary cells
show considerable agonist-driven internalization, in contrast to the NPY
Y2 receptor. Eur J Biochem, 268, 877-86.
PARKER, S. L., PARKER, M. S., BUSCHAUER, A. & BALASUBRAMANIAM, A.
2003. Ligand internalization by cloned neuropeptide Y Y5 receptors
excludes Y2 and Y4 receptor-selective peptides. Eur J Pharmacol, 474,
31-42.
PARKER, S. L., PARKER, M. S., LUNDELL, I., BALASUBRAMANIAM, A.,
BUSCHAUER, A., KANE, J. K., YALCIN, A. & BERGLUND, M. M. 2002.
Agonist internalization by cloned Y1 neuropeptide Y (NPY) receptor in
Chinese hamster ovary cells shows strong preference for NPY,
endosome-linked entry and fast receptor recycling. Regul Pept, 107,
49-62.
PATEL, R. C., KUMAR, U., LAMB, D. C., EID, J. S., ROCHEVILLE, M., GRANT,
M., RANI, A., HAZLETT, T., PATEL, S. C., GRATTON, E. & PATEL, Y. C.
2002. Ligand binding to somatostatin receptors induces receptor-
specific oligomer formation in live cells. Proc Natl Acad Sci U S A, 99,
3294-9.
PATTERSON, G. H. 2007. Fluorescent proteins for cell biology. Methods Mol
Biol, 411, 47-80.
PEDELACQ, J. D., CABANTOUS, S., TRAN, T., TERWILLIGER, T. C. & WALDO,
G. S. 2006. Engineering and characterization of a superfolder green
fluorescent protein. Nat Biotechnol, 24, 79-88.
PEDRAGOSA-BADIA, X., STICHEL, J. & BECK-SICKINGER, A. G. 2013.
Neuropeptide Y receptors: how to get subtype selectivity. Front
Endocrinol (Lausanne), 4, 5.
PEDRAZZINI, T., SEYDOUX, J., KUNSTNER, P., AUBERT, J. F., GROUZMANN,
E., BEERMANN, F. & BRUNNER, H. R. 1998. Cardiovascular response,
feeding behavior and locomotor activity in mice lacking the NPY Y1
receptor. Nat Med, 4, 722-6.
PEETERS, M. C., VAN WESTEN, G. J., GUO, D., WISSE, L. E., MULLER, C. E.,
BEUKERS, M. W. & IJZERMAN, A. P. 2011. GPCR structure and
activation: an essential role for the first extracellular loop in activating
the adenosine A2B receptor. FASEB J, 25, 632-43.
383
PEGG, A. E. 2011. Multifaceted roles of alkyltransferase and related proteins in
DNA repair, DNA damage, resistance to chemotherapy, and research
tools. Chem Res Toxicol, 24, 618-39.
PELLISSIER, L. P., BARTHET, G., GAVEN, F., CASSIER, E., TRINQUET, E., PIN,
J. P., MARIN, P., DUMUIS, A., BOCKAERT, J., BANERES, J. L. &
CLAEYSEN, S. 2011. G protein activation by serotonin type 4 receptor
dimers: evidence that turning on two protomers is more efficient. J Biol
Chem.
PFEIFFER, M., KIRSCHT, S., STUMM, R., KOCH, T., WU, D., LAUGSCH, M.,
SCHRODER, H., HOLLT, V. & SCHULZ, S. 2003. Heterodimerization of
substance P and mu-opioid receptors regulates receptor trafficking and
resensitization. J Biol Chem, 278, 51630-7.
PHENG, L. H., DUMONT, Y., FOURNIER, A., CHABOT, J. G., BEAUDET, A. &
QUIRION, R. 2003. Agonist- and antagonist-induced
sequestration/internalization of neuropeptide Y Y1 receptors in HEK293
cells. Br J Pharmacol, 139, 695-704.
PHILIP, F., SENGUPTA, P. & SCARLATA, S. 2007. Signaling through a G
Protein-coupled receptor and its corresponding G protein follows a
stoichiometrically limited model. J Biol Chem, 282, 19203-16.
PIECHOWSKI, C. L., REDIGER, A., LAGEMANN, C., MUHLHAUS, J., MULLER, A.,
PRATZKA, J., TARNOW, P., GRUTERS, A., KRUDE, H., KLEINAU, G. &
BIEBERMANN, H. 2013. Inhibition of melanocortin-4 receptor
dimerization by substitutions in intracellular loop 2. J Mol Endocrinol,
51, 109-18.
PIERCE, K. L., PREMONT, R. T. & LEFKOWITZ, R. J. 2002. Seven-
transmembrane receptors. Nat Rev Mol Cell Biol, 3, 639-50.
PIN, J. P., NEUBIG, R., BOUVIER, M., DEVI, L., FILIZOLA, M., JAVITCH, J. A.,
LOHSE, M. J., MILLIGAN, G., PALCZEWSKI, K., PARMENTIER, M. &
SPEDDING, M. 2007. International Union of Basic and Clinical
Pharmacology. LXVII. Recommendations for the recognition and
nomenclature of G protein-coupled receptor heteromultimers.
Pharmacol Rev, 59, 5-13.
PITTNER, R. A., MOORE, C. X., BHAVSAR, S. P., GEDULIN, B. R., SMITH, P. A.,
JODKA, C. M., PARKES, D. G., PATERNITI, J. R., SRIVASTAVA, V. P. &
YOUNG, A. A. 2004. Effects of PYY[3-36] in rodent models of diabetes
and obesity. Int J Obes Relat Metab Disord, 28, 963-71.
PORRELLO, E. R., PFLEGER, K. D., SEEBER, R. M., QIAN, H., ORO, C.,
ABOGADIE, F., DELBRIDGE, L. M. & THOMAS, W. G. 2011.
Heteromerization of angiotensin receptors changes trafficking and
arrestin recruitment profiles. Cell Signal, 23, 1767-76.
POU, C., MANNOURY LA COUR, C., STODDART, L. A., MILLAN, M. J. &
MILLIGAN, G. 2012. Functional homomers and heteromers of dopamine
D2L and D3 receptors co-exist at the cell surface. J Biol Chem, 287,
8864-78.
POULIN, B., BUTCHER, A., MCWILLIAMS, P., BOURGOGNON, J. M., PAWLAK,
R., KONG, K. C., BOTTRILL, A., MISTRY, S., WESS, J., ROSETHORNE,
E. M., CHARLTON, S. J. & TOBIN, A. B. 2010. The M3-muscarinic
receptor regulates learning and memory in a receptor
phosphorylation/arrestin-dependent manner. Proc Natl Acad Sci U S A,
107, 9440-5.
PRALONG, F. P., GONZALES, C., VOIROL, M. J., PALMITER, R. D., BRUNNER,
H. R., GAILLARD, R. C., SEYDOUX, J. & PEDRAZZINI, T. 2002. The
384
neuropeptide Y Y1 receptor regulates leptin-mediated control of energy
homeostasis and reproductive functions. FASEB J, 16, 712-4.
PRASHER, D. C., ECKENRODE, V. K., WARD, W. W., PRENDERGAST, F. G. &
CORMIER, M. J. 1992. Primary structure of the Aequorea victoria
green-fluorescent protein. Gene, 111, 229-33.
PREMONT, R. T. & GAINETDINOV, R. R. 2007. Physiological roles of G protein-
coupled receptor kinases and arrestins. Annu Rev Physiol, 69, 511-34.
PREZEAU, L., RIVES, M. L., COMPS-AGRAR, L., MAUREL, D., KNIAZEFF, J. &
PIN, J. P. 2010. Functional crosstalk between GPCRs: with or without
oligomerization. Curr Opin Pharmacol, 10, 6-13.
PRZYBYLA, J. A. & WATTS, V. J. 2010. Ligand-induced regulation and
localization of cannabinoid CB1 and dopamine D2L receptor
heterodimers. J Pharmacol Exp Ther, 332, 710-9.
PUCA, L. & BROU, C. 2014. Alpha-arrestins - new players in Notch and GPCR
signaling pathways in mammals. J Cell Sci, 127, 1359-67.
RABIET, M. J., HUET, E. & BOULAY, F. 2008. Complement component 5a
receptor oligomerization and homologous receptor down-regulation. J
Biol Chem, 283, 31038-46.
RAEHAL, K. M., SCHMID, C. L., GROER, C. E. & BOHN, L. M. 2011. Functional
selectivity at the mu-opioid receptor: implications for understanding
opioid analgesia and tolerance. Pharmacol Rev, 63, 1001-19.
RAJAGOPAL, S., KIM, J., AHN, S., CRAIG, S., LAM, C. M., GERARD, N. P.,
GERARD, C. & LEFKOWITZ, R. J. 2010. Beta-arrestin- but not G
protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl
Acad Sci U S A, 107, 628-32.
RAMAN, D., OSAWA, S. & WEISS, E. R. 1999. Binding of arrestin to
cytoplasmic loop mutants of bovine rhodopsin. Biochemistry, 38, 5117-
23.
RANG, H. P. 2003. Pharmacology, Churchill Livingstone.
RASHID, A. J., SO, C. H., KONG, M. M., FURTAK, T., EL-GHUNDI, M., CHENG,
R., O'DOWD, B. F. & GEORGE, S. R. 2007. D1-D2 dopamine receptor
heterooligomers with unique pharmacology are coupled to rapid
activation of Gq/11 in the striatum. Proc Natl Acad Sci U S A, 104, 654-
9.
RASMUSSEN, S. G., CHOI, H. J., FUNG, J. J., PARDON, E., CASAROSA, P.,
CHAE, P. S., DEVREE, B. T., ROSENBAUM, D. M., THIAN, F. S.,
KOBILKA, T. S., SCHNAPP, A., KONETZKI, I., SUNAHARA, R. K.,
GELLMAN, S. H., PAUTSCH, A., STEYAERT, J., WEIS, W. I. & KOBILKA,
B. K. 2011a. Structure of a nanobody-stabilized active state of the
beta(2) adrenoceptor. Nature, 469, 175-80.
RASMUSSEN, S. G., CHOI, H. J., ROSENBAUM, D. M., KOBILKA, T. S., THIAN,
F. S., EDWARDS, P. C., BURGHAMMER, M., RATNALA, V. R.,
SANISHVILI, R., FISCHETTI, R. F., SCHERTLER, G. F., WEIS, W. I. &
KOBILKA, B. K. 2007a. Crystal structure of the human beta2 adrenergic
G-protein-coupled receptor. Nature, 450, 383-7.
RASMUSSEN, S. G., DEVREE, B. T., ZOU, Y., KRUSE, A. C., CHUNG, K. Y.,
KOBILKA, T. S., THIAN, F. S., CHAE, P. S., PARDON, E., CALINSKI, D.,
MATHIESEN, J. M., SHAH, S. T., LYONS, J. A., CAFFREY, M., GELLMAN,
S. H., STEYAERT, J., SKINIOTIS, G., WEIS, W. I., SUNAHARA, R. K. &
KOBILKA, B. K. 2011b. Crystal structure of the beta2 adrenergic
receptor-Gs protein complex. Nature, 477, 549-55.
385
RASMUSSEN, S. G. F., CHOI, H.-J., ROSENBAUM, D. M., KOBILKA, T. S.,
THIAN, F. S., EDWARDS, P. C., BURGHAMMER, M., RATNALA, V. R. P.,
SANISHVILI, R., FISCHETTI, R. F., SCHERTLER, G. F. X., WEIS, W. I. &
KOBILKA, B. K. 2007b. Crystal structure of the human [bgr]2
adrenergic G-protein-coupled receptor. Nature, 450, 383-387.
REICH, N. C. 2007. STAT dynamics. Cytokine Growth Factor Rev, 18, 511-8.
REUVEN, E. M., FINK, A. & SHAI, Y. 2014. Regulation of innate immune
responses by transmembrane interactions: Lessons from the TLR
family. Biochim Biophys Acta, 1838, 1586-1593.
RICHARDSON, M. D., BALIUS, A. M., YAMAGUCHI, K., FREILICH, E. R.,
BARAK, L. S. & KWATRA, M. M. 2003. Human substance P receptor
lacking the C-terminal domain remains competent to desensitize and
internalize. J Neurochem, 84, 854-63.
RIVES, M. L., VOL, C., FUKAZAWA, Y., TINEL, N., TRINQUET, E., AYOUB, M.
A., SHIGEMOTO, R., PIN, J. P. & PREZEAU, L. 2009. Crosstalk between
GABAB and mGlu1a receptors reveals new insight into GPCR signal
integration. EMBO J, 28, 2195-208.
ROMANO, C., YANG, W. L. & O'MALLEY, K. L. 1996. Metabotropic glutamate
receptor 5 is a disulfide-linked dimer. J Biol Chem, 271, 28612-6.
ROMO, T. D., GROSSFIELD, A. & PITMAN, M. C. 2010. Concerted
interconversion between ionic lock substates of the beta(2) adrenergic
receptor revealed by microsecond timescale molecular dynamics.
Biophys J, 98, 76-84.
ROSE, P. M., LYNCH, J. S., FRAZIER, S. T., FISHER, S. M., CHUNG, W.,
BATTAGLINO, P., FATHI, Z., LEIBEL, R. & FERNANDES, P. 1997.
Molecular genetic analysis of a human neuropeptide Y receptor. The
human homolog of the murine "Y5" receptor may be a pseudogene. J
Biol Chem, 272, 3622-7.
ROSE, R. H., BRIDDON, S. J. & HILL, S. J. 2012. A novel fluorescent histamine
H(1) receptor antagonist demonstrates the advantage of using
fluorescence correlation spectroscopy to study the binding of lipophilic
ligands. Br J Pharmacol, 165, 1789-800.
ROSE RH, B. S., HOLLIDAY ND. 2010. Bimolecular fluorescence
complementation: lighting up seven transmembrane domain receptor
signalling networks. British Journal of Pharmacology, 159, 738-750.
ROSENBAUM, D. M., CHEREZOV, V., HANSON, M. A., RASMUSSEN, S. G.,
THIAN, F. S., KOBILKA, T. S., CHOI, H. J., YAO, X. J., WEIS, W. I.,
STEVENS, R. C. & KOBILKA, B. K. 2007. GPCR engineering yields high-
resolution structural insights into beta2-adrenergic receptor function.
Science, 318, 1266-73.
ROVIRA, X., VIVO, M., SERRA, J., ROCHE, D., STRANGE, P. G. & GIRALDO, J.
2009. Modelling the interdependence between the stoichiometry of
receptor oligomerization and ligand binding for a coexisting
dimer/tetramer receptor system. Br J Pharmacol, 156, 28-35.
ROZENFELD, R. & DEVI, L. A. 2007. Receptor heterodimerization leads to a
switch in signaling: beta-arrestin2-mediated ERK activation by mu-
delta opioid receptor heterodimers. FASEB J, 21, 2455-65.
ROZENFELD, R. & DEVI, L. A. 2010. Receptor heteromerization and drug
discovery. Trends Pharmacol Sci, 31, 124-30.
ROZENFELD, R., GUPTA, A., GAGNIDZE, K., LIM, M. P., GOMES, I., LEE-
RAMOS, D., NIETO, N. & DEVI, L. A. 2011. AT1R-CB(1)R
386
heteromerization reveals a new mechanism for the pathogenic
properties of angiotensin II. EMBO J, 30, 2350-63.
SAINSBURY, A., BALDOCK, P. A., SCHWARZER, C., UENO, N., ENRIQUEZ, R.
F., COUZENS, M., INUI, A., HERZOG, H. & GARDINER, E. M. 2003.
Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass
revealed in double knockout mice. Mol Cell Biol, 23, 5225-33.
SAINSBURY, A., SCHWARZER, C., COUZENS, M., FETISSOV, S., FURTINGER,
S., JENKINS, A., COX, H. M., SPERK, G., HOKFELT, T. & HERZOG, H.
2002. Important role of hypothalamic Y2 receptors in body weight
regulation revealed in conditional knockout mice. Proc Natl Acad Sci U
S A, 99, 8938-43.
SALAHPOUR, A., ESPINOZA, S., MASRI, B., LAM, V., BARAK, L. S. &
GAINETDINOV, R. R. 2012. BRET biosensors to study GPCR biology,
pharmacology, and signal transduction. Front Endocrinol (Lausanne), 3,
105.
SALOMON, Y., LONDOS, C. & RODBELL, M. 1974. A highly sensitive adenylate
cyclase assay. Anal Biochem, 58, 541-8.
SAMAMA, P., COTECCHIA, S., COSTA, T. & LEFKOWITZ, R. J. 1993. A
mutation-induced activated state of the beta 2-adrenergic receptor.
Extending the ternary complex model. J Biol Chem, 268, 4625-36.
SARTANIA, N., APPELBE, S., PEDIANI, J. D. & MILLIGAN, G. 2007. Agonist
occupancy of a single monomeric element is sufficient to cause
internalization of the dimeric beta2-adrenoceptor. Cell Signal, 19,
1928-38.
SATO, T., KOBAYASHI, H., NAGAO, T. & KUROSE, H. 1999. Ser203 as well as
Ser204 and Ser207 in fifth transmembrane domain of the human
beta2-adrenoceptor contributes to agonist binding and receptor
activation. Br J Pharmacol, 128, 272-4.
SATO, Y., KUROSE, H., ISOGAYA, M. & NAGAO, T. 1996. Molecular
characterization of pharmacological properties of T-0509 for beta-
adrenoceptors. Eur J Pharmacol, 315, 363-7.
SATOH, A. K., XIA, H., YAN, L., LIU, C. H., HARDIE, R. C. & READY, D. F.
2010. Arrestin translocation is stoichiometric to rhodopsin isomerization
and accelerated by phototransduction in Drosophila photoreceptors.
Neuron, 67, 997-1008.
SAULIERE, A., GAIBELET, G., MILLOT, C., MAZERES, S., LOPEZ, A. & SALOME,
L. 2006. Diffusion of the mu opioid receptor at the surface of human
neuroblastoma SH-SY5Y cells is restricted to permeable domains. FEBS
Lett, 580, 5227-31.
SAUTEL, M., MARTINEZ, R., MUNOZ, M., PEITSCH, M. C., BECK-SICKINGER,
A. G. & WALKER, P. 1995. Role of a hydrophobic pocket of the human
Y1 neuropeptide Y receptor in ligand binding. Mol Cell Endocrinol, 112,
215-22.
SAUTEL, M., RUDOLF, K., WITTNEBEN, H., HERZOG, H., MARTINEZ, R.,
MUNOZ, M., EBERLEIN, W., ENGEL, W., WALKER, P. & BECK-
SICKINGER, A. G. 1996. Neuropeptide Y and the nonpeptide antagonist
BIBP 3226 share an overlapping binding site at the human Y1 receptor.
Mol Pharmacol, 50, 285-92.
SAVARESE, T. M. & FRASER, C. M. 1992. In vitro mutagenesis and the search
for structure-function relationships among G protein-coupled receptors.
Biochem J, 283 ( Pt 1), 1-19.
387
SCARSELLI, M., NOVI, F., SCHALLMACH, E., LIN, R., BARAGLI, A., COLZI, A.,
GRIFFON, N., CORSINI, G. U., SOKOLOFF, P., LEVENSON, R., VOGEL,
Z. & MAGGIO, R. 2001. D2/D3 dopamine receptor heterodimers exhibit
unique functional properties. J Biol Chem, 276, 30308-14.
SCHEER, A., COSTA, T., FANELLI, F., DE BENEDETTI, P. G., MHAOUTY-KODJA,
S., ABUIN, L., NENNIGER-TOSATO, M. & COTECCHIA, S. 2000.
Mutational analysis of the highly conserved arginine within the Glu/Asp-
Arg-Tyr motif of the alpha(1b)-adrenergic receptor: effects on receptor
isomerization and activation. Mol Pharmacol, 57, 219-31.
SCHEERER, P., PARK, J. H., HILDEBRAND, P. W., KIM, Y. J., KRAUSS, N.,
CHOE, H. W., HOFMANN, K. P. & ERNST, O. P. 2008. Crystal structure
of opsin in its G-protein-interacting conformation. Nature, 455, 497-
502.
SCHWARTZ, T. W., HOLST, J. J., FAHRENKRUG, J., JENSEN, S. L., NIELSEN, O.
V., REHFELD, J. F., DE MUCKADELL, O. B. & STADIL, F. 1978. Vagal,
cholinergic regulation of pancreatic polypeptide secretion. J Clin Invest,
61, 781-9.
SCHWILLE, P. 2001. Fluorescence correlation spectroscopy and its potential for
intracellular applications. Cell Biochem Biophys, 34, 383-408.
SHAN, J., WEINSTEIN, H. & MEHLER, E. L. 2010. Probing the structural
determinants for the function of intracellular loop 2 in structurally
cognate G-protein-coupled receptors. Biochemistry, 49, 10691-701.
SHENOY, S. K. & LEFKOWITZ, R. J. 2003. Trafficking patterns of beta-arrestin
and G protein-coupled receptors determined by the kinetics of beta-
arrestin deubiquitination. J Biol Chem, 278, 14498-506.
SHERIFF, S., ALI, M., YAHYA, A., HAIDER, K. H., BALASUBRAMANIAM, A. &
AMLAL, H. 2010. Neuropeptide Y Y5 receptor promotes cell growth
through extracellular signal-regulated kinase signaling and cyclic AMP
inhibition in a human breast cancer cell line. Mol Cancer Res, 8, 604-
14.
SHI, Y. C., LIN, S., WONG, I. P., BALDOCK, P. A., ALJANOVA, A., ENRIQUEZ,
R. F., CASTILLO, L., MITCHELL, N. F., YE, J. M., ZHANG, L., MACIA, L.,
YULYANINGSIH, E., NGUYEN, A. D., RIEPLER, S. J., HERZOG, H. &
SAINSBURY, A. 2010. NPY neuron-specific Y2 receptors regulate
adipose tissue and trabecular bone but not cortical bone homeostasis in
mice. PLoS One, 5, e11361.
SHIMAMURA, T., SHIROISHI, M., WEYAND, S., TSUJIMOTO, H., WINTER, G.,
KATRITCH, V., ABAGYAN, R., CHEREZOV, V., LIU, W., HAN, G. W.,
KOBAYASHI, T., STEVENS, R. C. & IWATA, S. 2011. Structure of the
human histamine H1 receptor complex with doxepin. Nature, 475, 65-
70.
SHUKLA, A. K., MANGLIK, A., KRUSE, A. C., XIAO, K., REIS, R. I., TSENG, W.
C., STAUS, D. P., HILGER, D., UYSAL, S., HUANG, L. Y., PADUCH, M.,
TRIPATHI-SHUKLA, P., KOIDE, A., KOIDE, S., WEIS, W. I.,
KOSSIAKOFF, A. A., KOBILKA, B. K. & LEFKOWITZ, R. J. 2013.
Structure of active beta-arrestin-1 bound to a G-protein-coupled
receptor phosphopeptide. Nature, 497, 137-41.
SHUKLA, A. K., VIOLIN, J. D., WHALEN, E. J., GESTY-PALMER, D., SHENOY, S.
K. & LEFKOWITZ, R. J. 2008. Distinct conformational changes in beta-
arrestin report biased agonism at seven-transmembrane receptors.
Proc Natl Acad Sci U S A, 105, 9988-93.
388
SJODIN, P., HOLMBERG, S. K., AKERBERG, H., BERGLUND, M. M., MOHELL, N.
& LARHAMMAR, D. 2006. Re-evaluation of receptor-ligand interactions
of the human neuropeptide Y receptor Y1: a site-directed mutagenesis
study. Biochem J, 393, 161-9.
SKAKUN, V. V., ENGEL, R., BORST, J. W., APANASOVICH, V. V. & VISSER, A.
J. 2012. Simultaneous diffusion and brightness measurements and
brightness profile visualization from single fluorescence fluctuation
traces of GFP in living cells. Eur Biophys J, 41, 1055-64.
SLOTH, B., HOLST, J. J., FLINT, A., GREGERSEN, N. T. & ASTRUP, A. 2007.
Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy
expenditure, glucose and fat metabolism in obese and lean subjects.
Am J Physiol Endocrinol Metab, 292, E1062-8.
SMITH, N. J. & MILLIGAN, G. 2010. Allostery at G protein-coupled receptor
homo- and heteromers: uncharted pharmacological landscapes.
Pharmacol Rev, 62, 701-25.
SO, C. H., VERMA, V., ALIJANIARAM, M., CHENG, R., RASHID, A. J., O'DOWD,
B. F. & GEORGE, S. R. 2009. Calcium signaling by dopamine D5
receptor and D5-D2 receptor hetero-oligomers occurs by a mechanism
distinct from that for dopamine D1-D2 receptor hetero-oligomers. Mol
Pharmacol, 75, 843-54.
SOHY, D., PARMENTIER, M. & SPRINGAEL, J. Y. 2007. Allosteric transinhibition
by specific antagonists in CCR2/CXCR4 heterodimers. J Biol Chem, 282,
30062-9.
SOMMER, M. E., HOFMANN, K. P. & HECK, M. 2011. Arrestin-rhodopsin binding
stoichiometry in isolated rod outer segment membranes depends on
the percentage of activated receptors. J Biol Chem, 286, 7359-69.
SOMMER, M. E., HOFMANN, K. P. & HECK, M. 2012. Distinct loops in arrestin
differentially regulate ligand binding within the GPCR opsin. Nat
Commun, 3, 995.
SONG, X., COFFA, S., FU, H. & GUREVICH, V. V. 2009. How does arrestin
assemble MAPKs into a signaling complex? J Biol Chem, 284, 685-95.
SPRINGAEL, J. Y., LE MINH, P. N., URIZAR, E., COSTAGLIOLA, S., VASSART,
G. & PARMENTIER, M. 2006. Allosteric modulation of binding properties
between units of chemokine receptor homo- and hetero-oligomers. Mol
Pharmacol, 69, 1652-61.
SRIVASTAVA, A., YANO, J., HIROZANE, Y., KEFALA, G., GRUSWITZ, F., SNELL,
G., LANE, W., IVETAC, A., AERTGEERTS, K., NGUYEN, J., JENNINGS, A.
& OKADA, K. 2014. High-resolution structure of the human GPR40
receptor bound to allosteric agonist TAK-875. Nature.
STANLEY, B. G., KYRKOULI, S. E., LAMPERT, S. & LEIBOWITZ, S. F. 1986.
Neuropeptide Y chronically injected into the hypothalamus: a powerful
neurochemical inducer of hyperphagia and obesity. Peptides, 7, 1189-
92.
STANLEY, B. G. & LEIBOWITZ, S. F. 1985. Neuropeptide Y injected in the
paraventricular hypothalamus: a powerful stimulant of feeding
behavior. Proc Natl Acad Sci U S A, 82, 3940-3.
STEPHENS, T. W. & CARO, J. F. 1998. To be lean or not to be lean. Is leptin
the answer? Exp Clin Endocrinol Diabetes, 106, 1-15.
STRADER, C. D., CANDELORE, M. R., HILL, W. S., SIGAL, I. S. & DIXON, R. A.
1989. Identification of two serine residues involved in agonist activation
of the beta-adrenergic receptor. J Biol Chem, 264, 13572-8.
389
STRADER, C. D., SIGAL, I. S., CANDELORE, M. R., RANDS, E., HILL, W. S. &
DIXON, R. A. 1988. Conserved aspartic acid residues 79 and 113 of the
beta-adrenergic receptor have different roles in receptor function. J Biol
Chem, 263, 10267-71.
SUN, Q. Q., HUGUENARD, J. R. & PRINCE, D. A. 2001. Neuropeptide Y
receptors differentially modulate G-protein-activated inwardly rectifying
K+ channels and high-voltage-activated Ca2+ channels in rat thalamic
neurons. J Physiol, 531, 67-79.
SUZUKI, K., RITCHIE, K., KAJIKAWA, E., FUJIWARA, T. & KUSUMI, A. 2005.
Rapid hop diffusion of a G-protein-coupled receptor in the plasma
membrane as revealed by single-molecule techniques. Biophys J, 88,
3659-80.
SUZUKI, S., CHUANG, L. F., YAU, P., DOI, R. H. & CHUANG, R. Y. 2002.
Interactions of opioid and chemokine receptors: oligomerization of mu,
kappa, and delta with CCR5 on immune cells. Exp Cell Res, 280, 192-
200.
SZALAI, B., BARKAI, L., TURU, G., SZIDONYA, L., VARNAI, P. & HUNYADY, L.
2012. Allosteric interactions within the AT(1) angiotensin receptor
homodimer: role of the conserved DRY motif. Biochem Pharmacol, 84,
477-85.
TANG, W. J. & HURLEY, J. H. 1998. Catalytic mechanism and regulation of
mammalian adenylyl cyclases. Mol Pharmacol, 54, 231-40.
TER HAAR, E., HARRISON, S. C. & KIRCHHAUSEN, T. 2000. Peptide-in-groove
interactions link target proteins to the beta-propeller of clathrin. Proc
Natl Acad Sci U S A, 97, 1096-100.
TERRILLON, S. & BOUVIER, M. 2004. Receptor activity-independent
recruitment of betaarrestin2 reveals specific signalling modes. EMBO J,
23, 3950-61.
TERRILLON, S., DURROUX, T., MOUILLAC, B., BREIT, A., AYOUB, M. A.,
TAULAN, M., JOCKERS, R., BARBERIS, C. & BOUVIER, M. 2003.
Oxytocin and vasopressin V1a and V2 receptors form constitutive
homo- and heterodimers during biosynthesis. Mol Endocrinol, 17, 677-
91.
TESMER, J. J., SUNAHARA, R. K., GILMAN, A. G. & SPRANG, S. R. 1997.
Crystal structure of the catalytic domains of adenylyl cyclase in a
complex with Gsalpha.GTPgammaS. Science, 278, 1907-16.
TORVINEN, M., MARCELLINO, D., CANALS, M., AGNATI, L. F., LLUIS, C.,
FRANCO, R. & FUXE, K. 2005. Adenosine A2A receptor and dopamine
D3 receptor interactions: evidence of functional A2A/D3 heteromeric
complexes. Mol Pharmacol, 67, 400-7.
TOUGH, I. R., HOLLIDAY, N. D. & COX, H. M. 2006. Y(4) receptors mediate
the inhibitory responses of pancreatic polypeptide in human and mouse
colon mucosa. J Pharmacol Exp Ther, 319, 20-30.
TRIFILIEFF, P., RIVES, M. L., URIZAR, E., PISKOROWSKI, R. A.,
VISHWASRAO, H. D., CASTRILLON, J., SCHMAUSS, C., SLATTMAN, M.,
GULLBERG, M. & JAVITCH, J. A. 2011. Detection of antigen interactions
ex vivo by proximity ligation assay: endogenous dopamine D2-
adenosine A2A receptor complexes in the striatum. Biotechniques, 51,
111-8.
TSAO, P. I. & VON ZASTROW, M. 2001. Diversity and specificity in the
regulated endocytic membrane trafficking of G-protein-coupled
receptors. Pharmacol Ther, 89, 139-47.
390
TSIEN, R. Y. 1998. The green fluorescent protein. Annu Rev Biochem, 67, 509-
44.
TSUKAMOTO, H., SINHA, A., DEWITT, M. & FARRENS, D. L. 2010. Monomeric
rhodopsin is the minimal functional unit required for arrestin binding. J
Mol Biol, 399, 501-11.
UBERTI, M. A., HAGUE, C., OLLER, H., MINNEMAN, K. P. & HALL, R. A. 2005.
Heterodimerization with beta2-adrenergic receptors promotes surface
expression and functional activity of alpha1D-adrenergic receptors. J
Pharmacol Exp Ther, 313, 16-23.
UNAL, H., JAGANNATHAN, R. & KARNIK, S. S. 2012. Mechanism of GPCR-
directed autoantibodies in diseases. Adv Exp Med Biol, 749, 187-99.
UNGER, V. M. & SCHERTLER, G. F. 1995. Low resolution structure of bovine
rhodopsin determined by electron cryo-microscopy. Biophys J, 68,
1776-86.
URIBE, A., ZARINAN, T., PEREZ-SOLIS, M. A., GUTIERREZ-SAGAL, R.,
JARDON-VALADEZ, E., PINEIRO, A., DIAS, J. A. & ULLOA-AGUIRRE, A.
2008. Functional and structural roles of conserved cysteine residues in
the carboxyl-terminal domain of the follicle-stimulating hormone
receptor in human embryonic kidney 293 cells. Biol Reprod, 78, 869-
82.
URIZAR, E., MONTANELLI, L., LOY, T., BONOMI, M., SWILLENS, S., GALES, C.,
BOUVIER, M., SMITS, G., VASSART, G. & COSTAGLIOLA, S. 2005.
Glycoprotein hormone receptors: link between receptor
homodimerization and negative cooperativity. EMBO J, 24, 1954-64.
VENKATAKRISHNAN, A. J., DEUPI, X., LEBON, G., TATE, C. G., SCHERTLER, G.
F. & BABU, M. M. 2013. Molecular signatures of G-protein-coupled
receptors. Nature, 494, 185-94.
VIDI, P. A., CHEMEL, B. R., HU, C. D. & WATTS, V. J. 2008a. Ligand-
dependent oligomerization of dopamine D(2) and adenosine A(2A)
receptors in living neuronal cells. Mol Pharmacol, 74, 544-51.
VIDI, P. A., CHEN, J., IRUDAYARAJ, J. M. & WATTS, V. J. 2008b. Adenosine
A(2A) receptors assemble into higher-order oligomers at the plasma
membrane. FEBS Lett, 582, 3985-90.
VIDI, P. A. & WATTS, V. J. 2009. Fluorescent and bioluminescent protein-
fragment complementation assays in the study of G protein-coupled
receptor oligomerization and signaling. Mol Pharmacol, 75, 733-9.
VILARDAGA, J. P., JEAN-ALPHONSE, F. G. & GARDELLA, T. J. 2014. Endosomal
generation of cAMP in GPCR signaling. Nat Chem Biol, 10, 700-6.
VILARDAGA, J. P., NIKOLAEV, V. O., LORENZ, K., FERRANDON, S., ZHUANG,
Z. & LOHSE, M. J. 2008. Conformational cross-talk between alpha2A-
adrenergic and mu-opioid receptors controls cell signaling. Nat Chem
Biol, 4, 126-31.
VIOLIN, J. D., CROMBIE, A. L., SOERGEL, D. G. & LARK, M. W. 2014. Biased
ligands at G-protein-coupled receptors: promise and progress. Trends
Pharmacol Sci, 35, 308-16.
VIOLIN, J. D., DEWIRE, S. M., YAMASHITA, D., ROMINGER, D. H., NGUYEN,
L., SCHILLER, K., WHALEN, E. J., GOWEN, M. & LARK, M. W. 2010.
Selectively engaging beta-arrestins at the angiotensin II type 1
receptor reduces blood pressure and increases cardiac performance. J
Pharmacol Exp Ther, 335, 572-9.
391
VISHNIVETSKIY, S. A., FRANCIS, D., VAN EPS, N., KIM, M., HANSON, S. M.,
KLUG, C. S., HUBBELL, W. L. & GUREVICH, V. V. 2010. The role of
arrestin alpha-helix I in receptor binding. J Mol Biol, 395, 42-54.
VISHNIVETSKIY, S. A., GIMENEZ, L. E., FRANCIS, D. J., HANSON, S. M.,
HUBBELL, W. L., KLUG, C. S. & GUREVICH, V. V. 2011. Few residues
within an extensive binding interface drive receptor interaction and
determine the specificity of arrestin proteins. J Biol Chem, 286, 24288-
99.
VISHNIVETSKIY, S. A., HOSEY, M. M., BENOVIC, J. L. & GUREVICH, V. V.
2004. Mapping the arrestin-receptor interface. Structural elements
responsible for receptor specificity of arrestin proteins. J Biol Chem,
279, 1262-8.
VISHNIVETSKIY, S. A., SCHUBERT, C., CLIMACO, G. C., GUREVICH, Y. V.,
VELEZ, M. G. & GUREVICH, V. V. 2000. An additional phosphate-
binding element in arrestin molecule. Implications for the mechanism of
arrestin activation. J Biol Chem, 275, 41049-57.
VIVO, M., LIN, H. & STRANGE, P. G. 2006. Investigation of cooperativity in the
binding of ligands to the D(2) dopamine receptor. Mol Pharmacol, 69,
226-35.
VOISIN, T., GOUMAIN, M., LORINET, A. M., MAORET, J. J. & LABURTHE, M.
2000. Functional and molecular properties of the human recombinant
Y4 receptor: resistance to agonist-promoted desensitization. J
Pharmacol Exp Ther, 292, 638-46.
VON ZASTROW, M. & KOBILKA, B. K. 1992. Ligand-regulated internalization
and recycling of human beta 2-adrenergic receptors between the
plasma membrane and endosomes containing transferrin receptors.
Journal of Biological Chemistry, 267, 3530-3538.
WAHLESTEDT, C., GRUNDEMAR, L., HAKANSON, R., HEILIG, M., SHEN, G. H.,
ZUKOWSKA-GROJEC, Z. & REIS, D. J. 1990a. Neuropeptide Y receptor
subtypes, Y1 and Y2. Ann N Y Acad Sci, 611, 7-26.
WAHLESTEDT, C., HAKANSON, R., VAZ, C. A. & ZUKOWSKA-GROJEC, Z.
1990b. Norepinephrine and neuropeptide Y: vasoconstrictor
cooperation in vivo and in vitro. Am J Physiol, 258, R736-42.
WAHLESTEDT, C., REGUNATHAN, S. & REIS, D. J. 1992. Identification of
cultured cells selectively expressing Y1-, Y2-, or Y3-type receptors for
neuropeptide Y/peptide YY. Life Sci, 50, PL7-12.
WALDHOER, M., FONG, J., JONES, R. M., LUNZER, M. M., SHARMA, S. K.,
KOSTENIS, E., PORTOGHESE, P. S. & WHISTLER, J. L. 2005. A
heterodimer-selective agonist shows in vivo relevance of G protein-
coupled receptor dimers. Proc Natl Acad Sci U S A, 102, 9050-5.
WALKER, P., MUNOZ, M., MARTINEZ, R. & PEITSCH, M. C. 1994. Acidic
residues in extracellular loops of the human Y1 neuropeptide Y receptor
are essential for ligand binding. J Biol Chem, 269, 2863-9.
WALTHER, C., NAGEL, S., GIMENEZ, L. E., MORL, K., GUREVICH, V. V. &
BECK-SICKINGER, A. G. 2010. Ligand-induced internalization and
recycling of the human neuropeptide Y2 receptor is regulated by its
carboxyl-terminal tail. J Biol Chem, 285, 41578-90.
WANG, C., WU, H., KATRITCH, V., HAN, G. W., HUANG, X. P., LIU, W., SIU, F.
Y., ROTH, B. L., CHEREZOV, V. & STEVENS, R. C. 2013. Structure of
the human smoothened receptor bound to an antitumour agent.
Nature, 497, 338-43.
392
WANG, D., TAN, Y. C., KREITZER, G. E., NAKAI, Y., SHAN, D., ZHENG, Y. &
HUANG, X. Y. 2006. G proteins G12 and G13 control the dynamic
turnover of growth factor-induced dorsal ruffles. J Biol Chem, 281,
32660-7.
WANG, L., GOURCEROL, G., YUAN, P. Q., WU, S. V., MILLION, M., LARAUCHE,
M. & TACHE, Y. 2010. Peripheral peptide YY inhibits propulsive colonic
motor function through Y2 receptor in conscious mice. Am J Physiol
Gastrointest Liver Physiol, 298, G45-56.
WARD, R. J., PEDIANI, J. D. & MILLIGAN, G. 2011. Ligand-induced
internalization of the orexin OX(1) and cannabinoid CB(1) receptors
assessed via N-terminal SNAP and CLIP-tagging. Br J Pharmacol, 162,
1439-52.
WARNE, T., SERRANO-VEGA, M. J., BAKER, J. G., MOUKHAMETZIANOV, R.,
EDWARDS, P. C., HENDERSON, R., LESLIE, A. G., TATE, C. G. &
SCHERTLER, G. F. 2008. Structure of a beta1-adrenergic G-protein-
coupled receptor. Nature, 454, 486-91.
WATSON, S. J., BROWN, A. J. & HOLLIDAY, N. D. 2012. Differential signaling
by splice variants of the human free fatty acid receptor GPR120. Mol
Pharmacol, 81, 631-42.
WHITE, J. H., WISE, A., MAIN, M. J., GREEN, A., FRASER, N. J., DISNEY, G.
H., BARNES, A. A., EMSON, P., FOORD, S. M. & MARSHALL, F. H. 1998.
Heterodimerization is required for the formation of a functional
GABA(B) receptor. Nature, 396, 679-82.
WHORTON, M. R., BOKOCH, M. P., RASMUSSEN, S. G., HUANG, B., ZARE, R.
N., KOBILKA, B. & SUNAHARA, R. K. 2007. A monomeric G protein-
coupled receptor isolated in a high-density lipoprotein particle
efficiently activates its G protein. Proc Natl Acad Sci U S A, 104, 7682-
7.
WHORTON, M. R., JASTRZEBSKA, B., PARK, P. S., FOTIADIS, D., ENGEL, A.,
PALCZEWSKI, K. & SUNAHARA, R. K. 2008. Efficient coupling of
transducin to monomeric rhodopsin in a phospholipid bilayer. J Biol
Chem, 283, 4387-94.
WIELAND, H. A., ENGEL, W., EBERLEIN, W., RUDOLF, K. & DOODS, H. N.
1998. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1
receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J
Pharmacol, 125, 549-55.
WILDEN, U., WUST, E., WEYAND, I. & KUHN, H. 1986. Rapid affinity
purification of retinal arrestin (48 kDa protein) via its light-dependent
binding to phosphorylated rhodopsin. FEBS Lett, 207, 292-5.
WILLESEN, M. G., KRISTENSEN, P. & ROMER, J. 1999. Co-localization of
growth hormone secretagogue receptor and NPY mRNA in the arcuate
nucleus of the rat. Neuroendocrinology, 70, 306-16.
WILSON, P. C., LEE, M. H., APPLETON, K. M., EL-SHEWY, H. M., MORINELLI,
T. A., PETERSON, Y. K., LUTTRELL, L. M. & JAFFA, A. A. 2013. The
arrestin-selective angiotensin AT1 receptor agonist [Sar1,Ile4,Ile8]-
AngII negatively regulates bradykinin B2 receptor signaling via AT1-B2
receptor heterodimers. J Biol Chem, 288, 18872-84.
WILSON, S., WILKINSON, G. & MILLIGAN, G. 2005. The CXCR1 and CXCR2
receptors form constitutive homo- and heterodimers selectively and
with equal apparent affinities. J Biol Chem, 280, 28663-74.
WISLER, J. W., DEWIRE, S. M., WHALEN, E. J., VIOLIN, J. D., DRAKE, M. T.,
AHN, S., SHENOY, S. K. & LEFKOWITZ, R. J. 2007. A unique
393
mechanism of beta-blocker action: carvedilol stimulates beta-arrestin
signaling. Proc Natl Acad Sci U S A, 104, 16657-62.
WOLAK, M. L., DEJOSEPH, M. R., CATOR, A. D., MOKASHI, A. S.,
BROWNFIELD, M. S. & URBAN, J. H. 2003. Comparative distribution of
neuropeptide Y Y1 and Y5 receptors in the rat brain by using
immunohistochemistry. The Journal of Comparative Neurology, 464,
285-311.
WOLFE, B. L. & TREJO, J. 2007. Clathrin-Dependent Mechanisms of G Protein-
coupled Receptor Endocytosis. Traffic, 8, 462-470.
WORTLEY, K. E., GARCIA, K., OKAMOTO, H., THABET, K., ANDERSON, K. D.,
SHEN, V., HERMAN, J. P., VALENZUELA, D., YANCOPOULOS, G. D.,
TSCHOP, M. H., MURPHY, A. & SLEEMAN, M. W. 2007. Peptide YY
regulates bone turnover in rodents. Gastroenterology, 133, 1534-43.
WU, B., CHIEN, E. Y., MOL, C. D., FENALTI, G., LIU, W., KATRITCH, V.,
ABAGYAN, R., BROOUN, A., WELLS, P., BI, F. C., HAMEL, D. J., KUHN,
P., HANDEL, T. M., CHEREZOV, V. & STEVENS, R. C. 2010. Structures
of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide
antagonists. Science, 330, 1066-71.
WU, H., WACKER, D., MILENI, M., KATRITCH, V., HAN, G. W., VARDY, E., LIU,
W., THOMPSON, A. A., HUANG, X. P., CARROLL, F. I., MASCARELLA, S.
W., WESTKAEMPER, R. B., MOSIER, P. D., ROTH, B. L., CHEREZOV, V.
& STEVENS, R. C. 2012. Structure of the human kappa-opioid receptor
in complex with JDTic. Nature, 485, 327-32.
WU, S., BIRNBAUMER, M. & GUAN, Z. 2008. Phosphorylation analysis of G
protein-coupled receptor by mass spectrometry: identification of a
phosphorylation site in V2 vasopressin receptor. Anal Chem, 80, 6034-
7.
WYATT, D., MALIK, R., VESECKY, A. C. & MARCHESE, A. 2011. Small
ubiquitin-like modifier modification of arrestin-3 regulates receptor
trafficking. J Biol Chem, 286, 3884-93.
XIAO, K., MCCLATCHY, D. B., SHUKLA, A. K., ZHAO, Y., CHEN, M., SHENOY,
S. K., YATES, J. R., 3RD & LEFKOWITZ, R. J. 2007. Functional
specialization of beta-arrestin interactions revealed by proteomic
analysis. Proc Natl Acad Sci U S A, 104, 12011-6.
XIAO, K., SHENOY, S. K., NOBLES, K. & LEFKOWITZ, R. J. 2004. Activation-
dependent conformational changes in {beta}-arrestin 2. J Biol Chem,
279, 55744-53.
XU, B., FALLMAR, H., BOUKHARTA, L., PRUNER, J., LUNDELL, I., MOHELL, N.,
GUTIERREZ-DE-TERAN, H., AQVIST, J. & LARHAMMAR, D. 2013.
Mutagenesis and computational modeling of human G-protein-coupled
receptor Y2 for neuropeptide Y and peptide YY. Biochemistry, 52, 7987-
98.
YAO, F., SVENSJO, T., WINKLER, T., LU, M., ERIKSSON, C. & ERIKSSON, E.
1998. Tetracycline repressor, tetR, rather than the tetR-mammalian
cell transcription factor fusion derivatives, regulates inducible gene
expression in mammalian cells. Hum Gene Ther, 9, 1939-50.
YESILALTAY, A. & JENNESS, D. D. 2000. Homo-oligomeric complexes of the
yeast alpha-factor pheromone receptor are functional units of
endocytosis. Mol Biol Cell, 11, 2873-84.
YOSHIOKA, K., SAITOH, O. & NAKATA, H. 2001. Heteromeric association
creates a P2Y-like adenosine receptor. Proc Natl Acad Sci U S A, 98,
7617-22.
394
ZACHARIAS, D. A., VIOLIN, J. D., NEWTON, A. C. & TSIEN, R. Y. 2002.
Partitioning of lipid-modified monomeric GFPs into membrane
microdomains of live cells. Science, 296, 913-6.
ZARJEVSKI, N., CUSIN, I., VETTOR, R., ROHNER-JEANRENAUD, F. &
JEANRENAUD, B. 1993. Chronic intracerebroventricular neuropeptide-Y
administration to normal rats mimics hormonal and metabolic changes
of obesity. Endocrinology, 133, 1753-8.
ZENG, C., WANG, Z., LI, H., YU, P., ZHENG, S., WU, L., ASICO, L. D.,
HOPFER, U., EISNER, G. M., FELDER, R. A. & JOSE, P. A. 2006. D3
dopamine receptor directly interacts with D1 dopamine receptor in
immortalized renal proximal tubule cells. Hypertension, 47, 573-9.
ZHANG, J., FERGUSON, S. S., BARAK, L. S., MENARD, L. & CARON, M. G.
1996. Dynamin and beta-arrestin reveal distinct mechanisms for G
protein-coupled receptor internalization. J Biol Chem, 271, 18302-5.
ZHANG, L., BIJKER, M. S. & HERZOG, H. 2011. The neuropeptide Y system:
pathophysiological and therapeutic implications in obesity and cancer.
Pharmacol Ther, 131, 91-113.
ZHANG, L., RIEPLER, S. J., TURNER, N., ENRIQUEZ, R. F., LEE, I. C.,
BALDOCK, P. A., HERZOG, H. & SAINSBURY, A. 2010. Y2 and Y4
receptor signaling synergistically act on energy expenditure and
physical activity. Am J Physiol Regul Integr Comp Physiol, 299, R1618-
28.
ZHUANG, T., CHEN, Q., CHO, M. K., VISHNIVETSKIY, S. A., IVERSON, T. M.,
GUREVICH, V. V. & SANDERS, C. R. 2013. Involvement of distinct
arrestin-1 elements in binding to different functional forms of
rhodopsin. Proc Natl Acad Sci U S A, 110, 942-7.
ZIPF, W. B., O'DORISIO, T. M., CATALAND, S. & SOTOS, J. 1981. Blunted
pancreatic polypeptide responses in children with obesity of Prader-Willi
syndrome. J Clin Endocrinol Metab, 52, 1264-6.
